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PROLOGUEApproximately 3.8 billion years ago it is thought that life has started on Earth, of which the last 450 million years sharks dominated the oceans (reviewed by Sadava 
et al. 2007) [1]. Together with the evolution of other jawed vertebrates the adaptive 
immune system developed. All four T cell receptor (TCR) genes were identified in 
Raja erinacea, the small skate (Fig. 1a). These TCR loci were also traced back in early vertebrate phylogeny [2]. The complete origin of the adaptive immune system receptors 
lies in NAR-TCRs (new antigen receptor-TCRs) as identified from studies on nurse sharks 
Ginglymostoma cirratum (Fig. 1b). All currently known Immunoglobulin (Ig) and TCRs evolved from this single NAR-TCR-receptor type (Fig. 2) [3], which showed usage and thus support by the current T cell receptor delta variable region (TRDV) exons in all kinds of receptors (Fig. 3). The largest proportion of the shark immune system consists 
of cells expressing delta receptors (>50%, [3]), as also identified in birds (±25% of all lymphocytes, [4,5]), cattle (75%, [6]), sheep (30-60%, [7]), alpacas and llamas (16%, [8]), mice (5% of all T cells, [9]) and ultimately also in humans (1-5% of all circulating T cells, [10-13]).
This means that T cells bearing the γδ-TCR are highly evolutionary conserved, and that they are possibly the ancestors of all cells from our adaptive immune system. Not only the close relation with the NAR-TCRs suggests this, but also their combinatorial role in coupling innate with adaptive immunity, by sharing functions of both immune sys-
tems [12,13]. TCRγδ+ T cells are highly polyfunctional and exhibit important functions and features: from expression of a unique and highly evolutionary conserved TCR, to 
therefore unique antigen specificities (by both being dependent and independent from the unique TCR), to the broad and complex cellular interactions.  
As also illustrated by Pierre Vantourout & Adrian Hayday in 2013 (Fig. 4), TCRγδ+ T cells have pleiotropic functions by producing many types of cytokines (which could be Th1/2/17 related), prime other T cells, regulate the epithelium, help B cells in produc-ing the right antibodies, help dendritic cells to skew their maturation in the right way, and they can actively kill infected and stressed cells. Infected cells include infections with bacteria, especially Mycobacterium tuberculosis: specific TCRγδ+ T cells bearing the 
Vγ9/Vδ2 receptor recognize phosphoantigens which come from bacteria [14,15]. But also fungi, parasites, such as Plasmodium spp. [16], viruses; for instance, Herpesviruses 
such as Cytomegalovirus [17] and Epstein-Barr virus [18] can be recognized by TCRγδ+ T cells. During the last Ebola outbreak, investigators even found a protective role for 
effector Vδ2 cells in Ebola survivors [19]; therefore, the picture and arrow with “patho-




Approximately 3.8 billion years ago it is thought that life has started on Earth, of 
which the last 450 million years sharks dominated the oceans (reviewed by Sadava 
et al. 2007) [1]. Together with the evolution of other jawed vertebrates the adaptive 
immune system developed. All four T cell receptor (TCR) genes were identified in 
Raja erinacea, the small skate (Fig. 1a). These TCR loci were also traced back in early 
vertebrate phylogeny [2]. The complete origin of the adaptive immune system receptors 
lies in NAR-TCRs (new antigen receptor-TCRs) as identified from studies on nurse sharks 
Ginglymostoma cirratum (Fig. 1b). All currently known Immunoglobulin (Ig) and TCRs 
evolved from this single NAR-TCR-receptor type (Fig. 2) [3], which showed usage and 
thus support by the current T cell receptor delta variable region (TRDV) exons in all 
kinds of receptors (Fig. 3). The largest proportion of the shark immune system consists 
of cells expressing delta receptors (>50%, [3]), as also identified in birds (±25% of all 
lymphocytes, [4,5]), cattle (75%, [6]), sheep (30-60%, [7]), alpacas and llamas (16%, 
[8]), mice (5% of all T cells, [9]) and ultimately also in humans (1-5% of all circulating 
T cells, [10-13]).
This means that T cells bearing the γδ-TCR are highly evolutionary conserved, and 
that they are possibly the ancestors of all cells from our adaptive immune system. Not 
only the close relation with the NAR-TCRs suggests this, but also their combinatorial role 
in coupling innate with adaptive immunity, by sharing functions of both immune sys-
tems [12,13]. TCRγδ+ T cells are highly polyfunctional and exhibit important functions 
and features: from expression of a unique and highly evolutionary conserved TCR, to 
therefore unique antigen specificities (by both being dependent and independent from 
the unique TCR), to the broad and complex cellular interactions.  
As also illustrated by Pierre Vantourout & Adrian Hayday in 2013 (Fig. 4), TCRγδ+ T 
cells have pleiotropic functions by producing many types of cytokines (which could be 
Th1/2/17 related), prime other T cells, regulate the epithelium, help B cells in produc-
ing the right antibodies, help dendritic cells to skew their maturation in the right way, 
and they can actively kill infected and stressed cells. Infected cells include infections 
with bacteria, especially Mycobacterium tuberculosis: specific TCRγδ+ T cells bearing the 
Vγ9/Vδ2 receptor recognize phosphoantigens which come from bacteria [14,15]. But 
also fungi, parasites, such as Plasmodium spp. [16], viruses; for instance, Herpesviruses 
such as Cytomegalovirus [17] and Epstein-Barr virus [18] can be recognized by TCRγδ+ 
T cells. During the last Ebola outbreak, investigators even found a protective role for 
effector Vδ2 cells in Ebola survivors [19]; therefore, the picture and arrow with “patho-
gens” should be added to the polyfunctionality of TCRγδ+ T cells (Fig. 4). Stressed cells 
could be for instance infected cells, dysregulated cells or transformed cells such as (ear-
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ly) cancer cells, which could be readily killed by TCRγδ+ T cells (reviewed by Fleming et 
al. 2017) [20]: a novel therapeutic option in cancer treatment. By using all these properties at the same time, makes TCRγδ+ T cells very – even 
though the importance of their existence is often denied – promising when it comes to 
disease pathology and therapy. Hopefully, with this introduction and booklet, the Reader could be convinced about 
the importance of the humble, great and versatile TCRγδ+ T cells.
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P r o l o g u e
l y )  c a n c e r  c e l l s ,  w h i c h  c o u l d  b e  r e a d i l y  k i l l e d  b y  T C R γ δ +  T  c e l l s  ( r e v i e w e d  b y  F l e m i n g  e t  
a l .  2 0 1 7 )  [ 2 0 ] :  a  n o v e l  t h e r a p e u t i c  o p t i o n  i n  c a n c e r  t r e a t m e n t .
B y  u s i n g  a l l  t h e s e  p r o p e r t i e s  a t  t h e  s a m e  t i m e ,  m a k e s  T C R γ δ +  T  c e l l s  v e r y  –  e v e n  
t h o u g h  t h e  i m p o r t a n c e  o f  t h e i r  e x i s t e n c e  i s  o f t e n  d e n i e d  –  p r o m i s i n g  w h e n  i t  c o m e s  t o  
d i s e a s e  p a t h o l o g y  a n d  t h e r a p y .  
H o p e f u l l y ,  w i t h  t h i s  i n t r o d u c t i o n  a n d  b o o k l e t ,  t h e  R e a d e r  c o u l d  b e  c o n v i n c e d  a b o u t  
t h e  i m p o r t a n c e  o f  t h e  h u m b l e ,  g r e a t  a n d  v e r s a t i l e  T C R γ δ +  T  c e l l s .
Proloog
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PROLOOGOngeveer 3.8 miljard jaar geleden startte het leven op aarde, waarvan 450 miljoen jaar de haaien de oceanen  domineren (beschreven in Sadava et al. 2007) [1]. Samen met de evolutie van gewervelde dieren ontwikkelde ook het verworven immuunsys-
teem. Allevier de T cel receptor (TCR) genen werden geïdentificeerd in Raja erinacea, de kleine rog (Fig. 1a). Deze TCR loci werden tevens  teruggevonden in de fylogenie van vroege gewervelde dieren [2]. De complete oorsprong van de receptoren in het verwor-ven immuunsysteem ligt in die van de zogenaamde NAR-TCRs (nieuwe antigeen recep-
tor-TCRs) zoals geïdentificeerd in studies met de verpleegsterhaai Ginglymostoma cirra-
tum (Fig. 1b). Alle momenteel bekende Immuunglobuline (Ig) en TCRs evolueerden uit deze enkele NAR-TCR-receptor type (Fig. 2) [3]. Deze liet gebruik en steun vanuit de nu bekende T cel receptor delta variabele exonen zien in allerlei soorten receptoren (Fig.3). Het grootste deel van het haaien immuunsysteem bestaat uit cellen met een delta recep-
tor (>50%, [3]), wat later ook is gevonden in vogels (±25% van alle lymfocyten, [4,5]), vee (75%, [6]), schapen (30-60%,[7]), alpaca’s en lama’s (16%, [8]), muizen (5% van alle T cellen, [9]), en tenslotte ook in mensen (1-5% van circulerende T cellen, [10-13]). 
Dit betekent tevens dat T cellen met een γδ-TCR evolutionair zeer geconserveerd zijn, en dat zij mogelijk de voorouders van ons volledige verworven immuunsysteem zijn. Niet alleen de hoge correlatie met NAR-TCRs suggereert dit, maar ook hun rol in het kop-pelen van de aangeboren met verworven immuniteit middels het bezitten van functies 
van beiden [12,13]. TCRγδ+ T cellen zijn zeer polyfunctioneel en bezitten belangrijke eigenschappen: van de expressie van de unieke en geconserveerde receptor, tot unieke 
antigeen specificiteiten (door zowel afhankelijk en onafhankelijk te zijn van de unieke TCR), tot het brede scala aan complexe cellulaire interacties. Zoals ook geïllustreerd door Pierre Vantourout & Adrian Hayday in 2013 (Fig. 4), 
hebben TCRγδ+ T cellen pleiotrope functies door de productie van verschillende cyto-kines (welke van Th1/2/17 origine kunnen zijn), het activeren van andere T cellen, epi-theel regulatie, B cel hulp voor de juiste antilichaamproductie, dendritische cellen in de juiste richting sturen, en ze kunnen actief geïnfecteerde en gestresste cellen doodmak-en. Cellen kunnen bijvoorbeeld geïnfecteerd zijn met bacteriën, vooral Mycobacterium 
tuberculosis geeft een specifieke reactie van Vγ9/Vδ2 cellen, omdat ze fosfo-antigenen 
afkomstig van bacteriën kunnen herkennen [14,15]. Maar ook schimmels, parasieten, zoals Plasmodium spp. [16], virussen; bijvoorbeeld Herpesviridae zoals Cytomegalovirus 
[17], en Epstein-Barr virus [18] worden door TCRγδ+ T cellen herkend. Tijdens de re-
cente Ebola uitbraak vonden onderzoekers zelfs een beschermende rol van effector Vδ2 
cellen in Ebola overlevenden [19]; daarom zou deze figuur kunnen worden aangepast 
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jaar de haaien de oceanen  domineren (beschreven in Sadava et al. 2007) [1]. Samen 
met de evolutie van gewervelde dieren ontwikkelde ook het verworven immuunsys-
teem. Allevier de T cel receptor (TCR) genen werden geïdentificeerd in Raja erinacea, 
de kleine rog (Fig. 1a). Deze TCR loci werden tevens  teruggevonden in de fylogenie van 
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ven immuunsysteem ligt in die van de zogenaamde NAR-TCRs (nieuwe antigeen recep-
tor-TCRs) zoals geïdentificeerd in studies met de verpleegsterhaai Ginglymostoma cirra-
tum (Fig. 1b). Alle momenteel bekende Immuunglobuline (Ig) en TCRs evolueerden uit 
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bekende T cel receptor delta variabele exonen zien in allerlei soorten receptoren (Fig.3). 
Het grootste deel van het haaien immuunsysteem bestaat uit cellen met een delta recep-
tor (>50%, [3]), wat later ook is gevonden in vogels (±25% van alle lymfocyten, [4,5]), 
vee (75%, [6]), schapen (30-60%,[7]), alpaca’s en lama’s (16%, [8]), muizen (5% van 
alle T cellen, [9]), en tenslotte ook in mensen (1-5% van circulerende T cellen, [10-13]). 
Dit betekent tevens dat T cellen met een γδ-TCR evolutionair zeer geconserveerd zijn, 
en dat zij mogelijk de voorouders van ons volledige verworven immuunsysteem zijn. 
Niet alleen de hoge correlatie met NAR-TCRs suggereert dit, maar ook hun rol in het kop-
pelen van de aangeboren met verworven immuniteit middels het bezitten van functies 
van beiden [12,13]. TCRγδ+ T cellen zijn zeer polyfunctioneel en bezitten belangrijke 
eigenschappen: van de expressie van de unieke en geconserveerde receptor, tot unieke 
antigeen specificiteiten (door zowel afhankelijk en onafhankelijk te zijn van de unieke 
TCR), tot het brede scala aan complexe cellulaire interacties. 
Zoals ook geïllustreerd door Pierre Vantourout & Adrian Hayday in 2013 (Fig. 4), 
hebben TCRγδ+ T cellen pleiotrope functies door de productie van verschillende cyto-
kines (welke van Th1/2/17 origine kunnen zijn), het activeren van andere T cellen, epi-
theel regulatie, B cel hulp voor de juiste antilichaamproductie, dendritische cellen in de 
juiste richting sturen, en ze kunnen actief geïnfecteerde en gestresste cellen doodmak-
en. Cellen kunnen bijvoorbeeld geïnfecteerd zijn met bacteriën, vooral Mycobacterium 
tuberculosis geeft een specifieke reactie van Vγ9/Vδ2 cellen, omdat ze fosfo-antigenen 
afkomstig van bacteriën kunnen herkennen [14,15]. Maar ook schimmels, parasieten, 
zoals Plasmodium spp. [16], virussen; bijvoorbeeld Herpesviridae zoals Cytomegalovirus 
[17], en Epstein-Barr virus [18] worden door TCRγδ+ T cellen herkend. Tijdens de re-
cente Ebola uitbraak vonden onderzoekers zelfs een beschermende rol van effector Vδ2 
cellen in Ebola overlevenden [19]; daarom zou deze figuur kunnen worden aangepast 
met nog een extra pijl voor “pathogenen” (Fig. 4). Gestresste cellen zijn bijvoorbeeld 
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geïnfecteerde, ontregelde of getransformeerde (vroege) kankercellen [20], welke direct kunnen worden aangevallen door TCRγδ+ T cellen: een nieuwe optie voor kankerther-
apie. Door al deze eigenschappen op hetzelfde moment te kunnen gebruiken, maakt 
TCRγδ+ T cellen zeer – alhoewel het belang van hun bestaan vaak wordt genegeerd – 
veelbelovend wanneer het om ziekte pathologie en therapie gaat. Hopelijk, met deze introductie en dit boekje, kan de Lezer worden overtuigd van het 
belang van de bescheiden, grootse en veelzijdige TCRγδ+ T cellen.
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P r o l o o g
g e ï n f e c t e e r d e ,  o n t r e g e l d e  o f  g e t r a n s f o r m e e r d e  ( v r o e g e )  k a n k e r c e l l e n  [ 2 0 ] ,  w e l k e  d i r e c t  
k u n n e n  w o r d e n  a a n g e v a l l e n  d o o r  T C R γ δ +  T  c e l l e n :  e e n  n i e u w e  o p t i e  v o o r  k a n k e r t h e r -
a p i e .
D o o r  a l  d e z e  e i g e n s c h a p p e n  o p  h e t z e l f d e  m o m e n t  t e  k u n n e n  g e b r u i k e n ,  m a a k t  
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Figure 1. Raja erinacea (a) and Ginglymostoma cirratum (b).The little skate (a) and the nurse shark (b). Images adapted from www.elasmodriver.com.  
Figuur 1. Raja erinacea (a) en Ginglymostoma cirratum (b).De kleine rog (a) en de verpleegsterhaai (b). Beelden afkomstig van www.elasmodriver.com.
Prologue / Proloog
14
Figure 1. Raja erinacea (a) and Ginglymostoma cirratum (b).
The little skate (a) and the nurse shark (b). Images adapted from www.elasmodriver.com. 
 
Figuur 1. Raja erinacea (a) en Ginglymostoma cirratum (b).
De kleine rog (a) en de verpleegsterhaai (b). Beelden afkomstig van www.elasmodriver.com.
15
Prologue / Proloog
Figure 2. Adaptive immunity receptor phylogeny.
Phylogenetic tree of the Ig V domains showing early development of the NAR-TCRV which is supported by the TRDV locus. Figure adapted from Criscitiello et al. 2006.  
Figuur 2. Verworven immuniteit receptor verwantschap.
Fylogenetische stamboom van de Ig V domeinen, welke de vroege ontwikkeling van de NAR-TCRV illustreert. Deze wordt gesteund door het TRDV locus. Figuur afkomstig van Criscitiello et al. 2006.
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F i g u r e  2 .  A d a p t i v e  i m m u n i t y  r e c e p t o r  p h y l o g e n y .
P h y l o g e n e t i c  t r e e  o f  t h e  I g  V  d o m a i n s  s h o w i n g  e a r l y  d e v e l o p m e n t  o f  t h e  N A R - T C R V  w h i c h  i s  s u p p o r t e d  b y  t h e  
T R D V  l o c u s .  F i g u r e  a d a p t e d  f r o m  C r i s c i t i e l l o  e t  a l .  2 0 0 6 .
 
F i g u u r  2 .  V e r w o r v e n  i m m u n i t e i t  r e c e p t o r  v e r w a n t s c h a p .
F y l o g e n e t i s c h e  s t a m b o o m  v a n  d e  I g  V  d o m e i n e n ,  w e l k e  d e  v r o e g e  o n t w i k k e l i n g  v a n  d e  N A R - T C R V  i l l u s t r e e r t .  
D e z e  w o r d t  g e s t e u n d  d o o r  h e t  T R D V  l o c u s .  F i g u u r  a f k o m s t i g  v a n  C r i s c i t i e l l o  e t  a l .  2 0 0 6 .
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Figure 3. Receptor diversity and TRDV usage in the shark immune system.Three different immune tricks in the shark immune system with NAR-TCR extensions of the TRD chain (a), trans-rearrangements combining TRG with IGHV (b) and somatic hypermutation in T cells (c). Figure adapted from Criscitiello 2014 [21]. 
Figuur 3. Receptor diversiteit en TRDV gebruik in het immuun systeem van haaien.Drie verschillende manoeuvres van het immuun systeem in de haai met NAR-TCR verlengingen van de TRD keten (a), trans-herschikkingen met TRG en IGHV combinaties (b) en somatische hypermutatie in T cellen (c). 
Figuur afkomstig van Criscitiello 2014 [21].
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Figure 4. TCRγδ+ T cells’ pleiotropic functions.
TCRγδ+ T cells are able to prime TCRαβ+ T cells, dendritic cells and B cells, regulate the epithelium, 
lyse infected and stressed cells, produce various cytokines and chemokines, and respond to pathogens (bacteria, fungi, parasites, viruses). Figure adapted from Vantourout & Hayday 2013. 
Figuur 4. De veelzijdige functies van TCRγδ+ T cellen. TCRγδ+ T cellen kunnen TCRαβ+ T cellen, dendritische cellen en B cellen activeren, epitheelcellen reguleren, geïnfecteerde en gestresste cellen lyseren, vele verschillende cytokines en chemokines produceren en op 
pathogenen reageren (bacteriën, schimmels, parasieten, virussen). Figuur afkomstig van Vantourout & Hayday 
2013.
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F i g u r e  4 .  T C R γ δ +  T  c e l l s ’  p l e i o t r o p i c  f u n c t i o n s .
T C R γ δ +  T  c e l l s  a r e  a b l e  t o  p r i m e  T C R α β +  T  c e l l s ,  d e n d r i t i c  c e l l s  a n d  B  c e l l s ,  r e g u l a t e  t h e  e p i t h e l i u m ,  
l y s e  i n f e c t e d  a n d  s t r e s s e d  c e l l s ,  p r o d u c e  v a r i o u s  c y t o k i n e s  a n d  c h e m o k i n e s ,  a n d  r e s p o n d  t o  
p a t h o g e n s  ( b a c t e r i a ,  f u n g i ,  p a r a s i t e s ,  v i r u s e s ) .  F i g u r e  a d a p t e d  f r o m  V a n t o u r o u t  &  H a y d a y  2 0 1 3 .  
F i g u u r  4 .  D e  v e e l z i j d i g e  f u n c t i e s  v a n  T C R γ δ +  T  c e l l e n .  
T C R γ δ +  T  c e l l e n  k u n n e n  T C R α β +  T  c e l l e n ,  d e n d r i t i s c h e  c e l l e n  e n  B  c e l l e n  a c t i v e r e n ,  e p i t h e e l c e l l e n  r e g u l e r e n ,  
g e ï n f e c t e e r d e  e n  g e s t r e s s t e  c e l l e n  l y s e r e n ,  v e l e  v e r s c h i l l e n d e  c y t o k i n e s  e n  c h e m o k i n e s  p r o d u c e r e n  e n  o p  
p a t h o g e n e n  r e a g e r e n  ( b a c t e r i ë n ,  s c h i m m e l s ,  p a r a s i e t e n ,  v i r u s s e n ) .  F i g u u r  a f k o m s t i g  v a n  V a n t o u r o u t  &  H a y d a y  
2 0 1 3 .





A HISTORICAL PERSPECTIVE OF T CELLS 
The thymus has already been recognized and described by the ancient Greeks, who called it “θυμός”, which means heart, or life, based on the anatomic position of the organ 
in mammals (summarized in [1,2]). Centuries later in 1769 William Hewson wrote about a unified lymphatic system, to which nodes, the spleen and thymus were attached. 
In 1777 his investigation on the thymus was published by his friend Marcus Falconer, in which it was described that the organ was filled with particles, in much the same 
way as blood was [3,4] (Fig. 1). It was stated that the identified particles were neces- sary only in early stages of life, and that therefore only in that period the thymus would 
Figure 1. Original first page of the chapter containing the remaining part of the observations and 
experiments of the late Mr. William Hewson.
Original Chapter page from William Hewson’s work on the lymphatic glands, thymus and spleen, continued, finished and published by Magnus Falconer in 1777 (Hewson, 1777).
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G e n e r a l  I n t r o d u c t i o n  
A  H I S T O R I C A L  P E R S P E C T I V E  O F  T  C E L L S  
T h e  t h y m u s  h a s  a l r e a d y  b e e n  r e c o g n i z e d  a n d  d e s c r i b e d  b y  t h e  a n c i e n t  G r e e k s ,  w h o  
c a l l e d  i t  “ θ υ μ ό ς ” ,  w h i c h  m e a n s  h e a r t ,  o r  l i f e ,  b a s e d  o n  t h e  a n a t o m i c  p o s i t i o n  o f  t h e  o r g a n  
i n  m a m m a l s  ( s u m m a r i z e d  i n  [ 1 , 2 ] ) .  C e n t u r i e s  l a t e r  i n  1 7 6 9  W i l l i a m  H e w s o n  w r o t e  
a b o u t  a  u n i f i e d  l y m p h a t i c  s y s t e m ,  t o  w h i c h  n o d e s ,  t h e  s p l e e n  a n d  t h y m u s  w e r e  a t t a c h e d .  
I n  1 7 7 7  h i s  i n v e s t i g a t i o n  o n  t h e  t h y m u s  w a s  p u b l i s h e d  b y  h i s  f r i e n d  M a r c u s  F a l c o n e r ,  
i n  w h i c h  i t  w a s  d e s c r i b e d  t h a t  t h e  o r g a n  w a s  f i l l e d  w i t h  p a r t i c l e s ,  i n  m u c h  t h e  s a m e  
w a y  a s  b l o o d  w a s  [ 3 , 4 ]  ( F i g .  1 ) .  I t  w a s  s t a t e d  t h a t  t h e  i d e n t i f i e d  p a r t i c l e s  w e r e  n e c e s -
s a r y  o n l y  i n  e a r l y  s t a g e s  o f  l i f e ,  a n d  t h a t  t h e r e f o r e  o n l y  i n  t h a t  p e r i o d  t h e  t h y m u s  w o u l d  
F i g u r e  1 .  O r i g i n a l  f i r s t  p a g e  o f  t h e  c h a p t e r  c o n t a i n i n g  t h e  r e m a i n i n g  p a r t  o f  t h e  o b s e r v a t i o n s  a n d  
e x p e r i m e n t s  o f  t h e  l a t e  M r .  W i l l i a m  H e w s o n .
O r i g i n a l  C h a p t e r  p a g e  f r o m  W i l l i a m  H e w s o n ’ s  w o r k  o n  t h e  l y m p h a t i c  g l a n d s ,  t h y m u s  a n d  s p l e e n ,  c o n t i n u e d ,  
f i n i s h e d  a n d  p u b l i s h e d  b y  M a g n u s  F a l c o n e r  i n  1 7 7 7  ( H e w s o n ,  1 7 7 7 ) .
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exist [5]. In the years after, many speculations have risen on the origin, development, importance and function of the thymus in general. In 1954 J. Vadász described in his 
article “die Entstehung der Thymozyten in Gewebekulturen” the origin of thymocytes from the epithelium of the organ; under a microscope he noticed the development of small and rapidly dividing cells from the reticulum of the thymus [6]. A few years later, in 1961, Jacques Miller discovered the involvement of the thymus in cellular immunity through formation of lymphocytes, when he performed thymectomy in neonatal mice and observed poorly developed lymphoid organs, impaired immune responses and high susceptibility to infections [7]. Furthermore, he found that nude mice did not reject skin grafts, while immunocompetent mice did [2]. This implied that the thymus generates lymphocytes which have undergone a selection process, and upon maturation migrate to different parts of the body. The poorly developed lymphoid organs and impaired immune responses in thymectomized neonatal mice could be rescued by the transplantation of thymus grafts, again indicating that the particles or lymphocytes must originate from the thymus and/or the thymic epithelia [5,6]. In the years after, researchers could iden-tify that thymocytes do not develop from the thymic epithelium itself, but the thymic epi-thelium nurtures and teaches stem cells originating from the bone marrow to become T cells [7]. In fact, the progenitors entering the human thymus still have the potential to differentiate into B lymphoid, myeloid and erythroid lineages [8]. Upon entering the thymus, the progenitors receive Notch signals leading to full commitment to the T cell lineage (reviewed in [9]). A central event during T cell lineage commitment and further T cell development is the formation of the T cell receptor (TCR). The T cell receptor itself was discovered in 1983, along with the importance of antigen recognition via the TCR in the context of major histocompatibility complex (MHC) molecules [10]. A few years later also the 
genes encoding the T cell receptor were identified [11] (reviewed in [12-15]). First, the 
TCRαβ heterodimer (Fig. 2a) was identified when MHC-molecules were investigated in 
the context of T cells and vice versa. Later, also the T cell receptor γ (TRG) and T cell 
receptor δ (TRD) loci were mapped [16,17], which led to the discovery and recognition 
of a novel, alternative type of T cells, the TCRγδ+ T cells [18-20]. The TRD locus is located on chromosome 14 and is intertwined with the TRA locus. The locus is larger, although consisting of fewer genes than the TRG locus (Fig. 2b). The TRG locus is a small locus and located on chromosome 7. The genes group into several families (Fig. 2c). 
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receptor δ (TRD) loci were mapped [16,17], which led to the discovery and recognition 
of a novel, alternative type of T cells, the TCRγδ+ T cells [18-20]. The TRD locus is located 
on chromosome 14 and is intertwined with the TRA locus. The locus is larger, although 
consisting of fewer genes than the TRG locus (Fig. 2b). The TRG locus is a small locus and 
located on chromosome 7. The genes group into several families (Fig. 2c). 
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Figure 2. The T cell receptor heterodimer and TRD/TRG gene loci.
(a) T cell receptor as heterodimer, either consisting of a TCRα and TCRβ chain, or TCRγ and TCRδ chain. TCRβ and TCRδ chains are encoded after VDJ recombination, involving V, D and J genes, whilst TCRα and TCRγ chains only contain V and J gene encoded sequences. (b) TRD gene locus located on chromosome 14q11.2, 
intertwined with the TRA locus thus preventing nonfunctional αδ or γβ receptor combinations. All TRD 
genes are functional (green), although TRDV4-7 can also be used as TRAV genes (TRAV14, 29, 23 and 36 respectively). TRDV1-3 are most common, with TRDV3 reversely located in the locus. An enhancer is located in between TRDJ4 and TRDC. The locus is approx. 1000 kb in length. Black boxes indicate regions of TRAV and 
TRAJ genes. (c) TRG gene locus is located on chromosome 7p14. The locus is approx. 200 kb in length. The V-genes are divided into 4 families, with families 1 and 2 containing functional genes (green). TRGV1, 10 and 11 (yellow) are open reading frames (ORF), TRGV5P, 6 and 7(red) are pseudogenes. All J-genes are functional 
genes (dark green).  
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F i g u r e  2 .  T h e  T  c e l l  r e c e p t o r  h e t e r o d i m e r  a n d  T R D / T R G  g e n e  l o c i .
( a )  T  c e l l  r e c e p t o r  a s  h e t e r o d i m e r ,  e i t h e r  c o n s i s t i n g  o f  a  T C R α  a n d  T C R β  c h a i n ,  o r  T C R γ  a n d  T C R δ  c h a i n .  T C R β  
a n d  T C R δ  c h a i n s  a r e  e n c o d e d  a f t e r  V D J  r e c o m b i n a t i o n ,  i n v o l v i n g  V ,  D  a n d  J  g e n e s ,  w h i l s t  T C R α  a n d  T C R γ  
c h a i n s  o n l y  c o n t a i n  V  a n d  J  g e n e  e n c o d e d  s e q u e n c e s .  ( b )  T R D  g e n e  l o c u s  l o c a t e d  o n  c h r o m o s o m e  1 4 q 1 1 . 2 ,  
i n t e r t w i n e d  w i t h  t h e  T R A  l o c u s  t h u s  p r e v e n t i n g  n o n f u n c t i o n a l  α δ  o r  γ β  r e c e p t o r  c o m b i n a t i o n s .  A l l  T R D  
g e n e s  a r e  f u n c t i o n a l  ( g r e e n ) ,  a l t h o u g h  T R D V 4 - 7  c a n  a l s o  b e  u s e d  a s  T R A V  g e n e s  ( T R A V 1 4 ,  2 9 ,  2 3  a n d  3 6  
r e s p e c t i v e l y ) .  T R D V 1 - 3  a r e  m o s t  c o m m o n ,  w i t h  T R D V 3  r e v e r s e l y  l o c a t e d  i n  t h e  l o c u s .  A n  e n h a n c e r  i s  l o c a t e d  
i n  b e t w e e n  T R D J 4  a n d  T R D C .  T h e  l o c u s  i s  a p p r o x .  1 0 0 0  k b  i n  l e n g t h .  B l a c k  b o x e s  i n d i c a t e  r e g i o n s  o f  T R A V  a n d  
T R A J  g e n e s .  ( c )  T R G  g e n e  l o c u s  i s  l o c a t e d  o n  c h r o m o s o m e  7 p 1 4 .  T h e  l o c u s  i s  a p p r o x .  2 0 0  k b  i n  l e n g t h .  T h e  
V - g e n e s  a r e  d i v i d e d  i n t o  4  f a m i l i e s ,  w i t h  f a m i l i e s  1  a n d  2  c o n t a i n i n g  f u n c t i o n a l  g e n e s  ( g r e e n ) .  T R G V 1 ,  1 0  a n d  
1 1  ( y e l l o w )  a r e  o p e n  r e a d i n g  f r a m e s  ( O R F ) ,  T R G V 5 P,  6  a n d  7 ( r e d )  a r e  p s e u d o g e n e s .  A l l  J - g e n e s  a r e  f u n c t i o n a l  
g e n e s  ( d a r k  g r e e n ) .   
Chapter 1
24
PRECURSOR T CELL DEVELOPMENT AND TCR 
RECOMBINATION
TCR recombination
Both TCRαβ+ and TCRγδ+ T cells develop in the thymus, undergoing consecutive stages of development characterized by expression of different combinations of markers (reports reviewed by [21]). During the developmental stages, from double-negative (DN) for CD4 and CD8 stages 1-4, to immature single-positive (ISP, CD4 SP), to double-pos-itive (DP) and ultimately CD4 or CD8 single-positive (SP) they undergo several steps of maturation, involving TCR rearrangements and checkpoints, proliferation and selec-
tion. During stages DN3 – DN4 immature thymocytes undergo rearrangements of their Variable (V), Diversity (D) and Joining (J) genes (TRD, TRB), or only V and J genes (TRG, TRA), following the hierarchical order TRD > TRG > TRB > TRA [22,23] (Fig. 3). Since 
the TRD and TRA loci are intertwined, there will never be a (functional) TCRαδ receptor formed. V(D)J recombination is induced by the RAG1 and RAG2 proteins through the binding of these proteins to the recombination signal sequences (RSSs) [24].  The rep-ertoire diversity is increased dramatically by the terminal deoxynucleotidyl transferase (TdT) enzyme [25]. It adds random N nucleotides at the V-D, D-J and V-J junctional sites [26,27]. This could potentially lead to an increase of the total receptor diversities from 106 [28] up to over 1013 for both TCRαβ+ and TCRγδ+ T cell receptors [29]. Only one func-tionally recombined TRB allele will pair with a TRA allele, and only one TRD allele with one TRG allele will be expressed, a phenomenon also referred to as allelic exclusion [30]. 
TCRαβ development
During human TCRαβ+ T cell development the rearranged β-chain is checked for 
functionality with the pre-Tα chain (β-selection, from DN2-stage). Upon formation of a TCR that is expressed on the cell surface, developing thymocytes are positively selected 
for the functionality of the receptor. For TCRαβ+ T cells up-regulation of first CD4 (ISP) and then also CD8 (DP) is also part of the development. During positive selection of 
the functional TCR, TCRαβ+ T cells are still CD4 and CD8 double-positive, but already have committed machineries to one or the other cell type [22,23,31] (Fig. 3). Positive selection is mediated through cortical thymic epithelial cells (cTECs), which provide thymocytes with functional TCRs signals for further proliferation, differentiation and 
maturation [32]. After positive selection, TCRαβ+ T cells become either CD4 or CD8 sin-gle-positive, and negative selection occurs with the help of medullary thymic epithelial cells (mTECs), which express the transcription factor autoimmune regulator (AIRE), which, in turn, induces expression of self-antigens [33]. Upon recognition and strong 
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gle-positive, and negative selection occurs with the help of medullary thymic epithelial 
cells (mTECs), which express the transcription factor autoimmune regulator (AIRE), 
which, in turn, induces expression of self-antigens [33]. Upon recognition and strong 
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association with self-antigens, developing thymocytes will undergo apoptosis in order to maintain immune tolerance. After these processes, mature naive CD4 and CD8 sin-
gle-positive TCRαβ+ T cells move to the periphery [31]. 
TCRγδ development
In case of TCRγδ+ T cell development processes such as pre-TCR (tentatively pro- posed to be called “pre-Tγ”) signaling and positive and negative selection are not as evi-
dent as for TCRαβ+ T cell development. Commitment to either the TCRαβ+ or TCRγδ+ 
lineage appears to start early during development through Notch1 signaling: higher expression of Notch1 is in favor of TCRγδ+ T cell development (reviewed in [34]). Also, 
Figure 3. Thymic TCRαβ+ and TCRγδ+ development.
Summary of normal human precursor T cell development stages and T cell receptor (TCR) rearrangements. A CD34+ stem cell from the PB enters the thymus upon which the stem cell receives signals to commit to the T cell lineage.  Each developmental stage is characterized by different marker expression and TCR rearrangements 
that occur in the order TRD > TRG > TRB > TRA. The figure also includes incomplete rearrangements. Figure 
adapted from Staal et al. 2007.
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a s s o c i a t i o n  w i t h  s e l f - a n t i g e n s ,  d e v e l o p i n g  t h y m o c y t e s  w i l l  u n d e r g o  a p o p t o s i s  i n  o r d e r  
t o  m a i n t a i n  i m m u n e  t o l e r a n c e .  A f t e r  t h e s e  p r o c e s s e s ,  m a t u r e  n a i v e  C D 4  a n d  C D 8  s i n -
g l e - p o s i t i v e  T C R α β +  T  c e l l s  m o v e  t o  t h e  p e r i p h e r y  [ 3 1 ] .  
T C R γ δ  d e v e l o p m e n t
I n  c a s e  o f  T C R γ δ +  T  c e l l  d e v e l o p m e n t  p r o c e s s e s  s u c h  a s  p r e - T C R  ( t e n t a t i v e l y  p r o -
p o s e d  t o  b e  c a l l e d  “ p r e - T γ ” )  s i g n a l i n g  a n d  p o s i t i v e  a n d  n e g a t i v e  s e l e c t i o n  a r e  n o t  a s  e v i -
d e n t  a s  f o r  T C R α β +  T  c e l l  d e v e l o p m e n t .  C o m m i t m e n t  t o  e i t h e r  t h e  T C R α β +  o r  T C R γ δ +  
l i n e a g e  a p p e a r s  t o  s t a r t  e a r l y  d u r i n g  d e v e l o p m e n t  t h r o u g h  N o t c h 1  s i g n a l i n g :  h i g h e r  
e x p r e s s i o n  o f  N o t c h 1  i s  i n  f a v o r  o f  T C R γ δ +  T  c e l l  d e v e l o p m e n t  ( r e v i e w e d  i n  [ 3 4 ] ) .  A l s o ,  
F i g u r e  3 .  T h y m i c  T C R α β +  a n d  T C R γ δ +  d e v e l o p m e n t .
S u m m a r y  o f  n o r m a l  h u m a n  p r e c u r s o r  T  c e l l  d e v e l o p m e n t  s t a g e s  a n d  T  c e l l  r e c e p t o r  ( T C R )  r e a r r a n g e m e n t s .  A  
C D 3 4 +  s t e m  c e l l  f r o m  t h e  P B  e n t e r s  t h e  t h y m u s  u p o n  w h i c h  t h e  s t e m  c e l l  r e c e i v e s  s i g n a l s  t o  c o m m i t  t o  t h e  T  c e l l  
l i n e a g e .   E a c h  d e v e l o p m e n t a l  s t a g e  i s  c h a r a c t e r i z e d  b y  d i f f e r e n t  m a r k e r  e x p r e s s i o n  a n d  T C R  r e a r r a n g e m e n t s  
t h a t  o c c u r  i n  t h e  o r d e r  T R D  >  T R G  >  T R B  >  T R A .  T h e  f i g u r e  a l s o  i n c l u d e s  i n c o m p l e t e  r e a r r a n g e m e n t s .  F i g u r e  
a d a p t e d  f r o m  S t a a l  e t  a l .  2 0 0 7 .
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TCR signaling strength determines αβ or γδ lineage commitment: high TCR signaling 
favors γδ, weak signaling favors αβ lineage commitment [35-37]. However, signaling is 
not only ligand-dependent, as ligand-independent signaling is also important for TCRγδ 
development, given the lack of a pre-Tγ chain. In mice, efficient pairing of TRG and TRD 
chains above a certain threshold also determines TCRγδ+ T cell commitment fate [38]. 
TCRαβ+ and TCRγδ+ T cells follow rather different paths of development and matura-tion with respect to positive and negative selection. The only proposed type of selection 
or checkpoint during TCRγδ+ T cell development is the TCR dimerization of the δ-chain [39]. Furthermore, it has been found that thymic selection contributes little to nothing 
in constraining TCRγδ+ T cell antigenic specificity. In fact, TCRγδ+ T cells do not need 
to encounter (self-)ligands in the thymus in order to mature. Therefore, most TCRγδ+ T cells that are found in the periphery are still naive [40]. Also in mice, thymic development affects more the effector function. Lack of positive selection and TCR ligand encounter 
leads to a large fraction of antigen-naive TCRγδ+ T cells, with robust interleukin-17 
(IL-17) production. TCRγδ+ T cells that did have encountered TCR ligand in the thymic 
medulla rather produce interferon (IFN)-γ [41]. 
PERIPHERAL T CELL DEVELOPMENT
Peripheral TCRαβ+ T cells
Mature TCRαβ+ thymocytes leave the thymus to go to the periphery, into the cir-culation and/or secondary lymphoid organs. This process is regulated via the sphin-gosine-1-phosphate (S1P) signaling; mature thymocytes migrate to S1P due to their high S1P-receptor 1 (S1PR1) expression [42]. The S1P-S1PR1 axis in the periphery is also 
used for entering tissues [43]. In the periphery CD4+ and CD8+TCRαβ+ T cells respond 
to well-defined peptide antigens in the context of MHC-II and MHC-I molecules respec-tively, and typically need additional stimulation via co-stimulatory molecules and skew-ing via cytokines to become fully activated and functional [44]. After receiving these 
three activation signals the antigen-specific T cells start to proliferate, also called the 
clonal expansion phase. When the antigen is cleared, the T cells then undergo activa-
tion induced cell death (AICD) to restrict the inflammation, also called the contraction 
phase. A few antigen-specific T cells survive the contraction phase, and become long-lived memory T cells which either remain in the secondary lymphoid organs as central memory T cells, or they continue to circulate in the periphery as effector memory T cells. AICD occurs via the extrinsic apoptosis signaling pathway, which is Fas/FasL mediated [45,46]. The induction of the extrinsic apoptosis pathway could additionally further induce downstream the intrinsic pathway via up-regulation of Bim and down-regulation 
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of Bcl-2 [47,48], or via the activation of Bid through Caspase-8, which ultimately leads to mitochondrial outer membrane permeabilization, cytochrome-c release and formation 
of the apoptosome [49]. In case of CD8+ cytotoxic T lymphocytes (CTL) AICD can also be 
the result of auto- and paracrine killing through perforins and granzymes [50]. 
Peripheral TCRγδ+ T cells
As TCRγδ+ thymocytes do not undergo extensive positive and negative selection in 
the thymus, they egress faster from the thymus than their TCRαβ+ counterparts, and 
even without S1P/S1PR1 signaling [40]. Once in the periphery, TCRγδ+ T cells exert different unique functions and features 
when compared to TCRαβ+ T cells, which are more restricted when it comes to 
recognizing and responding to antigens [51]. As reviewed by Vantourout and Hayday in 2013 at least six unique features of TCRγδ+ T cells can be described, related to the type 
of antigens, antigenic recognition, antigenic responses, response kinetics, responses at anatomical sites and ontogeny [52]. TCRγδ+ T cells are non-MHC-restricted T cells, and 
therefore their (antigenic) specificity is rather unknown. Some molecules have been 
described as antigens, such as hydroxymethyl-but-2-enyl-pyrophosphate (HM-BPP), a non-mevalonate intermediate of the cholesterol synthesis pathway [53], isopentenyl 
pyrophosphate, a mevalonate intermediate of the canonical cholesterol synthesis pathway [54], other bisphosphonates such as aminobisphosphonates (nBPs) [55], 
or butyrophilins (BTNs) and other lipids that could be presented via CD1 molecules [56,57]. These antigens are often from specific pathogens, such as bacteria [58], but also 
eukaryotic organisms such as Plasmodium spp. [59] and mammals, or even cancer cells due to high cellular turnover [60-62]. 
The TCRγδ+ T cell response to the above mentioned antigens is in a CTL and NK cell 
like manner, with a fast cytokine release. Different cytokine-producing TCRγδ+ T cells 
have differential epigenetic and transcriptional signatures, although the cells show high plasticity when they encounter specific antigens [63]. The type of antigens encountered, 
but also the TCR signaling strength determines the cytokine production. High TCR sig- naling strength in TCRγδ+ T cells leads to IFN-γ producers, while weak or attenuated 
TCR signaling leads to IL-17 producing cells [64]. The ability to readily produce signifi- cant amounts of IL-17 during early infections in the acute response additionally forms a 
bridge to the adaptive immune response by recruiting CD4+TCRαβ+ T helper cells and 
B cells to the site of infection, and increases the crosstalk between these immune cells [40]. 
In order to respond, TCRγδ+ T cells do not necessarily require clonal expansion, 
and are therefore sometimes referred to as sensors of immune- or tissue dysregulation [52]. In case of such dysregulation, the so-called “epimmunome” can be observed: a 
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o f  B c l - 2  [ 4 7 , 4 8 ] ,  o r  v i a  t h e  a c t i v a t i o n  o f  B i d  t h r o u g h  C a s p a s e - 8 ,  w h i c h  u l t i m a t e l y  l e a d s  t o  
m i t o c h o n d r i a l  o u t e r  m e m b r a n e  p e r m e a b i l i z a t i o n ,  c y t o c h r o m e - c  r e l e a s e  a n d  f o r m a t i o n  
o f  t h e  a p o p t o s o m e  [ 4 9 ] .  I n  c a s e  o f  C D 8 +  c y t o t o x i c  T  l y m p h o c y t e s  ( C T L )  A I C D  c a n  a l s o  b e  
t h e  r e s u l t  o f  a u t o -  a n d  p a r a c r i n e  k i l l i n g  t h r o u g h  p e r f o r i n s  a n d  g r a n z y m e s  [ 5 0 ] .  
P e r i p h e r a l  T C R γ δ +  T  c e l l s
A s  T C R γ δ +  t h y m o c y t e s  d o  n o t  u n d e r g o  e x t e n s i v e  p o s i t i v e  a n d  n e g a t i v e  s e l e c t i o n  i n  
t h e  t h y m u s ,  t h e y  e g r e s s  f a s t e r  f r o m  t h e  t h y m u s  t h a n  t h e i r  T C R α β +  c o u n t e r p a r t s ,  a n d  
e v e n  w i t h o u t  S 1 P / S 1 P R 1  s i g n a l i n g  [ 4 0 ] .
O n c e  i n  t h e  p e r i p h e r y ,  T C R γ δ +  T  c e l l s  e x e r t  d i f f e r e n t  u n i q u e  f u n c t i o n s  a n d  f e a t u r e s  
w h e n  c o m p a r e d  t o  T C R α β +  T  c e l l s ,  w h i c h  a r e  m o r e  r e s t r i c t e d  w h e n  i t  c o m e s  t o  
r e c o g n i z i n g  a n d  r e s p o n d i n g  t o  a n t i g e n s  [ 5 1 ] .  A s  r e v i e w e d  b y  V a n t o u r o u t  a n d  H a y d a y  i n  
2 0 1 3  a t  l e a s t  s i x  u n i q u e  f e a t u r e s  o f  T C R γ δ +  T  c e l l s  c a n  b e  d e s c r i b e d ,  r e l a t e d  t o  t h e  t y p e  
o f  a n t i g e n s ,  a n t i g e n i c  r e c o g n i t i o n ,  a n t i g e n i c  r e s p o n s e s ,  r e s p o n s e  k i n e t i c s ,  r e s p o n s e s  a t  
a n a t o m i c a l  s i t e s  a n d  o n t o g e n y  [ 5 2 ] .  T C R γ δ +  T  c e l l s  a r e  n o n - M H C - r e s t r i c t e d  T  c e l l s ,  a n d  
t h e r e f o r e  t h e i r  ( a n t i g e n i c )  s p e c i f i c i t y  i s  r a t h e r  u n k n o w n .  S o m e  m o l e c u l e s  h a v e  b e e n  
d e s c r i b e d  a s  a n t i g e n s ,  s u c h  a s  h y d r o x y m e t h y l - b u t - 2 - e n y l - p y r o p h o s p h a t e  ( H M - B P P ) ,  a  
n o n - m e v a l o n a t e  i n t e r m e d i a t e  o f  t h e  c h o l e s t e r o l  s y n t h e s i s  p a t h w a y  [ 5 3 ] ,  i s o p e n t e n y l  
p y r o p h o s p h a t e ,  a  m e v a l o n a t e  i n t e r m e d i a t e  o f  t h e  c a n o n i c a l  c h o l e s t e r o l  s y n t h e s i s  
p a t h w a y  [ 5 4 ] ,  o t h e r  b i s p h o s p h o n a t e s  s u c h  a s  a m i n o b i s p h o s p h o n a t e s  ( n B P s )  [ 5 5 ] ,  
o r  b u t y r o p h i l i n s  ( B T N s )  a n d  o t h e r  l i p i d s  t h a t  c o u l d  b e  p r e s e n t e d  v i a  C D 1  m o l e c u l e s  
[ 5 6 , 5 7 ] .  T h e s e  a n t i g e n s  a r e  o f t e n  f r o m  s p e c i f i c  p a t h o g e n s ,  s u c h  a s  b a c t e r i a  [ 5 8 ] ,  b u t  a l s o  
e u k a r y o t i c  o r g a n i s m s  s u c h  a s  P l a s m o d i u m  s p p .  [ 5 9 ]  a n d  m a m m a l s ,  o r  e v e n  c a n c e r  c e l l s  
d u e  t o  h i g h  c e l l u l a r  t u r n o v e r  [ 6 0 - 6 2 ] .  
T h e  T C R γ δ +  T  c e l l  r e s p o n s e  t o  t h e  a b o v e  m e n t i o n e d  a n t i g e n s  i s  i n  a  C T L  a n d  N K  c e l l  
l i k e  m a n n e r ,  w i t h  a  f a s t  c y t o k i n e  r e l e a s e .  D i f f e r e n t  c y t o k i n e - p r o d u c i n g  T C R γ δ +  T  c e l l s  
h a v e  d i f f e r e n t i a l  e p i g e n e t i c  a n d  t r a n s c r i p t i o n a l  s i g n a t u r e s ,  a l t h o u g h  t h e  c e l l s  s h o w  h i g h  
p l a s t i c i t y  w h e n  t h e y  e n c o u n t e r  s p e c i f i c  a n t i g e n s  [ 6 3 ] .  T h e  t y p e  o f  a n t i g e n s  e n c o u n t e r e d ,  
b u t  a l s o  t h e  T C R  s i g n a l i n g  s t r e n g t h  d e t e r m i n e s  t h e  c y t o k i n e  p r o d u c t i o n .  H i g h  T C R  s i g -
n a l i n g  s t r e n g t h  i n  T C R γ δ +  T  c e l l s  l e a d s  t o  I F N - γ  p r o d u c e r s ,  w h i l e  w e a k  o r  a t t e n u a t e d  
T C R  s i g n a l i n g  l e a d s  t o  I L - 1 7  p r o d u c i n g  c e l l s  [ 6 4 ] .  T h e  a b i l i t y  t o  r e a d i l y  p r o d u c e  s i g n i f i -
c a n t  a m o u n t s  o f  I L - 1 7  d u r i n g  e a r l y  i n f e c t i o n s  i n  t h e  a c u t e  r e s p o n s e  a d d i t i o n a l l y  f o r m s  a  
b r i d g e  t o  t h e  a d a p t i v e  i m m u n e  r e s p o n s e  b y  r e c r u i t i n g  C D 4 + T C R α β +  T  h e l p e r  c e l l s  a n d  
B  c e l l s  t o  t h e  s i t e  o f  i n f e c t i o n ,  a n d  i n c r e a s e s  t h e  c r o s s t a l k  b e t w e e n  t h e s e  i m m u n e  c e l l s  
[ 4 0 ] .  
I n  o r d e r  t o  r e s p o n d ,  T C R γ δ +  T  c e l l s  d o  n o t  n e c e s s a r i l y  r e q u i r e  c l o n a l  e x p a n s i o n ,  
a n d  a r e  t h e r e f o r e  s o m e t i m e s  r e f e r r e d  t o  a s  s e n s o r s  o f  i m m u n e -  o r  t i s s u e  d y s r e g u l a t i o n  
[ 5 2 ] .  I n  c a s e  o f  s u c h  d y s r e g u l a t i o n ,  t h e  s o - c a l l e d  “ e p i m m u n o m e ”  c a n  b e  o b s e r v e d :  a  
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combination of cell surface molecules that are up-regulated in response to dysregulation 
[65]. Upon activation TCRγδ+ T cells have a broad spectrum of cytokines which they can produce, also in order to communicate with other immune or neighboring cells, to form a bridge between the innate, afferent phase, and the adaptive, efferent phase of 
the immune response. The type of response that TCRγδ+ T cells can exert also largely depends on the anatomical site and the type of tissue in which they are located. Both the recognition of antigens, the response to antigen and the anatomical location largely 
depends on the type of receptor the TCRγδ+ T cell is expressing. In mice, the occupation 
of different tissues is described to occur in consecutive waves [66]: Vγ5+ cells home to 
the skin as dendritic epidermal T cells (DETC), Vγ6+ colonize the uterus, tongue, lungs 
and peritoneum [67], Vγ4+ colonize the peritoneum, and Vγ7+ cells develop extrathymi-cally, based on epithelial support from the gut [68]. These cells (except the DETCs) are IL-17 producers. 
In human TCRγδ+ T cell development no Vγ-waves have been described; in contrast, 
in humans TCRγδ+ T cell definition is based on Vδ-usage [69]. TCRγδ+ T cells migrate mostly to epithelial tissues such as the gut, skin, urogenital tract and respiratory tract 
(Fig. 4). These TCRγδ+ T cells are largely Vδ1+ IL-17-producing cells in humans. A large 
fraction remains in the circulation, forming the common Vγ9/Vδ2 IFN-γ-producing 
population [37,70]. TCRγδ+ T cells expressing Vδ-genes 3-6 are extremely rare, espe-
cially in the circulation, although Vδ3+ cells can be found in the gut and synovial tissue 
[71-73], or clonally expanded in the peripheral blood (PB) in the context of a CD4+ T 
cell deficiency [74]. Vδ1+ cells can also be found in high titers in the human fetal and neonatal cord blood (CB), which readily produce IL-17 in order to provide protection for 
the neonate [75]. This protection by Vδ1+ cells in neonates is also reflected in the higher 
numbers of PB Vδ1+ cells compared to Vγ9/Vδ2 cells [76] (Fig. 4). TCRγδ+ T cells, espe-
cially Vγ9/Vδ2 cells, are highly plastic and heterogeneous, not only in case of infections or tumors, but also in homeostasis in healthy individuals. In humans, approximately six 
Vδ2 profiles could be defined based on expression of CD27, CD28 and CD16, alongside 
chemokine receptors and perforins and granzymes [77]. Among these profiles different 
relative distributions of four Vδ2+ subsets were identified: CD28+CD27+CD16- (γδ28+), 
CD28-CD27+CD16- (γδ28-) highly proliferative cells, and CD28-CD27-CD16- (γδ16-) 
and CD28-CD27-CD16+ (γδ16+) cells with co-expression of CD56, CD57, Perforins, Granzyme B, indicative of active large granular lymphocyte (LGL) functions of these cells.
Large granular lymphocytes
Upon (antigenic) stimulation CD8+TCRαβ+ CTL and TCRγδ+ T cells become acti-
vated, as well as a very small fraction of CD4+TCRαβ+ T-LGL cells [78]. This leads to the increased cellular activity of the cells and the increased production of granules to induce 
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Figure 4. Anatomical distribution of TCRγδ+ T cells.
TCRγδ+ T cells are most abundant in epithelial tissues as intraepithelial lymphocytes. These epithelial tissues 
include the respiratory, gastrointestinal and urogenital tracts, but also the skin. TCRγδ+ T cells occupying 
the epithelial tissues mainly contain the Vδ1-chain. Vδ3 cells can also be found in the gut and synovial tissue. 
On the contrary, circulating peripheral blood TCRγδ+ T cells mostly possess Vγ9/Vδ2 receptors, based on a 
different antigenic exposure, albeit that Vδ1 and Vδ3 cells can be found in the circulation as well.
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F i g u r e  4 .  A n a t o m i c a l  d i s t r i b u t i o n  o f  T C R γ δ +  T  c e l l s .
T C R γ δ +  T  c e l l s  a r e  m o s t  a b u n d a n t  i n  e p i t h e l i a l  t i s s u e s  a s  i n t r a e p i t h e l i a l  l y m p h o c y t e s .  T h e s e  e p i t h e l i a l  t i s s u e s  
i n c l u d e  t h e  r e s p i r a t o r y ,  g a s t r o i n t e s t i n a l  a n d  u r o g e n i t a l  t r a c t s ,  b u t  a l s o  t h e  s k i n .  T C R γ δ +  T  c e l l s  o c c u p y i n g  
t h e  e p i t h e l i a l  t i s s u e s  m a i n l y  c o n t a i n  t h e  V δ 1 - c h a i n .  V δ 3  c e l l s  c a n  a l s o  b e  f o u n d  i n  t h e  g u t  a n d  s y n o v i a l  t i s s u e .  
O n  t h e  c o n t r a r y ,  c i r c u l a t i n g  p e r i p h e r a l  b l o o d  T C R γ δ +  T  c e l l s  m o s t l y  p o s s e s s  V γ 9 / V δ 2  r e c e p t o r s ,  b a s e d  o n  a  
d i f f e r e n t  a n t i g e n i c  e x p o s u r e ,  a l b e i t  t h a t  V δ 1  a n d  V δ 3  c e l l s  c a n  b e  f o u n d  i n  t h e  c i r c u l a t i o n  a s  w e l l .
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killing of target cells that are infected with specific pathogens, or cells that are malig-nantly transformed. The T cells then become LGLs, with a characteristic morphology of eccentric nuclei and an abundance of cytotoxic azurophilic granules in their cytoplasm [79,80] (Fig. 5). LGLs comprise 10-15% of total T cells in the healthy PB [81], and are 
mainly present during infection or inflammation in order to clear the pathogen or anti-gen. Thus they can form small clonal expansions, even in healthy individuals [82]. These clonal expansions have also been shown to be age-related [83].
ANTIGENIC STIMULATION AND SHAPING OF THE TCR 
REPERTOIRE
Antigenic selection
Upon antigenic exposure the T cell repertoire is shaped, mirroring and reflecting processes such as infections, autoimmunity, cancer and ageing. In order to study the immune repertoire traditionally the spectratyping technique has been used [84,85]. 
Due to recent advances in the field of next-generation sequencing technologies deeper analysis of the repertoire of T cells can be performed. For example, Robins et al. applied in 2009 Genomic Analyzer technology on the TRB locus to study the diversity of the 
complementarity determining region-3 (CDR3) sequence – the antigen-binding part of 
Figure 5. Cytological smears of TCRγδ+ T cell large granular lymphocytes.(a) Normal CD3+ TCRγδ+ T-LGLs sorted from a healthy individual. Magnifications 63x. (b) TCRγδ+ T-LGL 
leukemia cells in the PB of a patient with TCRγδ+ T-LGL leukemia. Cellular cytoplasm is typically enlarged showing eccentric nucleus and azurophilic granules. Pictures adapted from Sandberg et al. 2006.
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Upon antigenic exposure the T cell repertoire is shaped, mirroring and reflecting 
processes such as infections, autoimmunity, cancer and ageing. In order to study the 
immune repertoire traditionally the spectratyping technique has been used [84,85]. 
Due to recent advances in the field of next-generation sequencing technologies deeper 
analysis of the repertoire of T cells can be performed. For example, Robins et al. applied 
in 2009 Genomic Analyzer technology on the TRB locus to study the diversity of the 
complementarity determining region-3 (CDR3) sequence – the antigen-binding part of 
Figure 5. Cytological smears of TCRγδ+ T cell large granular lymphocytes.
(a) Normal CD3+ TCRγδ+ T-LGLs sorted from a healthy individual. Magnifications 63x. (b) TCRγδ+ T-LGL 
leukemia cells in the PB of a patient with TCRγδ+ T-LGL leukemia. Cellular cytoplasm is typically enlarged 
showing eccentric nucleus and azurophilic granules. Pictures adapted from Sandberg et al. 2006.
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the immune receptor – between effector and memory CD4+ and CD8+ compartments 
[85]. Also in 2009, Freeman et al. were one of the first to apply deep sequencing on the investigation of the TRB repertoire diversity. In this study, the authors were able 
to identify 10-fold more distinct CDR3-β sequences than initially known, showing the 
promising capabilities of novel advances in DNA sequencing [86]. More recently, Yoshida et al. attempted to sequence the peripheral T cell receptors of the TRB locus in ageing 
individuals, and found that the TCR diversity of CD8+TCRαβ+ T cells decreased with 
0.99% per year, and that many (harmless) clones persisted and were able to expand over 20 years, indicating the presence of antigenic selection [87].
The effect of antigenic selection is even more evident in the TCRγδ+ T cell compart- ment. This effect is visible in already an early stage during development. In the fetus the 
epithelial tissues and blood are predominantly populated by the naive IL-17-producing Vδ1+ cells. Readily after birth a switch occurs in the predominant TCRγδ+ T cell popu-
lation from Vδ1+ to Vγ9/Vδ2, indicating antigenic selection upon antigenic exposure 
during and after birth [72]. So far, the human TRG/TRD repertoire has hardly been studied. Many different 
methodologies are available for sequencing immune receptor repertoires, starting from the material, to the amplification, to the data analysis, meaning there is no golden 
standard available yet (reviewed in [88]). Recently, Chen et al. attempted to sequence the CDR3-region of the γδ-receptor by applying IR-SEQ technology on total peripheral 
blood mononuclear cells (PBMCs) [89]. The disadvantage of this study was the use of total PBMCs or whole blood, while it has been known that also TCRγδ+ T cells exist 
in different subsets, based on the Vδ-receptor usage and antigen-specificity, but also 
on maturation levels. Therefore many different receptor specificities and subsets 
differences could remain unidentified.
Ageing of T cells
The effect of antigenic selection is thought to be extended throughout a life time, since also the immune system is heavily subjected to ageing, often referred to as immu-
nological ageing or immunosenescence. Cellular ageing as a process is defined as a result 
of damage inflicted by reactive oxygen species (ROS) during e.g. oxidative stress in mito- chondria [90]. Damage induced by ROS could lead to genomic instability and without 
proper DNA proofreading machinery this could contribute to carcinogenesis [91-93]. Since the immune system has a high turnover of cells, which also includes the self-re-
newal and maintenance of long-lived memory cells, the effects of ageing are obvious at the level of both innate and adaptive immunity. Most striking events are a reduced 
dendritic cell (DC) activation, impaired humoral responses [94,95] and for T cells most importantly thymic involution, as already described during the early discoveries of the 
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t h e  i m m u n e  r e c e p t o r  –  b e t w e e n  e f f e c t o r  a n d  m e m o r y  C D 4 +  a n d  C D 8 +  c o m p a r t m e n t s  
[ 8 5 ] .  A l s o  i n  2 0 0 9 ,  F r e e m a n  e t  a l .  w e r e  o n e  o f  t h e  f i r s t  t o  a p p l y  d e e p  s e q u e n c i n g  o n  
t h e  i n v e s t i g a t i o n  o f  t h e  T R B  r e p e r t o i r e  d i v e r s i t y .  I n  t h i s  s t u d y ,  t h e  a u t h o r s  w e r e  a b l e  
t o  i d e n t i f y  1 0 - f o l d  m o r e  d i s t i n c t  C D R 3 - β  s e q u e n c e s  t h a n  i n i t i a l l y  k n o w n ,  s h o w i n g  t h e  
p r o m i s i n g  c a p a b i l i t i e s  o f  n o v e l  a d v a n c e s  i n  D N A  s e q u e n c i n g  [ 8 6 ] .  M o r e  r e c e n t l y ,  Y o s h i d a  
e t  a l .  a t t e m p t e d  t o  s e q u e n c e  t h e  p e r i p h e r a l  T  c e l l  r e c e p t o r s  o f  t h e  T R B  l o c u s  i n  a g e i n g  
i n d i v i d u a l s ,  a n d  f o u n d  t h a t  t h e  T C R  d i v e r s i t y  o f  C D 8 + T C R α β +  T  c e l l s  d e c r e a s e d  w i t h  
0 . 9 9 %  p e r  y e a r ,  a n d  t h a t  m a n y  ( h a r m l e s s )  c l o n e s  p e r s i s t e d  a n d  w e r e  a b l e  t o  e x p a n d  o v e r  
2 0  y e a r s ,  i n d i c a t i n g  t h e  p r e s e n c e  o f  a n t i g e n i c  s e l e c t i o n  [ 8 7 ] .
T h e  e f f e c t  o f  a n t i g e n i c  s e l e c t i o n  i s  e v e n  m o r e  e v i d e n t  i n  t h e  T C R γ δ +  T  c e l l  c o m p a r t -
m e n t .  T h i s  e f f e c t  i s  v i s i b l e  i n  a l r e a d y  a n  e a r l y  s t a g e  d u r i n g  d e v e l o p m e n t .  I n  t h e  f e t u s  t h e  
e p i t h e l i a l  t i s s u e s  a n d  b l o o d  a r e  p r e d o m i n a n t l y  p o p u l a t e d  b y  t h e  n a i v e  I L - 1 7 - p r o d u c i n g  
V δ 1 +  c e l l s .  R e a d i l y  a f t e r  b i r t h  a  s w i t c h  o c c u r s  i n  t h e  p r e d o m i n a n t  T C R γ δ +  T  c e l l  p o p u -
l a t i o n  f r o m  V δ 1 +  t o  V γ 9 / V δ 2 ,  i n d i c a t i n g  a n t i g e n i c  s e l e c t i o n  u p o n  a n t i g e n i c  e x p o s u r e  
d u r i n g  a n d  a f t e r  b i r t h  [ 7 2 ] .
S o  f a r ,  t h e  h u m a n  T R G / T R D  r e p e r t o i r e  h a s  h a r d l y  b e e n  s t u d i e d .  M a n y  d i f f e r e n t  
m e t h o d o l o g i e s  a r e  a v a i l a b l e  f o r  s e q u e n c i n g  i m m u n e  r e c e p t o r  r e p e r t o i r e s ,  s t a r t i n g  
f r o m  t h e  m a t e r i a l ,  t o  t h e  a m p l i f i c a t i o n ,  t o  t h e  d a t a  a n a l y s i s ,  m e a n i n g  t h e r e  i s  n o  g o l d e n  
s t a n d a r d  a v a i l a b l e  y e t  ( r e v i e w e d  i n  [ 8 8 ] ) .  R e c e n t l y ,  C h e n  e t  a l .  a t t e m p t e d  t o  s e q u e n c e  
t h e  C D R 3 - r e g i o n  o f  t h e  γ δ - r e c e p t o r  b y  a p p l y i n g  I R - S E Q  t e c h n o l o g y  o n  t o t a l  p e r i p h e r a l  
b l o o d  m o n o n u c l e a r  c e l l s  ( P B M C s )  [ 8 9 ] .  T h e  d i s a d v a n t a g e  o f  t h i s  s t u d y  w a s  t h e  u s e  o f  
t o t a l  P B M C s  o r  w h o l e  b l o o d ,  w h i l e  i t  h a s  b e e n  k n o w n  t h a t  a l s o  T C R γ δ +  T  c e l l s  e x i s t  
i n  d i f f e r e n t  s u b s e t s ,  b a s e d  o n  t h e  V δ - r e c e p t o r  u s a g e  a n d  a n t i g e n - s p e c i f i c i t y ,  b u t  a l s o  
o n  m a t u r a t i o n  l e v e l s .  T h e r e f o r e  m a n y  d i f f e r e n t  r e c e p t o r  s p e c i f i c i t i e s  a n d  s u b s e t s  
d i f f e r e n c e s  c o u l d  r e m a i n  u n i d e n t i f i e d .
A g e i n g  o f  T  c e l l s
T h e  e f f e c t  o f  a n t i g e n i c  s e l e c t i o n  i s  t h o u g h t  t o  b e  e x t e n d e d  t h r o u g h o u t  a  l i f e  t i m e ,  
s i n c e  a l s o  t h e  i m m u n e  s y s t e m  i s  h e a v i l y  s u b j e c t e d  t o  a g e i n g ,  o f t e n  r e f e r r e d  t o  a s  i m m u -
n o l o g i c a l  a g e i n g  o r  i m m u n o s e n e s c e n c e .  C e l l u l a r  a g e i n g  a s  a  p r o c e s s  i s  d e f i n e d  a s  a  r e s u l t  
o f  d a m a g e  i n f l i c t e d  b y  r e a c t i v e  o x y g e n  s p e c i e s  ( R O S )  d u r i n g  e . g .  o x i d a t i v e  s t r e s s  i n  m i t o -
c h o n d r i a  [ 9 0 ] .  D a m a g e  i n d u c e d  b y  R O S  c o u l d  l e a d  t o  g e n o m i c  i n s t a b i l i t y  a n d  w i t h o u t  
p r o p e r  D N A  p r o o f r e a d i n g  m a c h i n e r y  t h i s  c o u l d  c o n t r i b u t e  t o  c a r c i n o g e n e s i s  [ 9 1 - 9 3 ] .  
S i n c e  t h e  i m m u n e  s y s t e m  h a s  a  h i g h  t u r n o v e r  o f  c e l l s ,  w h i c h  a l s o  i n c l u d e s  t h e  s e l f - r e -
n e w a l  a n d  m a i n t e n a n c e  o f  l o n g - l i v e d  m e m o r y  c e l l s ,  t h e  e f f e c t s  o f  a g e i n g  a r e  o b v i o u s  
a t  t h e  l e v e l  o f  b o t h  i n n a t e  a n d  a d a p t i v e  i m m u n i t y .  M o s t  s t r i k i n g  e v e n t s  a r e  a  r e d u c e d  
d e n d r i t i c  c e l l  ( D C )  a c t i v a t i o n ,  i m p a i r e d  h u m o r a l  r e s p o n s e s  [ 9 4 , 9 5 ]  a n d  f o r  T  c e l l s  m o s t  
i m p o r t a n t l y  t h y m i c  i n v o l u t i o n ,  a s  a l r e a d y  d e s c r i b e d  d u r i n g  t h e  e a r l y  d i s c o v e r i e s  o f  t h e  
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thymus by Galen [96] (Fig. 6a). Possible explanations for thymic involution could be the (side) effects of circulating (sex) hormones and cytokines, the loss of thymic architec-ture [97], and the reduced quantity and quality of bone marrow T cell precursors [98]. Eventually, thymic involution is believed to lead to a steady decline in the production of 
Figure 6. Effects of ageing on the immune system.(a) Thymic involution results in a decreased number of recent thymic emigrants (RTE) and thus a smaller naive T cell pool, compensated by an increased memory T cell pool. (b) T cell ageing is characterized by either 
senescence, characterized by a specific membrane marker profile, or exhaustion, with a different profile. Up-regulated markers are indicated in color, down-regulated markers are grey. (c) Functional changes and characteristics upon senescence or exhaustion. Senescent cells maintain their polyfunctional and cytotoxic potential, exhausted cells lose proliferative and cytotoxic abilities and undergo apoptosis. Figure adapted from Nikolich-Zugich 2008 and reviewed reports in Wherry 2011.
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General Introduction 
naive, undifferentiated T cells and thus to limited TCR repertoire [99]. Most T cells even- tually become memory T cells, which are, due to their long-living character, subjected to 
ageing processes such as clonal expansion, but also senescence and/or exhaustion (Fig. 6a). 
Senescence and exhaustion of T cells
Immunological ageing goes in parallel with the phenomenon of senescence and exhaustion. Senescence is marked by increased DNA damage, short telomeres, loss of 
proliferative capacity and low telomerase enzyme activity, but maintaining the ability to perform (polyfunctional) effector functions [100,101]. Exhaustion is mainly induced 
by persistent viral infections, primarily affects CD8+TCRαβ+ cytotoxic T lymphocytes 
(CTL), and is characterized by the gradual loss of effector functions and proliferative potential, and the gradual increase of the expression of inhibitory molecules (reviewed 
in [102]) (Fig. 6b, 6c).  The final stage of exhaustion is the induction of apoptosis, either 
spontaneously or via Fas-signaling. Upon chronic stimulation, CD8+TCRαβ+ CTLs shift 
towards more late-stage differentiated effector phenotypes [103]; an effect that is also observed in TCRγδ+ T cells [104]. However, recently it has been shown that even though 
similar effects of senescence and exhaustion can be observed between functionally simi- lar CD8+TCRαβ+ and TCRγδ+ T cells [105], Vδ2+ cells do follow different paths of ageing 
when compared to the TCRαβ+ T cell compartment in terms of differentiation status and 
cytokine production [106].  TCRγδ+ T cell exhaustion is observed and described more in 
the context of chronic infections, such as M. tuberculosis infection, where the exhaustion is regulated by cytokines, rather than continuous antigenic stimulation with for instance 
HM-BPP. More downstream mechanisms, such as reduced phosphorylated STAT3, are indicative of TCRγδ+ T cell exhaustion [107]. However, contradicting results were found 
in a study into the Vδ2-deficiency in granulomatosis polyangiitis (GPA, formerly known 
as Wegener’s granulomatosis). A selective depletion of Vδ2 cells was observed, possibly 
due to prolonged exposure to one of the etiologic agents of GPA: S. aureus. The microbial products of S. aureus could be a chronic stimulus for Vγ9/Vδ2 cells, inducing cellular 
exhaustion [108]. Exhaustion in TCRγδ+ T cells has not been fully defined yet.
CHRONIC T CELL LARGE GRANULAR LYMPHOCYTE 
LEUKEMIA
Both cellular ageing and persistent, chronic or continuous (antigenic) stimulation do not only affect the exhaustion of T cells, but also impact on immunopathology of 
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G e n e r a l  I n t r o d u c t i o n  
n a i v e ,  u n d i f f e r e n t i a t e d  T  c e l l s  a n d  t h u s  t o  l i m i t e d  T C R  r e p e r t o i r e  [ 9 9 ] .  M o s t  T  c e l l s  e v e n -
t u a l l y  b e c o m e  m e m o r y  T  c e l l s ,  w h i c h  a r e ,  d u e  t o  t h e i r  l o n g - l i v i n g  c h a r a c t e r ,  s u b j e c t e d  t o  
a g e i n g  p r o c e s s e s  s u c h  a s  c l o n a l  e x p a n s i o n ,  b u t  a l s o  s e n e s c e n c e  a n d / o r  e x h a u s t i o n  ( F i g .  
6 a ) .  
S e n e s c e n c e  a n d  e x h a u s t i o n  o f  T  c e l l s
I m m u n o l o g i c a l  a g e i n g  g o e s  i n  p a r a l l e l  w i t h  t h e  p h e n o m e n o n  o f  s e n e s c e n c e  a n d  
e x h a u s t i o n .  S e n e s c e n c e  i s  m a r k e d  b y  i n c r e a s e d  D N A  d a m a g e ,  s h o r t  t e l o m e r e s ,  l o s s  o f  
p r o l i f e r a t i v e  c a p a c i t y  a n d  l o w  t e l o m e r a s e  e n z y m e  a c t i v i t y ,  b u t  m a i n t a i n i n g  t h e  a b i l i t y  
t o  p e r f o r m  ( p o l y f u n c t i o n a l )  e f f e c t o r  f u n c t i o n s  [ 1 0 0 , 1 0 1 ] .  E x h a u s t i o n  i s  m a i n l y  i n d u c e d  
b y  p e r s i s t e n t  v i r a l  i n f e c t i o n s ,  p r i m a r i l y  a f f e c t s  C D 8 + T C R α β +  c y t o t o x i c  T  l y m p h o c y t e s  
( C T L ) ,  a n d  i s  c h a r a c t e r i z e d  b y  t h e  g r a d u a l  l o s s  o f  e f f e c t o r  f u n c t i o n s  a n d  p r o l i f e r a t i v e  
p o t e n t i a l ,  a n d  t h e  g r a d u a l  i n c r e a s e  o f  t h e  e x p r e s s i o n  o f  i n h i b i t o r y  m o l e c u l e s  ( r e v i e w e d  
i n  [ 1 0 2 ] )  ( F i g .  6 b ,  6 c ) .   T h e  f i n a l  s t a g e  o f  e x h a u s t i o n  i s  t h e  i n d u c t i o n  o f  a p o p t o s i s ,  e i t h e r  
s p o n t a n e o u s l y  o r  v i a  F a s - s i g n a l i n g .  U p o n  c h r o n i c  s t i m u l a t i o n ,  C D 8 + T C R α β +  C T L s  s h i f t  
t o w a r d s  m o r e  l a t e - s t a g e  d i f f e r e n t i a t e d  e f f e c t o r  p h e n o t y p e s  [ 1 0 3 ] ;  a n  e f f e c t  t h a t  i s  a l s o  
o b s e r v e d  i n  T C R γ δ +  T  c e l l s  [ 1 0 4 ] .  H o w e v e r ,  r e c e n t l y  i t  h a s  b e e n  s h o w n  t h a t  e v e n  t h o u g h  
s i m i l a r  e f f e c t s  o f  s e n e s c e n c e  a n d  e x h a u s t i o n  c a n  b e  o b s e r v e d  b e t w e e n  f u n c t i o n a l l y  s i m i -
l a r  C D 8 + T C R α β +  a n d  T C R γ δ +  T  c e l l s  [ 1 0 5 ] ,  V δ 2 +  c e l l s  d o  f o l l o w  d i f f e r e n t  p a t h s  o f  a g e i n g  
w h e n  c o m p a r e d  t o  t h e  T C R α β +  T  c e l l  c o m p a r t m e n t  i n  t e r m s  o f  d i f f e r e n t i a t i o n  s t a t u s  a n d  
c y t o k i n e  p r o d u c t i o n  [ 1 0 6 ] .   T C R γ δ +  T  c e l l  e x h a u s t i o n  i s  o b s e r v e d  a n d  d e s c r i b e d  m o r e  i n  
t h e  c o n t e x t  o f  c h r o n i c  i n f e c t i o n s ,  s u c h  a s  M .  t u b e r c u l o s i s  i n f e c t i o n ,  w h e r e  t h e  e x h a u s t i o n  
i s  r e g u l a t e d  b y  c y t o k i n e s ,  r a t h e r  t h a n  c o n t i n u o u s  a n t i g e n i c  s t i m u l a t i o n  w i t h  f o r  i n s t a n c e  
H M - B P P.  M o r e  d o w n s t r e a m  m e c h a n i s m s ,  s u c h  a s  r e d u c e d  p h o s p h o r y l a t e d  S T A T 3 ,  a r e  
i n d i c a t i v e  o f  T C R γ δ +  T  c e l l  e x h a u s t i o n  [ 1 0 7 ] .  H o w e v e r ,  c o n t r a d i c t i n g  r e s u l t s  w e r e  f o u n d  
i n  a  s t u d y  i n t o  t h e  V δ 2 - d e f i c i e n c y  i n  g r a n u l o m a t o s i s  p o l y a n g i i t i s  ( G P A ,  f o r m e r l y  k n o w n  
a s  W e g e n e r ’ s  g r a n u l o m a t o s i s ) .  A  s e l e c t i v e  d e p l e t i o n  o f  V δ 2  c e l l s  w a s  o b s e r v e d ,  p o s s i b l y  
d u e  t o  p r o l o n g e d  e x p o s u r e  t o  o n e  o f  t h e  e t i o l o g i c  a g e n t s  o f  G P A :  S .  a u r e u s .  T h e  m i c r o b i a l  
p r o d u c t s  o f  S .  a u r e u s  c o u l d  b e  a  c h r o n i c  s t i m u l u s  f o r  V γ 9 / V δ 2  c e l l s ,  i n d u c i n g  c e l l u l a r  
e x h a u s t i o n  [ 1 0 8 ] .  E x h a u s t i o n  i n  T C R γ δ +  T  c e l l s  h a s  n o t  b e e n  f u l l y  d e f i n e d  y e t .
C H R O N I C  T  C E L L  L A R G E  G R A N U L A R  L Y M P H O C Y T E  
L E U K E M I A
B o t h  c e l l u l a r  a g e i n g  a n d  p e r s i s t e n t ,  c h r o n i c  o r  c o n t i n u o u s  ( a n t i g e n i c )  s t i m u l a t i o n  
d o  n o t  o n l y  a f f e c t  t h e  e x h a u s t i o n  o f  T  c e l l s ,  b u t  a l s o  i m p a c t  o n  i m m u n o p a t h o l o g y  o f  
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especially lymphoproliferations and ultimately leukemias. Under normal circumstances, 
CD8+TCRαβ+ and TCRγδ+ T cells become activated upon a stimulus (antigen, cellular damage), undergo proliferation (the expansion phase), and produce granzymes and perforin for killing of target cells. After clearing the antigen, functional memory T cells are formed; the other activated T cells undergo AICD in order to keep the immune response under control. Normally, in case of a continuous, chronic (antigenic) stimu-
lation T cells can undergo the process of exhaustion, the state of functional “anergy” [102], with apoptosis as end-stage. However, in rare situations T cells persist, do not become exhausted, and do not undergo apoptosis; instead they remain actively present, chronically activated and proliferating. This could lead to a proliferation, which even-
tually could develop into leukemia. In 1985 LGL leukemia was described for the first time, in combination with chromosomal abnormalities, mainly trisomy 8 and 14, and cytopenias such as neutropenia, thrombocytopenia and anemia [109]. The disease was divided into two groups based on either T or NK cell origins [81]. Recently, the World 
Health Organization (WHO) revised their classification on lymphoid neoplasms, defin-ing T-LGL leukemia, aggressive NK cell leukemia and chronic lymphoproliferative disor-der of NK cells [110,111]. Since it results from chronic stimulation, the disease course often follows an indolent and chronic course. These LGL proliferations can be seen as a spectrum, ranging from normal activated and expanded T-LGL cells, to a T cell clonopa-
thy of undetermined significance (TCUS), ultimately ending in a large monoclonal com-ponent, also referred to as leukemia [112,113] (Fig. 7). The clinical spectrum is highly heterogeneous in terms of severity and aggression [112]. LGL patients often present with symptoms that are commonly observed among chronic leukemia patients, such as cytopenias, recurrent infections and B symptoms, although a considerable fraction of LGL patients remains asymptomatic. The aggressiveness of the disease was later also associated with the origin of the leukemia: the T-LGL leukemias are mainly indolent, 
but the NK-LGL origin reflects more malignantly aggressive disease [80,110,111]. T-LGL 
leukemia is typically presented by a persistent (>6 months) large monoclonal CD3+/
CD57+ population of >2x109/L LGL cells in the PB (Fig. 7) [114]. T-LGL can be divided 
based on immunophenotype in three separate entities: CD4+TCRαβ+, CD8+TCRαβ+ and 
TCRγδ+ (Table 1). In case of CD8+TCRαβ+ and TCRγδ+ T-LGL leukemias the disease is often associated with underlying autoimmune diseases, especially rheumatoid arthritis 
(RA)[115] and malignancies [116]; CD4+TCRαβ+ T cells from a separate group, which also showed a distinctive antigen involved: CMV [78]. However, levels of cytopenias, clinical symptoms and therapies are highly heterogeneous [115]. The etiology of both 
CD8+TCRαβ+ and TCRγδ+ T-LGL leukemias remain largely unknown, although several underlying mechanisms have been described including chromosomal aberrancies [109], 
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(RA)[115] and malignancies [116]; CD4+TCRαβ+ T cells from a separate group, which 
also showed a distinctive antigen involved: CMV [78]. However, levels of cytopenias, 
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STAT-mutations through whole-exome analysis [117,118], and neutral loss of hetero- zygosity at 17q11.2q25.3 with additional aberrations in oncogenes such as NF1 [119].
Figure 7. Spectrum of T cell large granular lymphocyte leukemias.
In the healthy situation T cells are polyclonally expanded and reactive in order to respond to and clear infections. During an infection cells with a specific receptor recognizing the specific epitope(s) are selected, activated and start to proliferate, leading to an oligoclonal population. The diverse polyclonal background is 
still present, and the oligoclonal population undergoes activation induced cell death after the antigen is cleared. Upon prolonged stimulation this oligoclonal population may persist, and continue to proliferate, leading to a monoclonal population called T cell clonopathy of undetermined significance (TCUS), still in the context of 
poly- or oligoclonal cells. Following chronic stimulation the monoclonal population persists, proliferates and represses the normal background, leading to a large monoclonal cell population. This ultimately leads to a clinically malignant situation: a chronic T cell large granular lymphocytic (T-LGL) leukemia. Diagnosis of T-LGL 
leukemia is based on a persistent (>6 months) monoclonal CD3+/CD57+ population with an absolute count of 
>0.5 x 109 cells per liter peripheral blood. Figure adapted from Langerak et al. 2003.
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G e n e r a l  I n t r o d u c t i o n  
S T A T - m u t a t i o n s  t h r o u g h  w h o l e - e x o m e  a n a l y s i s  [ 1 1 7 , 1 1 8 ] ,  a n d  n e u t r a l  l o s s  o f  h e t e r o -
z y g o s i t y  a t  1 7 q 1 1 . 2 q 2 5 . 3  w i t h  a d d i t i o n a l  a b e r r a t i o n s  i n  o n c o g e n e s  s u c h  a s  N F 1  [ 1 1 9 ] .
F i g u r e  7 .  S p e c t r u m  o f  T  c e l l  l a r g e  g r a n u l a r  l y m p h o c y t e  l e u k e m i a s .
I n  t h e  h e a l t h y  s i t u a t i o n  T  c e l l s  a r e  p o l y c l o n a l l y  e x p a n d e d  a n d  r e a c t i v e  i n  o r d e r  t o  r e s p o n d  t o  a n d  c l e a r  
i n f e c t i o n s .  D u r i n g  a n  i n f e c t i o n  c e l l s  w i t h  a  s p e c i f i c  r e c e p t o r  r e c o g n i z i n g  t h e  s p e c i f i c  e p i t o p e ( s )  a r e  s e l e c t e d ,  
a c t i v a t e d  a n d  s t a r t  t o  p r o l i f e r a t e ,  l e a d i n g  t o  a n  o l i g o c l o n a l  p o p u l a t i o n .  T h e  d i v e r s e  p o l y c l o n a l  b a c k g r o u n d  i s  
s t i l l  p r e s e n t ,  a n d  t h e  o l i g o c l o n a l  p o p u l a t i o n  u n d e r g o e s  a c t i v a t i o n  i n d u c e d  c e l l  d e a t h  a f t e r  t h e  a n t i g e n  i s  c l e a r e d .  
U p o n  p r o l o n g e d  s t i m u l a t i o n  t h i s  o l i g o c l o n a l  p o p u l a t i o n  m a y  p e r s i s t ,  a n d  c o n t i n u e  t o  p r o l i f e r a t e ,  l e a d i n g  t o  a  
m o n o c l o n a l  p o p u l a t i o n  c a l l e d  T  c e l l  c l o n o p a t h y  o f  u n d e t e r m i n e d  s i g n i f i c a n c e  ( T C U S ) ,  s t i l l  i n  t h e  c o n t e x t  o f  
p o l y -  o r  o l i g o c l o n a l  c e l l s .  F o l l o w i n g  c h r o n i c  s t i m u l a t i o n  t h e  m o n o c l o n a l  p o p u l a t i o n  p e r s i s t s ,  p r o l i f e r a t e s  a n d  
r e p r e s s e s  t h e  n o r m a l  b a c k g r o u n d ,  l e a d i n g  t o  a  l a r g e  m o n o c l o n a l  c e l l  p o p u l a t i o n .  T h i s  u l t i m a t e l y  l e a d s  t o  a  
c l i n i c a l l y  m a l i g n a n t  s i t u a t i o n :  a  c h r o n i c  T  c e l l  l a r g e  g r a n u l a r  l y m p h o c y t i c  ( T - L G L )  l e u k e m i a .  D i a g n o s i s  o f  T - L G L  
l e u k e m i a  i s  b a s e d  o n  a  p e r s i s t e n t  ( > 6  m o n t h s )  m o n o c l o n a l  C D 3 + / C D 5 7 +  p o p u l a t i o n  w i t h  a n  a b s o l u t e  c o u n t  o f  
> 0 . 5  x  1 0
9
 c e l l s  p e r  l i t e r  p e r i p h e r a l  b l o o d .  F i g u r e  a d a p t e d  f r o m  L a n g e r a k  e t  a l .  2 0 0 3 .
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Figure 8. Graphical abstract of this thesis.
Chapter 2 addresses the immunophenotype of normal TCRγδ+ T cells in the context of ageing. In Chapters 3 
and 4 TRG/TRD repertoire development in TCRγδ+ T cells is discussed. Chapter 5 is a review on the clinical 
features and immunophenotype, and clonotypic TCR repertoire of T-LGL leukemia, including TCRγδ+ T-LGL 
leukemia. Chapter 6 investigates gene expression profiles in T-LGL leukemia indicative of dysregulated processes, and Chapter 7 describes the deepest level in which aberrancies could occur, the genomic level, 
these last two Chapters have mainly focused on the TCRγδ+ variant.
SCOPE OF THE THESIS
Based on this chronic character and their antigen-experienced effector profiles T-LGL leukemia is believed to arise from normal T-LGL cells in the adult or elderly blood, upon chronic (antigenic) stimulation followed by secondary events in either signaling, gene expression or genome. Throughout this thesis different aspects of T cells and T-LGL 
leukemias – with special emphasis on TCRγδ-variants – are studied (see for graphical abstract Fig. 8). Immunological events during a life time are described in a spectrum 
starting from normal developing, to healthy existing, to finally aberrancies causing a chronic mature leukemia. 
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General Introduction 
In Chapter 2 healthy developing and ageing TCRγδ+ T cells are studied with respect to surface marker expression. The effect of immunological ageing – also referred to as 
immunosenescence – with the additional effect of persistent viruses like CMV on the 
TCRγδ+ T cell population is discussed in this chapter. Chapters 3 and 4 address the healthy ageing TCRγδ+ T cell receptor repertoire. In Chapter 3 a detailed description is 
given of the novel next generation sequencing technique that was applied to study the TRG and TRD repertoires. Next, the development of and further shaping of the TCRγδ+ 
T cell receptor repertoire is reported in Chapter 4, including novel insights on develop- ment and ageing on both cell surface marker expression and antigen receptor diversity. 
Chapter 5 provides an overview of all types of chronic mature T-LGL leukemias that can arise from the T cell type LGL: CD4+TCRαβ+, CD8+TCRαβ+ and TCRγδ+ T-LGL 
leukemias, and compares the different pathogenic events, but also the different clini- cal presentations and associated diseases. Alterations in TCRγδ+ T-LGL leukemia cells 
on the level of gene expression are described in Chapter 6, in comparison to different healthy TCRγδ+ T cell subsets. Chapter 7 reports on the deepest level of cellular aber-
rancies, namely the genetic abnormalities that could contribute to the TCRγδ+ T-LGL 
leukemogenesis. Finally, in the General Discussion in Chapter 8 an integrated view of all chapters is given, together with all (novel) findings and data reported in this thesis 
and previous literature on the corresponding topics. Future prospects on how to address newly identified issues are also included. 
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G e n e r a l  I n t r o d u c t i o n  
I n  C h a p t e r  2  h e a l t h y  d e v e l o p i n g  a n d  a g e i n g  T C R γ δ +  T  c e l l s  a r e  s t u d i e d  w i t h  r e s p e c t  
t o  s u r f a c e  m a r k e r  e x p r e s s i o n .  T h e  e f f e c t  o f  i m m u n o l o g i c a l  a g e i n g  –  a l s o  r e f e r r e d  t o  a s  
i m m u n o s e n e s c e n c e  –  w i t h  t h e  a d d i t i o n a l  e f f e c t  o f  p e r s i s t e n t  v i r u s e s  l i k e  C M V  o n  t h e  
T C R γ δ +  T  c e l l  p o p u l a t i o n  i s  d i s c u s s e d  i n  t h i s  c h a p t e r .  C h a p t e r s  3  a n d  4  a d d r e s s  t h e  
h e a l t h y  a g e i n g  T C R γ δ +  T  c e l l  r e c e p t o r  r e p e r t o i r e .  I n  C h a p t e r  3  a  d e t a i l e d  d e s c r i p t i o n  i s  
g i v e n  o f  t h e  n o v e l  n e x t  g e n e r a t i o n  s e q u e n c i n g  t e c h n i q u e  t h a t  w a s  a p p l i e d  t o  s t u d y  t h e  
T R G  a n d  T R D  r e p e r t o i r e s .  N e x t ,  t h e  d e v e l o p m e n t  o f  a n d  f u r t h e r  s h a p i n g  o f  t h e  T C R γ δ +  
T  c e l l  r e c e p t o r  r e p e r t o i r e  i s  r e p o r t e d  i n  C h a p t e r  4 ,  i n c l u d i n g  n o v e l  i n s i g h t s  o n  d e v e l o p -
m e n t  a n d  a g e i n g  o n  b o t h  c e l l  s u r f a c e  m a r k e r  e x p r e s s i o n  a n d  a n t i g e n  r e c e p t o r  d i v e r s i t y .  
C h a p t e r  5  p r o v i d e s  a n  o v e r v i e w  o f  a l l  t y p e s  o f  c h r o n i c  m a t u r e  T - L G L  l e u k e m i a s  
t h a t  c a n  a r i s e  f r o m  t h e  T  c e l l  t y p e  L G L :  C D 4 + T C R α β + ,  C D 8 + T C R α β +  a n d  T C R γ δ +  T - L G L  
l e u k e m i a s ,  a n d  c o m p a r e s  t h e  d i f f e r e n t  p a t h o g e n i c  e v e n t s ,  b u t  a l s o  t h e  d i f f e r e n t  c l i n i -
c a l  p r e s e n t a t i o n s  a n d  a s s o c i a t e d  d i s e a s e s .  A l t e r a t i o n s  i n  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  
o n  t h e  l e v e l  o f  g e n e  e x p r e s s i o n  a r e  d e s c r i b e d  i n  C h a p t e r  6 ,  i n  c o m p a r i s o n  t o  d i f f e r e n t  
h e a l t h y  T C R γ δ +  T  c e l l  s u b s e t s .  C h a p t e r  7  r e p o r t s  o n  t h e  d e e p e s t  l e v e l  o f  c e l l u l a r  a b e r -
r a n c i e s ,  n a m e l y  t h e  g e n e t i c  a b n o r m a l i t i e s  t h a t  c o u l d  c o n t r i b u t e  t o  t h e  T C R γ δ +  T - L G L  
l e u k e m o g e n e s i s .  F i n a l l y ,  i n  t h e  G e n e r a l  D i s c u s s i o n  i n  C h a p t e r  8  a n  i n t e g r a t e d  v i e w  o f  
a l l  c h a p t e r s  i s  g i v e n ,  t o g e t h e r  w i t h  a l l  ( n o v e l )  f i n d i n g s  a n d  d a t a  r e p o r t e d  i n  t h i s  t h e s i s  
a n d  p r e v i o u s  l i t e r a t u r e  o n  t h e  c o r r e s p o n d i n g  t o p i c s .  F u t u r e  p r o s p e c t s  o n  h o w  t o  a d d r e s s  
n e w l y  i d e n t i f i e d  i s s u e s  a r e  a l s o  i n c l u d e d .  
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ABSTRACT
Ageing is a broad cellular process, largely affecting the immune system, especially T lymphocytes. Additionally to immunosenescence alone, cytomegalovirus (CMV) infection is thought to have major impacts on T cell subset composition and exhaustion. These impacts have been 
studied extensively in TCRαβ+ T cells, with reduction in naive, increase in effector (memory) subsets and shifts in CD4/CD8-ratios, in conjunc-tion with morbidity and mortality in elderly. Effects of both ageing and 
CMV on the TCRγδ+ T cell compartment remain largely elusive. 
In the current study we investigated Vγ- and Vδ-usage, maturation, 
differentiation and exhaustion marker profiles of both CD4 and CD8 dou-
ble-negative (DN) and CD8+TCRγδ+ T cells in 157 individuals, age range 20-95. We observed a progressive decrease in absolute numbers of total 
TCRγδ+ T cells in blood, affecting the predominant Vγ9/Vδ2 population. 
Aged TCRγδ+ T cells appeared to shift from naive to more (late-stage) effector phenotypes, which appeared more prominent in case of per-sistent CMV infections. In addition, we found effects of both ageing and 
CMV on the absolute counts of exhausted TCRγδ+ T cells. Collectively, our data show a clear impact of ageing and CMV persistence on DN and 
CD8+TCRγδ+ T cells, similar to what has been reported in CD8+TCRαβ+ T cells, indicating that they undergo similar ageing processes. 
Keyword(s): ageing, immunosenescence, TCRγδ+ T cells, CMV, differ-
entiation, exhaustion, flow cytometry.
ABSTRACT
Ageing is a broad cellular process, largely affecting the immune 
system, especially T lymphocytes. Additionally to immunosenescence 
alone, cytomegalovirus (CMV) infection is thought to have major impacts 
on T cell subset composition and exhaustion. These impacts have been 
studied extensively in TCRαβ+ T cells, with reduction in naive, increase 
in effector (memory) subsets and shifts in CD4/CD8-ratios, in conjunc-
tion with morbidity and mortality in elderly. Effects of both ageing and 
CMV on the TCRγδ+ T cell compartment remain largely elusive. 
In the current study we investigated Vγ- and Vδ-usage, maturation, 
differentiation and exhaustion marker profiles of both CD4 and CD8 dou-
ble-negative (DN) and CD8+TCRγδ+ T cells in 157 individuals, age range 
20-95. 
We observed a progressive decrease in absolute numbers of total 
TCRγδ+ T cells in blood, affecting the predominant Vγ9/Vδ2 population. 
Aged TCRγδ+ T cells appeared to shift from naive to more (late-stage) 
effector phenotypes, which appeared more prominent in case of per-
sistent CMV infections. In addition, we found effects of both ageing and 
CMV on the absolute counts of exhausted TCRγδ+ T cells. Collectively, 
our data show a clear impact of ageing and CMV persistence on DN and 
CD8+TCRγδ+ T cells, similar to what has been reported in CD8+TCRαβ+ 
T cells, indicating that they undergo similar ageing processes.
 
Keyword(s): ageing, immunosenescence, TCRγδ+ T cells, CMV, differ-
entiation, exhaustion, flow cytometry.
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INTRODUCTION
Ageing is a general cellular process, defined as the result of damage created by reac- tive oxygen species (ROS) during oxidative stress in mitochondria [1]. ROS can cause 
cell membrane, protein, nucleic acid damage [2], and most importantly genome damage which leads to genomic instability, shortening of telomere length, and thus an increas-
ing chance of cancer development [3,4]. The process of ageing particularly affects the immune system, due to its high metabolic rate and high cellular turnover for maintaining 
homeostasis, and for protecting the host against infections and cancer. Immunological ageing (also called immunosenescence) is defined at different levels: desensitization of 
dendritic cells (DCs) leading to reduced TLR responses, low bone marrow (BM) output of naive B cells, insufficient T cell help in the spleen and lymph nodes (LN), resulting in 
decreased memory B cell expansions and antibody secretion, and decreased thymopoi- esis in the thymus [5,6]. Clinically this results in an inadequate response to infections in 
elderly, caused by reduced innate responses of macrophages, neutrophils and NK cells [6,7]. DCs are constitutively activated, which gives rise to an increased basal level of 
inflammation with increased tissue damage [8,9]. Defective antigen presentation and a 
reduced B cell repertoire lead to a reduced humoral response [10] and a reduced vaccine response [6,11]. 
A central feature in immunosenescence is involution of the thymus, which is characterized by thymic shrinkage and a significantly reduced naive T cell output 
[5,6,12]. This leads to a reduced T cell dependent antigen-specific response and thus 
fewer interactions with other immune cell types, such as reduced help to B cells in germinal centers [11]. During immune ageing, another major event has been described, 
which is referred to as T cell exhaustion. This exhaustion process is characterized by the progressive loss of robust effector functions and eventually the induction of apoptosis. T 
cell exhaustion is most clearly seen in chronic infections, e.g. in persistent viral infections, and in cancers. Due to continuous stimulation, T cells start to lose their effector functions 
in a hierarchical manner, starting with reduced IL-2 production, followed by reduced cytokine and chemokine productions, ending with the high expression of inhibitory 
molecules and eventually the induction of apoptosis [13,14]. Many different markers for exhausted CD8+ CTLs have been described, ranging from NK cell markers such as CD57 
[15-17], killer cell lectin-like receptor G1 (KLRG1) [13,18,19], and 2B4, also known as CD244 [20-22], to cell death-associated markers such as Programmed cell death 1 (PD1) 
which is a marker of early exhaustion [23-25], and FAS (CD95) [13,26]. Loss of the self- renewal-associated marker IL-7 receptor α subunit (CD127) is associated with an early 
stage of exhaustion [27,28]. 
2
5 1
E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
I N T R O D U C T I O N
A g e i n g  i s  a  g e n e r a l  c e l l u l a r  p r o c e s s ,  d e f i n e d  a s  t h e  r e s u l t  o f  d a m a g e  c r e a t e d  b y  r e a c -
t i v e  o x y g e n  s p e c i e s  ( R O S )  d u r i n g  o x i d a t i v e  s t r e s s  i n  m i t o c h o n d r i a  [ 1 ] .  R O S  c a n  c a u s e  
c e l l  m e m b r a n e ,  p r o t e i n ,  n u c l e i c  a c i d  d a m a g e  [ 2 ] ,  a n d  m o s t  i m p o r t a n t l y  g e n o m e  d a m a g e  
w h i c h  l e a d s  t o  g e n o m i c  i n s t a b i l i t y ,  s h o r t e n i n g  o f  t e l o m e r e  l e n g t h ,  a n d  t h u s  a n  i n c r e a s -
i n g  c h a n c e  o f  c a n c e r  d e v e l o p m e n t  [ 3 , 4 ] .  T h e  p r o c e s s  o f  a g e i n g  p a r t i c u l a r l y  a f f e c t s  t h e  
i m m u n e  s y s t e m ,  d u e  t o  i t s  h i g h  m e t a b o l i c  r a t e  a n d  h i g h  c e l l u l a r  t u r n o v e r  f o r  m a i n t a i n i n g  
h o m e o s t a s i s ,  a n d  f o r  p r o t e c t i n g  t h e  h o s t  a g a i n s t  i n f e c t i o n s  a n d  c a n c e r .  I m m u n o l o g i c a l  
a g e i n g  ( a l s o  c a l l e d  i m m u n o s e n e s c e n c e )  i s  d e f i n e d  a t  d i f f e r e n t  l e v e l s :  d e s e n s i t i z a t i o n  o f  
d e n d r i t i c  c e l l s  ( D C s )  l e a d i n g  t o  r e d u c e d  T L R  r e s p o n s e s ,  l o w  b o n e  m a r r o w  ( B M )  o u t p u t  
o f  n a i v e  B  c e l l s ,  i n s u f f i c i e n t  T  c e l l  h e l p  i n  t h e  s p l e e n  a n d  l y m p h  n o d e s  ( L N ) ,  r e s u l t i n g  i n  
d e c r e a s e d  m e m o r y  B  c e l l  e x p a n s i o n s  a n d  a n t i b o d y  s e c r e t i o n ,  a n d  d e c r e a s e d  t h y m o p o i -
e s i s  i n  t h e  t h y m u s  [ 5 , 6 ] .  C l i n i c a l l y  t h i s  r e s u l t s  i n  a n  i n a d e q u a t e  r e s p o n s e  t o  i n f e c t i o n s  i n  
e l d e r l y ,  c a u s e d  b y  r e d u c e d  i n n a t e  r e s p o n s e s  o f  m a c r o p h a g e s ,  n e u t r o p h i l s  a n d  N K  c e l l s  
[ 6 , 7 ] .  D C s  a r e  c o n s t i t u t i v e l y  a c t i v a t e d ,  w h i c h  g i v e s  r i s e  t o  a n  i n c r e a s e d  b a s a l  l e v e l  o f  
i n f l a m m a t i o n  w i t h  i n c r e a s e d  t i s s u e  d a m a g e  [ 8 , 9 ] .  D e f e c t i v e  a n t i g e n  p r e s e n t a t i o n  a n d  a  
r e d u c e d  B  c e l l  r e p e r t o i r e  l e a d  t o  a  r e d u c e d  h u m o r a l  r e s p o n s e  [ 1 0 ]  a n d  a  r e d u c e d  v a c c i n e  
r e s p o n s e  [ 6 , 1 1 ] .  
A  c e n t r a l  f e a t u r e  i n  i m m u n o s e n e s c e n c e  i s  i n v o l u t i o n  o f  t h e  t h y m u s ,  w h i c h  i s  
c h a r a c t e r i z e d  b y  t h y m i c  s h r i n k a g e  a n d  a  s i g n i f i c a n t l y  r e d u c e d  n a i v e  T  c e l l  o u t p u t  
[ 5 , 6 , 1 2 ] .  T h i s  l e a d s  t o  a  r e d u c e d  T  c e l l  d e p e n d e n t  a n t i g e n - s p e c i f i c  r e s p o n s e  a n d  t h u s  
f e w e r  i n t e r a c t i o n s  w i t h  o t h e r  i m m u n e  c e l l  t y p e s ,  s u c h  a s  r e d u c e d  h e l p  t o  B  c e l l s  i n  
g e r m i n a l  c e n t e r s  [ 1 1 ] .  D u r i n g  i m m u n e  a g e i n g ,  a n o t h e r  m a j o r  e v e n t  h a s  b e e n  d e s c r i b e d ,  
w h i c h  i s  r e f e r r e d  t o  a s  T  c e l l  e x h a u s t i o n .  T h i s  e x h a u s t i o n  p r o c e s s  i s  c h a r a c t e r i z e d  b y  t h e  
p r o g r e s s i v e  l o s s  o f  r o b u s t  e f f e c t o r  f u n c t i o n s  a n d  e v e n t u a l l y  t h e  i n d u c t i o n  o f  a p o p t o s i s .  T  
c e l l  e x h a u s t i o n  i s  m o s t  c l e a r l y  s e e n  i n  c h r o n i c  i n f e c t i o n s ,  e . g .  i n  p e r s i s t e n t  v i r a l  i n f e c t i o n s ,  
a n d  i n  c a n c e r s .  D u e  t o  c o n t i n u o u s  s t i m u l a t i o n ,  T  c e l l s  s t a r t  t o  l o s e  t h e i r  e f f e c t o r  f u n c t i o n s  
i n  a  h i e r a r c h i c a l  m a n n e r ,  s t a r t i n g  w i t h  r e d u c e d  I L - 2  p r o d u c t i o n ,  f o l l o w e d  b y  r e d u c e d  
c y t o k i n e  a n d  c h e m o k i n e  p r o d u c t i o n s ,  e n d i n g  w i t h  t h e  h i g h  e x p r e s s i o n  o f  i n h i b i t o r y  
m o l e c u l e s  a n d  e v e n t u a l l y  t h e  i n d u c t i o n  o f  a p o p t o s i s  [ 1 3 , 1 4 ] .  M a n y  d i f f e r e n t  m a r k e r s  f o r  
e x h a u s t e d  C D 8 +  C T L s  h a v e  b e e n  d e s c r i b e d ,  r a n g i n g  f r o m  N K  c e l l  m a r k e r s  s u c h  a s  C D 5 7  
[ 1 5 - 1 7 ] ,  k i l l e r  c e l l  l e c t i n - l i k e  r e c e p t o r  G 1  ( K L R G 1 )  [ 1 3 , 1 8 , 1 9 ] ,  a n d  2 B 4 ,  a l s o  k n o w n  a s  
C D 2 4 4  [ 2 0 - 2 2 ] ,  t o  c e l l  d e a t h - a s s o c i a t e d  m a r k e r s  s u c h  a s  P r o g r a m m e d  c e l l  d e a t h  1  ( P D 1 )  
w h i c h  i s  a  m a r k e r  o f  e a r l y  e x h a u s t i o n  [ 2 3 - 2 5 ] ,  a n d  F A S  ( C D 9 5 )  [ 1 3 , 2 6 ] .  L o s s  o f  t h e  s e l f -
r e n e w a l - a s s o c i a t e d  m a r k e r  I L - 7  r e c e p t o r  α  s u b u n i t  ( C D 1 2 7 )  i s  a s s o c i a t e d  w i t h  a n  e a r l y  
s t a g e  o f  e x h a u s t i o n  [ 2 7 , 2 8 ] .  
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The process of immunological ageing, including expression of the above markers has 
been extensively studied in CD8+TCRαβ+ T cells, but less so in TCRγδ+ T cells, which 
show functional overlap with the CD8+TCRαβ+ CTLs with respect to high levels of cyto-
toxicity [29], cytokine release – mainly IFN-γ and IL-17 based on antigen experience – 
[30,31], induction of inflammation, immunoregulation and cytoprotection upon antigen 
recognition. However, TCRγδ+ T cells form a distinctive group of unconventional T cells 
with features of both innate and adaptive immune cells [32]. TCRγδ+ T cells recognize antigens directly without major histocompatibility molecules (MHC), or in the context 
of CD1-molecules [33-35]. TCRγδ+ T cells thus have the ability to directly respond to 
specific pathogens, and readily form a bridge between the innate and adaptive systems. 
Upon ageing, TCRγδ+ T cells also tend to decrease in total numbers [36,37], leading to a possibly reduced response to pathogens. This relates not only to the blood, but also to epithelial tissues where they reside as intra-epithelial and innate-like lymphocytes 
[33,38]. Furthermore, TCRγδ+ T cells can specifically bind to viruses, such as human lymphotrophic virus type I (HTLV-I) and Epstein-Barr virus (EBV) [39], through the 
Vγ9/Vδ2 receptor. Non-Vγ9/Vδ1 cells specifically respond to cytomegalovirus (CMV) [40], increase upon ageing and can be expanded and stimulated with CMV ex vivo [41]. As CMV is one of the persistent herpesviruses [42], CMV infection has a high impact on 
immunosenescence and exhaustion [43-45]. CMV is known for altering TCRαβ+CD4+ 
and CD8+ maturation subsets (reviewed in [46]), and recently it has been found that 
CMV seropositivity in elderly individuals is associated with a lower percentage of Vδ2+, 
and an increased percentage of Vδ1+TCRγδ+ T cells, of which the latter has a late-stage 
differentiated effector phenotype [37]. However, the full profile of phenotypic alterations 
of TCRγδ+ T cells upon ageing in the presence or absence of persistent CMV infections remains elusive. 
Since TCRγδ+ T cells have innate features and show functional similarities to 
CD8+TCRαβ+ CTLs, we hypothesized that immunological ageing, especially in the 
presence of CMV, would similarly influence the TCRγδ+ T cell immune system with 
respect to subset compositions and exhaustion profiles. In the current study we included 157 healthy subjects from different age groups to investigate the effect of both ageing and 
CMV seropositivity on TCRγδ+ T cells. Our data illustrate the impact of immunological 
ageing on TCRγδ+ T cells, with a clear enhancing effect of CMV, as opposed to the more 
marginal contribution of CMV infection to increased TCRγδ+ T cell exhaustion in elderly.
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MATERIALS & METHODS
Study subjects
The NWO ageing study cohort consisted of immunologically healthy patients from the Orthopedics outpatient clinic, Erasmus MC, complemented with (immunologically) 
healthy controls in the younger age groups. After applying exclusion criteria (auto-im- mune or –inflammatory diseases at present or in the past; malignancies; usage of 
anti-inflammatory or immunosuppressive drugs; surgery in the past 30 days; alcohol or 
drug abuse) a total of 121 subjects were included. To increase the number of subjects in especially the age groups of >60 years, an additional 36 subjects participating in the 
SENEX study of healthy elderly in the Dutch region of Groningen were included via the UMC Groningen. Participants in the NWO Ageing Study gave written informed consent 
and the study was approved by the Medical Ethics Committee of the Erasmus MC under number MEC-2011-409 and MEC-2016-202. From subjects participating in the SENEX 
Study of the UMC Groningen written informed consent was obtained and approval for the study was provided by the Medical Ethics Committee of the UMCG under protocol 
number 2012375. All experimental studies were conducted in accordance with relevant guidelines and principles of the Declaration of Helsinki. Samples were divided into five 
age groups, 40 to 50 (mean age 45), 50 to 60 (mean age 55), 60 to 70 (mean age 66), 70-plus (mean age 77) versus a control group of samples from healthy adults age 20 to 
40 (mean age 25) (Table 1). Fresh peripheral blood mononuclear cells (PBMC) samples of a total of 157 participants of the NWO and SENEX studies were analyzed after lysis 
with ammonium chloride. CMV serostatus was determined on plasma with the use of the anti-CMV ELISA (IgG) according to the manufacturer’s protocol (EuroImmun, Lübeck, 
Germany). Remaining peripheral blood after analysis and plasma storage was subjected to Ficoll-Paque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden) density gradient sep-
aration and cryopreserved in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza, Basel, 
Switzerland) with dimethyl sulfoxide in vials at -180 ⁰C until further use. 
Flow cytometric immune phenotyping
Freshly obtained blood was lysed with ammonium chloride and washed with phos- phate buffered saline (PBS) pH 7.8 containing fetal bovine serum (FBS, 30% w/v) 
and sodium azide. Samples were stained using three antibody panels according to Supplementary Table 1. Data analysis and gating strategies were based on the standard-
ized protocols from the Generation R study [70]. Defining viable cells was based on FSC/
SSC gating strategies and validated with negative expression of Annexin V of viable cells in a small series of additional samples (data not shown). With the use of tube 1 Vγ- 
and Vδ-usage could be determined. With the use of T cell maturation markers CD45RO, 
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M A T E R I A L S  &  M E T H O D S
S t u d y  s u b j e c t s
T h e  N W O  a g e i n g  s t u d y  c o h o r t  c o n s i s t e d  o f  i m m u n o l o g i c a l l y  h e a l t h y  p a t i e n t s  f r o m  
t h e  O r t h o p e d i c s  o u t p a t i e n t  c l i n i c ,  E r a s m u s  M C ,  c o m p l e m e n t e d  w i t h  ( i m m u n o l o g i c a l l y )  
h e a l t h y  c o n t r o l s  i n  t h e  y o u n g e r  a g e  g r o u p s .  A f t e r  a p p l y i n g  e x c l u s i o n  c r i t e r i a  ( a u t o - i m -
m u n e  o r  – i n f l a m m a t o r y  d i s e a s e s  a t  p r e s e n t  o r  i n  t h e  p a s t ;  m a l i g n a n c i e s ;  u s a g e  o f  
a n t i - i n f l a m m a t o r y  o r  i m m u n o s u p p r e s s i v e  d r u g s ;  s u r g e r y  i n  t h e  p a s t  3 0  d a y s ;  a l c o h o l  o r  
d r u g  a b u s e )  a  t o t a l  o f  1 2 1  s u b j e c t s  w e r e  i n c l u d e d .  T o  i n c r e a s e  t h e  n u m b e r  o f  s u b j e c t s  
i n  e s p e c i a l l y  t h e  a g e  g r o u p s  o f  > 6 0  y e a r s ,  a n  a d d i t i o n a l  3 6  s u b j e c t s  p a r t i c i p a t i n g  i n  t h e  
S E N E X  s t u d y  o f  h e a l t h y  e l d e r l y  i n  t h e  D u t c h  r e g i o n  o f  G r o n i n g e n  w e r e  i n c l u d e d  v i a  t h e  
U M C  G r o n i n g e n .  P a r t i c i p a n t s  i n  t h e  N W O  A g e i n g  S t u d y  g a v e  w r i t t e n  i n f o r m e d  c o n s e n t  
a n d  t h e  s t u d y  w a s  a p p r o v e d  b y  t h e  M e d i c a l  E t h i c s  C o m m i t t e e  o f  t h e  E r a s m u s  M C  u n d e r  
n u m b e r  M E C - 2 0 1 1 - 4 0 9  a n d  M E C - 2 0 1 6 - 2 0 2 .  F r o m  s u b j e c t s  p a r t i c i p a t i n g  i n  t h e  S E N E X  
S t u d y  o f  t h e  U M C  G r o n i n g e n  w r i t t e n  i n f o r m e d  c o n s e n t  w a s  o b t a i n e d  a n d  a p p r o v a l  f o r  
t h e  s t u d y  w a s  p r o v i d e d  b y  t h e  M e d i c a l  E t h i c s  C o m m i t t e e  o f  t h e  U M C G  u n d e r  p r o t o c o l  
n u m b e r  2 0 1 2 3 7 5 .  A l l  e x p e r i m e n t a l  s t u d i e s  w e r e  c o n d u c t e d  i n  a c c o r d a n c e  w i t h  r e l e v a n t  
g u i d e l i n e s  a n d  p r i n c i p l e s  o f  t h e  D e c l a r a t i o n  o f  H e l s i n k i .  S a m p l e s  w e r e  d i v i d e d  i n t o  f i v e  
a g e  g r o u p s ,  4 0  t o  5 0  ( m e a n  a g e  4 5 ) ,  5 0  t o  6 0  ( m e a n  a g e  5 5 ) ,  6 0  t o  7 0  ( m e a n  a g e  6 6 ) ,  
7 0 - p l u s  ( m e a n  a g e  7 7 )  v e r s u s  a  c o n t r o l  g r o u p  o f  s a m p l e s  f r o m  h e a l t h y  a d u l t s  a g e  2 0  t o  
4 0  ( m e a n  a g e  2 5 )  ( T a b l e  1 ) .  F r e s h  p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  ( P B M C )  s a m p l e s  
o f  a  t o t a l  o f  1 5 7  p a r t i c i p a n t s  o f  t h e  N W O  a n d  S E N E X  s t u d i e s  w e r e  a n a l y z e d  a f t e r  l y s i s  
w i t h  a m m o n i u m  c h l o r i d e .  C M V  s e r o s t a t u s  w a s  d e t e r m i n e d  o n  p l a s m a  w i t h  t h e  u s e  o f  t h e  
a n t i - C M V  E L I S A  ( I g G )  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s  p r o t o c o l  ( E u r o I m m u n ,  L ü b e c k ,  
G e r m a n y ) .  R e m a i n i n g  p e r i p h e r a l  b l o o d  a f t e r  a n a l y s i s  a n d  p l a s m a  s t o r a g e  w a s  s u b j e c t e d  
t o  F i c o l l - P a q u e  ( d e n s i t y  1 . 0 7 7  g / m l ,  P h a r m a c i a ,  U p p s a l a ,  S w e d e n )  d e n s i t y  g r a d i e n t  s e p -
a r a t i o n  a n d  c r y o p r e s e r v e d  i n  I s c o v e ’ s  M o d i f i e d  D u l b e c c o ’ s  M e d i u m  ( I M D M ,  L o n z a ,  B a s e l ,  
S w i t z e r l a n d )  w i t h  d i m e t h y l  s u l f o x i d e  i n  v i a l s  a t  - 1 8 0  ⁰ C  u n t i l  f u r t h e r  u s e .  
F l o w  c y t o m e t r i c  i m m u n e  p h e n o t y p i n g
F r e s h l y  o b t a i n e d  b l o o d  w a s  l y s e d  w i t h  a m m o n i u m  c h l o r i d e  a n d  w a s h e d  w i t h  p h o s -
p h a t e  b u f f e r e d  s a l i n e  ( P B S )  p H  7 . 8  c o n t a i n i n g  f e t a l  b o v i n e  s e r u m  ( F B S ,  3 0 %  w / v )  
a n d  s o d i u m  a z i d e .  S a m p l e s  w e r e  s t a i n e d  u s i n g  t h r e e  a n t i b o d y  p a n e l s  a c c o r d i n g  t o  
S u p p l e m e n t a r y  T a b l e  1 .  D a t a  a n a l y s i s  a n d  g a t i n g  s t r a t e g i e s  w e r e  b a s e d  o n  t h e  s t a n d a r d -
i z e d  p r o t o c o l s  f r o m  t h e  G e n e r a t i o n  R  s t u d y  [ 7 0 ] .  D e f i n i n g  v i a b l e  c e l l s  w a s  b a s e d  o n  F S C /
S S C  g a t i n g  s t r a t e g i e s  a n d  v a l i d a t e d  w i t h  n e g a t i v e  e x p r e s s i o n  o f  A n n e x i n  V  o f  v i a b l e  c e l l s  
i n  a  s m a l l  s e r i e s  o f  a d d i t i o n a l  s a m p l e s  ( d a t a  n o t  s h o w n ) .  W i t h  t h e  u s e  o f  t u b e  1  V γ -  
a n d  V δ - u s a g e  c o u l d  b e  d e t e r m i n e d .  W i t h  t h e  u s e  o f  T  c e l l  m a t u r a t i o n  m a r k e r s  C D 4 5 R O ,  
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as TemRO cells), and effector (CD45RO-CD197-, also known as TemRA cells) TCRγδ+ T 
cells. Furthermore, CD27 and CD28 were used for subdivision into early-, intermedi- ate- and late-stage differentiated effector memory and effector cells. Tube 3 included 
markers for the evaluation of exhaustion profiles. Cells were acquired using the Fortessa 
LSR flow cytometer (BD Biosciences, San Jose, CA, USA). Compensation was based on 
single color controls. Data were analyzed with FACSDiva software (BD Biosciences). The gating strategy applied for the various tubes is displayed in Supplementary Figure 1. 
The absolute cell count per microliter of a particular TCRγδ+ T cell population was cal- culated based on the total percentage and the total absolute lymphocyte count. The 
latter was calculated with the use of the number of events in the lymphocyte gate using the TruCount tube (BD Biosciences) and the Canto II flow cytometer (BD Biosciences) 
(Supplementary Fig. 1a), the initial white blood cell count and the number of leukocyte events. 
Statistical analysis
The non-parametric one-way ANOVA Kruskal-Wallis test was performed to compare absolute numbers and frequencies between different age groups and between young 
and elderly CMV- and CMV+ groups on single immune subsets. The Dunn’s test was 
applied for correction for multiple testing. P-values of <0.05 were considered statisti- cally significant. The statistical analyses were performed in Prism 5 (GraphPad, La Jolla, 
CA, USA).
RESULTS
Clear decline in absolute numbers of the most common Vγ9/Vδ2 
TCRγδ+ T cell subset in peripheral blood of elderly subjects
When studying absolute numbers of TCRγδ expressing T cells, a significant decrease 
was observed with ageing, which was already apparent at age group 40-50 (Fig. 1a). In contrast, absolute numbers of TCRαβ+ T cells were hardly or not affected, although 
variation was high in elderly (Supplementary Fig. 2a). As a consequence the overall distribution of TCRαβ versus TCRγδ expressing T cells showed a significant increase in 
TCRαβ+ T cell frequencies and a significant decrease in TCRγδ+ T cell frequencies, again 
already at age group 40-50 (Supplementary Fig. 2b). When focusing more on subsets with specific Vδ receptor usage no significant differences in the absolute numbers of 
Vδ1+ cells were found (Fig. 1b). However the significant decrease in total TCRγδ+ T cells 
was rather paralleled by a significant decrease in Vδ2+ cells (Fig. 1c), and especially Vγ9/
Vδ2 cell populations (Fig. 1d). To determine whether this resulted in a clear shift in Vδ 
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5 5
E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
a s  T e m R O  c e l l s ) ,  a n d  e f f e c t o r  ( C D 4 5 R O - C D 1 9 7 - ,  a l s o  k n o w n  a s  T e m R A  c e l l s )  T C R γ δ +  T  
c e l l s .  F u r t h e r m o r e ,  C D 2 7  a n d  C D 2 8  w e r e  u s e d  f o r  s u b d i v i s i o n  i n t o  e a r l y - ,  i n t e r m e d i -
a t e -  a n d  l a t e - s t a g e  d i f f e r e n t i a t e d  e f f e c t o r  m e m o r y  a n d  e f f e c t o r  c e l l s .  T u b e  3  i n c l u d e d  
m a r k e r s  f o r  t h e  e v a l u a t i o n  o f  e x h a u s t i o n  p r o f i l e s .  C e l l s  w e r e  a c q u i r e d  u s i n g  t h e  F o r t e s s a  
L S R  f l o w  c y t o m e t e r  ( B D  B i o s c i e n c e s ,  S a n  J o s e ,  C A ,  U S A ) .  C o m p e n s a t i o n  w a s  b a s e d  o n  
s i n g l e  c o l o r  c o n t r o l s .  D a t a  w e r e  a n a l y z e d  w i t h  F A C S D i v a  s o f t w a r e  ( B D  B i o s c i e n c e s ) .  T h e  
g a t i n g  s t r a t e g y  a p p l i e d  f o r  t h e  v a r i o u s  t u b e s  i s  d i s p l a y e d  i n  S u p p l e m e n t a r y  F i g u r e  1 .  
T h e  a b s o l u t e  c e l l  c o u n t  p e r  m i c r o l i t e r  o f  a  p a r t i c u l a r  T C R γ δ +  T  c e l l  p o p u l a t i o n  w a s  c a l -
c u l a t e d  b a s e d  o n  t h e  t o t a l  p e r c e n t a g e  a n d  t h e  t o t a l  a b s o l u t e  l y m p h o c y t e  c o u n t .  T h e  
l a t t e r  w a s  c a l c u l a t e d  w i t h  t h e  u s e  o f  t h e  n u m b e r  o f  e v e n t s  i n  t h e  l y m p h o c y t e  g a t e  u s i n g  
t h e  T r u C o u n t  t u b e  ( B D  B i o s c i e n c e s )  a n d  t h e  C a n t o  I I  f l o w  c y t o m e t e r  ( B D  B i o s c i e n c e s )  
( S u p p l e m e n t a r y  F i g .  1 a ) ,  t h e  i n i t i a l  w h i t e  b l o o d  c e l l  c o u n t  a n d  t h e  n u m b e r  o f  l e u k o c y t e  
e v e n t s .  
S t a t i s t i c a l  a n a l y s i s
T h e  n o n - p a r a m e t r i c  o n e - w a y  A N O V A  K r u s k a l - W a l l i s  t e s t  w a s  p e r f o r m e d  t o  c o m p a r e  
a b s o l u t e  n u m b e r s  a n d  f r e q u e n c i e s  b e t w e e n  d i f f e r e n t  a g e  g r o u p s  a n d  b e t w e e n  y o u n g  
a n d  e l d e r l y  C M V -  a n d  C M V +  g r o u p s  o n  s i n g l e  i m m u n e  s u b s e t s .  T h e  D u n n ’ s  t e s t  w a s  
a p p l i e d  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  P - v a l u e s  o f  < 0 . 0 5  w e r e  c o n s i d e r e d  s t a t i s t i -
c a l l y  s i g n i f i c a n t .  T h e  s t a t i s t i c a l  a n a l y s e s  w e r e  p e r f o r m e d  i n  P r i s m  5  ( G r a p h P a d ,  L a  J o l l a ,  
C A ,  U S A ) .
R E S U LT S
C l e a r  d e c l i n e  i n  a b s o l u t e  n u m b e r s  o f  t h e  m o s t  c o m m o n  V γ 9 / V δ 2  
T C R γ δ +  T  c e l l  s u b s e t  i n  p e r i p h e r a l  b l o o d  o f  e l d e r l y  s u b j e c t s
W h e n  s t u d y i n g  a b s o l u t e  n u m b e r s  o f  T C R γ δ  e x p r e s s i n g  T  c e l l s ,  a  s i g n i f i c a n t  d e c r e a s e  
w a s  o b s e r v e d  w i t h  a g e i n g ,  w h i c h  w a s  a l r e a d y  a p p a r e n t  a t  a g e  g r o u p  4 0 - 5 0  ( F i g .  1 a ) .  
I n  c o n t r a s t ,  a b s o l u t e  n u m b e r s  o f  T C R α β +  T  c e l l s  w e r e  h a r d l y  o r  n o t  a f f e c t e d ,  a l t h o u g h  
v a r i a t i o n  w a s  h i g h  i n  e l d e r l y  ( S u p p l e m e n t a r y  F i g .  2 a ) .  A s  a  c o n s e q u e n c e  t h e  o v e r a l l  
d i s t r i b u t i o n  o f  T C R α β  v e r s u s  T C R γ δ  e x p r e s s i n g  T  c e l l s  s h o w e d  a  s i g n i f i c a n t  i n c r e a s e  i n  
T C R α β +  T  c e l l  f r e q u e n c i e s  a n d  a  s i g n i f i c a n t  d e c r e a s e  i n  T C R γ δ +  T  c e l l  f r e q u e n c i e s ,  a g a i n  
a l r e a d y  a t  a g e  g r o u p  4 0 - 5 0  ( S u p p l e m e n t a r y  F i g .  2 b ) .  W h e n  f o c u s i n g  m o r e  o n  s u b s e t s  
w i t h  s p e c i f i c  V δ  r e c e p t o r  u s a g e  n o  s i g n i f i c a n t  d i f f e r e n c e s  i n  t h e  a b s o l u t e  n u m b e r s  o f  
V δ 1 +  c e l l s  w e r e  f o u n d  ( F i g .  1 b ) .  H o w e v e r  t h e  s i g n i f i c a n t  d e c r e a s e  i n  t o t a l  T C R γ δ +  T  c e l l s  
w a s  r a t h e r  p a r a l l e l e d  b y  a  s i g n i f i c a n t  d e c r e a s e  i n  V δ 2 +  c e l l s  ( F i g .  1 c ) ,  a n d  e s p e c i a l l y  V γ 9 /
V δ 2  c e l l  p o p u l a t i o n s  ( F i g .  1 d ) .  T o  d e t e r m i n e  w h e t h e r  t h i s  r e s u l t e d  i n  a  c l e a r  s h i f t  i n  V δ  
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usage within the total TCRγδ+ T cell population, we then compared the distributions of 
Vδ1, Vδ2 and other Vδ (non-Vδ1, non-Vδ2) populations in the peripheral blood of all age 
groups. We found no significant alterations, although the percentage of Vδ2+ cells was decreased in age groups 40-50, 50-60 and 60-70, with a shift towards relatively more 
Vδ1+ cells (Supplementary Fig. 2c). Overall these data suggest a significant decrease in 
absolute numbers of TCRγδ+ T cells in elderly age groups, with a parallel decrease in 
numbers of the most dominant Vγ9/Vδ2 TCRγδ+ T cell population. 
Figure 1. Vγ/Vδ-gene usage in TCRγδ+ T cells in different age groups.(a) Absolute numbers of total TCRγδ+ T cells, (b) Vδ1+, (c) Vδ2+ and (d) Vγ9/Vδ2 TCRγδ+ T cells depicted as 
10-90% box-whisker-plots. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test to 
correct for multiple testing. Significance for the Dunn’s test is indicated in the plots: **, p<0.01; ***, p<0.001.
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During ageing the naive TCRγδ+ T cell compartment shrinks and 
shifts towards a late-differentiated effector phenotype
In analogy to the effects described for CD8+ cytotoxic T lymphocytes (CTL), we next 
investigated maturation and differentiation of TCRγδ+ T cells. From age 50 onwards 
slight shifts in the distribution of double-negative (DN), CD4 single-positive (SP), CD8 SP, and double-positive (DP) cells were visible, mostly affecting the predominant DN 
and CD8 SP compartments (Fig. 2a). TCRαβ+ T cells also showed significant differences 
in the CD4/CD8 distributions upon ageing (Supplementary Fig. 2d), with a clear shift in the CD4/CD8 ratio towards more CD4+ T cells (Supplementary Fig. 2e), as described 
before [47-50]. Even though in TCRγδ+ T cells CD4/CD8 ratios have a completely dif- ferent meaning, given that TCRγδ+ T cells usually do not express CD4 and the CD8αα 
dimer upon activation [38], we still checked these ratios and did not observe significant 
changes (Fig. 2b). Of note, earlier documented changes in CD8+TCRαβ+ CTL maturation were 
also observed in our cohort, with significant decreases in the naive and significant 
increases in effector CD8+TCRαβ+ T cell compartments (Supplementary Fig. 2f), whilst 
CD4+TCRαβ+ T cells did not show similar significant changes in these maturation subsets 
(Supplementary Fig. 2g). These TCRαβ+ T cell results thus validate our dataset as being 
representative for investigating immunological ageing of TCRγδ+ T cells. Therefore, 
next we determined maturation subsets of the DN and CD8+TCRγδ+ T cells. In general, 
for the DN TCRγδ+ T cell population no significant differences in absolute numbers of 
naive (CD45RO-CD197+) (Fig. 2c) or central memory (CD45RO+CD197+) cells (Fig. 2d) 
were found. In contrast, in the effector memory (CD45RO+CD197-) (Fig. 2e) and effector 
(CD45RO-CD197-) populations (Fig. 2f) numbers decreased significantly, with effec- tor memory cell numbers decreasing already in the age group 40-50 and effector cell 
numbers decreasing mainly in age groups 50-60 and 60-70. For CD8+TCRγδ+ T cells, 
only in the effector memory population a significant difference in absolute numbers 
was observed (Fig. 2h-k). Notably, when further studying relative distributions of these maturation subsets, which in addition to the cell numbers could reflect biologically rel-
evant shifts in subset composition, significant differences were observed for both DN 
and CD8+TCRγδ+ T cells. These concerned decreases in the naive subset fractions and 
increases in the effector subset fractions (Fig. 2g, 2l). This was especially true in the oldest age group (>70), although decreasing (naive) and increasing (effector) trends 
were in fact already visible from age 50 onwards. As TCRγδ+ effector T cells are known to have a rather late-stage differentiated pheno-
type [37], we then further focused on early (CD27+CD28+), intermediate (CD27+CD28-) 
and late (CD27-CD28-) subpopulations. This analysis showed significant decreases in 
absolute numbers of early and intermediate DN TCRγδ+ effector cells starting from age 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
D u r i n g  a g e i n g  t h e  n a i v e  T C R γ δ +  T  c e l l  c o m p a r t m e n t  s h r i n k s  a n d  
s h i f t s  t o w a r d s  a  l a t e - d i f f e r e n t i a t e d  e f f e c t o r  p h e n o t y p e
I n  a n a l o g y  t o  t h e  e f f e c t s  d e s c r i b e d  f o r  C D 8 +  c y t o t o x i c  T  l y m p h o c y t e s  ( C T L ) ,  w e  n e x t  
i n v e s t i g a t e d  m a t u r a t i o n  a n d  d i f f e r e n t i a t i o n  o f  T C R γ δ +  T  c e l l s .  F r o m  a g e  5 0  o n w a r d s  
s l i g h t  s h i f t s  i n  t h e  d i s t r i b u t i o n  o f  d o u b l e - n e g a t i v e  ( D N ) ,  C D 4  s i n g l e - p o s i t i v e  ( S P ) ,  C D 8  
S P,  a n d  d o u b l e - p o s i t i v e  ( D P )  c e l l s  w e r e  v i s i b l e ,  m o s t l y  a f f e c t i n g  t h e  p r e d o m i n a n t  D N  
a n d  C D 8  S P  c o m p a r t m e n t s  ( F i g .  2 a ) .  T C R α β +  T  c e l l s  a l s o  s h o w e d  s i g n i f i c a n t  d i f f e r e n c e s  
i n  t h e  C D 4 / C D 8  d i s t r i b u t i o n s  u p o n  a g e i n g  ( S u p p l e m e n t a r y  F i g .  2 d ) ,  w i t h  a  c l e a r  s h i f t  
i n  t h e  C D 4 / C D 8  r a t i o  t o w a r d s  m o r e  C D 4 +  T  c e l l s  ( S u p p l e m e n t a r y  F i g .  2 e ) ,  a s  d e s c r i b e d  
b e f o r e  [ 4 7 - 5 0 ] .  E v e n  t h o u g h  i n  T C R γ δ +  T  c e l l s  C D 4 / C D 8  r a t i o s  h a v e  a  c o m p l e t e l y  d i f -
f e r e n t  m e a n i n g ,  g i v e n  t h a t  T C R γ δ +  T  c e l l s  u s u a l l y  d o  n o t  e x p r e s s  C D 4  a n d  t h e  C D 8 α α  
d i m e r  u p o n  a c t i v a t i o n  [ 3 8 ] ,  w e  s t i l l  c h e c k e d  t h e s e  r a t i o s  a n d  d i d  n o t  o b s e r v e  s i g n i f i c a n t  
c h a n g e s  ( F i g .  2 b ) .  
O f  n o t e ,  e a r l i e r  d o c u m e n t e d  c h a n g e s  i n  C D 8 + T C R α β +  C T L  m a t u r a t i o n  w e r e  
a l s o  o b s e r v e d  i n  o u r  c o h o r t ,  w i t h  s i g n i f i c a n t  d e c r e a s e s  i n  t h e  n a i v e  a n d  s i g n i f i c a n t  
i n c r e a s e s  i n  e f f e c t o r  C D 8 + T C R α β +  T  c e l l  c o m p a r t m e n t s  ( S u p p l e m e n t a r y  F i g .  2 f ) ,  w h i l s t  
C D 4 + T C R α β +  T  c e l l s  d i d  n o t  s h o w  s i m i l a r  s i g n i f i c a n t  c h a n g e s  i n  t h e s e  m a t u r a t i o n  s u b s e t s  
( S u p p l e m e n t a r y  F i g .  2 g ) .  T h e s e  T C R α β +  T  c e l l  r e s u l t s  t h u s  v a l i d a t e  o u r  d a t a s e t  a s  b e i n g  
r e p r e s e n t a t i v e  f o r  i n v e s t i g a t i n g  i m m u n o l o g i c a l  a g e i n g  o f  T C R γ δ +  T  c e l l s .  T h e r e f o r e ,  
n e x t  w e  d e t e r m i n e d  m a t u r a t i o n  s u b s e t s  o f  t h e  D N  a n d  C D 8 + T C R γ δ +  T  c e l l s .  I n  g e n e r a l ,  
f o r  t h e  D N  T C R γ δ +  T  c e l l  p o p u l a t i o n  n o  s i g n i f i c a n t  d i f f e r e n c e s  i n  a b s o l u t e  n u m b e r s  o f  
n a i v e  ( C D 4 5 R O - C D 1 9 7 + )  ( F i g .  2 c )  o r  c e n t r a l  m e m o r y  ( C D 4 5 R O + C D 1 9 7 + )  c e l l s  ( F i g .  2 d )  
w e r e  f o u n d .  I n  c o n t r a s t ,  i n  t h e  e f f e c t o r  m e m o r y  ( C D 4 5 R O + C D 1 9 7 - )  ( F i g .  2 e )  a n d  e f f e c t o r  
( C D 4 5 R O - C D 1 9 7 - )  p o p u l a t i o n s  ( F i g .  2 f )  n u m b e r s  d e c r e a s e d  s i g n i f i c a n t l y ,  w i t h  e f f e c -
t o r  m e m o r y  c e l l  n u m b e r s  d e c r e a s i n g  a l r e a d y  i n  t h e  a g e  g r o u p  4 0 - 5 0  a n d  e f f e c t o r  c e l l  
n u m b e r s  d e c r e a s i n g  m a i n l y  i n  a g e  g r o u p s  5 0 - 6 0  a n d  6 0 - 7 0 .  F o r  C D 8 + T C R γ δ +  T  c e l l s ,  
o n l y  i n  t h e  e f f e c t o r  m e m o r y  p o p u l a t i o n  a  s i g n i f i c a n t  d i f f e r e n c e  i n  a b s o l u t e  n u m b e r s  
w a s  o b s e r v e d  ( F i g .  2 h - k ) .  N o t a b l y ,  w h e n  f u r t h e r  s t u d y i n g  r e l a t i v e  d i s t r i b u t i o n s  o f  t h e s e  
m a t u r a t i o n  s u b s e t s ,  w h i c h  i n  a d d i t i o n  t o  t h e  c e l l  n u m b e r s  c o u l d  r e f l e c t  b i o l o g i c a l l y  r e l -
e v a n t  s h i f t s  i n  s u b s e t  c o m p o s i t i o n ,  s i g n i f i c a n t  d i f f e r e n c e s  w e r e  o b s e r v e d  f o r  b o t h  D N  
a n d  C D 8 + T C R γ δ +  T  c e l l s .  T h e s e  c o n c e r n e d  d e c r e a s e s  i n  t h e  n a i v e  s u b s e t  f r a c t i o n s  a n d  
i n c r e a s e s  i n  t h e  e f f e c t o r  s u b s e t  f r a c t i o n s  ( F i g .  2 g ,  2 l ) .  T h i s  w a s  e s p e c i a l l y  t r u e  i n  t h e  
o l d e s t  a g e  g r o u p  ( > 7 0 ) ,  a l t h o u g h  d e c r e a s i n g  ( n a i v e )  a n d  i n c r e a s i n g  ( e f f e c t o r )  t r e n d s  
w e r e  i n  f a c t  a l r e a d y  v i s i b l e  f r o m  a g e  5 0  o n w a r d s .  
A s  T C R γ δ +  e f f e c t o r  T  c e l l s  a r e  k n o w n  t o  h a v e  a  r a t h e r  l a t e - s t a g e  d i f f e r e n t i a t e d  p h e n o -
t y p e  [ 3 7 ] ,  w e  t h e n  f u r t h e r  f o c u s e d  o n  e a r l y  ( C D 2 7 + C D 2 8 + ) ,  i n t e r m e d i a t e  ( C D 2 7 + C D 2 8 - )  
a n d  l a t e  ( C D 2 7 - C D 2 8 - )  s u b p o p u l a t i o n s .  T h i s  a n a l y s i s  s h o w e d  s i g n i f i c a n t  d e c r e a s e s  i n  
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group 40-50, but not of late-stage differentiated effector cells (Fig. 3a). Given that also the effector memory cells were found to relatively expand in the aged groups (Fig. 2g, 
2l), we additionally looked into early, intermediate and late differentiated cells within the effector memory subset. Significant decreases in early and intermediate DN TCRγδ+ 
effector memory cell numbers were found when all age groups were compared with the 20-40 age control group. Also a significant decrease in the absolute numbers of late-stage 
differentiated cells was observed, mainly when the oldest age group was compared with the control group (Fig. 3b). CD8+TCRγδ+ cells showed no significant differences in early, 
intermediate or late stages, except for a decrease in absolute numbers of late-differenti- ated effector memory cells in the oldest age group (Fig. 3c, 3d). 
Since absolute numbers of total TCRγδ+ T cells generally decreased (Fig. 1a), and 
the maturation subsets displayed clear shifts in distribution (Fig. 2g, 2l), we also inves- tigated the relative shifts of stages within the effector and effector memory cell popu-
lations as discussed above. Significant decreases were observed in early and interme- diate DN TCRγδ+ effector cell proportions with a concomitant significant increase in 
percentages of late-stage differentiated cells in especially the >70 age group when all age groups were compared to the control age group (Fig. 4a); this was rather reversed in the 
effector memory cells where an increase in the proportions of early differentiated cells was observed (Fig. 4b). Furthermore, even though in CD8+TCRγδ+ effector T cells no 
significant changes in absolute numbers were observed (Fig. 3c), their relative distribu- tions did show significant decreases in especially intermediate effector cells, concurrent 
with a significant increase in late-stage differentiated cells (Fig. 4c) at age 50-60. Within 
the CD8+TCRγδ+ effector memory population a significant decrease in the proportions 
of intermediate differentiated cells was observed (Fig. 4d).  Taken together, we conclude that ageing has a similar effect on TCRγδ+ maturation 
subsets as was reported for CD8+TCRαβ+ CTL. Despite an overall decrease in TCRγδ+ 
cell numbers, the relative increase in effector cells and the shift towards a late-stage differentiated phenotype result in stable numbers of the most differentiated effector cell 
population.
Figure 2 (see left page). TCRγδ+ T cell maturation statuses and subset distributions during ageing.
(a) Relative visualization of CD4 and CD8 single-positive, double-positive (DP, CD4+CD8+) and double-negative (DN, CD4-CD8-) distribution within the total TCRγδ+ T cell compartment between different age groups. (b) CD4:CD8 ratios in total TCRγδ+ T cell population. (c) Absolute numbers of DN naive (CD45RO-CD197+), 
(d) central memory (CD45RO+CD197+), (e) effector memory (CD45RO+CD197-, TemRO) and (f) effector (CD45RO-CD197-, TemRA) TCRγδ+ T cells. (g) Relative distributions of maturation subsets of DN TCRγδ+ T cells depicted in stacked bar plots. (h) Absolute numbers of CD8+ naive, (i) central memory, (j) effector 
memory and (k) effector CD8+ TCRγδ+ T cells. (l) Relative distributions of maturation subsets of CD8+ TCRγδ+ T cells depicted in stacked bar plots. Ratios and absolute numbers are indicated in scatter plots indicated with the median. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test for correction for 
multiple testing. Significance for the Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01, ***, p<0.001. 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
g r o u p  4 0 - 5 0 ,  b u t  n o t  o f  l a t e - s t a g e  d i f f e r e n t i a t e d  e f f e c t o r  c e l l s  ( F i g .  3 a ) .  G i v e n  t h a t  a l s o  
t h e  e f f e c t o r  m e m o r y  c e l l s  w e r e  f o u n d  t o  r e l a t i v e l y  e x p a n d  i n  t h e  a g e d  g r o u p s  ( F i g .  2 g ,  
2 l ) ,  w e  a d d i t i o n a l l y  l o o k e d  i n t o  e a r l y ,  i n t e r m e d i a t e  a n d  l a t e  d i f f e r e n t i a t e d  c e l l s  w i t h i n  
t h e  e f f e c t o r  m e m o r y  s u b s e t .  S i g n i f i c a n t  d e c r e a s e s  i n  e a r l y  a n d  i n t e r m e d i a t e  D N  T C R γ δ +  
e f f e c t o r  m e m o r y  c e l l  n u m b e r s  w e r e  f o u n d  w h e n  a l l  a g e  g r o u p s  w e r e  c o m p a r e d  w i t h  t h e  
2 0 - 4 0  a g e  c o n t r o l  g r o u p .  A l s o  a  s i g n i f i c a n t  d e c r e a s e  i n  t h e  a b s o l u t e  n u m b e r s  o f  l a t e - s t a g e  
d i f f e r e n t i a t e d  c e l l s  w a s  o b s e r v e d ,  m a i n l y  w h e n  t h e  o l d e s t  a g e  g r o u p  w a s  c o m p a r e d  w i t h  
t h e  c o n t r o l  g r o u p  ( F i g .  3 b ) .  C D 8 + T C R γ δ +  c e l l s  s h o w e d  n o  s i g n i f i c a n t  d i f f e r e n c e s  i n  e a r l y ,  
i n t e r m e d i a t e  o r  l a t e  s t a g e s ,  e x c e p t  f o r  a  d e c r e a s e  i n  a b s o l u t e  n u m b e r s  o f  l a t e - d i f f e r e n t i -
a t e d  e f f e c t o r  m e m o r y  c e l l s  i n  t h e  o l d e s t  a g e  g r o u p  ( F i g .  3 c ,  3 d ) .  
S i n c e  a b s o l u t e  n u m b e r s  o f  t o t a l  T C R γ δ +  T  c e l l s  g e n e r a l l y  d e c r e a s e d  ( F i g .  1 a ) ,  a n d  
t h e  m a t u r a t i o n  s u b s e t s  d i s p l a y e d  c l e a r  s h i f t s  i n  d i s t r i b u t i o n  ( F i g .  2 g ,  2 l ) ,  w e  a l s o  i n v e s -
t i g a t e d  t h e  r e l a t i v e  s h i f t s  o f  s t a g e s  w i t h i n  t h e  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  c e l l  p o p u -
l a t i o n s  a s  d i s c u s s e d  a b o v e .  S i g n i f i c a n t  d e c r e a s e s  w e r e  o b s e r v e d  i n  e a r l y  a n d  i n t e r m e -
d i a t e  D N  T C R γ δ +  e f f e c t o r  c e l l  p r o p o r t i o n s  w i t h  a  c o n c o m i t a n t  s i g n i f i c a n t  i n c r e a s e  i n  
p e r c e n t a g e s  o f  l a t e - s t a g e  d i f f e r e n t i a t e d  c e l l s  i n  e s p e c i a l l y  t h e  > 7 0  a g e  g r o u p  w h e n  a l l  a g e  
g r o u p s  w e r e  c o m p a r e d  t o  t h e  c o n t r o l  a g e  g r o u p  ( F i g .  4 a ) ;  t h i s  w a s  r a t h e r  r e v e r s e d  i n  t h e  
e f f e c t o r  m e m o r y  c e l l s  w h e r e  a n  i n c r e a s e  i n  t h e  p r o p o r t i o n s  o f  e a r l y  d i f f e r e n t i a t e d  c e l l s  
w a s  o b s e r v e d  ( F i g .  4 b ) .  F u r t h e r m o r e ,  e v e n  t h o u g h  i n  C D 8 + T C R γ δ +  e f f e c t o r  T  c e l l s  n o  
s i g n i f i c a n t  c h a n g e s  i n  a b s o l u t e  n u m b e r s  w e r e  o b s e r v e d  ( F i g .  3 c ) ,  t h e i r  r e l a t i v e  d i s t r i b u -
t i o n s  d i d  s h o w  s i g n i f i c a n t  d e c r e a s e s  i n  e s p e c i a l l y  i n t e r m e d i a t e  e f f e c t o r  c e l l s ,  c o n c u r r e n t  
w i t h  a  s i g n i f i c a n t  i n c r e a s e  i n  l a t e - s t a g e  d i f f e r e n t i a t e d  c e l l s  ( F i g .  4 c )  a t  a g e  5 0 - 6 0 .  W i t h i n  
t h e  C D 8 + T C R γ δ +  e f f e c t o r  m e m o r y  p o p u l a t i o n  a  s i g n i f i c a n t  d e c r e a s e  i n  t h e  p r o p o r t i o n s  
o f  i n t e r m e d i a t e  d i f f e r e n t i a t e d  c e l l s  w a s  o b s e r v e d  ( F i g .  4 d ) .   
T a k e n  t o g e t h e r ,  w e  c o n c l u d e  t h a t  a g e i n g  h a s  a  s i m i l a r  e f f e c t  o n  T C R γ δ +  m a t u r a t i o n  
s u b s e t s  a s  w a s  r e p o r t e d  f o r  C D 8 + T C R α β +  C T L .  D e s p i t e  a n  o v e r a l l  d e c r e a s e  i n  T C R γ δ +  
c e l l  n u m b e r s ,  t h e  r e l a t i v e  i n c r e a s e  i n  e f f e c t o r  c e l l s  a n d  t h e  s h i f t  t o w a r d s  a  l a t e - s t a g e  
d i f f e r e n t i a t e d  p h e n o t y p e  r e s u l t  i n  s t a b l e  n u m b e r s  o f  t h e  m o s t  d i f f e r e n t i a t e d  e f f e c t o r  c e l l  
p o p u l a t i o n .
F i g u r e  2  ( s e e  l e f t  p a g e ) .  T C R γ δ +  T  c e l l  m a t u r a t i o n  s t a t u s e s  a n d  s u b s e t  d i s t r i b u t i o n s  d u r i n g  a g e i n g .
( a )  R e l a t i v e  v i s u a l i z a t i o n  o f  C D 4  a n d  C D 8  s i n g l e - p o s i t i v e ,  d o u b l e - p o s i t i v e  ( D P,  C D 4 + C D 8 + )  a n d  d o u b l e - n e g a t i v e  
( D N ,  C D 4 - C D 8 - )  d i s t r i b u t i o n  w i t h i n  t h e  t o t a l  T C R γ δ +  T  c e l l  c o m p a r t m e n t  b e t w e e n  d i f f e r e n t  a g e  g r o u p s .  ( b )  
C D 4 : C D 8  r a t i o s  i n  t o t a l  T C R γ δ +  T  c e l l  p o p u l a t i o n .  ( c )  A b s o l u t e  n u m b e r s  o f  D N  n a i v e  ( C D 4 5 R O - C D 1 9 7 + ) ,  
( d )  c e n t r a l  m e m o r y  ( C D 4 5 R O + C D 1 9 7 + ) ,  ( e )  e f f e c t o r  m e m o r y  ( C D 4 5 R O + C D 1 9 7 - ,  T e m R O )  a n d  ( f )  e f f e c t o r  
( C D 4 5 R O - C D 1 9 7 - ,  T e m R A )  T C R γ δ +  T  c e l l s .  ( g )  R e l a t i v e  d i s t r i b u t i o n s  o f  m a t u r a t i o n  s u b s e t s  o f  D N  T C R γ δ +  
T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  ( h )  A b s o l u t e  n u m b e r s  o f  C D 8 +  n a i v e ,  ( i )  c e n t r a l  m e m o r y ,  ( j )  e f f e c t o r  
m e m o r y  a n d  ( k )  e f f e c t o r  C D 8 +  T C R γ δ +  T  c e l l s .  ( l )  R e l a t i v e  d i s t r i b u t i o n s  o f  m a t u r a t i o n  s u b s e t s  o f  C D 8 +  T C R γ δ +  
T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  R a t i o s  a n d  a b s o l u t e  n u m b e r s  a r e  i n d i c a t e d  i n  s c a t t e r  p l o t s  i n d i c a t e d  w i t h  
t h e  m e d i a n .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  c o r r e c t i o n  f o r  
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CMV-seropositivity impacts on Vδ-usage at old age
Persistent viruses and especially CMV are known to have major effects on the com- position, senescence, and exhaustion of the immune system [13,43,45,46,51]. We there-
fore studied the potential impact of CMV on immunological ageing of TCRγδ+ T cells. 
To this end we subdivided our study cohort, according to CMV serology. Furthermore, we also looked at gender as a potential confounding factor for immunological ageing. 
Although the proportion of CMV-seropositive individuals was higher with age in both males and females, these percentages were not significantly different in any age group 
Figure 3 (see left page). DN and CD8+TCRγδ+ effector and effector memory differentiation stages 
during ageing.
(a) Absolute numbers of early (CD27+CD28+), intermediate (CD27+CD28-) and late (CD27-CD28-) differentiated DN and (c) CD8+TCRγδ+ effector (CD45RO-CD197-, TemRA) T cells. (b) Absolute numbers of early, intermediate and late differentiated DN and (d) CD8+ TCRγδ+ effector memory (CD45RO+CD197-, 
TemRO) T cells. Early (E), intermediate (I) and late (L) definitions are indicated in the upper right corners 
of the graphs. Scatter plots are indicated with the median. Significance was tested by a Kruskal-Wallis test, 
followed by a post-Dunn’s test for correction for multiple testing. Significance for the Dunn’s test is indicated 
in the plots: **, p<0.01; ***, p<0.001.
Figure 4. DN and CD8+ TCRγδ+ effector and effector memory differentiation stage distributions during 
ageing.
(a) Relative differentiated subset distributions of percentages of DN and (c) CD8+ effector and (b) DN and (d) CD8+ effector memory TCRγδ+ T cells depicted in stacked bar plots. Significance was tested by a Kruskal- Wallis test, and followed by a post-Dunn’s test for correction for multiple testing. Data of different age groups 
was compared with the control age group. Significance for the Dunn’s test is indicated in the plots: *, p<0.05; 
**, p<0.01; ***, p<0.001. 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
C M V - s e r o p o s i t i v i t y  i m p a c t s  o n  V δ - u s a g e  a t  o l d  a g e
P e r s i s t e n t  v i r u s e s  a n d  e s p e c i a l l y  C M V  a r e  k n o w n  t o  h a v e  m a j o r  e f f e c t s  o n  t h e  c o m -
p o s i t i o n ,  s e n e s c e n c e ,  a n d  e x h a u s t i o n  o f  t h e  i m m u n e  s y s t e m  [ 1 3 , 4 3 , 4 5 , 4 6 , 5 1 ] .  W e  t h e r e -
f o r e  s t u d i e d  t h e  p o t e n t i a l  i m p a c t  o f  C M V  o n  i m m u n o l o g i c a l  a g e i n g  o f  T C R γ δ +  T  c e l l s .  
T o  t h i s  e n d  w e  s u b d i v i d e d  o u r  s t u d y  c o h o r t ,  a c c o r d i n g  t o  C M V  s e r o l o g y .  F u r t h e r m o r e ,  
w e  a l s o  l o o k e d  a t  g e n d e r  a s  a  p o t e n t i a l  c o n f o u n d i n g  f a c t o r  f o r  i m m u n o l o g i c a l  a g e i n g .  
A l t h o u g h  t h e  p r o p o r t i o n  o f  C M V - s e r o p o s i t i v e  i n d i v i d u a l s  w a s  h i g h e r  w i t h  a g e  i n  b o t h  
m a l e s  a n d  f e m a l e s ,  t h e s e  p e r c e n t a g e s  w e r e  n o t  s i g n i f i c a n t l y  d i f f e r e n t  i n  a n y  a g e  g r o u p  
F i g u r e  3  ( s e e  l e f t  p a g e ) .  D N  a n d  C D 8 + T C R γ δ +  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  d i f f e r e n t i a t i o n  s t a g e s  
d u r i n g  a g e i n g .
( a )  A b s o l u t e  n u m b e r s  o f  e a r l y  ( C D 2 7 + C D 2 8 + ) ,  i n t e r m e d i a t e  ( C D 2 7 + C D 2 8 - )  a n d  l a t e  ( C D 2 7 - C D 2 8 - )  
d i f f e r e n t i a t e d  D N  a n d  ( c )  C D 8 + T C R γ δ +  e f f e c t o r  ( C D 4 5 R O - C D 1 9 7 - ,  T e m R A )  T  c e l l s .  ( b )  A b s o l u t e  n u m b e r s  
o f  e a r l y ,  i n t e r m e d i a t e  a n d  l a t e  d i f f e r e n t i a t e d  D N  a n d  ( d )  C D 8 +  T C R γ δ +  e f f e c t o r  m e m o r y  ( C D 4 5 R O + C D 1 9 7 - ,  
T e m R O )  T  c e l l s .  E a r l y  ( E ) ,  i n t e r m e d i a t e  ( I )  a n d  l a t e  ( L )  d e f i n i t i o n s  a r e  i n d i c a t e d  i n  t h e  u p p e r  r i g h t  c o r n e r s  
o f  t h e  g r a p h s .  S c a t t e r  p l o t s  a r e  i n d i c a t e d  w i t h  t h e  m e d i a n .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  
f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  
i n  t h e  p l o t s :  * * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .
F i g u r e  4 .  D N  a n d  C D 8 +  T C R γ δ +  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  d i f f e r e n t i a t i o n  s t a g e  d i s t r i b u t i o n s  d u r i n g  
a g e i n g .
( a )  R e l a t i v e  d i f f e r e n t i a t e d  s u b s e t  d i s t r i b u t i o n s  o f  p e r c e n t a g e s  o f  D N  a n d  ( c )  C D 8 +  e f f e c t o r  a n d  ( b )  D N  a n d  
( d )  C D 8 +  e f f e c t o r  m e m o r y  T C R γ δ +  T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l -
W a l l i s  t e s t ,  a n d  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  D a t a  o f  d i f f e r e n t  a g e  g r o u p s  
w a s  c o m p a r e d  w i t h  t h e  c o n t r o l  a g e  g r o u p .  S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  
* * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .  
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(Supplementary Fig. 3); in fact the CMV seroprevalence of our age groups correlated well with previous reports [52,53]. Recently it was shown that gender and additionally CMV 
infection were associated with an expansion of late-stage differentiated TCRαβ+ T cell 
subsets and a reduction of naive, regulatory and CD8+ T cells in especially middle-aged (age category 50-65) males [54]. As we did not observe a gender effect (Supplementary 
Fig. 4) or specific differences in gender and CMV serology in the middle-aged 50-65 
group (data not shown) with respect to TCRγδ+ T cells in our cohort, we further focused our analyses on age and CMV serology only. In order to be able to make clear distinc-
tions, we defined groups of young controls (age 20-40) and elderly individuals (above age 60) (Table 1), and subdivided both groups into seronegative (CMV-) and seropositive 
(CMV+) subjects. 
First, total TCRγδ+ T cell absolute counts were compared between young vs. elderly, 
and CMV- vs. CMV+ groups, which showed a significantly higher total TCRγδ+ T cell count 
in young CMV+ individuals (Fig. 5a). In elderly the absolute numbers of total TCRγδ+ T 
cells were decreased, without a significant additional effect of CMV (Fig. 5a). Of note, 
TCRαβ+ T cell counts were not significantly affected in these subgroups (Supplementary 
Fig. 2h). The relative distributions of TCRαβ+ and TCRγδ+ T cells were also determined, 
showing significant alterations in elderly; particularly in CMV+ elderly the percentage 
of TCRγδ+ T cells was significantly reduced, with a parallel increase of the TCRαβ+ T 
cell fraction (Supplementary Fig. 2i). Furthermore, upon evaluation of Vγ/Vδ-usage, 
changes in absolute numbers of Vδ2+ and Vγ9/Vδ2 populations were largely similar as 
for total TCRγδ+ T cells, whilst absolute numbers of Vδ1+ cells were increased in both 
young and old CMV+ individuals (Fig. 5c, 5d). The overall Vδ-usage distribution showed 
significant changes in the composition in especially CMV-infected elderly, with an 
increased proportion of Vδ1+ and a decreased proportion of Vδ2+ cells (Supplementary Fig. 2j). The increase in CMV-seroprevalence in elderly (Supplementary Fig. 3) and the 
relative increase in Vδ1-usage (Supplementary Fig. 2j) in both elderly and young CMV+ 
individuals correlate with known Vδ1+ cell reactivity to CMV [55].Collectively, these data suggest that CMV has a profound effect on the numbers of all 
TCRγδ+ T cells in young infected individuals, and that in elderly the impact of CMV is 
more distinct TCRγδ+ subgroups showing different Vδ-usage. 
The shift towards an effector TCRγδ+ T cell phenotype in elderly is 
largely explained by CMV infection
Next we also investigated the impact of CMV on maturation phenotypes of TCRγδ+ T 
cells. Firstly, no significant alterations were seen in the frequencies of the predominant 
DN and CD8+TCRγδ+ T cell populations (Fig. 6a) or in the CD4/CD8 ratios of TCRγδ+ T cells (Fig. 6b), both in the absence and presence of CMV. In contrast, CD4, CD8, DN, DP 
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Collectively, these data suggest that CMV has a profound effect on the numbers of all 
TCRγδ+ T cells in young infected individuals, and that in elderly the impact of CMV is 
more distinct TCRγδ+ subgroups showing different Vδ-usage. 
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populations in TCRαβ+ T cells were significantly different, mainly in the elderly CMV- 
group (Supplementary Fig. 2k), with a shift in the CD4/CD8 ratio towards more CD4+ T 
cells (Supplementary Fig. 2l). In keeping with published data, clear changes were seen in the relative proportions of different maturation stages in the CD4+ and CD8+TCRαβ+ T 
cells upon CMV (Supplementary Fig. 2m, 2n), thus reinforcing the validity of our cohort for studying TCRγδ+ T cells. 
When focusing on the absolute numbers of naive and central memory DN TCRγδ+ 
cells no significant changes were observed (Fig. 6c, 6d). In contrast, we did find signifi- cant changes in effector memory and effector cell absolute counts, with increased num-
bers being present in especially the young CMV+ group (Fig. 6e, 6f). In the CD8+TCRγδ+ 
T cell population we did not observe significant changes in the naive and central memory 
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Figure 5. Effect of CMV seropositivity on Vγ/Vδ-usage. 
(a) Absolute numbers of total TCRγδ+ T cells, (b) Vδ1+, (c) Vδ2+ and (d) Vγ9/Vδ2 TCRγδ+ T cells depicted as 10-90% box-whisker-plots. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test to correct for multiple testing. Significance for the Dunn’s test is indicated in the plots: **, p<0.01; ***, p<0.001.
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
p o p u l a t i o n s  i n  T C R α β +  T  c e l l s  w e r e  s i g n i f i c a n t l y  d i f f e r e n t ,  m a i n l y  i n  t h e  e l d e r l y  C M V -  
g r o u p  ( S u p p l e m e n t a r y  F i g .  2 k ) ,  w i t h  a  s h i f t  i n  t h e  C D 4 / C D 8  r a t i o  t o w a r d s  m o r e  C D 4 +  T  
c e l l s  ( S u p p l e m e n t a r y  F i g .  2 l ) .  I n  k e e p i n g  w i t h  p u b l i s h e d  d a t a ,  c l e a r  c h a n g e s  w e r e  s e e n  i n  
t h e  r e l a t i v e  p r o p o r t i o n s  o f  d i f f e r e n t  m a t u r a t i o n  s t a g e s  i n  t h e  C D 4 +  a n d  C D 8 + T C R α β +  T  
c e l l s  u p o n  C M V  ( S u p p l e m e n t a r y  F i g .  2 m ,  2 n ) ,  t h u s  r e i n f o r c i n g  t h e  v a l i d i t y  o f  o u r  c o h o r t  
f o r  s t u d y i n g  T C R γ δ +  T  c e l l s .  
W h e n  f o c u s i n g  o n  t h e  a b s o l u t e  n u m b e r s  o f  n a i v e  a n d  c e n t r a l  m e m o r y  D N  T C R γ δ +  
c e l l s  n o  s i g n i f i c a n t  c h a n g e s  w e r e  o b s e r v e d  ( F i g .  6 c ,  6 d ) .  I n  c o n t r a s t ,  w e  d i d  f i n d  s i g n i f i -
c a n t  c h a n g e s  i n  e f f e c t o r  m e m o r y  a n d  e f f e c t o r  c e l l  a b s o l u t e  c o u n t s ,  w i t h  i n c r e a s e d  n u m -
b e r s  b e i n g  p r e s e n t  i n  e s p e c i a l l y  t h e  y o u n g  C M V +  g r o u p  ( F i g .  6 e ,  6 f ) .  I n  t h e  C D 8 + T C R γ δ +  
T  c e l l  p o p u l a t i o n  w e  d i d  n o t  o b s e r v e  s i g n i f i c a n t  c h a n g e s  i n  t h e  n a i v e  a n d  c e n t r a l  m e m o r y  











































































































































F i g u r e  5 .  E f f e c t  o f  C M V  s e r o p o s i t i v i t y  o n  V γ / V δ - u s a g e .  
( a )  A b s o l u t e  n u m b e r s  o f  t o t a l  T C R γ δ +  T  c e l l s ,  ( b )  V δ 1 + ,  ( c )  V δ 2 +  a n d  ( d )  V γ 9 / V δ 2  T C R γ δ +  T  c e l l s  d e p i c t e d  a s  
1 0 - 9 0 %  b o x - w h i s k e r - p l o t s .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  t o  





Effect of ageing and CMV infection on TCRγδ+ T cells 
memory and effector cell counts (Fig. 6j, 6k) in keeping with the significant increase 
in total TCRγδ+ T cells in young CMV+ individuals (Fig. 5a). In order to further investi- gate the biological impact of both ageing and CMV we then also focused on the relative 
subset distributions. We did not find significant differences in the subset distribution 
of DN TCRγδ+ T cells, despite an increasing trend in the effector population (Fig. 6g). 
However, the relative distributions of CD8+TCRγδ+ T cell maturation subsets did signifi- cantly alter. Especially upon the presence of CMV, the percentages of effector cells were 
increased, with a concomitant decrease in the naive compartment (Fig. 6l). The subset distribution pattern of young CMV+ individuals reflected that of elderly (Fig. 6l).
When looking more in-depth into the differentiation stages within effector and effec- tor memory cells, the absolute numbers of early and intermediate effector DN TCRγδ+ T 
cells increased, whilst late effector cells showed a significant increase in predominantly 
the young CMV+ individuals (Fig. 7a). The effector memory DN TCRγδ+ T cells showed 
increased numbers in all differentiation stages when it comes to ageing in the presence of CMV, although this was not significant for the early differentiated cells (Fig. 7b). In 
CMV+ elderly the absolute numbers of CD8+TCRγδ+ effector and effector memory cells 
were significantly higher in almost all differentiation stages, except for intermediate 
effector memory cells (Fig. 7c, 7d). As we observed in all differentiation stages an increase in absolute numbers in 
elderly CMV+ individuals, we then further looked into the relative composition. When 
evaluating the overall distribution patterns, comparing all groups with each other, young and old CMV- individuals were showing very similar distribution patterns, as well as 
young and old CMV+ individuals (Fig. 8). In the presence of CMV – in both young and 
elderly – percentages of DN TCRγδ+ intermediate effector cells decreased, whilst those 
of late effector cells increased (Fig. 8a). This effect was similar and even more pro- nounced for the CD8+TCRγδ+ effector population (Fig. 8c). When investigating effector 
memory subpopulations, analogous to what was seen in elderly age groups, significant 
increases in absolute numbers and relative distributions were noted, mainly in CMV+ 
elderly (Fig. 8b, 8d). 
Figure 6 (see left page). Effect of CMV on TCRγδ+ T cell maturation.
(a) Relative visualization of CD4 and CD8 single-positive, double-positive (DP, CD4+CD8+) and double- negative (DN, CD4-CD8-) distribution within the total TCRγδ+ T cell compartment between different age and CMV groups. (b) CD4:CD8 ratios in total TCRγδ+ T cell population. (c) Absolute numbers of DN naive 
(CD45RO-CD197+), (d) central memory (CD45RO+CD197+), (e) effector memory (CD45RO+CD197-, TemRO) 
and (f) effector (CD45RO-CD197-, TemRA) TCRγδ+ T cells. (g) Relative distributions of maturation subsets of DN TCRγδ+ T cells depicted in stacked bar plots. (h) Absolute numbers of CD8+ naive, (i) central memory, (j) effector memory and (k) effector CD8+ TCRγδ+ T cells. (l) Relative distributions of maturation subsets of 
CD8+ TCRγδ+ T cells depicted in stacked bar plots. Ratios and absolute numbers are indicated in scatter plots 
indicated with the median. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test for 




E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
m e m o r y  a n d  e f f e c t o r  c e l l  c o u n t s  ( F i g .  6 j ,  6 k )  i n  k e e p i n g  w i t h  t h e  s i g n i f i c a n t  i n c r e a s e  
i n  t o t a l  T C R γ δ +  T  c e l l s  i n  y o u n g  C M V +  i n d i v i d u a l s  ( F i g .  5 a ) .  I n  o r d e r  t o  f u r t h e r  i n v e s t i -
g a t e  t h e  b i o l o g i c a l  i m p a c t  o f  b o t h  a g e i n g  a n d  C M V  w e  t h e n  a l s o  f o c u s e d  o n  t h e  r e l a t i v e  
s u b s e t  d i s t r i b u t i o n s .  W e  d i d  n o t  f i n d  s i g n i f i c a n t  d i f f e r e n c e s  i n  t h e  s u b s e t  d i s t r i b u t i o n  
o f  D N  T C R γ δ +  T  c e l l s ,  d e s p i t e  a n  i n c r e a s i n g  t r e n d  i n  t h e  e f f e c t o r  p o p u l a t i o n  ( F i g .  6 g ) .  
H o w e v e r ,  t h e  r e l a t i v e  d i s t r i b u t i o n s  o f  C D 8 + T C R γ δ +  T  c e l l  m a t u r a t i o n  s u b s e t s  d i d  s i g n i f i -
c a n t l y  a l t e r .  E s p e c i a l l y  u p o n  t h e  p r e s e n c e  o f  C M V ,  t h e  p e r c e n t a g e s  o f  e f f e c t o r  c e l l s  w e r e  
i n c r e a s e d ,  w i t h  a  c o n c o m i t a n t  d e c r e a s e  i n  t h e  n a i v e  c o m p a r t m e n t  ( F i g .  6 l ) .  T h e  s u b s e t  
d i s t r i b u t i o n  p a t t e r n  o f  y o u n g  C M V +  i n d i v i d u a l s  r e f l e c t e d  t h a t  o f  e l d e r l y  ( F i g .  6 l ) .
W h e n  l o o k i n g  m o r e  i n - d e p t h  i n t o  t h e  d i f f e r e n t i a t i o n  s t a g e s  w i t h i n  e f f e c t o r  a n d  e f f e c -
t o r  m e m o r y  c e l l s ,  t h e  a b s o l u t e  n u m b e r s  o f  e a r l y  a n d  i n t e r m e d i a t e  e f f e c t o r  D N  T C R γ δ +  T  
c e l l s  i n c r e a s e d ,  w h i l s t  l a t e  e f f e c t o r  c e l l s  s h o w e d  a  s i g n i f i c a n t  i n c r e a s e  i n  p r e d o m i n a n t l y  
t h e  y o u n g  C M V +  i n d i v i d u a l s  ( F i g .  7 a ) .  T h e  e f f e c t o r  m e m o r y  D N  T C R γ δ +  T  c e l l s  s h o w e d  
i n c r e a s e d  n u m b e r s  i n  a l l  d i f f e r e n t i a t i o n  s t a g e s  w h e n  i t  c o m e s  t o  a g e i n g  i n  t h e  p r e s e n c e  
o f  C M V ,  a l t h o u g h  t h i s  w a s  n o t  s i g n i f i c a n t  f o r  t h e  e a r l y  d i f f e r e n t i a t e d  c e l l s  ( F i g .  7 b ) .  I n  
C M V +  e l d e r l y  t h e  a b s o l u t e  n u m b e r s  o f  C D 8 + T C R γ δ +  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  c e l l s  
w e r e  s i g n i f i c a n t l y  h i g h e r  i n  a l m o s t  a l l  d i f f e r e n t i a t i o n  s t a g e s ,  e x c e p t  f o r  i n t e r m e d i a t e  
e f f e c t o r  m e m o r y  c e l l s  ( F i g .  7 c ,  7 d ) .  
A s  w e  o b s e r v e d  i n  a l l  d i f f e r e n t i a t i o n  s t a g e s  a n  i n c r e a s e  i n  a b s o l u t e  n u m b e r s  i n  
e l d e r l y  C M V +  i n d i v i d u a l s ,  w e  t h e n  f u r t h e r  l o o k e d  i n t o  t h e  r e l a t i v e  c o m p o s i t i o n .  W h e n  
e v a l u a t i n g  t h e  o v e r a l l  d i s t r i b u t i o n  p a t t e r n s ,  c o m p a r i n g  a l l  g r o u p s  w i t h  e a c h  o t h e r ,  y o u n g  
a n d  o l d  C M V -  i n d i v i d u a l s  w e r e  s h o w i n g  v e r y  s i m i l a r  d i s t r i b u t i o n  p a t t e r n s ,  a s  w e l l  a s  
y o u n g  a n d  o l d  C M V +  i n d i v i d u a l s  ( F i g .  8 ) .  I n  t h e  p r e s e n c e  o f  C M V  –  i n  b o t h  y o u n g  a n d  
e l d e r l y  –  p e r c e n t a g e s  o f  D N  T C R γ δ +  i n t e r m e d i a t e  e f f e c t o r  c e l l s  d e c r e a s e d ,  w h i l s t  t h o s e  
o f  l a t e  e f f e c t o r  c e l l s  i n c r e a s e d  ( F i g .  8 a ) .  T h i s  e f f e c t  w a s  s i m i l a r  a n d  e v e n  m o r e  p r o -
n o u n c e d  f o r  t h e  C D 8 + T C R γ δ +  e f f e c t o r  p o p u l a t i o n  ( F i g .  8 c ) .  W h e n  i n v e s t i g a t i n g  e f f e c t o r  
m e m o r y  s u b p o p u l a t i o n s ,  a n a l o g o u s  t o  w h a t  w a s  s e e n  i n  e l d e r l y  a g e  g r o u p s ,  s i g n i f i c a n t  
i n c r e a s e s  i n  a b s o l u t e  n u m b e r s  a n d  r e l a t i v e  d i s t r i b u t i o n s  w e r e  n o t e d ,  m a i n l y  i n  C M V +  
e l d e r l y  ( F i g .  8 b ,  8 d ) .  
F i g u r e  6  ( s e e  l e f t  p a g e ) .  E f f e c t  o f  C M V  o n  T C R γ δ +  T  c e l l  m a t u r a t i o n .
( a )  R e l a t i v e  v i s u a l i z a t i o n  o f  C D 4  a n d  C D 8  s i n g l e - p o s i t i v e ,  d o u b l e - p o s i t i v e  ( D P,  C D 4 + C D 8 + )  a n d  d o u b l e -
n e g a t i v e  ( D N ,  C D 4 - C D 8 - )  d i s t r i b u t i o n  w i t h i n  t h e  t o t a l  T C R γ δ +  T  c e l l  c o m p a r t m e n t  b e t w e e n  d i f f e r e n t  a g e  
a n d  C M V  g r o u p s .  ( b )  C D 4 : C D 8  r a t i o s  i n  t o t a l  T C R γ δ +  T  c e l l  p o p u l a t i o n .  ( c )  A b s o l u t e  n u m b e r s  o f  D N  n a i v e  
( C D 4 5 R O - C D 1 9 7 + ) ,  ( d )  c e n t r a l  m e m o r y  ( C D 4 5 R O + C D 1 9 7 + ) ,  ( e )  e f f e c t o r  m e m o r y  ( C D 4 5 R O + C D 1 9 7 - ,  T e m R O )  
a n d  ( f )  e f f e c t o r  ( C D 4 5 R O - C D 1 9 7 - ,  T e m R A )  T C R γ δ +  T  c e l l s .  ( g )  R e l a t i v e  d i s t r i b u t i o n s  o f  m a t u r a t i o n  s u b s e t s  
o f  D N  T C R γ δ +  T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  ( h )  A b s o l u t e  n u m b e r s  o f  C D 8 +  n a i v e ,  ( i )  c e n t r a l  m e m o r y ,  
( j )  e f f e c t o r  m e m o r y  a n d  ( k )  e f f e c t o r  C D 8 +  T C R γ δ +  T  c e l l s .  ( l )  R e l a t i v e  d i s t r i b u t i o n s  o f  m a t u r a t i o n  s u b s e t s  o f  
C D 8 +  T C R γ δ +  T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  R a t i o s  a n d  a b s o l u t e  n u m b e r s  a r e  i n d i c a t e d  i n  s c a t t e r  p l o t s  
i n d i c a t e d  w i t h  t h e  m e d i a n .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  
c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  * * ,  p < 0 . 0 1 ,  





Effect of ageing and CMV infection on TCRγδ+ T cells 
Altogether these data clearly indicate that the presence of CMV greatly impacts on the absolute numbers of differentiated effector and effector memory populations, as well 
as induces shifts in maturation subset compositions of TCRγδ+ T cells similar to what 
is seen in elderly, i.e. a main shift towards effector and effector memory phenotypes, showing more late-staged differentiated effector cells and early-stage differentiated 
effector memory cells.
Figure 7 (see left page). Effect of CMV on effector and effector memory differentiation stages.
(a) Absolute numbers of early (CD27+CD28+), intermediate (CD27+CD28-) and late (CD27-CD28-) differentiated DN and (c) CD8+TCRγδ+ effector (CD45RO-CD197-, TemRA) T cells. (b) Absolute numbers of early, intermediate and late differentiated DN and (d) CD8+ TCRγδ+ effector memory (CD45RO+CD197-, 
TemRO) T cells. Early (E), intermediate (I) and late (L) definitions are indicated in the upper right corners 
of the graphs. Scatter plots are indicated with the median. Significance was tested by a Kruskal-Wallis test, 
followed by a post-Dunn’s test for correction for multiple testing. Significance for the Dunn’s test is indicated 
in the plots: **, p<0.01; ***, p<0.001.
Figure 8. DN and CD8+ TCRγδ+ effector and effector memory differentiation stage distributions during 
ageing and in absence or presence of CMV.
(a) Relative differentiated subset distributions of percentages of DN and (c) CD8+ effector and (b) DN and (d) CD8+ effector memory TCRγδ+ T cells depicted in stacked bar plots. Significant differences between all groups was tested by a Kruskal-Wallis test, and followed by a post-Dunn’s test for correction for multiple testing. 
Significance for the Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001. 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
A l t o g e t h e r  t h e s e  d a t a  c l e a r l y  i n d i c a t e  t h a t  t h e  p r e s e n c e  o f  C M V  g r e a t l y  i m p a c t s  o n  t h e  
a b s o l u t e  n u m b e r s  o f  d i f f e r e n t i a t e d  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  p o p u l a t i o n s ,  a s  w e l l  
a s  i n d u c e s  s h i f t s  i n  m a t u r a t i o n  s u b s e t  c o m p o s i t i o n s  o f  T C R γ δ +  T  c e l l s  s i m i l a r  t o  w h a t  
i s  s e e n  i n  e l d e r l y ,  i . e .  a  m a i n  s h i f t  t o w a r d s  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  p h e n o t y p e s ,  
s h o w i n g  m o r e  l a t e - s t a g e d  d i f f e r e n t i a t e d  e f f e c t o r  c e l l s  a n d  e a r l y - s t a g e  d i f f e r e n t i a t e d  
e f f e c t o r  m e m o r y  c e l l s .
F i g u r e  7  ( s e e  l e f t  p a g e ) .  E f f e c t  o f  C M V  o n  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  d i f f e r e n t i a t i o n  s t a g e s .
( a )  A b s o l u t e  n u m b e r s  o f  e a r l y  ( C D 2 7 + C D 2 8 + ) ,  i n t e r m e d i a t e  ( C D 2 7 + C D 2 8 - )  a n d  l a t e  ( C D 2 7 - C D 2 8 - )  
d i f f e r e n t i a t e d  D N  a n d  ( c )  C D 8 + T C R γ δ +  e f f e c t o r  ( C D 4 5 R O - C D 1 9 7 - ,  T e m R A )  T  c e l l s .  ( b )  A b s o l u t e  n u m b e r s  
o f  e a r l y ,  i n t e r m e d i a t e  a n d  l a t e  d i f f e r e n t i a t e d  D N  a n d  ( d )  C D 8 +  T C R γ δ +  e f f e c t o r  m e m o r y  ( C D 4 5 R O + C D 1 9 7 - ,  
T e m R O )  T  c e l l s .  E a r l y  ( E ) ,  i n t e r m e d i a t e  ( I )  a n d  l a t e  ( L )  d e f i n i t i o n s  a r e  i n d i c a t e d  i n  t h e  u p p e r  r i g h t  c o r n e r s  
o f  t h e  g r a p h s .  S c a t t e r  p l o t s  a r e  i n d i c a t e d  w i t h  t h e  m e d i a n .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  
f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  
i n  t h e  p l o t s :  * * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .
F i g u r e  8 .  D N  a n d  C D 8 +  T C R γ δ +  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  d i f f e r e n t i a t i o n  s t a g e  d i s t r i b u t i o n s  d u r i n g  
a g e i n g  a n d  i n  a b s e n c e  o r  p r e s e n c e  o f  C M V.
( a )  R e l a t i v e  d i f f e r e n t i a t e d  s u b s e t  d i s t r i b u t i o n s  o f  p e r c e n t a g e s  o f  D N  a n d  ( c )  C D 8 +  e f f e c t o r  a n d  ( b )  D N  a n d  ( d )  
C D 8 +  e f f e c t o r  m e m o r y  T C R γ δ +  T  c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  S i g n i f i c a n t  d i f f e r e n c e s  b e t w e e n  a l l  g r o u p s  
w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  a n d  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  
S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  * * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .  
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CMV infection marginally contributes to the increased exhaustion 
profile of TCRγδ+ T cells in elderlyT cell exhaustion is a phenomenon that is often seen in persistent viral infections 
like CMV [13,14,56], and that largely shapes the CD8+TCRαβ+ T cell compartment of the immune system [42,46,51]. Within our cohort we also observed increased absolute num-
bers (Supplementary Fig. 5) and percentages (Supplementary Fig. 6) of CD8+ non-TCRγδ 
(TCRαβ) T cells expressing exhaustion markers. As the level of exhaustion of TCRγδ+ T cells during ageing and upon the presence of persistent viral infections like CMV has not 
been properly documented, we investigated absolute numbers of total TCRγδ+ T cells expressing or lacking the senescence and exhaustion associated markers. We observed 
increased absolute numbers of KLRG1- (Fig.9a), FAS+ (Fig. 9b), CD57+ (Fig. 9d), PD1+ 
(Fig. 9e) and IL7Rα- (Fig. 9f) TCRγδ+ T cells especially in the context of CMV, in both 
young and elderly. 2B4+ TCRγδ+ T cells were also increased in case of young CMV+ 
individuals, although this was not significant (Fig. 9b). Since senescence and exhaustion 
processes are difficult to separate, and since there are no concrete definitions, we also 
looked into combinations of different markers. IL7Rα is lost already during early stages of both exhaustion and senescence, and therefore we studied the marker combinations 
within the IL7Rα- TCRγδ+ T cell population (Fig. 9g-i). We observed only a significant 
increase in IL7Rα-KLRG1-CD57+ TCRγδ+ T cells, mainly in the young CMV+ population (Fig. 9i). 
In view of our findings of increased TCRγδ+ T cell numbers in young but not old 
CMV+ individuals (Fig. 5a), we considered an exhaustion phenotype in especially elderly 
and thus looked for the fractions of TCRγδ+ T cells showing exhaustion markers. When analyzing the percentages increasing trends could be appreciated, however there were 
no significant differences observed, although the variation among younger individuals was higher when compared to elderly, independent of CMV infection (Supplementary Fig. 7). Overall, these data suggest that immunological ageing does contribute to a more 
increased exhaustion phenotype of TCRγδ+ T cells, and that CMV plays an additional role.
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increased exhaustion phenotype of TCRγδ+ T cells, and that CMV plays an additional 
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Figure 9. Effect of CMV on exhaustion and senescence profiles of TCRγδ+ T cells. 
(a) Absolute numbers of TCRγδ+ T cells lacking KLRG1 expression, (b) TCRγδ+ T cells expressing 2B4, (c) FAS death receptor, (d) CD57, (e) PD1, (f) TCRγδ+ T cells lacking IL7Rα, (g) and IL7Rα- TCRγδ+ T cells co- expressing PD1 and FAS, (h) PD1 and 2B4, and (i) expressing CD57 and lacking KLRG1. Scatter plots are 
indicated with the median. Significance was tested by a Kruskal-Wallis test, and followed by a post-Dunn’s 
test for correction for multiple testing. Significance for the Dunn’s test is indicated in the plots: *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
F i g u r e  9 .  E f f e c t  o f  C M V  o n  e x h a u s t i o n  a n d  s e n e s c e n c e  p r o f i l e s  o f  T C R γ δ +  T  c e l l s .  
( a )  A b s o l u t e  n u m b e r s  o f  T C R γ δ +  T  c e l l s  l a c k i n g  K L R G 1  e x p r e s s i o n ,  ( b )  T C R γ δ +  T  c e l l s  e x p r e s s i n g  2 B 4 ,  ( c )  
F A S  d e a t h  r e c e p t o r ,  ( d )  C D 5 7 ,  ( e )  P D 1 ,  ( f )  T C R γ δ +  T  c e l l s  l a c k i n g  I L 7 R α ,  ( g )  a n d  I L 7 R α -  T C R γ δ +  T  c e l l s  c o -
e x p r e s s i n g  P D 1  a n d  F A S ,  ( h )  P D 1  a n d  2 B 4 ,  a n d  ( i )  e x p r e s s i n g  C D 5 7  a n d  l a c k i n g  K L R G 1 .  S c a t t e r  p l o t s  a r e  
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t e s t  f o r  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g .  S i g n i f i c a n c e  f o r  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  * * ,  




With increasing hygiene and improved health care individuals in the Western 
world become significantly older according to the World Health Organization [57,58]. Immunological ageing, also referred to as immunosenescence, has large impacts on 
elderly individual’s health as evidenced from less efficient responses to infectious agents [11], reduced vaccine responses [5,6], and increased risks of developing cancer due to 
insufficient anti-tumor activity of the immune system [59]. Immunosenescence has been 
described at different levels in the immune system with the most well-defined effect 
of ageing concerning subset changes in CD4+ and CD8+TCRαβ+ T cells [47-50]. T cell exhaustion, characterized by a stepwise loss of effector functions, plays a major role in 
immunosenescence [13]. This has mainly been investigated in the TCRαβ+ T cell com-
partment as well, most notably affecting CD8+ T cells. We hypothesized that ageing has 
similar effects on the TCRγδ+ T cell population, which could largely affect the elderly 
individuals due to the reduced or aberrant response of TCRγδ+ T cells to pathogens. 
TCRγδ+ T cells implement different functions from both innate and adaptive immunity 
by readily responding to antigens in both CD8+ CTL and NK cell like manners [33]. The majority of our data presented here is based on absolute counts, in order to determine direct effects, but in some cases this is complemented with information about biological 
shifts in the overall composition of TCRγδ+ T cells. We conclude from our data that ageing 
decreases absolute numbers of total TCRγδ+ T cells, without significantly affecting the 
absolute numbers of TCRαβ+ T cells, starting at age 40-50, confirming earlier findings 
[60]. This decrease in total TCRγδ+ T cells mostly affected the most common TCRγδ+ T 
cell type in the peripheral blood: Vγ9/Vδ2 cells [61]. In contrast, Vδ1+ cells showed a slight increasing trend in absolute numbers during ageing, implicating a potential role of 
Vδ1+-specific antigens which could maintain this population over time. Immunological 
ageing is not solely defined by chronological ageing, but also by persistent viruses like 
CMV [56]. Vδ1+ cells are often CMV-specific [41,55,62], and CMV+ individuals have 
higher numbers of Vδ1+ cells, as described in earlier studies [40,45]. This could explain 
the increasing trend in absolute numbers and percentages of Vδ1+ cells as observed in our cohort in elderly individuals. When CMV serology was included in the analysis, 
we observed a significant increase in absolute counts of total TCRγδ+ T cells in young 
CMV+ individuals, in line with previous findings [37]. This could indicate a prolonged activation state, even during early phases of latency, as described by van de Berg et al., 2010 [63].
This latency of e.g. CMV does not only influence cells bearing specific receptors for its epitopes, it also shapes the immune system in terms of maturation subsets. 
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elderly individual’s health as evidenced from less efficient responses to infectious agents 
[11], reduced vaccine responses [5,6], and increased risks of developing cancer due to 
insufficient anti-tumor activity of the immune system [59]. Immunosenescence has been 
described at different levels in the immune system with the most well-defined effect 
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This latency of e.g. CMV does not only influence cells bearing specific receptors 
for its epitopes, it also shapes the immune system in terms of maturation subsets. 
Ageing alone caused a significant decrease in total TCRγδ+ T cells, and thus decreasing 
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absolute numbers of effector and effector memory phenotype cells. However, when considering relative TCRγδ+ T cell subset distributions a significant increase in effector 
and effector memory phenotypes were observed, similar to what has been described for CD8+TCRαβ+ T cell subset distributions [64], suggesting similar underlying ageing 
processes. The effect of ageing became more evident when CMV serological status was included in the analysis, showing increased absolute numbers of effector and effector 
memory cells. Again, when evaluating relative subset distributions, the effects of both ageing and CMV persistence became more evident, for both maturation and effector and 
effector memory differentiation stages. We mainly found decreased proportions of naive, and increased proportions of effector cells, which have a late-stage differentiated profile, 
as described before [37,46]. In contrast to the effector cells, we observed increased proportions of early-stage differentiated effector memory cells, which could correlate 
with a more general memory-like response to antigens in elderly upon prior antigen exposure. Furthermore, we could observe an age-independent effect of CMV on the 
differentiation stages of effector and effector memory TCRγδ+ T cells, which correlates 
with previous data of Roux et al. [45]. Immune ageing is however not only accompanied by shifts from naive to effector cells, 
since effector cells also progressively lose their function (exhaustion) during the ageing process [13]. We noticed a significantly enlarged TCRγδ+ T cell population expressing 
exhaustion-related markers in young CMV+ individuals, while CMV serology did not add 
to T cell exhaustion in elderly. Loss of IL7Rα marked the loss of self-renewal and early 
stages of T cell exhaustion. We observed a clear increase in absolute counts of IL7Rα- 
TCRγδ+ T cells in elderly. Also, we observed increased expression of CD57, which is also 
highly expressed on terminally differentiated CD8+ CTL with high proliferative activity 
[15], thus marking replicative senescence and susceptibility to activation-induced cell death (AICD) [16]. High expression is also associated with chronic viral infections like 
CMV [17]. Our data showed significantly increased numbers of CD57+TCRγδ+ T cells, in 
both young and old CMV+ individuals. Another NK cell marker which is associated with 
T cell exhaustion is KLRG1, of which high expression marks terminally differentiated or senescent T cells [13,18], whilst severely exhausted CD8+ CTLs are KLRG1-negative [19]. 
We observed higher numbers of KLRG1-negative cells in CMV-infected individuals. Also, our data showed that exhausted CD8+ CTL cells were present in higher numbers in CMV+ 
individuals. Combination of loss of IL7Rα, high CD57 and low KLRG1 expression may 
function as a marker of exhausted cells. Our data confirmed this with an increased cell 
count of such exhausted cells, especially already in the young CMV+ group. Furthermore, 
we saw increasing but not significant numbers of TCRγδ+ T cells expressing the NK cell 
marker 2B4 (CD244), which is normally expressed on memory CD8+ T cells [20,21]. 
The percentages did show an increasing trend from young to elderly, but this was not as 
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
a b s o l u t e  n u m b e r s  o f  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  p h e n o t y p e  c e l l s .  H o w e v e r ,  w h e n  
c o n s i d e r i n g  r e l a t i v e  T C R γ δ +  T  c e l l  s u b s e t  d i s t r i b u t i o n s  a  s i g n i f i c a n t  i n c r e a s e  i n  e f f e c t o r  
a n d  e f f e c t o r  m e m o r y  p h e n o t y p e s  w e r e  o b s e r v e d ,  s i m i l a r  t o  w h a t  h a s  b e e n  d e s c r i b e d  
f o r  C D 8 + T C R α β +  T  c e l l  s u b s e t  d i s t r i b u t i o n s  [ 6 4 ] ,  s u g g e s t i n g  s i m i l a r  u n d e r l y i n g  a g e i n g  
p r o c e s s e s .  T h e  e f f e c t  o f  a g e i n g  b e c a m e  m o r e  e v i d e n t  w h e n  C M V  s e r o l o g i c a l  s t a t u s  w a s  
i n c l u d e d  i n  t h e  a n a l y s i s ,  s h o w i n g  i n c r e a s e d  a b s o l u t e  n u m b e r s  o f  e f f e c t o r  a n d  e f f e c t o r  
m e m o r y  c e l l s .  A g a i n ,  w h e n  e v a l u a t i n g  r e l a t i v e  s u b s e t  d i s t r i b u t i o n s ,  t h e  e f f e c t s  o f  b o t h  
a g e i n g  a n d  C M V  p e r s i s t e n c e  b e c a m e  m o r e  e v i d e n t ,  f o r  b o t h  m a t u r a t i o n  a n d  e f f e c t o r  a n d  
e f f e c t o r  m e m o r y  d i f f e r e n t i a t i o n  s t a g e s .  W e  m a i n l y  f o u n d  d e c r e a s e d  p r o p o r t i o n s  o f  n a i v e ,  
a n d  i n c r e a s e d  p r o p o r t i o n s  o f  e f f e c t o r  c e l l s ,  w h i c h  h a v e  a  l a t e - s t a g e  d i f f e r e n t i a t e d  p r o f i l e ,  
a s  d e s c r i b e d  b e f o r e  [ 3 7 , 4 6 ] .  I n  c o n t r a s t  t o  t h e  e f f e c t o r  c e l l s ,  w e  o b s e r v e d  i n c r e a s e d  
p r o p o r t i o n s  o f  e a r l y - s t a g e  d i f f e r e n t i a t e d  e f f e c t o r  m e m o r y  c e l l s ,  w h i c h  c o u l d  c o r r e l a t e  
w i t h  a  m o r e  g e n e r a l  m e m o r y - l i k e  r e s p o n s e  t o  a n t i g e n s  i n  e l d e r l y  u p o n  p r i o r  a n t i g e n  
e x p o s u r e .  F u r t h e r m o r e ,  w e  c o u l d  o b s e r v e  a n  a g e - i n d e p e n d e n t  e f f e c t  o f  C M V  o n  t h e  
d i f f e r e n t i a t i o n  s t a g e s  o f  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  T C R γ δ +  T  c e l l s ,  w h i c h  c o r r e l a t e s  
w i t h  p r e v i o u s  d a t a  o f  R o u x  e t  a l .  [ 4 5 ] .
I m m u n e  a g e i n g  i s  h o w e v e r  n o t  o n l y  a c c o m p a n i e d  b y  s h i f t s  f r o m  n a i v e  t o  e f f e c t o r  c e l l s ,  
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e x h a u s t i o n - r e l a t e d  m a r k e r s  i n  y o u n g  C M V +  i n d i v i d u a l s ,  w h i l e  C M V  s e r o l o g y  d i d  n o t  a d d  
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T C R γ δ +  T  c e l l s  i n  e l d e r l y .  A l s o ,  w e  o b s e r v e d  i n c r e a s e d  e x p r e s s i o n  o f  C D 5 7 ,  w h i c h  i s  a l s o  
h i g h l y  e x p r e s s e d  o n  t e r m i n a l l y  d i f f e r e n t i a t e d  C D 8 +  C T L  w i t h  h i g h  p r o l i f e r a t i v e  a c t i v i t y  
[ 1 5 ] ,  t h u s  m a r k i n g  r e p l i c a t i v e  s e n e s c e n c e  a n d  s u s c e p t i b i l i t y  t o  a c t i v a t i o n - i n d u c e d  c e l l  
d e a t h  ( A I C D )  [ 1 6 ] .  H i g h  e x p r e s s i o n  i s  a l s o  a s s o c i a t e d  w i t h  c h r o n i c  v i r a l  i n f e c t i o n s  l i k e  
C M V  [ 1 7 ] .  O u r  d a t a  s h o w e d  s i g n i f i c a n t l y  i n c r e a s e d  n u m b e r s  o f  C D 5 7 + T C R γ δ +  T  c e l l s ,  i n  
b o t h  y o u n g  a n d  o l d  C M V +  i n d i v i d u a l s .  A n o t h e r  N K  c e l l  m a r k e r  w h i c h  i s  a s s o c i a t e d  w i t h  
T  c e l l  e x h a u s t i o n  i s  K L R G 1 ,  o f  w h i c h  h i g h  e x p r e s s i o n  m a r k s  t e r m i n a l l y  d i f f e r e n t i a t e d  o r  
s e n e s c e n t  T  c e l l s  [ 1 3 , 1 8 ] ,  w h i l s t  s e v e r e l y  e x h a u s t e d  C D 8 +  C T L s  a r e  K L R G 1 - n e g a t i v e  [ 1 9 ] .  
W e  o b s e r v e d  h i g h e r  n u m b e r s  o f  K L R G 1 - n e g a t i v e  c e l l s  i n  C M V - i n f e c t e d  i n d i v i d u a l s .  A l s o ,  
o u r  d a t a  s h o w e d  t h a t  e x h a u s t e d  C D 8 +  C T L  c e l l s  w e r e  p r e s e n t  i n  h i g h e r  n u m b e r s  i n  C M V +  
i n d i v i d u a l s .  C o m b i n a t i o n  o f  l o s s  o f  I L 7 R α ,  h i g h  C D 5 7  a n d  l o w  K L R G 1  e x p r e s s i o n  m a y  
f u n c t i o n  a s  a  m a r k e r  o f  e x h a u s t e d  c e l l s .  O u r  d a t a  c o n f i r m e d  t h i s  w i t h  a n  i n c r e a s e d  c e l l  
c o u n t  o f  s u c h  e x h a u s t e d  c e l l s ,  e s p e c i a l l y  a l r e a d y  i n  t h e  y o u n g  C M V +  g r o u p .  F u r t h e r m o r e ,  
w e  s a w  i n c r e a s i n g  b u t  n o t  s i g n i f i c a n t  n u m b e r s  o f  T C R γ δ +  T  c e l l s  e x p r e s s i n g  t h e  N K  c e l l  
m a r k e r  2 B 4  ( C D 2 4 4 ) ,  w h i c h  i s  n o r m a l l y  e x p r e s s e d  o n  m e m o r y  C D 8 +  T  c e l l s  [ 2 0 , 2 1 ] .  
T h e  p e r c e n t a g e s  d i d  s h o w  a n  i n c r e a s i n g  t r e n d  f r o m  y o u n g  t o  e l d e r l y ,  b u t  t h i s  w a s  n o t  a s  
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evident as described earlier [13]. Of note, 2B4 expression is positively associated with 
Programmed cell death 1 (PD1) in exhausted CD8+ T cells [23], mediating decreasing TCR-mediated proliferation and cytokine production by providing downstream 
inhibitory signals [24,25]. Our data did show significant increases in PD1+ TCRγδ+ T cells 
counts, but IL7Rα-PD1+2B4+ TCRγδ+ T cell counts were not altered. IL7Rα- TCRγδ+ T 
cells co-expressing PD1 with the apoptosis inducer FAS (CD95) did not significantly alter 
upon ageing and CMV persistence, however, total PD1+ TCRγδ+ T cells did increase upon 
CMV persistence, although this was only most obvious for the young CMV+ individuals. However, PD1 is also associated with T cell activation, and might be in case of young 
CMV+ individuals more indicative of a response to CMV, rather than exhaustion. 
In order to further investigate the full exhaustion and senescence profile, and to better discriminate between these processes, it would be relevant to extend marker analysis to other exhaustion markers, such as CD160, Tim3 and Lag3 in combination 
with PD1 and 2B4 [65], and to assess transcription factors that define T cell subsets (such as FoxP3, Blimp1, Eomes, T-bet) [66,67]. Furthermore, functional analyses would be helpful to assess in vitro the proliferative potential, activation status and apoptosis of 
TCRγδ+ T cells from CMV- and CMV+ individuals at young and old age. Also, studying the 
epigenetic landscape of exhaustion-, senescence- and activation-related gene profiles 
of TCRγδ+ T cells could shed more insights on the actual effects of ageing on TCRγδ+ T cells [68]. 
In summary, we conclude that ageing by itself impacts on TCRγδ+ T cells, leading 
to a decrease in the absolute counts of total TCRγδ+ T cells and to shifts in maturation 
and differentiation subsets. Furthermore, CMV has an additional impact on TCRγδ+ T 
cell receptor usage, maturation subsets, effector differentiation profiles, as recently reviewed by Khairallah et al. [69], and ultimately on exhaustion marker profiles. This 
indicates that TCRγδ+ T cells are subjected to ageing and exhaustion processes in much 
the same way as CD8+TCRαβ+ CTLs.
ACKNOWLEDGEMENTS
We thank Diana van den Heuvel (LUMC, the Netherlands) for advice on data analysis and statistical support, and Kim Heezen (Erasmus MC, the Netherlands) for technical 
advice on flow cytometry gating strategies and database building. The study was sup-ported through an unrestricted research grant from Roche. The research for this man-uscript was (in part) performed within the framework of the Erasmus Postgraduate School Molecular Medicine. 
Chapter 2
72
evident as described earlier [13]. Of note, 2B4 expression is positively associated with 
Programmed cell death 1 (PD1) in exhausted CD8+ T cells [23], mediating decreasing 
TCR-mediated proliferation and cytokine production by providing downstream 
inhibitory signals [24,25]. Our data did show significant increases in PD1+ TCRγδ+ T cells 
counts, but IL7Rα-PD1+2B4+ TCRγδ+ T cell counts were not altered. IL7Rα- TCRγδ+ T 
cells co-expressing PD1 with the apoptosis inducer FAS (CD95) did not significantly alter 
upon ageing and CMV persistence, however, total PD1+ TCRγδ+ T cells did increase upon 
CMV persistence, although this was only most obvious for the young CMV+ individuals. 
However, PD1 is also associated with T cell activation, and might be in case of young 
CMV+ individuals more indicative of a response to CMV, rather than exhaustion. 
In order to further investigate the full exhaustion and senescence profile, and to 
better discriminate between these processes, it would be relevant to extend marker 
analysis to other exhaustion markers, such as CD160, Tim3 and Lag3 in combination 
with PD1 and 2B4 [65], and to assess transcription factors that define T cell subsets 
(such as FoxP3, Blimp1, Eomes, T-bet) [66,67]. Furthermore, functional analyses would 
be helpful to assess in vitro the proliferative potential, activation status and apoptosis of 
TCRγδ+ T cells from CMV- and CMV+ individuals at young and old age. Also, studying the 
epigenetic landscape of exhaustion-, senescence- and activation-related gene profiles 
of TCRγδ+ T cells could shed more insights on the actual effects of ageing on TCRγδ+ T 
cells [68]. 
In summary, we conclude that ageing by itself impacts on TCRγδ+ T cells, leading 
to a decrease in the absolute counts of total TCRγδ+ T cells and to shifts in maturation 
and differentiation subsets. Furthermore, CMV has an additional impact on TCRγδ+ T 
cell receptor usage, maturation subsets, effector differentiation profiles, as recently 
reviewed by Khairallah et al. [69], and ultimately on exhaustion marker profiles. This 
indicates that TCRγδ+ T cells are subjected to ageing and exhaustion processes in much 
the same way as CD8+TCRαβ+ CTLs.
ACKNOWLEDGEMENTS
We thank Diana van den Heuvel (LUMC, the Netherlands) for advice on data analysis 
and statistical support, and Kim Heezen (Erasmus MC, the Netherlands) for technical 
advice on flow cytometry gating strategies and database building. The study was sup-
ported through an unrestricted research grant from Roche. The research for this man-
uscript was (in part) performed within the framework of the Erasmus Postgraduate 
School Molecular Medicine. 
273
Effect of ageing and CMV infection on TCRγδ+ T cells 
CONFLICT OF INTEREST
The authors have nothing to disclose. M.J.K., J.J.M.v.D. and A.W.L. designed the experiments. E.B., A.M.H.B., W.H.A. and J.A.N.V. 
coordinated the clinical work. M.J.K. and M.Y.v.d.K. executed the laboratory experimental procedures. M.J.K., M.Y.v.d.K. and A.W.L. analysed the data. M.J.K. prepared the Figures. 
M.J.K. and A.W.L. wrote the manuscript. All authors revised the manuscript critically.
REFERENCES
1. Lee, H.C. & Wei, Y.H. Mitochondria and ageing. Adv. Exp. Med. Biol. 942, 311-327 (2012). 2. Gilbert, S.F. Ageing: the biology of senescence in Developmental Biology (ed. 6) Sunderland (MA) (Si-
nauer Associates, 2000). 3. Sosa, V. et al. Oxidative stress and cancer: an overview. Ageing Res. Rev. 12(1), 3376-390 (2013).
4. Lauri, A., Pompilio, G. & Capogrossi, M.C. The mitochondrial genome in ageing and senescence. Ageing Res. Rev. 18, 1-15 (2014).
5. Weiskopf, D., Weinberger, B. & Grubeck-Loebenstein, B. The ageing of the immune system. Transpl. Int. 22, 1041-1050 (2009).
6. Boraschi, D. et al. The gracefully ageing immune system. Ageing 5(185), 185ps8 (2013). 7. Müller, L., Fülöp, T. & Pawelec, G. Immunosenescence in vertebrates and invertebrates. Immun. Ageing 
10(12), 1-14 (2013). 8. Franceschi, C. Inflammageing as a major characteristic of old people: can it be prevented or cured? 
Nutr. Rev. 65, S173-S176 (2007). 9. Panda, A. et al. Age-associated decrease in TLR function in primary human dendritic cells predicts 
influenza vaccine response. J. Immunol. 184, 2518-2527 (2010). 10. Gibson, K.L. et al. B cell diversity decreases in old age and is correlated with poor health status. Ageing 
Cell 8, 18-25 (2009). 11. Linton, P.J. & Dorschkind, K. Age-related changes in lymphocyte development and function. Nat. Rev. 
Immunol. 5(20), 133-139 (2004). 12. Aspinall, R. & Andrew, P. Thymic involution in ageing. J. Clin. Immunol. 20(4), 250-256 (2000).
13. Wherry, E.J. T cell exhaustion. Nat. Rev. Immunol. 12(6), 492-499 (2011). 14. Wherry, E.J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 
15, 486-499 (2015). 15. Lopez-Vergès, S. et al. CD57 defines a functionally distinct population of mature NK-cells in the hu-
man CD56dimCD16+ NK-cell subset. Blood 116(19), 3865-3874 (2010). 16. Focosi, D., Bestagno, B., Burrone, O. & Petrini, M. CD57+ T-lymphocytes and functional immune defi-
ciency. J. Leukoc. Biol. 87, 107-116 (2010).
2
7 3
E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
C O N F L I C T  O F  I N T E R E S T
T h e  a u t h o r s  h a v e  n o t h i n g  t o  d i s c l o s e .
M . J . K . ,  J . J . M . v . D .  a n d  A . W . L .  d e s i g n e d  t h e  e x p e r i m e n t s .  E . B . ,  A . M . H . B . ,  W . H . A .  a n d  J . A . N . V .  
c o o r d i n a t e d  t h e  c l i n i c a l  w o r k .  M . J . K .  a n d  M . Y . v . d . K .  e x e c u t e d  t h e  l a b o r a t o r y  e x p e r i m e n t a l  
p r o c e d u r e s .  M . J . K . ,  M . Y . v . d . K .  a n d  A . W . L .  a n a l y s e d  t h e  d a t a .  M . J . K .  p r e p a r e d  t h e  F i g u r e s .  
M . J . K .  a n d  A . W . L .  w r o t e  t h e  m a n u s c r i p t .  A l l  a u t h o r s  r e v i s e d  t h e  m a n u s c r i p t  c r i t i c a l l y .
R E F E R E N C E S
1 .  L e e ,  H . C .  &  W e i ,  Y . H .  M i t o c h o n d r i a  a n d  a g e i n g .  A d v .  E x p .  M e d .  B i o l .  9 4 2 ,  3 1 1 - 3 2 7  ( 2 0 1 2 ) .
2 .  G i l b e r t ,  S . F .  A g e i n g :  t h e  b i o l o g y  o f  s e n e s c e n c e  i n  D e v e l o p m e n t a l  B i o l o g y  ( e d .  6 )  S u n d e r l a n d  ( M A )  ( S i -
n a u e r  A s s o c i a t e s ,  2 0 0 0 ) .
3 .  S o s a ,  V .  e t  a l .  O x i d a t i v e  s t r e s s  a n d  c a n c e r :  a n  o v e r v i e w .  A g e i n g  R e s .  R e v .  1 2 ( 1 ) ,  3 3 7 6 - 3 9 0  ( 2 0 1 3 ) .
4 .  L a u r i ,  A . ,  P o m p i l i o ,  G .  &  C a p o g r o s s i ,  M . C .  T h e  m i t o c h o n d r i a l  g e n o m e  i n  a g e i n g  a n d  s e n e s c e n c e .  A g e i n g  
R e s .  R e v .  1 8 ,  1 - 1 5  ( 2 0 1 4 ) .
5 .  W e i s k o p f ,  D . ,  W e i n b e r g e r ,  B .  &  G r u b e c k - L o e b e n s t e i n ,  B .  T h e  a g e i n g  o f  t h e  i m m u n e  s y s t e m .  T r a n s p l .  
I n t .  2 2 ,  1 0 4 1 - 1 0 5 0  ( 2 0 0 9 ) .
6 .  B o r a s c h i ,  D .  e t  a l .  T h e  g r a c e f u l l y  a g e i n g  i m m u n e  s y s t e m .  A g e i n g  5 ( 1 8 5 ) ,  1 8 5 p s 8  ( 2 0 1 3 ) .
7 .  M ü l l e r ,  L . ,  F ü l ö p ,  T.  &  P a w e l e c ,  G .  I m m u n o s e n e s c e n c e  i n  v e r t e b r a t e s  a n d  i n v e r t e b r a t e s .  I m m u n .  A g e i n g  
1 0 ( 1 2 ) ,  1 - 1 4  ( 2 0 1 3 ) .
8 .  F r a n c e s c h i ,  C .  I n f l a m m a g e i n g  a s  a  m a j o r  c h a r a c t e r i s t i c  o f  o l d  p e o p l e :  c a n  i t  b e  p r e v e n t e d  o r  c u r e d ?  
N u t r .  R e v .  6 5 ,  S 1 7 3 - S 1 7 6  ( 2 0 0 7 ) .
9 .  P a n d a ,  A .  e t  a l .  A g e - a s s o c i a t e d  d e c r e a s e  i n  T L R  f u n c t i o n  i n  p r i m a r y  h u m a n  d e n d r i t i c  c e l l s  p r e d i c t s  
i n f l u e n z a  v a c c i n e  r e s p o n s e .  J .  I m m u n o l .  1 8 4 ,  2 5 1 8 - 2 5 2 7  ( 2 0 1 0 ) .
1 0 .  G i b s o n ,  K . L .  e t  a l .  B  c e l l  d i v e r s i t y  d e c r e a s e s  i n  o l d  a g e  a n d  i s  c o r r e l a t e d  w i t h  p o o r  h e a l t h  s t a t u s .  A g e i n g  
C e l l  8 ,  1 8 - 2 5  ( 2 0 0 9 ) .
1 1 .  L i n t o n ,  P. J .  &  D o r s c h k i n d ,  K .  A g e - r e l a t e d  c h a n g e s  i n  l y m p h o c y t e  d e v e l o p m e n t  a n d  f u n c t i o n .  N a t .  R e v .  
I m m u n o l .  5 ( 2 0 ) ,  1 3 3 - 1 3 9  ( 2 0 0 4 ) .
1 2 .  A s p i n a l l ,  R .  &  A n d r e w ,  P.  T h y m i c  i n v o l u t i o n  i n  a g e i n g .  J .  C l i n .  I m m u n o l .  2 0 ( 4 ) ,  2 5 0 - 2 5 6  ( 2 0 0 0 ) .
1 3 .  W h e r r y ,  E . J .  T  c e l l  e x h a u s t i o n .  N a t .  R e v .  I m m u n o l .  1 2 ( 6 ) ,  4 9 2 - 4 9 9  ( 2 0 1 1 ) .
1 4 .  W h e r r y ,  E . J .  &  K u r a c h i ,  M .  M o l e c u l a r  a n d  c e l l u l a r  i n s i g h t s  i n t o  T  c e l l  e x h a u s t i o n .  N a t .  R e v .  I m m u n o l .  
1 5 ,  4 8 6 - 4 9 9  ( 2 0 1 5 ) .
1 5 .  L o p e z - V e r g è s ,  S .  e t  a l .  C D 5 7  d e f i n e s  a  f u n c t i o n a l l y  d i s t i n c t  p o p u l a t i o n  o f  m a t u r e  N K - c e l l s  i n  t h e  h u -
m a n  C D 5 6 d i m C D 1 6 +  N K - c e l l  s u b s e t .  B l o o d  1 1 6 ( 1 9 ) ,  3 8 6 5 - 3 8 7 4  ( 2 0 1 0 ) .
1 6 .  F o c o s i ,  D . ,  B e s t a g n o ,  B . ,  B u r r o n e ,  O .  &  P e t r i n i ,  M .  C D 5 7 +  T - l y m p h o c y t e s  a n d  f u n c t i o n a l  i m m u n e  d e f i -
c i e n c y .  J .  L e u k o c .  B i o l .  8 7 ,  1 0 7 - 1 1 6  ( 2 0 1 0 ) .
Chapter 2
74
17. Chong, L.K. et al. Proliferation and IL-5 production by CD8hiCD57+ T cells. Eur. J. Immunol. 38(4), 995-1000 (2008).18. Rosshart, S. et al. Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur. J. 
Immunol. 38, 3354-3364 (2008).19. Wherry, E.J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immu-
nity 27(5), 670-684 (2007).20. McNerney, M.E., Lee, K.M. & Kumar, V. 2B4 (CD244) is a non-MHC binding receptor with multiple 
functions on natural kicker cells and CD8+ T cells. Mol. Immunol. 42, 489-494 (2005).21. Schlaphoff, V. et al. Dual function of the NK-cell receptor 2B4 (CD244) in the regulation of HCV-specif-
ic CD8+ T cells. PLoS Pathog. 7(5), e1002045 (2011).
22. Yang, B., Wang, X., Jiang, J. & Cheng, X. Involvement of CD244 in regulating CD4+ T cell immunity in patients with active tuberculosis. PLoS ONE 8(4), e63261 (2013).23. Bensch, B. et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6(6), e1000947 (2010).24. Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T cell exhaustion: an update in implications on chronic infections and tumor evasion. Cancer Immunol. Immunother. 56, 739-745 (2007).25. Zhang, J.Y. et al. PD-1 up-regulated is correlated with HIV-specific memory CD8+ T cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109, 4671-4678 (2007).26. Petrovas, C. et al. Differential association of programmed death-1 and CD57 with ex vivo survival of 
CD8+ T cells in HIV infection. J. Immunol. 183, 1120-1132 (2009).
27. Vranjkovic, A., Crawley, A.M., Gee, K., Kumar, A. & Angel, J.B. IL-7 decreases IL-7 receptor α (CD127) 
expression and induces the shedding of CD127 by human CD8+ T cells. Int. Immunol. 19(12), 1329-1339 (2007).28. Kared, H., Saeed, S., Klein, M.B. & Shoukry, N.H. CD127 expression, exhaustion status and antigen 
specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals. 
PLoS ONE  9(7), e101441 (2014).
29. Ensslin, A.S. & Formby, B. Comparison of cytolytic and proliferative activities of human γδ and αβ T cells from peripheral blood against various human tumor cell lines. J. Natl. Cancer Inst. 83, 1564-1569 (1991).30. Jensen, K.D.C. et al. Thymic selection determines γδ T cell effector fate: antigen-naive cells make In-
terleukin-17 and antigen-experienced cells make Interferon γ. Immunity 29, 90-100 (2008).
31. Turchinovich, G. & Hayday, A.C. Skin-1 identifies a common molecular mechanism for the develop-ment of interferon-gamma-secreting versus interleukin-17-secreting gamma-delta T cells. Immunity 
35, 59-68 (2011).
32. Bonneville, M., O’Brien, R.L. & Born, W.K. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467-478 (2010).
Chapter 2
74
17. Chong, L.K. et al. Proliferation and IL-5 production by CD8hiCD57+ T cells. Eur. J. Immunol. 38(4), 
995-1000 (2008).
18. Rosshart, S. et al. Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur. J. 
Immunol. 38, 3354-3364 (2008).
19. Wherry, E.J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immu-
nity 27(5), 670-684 (2007).
20. McNerney, M.E., Lee, K.M. & Kumar, V. 2B4 (CD244) is a non-MHC binding receptor with multiple 
functions on natural kicker cells and CD8+ T cells. Mol. Immunol. 42, 489-494 (2005).
21. Schlaphoff, V. et al. Dual function of the NK-cell receptor 2B4 (CD244) in the regulation of HCV-specif-
ic CD8+ T cells. PLoS Pathog. 7(5), e1002045 (2011).
22. Yang, B., Wang, X., Jiang, J. & Cheng, X. Involvement of CD244 in regulating CD4+ T cell immunity in 
patients with active tuberculosis. PLoS ONE 8(4), e63261 (2013).
23. Bensch, B. et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T 
cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6(6), e1000947 (2010).
24. Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T cell exhaustion: an update 
in implications on chronic infections and tumor evasion. Cancer Immunol. Immunother. 56, 739-745 
(2007).
25. Zhang, J.Y. et al. PD-1 up-regulated is correlated with HIV-specific memory CD8+ T cell exhaustion in 
typical progressors but not in long-term nonprogressors. Blood 109, 4671-4678 (2007).
26. Petrovas, C. et al. Differential association of programmed death-1 and CD57 with ex vivo survival of 
CD8+ T cells in HIV infection. J. Immunol. 183, 1120-1132 (2009).
27. Vranjkovic, A., Crawley, A.M., Gee, K., Kumar, A. & Angel, J.B. IL-7 decreases IL-7 receptor α (CD127) 
expression and induces the shedding of CD127 by human CD8+ T cells. Int. Immunol. 19(12), 1329-
1339 (2007).
28. Kared, H., Saeed, S., Klein, M.B. & Shoukry, N.H. CD127 expression, exhaustion status and antigen 
specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals. 
PLoS ONE  9(7), e101441 (2014).
29. Ensslin, A.S. & Formby, B. Comparison of cytolytic and proliferative activities of human γδ and αβ T 
cells from peripheral blood against various human tumor cell lines. J. Natl. Cancer Inst. 83, 1564-1569 
(1991).
30. Jensen, K.D.C. et al. Thymic selection determines γδ T cell effector fate: antigen-naive cells make In-
terleukin-17 and antigen-experienced cells make Interferon γ. Immunity 29, 90-100 (2008).
31. Turchinovich, G. & Hayday, A.C. Skin-1 identifies a common molecular mechanism for the develop-
ment of interferon-gamma-secreting versus interleukin-17-secreting gamma-delta T cells. Immunity 
35, 59-68 (2011).
32. Bonneville, M., O’Brien, R.L. & Born, W.K. γδ T cell effector functions: a blend of innate programming 
and acquired plasticity. Nat. Rev. Immunol. 10, 467-478 (2010).
275
Effect of ageing and CMV infection on TCRγδ+ T cells 
33. Vantourout, P. & Hayday, A.C. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat. Rev. Immunol. 13(2), 88-100 (2013).
34. Luoma, A.M., Castro, C.D. & Adams, E.J. γδ T cell surveillance via CD1 molecules. Trends Immunol. 
35(12), 613-621 (2014). 35. Godfrey, D.I., Uldrich, A.P., McCluskey, J., Rossjohn, J. & Moody, D.B. The burgeoning family of uncon-
ventional T cells. Nat. Rev. Immunol. 16(11), 1114-1123 (2015). 36. Vasudev, A. et al. γ/δ T cell subsets in human aging using the classical α/β T cell model. J. Leukoc. Biol. 
96(4), 647-655 (2014). 37. Wistuba-Hamprecht, K., Haehnel, K., Janssen, N., Demuth, I. & Pawelec, G. Peripheral blood T cell sig-
natures from high-resolution immune phenotyping of γδ and αβ T cells in younger and older subjects 
in the Berlin Ageing Study II. Immun. Ageing 12, 25 (2015). 38. Sheridan, B.S. & Lefrançois, L. Intraepithelial lymphocytes: to serve and protect. Curr. Gastroenterol. 
Rep. 12(6), 513-521 (2010). 39. Garrido, P. et al. Monoclonal TCR-Vβ13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence 
for an antigen-driven chronic T cell stimulation origin. Blood 109, 4890-4898 (2009). 40. Kabelitz, D., Kalyan, S., Oberg, H.H. & Wesch, D. Human Vδ2 versus non-Vδ2 γδ T cells in antitumor 
immunity. Oncoimmunology 2(3), e23304 (2013). 41. Alejenef, A. et al. Cytomegalovirus drives Vδ2neg γδ T cell inflation in many healthy virus carriers 
with increasing age. Clin. Exp. Immunol. 176(3), 418-428 (2014). 42. Sinclair, J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol. 41, 
180-185 (2008). 43. Looney, R.H. et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin. Im-
munol. 90(2), 213-219 (1999). 44. Shin, H. & Wherry, E.J. CD8 T cell dysfunction during chronic viral infection. Curr. Opin. Immunol. 19, 
408-415 (2007). 45. Roux, A. et al. Differential impact of age and cytomegalovirus infection on the γδ T cell compartment. 
J. Immunol. 191, 1300-1306 (2013). 46. Weltevrede, M., Eilers, R., de Melker, H.E. & van Baarle, D. Cytomegalovirus persistence and T cell 
immunosenescence in people age fifty and older: a systematic review. Exp. Geront. 77, 87-95 (2016). 47. Yan, J. et al. The effect of ageing on human lymphocyte subsets: comparisons of males and females. 
Immunity & Ageing 7:4 (2010). 48. Kennedy, R.B. et al. Immunosenescence-related transcriptomic and immunologic changes in older 
individuals following influenza vaccination. Front. Immunol. 7:450 (2016). 49. Spyridopoulos, I. et al. CMV seropositivity and T cell senescence predict increased cardiovascular 
mortality in octogenarians: results from the Newcastle 85+ study. Aging Cell 15(2), 389-392 (2016). 50. Johnstone, J. et al. T cell phenotypes predictive of fratility and mortality in elderly nursing home res-
idents. J. Am. Geriatr. Soc. 65(1), 153-159 (2017).
2
7 5
E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
3 3 .  V a n t o u r o u t ,  P.  &  H a y d a y ,  A . C .  S i x - o f - t h e - b e s t :  u n i q u e  c o n t r i b u t i o n s  o f  γ δ  T  c e l l s  t o  i m m u n o l o g y .  N a t .  
R e v .  I m m u n o l .  1 3 ( 2 ) ,  8 8 - 1 0 0  ( 2 0 1 3 ) .
3 4 .  L u o m a ,  A . M . ,  C a s t r o ,  C . D .  &  A d a m s ,  E . J .  γ δ  T  c e l l  s u r v e i l l a n c e  v i a  C D 1  m o l e c u l e s .  T r e n d s  I m m u n o l .  
3 5 ( 1 2 ) ,  6 1 3 - 6 2 1  ( 2 0 1 4 ) .
3 5 .  G o d f r e y ,  D . I . ,  U l d r i c h ,  A . P. ,  M c C l u s k e y ,  J . ,  R o s s j o h n ,  J .  &  M o o d y ,  D . B .  T h e  b u r g e o n i n g  f a m i l y  o f  u n c o n -
v e n t i o n a l  T  c e l l s .  N a t .  R e v .  I m m u n o l .  1 6 ( 1 1 ) ,  1 1 1 4 - 1 1 2 3  ( 2 0 1 5 ) .
3 6 .  V a s u d e v ,  A .  e t  a l .  γ / δ  T  c e l l  s u b s e t s  i n  h u m a n  a g i n g  u s i n g  t h e  c l a s s i c a l  α / β  T  c e l l  m o d e l .  J .  L e u k o c .  B i o l .  
9 6 ( 4 ) ,  6 4 7 - 6 5 5  ( 2 0 1 4 ) .  
3 7 .  W i s t u b a - H a m p r e c h t ,  K . ,  H a e h n e l ,  K . ,  J a n s s e n ,  N . ,  D e m u t h ,  I .  &  P a w e l e c ,  G .  P e r i p h e r a l  b l o o d  T  c e l l  s i g -
n a t u r e s  f r o m  h i g h - r e s o l u t i o n  i m m u n e  p h e n o t y p i n g  o f  γ δ  a n d  α β  T  c e l l s  i n  y o u n g e r  a n d  o l d e r  s u b j e c t s  
i n  t h e  B e r l i n  A g e i n g  S t u d y  I I .  I m m u n .  A g e i n g  1 2 ,  2 5  ( 2 0 1 5 ) .
3 8 .  S h e r i d a n ,  B . S .  &  L e f r a n ç o i s ,  L .  I n t r a e p i t h e l i a l  l y m p h o c y t e s :  t o  s e r v e  a n d  p r o t e c t .  C u r r .  G a s t r o e n t e r o l .  
R e p .  1 2 ( 6 ) ,  5 1 3 - 5 2 1  ( 2 0 1 0 ) .
3 9 .  G a r r i d o ,  P.  e t  a l .  M o n o c l o n a l  T C R - V β 1 3 . 1 + / C D 4 + / N K a + / C D 8 - / + d i m  T - L G L  l y m p h o c y t o s i s :  e v i d e n c e  
f o r  a n  a n t i g e n - d r i v e n  c h r o n i c  T  c e l l  s t i m u l a t i o n  o r i g i n .  B l o o d  1 0 9 ,  4 8 9 0 - 4 8 9 8  ( 2 0 0 9 ) .
4 0 .  K a b e l i t z ,  D . ,  K a l y a n ,  S . ,  O b e r g ,  H . H .  &  W e s c h ,  D .  H u m a n  V δ 2  v e r s u s  n o n - V δ 2  γ δ  T  c e l l s  i n  a n t i t u m o r  
i m m u n i t y .  O n c o i m m u n o l o g y  2 ( 3 ) ,  e 2 3 3 0 4  ( 2 0 1 3 ) .
4 1 .  A l e j e n e f ,  A .  e t  a l .  C y t o m e g a l o v i r u s  d r i v e s  V δ 2 n e g  γ δ  T  c e l l  i n f l a t i o n  i n  m a n y  h e a l t h y  v i r u s  c a r r i e r s  
w i t h  i n c r e a s i n g  a g e .  C l i n .  E x p .  I m m u n o l .  1 7 6 ( 3 ) ,  4 1 8 - 4 2 8  ( 2 0 1 4 ) .
4 2 .  S i n c l a i r ,  J .  H u m a n  c y t o m e g a l o v i r u s :  l a t e n c y  a n d  r e a c t i v a t i o n  i n  t h e  m y e l o i d  l i n e a g e .  J .  C l i n .  V i r o l .  4 1 ,  
1 8 0 - 1 8 5  ( 2 0 0 8 ) .
4 3 .  L o o n e y ,  R . H .  e t  a l .  R o l e  o f  c y t o m e g a l o v i r u s  i n  t h e  T  c e l l  c h a n g e s  s e e n  i n  e l d e r l y  i n d i v i d u a l s .  C l i n .  I m -
m u n o l .  9 0 ( 2 ) ,  2 1 3 - 2 1 9  ( 1 9 9 9 ) .
4 4 .  S h i n ,  H .  &  W h e r r y ,  E . J .  C D 8  T  c e l l  d y s f u n c t i o n  d u r i n g  c h r o n i c  v i r a l  i n f e c t i o n .  C u r r .  O p i n .  I m m u n o l .  1 9 ,  
4 0 8 - 4 1 5  ( 2 0 0 7 ) .
4 5 .  R o u x ,  A .  e t  a l .  D i f f e r e n t i a l  i m p a c t  o f  a g e  a n d  c y t o m e g a l o v i r u s  i n f e c t i o n  o n  t h e  γ δ  T  c e l l  c o m p a r t m e n t .  
J .  I m m u n o l .  1 9 1 ,  1 3 0 0 - 1 3 0 6  ( 2 0 1 3 ) .
4 6 .  W e l t e v r e d e ,  M . ,  E i l e r s ,  R . ,  d e  M e l k e r ,  H . E .  &  v a n  B a a r l e ,  D .  C y t o m e g a l o v i r u s  p e r s i s t e n c e  a n d  T  c e l l  
i m m u n o s e n e s c e n c e  i n  p e o p l e  a g e  f i f t y  a n d  o l d e r :  a  s y s t e m a t i c  r e v i e w .  E x p .  G e r o n t .  7 7 ,  8 7 - 9 5  ( 2 0 1 6 ) .
4 7 .  Y a n ,  J .  e t  a l .  T h e  e f f e c t  o f  a g e i n g  o n  h u m a n  l y m p h o c y t e  s u b s e t s :  c o m p a r i s o n s  o f  m a l e s  a n d  f e m a l e s .  
I m m u n i t y  &  A g e i n g  7 : 4  ( 2 0 1 0 ) .
4 8 .  K e n n e d y ,  R . B .  e t  a l .  I m m u n o s e n e s c e n c e - r e l a t e d  t r a n s c r i p t o m i c  a n d  i m m u n o l o g i c  c h a n g e s  i n  o l d e r  
i n d i v i d u a l s  f o l l o w i n g  i n f l u e n z a  v a c c i n a t i o n .  F r o n t .  I m m u n o l .  7 : 4 5 0  ( 2 0 1 6 ) .
4 9 .  S p y r i d o p o u l o s ,  I .  e t  a l .  C M V  s e r o p o s i t i v i t y  a n d  T  c e l l  s e n e s c e n c e  p r e d i c t  i n c r e a s e d  c a r d i o v a s c u l a r  
m o r t a l i t y  i n  o c t o g e n a r i a n s :  r e s u l t s  f r o m  t h e  N e w c a s t l e  8 5 +  s t u d y .  A g i n g  C e l l  1 5 ( 2 ) ,  3 8 9 - 3 9 2  ( 2 0 1 6 ) .
5 0 .  J o h n s t o n e ,  J .  e t  a l .  T  c e l l  p h e n o t y p e s  p r e d i c t i v e  o f  f r a t i l i t y  a n d  m o r t a l i t y  i n  e l d e r l y  n u r s i n g  h o m e  r e s -
i d e n t s .  J .  A m .  G e r i a t r .  S o c .  6 5 ( 1 ) ,  1 5 3 - 1 5 9  ( 2 0 1 7 ) .
Chapter 2
76
51. Koch, S., Solana, R., Dela Rosa, O. & Pawelec, G. Human cytomegalovirus infection and T cell immu-nosenescence: a mini review. Mech. Ageing Dev. 127, 538-543 (2006).52. Korndewal, M.J. et al. Cytomegalovirus infection in the Netherlands: Seroprevalence, risk risk factors, and implications. J. Clin. Virol. 63, 53-58 (2015).53. Jansen, M.A. et al. Determinants of ethnic differences in Cytomegalovirus, Epstein-Barr Virus, and Herpes Simplex Virus Type 1 seroprevalence in childhood. J. Pediatr. 170: 126-134 (2016). 54. van der Heiden, M. et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci. Rep. 6, 26892; doi: 10.1038/srep26892 (2016).55. Déchanet, J. et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J. Clin. 
Invest. 103, 1437-1449 (1999).56. Kahan, S.M., Wherry, E.J. & Zajac, A.J. T cell exhaustion during persistent viral infections. J. Virol. 0, 180-193 (2015).57. World Report on Ageing and Health. World Health Organization 2015.58. Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J.W. Ageing populations: the challenges ahead. 
Lancet Glob. Health 374(9696), 1196-1208 (2009).59. Gruver, A.L., Hudson, L.L. & Sempowski, G.D. Immunosenescence of ageing. J. Pathol. 211(2), 144-156 (2007).60. Colonna-Romano, G. et al. Impairment of gamma/delta T-lymphocytes in elderly: implications for immunosenescence. Exp. Gerontol. 39, 1439-1446 (2004).61. Breit, T.M., Wolvers-Tettero, I.L.M. & van Dongen, J.J.M. Receptor diversity of human T cell receptor γδ expressing cells. Prog. Histochem. Cytochem. 26, 183-193 (1992).62. Lewis, D. et al. Cytomegalovirus infection is associated with expansions of CD8 T cells and highly oligoclonal Vdelta1 gamma/delta T cells in patients treated with Dasatinib for chronic myelogenous leukaemia. Blood 124: 1814 (2014).63. van de Berg, P.J. et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J. Infect. Dis. 202, 690-699 (2010).64. Czesnikiewicz-Guzik, M. et al. T cell subset-specific susceptibility to ageing. Clin. Immunol. 127, 107-118 (2008).65. Pombo, C., Wherry, E.J., Gostick, E., Price, D.A. & Betts, M.R. Elevated expression of CD160 and 2B4 
defines a cytolytic HIV-specific CD8+ T cell population in elite controllers. J. Infect. Dis. 212(9), 1376-1386 (2015).66. Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 10(7), e1004251 (2014).67. Barathan, M. et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononu-cleocytes. Apoptosis 20(4), 466-480 (2015).
Chapter 2
76
51. Koch, S., Solana, R., Dela Rosa, O. & Pawelec, G. Human cytomegalovirus infection and T cell immu-
nosenescence: a mini review. Mech. Ageing Dev. 127, 538-543 (2006).
52. Korndewal, M.J. et al. Cytomegalovirus infection in the Netherlands: Seroprevalence, risk risk factors, 
and implications. J. Clin. Virol. 63, 53-58 (2015).
53. Jansen, M.A. et al. Determinants of ethnic differences in Cytomegalovirus, Epstein-Barr Virus, and 
Herpes Simplex Virus Type 1 seroprevalence in childhood. J. Pediatr. 170: 126-134 (2016). 
54. van der Heiden, M. et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of 
middle-aged males and females. Sci. Rep. 6, 26892; doi: 10.1038/srep26892 (2016).
55. Déchanet, J. et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J. Clin. 
Invest. 103, 1437-1449 (1999).
56. Kahan, S.M., Wherry, E.J. & Zajac, A.J. T cell exhaustion during persistent viral infections. J. Virol. 0, 
180-193 (2015).
57. World Report on Ageing and Health. World Health Organization 2015.
58. Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J.W. Ageing populations: the challenges ahead. 
Lancet Glob. Health 374(9696), 1196-1208 (2009).
59. Gruver, A.L., Hudson, L.L. & Sempowski, G.D. Immunosenescence of ageing. J. Pathol. 211(2), 144-156 
(2007).
60. Colonna-Romano, G. et al. Impairment of gamma/delta T-lymphocytes in elderly: implications for 
immunosenescence. Exp. Gerontol. 39, 1439-1446 (2004).
61. Breit, T.M., Wolvers-Tettero, I.L.M. & van Dongen, J.J.M. Receptor diversity of human T cell receptor γδ 
expressing cells. Prog. Histochem. Cytochem. 26, 183-193 (1992).
62. Lewis, D. et al. Cytomegalovirus infection is associated with expansions of CD8 T cells and highly 
oligoclonal Vdelta1 gamma/delta T cells in patients treated with Dasatinib for chronic myelogenous 
leukaemia. Blood 124: 1814 (2014).
63. van de Berg, P.J. et al. Human cytomegalovirus induces systemic immune activation characterized by 
a type 1 cytokine signature. J. Infect. Dis. 202, 690-699 (2010).
64. Czesnikiewicz-Guzik, M. et al. T cell subset-specific susceptibility to ageing. Clin. Immunol. 127, 107-
118 (2008).
65. Pombo, C., Wherry, E.J., Gostick, E., Price, D.A. & Betts, M.R. Elevated expression of CD160 and 2B4 
defines a cytolytic HIV-specific CD8+ T cell population in elite controllers. J. Infect. Dis. 212(9), 1376-
1386 (2015).
66. Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells 
in HIV infection. PLoS Pathog. 10(7), e1004251 (2014).
67. Barathan, M. et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of 
biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononu-
cleocytes. Apoptosis 20(4), 466-480 (2015).
277
Effect of ageing and CMV infection on TCRγδ+ T cells 
68. Schmolka, N., Wencker, M., Hayday, A.C. & Silva-Santos, B. Epigenetic and transcriptional regulation of γδ T cell differentiation: programming cells for responses in time and space. Semin. Immunol. 27(1), 
19-25 (2015). 69. Khairallah, C., Déchanet-Merville, J. & Capone, M. γδ  T cell-mediated immunity to cytomegalovirus 
infection. Front. Immunol. 8: 105 (2017). 70. Van Den Heuvel, D. et al. Effects of nongenetic factors on immune cell dynamics in early childhood: the 
Generation R Study. J. Allergy. Clin. Immunol. S0091-6749 (16), 31379-3 (2016).
2
7 7
E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
6 8 .  S c h m o l k a ,  N . ,  W e n c k e r ,  M . ,  H a y d a y ,  A . C .  &  S i l v a - S a n t o s ,  B .  E p i g e n e t i c  a n d  t r a n s c r i p t i o n a l  r e g u l a t i o n  o f  
γ δ  T  c e l l  d i f f e r e n t i a t i o n :  p r o g r a m m i n g  c e l l s  f o r  r e s p o n s e s  i n  t i m e  a n d  s p a c e .  S e m i n .  I m m u n o l .  2 7 ( 1 ) ,  
1 9 - 2 5  ( 2 0 1 5 ) .
6 9 .  K h a i r a l l a h ,  C . ,  D é c h a n e t - M e r v i l l e ,  J .  &  C a p o n e ,  M .  γ δ   T  c e l l - m e d i a t e d  i m m u n i t y  t o  c y t o m e g a l o v i r u s  
i n f e c t i o n .  F r o n t .  I m m u n o l .  8 :  1 0 5  ( 2 0 1 7 ) .
7 0 .  V a n  D e n  H e u v e l ,  D .  e t  a l .  E f f e c t s  o f  n o n g e n e t i c  f a c t o r s  o n  i m m u n e  c e l l  d y n a m i c s  i n  e a r l y  c h i l d h o o d :  t h e  
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Supplementary Figure 1. Gating strategies for analysis.
(a) TruCount gating strategy for determining absolute lymphocyte counts and absolute cell number calculations. (b) General gating strategy with the use of TCRαβ antibody in case of Vγ- and Vδ-usage investigation, (c) gating strategy using TCRγδ antibody. (d) CD4/CD8 usage, maturation and differentiation within effector (TemRA) and 
effector memory (TemRO) populations. (e) Exhaustion profile determination including separate exhaustion marker expressions and exhaustion marker combinations within the CD127- population.
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Supplementary Figure 1 continued (see left page). Gating strategies for analysis.
(a) TruCount gating strategy for determining absolute lymphocyte counts and absolute cell number calculations. (b) General gating strategy with the use of TCRαβ antibody in case of Vγ- and Vδ-usage investigation, (c) gating strategy using TCRγδ antibody. (d) CD4/CD8 usage, maturation and differentiation within effector 
(TemRA) and effector memory (TemRO) populations. (e) Exhaustion profile determination including separate exhaustion marker expressions and exhaustion marker combinations within the CD127- population.
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S u p p l e m e n t a r y  F i g u r e  1  c o n t i n u e d  ( s e e  l e f t  p a g e ) .  G a t i n g  s t r a t e g i e s  f o r  a n a l y s i s .
( a )  T r u C o u n t  g a t i n g  s t r a t e g y  f o r  d e t e r m i n i n g  a b s o l u t e  l y m p h o c y t e  c o u n t s  a n d  a b s o l u t e  c e l l  n u m b e r  c a l c u l a t i o n s .  
( b )  G e n e r a l  g a t i n g  s t r a t e g y  w i t h  t h e  u s e  o f  T C R α β  a n t i b o d y  i n  c a s e  o f  V γ -  a n d  V δ - u s a g e  i n v e s t i g a t i o n ,  ( c )  
g a t i n g  s t r a t e g y  u s i n g  T C R γ δ  a n t i b o d y .  ( d )  C D 4 / C D 8  u s a g e ,  m a t u r a t i o n  a n d  d i f f e r e n t i a t i o n  w i t h i n  e f f e c t o r  
( T e m R A )  a n d  e f f e c t o r  m e m o r y  ( T e m R O )  p o p u l a t i o n s .  ( e )  E x h a u s t i o n  p r o f i l e  d e t e r m i n a t i o n  i n c l u d i n g  s e p a r a t e  





Effect of ageing and CMV infection on TCRγδ+ T cells 
Supplementary Figure 2 (see left page). TCRαβ+ and TCRγδ+ T cell supplementary figure.
(a,h) Absolute numbers of TCRαβ+ T cells depicted in 10-90% box-whiskers-plots. (b,i) Relative distributions of TCRαβ+ and TCRγδ+ T cells within the total T cell compartment of all groups. (c,j) Relative Vδ1+, Vδ2+, and non-Vδ1/non-Vδ2 usage distribution in the peripheral blood total TCRγδ+ T cell compartment. (d,k) TCRαβ+ 
CD4 and CD8 single-positive, double-positive (DP, CD4+CD8+) and double-negative (DN, CD4-CD8-) subset 
distribution depicted in stacked bar plots. (e,l) CD4:CD8 ratios of total TCRαβ+ T cells depicted in scatter plots indicated with the median. (f,m) Maturation subset distributions of CD8+TCRαβ+ and (g,n) CD4+TCRαβ+ T cells depicted in stacked bar plots. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s 

















































Supplementary Figure 3. CMV serology.
(a) Percentages of overall CMV serostatus. (b) CMV-positivity and –negativity among males and (c) females. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test.
Supplementary Figure 4. Effect of CMV, gender and age on V-gene usage.
Supplementary to Figure 4 and Supplementary Table 4. (a) Absolute numbers and (b) percentages of total TCRγδ+ T cells in young / elderly CMV- and CMV+ males and females depicted in 10-90% box-whiskers-plots. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test. Significance of the Dunn’s test 
is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001.
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
S u p p l e m e n t a r y  F i g u r e  2  ( s e e  l e f t  p a g e ) .  T C R α β +  a n d  T C R γ δ +  T  c e l l  s u p p l e m e n t a r y  f i g u r e .
( a , h )  A b s o l u t e  n u m b e r s  o f  T C R α β +  T  c e l l s  d e p i c t e d  i n  1 0 - 9 0 %  b o x - w h i s k e r s - p l o t s .  ( b , i )  R e l a t i v e  d i s t r i b u t i o n s  
o f  T C R α β +  a n d  T C R γ δ +  T  c e l l s  w i t h i n  t h e  t o t a l  T  c e l l  c o m p a r t m e n t  o f  a l l  g r o u p s .  ( c , j )  R e l a t i v e  V δ 1 + ,  V δ 2 + ,  a n d  
n o n - V δ 1 / n o n - V δ 2  u s a g e  d i s t r i b u t i o n  i n  t h e  p e r i p h e r a l  b l o o d  t o t a l  T C R γ δ +  T  c e l l  c o m p a r t m e n t .  ( d , k )  T C R α β +  
C D 4  a n d  C D 8  s i n g l e - p o s i t i v e ,  d o u b l e - p o s i t i v e  ( D P,  C D 4 + C D 8 + )  a n d  d o u b l e - n e g a t i v e  ( D N ,  C D 4 - C D 8 - )  s u b s e t  
d i s t r i b u t i o n  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  ( e , l )  C D 4 : C D 8  r a t i o s  o f  t o t a l  T C R α β +  T  c e l l s  d e p i c t e d  i n  s c a t t e r  p l o t s  
i n d i c a t e d  w i t h  t h e  m e d i a n .  ( f , m )  M a t u r a t i o n  s u b s e t  d i s t r i b u t i o n s  o f  C D 8 + T C R α β +  a n d  ( g , n )  C D 4 + T C R α β +  T  
c e l l s  d e p i c t e d  i n  s t a c k e d  b a r  p l o t s .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  
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S u p p l e m e n t a r y  F i g u r e  3 .  C M V  s e r o l o g y .
( a )  P e r c e n t a g e s  o f  o v e r a l l  C M V  s e r o s t a t u s .  ( b )  C M V - p o s i t i v i t y  a n d  – n e g a t i v i t y  a m o n g  m a l e s  a n d  ( c )  f e m a l e s .  
S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t .
S u p p l e m e n t a r y  F i g u r e  4 .  E f f e c t  o f  C M V,  g e n d e r  a n d  a g e  o n  V - g e n e  u s a g e .
S u p p l e m e n t a r y  t o  F i g u r e  4  a n d  S u p p l e m e n t a r y  T a b l e  4 .  ( a )  A b s o l u t e  n u m b e r s  a n d  ( b )  p e r c e n t a g e s  o f  t o t a l  
T C R γ δ +  T  c e l l s  i n  y o u n g  /  e l d e r l y  C M V -  a n d  C M V +  m a l e s  a n d  f e m a l e s  d e p i c t e d  i n  1 0 - 9 0 %  b o x - w h i s k e r s - p l o t s .  
S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t .  S i g n i f i c a n c e  o f  t h e  D u n n ’ s  t e s t  
i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  * * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .
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Supplementary Figure 5. Effect of CMV on the exhaustion and senescence of nonTCRγδ (TCRαβ+) CD8+ 
T cells.
Absolute numbers of TCRαβ+ (TCRγδ-negative T cells) CD8+ T cells (a) lacking KLRG1, (b) expressing 2B4, (c) FAS death receptor, (d) CD57, (e) PD1, and (f) lacking IL7Rα. Absolute numbers of TCRαβ+CD8+ IL7Rα- T cells coexpressing (g) PD1 and FAS, (h) PD1 and 2B4, (i) CD57 and lacking KLRG1. Scatter plots are indicated with 
the median. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test. Significance of the 
Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001.
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Supplementary Figure 5. Effect of CMV on the exhaustion and senescence of nonTCRγδ (TCRαβ+) CD8+ 
T cells.
Absolute numbers of TCRαβ+ (TCRγδ-negative T cells) CD8+ T cells (a) lacking KLRG1, (b) expressing 2B4, (c) 
FAS death receptor, (d) CD57, (e) PD1, and (f) lacking IL7Rα. Absolute numbers of TCRαβ+CD8+ IL7Rα- T cells 
coexpressing (g) PD1 and FAS, (h) PD1 and 2B4, (i) CD57 and lacking KLRG1. Scatter plots are indicated with 
the median. Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test. Significance of the 
Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001.
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Supplementary Figure 6. Relative effects of CMV on the exhaustion marker profile of nonTCRγδ 
(TCRαβ+) CD8+ T cells. 
(a) Percentages of KLRG1-, (b) 2B4+, (c) FAS+, (d) CD57+, (e) PD1+ and (f) IL7Rα- TCRαβ+ (TCRγδ-negative T cells) CD8+ T cells are depicted in 10-90% box-whiskers-plots. (g) Percentages of IL7Rα- TCRαβ+ T cells co-expressing PD1 and FAS, (h) PD1 and 2B4 and (i) lacking KLRG1 with expression of CD57 depicted in 
scatterplots indicated with the medians. Significance was tested by a Kruskal-Wallis test, followed by a post-
Dunn’s test. Significance of the Dunn’s test is indicated in the plots: *, p<0.05; **, p<0.01; ***, p<0.001.
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E f f e c t  o f  a g e i n g  a n d  C M V  i n f e c t i o n  o n  T C R γ δ +  T  c e l l s  
S u p p l e m e n t a r y  F i g u r e  6 .  R e l a t i v e  e f f e c t s  o f  C M V  o n  t h e  e x h a u s t i o n  m a r k e r  p r o f i l e  o f  n o n T C R γ δ  
( T C R α β + )  C D 8 +  T  c e l l s .  
( a )  P e r c e n t a g e s  o f  K L R G 1 - ,  ( b )  2 B 4 + ,  ( c )  F A S + ,  ( d )  C D 5 7 + ,  ( e )  P D 1 +  a n d  ( f )  I L 7 R α -  T C R α β +  ( T C R γ δ - n e g a t i v e  
T  c e l l s )  C D 8 +  T  c e l l s  a r e  d e p i c t e d  i n  1 0 - 9 0 %  b o x - w h i s k e r s - p l o t s .  ( g )  P e r c e n t a g e s  o f  I L 7 R α -  T C R α β +  T  c e l l s  
c o - e x p r e s s i n g  P D 1  a n d  F A S ,  ( h )  P D 1  a n d  2 B 4  a n d  ( i )  l a c k i n g  K L R G 1  w i t h  e x p r e s s i o n  o f  C D 5 7  d e p i c t e d  i n  
s c a t t e r p l o t s  i n d i c a t e d  w i t h  t h e  m e d i a n s .  S i g n i f i c a n c e  w a s  t e s t e d  b y  a  K r u s k a l - W a l l i s  t e s t ,  f o l l o w e d  b y  a  p o s t -
D u n n ’ s  t e s t .  S i g n i f i c a n c e  o f  t h e  D u n n ’ s  t e s t  i s  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  * * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .
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Supplementary Figure 7. Relative effects of CMV on the exhaustion marker profile of TCRγδ+ T cells.(a) Percentages of KLRG1-, (b) 2B4+, (c) FAS+, (d) CD57+, (e) PD1+ and (f) IL7Rα- TCRγδ+ T cells are depicted in 10-90% box-whiskers-plots. (g) Percentages of IL7Rα- TCRγδ+ T cells co-expressing PD1 and FAS, (h) PD1 and 2B4 and (i) lacking KLRG1 with expression of CD57 depicted in scatterplots indicated with the medians. 
Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test. 
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Supplementary Figure 7. Relative effects of CMV on the exhaustion marker profile of TCRγδ+ T cells.
(a) Percentages of KLRG1-, (b) 2B4+, (c) FAS+, (d) CD57+, (e) PD1+ and (f) IL7Rα- TCRγδ+ T cells are depicted 
in 10-90% box-whiskers-plots. (g) Percentages of IL7Rα- TCRγδ+ T cells co-expressing PD1 and FAS, (h) PD1 
and 2B4 and (i) lacking KLRG1 with expression of CD57 depicted in scatterplots indicated with the medians. 
Significance was tested by a Kruskal-Wallis test, followed by a post-Dunn’s test. 
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ABSTRACT
Next-generation sequencing is a novel tool which can be applied for many research purposes; from mapping whole genomes to the repertoire diversity of the immune system. Different companies have 
established different sequencing technologies, all having their specific traits and trade-offs: deep sequencing often present with sequencing errors and other biases, resulting from either preparation steps or the sequencing technology itself. Several quality internal control mechanisms and analysis algorithms have been developed in order to reduce the sequencing biases, however, in case of repertoire studies 
the amplification steps induce the major part of sequencing errors. PCR 
amplification steps are necessary in order to obtain sufficient material for sequencing, but also bring along many factors which could introduce errors: primers, reagents, annealing temperatures, cycle numbers, et 
cetera. In order to reduce the errors introduced in this amplification step for unbiased TRG / TRD repertoire sequencing we applied stepwise optimization experiments, based on a spike-in method using plasmid DNA. By using samples with known input, we were able to titrate primer concentrations, annealing temperatures and cycle numbers to establish low levels of primer competition and preference, optimized annealing temperatures and preventing PCR plateau phases to maintain receptor diversity. After extensive iterative experiments we were next able to validate the formulated TRG / TRD multiplex PCR assays on genomic DNA and further optimized the assays. Conclusively, we have generated most optimal TRG / TRD multiplex PCR assays for NGS methods with lowest PCR bias and inter-assay variance, which could furthermore become useful in repertoire diversity studies, but also in diagnostic 
test for diagnosis leukemic clones and for the quantification of minimal residual disease.
ABSTRACT
Next-generation sequencing is a novel tool which can be applied 
for many research purposes; from mapping whole genomes to the 
repertoire diversity of the immune system. Different companies have 
established different sequencing technologies, all having their specific 
traits and trade-offs: deep sequencing often present with sequencing 
errors and other biases, resulting from either preparation steps or 
the sequencing technology itself. Several quality internal control 
mechanisms and analysis algorithms have been developed in order to 
reduce the sequencing biases, however, in case of repertoire studies 
the amplification steps induce the major part of sequencing errors. PCR 
amplification steps are necessary in order to obtain sufficient material 
for sequencing, but also bring along many factors which could introduce 
errors: primers, reagents, annealing temperatures, cycle numbers, et 
cetera. In order to reduce the errors introduced in this amplification 
step for unbiased TRG / TRD repertoire sequencing we applied stepwise 
optimization experiments, based on a spike-in method using plasmid 
DNA. By using samples with known input, we were able to titrate primer 
concentrations, annealing temperatures and cycle numbers to establish 
low levels of primer competition and preference, optimized annealing 
temperatures and preventing PCR plateau phases to maintain receptor 
diversity. After extensive iterative experiments we were next able to 
validate the formulated TRG / TRD multiplex PCR assays on genomic 
DNA and further optimized the assays. Conclusively, we have generated 
most optimal TRG / TRD multiplex PCR assays for NGS methods with 
lowest PCR bias and inter-assay variance, which could furthermore 
become useful in repertoire diversity studies, but also in diagnostic 
test for diagnosis leukemic clones and for the quantification of minimal 
residual disease.
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INTRODUCTION
Next-generation sequencing (NGS) methods to study cancer mutagenesis, microbiome compositions and antibody and T cell repertoire diversity evolve rapidly 
into highly advanced sensitive and accurate techniques. A large spectrum of platforms for NGS techniques have become available over time from different companies: Roche 
454 sequencing technology [1], Illumina sequencing platforms [2], Applied Biosystems’ SOLiD System [3], Life Technologies Ion Torrent [4], Pacific Biosciences PacBio System 
[5] for long reads (>1 kb), and many more [6-8]. Each system provides its traits and trade-offs in terms of costs, read yield per run and sequencing read length [6,7,9]. 
Research questions determine often which platform is most suitable. In case of visualizing mutations associated with cancers deep sequencing of the whole genome is 
most applicable, involving the Illumina HiSeq and TruSeq systems [9]. However, in case of repertoire diversity studies, which targets a specific region in the genome leading 
to relatively large amplicons, 454 sequencing technology or Illumina MiSeq platforms were most suitable [10,11], since also major analysis pipelines are designed for 454 
sequencing technology and Illumina MiSeq datasets [10,12]. All NGS platforms and methodologies bring errors along: from sequencing errors 
in the sequencing technique itself, to data analysis errors, but also pre-amplification 
steps in the preparation of samples for NGS cause high degrees of sequencing biases and errors. Usually, this pre-amplification step includes PCR, upon which amplification 
errors can occur very early. To correct for sequencing errors, a polymerase enzyme with proofreading can be used, but also increasing of the sequencing depth is an option to 
solve this.  The latter implies that every region is covered by a high number of reads, preferably sequenced from both ends (paired-end), upon which data is aligned to a 
reference genome [9,13]. Furthermore, several data analysis algorithms have been designed to correct for these sequencing errors, or linkage disequilibrium principles are 
applied [14]. In case of sequencing errors in studying B and T cell repertoire diversities correction 
is rather difficult, since the junctional regions between the variable (V), diversity (D) and 
joining (J) genes during VDJ recombination are highly diverse and thus contain many “mutations” according to sequencing analysis software. Next to that, in order to obtain 
representative data for repertoire diversity, deep sequencing of a given region reduces the diversity of the reads yielded per run. Therefore, also prior PCR steps should be 
reduced in their cycle numbers, in order to prevent reaching plateau phases. To further include all possible gene combinations which are possibly present in the repertoire 
of healthy individuals, different primer sets should be included in a multiplex setting. 
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O p t i m i z e d  N G S  m e t h o d  f o r  T R G  /  T R D  r e p e r t o i r e  s e q u e n c i n g  
I N T R O D U C T I O N
N e x t - g e n e r a t i o n  s e q u e n c i n g  ( N G S )  m e t h o d s  t o  s t u d y  c a n c e r  m u t a g e n e s i s ,  
m i c r o b i o m e  c o m p o s i t i o n s  a n d  a n t i b o d y  a n d  T  c e l l  r e p e r t o i r e  d i v e r s i t y  e v o l v e  r a p i d l y  
i n t o  h i g h l y  a d v a n c e d  s e n s i t i v e  a n d  a c c u r a t e  t e c h n i q u e s .  A  l a r g e  s p e c t r u m  o f  p l a t f o r m s  
f o r  N G S  t e c h n i q u e s  h a v e  b e c o m e  a v a i l a b l e  o v e r  t i m e  f r o m  d i f f e r e n t  c o m p a n i e s :  R o c h e  
4 5 4  s e q u e n c i n g  t e c h n o l o g y  [ 1 ] ,  I l l u m i n a  s e q u e n c i n g  p l a t f o r m s  [ 2 ] ,  A p p l i e d  B i o s y s t e m s ’  
S O L i D  S y s t e m  [ 3 ] ,  L i f e  T e c h n o l o g i e s  I o n  T o r r e n t  [ 4 ] ,  P a c i f i c  B i o s c i e n c e s  P a c B i o  S y s t e m  
[ 5 ]  f o r  l o n g  r e a d s  ( > 1  k b ) ,  a n d  m a n y  m o r e  [ 6 - 8 ] .  E a c h  s y s t e m  p r o v i d e s  i t s  t r a i t s  a n d  
t r a d e - o f f s  i n  t e r m s  o f  c o s t s ,  r e a d  y i e l d  p e r  r u n  a n d  s e q u e n c i n g  r e a d  l e n g t h  [ 6 , 7 , 9 ] .  
R e s e a r c h  q u e s t i o n s  d e t e r m i n e  o f t e n  w h i c h  p l a t f o r m  i s  m o s t  s u i t a b l e .  I n  c a s e  o f  
v i s u a l i z i n g  m u t a t i o n s  a s s o c i a t e d  w i t h  c a n c e r s  d e e p  s e q u e n c i n g  o f  t h e  w h o l e  g e n o m e  i s  
m o s t  a p p l i c a b l e ,  i n v o l v i n g  t h e  I l l u m i n a  H i S e q  a n d  T r u S e q  s y s t e m s  [ 9 ] .  H o w e v e r ,  i n  c a s e  
o f  r e p e r t o i r e  d i v e r s i t y  s t u d i e s ,  w h i c h  t a r g e t s  a  s p e c i f i c  r e g i o n  i n  t h e  g e n o m e  l e a d i n g  
t o  r e l a t i v e l y  l a r g e  a m p l i c o n s ,  4 5 4  s e q u e n c i n g  t e c h n o l o g y  o r  I l l u m i n a  M i S e q  p l a t f o r m s  
w e r e  m o s t  s u i t a b l e  [ 1 0 , 1 1 ] ,  s i n c e  a l s o  m a j o r  a n a l y s i s  p i p e l i n e s  a r e  d e s i g n e d  f o r  4 5 4  
s e q u e n c i n g  t e c h n o l o g y  a n d  I l l u m i n a  M i S e q  d a t a s e t s  [ 1 0 , 1 2 ] .  
A l l  N G S  p l a t f o r m s  a n d  m e t h o d o l o g i e s  b r i n g  e r r o r s  a l o n g :  f r o m  s e q u e n c i n g  e r r o r s  
i n  t h e  s e q u e n c i n g  t e c h n i q u e  i t s e l f ,  t o  d a t a  a n a l y s i s  e r r o r s ,  b u t  a l s o  p r e - a m p l i f i c a t i o n  
s t e p s  i n  t h e  p r e p a r a t i o n  o f  s a m p l e s  f o r  N G S  c a u s e  h i g h  d e g r e e s  o f  s e q u e n c i n g  b i a s e s  
a n d  e r r o r s .  U s u a l l y ,  t h i s  p r e - a m p l i f i c a t i o n  s t e p  i n c l u d e s  P C R ,  u p o n  w h i c h  a m p l i f i c a t i o n  
e r r o r s  c a n  o c c u r  v e r y  e a r l y .  T o  c o r r e c t  f o r  s e q u e n c i n g  e r r o r s ,  a  p o l y m e r a s e  e n z y m e  w i t h  
p r o o f r e a d i n g  c a n  b e  u s e d ,  b u t  a l s o  i n c r e a s i n g  o f  t h e  s e q u e n c i n g  d e p t h  i s  a n  o p t i o n  t o  
s o l v e  t h i s .   T h e  l a t t e r  i m p l i e s  t h a t  e v e r y  r e g i o n  i s  c o v e r e d  b y  a  h i g h  n u m b e r  o f  r e a d s ,  
p r e f e r a b l y  s e q u e n c e d  f r o m  b o t h  e n d s  ( p a i r e d - e n d ) ,  u p o n  w h i c h  d a t a  i s  a l i g n e d  t o  a  
r e f e r e n c e  g e n o m e  [ 9 , 1 3 ] .  F u r t h e r m o r e ,  s e v e r a l  d a t a  a n a l y s i s  a l g o r i t h m s  h a v e  b e e n  
d e s i g n e d  t o  c o r r e c t  f o r  t h e s e  s e q u e n c i n g  e r r o r s ,  o r  l i n k a g e  d i s e q u i l i b r i u m  p r i n c i p l e s  a r e  
a p p l i e d  [ 1 4 ] .  
I n  c a s e  o f  s e q u e n c i n g  e r r o r s  i n  s t u d y i n g  B  a n d  T  c e l l  r e p e r t o i r e  d i v e r s i t i e s  c o r r e c t i o n  
i s  r a t h e r  d i f f i c u l t ,  s i n c e  t h e  j u n c t i o n a l  r e g i o n s  b e t w e e n  t h e  v a r i a b l e  ( V ) ,  d i v e r s i t y  ( D )  a n d  
j o i n i n g  ( J )  g e n e s  d u r i n g  V D J  r e c o m b i n a t i o n  a r e  h i g h l y  d i v e r s e  a n d  t h u s  c o n t a i n  m a n y  
“ m u t a t i o n s ”  a c c o r d i n g  t o  s e q u e n c i n g  a n a l y s i s  s o f t w a r e .  N e x t  t o  t h a t ,  i n  o r d e r  t o  o b t a i n  
r e p r e s e n t a t i v e  d a t a  f o r  r e p e r t o i r e  d i v e r s i t y ,  d e e p  s e q u e n c i n g  o f  a  g i v e n  r e g i o n  r e d u c e s  
t h e  d i v e r s i t y  o f  t h e  r e a d s  y i e l d e d  p e r  r u n .  T h e r e f o r e ,  a l s o  p r i o r  P C R  s t e p s  s h o u l d  b e  
r e d u c e d  i n  t h e i r  c y c l e  n u m b e r s ,  i n  o r d e r  t o  p r e v e n t  r e a c h i n g  p l a t e a u  p h a s e s .  T o  f u r t h e r  
i n c l u d e  a l l  p o s s i b l e  g e n e  c o m b i n a t i o n s  w h i c h  a r e  p o s s i b l y  p r e s e n t  i n  t h e  r e p e r t o i r e  
o f  h e a l t h y  i n d i v i d u a l s ,  d i f f e r e n t  p r i m e r  s e t s  s h o u l d  b e  i n c l u d e d  i n  a  m u l t i p l e x  s e t t i n g .  
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However, different primers could anneal to similar or different regions. In fact, different primers have different annealing temperatures (Ta), which could result in primer competition. To also reduce the build-in of wrong nucleotides, a Taq polymerase with 
proofreading can be used in both amplification steps, i.e. initial amplification of the 
target genomic regions, and consecutive amplification that includes addition of sample 
identification tags. In the current study we aimed to optimize multiplex PCR methods for an Illumina-
based NGS application in studying the T cell receptor (TCR) repertoire of TCRγδ+ T cells. 
To do so, we developed two multiplex PCR mixes for the T cell receptor γ (TRG) and T 
cell receptor δ (TRD) loci and tested these using artificial samples based on a spike-in method. Optimization of the protocol also included the titration of primer concentra-tions, application of different annealing temperatures and variable PCR cycle numbers. 
MATERIALS & METHODS
Study subjectsCryopreserved thymus material (N=5) was obtained from the biobank from the department of Immunology, Erasmus MC, University Medical Center (Rotterdam, the Netherlands). Thymic lobes were removed upon open heart surgery in individuals under the age of two years and obtained upon written informed consent from parents. Whole thymic material was ruptured and prepared for cryopreservation. Fresh cord blood (N=5) mononuclear cells (CBMNCs) were obtained with CB Collect Bags containing citrate phosphate dextrose (CPD) (Fresenius Kabi, Bad Homburg vor der Höhe, Germany) post-partum or after Caesarian section upon written informed consent in collaboration with the department of Obstetrics, Sophia Children’s Hospital, Erasmus MC and the depart-ment of Hematology, Erasmus MC. Both thymic and cord blood material were obtained under Medical Ethics Committee approval project number hmPOO2004-003. Healthy adult blood donors (N=5) from Sanquin Blood Bank (Amsterdam, the Netherlands) were included upon written informed consent at the blood bank under project number NVT0012.01. CB- and PBMNCs were isolated by means of Ficoll-Paque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden) density gradient separation. PBMNCs were cryopre-
served in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza, Basel, Switzerland) with dimethyl sulfoxide and stored in vials at -180 °C until further use, CBMNCs were directly used after obtaining. Materials from all study subjects were anonymized for further use. Studies were conducted in accordance with the principles of the Declaration of Helsinki.
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TCRγδ+ T cell isolation and DNA isolation
Fresh cord blood mononuclear cells (CBMNCs) and cryopreserved and thawed thy- mocytes and healthy control adult peripheral blood mononuclear cells (PBMNCs) were 
subjected to manual magnetic separation using the Anti-TCRγ/δ MicroBead kit from 
Miltenyi (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufactur- er’s protocol. Directly after isolation cells were lysed in RLT+ lysis buffer supplemented 
with 1% beta-mercaptoethanol and further subjected to combined DNA/RNA/miRNA isolation with the QIAGEN DNA/RNA/miRNA AllPrepKit (QIAGEN, Hilden, Germany). 
DNA concentration and quality evaluation was performed with Nanodrop measure- ments (Thermo Scientific, Waltham, MA, USA).
Primer design
Primers for cloning and as basis for Illumina sequencing technology were largely based on the BIOMED-2 protocol [15]. Vδ3 primer was redesigned based on target 
amplicon length and in closer proximity of existing Vδ1 and Vδ2 primers. A Jγ1.2 
primer was newly designed, as this was not included in the BIOMED-2 protocol. Primer adaptation for Illumina MiSeq technology involved adding Illumina forward Rd1 
adaptor (5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’) and reverse Rd2 adaptor (5’-TCGCGAGTTAATGCAACGATCGTCGAAATTCGC-3’). Adaptor sequences functioned as 
templates for indexprimers with sample-specific identification tags in second-step PCR, 
and for attachment of amplicons to the flowcell for bridge amplification. Primers are 
summarized in Supplementary Table 1.
Plasmid pool preparation
Single V-J gene combinations were singleplex-PCR amplified and cloned from either 
DNA from T-ALL patient cell lines or thymus DNA into pGEM T-Easy vector in a 3:1 insert:vector ratio according to the manufacturer’s protocol (Promega, Madison, WI, 
USA). From the TRD locus all possible combinations could be cloned. Even though not all TRG combinations could be obtained two different plasmid pools were generated, at 
least covering all V- and J-gene primers (Supplementary Table 2). 
Two-step PCR amplifications
PCRs were first tested in singleplex and multiplex settings with varying primer 
concentrations, annealing temperatures and PCR cycle numbers. Each initial PCR mix contained GeneAmp PCR Buffer II (1x), magnesium chloride (2.5 mM), deoxynucle-
otides (2.0 mM) and AmpliTaqGold (1 U) (Thermo Fischer Scientific). Total forward and 
reverse primer(s) amounts were 10 pmol. The PCR protocol was largely based on the BIOMED-2 publication (23), with varying annealing temperatures (Tm = 58/59/60/62) 
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T C R γ δ +  T  c e l l  i s o l a t i o n  a n d  D N A  i s o l a t i o n
F r e s h  c o r d  b l o o d  m o n o n u c l e a r  c e l l s  ( C B M N C s )  a n d  c r y o p r e s e r v e d  a n d  t h a w e d  t h y -
m o c y t e s  a n d  h e a l t h y  c o n t r o l  a d u l t  p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  ( P B M N C s )  w e r e  
s u b j e c t e d  t o  m a n u a l  m a g n e t i c  s e p a r a t i o n  u s i n g  t h e  A n t i - T C R γ / δ  M i c r o B e a d  k i t  f r o m  
M i l t e n y i  ( M i l t e n y i  B i o t e c h ,  B e r g i s c h  G l a d b a c h ,  G e r m a n y )  a c c o r d i n g  t o  t h e  m a n u f a c t u r -
e r ’ s  p r o t o c o l .  D i r e c t l y  a f t e r  i s o l a t i o n  c e l l s  w e r e  l y s e d  i n  R L T +  l y s i s  b u f f e r  s u p p l e m e n t e d  
w i t h  1 %  b e t a - m e r c a p t o e t h a n o l  a n d  f u r t h e r  s u b j e c t e d  t o  c o m b i n e d  D N A / R N A / m i R N A  
i s o l a t i o n  w i t h  t h e  Q I A G E N  D N A / R N A / m i R N A  A l l P r e p K i t  ( Q I A G E N ,  H i l d e n ,  G e r m a n y ) .  
D N A  c o n c e n t r a t i o n  a n d  q u a l i t y  e v a l u a t i o n  w a s  p e r f o r m e d  w i t h  N a n o d r o p  m e a s u r e -
m e n t s  ( T h e r m o  S c i e n t i f i c ,  W a l t h a m ,  M A ,  U S A ) .
P r i m e r  d e s i g n
P r i m e r s  f o r  c l o n i n g  a n d  a s  b a s i s  f o r  I l l u m i n a  s e q u e n c i n g  t e c h n o l o g y  w e r e  l a r g e l y  
b a s e d  o n  t h e  B I O M E D - 2  p r o t o c o l  [ 1 5 ] .  V δ 3  p r i m e r  w a s  r e d e s i g n e d  b a s e d  o n  t a r g e t  
a m p l i c o n  l e n g t h  a n d  i n  c l o s e r  p r o x i m i t y  o f  e x i s t i n g  V δ 1  a n d  V δ 2  p r i m e r s .  A  J γ 1 . 2  
p r i m e r  w a s  n e w l y  d e s i g n e d ,  a s  t h i s  w a s  n o t  i n c l u d e d  i n  t h e  B I O M E D - 2  p r o t o c o l .  P r i m e r  
a d a p t a t i o n  f o r  I l l u m i n a  M i S e q  t e c h n o l o g y  i n v o l v e d  a d d i n g  I l l u m i n a  f o r w a r d  R d 1  
a d a p t o r  ( 5 ’ - A C A C T C T T T C C C T A C A C G A C G C T C T T C C G A T C T - 3 ’ )  a n d  r e v e r s e  R d 2  a d a p t o r  
( 5 ’ - T C G C G A G T T A A T G C A A C G A T C G T C G A A A T T C G C - 3 ’ ) .  A d a p t o r  s e q u e n c e s  f u n c t i o n e d  a s  
t e m p l a t e s  f o r  i n d e x p r i m e r s  w i t h  s a m p l e - s p e c i f i c  i d e n t i f i c a t i o n  t a g s  i n  s e c o n d - s t e p  P C R ,  
a n d  f o r  a t t a c h m e n t  o f  a m p l i c o n s  t o  t h e  f l o w c e l l  f o r  b r i d g e  a m p l i f i c a t i o n .  P r i m e r s  a r e  
s u m m a r i z e d  i n  S u p p l e m e n t a r y  T a b l e  1 .
P l a s m i d  p o o l  p r e p a r a t i o n
S i n g l e  V - J  g e n e  c o m b i n a t i o n s  w e r e  s i n g l e p l e x - P C R  a m p l i f i e d  a n d  c l o n e d  f r o m  e i t h e r  
D N A  f r o m  T - A L L  p a t i e n t  c e l l  l i n e s  o r  t h y m u s  D N A  i n t o  p G E M  T - E a s y  v e c t o r  i n  a  3 : 1  
i n s e r t : v e c t o r  r a t i o  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s  p r o t o c o l  ( P r o m e g a ,  M a d i s o n ,  W I ,  
U S A ) .  F r o m  t h e  T R D  l o c u s  a l l  p o s s i b l e  c o m b i n a t i o n s  c o u l d  b e  c l o n e d .  E v e n  t h o u g h  n o t  
a l l  T R G  c o m b i n a t i o n s  c o u l d  b e  o b t a i n e d  t w o  d i f f e r e n t  p l a s m i d  p o o l s  w e r e  g e n e r a t e d ,  a t  
l e a s t  c o v e r i n g  a l l  V -  a n d  J - g e n e  p r i m e r s  ( S u p p l e m e n t a r y  T a b l e  2 ) .  
T w o - s t e p  P C R  a m p l i f i c a t i o n s
P C R s  w e r e  f i r s t  t e s t e d  i n  s i n g l e p l e x  a n d  m u l t i p l e x  s e t t i n g s  w i t h  v a r y i n g  p r i m e r  
c o n c e n t r a t i o n s ,  a n n e a l i n g  t e m p e r a t u r e s  a n d  P C R  c y c l e  n u m b e r s .  E a c h  i n i t i a l  P C R  m i x  
c o n t a i n e d  G e n e A m p  P C R  B u f f e r  I I  ( 1 x ) ,  m a g n e s i u m  c h l o r i d e  ( 2 . 5  m M ) ,  d e o x y n u c l e -
o t i d e s  ( 2 . 0  m M )  a n d  A m p l i T a q G o l d  ( 1  U )  ( T h e r m o  F i s c h e r  S c i e n t i f i c ) .  T o t a l  f o r w a r d  a n d  
r e v e r s e  p r i m e r ( s )  a m o u n t s  w e r e  1 0  p m o l .  T h e  P C R  p r o t o c o l  w a s  l a r g e l y  b a s e d  o n  t h e  
B I O M E D - 2  p u b l i c a t i o n  ( 2 3 ) ,  w i t h  v a r y i n g  a n n e a l i n g  t e m p e r a t u r e s  ( T m  =  5 8 / 5 9 / 6 0 / 6 2 )  
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and different numbers of cycles (20 and 25 cycles). In general total forward and reverse primer(s) amount was 10 pmol. Primer concentration adjustment, and optimization of annealing temperatures and number of PCR cycles were based on the results of itera-
tive optimization experiments. Amplicons from the first step PCR were purified using 
the Agencourt AMPure XP bead purification kit (Beckman Coulter, Fullerton, CA, USA), 
whereafter concentrations were measured with the Quant-iT PicoGreen dsDNA Assay Kit 
(Thermo Fischer Scientific), and the amplicons were adjusted to similar concentrations. The second step PCR was performed with primers from the Illumina TruSeq Custom Amplicon Index Kit (Illumina) using the KAPA HiFi HotStart PCR Kit (Kapa Biosystems, Wilmington, MA, USA). Second PCR amplicons were evaluated with agarose gel electro-phoresis or PicoGreen concentration measurement. Library pool preparation was per-formed based on the gel image or PicoGreen measurement results. The library pool was 
further purified with Agencourt AMPure XP beads and normalized from Illumina-based sequencing, according to the manufacturer’s protocol (Illumina). 
Next-generation sequencingNext-generation paired-end (2x221 bp) sequencing was performed on the Illumina MiSeq Kit platform (Illumina, San Diego, CA, USA) using the Illumina MiSeq Reagent Kit V3 according to the manufacturer’s protocol (Illumina).
Bio-informatic data analysis
Illumina NGS data was obtained in FASTQ format. Paired-end reads were joined with the Pear Paired-End read merger tool [16] in the Erasmus MC Galaxy Server [17]. 
Joined FASTQ reads were converted into FASTA format [18]. Sequencing annotations were performed with IMmunoGeneTics (IMGT) High V-quest database [19-22]. Data analysis was performed using the Antigen Receptor Galaxy (ARGalaxy) tool [12], which included analysis of V-, D- and J-gene frequencies with bar graphs and heatmaps, CDR3 characteristics (length and amino acid compositions), clonality scores [23] and junction analysis (insertions/deletions, P and N nucleotides). Circoletto plots were generated using the Circos online software (https://www.circos.ca) [24].
Statistical analysesThe Hartigan’s Dip Test Statistic for Unimodality [25] was applied to test for normal distribution of the sequencing data using R package version 3.3.0. 
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RESULTS
Primer target specificity and exclusivity experiments illustrate the 
need for primer optimization to reduce competition bias
Primers targeting V- and J-genes of TRG / TRD loci were adjusted in view of Illumina MiSeq next-generation sequencing technology with the addition of forward and reverse 
adaptors (Supplementary Table 1). Since the adaptors are 33 nucleotides in length – and 
thus longer than the target primers – we first performed singleplex and multiplex PCRs 
on plasmids to validate primer target specificity and exclusivity. In the singleplex assay 10 
pmol forward and 10 pmol reverse primer was used, whereas in the multiplex assay the total amounts of forward and reverse primers were 10 pmol each. Both assays showed 
that the primer specificity and exclusivity did not alter upon attachment of the forward 
and reverse adaptors, although some primer combinations also resulted in other V-J rearrangements than the ones expected based on the plasmids used. This was especially 
true for the TRG assay (Vγ2-Jγ1.1, Vγ8-Jγ1.1 and Vγ9-Jγ2.3) (Table 1), which may be at 
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R E S U LT S
P r i m e r  t a r g e t  s p e c i f i c i t y  a n d  e x c l u s i v i t y  e x p e r i m e n t s  i l l u s t r a t e  t h e  
n e e d  f o r  p r i m e r  o p t i m i z a t i o n  t o  r e d u c e  c o m p e t i t i o n  b i a s
P r i m e r s  t a r g e t i n g  V -  a n d  J - g e n e s  o f  T R G  /  T R D  l o c i  w e r e  a d j u s t e d  i n  v i e w  o f  I l l u m i n a  
M i S e q  n e x t - g e n e r a t i o n  s e q u e n c i n g  t e c h n o l o g y  w i t h  t h e  a d d i t i o n  o f  f o r w a r d  a n d  r e v e r s e  
a d a p t o r s  ( S u p p l e m e n t a r y  T a b l e  1 ) .  S i n c e  t h e  a d a p t o r s  a r e  3 3  n u c l e o t i d e s  i n  l e n g t h  –  a n d  
t h u s  l o n g e r  t h a n  t h e  t a r g e t  p r i m e r s  –  w e  f i r s t  p e r f o r m e d  s i n g l e p l e x  a n d  m u l t i p l e x  P C R s  
o n  p l a s m i d s  t o  v a l i d a t e  p r i m e r  t a r g e t  s p e c i f i c i t y  a n d  e x c l u s i v i t y .  I n  t h e  s i n g l e p l e x  a s s a y  1 0  
p m o l  f o r w a r d  a n d  1 0  p m o l  r e v e r s e  p r i m e r  w a s  u s e d ,  w h e r e a s  i n  t h e  m u l t i p l e x  a s s a y  t h e  
t o t a l  a m o u n t s  o f  f o r w a r d  a n d  r e v e r s e  p r i m e r s  w e r e  1 0  p m o l  e a c h .  B o t h  a s s a y s  s h o w e d  
t h a t  t h e  p r i m e r  s p e c i f i c i t y  a n d  e x c l u s i v i t y  d i d  n o t  a l t e r  u p o n  a t t a c h m e n t  o f  t h e  f o r w a r d  
a n d  r e v e r s e  a d a p t o r s ,  a l t h o u g h  s o m e  p r i m e r  c o m b i n a t i o n s  a l s o  r e s u l t e d  i n  o t h e r  V - J  
r e a r r a n g e m e n t s  t h a n  t h e  o n e s  e x p e c t e d  b a s e d  o n  t h e  p l a s m i d s  u s e d .  T h i s  w a s  e s p e c i a l l y  
t r u e  f o r  t h e  T R G  a s s a y  ( V γ 2 - J γ 1 . 1 ,  V γ 8 - J γ 1 . 1  a n d  V γ 9 - J γ 2 . 3 )  ( T a b l e  1 ) ,  w h i c h  m a y  b e  a t  
Chapter 3
96
least partly due to the fact that the Vγ1 Family (Vγ1F) primer covers the Vγ2, Vγ3, Vγ4, 
Vγ5 and Vγ8 genes. Upon repetitive deep sequencing all correct rearrangements were observed. In order to prevent other rearrangements as indicated in Table 1, multiple 
replicates were applied. The broader coverage as for the Vγ1F genes also holds for the Jγ 
primers that cover the Jγ1.1 / Jγ2.1 and Jγ1.3 / Jγ2.3 genes, respectively (TRGJP1 / TRGJP2, 
and TRGJ1 / TRGJ2  according to IMGT nomenclature [26]). Hereafter Jγ primers are 
named Jγ1.1/2.1, Jγ1.3/2.3, and Jγ1.2 for the primer recognizing the IMGT TRGJP gene. 
The first testing round for the multiplex PCR on plasmid pools showed discrepan-cies in the percentages of expected and observed reads (Fig. 1). All these multiplex 
Figure 1. First TRG / TRD multiplex PCR assay on plasmid pools.Multiplex PCR test on plasmid pools with compositions indicated in Supplementary Table 2, columns A and B, and primer concentrations and assay numbers as summarized in Table 2. %Expected reads were calculated based on the input material of the plasmid pools. %Observed reads represented the percentage of reads 
identified with the expected V or J gene. TRGV assay with Vγ2/3/4/5/8 genes covered by the Vγ1F primer, and 
Vγ9 (a), TRGJ assay with combined Jγ1.1/2.1 and Jγ1.3/2.3 primers with separate Jγ1.2 primer (b). TRDV (c) and TRDJ assays (d). Bar graphs represent median and SD; replicates per assay N=4.
Chapter 3
96
least partly due to the fact that the Vγ1 Family (Vγ1F) primer covers the Vγ2, Vγ3, Vγ4, 
Vγ5 and Vγ8 genes. Upon repetitive deep sequencing all correct rearrangements were 
observed. In order to prevent other rearrangements as indicated in Table 1, multiple 
replicates were applied. The broader coverage as for the Vγ1F genes also holds for the Jγ 
primers that cover the Jγ1.1 / Jγ2.1 and Jγ1.3 / Jγ2.3 genes, respectively (TRGJP1 / TRGJP2, 
and TRGJ1 / TRGJ2  according to IMGT nomenclature [26]). Hereafter Jγ primers are 
named Jγ1.1/2.1, Jγ1.3/2.3, and Jγ1.2 for the primer recognizing the IMGT TRGJP gene. 
The first testing round for the multiplex PCR on plasmid pools showed discrepan-
cies in the percentages of expected and observed reads (Fig. 1). All these multiplex 
Figure 1. First TRG / TRD multiplex PCR assay on plasmid pools.
Multiplex PCR test on plasmid pools with compositions indicated in Supplementary Table 2, columns A and B, 
and primer concentrations and assay numbers as summarized in Table 2. %Expected reads were calculated 
based on the input material of the plasmid pools. %Observed reads represented the percentage of reads 
identified with the expected V or J gene. TRGV assay with Vγ2/3/4/5/8 genes covered by the Vγ1F primer, and 
Vγ9 (a), TRGJ assay with combined Jγ1.1/2.1 and Jγ1.3/2.3 primers with separate Jγ1.2 primer (b). TRDV (c) 
and TRDJ assays (d). Bar graphs represent median and SD; replicates per assay N=4.
397
Optimized NGS method for TRG / TRD repertoire sequencing 
PCR assays were performed on plasmid pools in four independent replicates. The TRG assay showed differences between expected and observed percentages for some 
V genes, although correction would be difficult because of the common Vγ1F primer 
(Fig. 1a). Similarly, the Jγ1.3/2.3 and Jγ1.2 primers also required some correction (Fig. 1b). However,  the TRD assay showed most clear discrepancies: Vδ1 and Jδ1 being 
over-represented, while Vδ2 and Jδ2 were heavily under-represented (Fig. 1c, 1d). 
Based on these first results we concluded that the primer specificity and exclusivity 
for the different targets were not affected by the adaptors added for Illumina MiSeq next-generation sequencing technology, but that in the context of multiplex PCR assays 
primer concentration adjustments were necessary to reduce primer-based amplifica- tion bias.
Multiplex PCR fine-tuning with different primer concentrations, 
annealing temperatures and PCR cycle numbers 
The discrepancies as found in the first round of testing could be explained by dif- ferences in primer concentration, primer binding efficiency, CG-nucleotide enrichment, 
Ta’s and PCR cycle numbers. Of note, the Illumina forward and reverse adaptors each have a GC-composition of 17/33 and 16/33 nucleotides respectively. Furthermore, the 
Vγ9, Jδ1 and Jδ3 primers showed the highest %GC content (>50%) (Supplementary 
Table 2), whereas the Vγ9, Jγ1.2, Vδ3 and Jδ3 primers contained particular GC-stretches 
(lengths of 4, 5, 4, 6 nt, respectively). As this could highly influence the most optimal Ta 
of the primers (Supplementary Table 2), and thus impact on performance of the mul- tiplex assay,  we then performed primer concentration titration experiments and also 
varied with  Ta’s and PCR cycle numbers (Table 2). Since it would be difficult to adjust 
for gene discrepancies caused by the common Vγ1F primer, we repeated the experiment 
with similar primer concentrations as used in the initial experiment, which included the first multiplex PCR assay on plasmid pools (Table 2, EXP1/2 column). We did adjust 
the Jγ primer concentrations in an attempt to correct the discrepancies as observed 
in the first round. Since the TRD assay showed considerable differences between 
the %expected and %observed reads, we also adjusted TRD primer concentrations accordingly and formulated four different mixes (Table 2, EXP3 column). Along with 
the different primer concentrations, we tested several Ta’s (58, 60 and 62 ⁰C), which 
correlated with the calculated Ta’s as indicated in Supplementary Table 1. Furthermore, we tested a reduced PCR cycle number (20 vs. 25 cycles). Each condition, consisting of 
a specific primer mixture, Ta and PCR cycle number combination, was tested once in 
order to obtain insights in what the different conditions would possibly lead to (Fig. 2). While using the same mix as in the previous experiment, the %observed values of Vγ1F 
primers were close to the %expected values (Fig. 2a), as indicated with the dashed 
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O p t i m i z e d  N G S  m e t h o d  f o r  T R G  /  T R D  r e p e r t o i r e  s e q u e n c i n g  
P C R  a s s a y s  w e r e  p e r f o r m e d  o n  p l a s m i d  p o o l s  i n  f o u r  i n d e p e n d e n t  r e p l i c a t e s .  T h e  
T R G  a s s a y  s h o w e d  d i f f e r e n c e s  b e t w e e n  e x p e c t e d  a n d  o b s e r v e d  p e r c e n t a g e s  f o r  s o m e  
V  g e n e s ,  a l t h o u g h  c o r r e c t i o n  w o u l d  b e  d i f f i c u l t  b e c a u s e  o f  t h e  c o m m o n  V γ 1 F  p r i m e r  
( F i g .
 
1 a ) .  S i m i l a r l y ,  t h e  J γ 1 . 3 / 2 . 3  a n d  J γ 1 . 2  p r i m e r s  a l s o  r e q u i r e d  s o m e  c o r r e c t i o n  
( F i g .  1 b ) .  H o w e v e r ,   t h e  T R D  a s s a y  s h o w e d  m o s t  c l e a r  d i s c r e p a n c i e s :  V δ 1  a n d  J δ 1  b e i n g  
o v e r - r e p r e s e n t e d ,  w h i l e  V δ 2  a n d  J δ 2  w e r e  h e a v i l y  u n d e r - r e p r e s e n t e d  ( F i g .  1 c ,  1 d ) .  
B a s e d  o n  t h e s e  f i r s t  r e s u l t s  w e  c o n c l u d e d  t h a t  t h e  p r i m e r  s p e c i f i c i t y  a n d  e x c l u s i v i t y  
f o r  t h e  d i f f e r e n t  t a r g e t s  w e r e  n o t  a f f e c t e d  b y  t h e  a d a p t o r s  a d d e d  f o r  I l l u m i n a  M i S e q  
n e x t - g e n e r a t i o n  s e q u e n c i n g  t e c h n o l o g y ,  b u t  t h a t  i n  t h e  c o n t e x t  o f  m u l t i p l e x  P C R  a s s a y s  
p r i m e r  c o n c e n t r a t i o n  a d j u s t m e n t s  w e r e  n e c e s s a r y  t o  r e d u c e  p r i m e r - b a s e d  a m p l i f i c a -
t i o n  b i a s .
M u l t i p l e x  P C R  f i n e - t u n i n g  w i t h  d i f f e r e n t  p r i m e r  c o n c e n t r a t i o n s ,  
a n n e a l i n g  t e m p e r a t u r e s  a n d  P C R  c y c l e  n u m b e r s  
T h e  d i s c r e p a n c i e s  a s  f o u n d  i n  t h e  f i r s t  r o u n d  o f  t e s t i n g  c o u l d  b e  e x p l a i n e d  b y  d i f -
f e r e n c e s  i n  p r i m e r  c o n c e n t r a t i o n ,  p r i m e r  b i n d i n g  e f f i c i e n c y ,  C G - n u c l e o t i d e  e n r i c h m e n t ,  
T a ’ s  a n d  P C R  c y c l e  n u m b e r s .  O f  n o t e ,  t h e  I l l u m i n a  f o r w a r d  a n d  r e v e r s e  a d a p t o r s  e a c h  
h a v e  a  G C - c o m p o s i t i o n  o f  1 7 / 3 3  a n d  1 6 / 3 3  n u c l e o t i d e s  r e s p e c t i v e l y .  F u r t h e r m o r e ,  t h e  
V γ 9 ,  J δ 1  a n d  J δ 3  p r i m e r s  s h o w e d  t h e  h i g h e s t  % G C  c o n t e n t  ( > 5 0 % )  ( S u p p l e m e n t a r y  
T a b l e  2 ) ,  w h e r e a s  t h e  V γ 9 ,  J γ 1 . 2 ,  V δ 3  a n d  J δ 3  p r i m e r s  c o n t a i n e d  p a r t i c u l a r  G C - s t r e t c h e s  
( l e n g t h s  o f  4 ,  5 ,  4 ,  6  n t ,  r e s p e c t i v e l y ) .  A s  t h i s  c o u l d  h i g h l y  i n f l u e n c e  t h e  m o s t  o p t i m a l  T a  
o f  t h e  p r i m e r s  ( S u p p l e m e n t a r y  T a b l e  2 ) ,  a n d  t h u s  i m p a c t  o n  p e r f o r m a n c e  o f  t h e  m u l -
t i p l e x  a s s a y ,   w e  t h e n  p e r f o r m e d  p r i m e r  c o n c e n t r a t i o n  t i t r a t i o n  e x p e r i m e n t s  a n d  a l s o  
v a r i e d  w i t h   T a ’ s  a n d  P C R  c y c l e  n u m b e r s  ( T a b l e  2 ) .  S i n c e  i t  w o u l d  b e  d i f f i c u l t  t o  a d j u s t  
f o r  g e n e  d i s c r e p a n c i e s  c a u s e d  b y  t h e  c o m m o n  V γ 1 F  p r i m e r ,  w e  r e p e a t e d  t h e  e x p e r i m e n t  
w i t h  s i m i l a r  p r i m e r  c o n c e n t r a t i o n s  a s  u s e d  i n  t h e  i n i t i a l  e x p e r i m e n t ,  w h i c h  i n c l u d e d  
t h e  f i r s t  m u l t i p l e x  P C R  a s s a y  o n  p l a s m i d  p o o l s  ( T a b l e  2 ,  E X P 1 / 2  c o l u m n ) .  W e  d i d  a d j u s t  
t h e  J γ  p r i m e r  c o n c e n t r a t i o n s  i n  a n  a t t e m p t  t o  c o r r e c t  t h e  d i s c r e p a n c i e s  a s  o b s e r v e d  
i n  t h e  f i r s t  r o u n d .  S i n c e  t h e  T R D  a s s a y  s h o w e d  c o n s i d e r a b l e  d i f f e r e n c e s  b e t w e e n  
t h e  % e x p e c t e d  a n d  % o b s e r v e d  r e a d s ,  w e  a l s o  a d j u s t e d  T R D  p r i m e r  c o n c e n t r a t i o n s  
a c c o r d i n g l y  a n d  f o r m u l a t e d  f o u r  d i f f e r e n t  m i x e s  ( T a b l e  2 ,  E X P 3  c o l u m n ) .  A l o n g  w i t h  
t h e  d i f f e r e n t  p r i m e r  c o n c e n t r a t i o n s ,  w e  t e s t e d  s e v e r a l  T a ’ s  ( 5 8 ,  6 0  a n d  6 2  ⁰ C ) ,  w h i c h  
c o r r e l a t e d  w i t h  t h e  c a l c u l a t e d  T a ’ s  a s  i n d i c a t e d  i n  S u p p l e m e n t a r y  T a b l e  1 .  F u r t h e r m o r e ,  
w e  t e s t e d  a  r e d u c e d  P C R  c y c l e  n u m b e r  ( 2 0  v s .  2 5  c y c l e s ) .  E a c h  c o n d i t i o n ,  c o n s i s t i n g  o f  
a  s p e c i f i c  p r i m e r  m i x t u r e ,  T a  a n d  P C R  c y c l e  n u m b e r  c o m b i n a t i o n ,  w a s  t e s t e d  o n c e  i n  
o r d e r  t o  o b t a i n  i n s i g h t s  i n  w h a t  t h e  d i f f e r e n t  c o n d i t i o n s  w o u l d  p o s s i b l y  l e a d  t o  ( F i g .  2 ) .  
W h i l e  u s i n g  t h e  s a m e  m i x  a s  i n  t h e  p r e v i o u s  e x p e r i m e n t ,  t h e  % o b s e r v e d  v a l u e s  o f  V γ 1 F  
p r i m e r s  w e r e  c l o s e  t o  t h e  % e x p e c t e d  v a l u e s  ( F i g .  2 a ) ,  a s  i n d i c a t e d  w i t h  t h e  d a s h e d  
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lines, except for Vγ8 and Vγ9. Different Ta’s gave variable results, and the number of 
cycles also heavily influenced the results. Jγ1.2 %expected and %observed values were 
in close proximity, with a slight Jγ1.3/2.3 dominance, and also showing varying effects 
of both Ta and cycle numbers (Fig. 2b). Since in the previous experiment the Vδ2 and 
Jδ2 genes were highly under-represented, four different mixes were developed with 
increased Vδ2 and Jδ2 primer concentrations in order to adjust for these under-rep-
resentations. In all four mixes Vδ2 and Jδ2 were now over-represented, indicating the adjustments were too high. Mixes D2 and D4 showed %expected and %observed 
values that were more closely together, especially Vδ3 gene was represented well in 
these mixes (Fig. 2c). Similar results were observed for the Jδ genes, with over-repre-
sentation of Jδ2 genes. The Jδ3 and Jδ4 %observed and %expected values correlated best (Fig. 2d). Only a small effect of Ta was observed, showing better results at Ta=60. There were few differences in the results due to different PCR cycle numbers; although in some cases 20 cycles gave results closer to %expected values (Fig. 2c, 2d). Based on 
the results of this first fine-tuning experiment further adjustments in primer concentra-tions and Ta’s were deemed necessary. Furthermore, as the PCR cycle number seemed to 
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have influence on %expected and %observed values, it also still needed further testing. 
Based on these results we therefore formulated a next optimization experiment, again including different primer concentrations, different Ta’s (58, 59 and 60 ⁰C) and vari-
able (20, 25) PCR cycles (Fig. 2e-h, Table 2 EXP4 column). With the adjustment of TRG 
Figure 2. TRG / TRD primer titration and PCR optimization experiments.
Multiplex PCR tests on plasmid pools with compositions as indicated in Supplementary Table 2 and primer concentrations and PCR assay layout as described in Table 2. Different annealing temperatures (Ta) of 58, 60 and 62 ⁰a (a-d) and 58, 59 and 60 ⁰C (e-h), and two different cycle numbers (20x versus 25x) were tested. 
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h a v e  i n f l u e n c e  o n  % e x p e c t e d  a n d  % o b s e r v e d  v a l u e s ,  i t  a l s o  s t i l l  n e e d e d  f u r t h e r  t e s t i n g .  
B a s e d  o n  t h e s e  r e s u l t s  w e  t h e r e f o r e  f o r m u l a t e d  a  n e x t  o p t i m i z a t i o n  e x p e r i m e n t ,  a g a i n  
i n c l u d i n g  d i f f e r e n t  p r i m e r  c o n c e n t r a t i o n s ,  d i f f e r e n t  T a ’ s  ( 5 8 ,  5 9  a n d  6 0  ⁰ C )  a n d  v a r i -
a b l e  ( 2 0 ,  2 5 )  P C R  c y c l e s  ( F i g .  2 e - h ,  T a b l e  2  E X P 4  c o l u m n ) .  W i t h  t h e  a d j u s t m e n t  o f  T R G  
F i g u r e  2 .  T R G  /  T R D  p r i m e r  t i t r a t i o n  a n d  P C R  o p t i m i z a t i o n  e x p e r i m e n t s .
M u l t i p l e x  P C R  t e s t s  o n  p l a s m i d  p o o l s  w i t h  c o m p o s i t i o n s  a s  i n d i c a t e d  i n  S u p p l e m e n t a r y  T a b l e  2  a n d  p r i m e r  
c o n c e n t r a t i o n s  a n d  P C R  a s s a y  l a y o u t  a s  d e s c r i b e d  i n  T a b l e  2 .  D i f f e r e n t  a n n e a l i n g  t e m p e r a t u r e s  ( T a )  o f  5 8 ,  6 0  
a n d  6 2  ⁰ a  ( a - d )  a n d  5 8 ,  5 9  a n d  6 0  ⁰ C  ( e - h ) ,  a n d  t w o  d i f f e r e n t  c y c l e  n u m b e r s  ( 2 0 x  v e r s u s  2 5 x )  w e r e  t e s t e d .  
T h e  d i f f e r e n t  a n n e a l i n g  t e m p e r a t u r e s  a n d  c y c l e  n u m b e r s  a r e  i n d i c a t e d  i n  t h e  l e g e n d  w i t h  d i f f e r e n t  c o l o r s .  
% E x p e c t e d  i n d i c a t e d  w i t h  b l a c k  b a r  g r a p h  a n d  d a s h e d  l i n e  i n  g r a p h s .  V a r y i n g  % E x p e c t e d  v a l u e s  f o r  T R G V 1 F  
g e n e s  d u e  t o  d i f f e r e n t i a l  p l a s m i d  p o o l  c o m p o s i t i o n s .  E a c h  m i x ,  i n  c o m b i n a t i o n  w i t h  T a  a n d  c y c l e  n u m b e r ,  
t e s t e d  o n c e .
Chapter 3
100
forward primers we generally observed high variability in the %observed values of the 
Vγ1F genes, but mix G2, with lower Vγ9 and higher Vγ1F primer concentrations, partly 
reduced the overrepresentation of Vγ9 genes (Fig. 2e). Both TRG mixes contained similar 
Jγ primer concentrations, and showed largely similar results, albeit with some inter-as-
say variability (Fig. 2f). For the TRG assay 25 cycles and Ta=58 ⁰C showed most optimal 
results. Higher Ta’s were associated with increased primer competition of Jγ1.3/2.3 over 
Jγ1.1/2.1 (Fig. 2f).  Since in the initial experiment the TRD assay showed over-repre-
sentations of Vδ2 and Jδ2 genes, two new mixes were formulated. As in the previous 
experiment Ta’s 58 and 60 ⁰C showed the best results,  different Ta’s (58, 59 and 60 ⁰C) 
were tested in combination with 20 vs. 25 cycles.  Vδ2 primer adjustment indeed resulted 
in decreased Vδ2 gene detection, with mainly mix D5 showing %observed values closest 
to %expected values (Fig. 2g). This mix also lead to more %expected values in Jδ genes 
(Fig. 2h). For the TRD assay Ta=59 ⁰C showed the best correlations between %expected 
and %observed values, especially with 20 cycles (Fig. 2g, 2h). Based on these fine-tuning experiments on plasmid pools the most optimal assays (TRG assay with primer con-
centration mix G2, Ta=58 ⁰C, 25 cycles; TRD assay with primer concentration mix D5, 
Ta=59 ⁰C, 20 cycles; Table 2) were defined for further biological validation studies on genomic DNA.
Initial assay validation on genomic DNA and further fine-tuning 
experiments result in the most optimal TRG / TRD multiplex PCR 
assays for NGS purposes
Primary PCR fine-tuning experiments were performed on plasmid DNA, consisting of a 3015 bp vector, and TRD or TRG inserts of 200-400 bp. Even though the use of 
plasmid DNA is valuable for technical titration experiments, it does not reflect genomic 
DNA (gDNA) in which the region of interest is more difficult to target with specific 
primers. Therefore in the next experiment gDNA of total TCRγδ+ T cells was used to 
further test the most optimal assay as defined in the plasmid fine-tuning experiments. Initially four different thymus (Thy), cord blood (CB) and adult peripheral blood (PB) samples were used to validate the TRG / TRD assays on gDNA. First results showed low TRD absolute read numbers, while the TRG assay showed high numbers, espe-cially for the Thy samples (Supplementary Table 3). The low TRD read numbers could be explained by the lower number of PCR cycles (20) as compared to the TRG assay (25 cycles). Based on the low numbers of productive reads two samples were excluded from further TRD assay analyses (samples Thy11-03 and CB4, Supplementary Table 3). In the Thy samples the frequency of unproductive TRG reads was higher than that of productive TRG sequences, whereas CB and PB samples showed more productive than unproductive TRG rearrangements (Fig. 3a). The naive immature and non-antigen 
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forward primers we generally observed high variability in the %observed values of the 
Vγ1F genes, but mix G2, with lower Vγ9 and higher Vγ1F primer concentrations, partly 
reduced the overrepresentation of Vγ9 genes (Fig. 2e). Both TRG mixes contained similar 
Jγ primer concentrations, and showed largely similar results, albeit with some inter-as-
say variability (Fig. 2f). For the TRG assay 25 cycles and Ta=58 ⁰C showed most optimal 
results. Higher Ta’s were associated with increased primer competition of Jγ1.3/2.3 over 
Jγ1.1/2.1 (Fig. 2f).  Since in the initial experiment the TRD assay showed over-repre-
sentations of Vδ2 and Jδ2 genes, two new mixes were formulated. As in the previous 
experiment Ta’s 58 and 60 ⁰C showed the best results,  different Ta’s (58, 59 and 60 ⁰C) 
were tested in combination with 20 vs. 25 cycles.  Vδ2 primer adjustment indeed resulted 
in decreased Vδ2 gene detection, with mainly mix D5 showing %observed values closest 
to %expected values (Fig. 2g). This mix also lead to more %expected values in Jδ genes 
(Fig. 2h). For the TRD assay Ta=59 ⁰C showed the best correlations between %expected 
and %observed values, especially with 20 cycles (Fig. 2g, 2h). Based on these fine-tuning 
experiments on plasmid pools the most optimal assays (TRG assay with primer con-
centration mix G2, Ta=58 ⁰C, 25 cycles; TRD assay with primer concentration mix D5, 
Ta=59 ⁰C, 20 cycles; Table 2) were defined for further biological validation studies on 
genomic DNA.
Initial assay validation on genomic DNA and further fine-tuning 
experiments result in the most optimal TRG / TRD multiplex PCR 
assays for NGS purposes
Primary PCR fine-tuning experiments were performed on plasmid DNA, consisting 
of a 3015 bp vector, and TRD or TRG inserts of 200-400 bp. Even though the use of 
plasmid DNA is valuable for technical titration experiments, it does not reflect genomic 
DNA (gDNA) in which the region of interest is more difficult to target with specific 
primers. Therefore in the next experiment gDNA of total TCRγδ+ T cells was used to 
further test the most optimal assay as defined in the plasmid fine-tuning experiments. 
Initially four different thymus (Thy), cord blood (CB) and adult peripheral blood (PB) 
samples were used to validate the TRG / TRD assays on gDNA. First results showed 
low TRD absolute read numbers, while the TRG assay showed high numbers, espe-
cially for the Thy samples (Supplementary Table 3). The low TRD read numbers could 
be explained by the lower number of PCR cycles (20) as compared to the TRG assay 
(25 cycles). Based on the low numbers of productive reads two samples were excluded 
from further TRD assay analyses (samples Thy11-03 and CB4, Supplementary Table 3). 
In the Thy samples the frequency of unproductive TRG reads was higher than that of 
productive TRG sequences, whereas CB and PB samples showed more productive than 
unproductive TRG rearrangements (Fig. 3a). The naive immature and non-antigen 
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selected stage of the thymocytes was also reflected in the diversity of the rearrange- ments; also, the naive mature TCRγδ+ T cells from CB samples still showed a high 
diversity. Actually the Thy and CB samples showed similar patterns of rearrangements and diversity, while the patterns observed in the PB samples were donor-specific 
with skewing towards Vγ9-Jγ1.2 rearrangements (Fig. 3b). The TRD assay yielded 
significant lower read numbers (Supplementary Table 3), which heavily influenced 
the data. Nonetheless, the Thy samples again contained more unproductive than productive reads, which was reversed in the CB and PB samples (Fig. 3c). Also, all Vδ 
genes were observed in the naive immature and mature Thy and CB TCRγδ+ T cells, 
albeit with a clear Vδ1-Jδ1 dominance. The Thy and CB samples showed similar pat- terns of rearrangement distributions, in contrast to the more skewed profiles in 
the adult PB samples, with donor-specific patterns, and Vδ2 dominance (Fig. 3d). 
Based on the initial biological validation of the TRG / TRD multiplex PCR assays as opti- mized using plasmid DNA tests, the TRG assay looked promising.  TRG read numbers 
were high and data were in line with previous literature [27,28], albeit that Vγ9 and 
Figure 3. Initial biological validation experiments using the most optimal TRG and TRD PCR assays as 
based on plasmid pools.
TRG mix G2 with Ta=58.0 and 25 cycles, TRD mix D5 with Ta=59.0 and 20 cycles validation on genomic DNA from total TCRγδ+ T cells from thymus (Thy), cord blood (CB) and adult peripheral blood (PB) samples (N=4 each sample). IMGT annotation resulting in productive, unproductive or not annotated reads (a, c). V-J 
rearrangements depicted as Circoletto plots (www.circos.ca), with Thy, CB and PB samples in the following order (left-right): Thy05-13, Thy10-09, Thy10-13, Thy11-03; CB2, CB3, CB4, CB5; PB30, PB31, PB34, PB37 (b) and Thy05-13, Thy10-09, Thy10-13; CB2, CB3, CB5; PB30, PB31, PB34, PB37 (d). 
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1 0 1
O p t i m i z e d  N G S  m e t h o d  f o r  T R G  /  T R D  r e p e r t o i r e  s e q u e n c i n g  
s e l e c t e d  s t a g e  o f  t h e  t h y m o c y t e s  w a s  a l s o  r e f l e c t e d  i n  t h e  d i v e r s i t y  o f  t h e  r e a r r a n g e -
m e n t s ;  a l s o ,  t h e  n a i v e  m a t u r e  T C R γ δ +  T  c e l l s  f r o m  C B  s a m p l e s  s t i l l  s h o w e d  a  h i g h  
d i v e r s i t y .  A c t u a l l y  t h e  T h y  a n d  C B  s a m p l e s  s h o w e d  s i m i l a r  p a t t e r n s  o f  r e a r r a n g e m e n t s  
a n d  d i v e r s i t y ,  w h i l e  t h e  p a t t e r n s  o b s e r v e d  i n  t h e  P B  s a m p l e s  w e r e  d o n o r - s p e c i f i c  
w i t h  s k e w i n g  t o w a r d s  V γ 9 - J γ 1 . 2  r e a r r a n g e m e n t s  ( F i g .  3 b ) .  T h e  T R D  a s s a y  y i e l d e d  
s i g n i f i c a n t  l o w e r  r e a d  n u m b e r s  ( S u p p l e m e n t a r y  T a b l e  3 ) ,  w h i c h  h e a v i l y  i n f l u e n c e d  
t h e  d a t a .  N o n e t h e l e s s ,  t h e  T h y  s a m p l e s  a g a i n  c o n t a i n e d  m o r e  u n p r o d u c t i v e  t h a n  
p r o d u c t i v e  r e a d s ,  w h i c h  w a s  r e v e r s e d  i n  t h e  C B  a n d  P B  s a m p l e s  ( F i g .  3 c ) .  A l s o ,  a l l  V δ  
g e n e s  w e r e  o b s e r v e d  i n  t h e  n a i v e  i m m a t u r e  a n d  m a t u r e  T h y  a n d  C B  T C R γ δ +  T  c e l l s ,  
a l b e i t  w i t h  a  c l e a r  V δ 1 - J δ 1  d o m i n a n c e .  T h e  T h y  a n d  C B  s a m p l e s  s h o w e d  s i m i l a r  p a t -
t e r n s  o f  r e a r r a n g e m e n t  d i s t r i b u t i o n s ,  i n  c o n t r a s t  t o  t h e  m o r e  s k e w e d  p r o f i l e s  i n  
t h e  a d u l t  P B  s a m p l e s ,  w i t h  d o n o r - s p e c i f i c  p a t t e r n s ,  a n d  V δ 2  d o m i n a n c e  ( F i g .  3 d ) .  
B a s e d  o n  t h e  i n i t i a l  b i o l o g i c a l  v a l i d a t i o n  o f  t h e  T R G  /  T R D  m u l t i p l e x  P C R  a s s a y s  a s  o p t i -
m i z e d  u s i n g  p l a s m i d  D N A  t e s t s ,  t h e  T R G  a s s a y  l o o k e d  p r o m i s i n g .   T R G  r e a d  n u m b e r s  
w e r e  h i g h  a n d  d a t a  w e r e  i n  l i n e  w i t h  p r e v i o u s  l i t e r a t u r e  [ 2 7 , 2 8 ] ,  a l b e i t  t h a t  V γ 9  a n d  
F i g u r e  3 .  I n i t i a l  b i o l o g i c a l  v a l i d a t i o n  e x p e r i m e n t s  u s i n g  t h e  m o s t  o p t i m a l  T R G  a n d  T R D  P C R  a s s a y s  a s  
b a s e d  o n  p l a s m i d  p o o l s .
T R G  m i x  G 2  w i t h  T a = 5 8 . 0  a n d  2 5  c y c l e s ,  T R D  m i x  D 5  w i t h  T a = 5 9 . 0  a n d  2 0  c y c l e s  v a l i d a t i o n  o n  g e n o m i c  D N A  
f r o m  t o t a l  T C R γ δ +  T  c e l l s  f r o m  t h y m u s  ( T h y ) ,  c o r d  b l o o d  ( C B )  a n d  a d u l t  p e r i p h e r a l  b l o o d  ( P B )  s a m p l e s  
( N = 4  e a c h  s a m p l e ) .  I M G T  a n n o t a t i o n  r e s u l t i n g  i n  p r o d u c t i v e ,  u n p r o d u c t i v e  o r  n o t  a n n o t a t e d  r e a d s  ( a ,  c ) .  V - J  
r e a r r a n g e m e n t s  d e p i c t e d  a s  C i r c o l e t t o  p l o t s  ( w w w . c i r c o s . c a ) ,  w i t h  T h y ,  C B  a n d  P B  s a m p l e s  i n  t h e  f o l l o w i n g  
o r d e r  ( l e f t - r i g h t ) :  T h y 0 5 - 1 3 ,  T h y 1 0 - 0 9 ,  T h y 1 0 - 1 3 ,  T h y 1 1 - 0 3 ;  C B 2 ,  C B 3 ,  C B 4 ,  C B 5 ;  P B 3 0 ,  P B 3 1 ,  P B 3 4 ,  P B 3 7  ( b )  
a n d  T h y 0 5 - 1 3 ,  T h y 1 0 - 0 9 ,  T h y 1 0 - 1 3 ;  C B 2 ,  C B 3 ,  C B 5 ;  P B 3 0 ,  P B 3 1 ,  P B 3 4 ,  P B 3 7  ( d ) .  
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Jγ1.3/2.3 were still over-represented, and some Vγ1F genes were under-represented. In contrast, the TRD assay appeared to still require more optimization, due to low read yields using genomic DNA. We therefore formulated two novel TRG mixes in order to further optimize the assay (Table 2, column EXP6). Furthermore, as the TRD assay still 
showed discrepancies in Vδ1 and Vδ2 %expected vs, %observed values, we formulated 
two novel TRD mixes as well. Furthermore, in order to obtain sufficient TRD amplicon 
for sequencing the cycle number was increased to 25. The Ta’s were kept at Ta=58 ⁰C 
(TRG) and Ta=59 ⁰C (TRD) based on the results of the plasmid fine-tuning experiments. These additional primer titration experiments (Table 2, columns EXP6), performed in 
quadruplicates according to Boyd et al. [23] now showed under-representation of Vγ9 
(Fig. 4a) and Jγ1.3/2.3 (Fig. 4b) with mix G3, and even more so with mix G4 (Fig. 4c, 4d). Mix G2, which was included in this experiment as well, actually showed the most optimal 
results (Fig. 4e, 4f). The TRD assay was rather optimal following the final primer concen-
tration adaptations, without significant differences between %expected and %observed 
of Vδ and Jδ genes (Fig. 4g, 4h). Further Vδ2 primer compensation in mix D8 did not show 
an obvious difference, but rather created over-representation of Vδ1 and under-repre-
sentation of Vδ3 genes (Fig. 4g). Jδ primer concentrations did not differ between mixes D7 and D8, and still some differences between %expected and %observed values of all 
Jδ genes were found (Fig. 4h). 
Based on these final fine-tuning experiments we finally chose for the most optimal 
TRG / TRD multiplex PCR assays, consisting of mix G2 with Ta=58⁰C and 25 cycles for 
TRG, and mix D7 with Ta=59⁰C and 25 cycles for TRD (Table 2). 
Sequencing analysis of total TCRγδ+ T cells isolated from different 
compartments confirmed the most optimal PCR assays
After several rounds of plasmid pool validations, which – despite some level of 
inter-assay variance – showed high correlations between %expected and %observed values, we then used these most optimal assay designs for evaluating repertoire diversity 
of total TCRγδ+ T cells from different T cell compartments including thymus, cord blood and peripheral blood. All samples showed high sequencing read yields (except for CB10 TRD assay) and high sequencing reproducibility (Table 3). Thy samples showed rela-tively more unproductive than productive sequences, while CB and PB samples showed more productive than unproductive rearrangements for both TRG and TRD (Fig. 5a). The low sequencing yield of the TRD assay of CB10 has also lead to higher percentages of sequences that could not be annotated with IMGT. Productive sequences were used for further analysis. The level of diversity could not only be detected through the different V-J 
combinations, but also through the identification of unique (productive) reads: unique-
ness was defined based on V-J combination and amino acid CDR3 (aaCDR3) level. Thy 
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Jγ1.3/2.3 were still over-represented, and some Vγ1F genes were under-represented. 
In contrast, the TRD assay appeared to still require more optimization, due to low read 
yields using genomic DNA. We therefore formulated two novel TRG mixes in order to 
further optimize the assay (Table 2, column EXP6). Furthermore, as the TRD assay still 
showed discrepancies in Vδ1 and Vδ2 %expected vs, %observed values, we formulated 
two novel TRD mixes as well. Furthermore, in order to obtain sufficient TRD amplicon 
for sequencing the cycle number was increased to 25. The Ta’s were kept at Ta=58 ⁰C 
(TRG) and Ta=59 ⁰C (TRD) based on the results of the plasmid fine-tuning experiments. 
These additional primer titration experiments (Table 2, columns EXP6), performed in 
quadruplicates according to Boyd et al. [23] now showed under-representation of Vγ9 
(Fig. 4a) and Jγ1.3/2.3 (Fig. 4b) with mix G3, and even more so with mix G4 (Fig. 4c, 4d). 
Mix G2, which was included in this experiment as well, actually showed the most optimal 
results (Fig. 4e, 4f). The TRD assay was rather optimal following the final primer concen-
tration adaptations, without significant differences between %expected and %observed 
of Vδ and Jδ genes (Fig. 4g, 4h). Further Vδ2 primer compensation in mix D8 did not show 
an obvious difference, but rather created over-representation of Vδ1 and under-repre-
sentation of Vδ3 genes (Fig. 4g). Jδ primer concentrations did not differ between mixes 
D7 and D8, and still some differences between %expected and %observed values of all 
Jδ genes were found (Fig. 4h). 
Based on these final fine-tuning experiments we finally chose for the most optimal 
TRG / TRD multiplex PCR assays, consisting of mix G2 with Ta=58⁰C and 25 cycles for 
TRG, and mix D7 with Ta=59⁰C and 25 cycles for TRD (Table 2). 
Sequencing analysis of total TCRγδ+ T cells isolated from different 
compartments confirmed the most optimal PCR assays
After several rounds of plasmid pool validations, which – despite some level of 
inter-assay variance – showed high correlations between %expected and %observed 
values, we then used these most optimal assay designs for evaluating repertoire diversity 
of total TCRγδ+ T cells from different T cell compartments including thymus, cord blood 
and peripheral blood. All samples showed high sequencing read yields (except for CB10 
TRD assay) and high sequencing reproducibility (Table 3). Thy samples showed rela-
tively more unproductive than productive sequences, while CB and PB samples showed 
more productive than unproductive rearrangements for both TRG and TRD (Fig. 5a). The 
low sequencing yield of the TRD assay of CB10 has also lead to higher percentages of 
sequences that could not be annotated with IMGT. Productive sequences were used for 
further analysis. The level of diversity could not only be detected through the different V-J 
combinations, but also through the identification of unique (productive) reads: unique-
ness was defined based on V-J combination and amino acid CDR3 (aaCDR3) level. Thy 
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samples showed the highest percentage of unique reads among productive sequences, PB samples the lowest percentage, especially the TRG locus (Fig. 5b). Productive rear-
rangements were visualized with stacked bar graphs, showing a high diversity in all Thy samples, a generally high diversity - albeit with some skewing - in CB samples, and a 
high level of skewing and selection in PB samples (Fig. 5c, left panel). Productive TRD 
Figure 4. Final PCR fine-tuning experiments on plasmid pool DNA leading to most optimal assays.
Further attempts for PCR assay optimization to maximally reduce primer bias using multiplex PCR on plasmid pools with compositions indicated in Supplementary Table 1, and primer concentrations and assay numbers as summarized in Table 2. TRGV results (a, c, e) and TRGJ results (b, d, f) of mixes G3 (a, b), G4 (c, d) and G2 
as comparison (e, f). TRDV results (e, g) and TRDJ results (f, h) of mixes D7 (e, f) and D8 (g, h).Ta for TRG was set at 58.0, for TRD 59.0⁰C. Cycle number for both TRG and TRD PCR assays was 25. Black bars indicate %Expected, colored bars represent the %Observed values. Number of replicates per assay is 4. 
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1 0 3
O p t i m i z e d  N G S  m e t h o d  f o r  T R G  /  T R D  r e p e r t o i r e  s e q u e n c i n g  
s a m p l e s  s h o w e d  t h e  h i g h e s t  p e r c e n t a g e  o f  u n i q u e  r e a d s  a m o n g  p r o d u c t i v e  s e q u e n c e s ,  
P B  s a m p l e s  t h e  l o w e s t  p e r c e n t a g e ,  e s p e c i a l l y  t h e  T R G  l o c u s  ( F i g .  5 b ) .  P r o d u c t i v e  r e a r -
r a n g e m e n t s  w e r e  v i s u a l i z e d  w i t h  s t a c k e d  b a r  g r a p h s ,  s h o w i n g  a  h i g h  d i v e r s i t y  i n  a l l  T h y  
s a m p l e s ,  a  g e n e r a l l y  h i g h  d i v e r s i t y  -  a l b e i t  w i t h  s o m e  s k e w i n g  -  i n  C B  s a m p l e s ,  a n d  a  
h i g h  l e v e l  o f  s k e w i n g  a n d  s e l e c t i o n  i n  P B  s a m p l e s  ( F i g .  5 c ,  l e f t  p a n e l ) .  P r o d u c t i v e  T R D  
F i g u r e  4 .  F i n a l  P C R  f i n e - t u n i n g  e x p e r i m e n t s  o n  p l a s m i d  p o o l  D N A  l e a d i n g  t o  m o s t  o p t i m a l  a s s a y s .
F u r t h e r  a t t e m p t s  f o r  P C R  a s s a y  o p t i m i z a t i o n  t o  m a x i m a l l y  r e d u c e  p r i m e r  b i a s  u s i n g  m u l t i p l e x  P C R  o n  p l a s m i d  
p o o l s  w i t h  c o m p o s i t i o n s  i n d i c a t e d  i n  S u p p l e m e n t a r y  T a b l e  1 ,  a n d  p r i m e r  c o n c e n t r a t i o n s  a n d  a s s a y  n u m b e r s  
a s  s u m m a r i z e d  i n  T a b l e  2 .  T R G V  r e s u l t s  ( a ,  c ,  e )  a n d  T R G J  r e s u l t s  ( b ,  d ,  f )  o f  m i x e s  G 3  ( a ,  b ) ,  G 4  ( c ,  d )  a n d  G 2  
a s  c o m p a r i s o n  ( e ,  f ) .  T R D V  r e s u l t s  ( e ,  g )  a n d  T R D J  r e s u l t s  ( f ,  h )  o f  m i x e s  D 7  ( e ,  f )  a n d  D 8  ( g ,  h ) . T a  f o r  T R G  
w a s  s e t  a t  5 8 . 0 ,  f o r  T R D  5 9 . 0 ⁰ C .  C y c l e  n u m b e r  f o r  b o t h  T R G  a n d  T R D  P C R  a s s a y s  w a s  2 5 .  B l a c k  b a r s  i n d i c a t e  
% E x p e c t e d ,  c o l o r e d  b a r s  r e p r e s e n t  t h e  % O b s e r v e d  v a l u e s .  N u m b e r  o f  r e p l i c a t e s  p e r  a s s a y  i s  4 .  
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rearrangements generally showed less diversity due to fewer Vδ-Jδ combinations, but 
the diversity of Thy and CB samples was reasonably broad, despite the Vδ1 predomi-nance. In contrast, PB samples showed a higher level of skewing and selection for even 
Vδ2 (Fig. 5c, right panel).  The Thy and CB samples showed low levels of inter-individ-
ual variance,  whereas PB samples showed donor-specific patterns (Fig. 5c). Finally, diversity was analyzed by means of CDR3-length distributions, showing clear Gaussian 
Chapter 3
104
rearrangements generally showed less diversity due to fewer Vδ-Jδ combinations, but 
the diversity of Thy and CB samples was reasonably broad, despite the Vδ1 predomi-
nance. In contrast, PB samples showed a higher level of skewing and selection for even 
Vδ2 (Fig. 5c, right panel).  The Thy and CB samples showed low levels of inter-individ-
ual variance,  whereas PB samples showed donor-specific patterns (Fig. 5c). Finally, 
diversity was analyzed by means of CDR3-length distributions, showing clear Gaussian 
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distributions in Thy and CB samples in both the TRG and TRD assays, with some level of selection in CB TCRγδ+ T cells, and  high level of skewing in PB samples (Fig. 5d). 
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DISCUSSION
Recent advances in immune repertoire sequencing methods have increased expo- nentially over the past 10-15 years with the development of next-generation DNA / RNA 
sequencing methods and high-throughput sequencing platforms. For many years, Sanger sequencing [29] served as the gold standard for sequencing in all fields [30], but due to a 
high demand for a faster, higher, cheaper and more accurate sequencing yield in immune repertoire studies several different platforms have been developed, [31-34]. Currently, 
most sequencing methods rely on cyclic-array sequencing, involving the sequencing of dense DNA strands by iterative cycles of enzymatic manipulation. The data collection is 
based on imaging, by means of pyrosequencing (Roche 454, Illumina) [35] or chemical gradients (IonTorrent). In our study we used Illumina MiSeq paired-end sequencing to 
study the build-up of the TRG and TRD immune repertoire. Applying NGS to immune repertoire studies is highly prone to errors at different levels 
in the total workflow, starting from experimental design, to sample preparation, to PCR 
amplification including primer bias and PCR cycling temperatures, to finally sequencing, 
imaging and data analysis: numerous reviews have been devoted to the identification 
and possible solutions for such sequencing errors [36-39]. Quality of the input DNA can 
be achieved by quick isolations without the use of formalin fixative; in order to pre- vent preferential amplification 5’ rapid amplification of cDNA ends (5’RACE) primers 
can be used, and in order to reduce further experimental errors the sequencing depth can be increased and replicates can be applied. Here in the current study we attempted 
to address the most important problems foreseen with immune repertoire sequencing by quick isolation of DNA without the use of formalin fixative, titrations of primer con-
centrations and fine-tuning of PCR cycling temperatures. Previously, the use of artificial 
DNA as spike-ins has been applied as a quantitative resource against genetic variation measurement versus sequencing errors [40]. In their study these authors created arti-
ficial human DNA based on the human genome (Hg38) which they inserted into vectors 
and therefore clear distinction between human genome and artificial DNA could be per- formed. The use of these artificial DNAs is particularly useful for constituting internal 
Figure 5 (see left page). Compartment analysis and assay validation on genomic DNA from total TCRγδ+ 
T cells from thymus, cord blood and adult peripheral blood.
Distribution of productive sequences, unproductive sequences and sequences which could not be annotated through IMGT analysis (no results). IMGT results with annotations productive, unproductive or not annotated (a). Frequencies of unique reads within total productive reads (b). V-J rearrangements depicted in stacked 
bar graphs; legends indicate most recurring rearrangements in bar graphs (c). All bar graphs indicated with median and SD error bars. CDR3-length distributions (in amino acids) indicated with median frequencies of reads of a certain length with SD error bars (two-sided) (d). 
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D I S C U S S I O N
R e c e n t  a d v a n c e s  i n  i m m u n e  r e p e r t o i r e  s e q u e n c i n g  m e t h o d s  h a v e  i n c r e a s e d  e x p o -
n e n t i a l l y  o v e r  t h e  p a s t  1 0 - 1 5  y e a r s  w i t h  t h e  d e v e l o p m e n t  o f  n e x t - g e n e r a t i o n  D N A  /  R N A  
s e q u e n c i n g  m e t h o d s  a n d  h i g h - t h r o u g h p u t  s e q u e n c i n g  p l a t f o r m s .  F o r  m a n y  y e a r s ,  S a n g e r  
s e q u e n c i n g  [ 2 9 ]  s e r v e d  a s  t h e  g o l d  s t a n d a r d  f o r  s e q u e n c i n g  i n  a l l  f i e l d s  [ 3 0 ] ,  b u t  d u e  t o  a  
h i g h  d e m a n d  f o r  a  f a s t e r ,  h i g h e r ,  c h e a p e r  a n d  m o r e  a c c u r a t e  s e q u e n c i n g  y i e l d  i n  i m m u n e  
r e p e r t o i r e  s t u d i e s  s e v e r a l  d i f f e r e n t  p l a t f o r m s  h a v e  b e e n  d e v e l o p e d ,  [ 3 1 - 3 4 ] .  C u r r e n t l y ,  
m o s t  s e q u e n c i n g  m e t h o d s  r e l y  o n  c y c l i c - a r r a y  s e q u e n c i n g ,  i n v o l v i n g  t h e  s e q u e n c i n g  o f  
d e n s e  D N A  s t r a n d s  b y  i t e r a t i v e  c y c l e s  o f  e n z y m a t i c  m a n i p u l a t i o n .  T h e  d a t a  c o l l e c t i o n  i s  
b a s e d  o n  i m a g i n g ,  b y  m e a n s  o f  p y r o s e q u e n c i n g  ( R o c h e  4 5 4 ,  I l l u m i n a )  [ 3 5 ]  o r  c h e m i c a l  
g r a d i e n t s  ( I o n T o r r e n t ) .  I n  o u r  s t u d y  w e  u s e d  I l l u m i n a  M i S e q  p a i r e d - e n d  s e q u e n c i n g  t o  
s t u d y  t h e  b u i l d - u p  o f  t h e  T R G  a n d  T R D  i m m u n e  r e p e r t o i r e .  
A p p l y i n g  N G S  t o  i m m u n e  r e p e r t o i r e  s t u d i e s  i s  h i g h l y  p r o n e  t o  e r r o r s  a t  d i f f e r e n t  l e v e l s  
i n  t h e  t o t a l  w o r k f l o w ,  s t a r t i n g  f r o m  e x p e r i m e n t a l  d e s i g n ,  t o  s a m p l e  p r e p a r a t i o n ,  t o  P C R  
a m p l i f i c a t i o n  i n c l u d i n g  p r i m e r  b i a s  a n d  P C R  c y c l i n g  t e m p e r a t u r e s ,  t o  f i n a l l y  s e q u e n c i n g ,  
i m a g i n g  a n d  d a t a  a n a l y s i s :  n u m e r o u s  r e v i e w s  h a v e  b e e n  d e v o t e d  t o  t h e  i d e n t i f i c a t i o n  
a n d  p o s s i b l e  s o l u t i o n s  f o r  s u c h  s e q u e n c i n g  e r r o r s  [ 3 6 - 3 9 ] .  Q u a l i t y  o f  t h e  i n p u t  D N A  c a n  
b e  a c h i e v e d  b y  q u i c k  i s o l a t i o n s  w i t h o u t  t h e  u s e  o f  f o r m a l i n  f i x a t i v e ;  i n  o r d e r  t o  p r e -
v e n t  p r e f e r e n t i a l  a m p l i f i c a t i o n  5 ’  r a p i d  a m p l i f i c a t i o n  o f  c D N A  e n d s  ( 5 ’ R A C E )  p r i m e r s  
c a n  b e  u s e d ,  a n d  i n  o r d e r  t o  r e d u c e  f u r t h e r  e x p e r i m e n t a l  e r r o r s  t h e  s e q u e n c i n g  d e p t h  
c a n  b e  i n c r e a s e d  a n d  r e p l i c a t e s  c a n  b e  a p p l i e d .  H e r e  i n  t h e  c u r r e n t  s t u d y  w e  a t t e m p t e d  
t o  a d d r e s s  t h e  m o s t  i m p o r t a n t  p r o b l e m s  f o r e s e e n  w i t h  i m m u n e  r e p e r t o i r e  s e q u e n c i n g  
b y  q u i c k  i s o l a t i o n  o f  D N A  w i t h o u t  t h e  u s e  o f  f o r m a l i n  f i x a t i v e ,  t i t r a t i o n s  o f  p r i m e r  c o n -
c e n t r a t i o n s  a n d  f i n e - t u n i n g  o f  P C R  c y c l i n g  t e m p e r a t u r e s .  P r e v i o u s l y ,  t h e  u s e  o f  a r t i f i c i a l  
D N A  a s  s p i k e - i n s  h a s  b e e n  a p p l i e d  a s  a  q u a n t i t a t i v e  r e s o u r c e  a g a i n s t  g e n e t i c  v a r i a t i o n  
m e a s u r e m e n t  v e r s u s  s e q u e n c i n g  e r r o r s  [ 4 0 ] .  I n  t h e i r  s t u d y  t h e s e  a u t h o r s  c r e a t e d  a r t i -
f i c i a l  h u m a n  D N A  b a s e d  o n  t h e  h u m a n  g e n o m e  ( H g 3 8 )  w h i c h  t h e y  i n s e r t e d  i n t o  v e c t o r s  
a n d  t h e r e f o r e  c l e a r  d i s t i n c t i o n  b e t w e e n  h u m a n  g e n o m e  a n d  a r t i f i c i a l  D N A  c o u l d  b e  p e r -
f o r m e d .  T h e  u s e  o f  t h e s e  a r t i f i c i a l  D N A s  i s  p a r t i c u l a r l y  u s e f u l  f o r  c o n s t i t u t i n g  i n t e r n a l  
F i g u r e  5  ( s e e  l e f t  p a g e ) .  C o m p a r t m e n t  a n a l y s i s  a n d  a s s a y  v a l i d a t i o n  o n  g e n o m i c  D N A  f r o m  t o t a l  T C R γ δ +  
T  c e l l s  f r o m  t h y m u s ,  c o r d  b l o o d  a n d  a d u l t  p e r i p h e r a l  b l o o d .
D i s t r i b u t i o n  o f  p r o d u c t i v e  s e q u e n c e s ,  u n p r o d u c t i v e  s e q u e n c e s  a n d  s e q u e n c e s  w h i c h  c o u l d  n o t  b e  a n n o t a t e d  
t h r o u g h  I M G T  a n a l y s i s  ( n o  r e s u l t s ) .  I M G T  r e s u l t s  w i t h  a n n o t a t i o n s  p r o d u c t i v e ,  u n p r o d u c t i v e  o r  n o t  a n n o t a t e d  
( a ) .  F r e q u e n c i e s  o f  u n i q u e  r e a d s  w i t h i n  t o t a l  p r o d u c t i v e  r e a d s  ( b ) .  V - J  r e a r r a n g e m e n t s  d e p i c t e d  i n  s t a c k e d  
b a r  g r a p h s ;  l e g e n d s  i n d i c a t e  m o s t  r e c u r r i n g  r e a r r a n g e m e n t s  i n  b a r  g r a p h s  ( c ) .  A l l  b a r  g r a p h s  i n d i c a t e d  w i t h  
m e d i a n  a n d  S D  e r r o r  b a r s .  C D R 3 - l e n g t h  d i s t r i b u t i o n s  ( i n  a m i n o  a c i d s )  i n d i c a t e d  w i t h  m e d i a n  f r e q u e n c i e s  o f  
r e a d s  o f  a  c e r t a i n  l e n g t h  w i t h  S D  e r r o r  b a r s  ( t w o - s i d e d )  ( d ) .  
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controls that enable quantification of artifacts and variability that occurs during sample preparation, processing and comparing different samples. In our study we applied a similar approach by using cloned TRG and TRD rearrange-ments in vectors to carefully quantify the output with varying primer concentrations and PCR cycling temperatures in order to fully optimize TRG and TRD assays to assess quantitative features of the TRG and TRD repertoire. However, even with the use of technical replicates, which involves the repeated processing, sequencing and analy-sis of the exactly the same sample, and biological replicates, using multiple biological samples from the same input DNA under similar conditions [36,37], still some level of inter-assay variance was observed. This phenomenon was also observed earlier by Deveson et al. [40]. These variances could have arisen from intrinsic sequence-specific biases during e.g. sample preparation or library preparation, the sequencing procedure and alignment to the IMGT database [19-22]. Also, such variance could be originating from aliquot variability and pipetting variation [40]. Nevertheless, the majority of the 
variability was reproducible and especially in case of the genes in the Vγ1F inevitable 
since one primer covers the Vγ2, Vγ3, Vγ4, Vγ5 and Vγ8 genes. Despite the inter-assay variability and the coverage of multiple TRGV genes by one common primer, the results 
from our analysis of TCRγδ+ T cells from different compartments were quite in line with previously reported results [27,28]. Results on the biological samples were also in accordance with the hypothesis that the thymus and cord blood compartments show a relatively highly diverse repertoire, with generally  low inter-sample variability, whereas selection and skewing would be most apparent in adult peripheral blood samples, with 
clear donor-specific patterns. Not only should PCR assay aspects of immune repertoire sequencing meth-ods  be addressed when it comes to reducing PCR and sequencing biases and errors. Experimental design could be highly underestimated when it comes to the material from which the target DNA is isolated, but also the number of replicates that are required for optimal data analysis when using quantitative features of the sequence data [23,36,37]. Therefore we used in screening experiments single samples, while in validation exper-iments at least 4 replicates per sample were included. Furthermore it is important to formulate different mixes, perform the PCR programs in different machines, even when using the same primer concentration combinations, annealing temperatures and cycle numbers (technical replicates), and in different types of samples (plasmid DNA versus genomic DNA, including genomic DNA samples from different body compartments; bio-logical replicates). After performing the sequencing experiments, adequate data analysis is vital in order to reduce the number of false positive and false negative variants that are being 
identified. In case of immune repertoire sequencing the determination of variants can 
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controls that enable quantification of artifacts and variability that occurs during sample 
preparation, processing and comparing different samples. 
In our study we applied a similar approach by using cloned TRG and TRD rearrange-
ments in vectors to carefully quantify the output with varying primer concentrations 
and PCR cycling temperatures in order to fully optimize TRG and TRD assays to assess 
quantitative features of the TRG and TRD repertoire. However, even with the use of 
technical replicates, which involves the repeated processing, sequencing and analy-
sis of the exactly the same sample, and biological replicates, using multiple biological 
samples from the same input DNA under similar conditions [36,37], still some level 
of inter-assay variance was observed. This phenomenon was also observed earlier by 
Deveson et al. [40]. These variances could have arisen from intrinsic sequence-specific 
biases during e.g. sample preparation or library preparation, the sequencing procedure 
and alignment to the IMGT database [19-22]. Also, such variance could be originating 
from aliquot variability and pipetting variation [40]. Nevertheless, the majority of the 
variability was reproducible and especially in case of the genes in the Vγ1F inevitable 
since one primer covers the Vγ2, Vγ3, Vγ4, Vγ5 and Vγ8 genes. Despite the inter-assay 
variability and the coverage of multiple TRGV genes by one common primer, the results 
from our analysis of TCRγδ+ T cells from different compartments were quite in line 
with previously reported results [27,28]. Results on the biological samples were also in 
accordance with the hypothesis that the thymus and cord blood compartments show a 
relatively highly diverse repertoire, with generally  low inter-sample variability, whereas 
selection and skewing would be most apparent in adult peripheral blood samples, with 
clear donor-specific patterns. 
Not only should PCR assay aspects of immune repertoire sequencing meth-
ods  be addressed when it comes to reducing PCR and sequencing biases and errors. 
Experimental design could be highly underestimated when it comes to the material from 
which the target DNA is isolated, but also the number of replicates that are required for 
optimal data analysis when using quantitative features of the sequence data [23,36,37]. 
Therefore we used in screening experiments single samples, while in validation exper-
iments at least 4 replicates per sample were included. Furthermore it is important to 
formulate different mixes, perform the PCR programs in different machines, even when 
using the same primer concentration combinations, annealing temperatures and cycle 
numbers (technical replicates), and in different types of samples (plasmid DNA versus 
genomic DNA, including genomic DNA samples from different body compartments; bio-
logical replicates). 
After performing the sequencing experiments, adequate data analysis is vital in 
order to reduce the number of false positive and false negative variants that are being 
identified. In case of immune repertoire sequencing the determination of variants can 
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Optimized NGS method for TRG / TRD repertoire sequencing 
be challenging, since it can be difficult to distinguish between falsely annotated vari- ants and biologically relevant variants [37]. Here we used Illumina MiSeq paired-end 
sequencing, upon which directly after sequencing quality controls are performed and paired-end sequences are merged, which increases the overlapping region quality. In 
order to determine diversity in the TRG and TRD loci the CDR3-region, which is deter- mined through V-J combination and the junctional region at the amino acid or nucleotide 
level, is of most interest. Since this is the overlapping region, which is of most impor- tance in immune repertoire studies, we could in this way exclude low quality sequences 
as well: reads that could not be aligned, have a high probability of containing sequencing or PCR errors, and are thus excluded. Furthermore, the ARGalaxy pipeline analysis [12] 
excludes possible scarce clones by only focusing on unique sequences, based on V-J com- binations and amino acid or nucleotide CDR3 regions, as also an important manner to 
exclude falsely identified sequences. Additionally,  ARGalaxy pipeline also contains a fea- ture to calculate so-called clonality scores, based on identical sequences that are present 
in all technical and/or biological replicates, dependent on the study design. In this way, falsely identified sequences should be removed as well, presenting immune repertoire 
sequencing data as much filtered as possible, which optimize the available data set for 
evaluation of quantitative features [12]. Other approaches to even further exclude PCR and sequencing errors and biases 
could be to perform single cell sequencing, preferably on mRNA/cDNA level to determine the actual productive receptor as being expressed on the sorted cell. However, this still 
is a more time consuming and labor intensive approach, especially due to the required sorting procedures. In order to obtain sufficient cells and sequences as being represen-
tative for the individual, at least a few thousand cells should be sorted. For analyzing TRG and TRD repertoires this could be challenging due to the scarcity of these cells in 
the healthy adult peripheral blood [41]. In order to obtain sufficient numbers of these 
cells, especially in case of studying different subsets such as naive, effector or memory cells, large amounts of blood are thus needed, leading to extensive sorting protocols. 
Sorting procedures might influence DNA quality, but definitely influence mRNA quality 
for later cDNA-based repertoire evaluation. However, the greatest advantage would be that from one single cell the combined TRG / TRD chains could be determined, and that 
the full receptor can thus be visualized which  has further implications for insight in normal development, repertoire shaping, and ultimately in infections and malignancies.
In conclusion, through extensive plasmid pool validations and additional assay adjustments with respect to primer concentrations, annealing temperatures and cycle 
numbers upon tests with genomic DNA, the most optimal TRG and TRD multiplex PCR assays for NGS methods were defined, which also showed compartment analysis results 
correlating with previous literature. In this way we have formulated the most optimal 
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b e  c h a l l e n g i n g ,  s i n c e  i t  c a n  b e  d i f f i c u l t  t o  d i s t i n g u i s h  b e t w e e n  f a l s e l y  a n n o t a t e d  v a r i -
a n t s  a n d  b i o l o g i c a l l y  r e l e v a n t  v a r i a n t s  [ 3 7 ] .  H e r e  w e  u s e d  I l l u m i n a  M i S e q  p a i r e d - e n d  
s e q u e n c i n g ,  u p o n  w h i c h  d i r e c t l y  a f t e r  s e q u e n c i n g  q u a l i t y  c o n t r o l s  a r e  p e r f o r m e d  a n d  
p a i r e d - e n d  s e q u e n c e s  a r e  m e r g e d ,  w h i c h  i n c r e a s e s  t h e  o v e r l a p p i n g  r e g i o n  q u a l i t y .  I n  
o r d e r  t o  d e t e r m i n e  d i v e r s i t y  i n  t h e  T R G  a n d  T R D  l o c i  t h e  C D R 3 - r e g i o n ,  w h i c h  i s  d e t e r -
m i n e d  t h r o u g h  V - J  c o m b i n a t i o n  a n d  t h e  j u n c t i o n a l  r e g i o n  a t  t h e  a m i n o  a c i d  o r  n u c l e o t i d e  
l e v e l ,  i s  o f  m o s t  i n t e r e s t .  S i n c e  t h i s  i s  t h e  o v e r l a p p i n g  r e g i o n ,  w h i c h  i s  o f  m o s t  i m p o r -
t a n c e  i n  i m m u n e  r e p e r t o i r e  s t u d i e s ,  w e  c o u l d  i n  t h i s  w a y  e x c l u d e  l o w  q u a l i t y  s e q u e n c e s  
a s  w e l l :  r e a d s  t h a t  c o u l d  n o t  b e  a l i g n e d ,  h a v e  a  h i g h  p r o b a b i l i t y  o f  c o n t a i n i n g  s e q u e n c i n g  
o r  P C R  e r r o r s ,  a n d  a r e  t h u s  e x c l u d e d .  F u r t h e r m o r e ,  t h e  A R G a l a x y  p i p e l i n e  a n a l y s i s  [ 1 2 ]  
e x c l u d e s  p o s s i b l e  s c a r c e  c l o n e s  b y  o n l y  f o c u s i n g  o n  u n i q u e  s e q u e n c e s ,  b a s e d  o n  V - J  c o m -
b i n a t i o n s  a n d  a m i n o  a c i d  o r  n u c l e o t i d e  C D R 3  r e g i o n s ,  a s  a l s o  a n  i m p o r t a n t  m a n n e r  t o  
e x c l u d e  f a l s e l y  i d e n t i f i e d  s e q u e n c e s .  A d d i t i o n a l l y ,   A R G a l a x y  p i p e l i n e  a l s o  c o n t a i n s  a  f e a -
t u r e  t o  c a l c u l a t e  s o - c a l l e d  c l o n a l i t y  s c o r e s ,  b a s e d  o n  i d e n t i c a l  s e q u e n c e s  t h a t  a r e  p r e s e n t  
i n  a l l  t e c h n i c a l  a n d / o r  b i o l o g i c a l  r e p l i c a t e s ,  d e p e n d e n t  o n  t h e  s t u d y  d e s i g n .  I n  t h i s  w a y ,  
f a l s e l y  i d e n t i f i e d  s e q u e n c e s  s h o u l d  b e  r e m o v e d  a s  w e l l ,  p r e s e n t i n g  i m m u n e  r e p e r t o i r e  
s e q u e n c i n g  d a t a  a s  m u c h  f i l t e r e d  a s  p o s s i b l e ,  w h i c h  o p t i m i z e  t h e  a v a i l a b l e  d a t a  s e t  f o r  
e v a l u a t i o n  o f  q u a n t i t a t i v e  f e a t u r e s  [ 1 2 ] .  
O t h e r  a p p r o a c h e s  t o  e v e n  f u r t h e r  e x c l u d e  P C R  a n d  s e q u e n c i n g  e r r o r s  a n d  b i a s e s  
c o u l d  b e  t o  p e r f o r m  s i n g l e  c e l l  s e q u e n c i n g ,  p r e f e r a b l y  o n  m R N A / c D N A  l e v e l  t o  d e t e r m i n e  
t h e  a c t u a l  p r o d u c t i v e  r e c e p t o r  a s  b e i n g  e x p r e s s e d  o n  t h e  s o r t e d  c e l l .  H o w e v e r ,  t h i s  s t i l l  
i s  a  m o r e  t i m e  c o n s u m i n g  a n d  l a b o r  i n t e n s i v e  a p p r o a c h ,  e s p e c i a l l y  d u e  t o  t h e  r e q u i r e d  
s o r t i n g  p r o c e d u r e s .  I n  o r d e r  t o  o b t a i n  s u f f i c i e n t  c e l l s  a n d  s e q u e n c e s  a s  b e i n g  r e p r e s e n -
t a t i v e  f o r  t h e  i n d i v i d u a l ,  a t  l e a s t  a  f e w  t h o u s a n d  c e l l s  s h o u l d  b e  s o r t e d .  F o r  a n a l y z i n g  
T R G  a n d  T R D  r e p e r t o i r e s  t h i s  c o u l d  b e  c h a l l e n g i n g  d u e  t o  t h e  s c a r c i t y  o f  t h e s e  c e l l s  i n  
t h e  h e a l t h y  a d u l t  p e r i p h e r a l  b l o o d  [ 4 1 ] .  I n  o r d e r  t o  o b t a i n  s u f f i c i e n t  n u m b e r s  o f  t h e s e  
c e l l s ,  e s p e c i a l l y  i n  c a s e  o f  s t u d y i n g  d i f f e r e n t  s u b s e t s  s u c h  a s  n a i v e ,  e f f e c t o r  o r  m e m o r y  
c e l l s ,  l a r g e  a m o u n t s  o f  b l o o d  a r e  t h u s  n e e d e d ,  l e a d i n g  t o  e x t e n s i v e  s o r t i n g  p r o t o c o l s .  
S o r t i n g  p r o c e d u r e s  m i g h t  i n f l u e n c e  D N A  q u a l i t y ,  b u t  d e f i n i t e l y  i n f l u e n c e  m R N A  q u a l i t y  
f o r  l a t e r  c D N A - b a s e d  r e p e r t o i r e  e v a l u a t i o n .  H o w e v e r ,  t h e  g r e a t e s t  a d v a n t a g e  w o u l d  b e  
t h a t  f r o m  o n e  s i n g l e  c e l l  t h e  c o m b i n e d  T R G  /  T R D  c h a i n s  c o u l d  b e  d e t e r m i n e d ,  a n d  t h a t  
t h e  f u l l  r e c e p t o r  c a n  t h u s  b e  v i s u a l i z e d  w h i c h   h a s  f u r t h e r  i m p l i c a t i o n s  f o r  i n s i g h t  i n  
n o r m a l  d e v e l o p m e n t ,  r e p e r t o i r e  s h a p i n g ,  a n d  u l t i m a t e l y  i n  i n f e c t i o n s  a n d  m a l i g n a n c i e s .
I n  c o n c l u s i o n ,  t h r o u g h  e x t e n s i v e  p l a s m i d  p o o l  v a l i d a t i o n s  a n d  a d d i t i o n a l  a s s a y  
a d j u s t m e n t s  w i t h  r e s p e c t  t o  p r i m e r  c o n c e n t r a t i o n s ,  a n n e a l i n g  t e m p e r a t u r e s  a n d  c y c l e  
n u m b e r s  u p o n  t e s t s  w i t h  g e n o m i c  D N A ,  t h e  m o s t  o p t i m a l  T R G  a n d  T R D  m u l t i p l e x  P C R  
a s s a y s  f o r  N G S  m e t h o d s  w e r e  d e f i n e d ,  w h i c h  a l s o  s h o w e d  c o m p a r t m e n t  a n a l y s i s  r e s u l t s  
c o r r e l a t i n g  w i t h  p r e v i o u s  l i t e r a t u r e .  I n  t h i s  w a y  w e  h a v e  f o r m u l a t e d  t h e  m o s t  o p t i m a l  
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multiplex PCR assays for TRG / TRD repertoire analysis with the lowest PCR bias and inter-assay variance as possible. Further applications could therefore be used in diag-nostic tests, in for instance the diagnosis of leukemic clones, but also in the quantitative detection of minimal residual disease [43,44]. 
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ABSTRACT
Immunological ageing remodels the immune system at several levels. 
This has been documented in particular for the T cell receptor (TCR)αβ+ T cell compartment, showing reduced naive T cell outputs and an accumula-tion of terminally differentiated clonally expanding effector T cells, leading to increased proneness to autoimmunity and cancer development at older age. 
Even though TCRαβ+ and TCRγδ+ T cells follow similar paths of development 
involving V(D)J-recombination of TCR genes in the thymus, TCRγδ+ T cells tend to be more subjected to peripheral selection rather than central selection. 
Age-related chronic (antigenic) stimulation could contribute to TCRγδ+ T cell large granular lymphocyte (T-LGL) leukemia pathogenesis. However, the role of ageing in shaping of the peripheral TRG / TRD repertoire remains largely elusive. NGS analysis methods were optimized using plasmid vector DNA-samples based on a 
spike-in method for accurate TRG / TRD receptor diversity quantification, resulting in 
optimally defined primer concentrations, annealing temperatures and cycle numbers. Thymic and cord blood samples were used to study TRG / TRD repertoire diver-
sity during TCRγδ+ T cell ontogeny, showing a broad and diverse repertoire with Gaussian CDR3-length distributions, in contrast to the more skewed reper-
toire in mature circulating total TCRγδ+ T cells in adult peripheral blood (PB). During ageing the naive repertoire maintained its diversity with Gaussian CDR3-length distributions, while in the central and effector memory populations a 
clear shift from Vγ9/Vδ2 dominance in young to Vγ2/Vδ1 dominance in elderly was observed. Together with less clear Gaussian CDR3-length distributions, this is highly suggestive of differentially heavily selected repertoires. Despite the 
age-related shift from Vγ9/Vδ2 to Vγ2/Vδ1 no clear ageing-effect was observed 
on the Vδ2 invariant T nucleotide and canonical Vγ9-Jγ1.2 selection determinants. 
When zooming in on specific TRG and TRD clonotypes, pathogen-related clono-
types such as for CMV were identified in a few donors without a significant age-ing-effect, while M.tuberculosis-specific clonotypes were absent in the repertoire of 
healthy individuals. Interestingly, TCRγδ+ T-LGL leukemia-related receptor chains 
were identified in effector subsets of elderly individuals. This could correlate with 
the concept that TCRγδ+ T-LGL leukemia is an ageing-associated disease, originat-ing from normal antigen-experienced effector cells that are present in peripheral blood of elderly.  
Keywords: TCRγδ+, development, ageing, repertoire, next-generation sequencing. ABSTRACT
Immunological ageing remodels the immune system at several levels. 
This has been documented in particular for the T cell receptor (TCR)αβ+ T 
cell compartment, showing reduced naive T cell outputs and an accumula-
tion of terminally differentiated clonally expanding effector T cells, leading to 
increased proneness to autoimmunity and cancer development at older age. 
Even though TCRαβ+ and TCRγδ+ T cells follow similar paths of development 
involving V(D)J-recombination of TCR genes in the thymus, TCRγδ+ T cells 
tend to be more subjected to peripheral selection rather than central selection. 
Age-related chronic (antigenic) stimulation could contribute to TCRγδ+ T cell 
large granular lymphocyte (T-LGL) leukemia pathogenesis. However, the role of 
ageing in shaping of the peripheral TRG / TRD repertoire remains largely elusive. 
NGS analysis methods were optimized using plasmid vector DNA-samples based on a 
spike-in method for accurate TRG / TRD receptor diversity quantification, resulting in 
optimally defined primer concentrations, annealing temperatures and cycle numbers. 
Thymic and cord blood samples were used to study TRG / TRD repertoire diver-
sity during TCRγδ+ T cell ontogeny, showing a broad and diverse repertoire 
with Gaussian CDR3-length distributions, in contrast to the more skewed reper-
toire in mature circulating total TCRγδ+ T cells in adult peripheral blood (PB). 
During ageing the naive repertoire maintained its diversity with Gaussian CDR3-
length distributions, while in the central and effector memory populations a 
clear shift from Vγ9/Vδ2 dominance in young to Vγ2/Vδ1 dominance in elderly 
was observed. Together with less clear Gaussian CDR3-length distributions, this 
is highly suggestive of differentially heavily selected repertoires. Despite the 
age-related shift from Vγ9/Vδ2 to Vγ2/Vδ1 no clear ageing-effect was observed 
on the Vδ2 invariant T nucleotide and canonical Vγ9-Jγ1.2 selection determinants. 
When zooming in on specific TRG and TRD clonotypes, pathogen-related clono-
types such as for CMV were identified in a few donors without a significant age-
ing-effect, while M.tuberculosis-specific clonotypes were absent in the repertoire of 
healthy individuals. Interestingly, TCRγδ+ T-LGL leukemia-related receptor chains 
were identified in effector subsets of elderly individuals. This could correlate with 
the concept that TCRγδ+ T-LGL leukemia is an ageing-associated disease, originat-
ing from normal antigen-experienced effector cells that are present in peripheral 
blood of elderly.  
Keywords: TCRγδ+, development, ageing, repertoire, next-generation 
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INTRODUCTION
Immunological ageing, also referred to as immunosenescence, is a complex phenomenon consisting of senescence and exhaustion processes, which are characterized 
by different functional and marker expression profiles [1,2]. Immunosenescence acts on 
different levels in the immune system e.g. reduced antigen-specific responses [3], thymic 
shrinkage, and a significantly reduced naive T cell output [3-5], convergence of the innate 
and adaptive immunity [6], and ultimately T cell exhaustion [1]. Immunosenescence is believed to play a major role in shaping of the antigen receptor repertoire of T cells. 
T cells develop in the thymus, where they undergo commitment, rearrangement, selection and maturation processes. The main event during T cell development is the 
rearrangements of the variable (V), diversity (D) and joining (J) genes of the T cell receptor (TR) loci, in order to establish a large diversity of antigen receptors [7,8]. Two 
main types of T cells are generated; firstly, TCRγδ+ thymocytes, through early TR delta 
and gamma (TRD, TRG) rearrangements, then followed by TCRαβ+ thymocytes upon TR 
beta and alpha (TRB, TRA) rearrangements [8]. TCRαβ+ thymocytes undergo positive 
selection through TCR signaling to subsequently mature into functional T cells, followed by negative selection in order to eliminate self-reactive T cell precursors [9]. In contrast, 
TCRγδ+ thymocytes do not undergo positive and/or negative selection in the thymus 
[10], but extrathymic development and peripheral (antigenic) selection of TCRγδ+ T 
cells have been described [11]. TCRγδ+ T cells appear to be the first functional population of circulating T lympho-
cytes in both murine and human PB (reviewed in [12]). In the human fetal and neo- natal situation these functional circulating TCRγδ+ T cells mainly concern Vδ1+ cells. 
Readily after birth and during further development to adulthood a switch occurs in the circulating TCRγδ+ T cell population with the number of Vδ1+ cells decreasing and 
Vγ9/Vδ2 cells becoming the predominant TCRγδ+ T cell types [13]. This process is 
believed to be the result of peripheral antigenic selection, exemplified by the presence 
of an invariant T nucleotide in the majority of the selected Vδ2 – Jδ1 rearrangements 
[13-15]. Furthermore, pathogens or other antigens providing epitopes that could stim- ulate and select TCRγδ+ T cell types have been described: Mycobacterium tuberculosis 
has been found to be a major stimulator of Vγ9/Vδ2 cells in both infected lungs and 
PB [16], whereas non-Vγ9/Vδ1 cells are known to be stimulated by viruses, such as 
cytomegalovirus (CMV) [17,18] and Epstein-Barr virus (EBV) [19]. TCRγδ+ T cells do 
not only recognize antigens via their receptor, but they also respond to lipid antigens presented on CD1d-molecules, and that are associated with stress, inflammation and 
cancer (reviewed by [20]). Most TCRγδ+ T cells recognizing these CD1d-lipid antigen 
complexes are Vδ1 or Vδ3 cells, commonly located in the gut [21]. TCRγδ+ T cells can 
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I m m u n o l o g i c a l  a g e i n g ,  a l s o  r e f e r r e d  t o  a s  i m m u n o s e n e s c e n c e ,  i s  a  c o m p l e x  
p h e n o m e n o n  c o n s i s t i n g  o f  s e n e s c e n c e  a n d  e x h a u s t i o n  p r o c e s s e s ,  w h i c h  a r e  c h a r a c t e r i z e d  
b y  d i f f e r e n t  f u n c t i o n a l  a n d  m a r k e r  e x p r e s s i o n  p r o f i l e s  [ 1 , 2 ] .  I m m u n o s e n e s c e n c e  a c t s  o n  
d i f f e r e n t  l e v e l s  i n  t h e  i m m u n e  s y s t e m  e . g .  r e d u c e d  a n t i g e n - s p e c i f i c  r e s p o n s e s  [ 3 ] ,  t h y m i c  
s h r i n k a g e ,  a n d  a  s i g n i f i c a n t l y  r e d u c e d  n a i v e  T  c e l l  o u t p u t  [ 3 - 5 ] ,  c o n v e r g e n c e  o f  t h e  i n n a t e  
a n d  a d a p t i v e  i m m u n i t y  [ 6 ] ,  a n d  u l t i m a t e l y  T  c e l l  e x h a u s t i o n  [ 1 ] .  I m m u n o s e n e s c e n c e  i s  
b e l i e v e d  t o  p l a y  a  m a j o r  r o l e  i n  s h a p i n g  o f  t h e  a n t i g e n  r e c e p t o r  r e p e r t o i r e  o f  T  c e l l s .  
T  c e l l s  d e v e l o p  i n  t h e  t h y m u s ,  w h e r e  t h e y  u n d e r g o  c o m m i t m e n t ,  r e a r r a n g e m e n t ,  
s e l e c t i o n  a n d  m a t u r a t i o n  p r o c e s s e s .  T h e  m a i n  e v e n t  d u r i n g  T  c e l l  d e v e l o p m e n t  i s  t h e  
r e a r r a n g e m e n t s  o f  t h e  v a r i a b l e  ( V ) ,  d i v e r s i t y  ( D )  a n d  j o i n i n g  ( J )  g e n e s  o f  t h e  T  c e l l  
r e c e p t o r  ( T R )  l o c i ,  i n  o r d e r  t o  e s t a b l i s h  a  l a r g e  d i v e r s i t y  o f  a n t i g e n  r e c e p t o r s  [ 7 , 8 ] .  T w o  
m a i n  t y p e s  o f  T  c e l l s  a r e  g e n e r a t e d ;  f i r s t l y ,  T C R γ δ +  t h y m o c y t e s ,  t h r o u g h  e a r l y  T R  d e l t a  
a n d  g a m m a  ( T R D ,  T R G )  r e a r r a n g e m e n t s ,  t h e n  f o l l o w e d  b y  T C R α β +  t h y m o c y t e s  u p o n  T R  
b e t a  a n d  a l p h a  ( T R B ,  T R A )  r e a r r a n g e m e n t s  [ 8 ] .  T C R α β +  t h y m o c y t e s  u n d e r g o  p o s i t i v e  
s e l e c t i o n  t h r o u g h  T C R  s i g n a l i n g  t o  s u b s e q u e n t l y  m a t u r e  i n t o  f u n c t i o n a l  T  c e l l s ,  f o l l o w e d  
b y  n e g a t i v e  s e l e c t i o n  i n  o r d e r  t o  e l i m i n a t e  s e l f - r e a c t i v e  T  c e l l  p r e c u r s o r s  [ 9 ] .  I n  c o n t r a s t ,  
T C R γ δ +  t h y m o c y t e s  d o  n o t  u n d e r g o  p o s i t i v e  a n d / o r  n e g a t i v e  s e l e c t i o n  i n  t h e  t h y m u s  
[ 1 0 ] ,  b u t  e x t r a t h y m i c  d e v e l o p m e n t  a n d  p e r i p h e r a l  ( a n t i g e n i c )  s e l e c t i o n  o f  T C R γ δ +  T  
c e l l s  h a v e  b e e n  d e s c r i b e d  [ 1 1 ] .
T C R γ δ +  T  c e l l s  a p p e a r  t o  b e  t h e  f i r s t  f u n c t i o n a l  p o p u l a t i o n  o f  c i r c u l a t i n g  T  l y m p h o -
c y t e s  i n  b o t h  m u r i n e  a n d  h u m a n  P B  ( r e v i e w e d  i n  [ 1 2 ] ) .  I n  t h e  h u m a n  f e t a l  a n d  n e o -
n a t a l  s i t u a t i o n  t h e s e  f u n c t i o n a l  c i r c u l a t i n g  T C R γ δ +  T  c e l l s  m a i n l y  c o n c e r n  V δ 1 +  c e l l s .  
R e a d i l y  a f t e r  b i r t h  a n d  d u r i n g  f u r t h e r  d e v e l o p m e n t  t o  a d u l t h o o d  a  s w i t c h  o c c u r s  i n  
t h e  c i r c u l a t i n g  T C R γ δ +  T  c e l l  p o p u l a t i o n  w i t h  t h e  n u m b e r  o f  V δ 1 +  c e l l s  d e c r e a s i n g  a n d  
V γ 9 / V δ 2  c e l l s  b e c o m i n g  t h e  p r e d o m i n a n t  T C R γ δ +  T  c e l l  t y p e s  [ 1 3 ] .  T h i s  p r o c e s s  i s  
b e l i e v e d  t o  b e  t h e  r e s u l t  o f  p e r i p h e r a l  a n t i g e n i c  s e l e c t i o n ,  e x e m p l i f i e d  b y  t h e  p r e s e n c e  
o f  a n  i n v a r i a n t  T  n u c l e o t i d e  i n  t h e  m a j o r i t y  o f  t h e  s e l e c t e d  V δ 2  –  J δ 1  r e a r r a n g e m e n t s  
[ 1 3 - 1 5 ] .  F u r t h e r m o r e ,  p a t h o g e n s  o r  o t h e r  a n t i g e n s  p r o v i d i n g  e p i t o p e s  t h a t  c o u l d  s t i m -
u l a t e  a n d  s e l e c t  T C R γ δ +  T  c e l l  t y p e s  h a v e  b e e n  d e s c r i b e d :  M y c o b a c t e r i u m  t u b e r c u l o s i s  
h a s  b e e n  f o u n d  t o  b e  a  m a j o r  s t i m u l a t o r  o f  V γ 9 / V δ 2  c e l l s  i n  b o t h  i n f e c t e d  l u n g s  a n d  
P B  [ 1 6 ] ,  w h e r e a s  n o n - V γ 9 / V δ 1  c e l l s  a r e  k n o w n  t o  b e  s t i m u l a t e d  b y  v i r u s e s ,  s u c h  a s  
c y t o m e g a l o v i r u s  ( C M V )  [ 1 7 , 1 8 ]  a n d  E p s t e i n - B a r r  v i r u s  ( E B V )  [ 1 9 ] .  T C R γ δ +  T  c e l l s  d o  
n o t  o n l y  r e c o g n i z e  a n t i g e n s  v i a  t h e i r  r e c e p t o r ,  b u t  t h e y  a l s o  r e s p o n d  t o  l i p i d  a n t i g e n s  
p r e s e n t e d  o n  C D 1 d - m o l e c u l e s ,  a n d  t h a t  a r e  a s s o c i a t e d  w i t h  s t r e s s ,  i n f l a m m a t i o n  a n d  
c a n c e r  ( r e v i e w e d  b y  [ 2 0 ] ) .  M o s t  T C R γ δ +  T  c e l l s  r e c o g n i z i n g  t h e s e  C D 1 d - l i p i d  a n t i g e n  
c o m p l e x e s  a r e  V δ 1  o r  V δ 3  c e l l s ,  c o m m o n l y  l o c a t e d  i n  t h e  g u t  [ 2 1 ] .  T C R γ δ +  T  c e l l s  c a n  
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also recognize butyrophilins (BTN), tumor-antigens, endothelial antigens, antigen-pre-senting cells (APCs) and Toll-like Receptors (TLRs) (reviewed by [22]), all of which are 
postulated to contribute to shaping of the TCRγδ+ T cell repertoire. 
TCRγδ+ T cell recognition and selection has been mostly described in the context 
of the developing immune system from fetus to neonate and adulthood, but – contrary 
to the TCRαβ+ T cell repertoire – effects of ageing on the TCRγδ+ T cell repertoire have 
not been extensively addressed. Since it has been found that TCRγδ+ T cells follow the 
classical ageing model as found in mainly CD8+TCRαβ+ T cells [23], we hypothesized that 
the naive mature TCRγδ+ T cell repertoire depicts a broad spectrum of rearrangements, which will show a more skewed pattern during further development from neonates to young adults and eventually elderly individuals. Here, we investigated the developing 
and ageing TRG / TRD repertoire in TCRγδ+ T cell subsets, using optimized experimental next-generation sequencing (NGS) procedure to minimize technical biases of PCR-based 
methods. Our data show subset- and donor-specific TRG / TRD repertoires, suggestive 
of selection, with significant differences in the combinatorial repertoire in especially memory populations between young and elderly individuals. Furthermore, when 
looking closer into TRG / TRD clonotypes, TCRγδ+ T-LGL leukemia receptor chains could be traced in especially the effector subsets of elderly individuals, suggesting that TCRγδ+ 
T-LGL leukemia cells originate from the normal healthy antigen-experienced TCRγδ+ T cells. 
MATERIALS & METHODS
Subjects and materialsBlood from healthy blood donors from Sanquin Blood Bank (Amsterdam, The Netherlands) in the age ranges 20-35 (young adults, N=11) and 56-70 (elderly, N=12) was used upon written informed consent at the blood bank (project number NVT0012.01) and anonymized for further use. The maximum age to donate blood is 70 years. Healthy neonatal cord blood was obtained postpartum or after Caesarian section through collaboration and upon written informed consent at the departments of Obstetrics and Hematology. Cord blood was drawn using CB Collect bags containing citrate phosphate dextrose (CPD) solution as anticoagulant. Thymic lobes were removed upon heart surgery in individuals under the age of two years upon written informed consent from parents. Both cord blood and thymus material was obtained under Medical Ethics Committee approval (project number hmPOO2004-003). Whole thymic material was sliced and prepared prior to cryopreservation. Peripheral blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs) were obtained through Ficoll 
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Blood from healthy blood donors from Sanquin Blood Bank (Amsterdam, The 
Netherlands) in the age ranges 20-35 (young adults, N=11) and 56-70 (elderly, 
N=12) was used upon written informed consent at the blood bank (project number 
NVT0012.01) and anonymized for further use. The maximum age to donate blood is 
70 years. Healthy neonatal cord blood was obtained postpartum or after Caesarian 
section through collaboration and upon written informed consent at the departments 
of Obstetrics and Hematology. Cord blood was drawn using CB Collect bags containing 
citrate phosphate dextrose (CPD) solution as anticoagulant. Thymic lobes were removed 
upon heart surgery in individuals under the age of two years upon written informed 
consent from parents. Both cord blood and thymus material was obtained under Medical 
Ethics Committee approval (project number hmPOO2004-003). Whole thymic material 
was sliced and prepared prior to cryopreservation. Peripheral blood mononuclear cells 
(PBMCs) and cord blood mononuclear cells (CBMCs) were obtained through Ficoll 
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density gradient separation. Isolated PBMCs, CBMCs, and thymocytes were cryopre- served in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza, Basel, Switzerland) with 
dimethyl sulfoxide and stored in vials at -180 °C until further use. All studies were con- ducted in accordance with the principles of the Declaration of Helsinki. 
Cell sorting
Cryopreserved material was thawed and sorted using CD3, CD45, TCRαβ, TCRγδ, 
CD45RA, CD45RO, CD27 and CD197 antibodies (Supplementary Table 1) to obtain TCRγδ+ 
naive (CD45RA+CD27+CD197+), central memory (CD45RA-CD45RO+CD27+CD197+), 
effector memory (TemRO population defined as CD45RA-CD45RO+CD27-CD197-), and 
effector (TemRA population, CD45RA+CD27-CD197-) T cells (Supplementary Fig. 1). 
Cell sorting was performed with FACS Aria I and III instruments (BD Biosciences, San Jose, CA, USA). 
DNA isolation
Following isolation, cells were lysed and subjected to DNA isolation using the DNA/ RNA/miRNA AllPrepKit according to the manufacturer’s protocol (Qiagen, Hilden, 
Germany). DNA concentration and quality (A260/A280 absorption ratio) were deter- mined by Nanodrop measurements (Thermo Fischer Scientific, Waltham, MA, USA). 
Primer design
Primers for cloning and Illumina-based sequencing were largely based on those reported in BIOMED-2 assays [24]. The Vδ3 primer was redesigned to better fit ampli-
con length of PCR products generated with the existing Vδ1 and Vδ2 primers. The Jγ1.2 
primer was newly designed, as this primer was not included in the BIOMED-2 TRG assay. Vγ1F and Jγ1.3/2.3 primers were adjusted compared with the BIOMED-2 protocol 
(Supplementary Table 2). Primers were adapted for Illumina-based sequencing by adding Illumina forward (5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’) and reverse 
(5’-TCGCGAGTTAATGCAACGATCGTCGAAATTCGC-3’) overhang adaptor sequences to the respective primers. The second PCR, by means of these overhang adaptor sequences, 
attaches sample-specific dual indices for sample identification and Illumina sequencing 
adaptors using primers from the Illumina TruSeq Custom Amplicon Index Kit (Illumina, San Diego, CA, USA). 
Plasmid pool preparation
Primer validation and titration was done using plasmid vectors with cloned TRD and TRG gene rearrangements. All possible V-J gene combinations were PCR amplified and 
cloned from immature T cell lines [25] and thymus DNA into the pGEM T-Easy vector in 
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1 2 1
N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
d e n s i t y  g r a d i e n t  s e p a r a t i o n .  I s o l a t e d  P B M C s ,  C B M C s ,  a n d  t h y m o c y t e s  w e r e  c r y o p r e -
s e r v e d  i n  I s c o v e ’ s  M o d i f i e d  D u l b e c c o ’ s  M e d i u m  ( I M D M ,  L o n z a ,  B a s e l ,  S w i t z e r l a n d )  w i t h  
d i m e t h y l  s u l f o x i d e  a n d  s t o r e d  i n  v i a l s  a t  - 1 8 0  ° C  u n t i l  f u r t h e r  u s e .  A l l  s t u d i e s  w e r e  c o n -
d u c t e d  i n  a c c o r d a n c e  w i t h  t h e  p r i n c i p l e s  o f  t h e  D e c l a r a t i o n  o f  H e l s i n k i .  
C e l l  s o r t i n g
C r y o p r e s e r v e d  m a t e r i a l  w a s  t h a w e d  a n d  s o r t e d  u s i n g  C D 3 ,  C D 4 5 ,  T C R α β ,  T C R γ δ ,  
C D 4 5 R A ,  C D 4 5 R O ,  C D 2 7  a n d  C D 1 9 7  a n t i b o d i e s  ( S u p p l e m e n t a r y  T a b l e  1 )  t o  o b t a i n  T C R γ δ +  
n a i v e  ( C D 4 5 R A + C D 2 7 + C D 1 9 7 + ) ,  c e n t r a l  m e m o r y  ( C D 4 5 R A - C D 4 5 R O + C D 2 7 + C D 1 9 7 + ) ,  
e f f e c t o r  m e m o r y  ( T e m R O  p o p u l a t i o n  d e f i n e d  a s  C D 4 5 R A - C D 4 5 R O + C D 2 7 - C D 1 9 7 - ) ,  a n d  
e f f e c t o r  ( T e m R A  p o p u l a t i o n ,  C D 4 5 R A + C D 2 7 - C D 1 9 7 - )  T  c e l l s  ( S u p p l e m e n t a r y  F i g .  1 ) .  
C e l l  s o r t i n g  w a s  p e r f o r m e d  w i t h  F A C S  A r i a  I  a n d  I I I  i n s t r u m e n t s  ( B D  B i o s c i e n c e s ,  S a n  
J o s e ,  C A ,  U S A ) .  
D N A  i s o l a t i o n
F o l l o w i n g  i s o l a t i o n ,  c e l l s  w e r e  l y s e d  a n d  s u b j e c t e d  t o  D N A  i s o l a t i o n  u s i n g  t h e  D N A /
R N A / m i R N A  A l l P r e p K i t  a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s  p r o t o c o l  ( Q i a g e n ,  H i l d e n ,  
G e r m a n y ) .  D N A  c o n c e n t r a t i o n  a n d  q u a l i t y  ( A 2 6 0 / A 2 8 0  a b s o r p t i o n  r a t i o )  w e r e  d e t e r -
m i n e d  b y  N a n o d r o p  m e a s u r e m e n t s  ( T h e r m o  F i s c h e r  S c i e n t i f i c ,  W a l t h a m ,  M A ,  U S A ) .  
P r i m e r  d e s i g n
P r i m e r s  f o r  c l o n i n g  a n d  I l l u m i n a - b a s e d  s e q u e n c i n g  w e r e  l a r g e l y  b a s e d  o n  t h o s e  
r e p o r t e d  i n  B I O M E D - 2  a s s a y s  [ 2 4 ] .  T h e  V δ 3  p r i m e r  w a s  r e d e s i g n e d  t o  b e t t e r  f i t  a m p l i -
c o n  l e n g t h  o f  P C R  p r o d u c t s  g e n e r a t e d  w i t h  t h e  e x i s t i n g  V δ 1  a n d  V δ 2  p r i m e r s .  T h e  J γ 1 . 2  
p r i m e r  w a s  n e w l y  d e s i g n e d ,  a s  t h i s  p r i m e r  w a s  n o t  i n c l u d e d  i n  t h e  B I O M E D - 2  T R G  
a s s a y .  V γ 1 F  a n d  J γ 1 . 3 / 2 . 3  p r i m e r s  w e r e  a d j u s t e d  c o m p a r e d  w i t h  t h e  B I O M E D - 2  p r o t o c o l  
( S u p p l e m e n t a r y  T a b l e  2 ) .  P r i m e r s  w e r e  a d a p t e d  f o r  I l l u m i n a - b a s e d  s e q u e n c i n g  b y  a d d i n g  
I l l u m i n a  f o r w a r d  ( 5 ’ - A C A C T C T T T C C C T A C A C G A C G C T C T T C C G A T C T - 3 ’ )  a n d  r e v e r s e  
( 5 ’ - T C G C G A G T T A A T G C A A C G A T C G T C G A A A T T C G C - 3 ’ )  o v e r h a n g  a d a p t o r  s e q u e n c e s  t o  t h e  
r e s p e c t i v e  p r i m e r s .  T h e  s e c o n d  P C R ,  b y  m e a n s  o f  t h e s e  o v e r h a n g  a d a p t o r  s e q u e n c e s ,  
a t t a c h e s  s a m p l e - s p e c i f i c  d u a l  i n d i c e s  f o r  s a m p l e  i d e n t i f i c a t i o n  a n d  I l l u m i n a  s e q u e n c i n g  
a d a p t o r s  u s i n g  p r i m e r s  f r o m  t h e  I l l u m i n a  T r u S e q  C u s t o m  A m p l i c o n  I n d e x  K i t  ( I l l u m i n a ,  
S a n  D i e g o ,  C A ,  U S A ) .  
P l a s m i d  p o o l  p r e p a r a t i o n
P r i m e r  v a l i d a t i o n  a n d  t i t r a t i o n  w a s  d o n e  u s i n g  p l a s m i d  v e c t o r s  w i t h  c l o n e d  T R D  a n d  
T R G  g e n e  r e a r r a n g e m e n t s .  A l l  p o s s i b l e  V - J  g e n e  c o m b i n a t i o n s  w e r e  P C R  a m p l i f i e d  a n d  
c l o n e d  f r o m  i m m a t u r e  T  c e l l  l i n e s  [ 2 5 ]  a n d  t h y m u s  D N A  i n t o  t h e  p G E M  T - E a s y  v e c t o r  i n  
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a 3:1 insert:vector ratio according to the manufacturer’s protocol (Promega, Madison, WI, USA). Composition of the plasmid pools is summarized in Supplementary Table 3.
Assay optimization experiments 
PCRs were first tested in singleplex and multiplex settings with varying primer concentrations, annealing temperatures and PCR cycle numbers. Each initial PCR mix contained GeneAmp PCR Buffer II (1x), magnesium chloride (2.5 mM), deoxynucle-
otides (2.0 mM) and AmpliTaqGold (1 U) (Thermo Fischer Scientific). Total forward and reverse primer(s) amounts were 10 pmol. The PCR protocol was largely based on the BIOMED-2 publication [24], with varying annealing temperatures (Tm = 58/59/60/62) and different numbers of cycles (20 and 25 cycles). In general total forward and reverse primer(s) amount was 10 pmol. Primer concentration adjustment, and optimization of annealing temperatures and number of PCR cycles were based on the results of iterative optimization experiments as summarized in Supplementary Table 4 and Figures 2 and 4 from Chapter 3. 
Amplicon preparation
Amplicons from the first step PCR were purified using the Agencourt AMPure XP 
bead purification kit (Beckman Coulter, Fullerton, CA, USA), whereafter concentra-
tions were measured with the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fischer 
Scientific), and the amplicons were adjusted to similar concentrations. The second step PCR was performed with primers from the Illumina TruSeq Custom Amplicon Index Kit (Illumina) using the KAPA HiFi HotStart PCR Kit (Kapa Biosystems, Wilmington, MA, USA). Second PCR amplicons were evaluated with agarose gel electrophoresis or PicoGreen concentration measurement. Library pool preparation was performed based on the gel image or PicoGreen measurement results. The library pool was further puri-
fied with Agencourt AMPure XP beads and normalized from Illumina-based sequencing, according to the manufacturer’s protocol (Illumina). 
Next-generation sequencingPaired-end next-generation sequencing (2x221 bp) was performed on the MiSeq platform (Illumina, San Diego, CA, USA) with the use of an Illumina MiSeq Reagent Kit V3, according to the manufacturer’s protocol (Illumina).
Bio-informatic data analysis
Illumina NGS data was obtained in FASTQ format. Paired-end reads were com-
bined using the FASTQ-join tool in the Erasmus MC Galaxy Server [26], with the use 
of usegalaxy.org [27-29] converted from FASTQ to FASTA with the converter tool [30]. 
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V3, according to the manufacturer’s protocol (Illumina).
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Sequencing annotations were made via the IMGT High V-quest database [31-34]. Calculation of the clonality score for multiple replicates was based on the algorithm 
described by Boyd et al. [35]. Clonal type definition was based on V and J gene usage and 
CDR3-region at the nucleotide level. Rearrangements were visualized using Circoletto plots (www.circos.ca, [36]). CDR3 amino acid compositions were visualized using 
WebLogo online tool (www.weblogo.berkeley.edu, [37,38])
Statistical analysis
Data was checked for normal distributions using the Hartigan’s Dip Test Statistic for Unimodality package [39-41] in R version 3.4.1 [42]. All statistical analyses were per-
formed with Prism 5 (GraphPad, La Jolla, CA, USA).
RESULTS
Multiplex PCR assay fine-tuning leads to an optimized, bias-free NGS 
assay for reliable quantification of the TRG / TRD repertoire
The multiplex PCR assay to be analyzed by NGS was optimized and fine-tuned for 
more accurate quantification and receptor diversity analysis of the TRG and TRD loci 
using a diverse set of artificial DNA spike-in samples and primer concentration titration 
experiments (Supplementary Table 4 and 5, Fig. 2 and 4 from Chapter 3). Each artificial 
DNA sample, represented by plasmid vector DNA, contained a mixture of known V(D)J rearrangements, cloned from either immature T cell lines or thymus DNA in equimolar 
proportions (Supplementary Table 3). After several rounds of fine-tuning (Fig. 2 and 
4 from Chapter 3), and repeated technical validation with plasmid spike-in pools we established the most optimal PCR conditions for both TRG (Fig. 1a) and TRD (Fig. 1b) 
multiplex assays in view of unbiased NGS data. Slight differences between observed and expected read frequencies are due to random chance introduced by PCR and inevitable 
inter-assay variation, which were reduced to minimal using approx. four replicates for each sample, which included differently pipetted mixes to reduce pipetting bias and the 
use of four different PCR machines to reduce machine-dependent bias. These optimi- zation experiments resulted in variable primer concentrations and defined annealing 
temperatures and cycle numbers for the TRG and TRD multiplex PCR reactions (Supplementary Table 5).
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1 2 3
N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
S e q u e n c i n g  a n n o t a t i o n s  w e r e  m a d e  v i a  t h e  I M G T  H i g h  V - q u e s t  d a t a b a s e  [ 3 1 - 3 4 ] .  
C a l c u l a t i o n  o f  t h e  c l o n a l i t y  s c o r e  f o r  m u l t i p l e  r e p l i c a t e s  w a s  b a s e d  o n  t h e  a l g o r i t h m  
d e s c r i b e d  b y  B o y d  e t  a l .  [ 3 5 ] .  C l o n a l  t y p e  d e f i n i t i o n  w a s  b a s e d  o n  V  a n d  J  g e n e  u s a g e  a n d  
C D R 3 - r e g i o n  a t  t h e  n u c l e o t i d e  l e v e l .  R e a r r a n g e m e n t s  w e r e  v i s u a l i z e d  u s i n g  C i r c o l e t t o  
p l o t s  ( w w w . c i r c o s . c a ,  [ 3 6 ] ) .  C D R 3  a m i n o  a c i d  c o m p o s i t i o n s  w e r e  v i s u a l i z e d  u s i n g  
W e b L o g o  o n l i n e  t o o l  ( w w w . w e b l o g o . b e r k e l e y . e d u ,  [ 3 7 , 3 8 ] )
S t a t i s t i c a l  a n a l y s i s
D a t a  w a s  c h e c k e d  f o r  n o r m a l  d i s t r i b u t i o n s  u s i n g  t h e  H a r t i g a n ’ s  D i p  T e s t  S t a t i s t i c  f o r  
U n i m o d a l i t y  p a c k a g e  [ 3 9 - 4 1 ]  i n  R  v e r s i o n  3 . 4 . 1  [ 4 2 ] .  A l l  s t a t i s t i c a l  a n a l y s e s  w e r e  p e r -
f o r m e d  w i t h  P r i s m  5  ( G r a p h P a d ,  L a  J o l l a ,  C A ,  U S A ) .
R E S U LT S
M u l t i p l e x  P C R  a s s a y  f i n e - t u n i n g  l e a d s  t o  a n  o p t i m i z e d ,  b i a s - f r e e  N G S  
a s s a y  f o r  r e l i a b l e  q u a n t i f i c a t i o n  o f  t h e  T R G  /  T R D  r e p e r t o i r e
T h e  m u l t i p l e x  P C R  a s s a y  t o  b e  a n a l y z e d  b y  N G S  w a s  o p t i m i z e d  a n d  f i n e - t u n e d  f o r  
m o r e  a c c u r a t e  q u a n t i f i c a t i o n  a n d  r e c e p t o r  d i v e r s i t y  a n a l y s i s  o f  t h e  T R G  a n d  T R D  l o c i  
u s i n g  a  d i v e r s e  s e t  o f  a r t i f i c i a l  D N A  s p i k e - i n  s a m p l e s  a n d  p r i m e r  c o n c e n t r a t i o n  t i t r a t i o n  
e x p e r i m e n t s  ( S u p p l e m e n t a r y  T a b l e  4  a n d  5 ,  F i g .  2  a n d  4  f r o m  C h a p t e r  3 ) .  E a c h  a r t i f i c i a l  
D N A  s a m p l e ,  r e p r e s e n t e d  b y  p l a s m i d  v e c t o r  D N A ,  c o n t a i n e d  a  m i x t u r e  o f  k n o w n  V ( D ) J  
r e a r r a n g e m e n t s ,  c l o n e d  f r o m  e i t h e r  i m m a t u r e  T  c e l l  l i n e s  o r  t h y m u s  D N A  i n  e q u i m o l a r  
p r o p o r t i o n s  ( S u p p l e m e n t a r y  T a b l e  3 ) .  A f t e r  s e v e r a l  r o u n d s  o f  f i n e - t u n i n g  ( F i g .  2  a n d  
4  f r o m  C h a p t e r  3 ) ,  a n d  r e p e a t e d  t e c h n i c a l  v a l i d a t i o n  w i t h  p l a s m i d  s p i k e - i n  p o o l s  w e  
e s t a b l i s h e d  t h e  m o s t  o p t i m a l  P C R  c o n d i t i o n s  f o r  b o t h  T R G  ( F i g .  1 a )  a n d  T R D  ( F i g .  1 b )  
m u l t i p l e x  a s s a y s  i n  v i e w  o f  u n b i a s e d  N G S  d a t a .  S l i g h t  d i f f e r e n c e s  b e t w e e n  o b s e r v e d  a n d  
e x p e c t e d  r e a d  f r e q u e n c i e s  a r e  d u e  t o  r a n d o m  c h a n c e  i n t r o d u c e d  b y  P C R  a n d  i n e v i t a b l e  
i n t e r - a s s a y  v a r i a t i o n ,  w h i c h  w e r e  r e d u c e d  t o  m i n i m a l  u s i n g  a p p r o x .  f o u r  r e p l i c a t e s  f o r  
e a c h  s a m p l e ,  w h i c h  i n c l u d e d  d i f f e r e n t l y  p i p e t t e d  m i x e s  t o  r e d u c e  p i p e t t i n g  b i a s  a n d  t h e  
u s e  o f  f o u r  d i f f e r e n t  P C R  m a c h i n e s  t o  r e d u c e  m a c h i n e - d e p e n d e n t  b i a s .  T h e s e  o p t i m i -
z a t i o n  e x p e r i m e n t s  r e s u l t e d  i n  v a r i a b l e  p r i m e r  c o n c e n t r a t i o n s  a n d  d e f i n e d  a n n e a l i n g  
t e m p e r a t u r e s  a n d  c y c l e  n u m b e r s  f o r  t h e  T R G  a n d  T R D  m u l t i p l e x  P C R  r e a c t i o n s  
( S u p p l e m e n t a r y  T a b l e  5 ) .
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The TRG / TRD repertoire is diverse in immature thymus and cord 
blood, and more skewed in mature circulating TCRγδ+ T cells
In order to determine changes in TCRγδ+ T cell repertoire in healthy individuals we 
first investigated TRG / TRD repertoire diversity during ontogeny using purified TCRγδ+ T cells from different compartments i.e. thymus (Thy) and neonatal cord blood (CB). 
In addition we sequenced the total mature TCRγδ+ T cell population of healthy adult peripheral blood (PB) samples. TRG rearrangements in Thy and CB samples were highly diverse (Fig. 2a, upper 2 rows), and the inter-sample variation of especially Thy samples 
Figure 1. Technical optimization of NGS assays for TRG / TRD loci.Multiplex PCR assays were optimized with balanced primer concentrations, annealing temperatures and cycle numbers as summarized in Supplementary Table 3. Plasmid pools were used as spike-in samples to determine the percentage expected sequences per V and J gene vs. the observed percentage after sequencing (Supplementary Table 2). Expected percentages are indicated in black bars, observed percentages are indicated in colored bars. TRG assays showed high overlap between frequencies of expected and observed 
sequences for Vγ and Jγ (a) genes, with some variation due to single primers covering multiple genes (Vγ1F 
covering Vγ2-8, Jγ1.1/2.1 covering Jγ1.1 and Jγ2.1, and Jγ1.3/2.3 covering Jγ1.3 and Jγ2.3). TRD assays showed 
nearly similar percentages of expected and observed sequences for Vδ and Jδ (b) genes. Error bars represent SD of PCR replicates (N=3/4).
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Figure 2. Circoletto visualization of the TRG / TRD repertoire during ontogeny.
Optimized multiplex PCR NGS assays were applied on total TCRγδ+ T cells sorted from thymus (Thy), neonatal 
cord blood (CB) and adult peripheral blood (PB). TRG assays showed high repertoire diversity in both Thy and CB samples, with low inter-individual variation, while adult PB samples showed individual-specific repertoire patterns with less receptor diversity (a). TRD assays showed high dominance of Vδ1 (light blue bars), which 
was also observed in CB samples, both with low inter-sample variation. Adult PB samples showed donor- specific patterns with sometimes skewing towards Vδ2 and even Vδ3 (b). Three representative samples of each samples type are visualized: Thy04-10, Thy05-13, Thy10-13, CB2, CB3, CB4, PB30, PB31 and PB50. 
Plots were made using the Circoletto online software tool (www.circos.ca, [35]). Each band represents a V-J rearrangement, with colors based on V-gene usage.
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1 2 5
N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
F i g u r e  2 .  C i r c o l e t t o  v i s u a l i z a t i o n  o f  t h e  T R G  /  T R D  r e p e r t o i r e  d u r i n g  o n t o g e n y .
O p t i m i z e d  m u l t i p l e x  P C R  N G S  a s s a y s  w e r e  a p p l i e d  o n  t o t a l  T C R γ δ +  T  c e l l s  s o r t e d  f r o m  t h y m u s  ( T h y ) ,  n e o n a t a l  
c o r d  b l o o d  ( C B )  a n d  a d u l t  p e r i p h e r a l  b l o o d  ( P B ) .  T R G  a s s a y s  s h o w e d  h i g h  r e p e r t o i r e  d i v e r s i t y  i n  b o t h  T h y  a n d  
C B  s a m p l e s ,  w i t h  l o w  i n t e r - i n d i v i d u a l  v a r i a t i o n ,  w h i l e  a d u l t  P B  s a m p l e s  s h o w e d  i n d i v i d u a l - s p e c i f i c  r e p e r t o i r e  
p a t t e r n s  w i t h  l e s s  r e c e p t o r  d i v e r s i t y  ( a ) .  T R D  a s s a y s  s h o w e d  h i g h  d o m i n a n c e  o f  V δ 1  ( l i g h t  b l u e  b a r s ) ,  w h i c h  
w a s  a l s o  o b s e r v e d  i n  C B  s a m p l e s ,  b o t h  w i t h  l o w  i n t e r - s a m p l e  v a r i a t i o n .  A d u l t  P B  s a m p l e s  s h o w e d  d o n o r -
s p e c i f i c  p a t t e r n s  w i t h  s o m e t i m e s  s k e w i n g  t o w a r d s  V δ 2  a n d  e v e n  V δ 3  ( b ) .  T h r e e  r e p r e s e n t a t i v e  s a m p l e s  o f  
e a c h  s a m p l e s  t y p e  a r e  v i s u a l i z e d :  T h y 0 4 - 1 0 ,  T h y 0 5 - 1 3 ,  T h y 1 0 - 1 3 ,  C B 2 ,  C B 3 ,  C B 4 ,  P B 3 0 ,  P B 3 1  a n d  P B 5 0 .  
P l o t s  w e r e  m a d e  u s i n g  t h e  C i r c o l e t t o  o n l i n e  s o f t w a r e  t o o l  ( w w w . c i r c o s . c a ,  [ 3 5 ] ) .  E a c h  b a n d  r e p r e s e n t s  a  V - J  
r e a r r a n g e m e n t ,  w i t h  c o l o r s  b a s e d  o n  V - g e n e  u s a g e .
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was low, in keeping with the non-selected character of the TCRγδ+ T cells in these com-
partments. These findings were in strong contrast to PB samples, which showed a high 
level of skewing and predominance of certain receptors (including Vγ9-Jγ1.2 sequences) were observed (Fig. 2a, bottom row), albeit with high inter-individual differences, illus-trating the dominant role of (antigenic) selection. TRD diversity was less apparent, 
although in Thy and CB samples (Fig. 2b, upper 2 rows) all three predominant Vδ-genes 
were identified. Again, inter-sample variation was low, illustrating the non-selected character of Thy and CB cells. Inter-sample variation was more evident for the PB sam-
ples (Fig. 2b, bottom row), with predominance of Vδ2 usage, but also Vδ3 usage in some 
cases, reflecting different types of (antigenic) selection between individuals. 
Collectively, these data confirmed our hypothesis of a broad and diverse TRG / TRD repertoire in the immature Thy and CB samples and a more skewed TRG / TRD reper-
toire in mature circulating TCRγδ+ T cells in adults, thereby validating our optimized multiplex PCR-based TRG / TRD NGS assays.
Upon ageing memory TCRγδ+ T cells show shifts in V-gene usage, 
whereas naive and effector populations do not As it has become evident that ageing plays a major role in shaping the elderly immune system [43], we next evaluated the role of ageing on the combinatorial TRG / TRD reper-
toire. To this end, we sorted TCRγδ+ T cells from healthy young (N=11; age range 20-35) and 
elderly (N=12; age range 56-70) individuals into four subsets: naive (CD45RA+CD45RO-
CD27+CD197+), central memory (CD45RA-CD45RO+CD27+CD197+), effector memory 
(TemRO; CD45RA-CD45RO+CD27-CD197-) and effector (TemRA; CD45RA+CD45RO-
CD27-CD197-) TCRγδ+ T cells. Subset distributions of young and elderly individuals (Supplementary Fig. 2) correlated with those from our previous ageing study, as it 
is known that TCRγδ+ T cells have little CCR7 expression and thus low absolute and relative numbers of naive and central memory cells [44]. Even though the spectrum of 
V-J combinations for both TRG and TRD varied in a donor-specific way between indi-viduals (Supplementary Fig. 3), the overall TRG/ TRD combinatorial diversity appeared 
to be mostly determined by differences in Vγ / Vδ usage rather than Jγ / Jδ gene usage. 
Naive TCRγδ+ T cells of both young and elderly individuals showed a relatively diverse TRG repertoire, which was in strong contrast to (central and effector) memory 
TCRγδ+ T cells that showed dominant Vγ9 gene usage. Effector TCRγδ+ T cells of both 
age groups were more diverse again. Of note, significant differences between young and 
elderly could be observed in mainly the memory populations, as reflected by a signifi-
cant increase of Vγ2-usage in central memory TCRγδ+ T cells in elderly, as well as sig-
nificantly increased Vγ2-8-usage and significantly decreased Vγ9 gene usage in effector memory cells of elderly (Fig. 3a). 
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were observed (Fig. 2a, bottom row), albeit with high inter-individual differences, illus-
trating the dominant role of (antigenic) selection. TRD diversity was less apparent, 
although in Thy and CB samples (Fig. 2b, upper 2 rows) all three predominant Vδ-genes 
were identified. Again, inter-sample variation was low, illustrating the non-selected 
character of Thy and CB cells. Inter-sample variation was more evident for the PB sam-
ples (Fig. 2b, bottom row), with predominance of Vδ2 usage, but also Vδ3 usage in some 
cases, reflecting different types of (antigenic) selection between individuals. 
Collectively, these data confirmed our hypothesis of a broad and diverse TRG / TRD 
repertoire in the immature Thy and CB samples and a more skewed TRG / TRD reper-
toire in mature circulating TCRγδ+ T cells in adults, thereby validating our optimized 
multiplex PCR-based TRG / TRD NGS assays.
Upon ageing memory TCRγδ+ T cells show shifts in V-gene usage, 
whereas naive and effector populations do not 
As it has become evident that ageing plays a major role in shaping the elderly immune 
system [43], we next evaluated the role of ageing on the combinatorial TRG / TRD reper-
toire. To this end, we sorted TCRγδ+ T cells from healthy young (N=11; age range 20-35) and 
elderly (N=12; age range 56-70) individuals into four subsets: naive (CD45RA+CD45RO-
CD27+CD197+), central memory (CD45RA-CD45RO+CD27+CD197+), effector memory 
(TemRO; CD45RA-CD45RO+CD27-CD197-) and effector (TemRA; CD45RA+CD45RO-
CD27-CD197-) TCRγδ+ T cells. Subset distributions of young and elderly individuals 
(Supplementary Fig. 2) correlated with those from our previous ageing study, as it 
is known that TCRγδ+ T cells have little CCR7 expression and thus low absolute and 
relative numbers of naive and central memory cells [44]. Even though the spectrum of 
V-J combinations for both TRG and TRD varied in a donor-specific way between indi-
viduals (Supplementary Fig. 3), the overall TRG/ TRD combinatorial diversity appeared 
to be mostly determined by differences in Vγ / Vδ usage rather than Jγ / Jδ gene usage. 
Naive TCRγδ+ T cells of both young and elderly individuals showed a relatively 
diverse TRG repertoire, which was in strong contrast to (central and effector) memory 
TCRγδ+ T cells that showed dominant Vγ9 gene usage. Effector TCRγδ+ T cells of both 
age groups were more diverse again. Of note, significant differences between young and 
elderly could be observed in mainly the memory populations, as reflected by a signifi-
cant increase of Vγ2-usage in central memory TCRγδ+ T cells in elderly, as well as sig-
nificantly increased Vγ2-8-usage and significantly decreased Vγ9 gene usage in effector 
memory cells of elderly (Fig. 3a). 
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When comparing TRD combinatorial profiles in the different subsets between young 
and elderly individuals, significantly increased Vδ1 and significantly decreased Vδ2 gene usage was observed in memory populations of elderly individuals. This effect was 
also observed in the effector population. In the effector memory cells of elderly Vδ3 gene 
usage was also significantly increased (Fig. 3b). Overall, these data show clear differences in the TRG / TRD combinatorial repertoire 
between naive TCRγδ+ T cells on the one hand and especially memory TCRγδ+ T cells on 
the other hand. Notably, the clear dominance of Vγ9 and Vδ2 usage in memory and effec-
tor TCRγδ+ T cells in young individuals was less prominent in elderly individuals, who 
on average showed significant shifts towards more Vγ2 and Vδ1 gene usage in addition 
to Vγ9 and Vδ2. Most significant differences between young and elderly were identified in central and effector memory populations.
The TRG / TRD junctional region repertoire shows signs of selection in 
memory and effector cell populations of both young and old individualsFor a more detailed view of the TRG / TRD repertoire we then studied CDR3-regions, 
which reflect the most relevant antigen-binding part of the antigen receptors. These CDR3-length distributions are indicative of the junctional repertoire. TRG / TRD CDR3-
length distributions of Thy TCRγδ+ T cells showed Gaussian profiles, just like the TRD 
CDR3-length distributions of CB TCRγδ+ T cells; TRG CDR3-lengths of CB TCRγδ+ T cells 
showed less clear Gaussian distributions and more prominent peaks, probably reflecting low-level selection (Supplementary Fig. 4). The effect of selection became even more 
evident in adult individuals; naive TCRγδ+ T cells showed mostly Gaussian CDR3 pro-
files, in contrast to memory and effector TCRγδ+ T cells of young individuals, which showed dominant peaks for both the TRG and TRD CDR3-regions (Fig. 4a, 4b). Elderly 
individuals did not show clear Gaussian profiles, and even prominent peaks in all sub-
sets, thus reflecting a more heavily selected repertoire (Fig. 4a, 4b). The average TRG and TRD CDR3-lengths were not markedly different between young and elderly individuals.
TRG canonical and TRD invariant T selection determinants are 
detectable in normal TCRγδ+ T cells but do not increase upon ageing
During development selection of TCRγδ+ T cells is known to be associated with 
so-called selection determinants, which represent molecular fingerprints in the CDR3-
regions of TRG and TRD chains. In circulating TCRγδ+ T cells a high frequency of Vγ9 
– Jγ1.2 recombinations with preferential joining at the GCA sequence has been noted 
(Fig. 5a). We therefore studied this so-called canonical Vγ9 – Jγ1.2 rearrangement, 
characterized by a defined CDR3-length and amino acid composition (Fig. 5a), in dif-ferent subsets of young and elderly healthy controls.  Approximately 10-20% of all 
Chapter 4
128
When comparing TRD combinatorial profiles in the different subsets between young 
and elderly individuals, significantly increased Vδ1 and significantly decreased Vδ2 
gene usage was observed in memory populations of elderly individuals. This effect was 
also observed in the effector population. In the effector memory cells of elderly Vδ3 gene 
usage was also significantly increased (Fig. 3b). 
Overall, these data show clear differences in the TRG / TRD combinatorial repertoire 
between naive TCRγδ+ T cells on the one hand and especially memory TCRγδ+ T cells on 
the other hand. Notably, the clear dominance of Vγ9 and Vδ2 usage in memory and effec-
tor TCRγδ+ T cells in young individuals was less prominent in elderly individuals, who 
on average showed significant shifts towards more Vγ2 and Vδ1 gene usage in addition 
to Vγ9 and Vδ2. Most significant differences between young and elderly were identified 
in central and effector memory populations.
The TRG / TRD junctional region repertoire shows signs of selection in 
memory and effector cell populations of both young and old individuals
For a more detailed view of the TRG / TRD repertoire we then studied CDR3-regions, 
which reflect the most relevant antigen-binding part of the antigen receptors. These 
CDR3-length distributions are indicative of the junctional repertoire. TRG / TRD CDR3-
length distributions of Thy TCRγδ+ T cells showed Gaussian profiles, just like the TRD 
CDR3-length distributions of CB TCRγδ+ T cells; TRG CDR3-lengths of CB TCRγδ+ T cells 
showed less clear Gaussian distributions and more prominent peaks, probably reflecting 
low-level selection (Supplementary Fig. 4). The effect of selection became even more 
evident in adult individuals; naive TCRγδ+ T cells showed mostly Gaussian CDR3 pro-
files, in contrast to memory and effector TCRγδ+ T cells of young individuals, which 
showed dominant peaks for both the TRG and TRD CDR3-regions (Fig. 4a, 4b). Elderly 
individuals did not show clear Gaussian profiles, and even prominent peaks in all sub-
sets, thus reflecting a more heavily selected repertoire (Fig. 4a, 4b). The average TRG and 
TRD CDR3-lengths were not markedly different between young and elderly individuals.
TRG canonical and TRD invariant T selection determinants are 
detectable in normal TCRγδ+ T cells but do not increase upon ageing
During development selection of TCRγδ+ T cells is known to be associated with 
so-called selection determinants, which represent molecular fingerprints in the CDR3-
regions of TRG and TRD chains. In circulating TCRγδ+ T cells a high frequency of Vγ9 
– Jγ1.2 recombinations with preferential joining at the GCA sequence has been noted 
(Fig. 5a). We therefore studied this so-called canonical Vγ9 – Jγ1.2 rearrangement, 
characterized by a defined CDR3-length and amino acid composition (Fig. 5a), in dif-
ferent subsets of young and elderly healthy controls.  Approximately 10-20% of all 
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productive Vγ9 – Jγ1.2 rearrangements contained the canonical sequence (Fig. 5b). The 
frequencies of canonical Vγ9 – Jγ1.2 sequences did not clearly differ between different 
subsets in young and elderly (Fig. 5b). In TCRγδ-receptors the canonical Vγ9 – Jγ1.2 
chain is frequently combined with a Vδ2-derived chain, especially resulting from Vδ2 – 
Jδ1 recombination. These Vδ2 – Jδ1 rearrangements often contain a so-called invariant 
T nucleotide, a selection determinant at the relative second position of the first codon 
of the junctional region (Fig. 5c), translating into Leucine (L), Valine (V) or Isoleucine (I) amino acids at that first codon in the junction. The invariant T was observed in all 
individuals (Fig. 5d, outer grey circles), and resulted in L, V or I amino acids at this posi- tion (Fig. 5d, inner blue pie charts). The invariant T was present at higher frequency 
Figure 4. CDR3-length distributions of TCRγδ+ T cell subsets from young and elderly individuals.
Frequencies of CDR3-lengths from different TCRγδ+ T cell subsets are summarized per TCR receptor chain and 
age group. Naive subsets (red lines) showed distributions resembling Gaussian profiles, while memory subsets 
showed dominant peaks suggestive of selection and receptor skewing (green and purple lines). TRG CDR3- lengths showed similar distributions between young and elderly (a), TRD CDR3-lengths in young individuals showed a Gaussian profile in the naive subset and more skewing in memory and effector subsets, whereas in 
elderly individuals all subsets showed dominant peaks (b). Mean frequencies per subset were indicated for young (N=11) and elderly (N=12) individuals. Data normality was tested using the diptest package in R.
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N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
p r o d u c t i v e  V γ 9  –  J γ 1 . 2  r e a r r a n g e m e n t s  c o n t a i n e d  t h e  c a n o n i c a l  s e q u e n c e  ( F i g .  5 b ) .  T h e  
f r e q u e n c i e s  o f  c a n o n i c a l  V γ 9  –  J γ 1 . 2  s e q u e n c e s  d i d  n o t  c l e a r l y  d i f f e r  b e t w e e n  d i f f e r e n t  
s u b s e t s  i n  y o u n g  a n d  e l d e r l y  ( F i g .  5 b ) .  I n  T C R γ δ - r e c e p t o r s  t h e  c a n o n i c a l  V γ 9  –  J γ 1 . 2  
c h a i n  i s  f r e q u e n t l y  c o m b i n e d  w i t h  a  V δ 2 - d e r i v e d  c h a i n ,  e s p e c i a l l y  r e s u l t i n g  f r o m  V δ 2  –  
J δ 1  r e c o m b i n a t i o n .  T h e s e  V δ 2  –  J δ 1  r e a r r a n g e m e n t s  o f t e n  c o n t a i n  a  s o - c a l l e d  i n v a r i a n t  
T  n u c l e o t i d e ,  a  s e l e c t i o n  d e t e r m i n a n t  a t  t h e  r e l a t i v e  s e c o n d  p o s i t i o n  o f  t h e  f i r s t  c o d o n  
o f  t h e  j u n c t i o n a l  r e g i o n  ( F i g .  5 c ) ,  t r a n s l a t i n g  i n t o  L e u c i n e  ( L ) ,  V a l i n e  ( V )  o r  I s o l e u c i n e  
( I )  a m i n o  a c i d s  a t  t h a t  f i r s t  c o d o n  i n  t h e  j u n c t i o n .  T h e  i n v a r i a n t  T  w a s  o b s e r v e d  i n  a l l  
i n d i v i d u a l s  ( F i g .  5 d ,  o u t e r  g r e y  c i r c l e s ) ,  a n d  r e s u l t e d  i n  L ,  V  o r  I  a m i n o  a c i d s  a t  t h i s  p o s i -
t i o n  ( F i g .  5 d ,  i n n e r  b l u e  p i e  c h a r t s ) .  T h e  i n v a r i a n t  T  w a s  p r e s e n t  a t  h i g h e r  f r e q u e n c y  
F i g u r e  4 .  C D R 3 - l e n g t h  d i s t r i b u t i o n s  o f  T C R γ δ +  T  c e l l  s u b s e t s  f r o m  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s .
F r e q u e n c i e s  o f  C D R 3 - l e n g t h s  f r o m  d i f f e r e n t  T C R γ δ +  T  c e l l  s u b s e t s  a r e  s u m m a r i z e d  p e r  T C R  r e c e p t o r  c h a i n  a n d  
a g e  g r o u p .  N a i v e  s u b s e t s  ( r e d  l i n e s )  s h o w e d  d i s t r i b u t i o n s  r e s e m b l i n g  G a u s s i a n  p r o f i l e s ,  w h i l e  m e m o r y  s u b s e t s  
s h o w e d  d o m i n a n t  p e a k s  s u g g e s t i v e  o f  s e l e c t i o n  a n d  r e c e p t o r  s k e w i n g  ( g r e e n  a n d  p u r p l e  l i n e s ) .  T R G  C D R 3 -
l e n g t h s  s h o w e d  s i m i l a r  d i s t r i b u t i o n s  b e t w e e n  y o u n g  a n d  e l d e r l y  ( a ) ,  T R D  C D R 3 - l e n g t h s  i n  y o u n g  i n d i v i d u a l s  
s h o w e d  a  G a u s s i a n  p r o f i l e  i n  t h e  n a i v e  s u b s e t  a n d  m o r e  s k e w i n g  i n  m e m o r y  a n d  e f f e c t o r  s u b s e t s ,  w h e r e a s  i n  
e l d e r l y  i n d i v i d u a l s  a l l  s u b s e t s  s h o w e d  d o m i n a n t  p e a k s  ( b ) .  M e a n  f r e q u e n c i e s  p e r  s u b s e t  w e r e  i n d i c a t e d  f o r  
y o u n g  ( N = 1 1 )  a n d  e l d e r l y  ( N = 1 2 )  i n d i v i d u a l s .  D a t a  n o r m a l i t y  w a s  t e s t e d  u s i n g  t h e  d i p t e s t  p a c k a g e  i n  R .
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in memory and effector subsets compared to naive TCRγδ+ T cell subsets. On average, invariant T frequencies per subset did not differ much between young and elderly indi-viduals, although the percentage of invariant T-containing sequences at the nucleotide 
level of naive TCRγδ+ T cells of young individuals was clearly lower than that of elderly 
naive TCRγδ+ T cells (Fig. 5d). 
Taken together, the most common selection determinants described in TCRγδ+ T 
cells (i.e. the Vγ9 – Jγ1.2 canonical sequence and the Vδ2 – Jδ1 invariant T nucleotide) 
were readily identified in different TCRγδ+ T cell subsets in our healthy control cohort, albeit that frequencies did not clearly differ between young and elderly. 
Figure 5. Canonical Vγ9 – Jγ1.2 sequences and Vδ2 – Jδ1 invariant T selection determinant in young 
and elderly healthy individuals.
GCA sequence in bold mediates preferential recombination of Vγ9 with Jγ1.2, resulting in specific CDR3 length and amino acid composition, adapted from [61] (a). Frequencies of all productive Vγ9 – Jγ1.2 sequences 
containing the canonical sequence per age group and subset marked in dark grey. In light grey Vγ9 – Jγ1.2 
rearrangements with other, non-canonical sequences are indicated. Numbers of total Vγ9 – Jγ1.2 sequences are indicated in center of plots (b). The invariant T selection determinant is located at the relative second 
position of the first codon in the junction of Vδ2 – Jδ1 rearrangements. Adapted from [13] (c). Frequencies of invariant T selection determinant in young and elderly subsets (dark grey part outer ring), leading to L, V or 
I amino acid residues (inner blue pie chart, dark blue part. Absolute number of unique productive Vδ2 – Jδ1 sequences indicated next to plots (d). 
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in memory and effector subsets compared to naive TCRγδ+ T cell subsets. On average, 
invariant T frequencies per subset did not differ much between young and elderly indi-
viduals, although the percentage of invariant T-containing sequences at the nucleotide 
level of naive TCRγδ+ T cells of young individuals was clearly lower than that of elderly 
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Taken together, the most common selection determinants described in TCRγδ+ T 
cells (i.e. the Vγ9 – Jγ1.2 canonical sequence and the Vδ2 – Jδ1 invariant T nucleotide) 
were readily identified in different TCRγδ+ T cell subsets in our healthy control cohort, 
albeit that frequencies did not clearly differ between young and elderly. 
Figure 5. Canonical Vγ9 – Jγ1.2 sequences and Vδ2 – Jδ1 invariant T selection determinant in young 
and elderly healthy individuals.
GCA sequence in bold mediates preferential recombination of Vγ9 with Jγ1.2, resulting in specific CDR3 length 
and amino acid composition, adapted from [61] (a). Frequencies of all productive Vγ9 – Jγ1.2 sequences 
containing the canonical sequence per age group and subset marked in dark grey. In light grey Vγ9 – Jγ1.2 
rearrangements with other, non-canonical sequences are indicated. Numbers of total Vγ9 – Jγ1.2 sequences 
are indicated in center of plots (b). The invariant T selection determinant is located at the relative second 
position of the first codon in the junction of Vδ2 – Jδ1 rearrangements. Adapted from [13] (c). Frequencies of 
invariant T selection determinant in young and elderly subsets (dark grey part outer ring), leading to L, V or 
I amino acid residues (inner blue pie chart, dark blue part. Absolute number of unique productive Vδ2 – Jδ1 
sequences indicated next to plots (d). 
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Analysis of TRG / TRD clonotypes shows the presence of TCRγδ+ T-LGL 
leukemia related clonotypes in especially effector cells of elderly
In view of TCRγδ+ T cell selection processes, we then studied the possible recurrence 
of specific TRG / TRD clonotypes in the repertoire of young and elderly individuals, as 
a sign of activated TCRγδ+ T cell clones. To this end multiple replicates (N=3) of each 
TCRγδ+ T cell subset were studied in independent PCR reactions and the number of 
so-called coincident sequences was determined [35,45]. In all subsets, both young and elderly, the frequency of clonotype sequences found in only one of the replicates was the 
highest, while the frequencies of coincidences found in 2 or 3 replicates were relatively low for both TRG and TRD (Supplementary Fig. 4). When comparing young and elderly, 
small shifts leading to higher numbers of coincidences in 2 or 3 replicates were seen in the latter (Supplementary Fig. 5). We then only focused on the coincidences present in 
all three replicates, since these sequences best reflect the individuals’ repertoire selec- tion. Especially in the effector memory population absolute numbers of sequences found 
in all three replicates were higher, while in naive subsets from both young and elderly these numbers were lower, except for a few cases (Supplementary Table 5).
To understand if the recurrence of clonotypes would be associated with particular infections, we next evaluated receptor clonotypes linked to pathogens such as 
Mycobacterium tuberculosis [16,46] and herpesviruses such as cytomegalovirus (CMV) [18]. Whereas in our healthy controls no M.tuberculosis-specific clonotypes could be 
identified, CMV-specific TRG or TRD clonotypes were found in most controls, and in one 
case even a complete CMV-specific TCRγδ receptor could be identified (data not shown). 
However, there were no evident differences between young and elderly individuals. Finally, as leukemic TCRγδ+ T cells can be associated with specific clonotypes, we 
retrospectively reviewed our TCRγδ+ T-LGL leukemia database of clonal TRG / TRD 
sequences [13,46] and searched for these LGL clonotypes in the normal TCRγδ+ T cell 
repertoire of young and elderly. Interestingly, two TCRγδ+ T-LGL leukemia-associated 
TRG and TRD clonotypes were found in four older individuals and in in one young indi- vidual (Table 1). The Vδ3 – Jδ1 receptor as identified in TCRγδ+ T-LGL leukemia case 
12-098 was identified in one young individual (naive subset, 26-year-old female), and 
in three older individuals (naive subset, 56-year-old male; effector subset, 69-year-old female and 68-year-old male) (Table 1). The TCRγδ+ T-LGL leukemia related receptor 
from case 10-200 was found twice in older individuals (naive subset, 56-year-old male; effector subset, 70-year-old male) (Table 1). Although the numbers are low, the fact that 
two TCRγδ+ T-LGL leukemia related receptors could specifically be identified in effector 
cells of elderly would support the idea that TCRγδ+ T-LGL leukemia cells originate from 
the normal TCRγδ repertoire, especially from antigen-experienced TCRγδ+ T cells of 
individuals of older age [13,47,48].
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N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
A n a l y s i s  o f  T R G  /  T R D  c l o n o t y p e s  s h o w s  t h e  p r e s e n c e  o f  T C R γ δ +  T - L G L  
l e u k e m i a  r e l a t e d  c l o n o t y p e s  i n  e s p e c i a l l y  e f f e c t o r  c e l l s  o f  e l d e r l y
I n  v i e w  o f  T C R γ δ +  T  c e l l  s e l e c t i o n  p r o c e s s e s ,  w e  t h e n  s t u d i e d  t h e  p o s s i b l e  r e c u r r e n c e  
o f  s p e c i f i c  T R G  /  T R D  c l o n o t y p e s  i n  t h e  r e p e r t o i r e  o f  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s ,  a s  
a  s i g n  o f  a c t i v a t e d  T C R γ δ +  T  c e l l  c l o n e s .  T o  t h i s  e n d  m u l t i p l e  r e p l i c a t e s  ( N = 3 )  o f  e a c h  
T C R γ δ +  T  c e l l  s u b s e t  w e r e  s t u d i e d  i n  i n d e p e n d e n t  P C R  r e a c t i o n s  a n d  t h e  n u m b e r  o f  
s o - c a l l e d  c o i n c i d e n t  s e q u e n c e s  w a s  d e t e r m i n e d  [ 3 5 , 4 5 ] .  I n  a l l  s u b s e t s ,  b o t h  y o u n g  a n d  
e l d e r l y ,  t h e  f r e q u e n c y  o f  c l o n o t y p e  s e q u e n c e s  f o u n d  i n  o n l y  o n e  o f  t h e  r e p l i c a t e s  w a s  t h e  
h i g h e s t ,  w h i l e  t h e  f r e q u e n c i e s  o f  c o i n c i d e n c e s  f o u n d  i n  2  o r  3  r e p l i c a t e s  w e r e  r e l a t i v e l y  
l o w  f o r  b o t h  T R G  a n d  T R D  ( S u p p l e m e n t a r y  F i g .  4 ) .  W h e n  c o m p a r i n g  y o u n g  a n d  e l d e r l y ,  
s m a l l  s h i f t s  l e a d i n g  t o  h i g h e r  n u m b e r s  o f  c o i n c i d e n c e s  i n  2  o r  3  r e p l i c a t e s  w e r e  s e e n  i n  
t h e  l a t t e r  ( S u p p l e m e n t a r y  F i g .  5 ) .  W e  t h e n  o n l y  f o c u s e d  o n  t h e  c o i n c i d e n c e s  p r e s e n t  i n  
a l l  t h r e e  r e p l i c a t e s ,  s i n c e  t h e s e  s e q u e n c e s  b e s t  r e f l e c t  t h e  i n d i v i d u a l s ’  r e p e r t o i r e  s e l e c -
t i o n .  E s p e c i a l l y  i n  t h e  e f f e c t o r  m e m o r y  p o p u l a t i o n  a b s o l u t e  n u m b e r s  o f  s e q u e n c e s  f o u n d  
i n  a l l  t h r e e  r e p l i c a t e s  w e r e  h i g h e r ,  w h i l e  i n  n a i v e  s u b s e t s  f r o m  b o t h  y o u n g  a n d  e l d e r l y  
t h e s e  n u m b e r s  w e r e  l o w e r ,  e x c e p t  f o r  a  f e w  c a s e s  ( S u p p l e m e n t a r y  T a b l e  5 ) .
T o  u n d e r s t a n d  i f  t h e  r e c u r r e n c e  o f  c l o n o t y p e s  w o u l d  b e  a s s o c i a t e d  w i t h  p a r t i c u l a r  
i n f e c t i o n s ,  w e  n e x t  e v a l u a t e d  r e c e p t o r  c l o n o t y p e s  l i n k e d  t o  p a t h o g e n s  s u c h  a s  
M y c o b a c t e r i u m  t u b e r c u l o s i s  [ 1 6 , 4 6 ]  a n d  h e r p e s v i r u s e s  s u c h  a s  c y t o m e g a l o v i r u s  ( C M V )  
[ 1 8 ] .  W h e r e a s  i n  o u r  h e a l t h y  c o n t r o l s  n o  M . t u b e r c u l o s i s - s p e c i f i c  c l o n o t y p e s  c o u l d  b e  
i d e n t i f i e d ,  C M V - s p e c i f i c  T R G  o r  T R D  c l o n o t y p e s  w e r e  f o u n d  i n  m o s t  c o n t r o l s ,  a n d  i n  o n e  
c a s e  e v e n  a  c o m p l e t e  C M V - s p e c i f i c  T C R γ δ  r e c e p t o r  c o u l d  b e  i d e n t i f i e d  ( d a t a  n o t  s h o w n ) .  
H o w e v e r ,  t h e r e  w e r e  n o  e v i d e n t  d i f f e r e n c e s  b e t w e e n  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s .  
F i n a l l y ,  a s  l e u k e m i c  T C R γ δ +  T  c e l l s  c a n  b e  a s s o c i a t e d  w i t h  s p e c i f i c  c l o n o t y p e s ,  w e  
r e t r o s p e c t i v e l y  r e v i e w e d  o u r  T C R γ δ +  T - L G L  l e u k e m i a  d a t a b a s e  o f  c l o n a l  T R G  /  T R D  
s e q u e n c e s  [ 1 3 , 4 6 ]  a n d  s e a r c h e d  f o r  t h e s e  L G L  c l o n o t y p e s  i n  t h e  n o r m a l  T C R γ δ +  T  c e l l  
r e p e r t o i r e  o f  y o u n g  a n d  e l d e r l y .  I n t e r e s t i n g l y ,  t w o  T C R γ δ +  T - L G L  l e u k e m i a - a s s o c i a t e d  
T R G  a n d  T R D  c l o n o t y p e s  w e r e  f o u n d  i n  f o u r  o l d e r  i n d i v i d u a l s  a n d  i n  i n  o n e  y o u n g  i n d i -
v i d u a l  ( T a b l e  1 ) .  T h e  V δ 3  –  J δ 1  r e c e p t o r  a s  i d e n t i f i e d  i n  T C R γ δ +  T - L G L  l e u k e m i a  c a s e  
1 2 - 0 9 8  w a s  i d e n t i f i e d  i n  o n e  y o u n g  i n d i v i d u a l  ( n a i v e  s u b s e t ,  2 6 - y e a r - o l d  f e m a l e ) ,  a n d  
i n  t h r e e  o l d e r  i n d i v i d u a l s  ( n a i v e  s u b s e t ,  5 6 - y e a r - o l d  m a l e ;  e f f e c t o r  s u b s e t ,  6 9 - y e a r - o l d  
f e m a l e  a n d  6 8 - y e a r - o l d  m a l e )  ( T a b l e  1 ) .  T h e  T C R γ δ +  T - L G L  l e u k e m i a  r e l a t e d  r e c e p t o r  
f r o m  c a s e  1 0 - 2 0 0  w a s  f o u n d  t w i c e  i n  o l d e r  i n d i v i d u a l s  ( n a i v e  s u b s e t ,  5 6 - y e a r - o l d  m a l e ;  
e f f e c t o r  s u b s e t ,  7 0 - y e a r - o l d  m a l e )  ( T a b l e  1 ) .  A l t h o u g h  t h e  n u m b e r s  a r e  l o w ,  t h e  f a c t  t h a t  
t w o  T C R γ δ +  T - L G L  l e u k e m i a  r e l a t e d  r e c e p t o r s  c o u l d  s p e c i f i c a l l y  b e  i d e n t i f i e d  i n  e f f e c t o r  
c e l l s  o f  e l d e r l y  w o u l d  s u p p o r t  t h e  i d e a  t h a t  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  o r i g i n a t e  f r o m  
t h e  n o r m a l  T C R γ δ  r e p e r t o i r e ,  e s p e c i a l l y  f r o m  a n t i g e n - e x p e r i e n c e d  T C R γ δ +  T  c e l l s  o f  




Ageing of the immune system has become increasingly important due to increased hygiene and higher life expectancies in the Western World [3,5,49]. Immunosenescence plays an additional role in shaping the immune repertoire. Shaping of the immune system during ontogeny and upon ageing relies on continuous antigenic exposures, varying from pathogens to cellular stress. In the current study we showed that (anti-genic) selection starts during early ontogeny in the thymus and cord blood samples and 
continues in circulating TCRγδ+ T cells in young and elderly individuals. While main-
taining diversity in the naive subsets, the effect of ageing is most significant in memory subsets with strong receptor skewing, and effector subsets.Following technical optimization of multiplex PCR assays for NGS analysis we 
demonstrated highly diverse TRG, but Vδ1-skewed TCRγδ+ T cell repertoires in pre-
cursor TCRγδ+ T cells from thymus and cord blood, with low inter-sample variation. 
This was in clear contrast to circulating mature TCRγδ+ T cells that showed Vγ9/Vδ2 
receptor skewing with high inter-sample variation and donor-specific patterns. As we 
recently showed significant effects of ageing on maturation profiles of TCRγδ+ T cells 
[48] we investigated the immune repertoire composition of different TCRγδ+ T cell sub-sets including naive, central, effector memory and effector cells. Even though the naive 
TCRγδ+ T cell population shrinks upon ageing [3,5,48], its diversity – being the primary 
source for mounting immune responses – was maintained in elderly individuals. To date, 
only one study documented the maintenance of the naive CD4+TCRαβ+ T cell repertoire until the age of 70, after which the repertoire profoundly declined [50] (reviewed by 




Ageing of the immune system has become increasingly important due to increased 
hygiene and higher life expectancies in the Western World [3,5,49]. Immunosenescence 
plays an additional role in shaping the immune repertoire. Shaping of the immune 
system during ontogeny and upon ageing relies on continuous antigenic exposures, 
varying from pathogens to cellular stress. In the current study we showed that (anti-
genic) selection starts during early ontogeny in the thymus and cord blood samples and 
continues in circulating TCRγδ+ T cells in young and elderly individuals. While main-
taining diversity in the naive subsets, the effect of ageing is most significant in memory 
subsets with strong receptor skewing, and effector subsets.
Following technical optimization of multiplex PCR assays for NGS analysis we 
demonstrated highly diverse TRG, but Vδ1-skewed TCRγδ+ T cell repertoires in pre-
cursor TCRγδ+ T cells from thymus and cord blood, with low inter-sample variation. 
This was in clear contrast to circulating mature TCRγδ+ T cells that showed Vγ9/Vδ2 
receptor skewing with high inter-sample variation and donor-specific patterns. As we 
recently showed significant effects of ageing on maturation profiles of TCRγδ+ T cells 
[48] we investigated the immune repertoire composition of different TCRγδ+ T cell sub-
sets including naive, central, effector memory and effector cells. Even though the naive 
TCRγδ+ T cell population shrinks upon ageing [3,5,48], its diversity – being the primary 
source for mounting immune responses – was maintained in elderly individuals. To date, 
only one study documented the maintenance of the naive CD4+TCRαβ+ T cell repertoire 
until the age of 70, after which the repertoire profoundly declined [50] (reviewed by 
[51]). These results are in keeping with our findings, although our cohort consisted of 
elderly until the age of 70, since 70 is the maximum age to donate blood at our national 
blood bank. It would however be interesting to also study healthy individuals >70 years 
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of age, but high volumes of blood are needed to obtain sufficient numbers of naive 
TCRγδ+ T cells complicate such studies. Furthermore, low cell numbers form limitations 
in studying the repertoire due to possibly low levels of input DNA. To overcome such limitations and to directly link overall receptor usage for both TRG and TRD loci e.g. 
single molecule-based assays could be applied. However, these assays require extensive optimization and validation experiments as well. 
Age-related differences were most evident in central and effector memory popula- tions: Vγ9 usage was highly important in young individuals, while a shift towards Vγ2, 
but also to other Vγ1-family genes was observed in effector memory TCRγδ+ T cells of 
elderly. The significant increase in Vγ2 usage in elderly was accompanied by a significant 
decrease in Vδ2 and increase in Vδ1 usage, collectively indicating a shift from Vγ9/Vδ2 
specificity in young to Vγ2/Vδ1 in elderly. These findings might suggest differences in 
antigenic selection, or might be due to underlying clonal expansion in these populations [52]. Furthermore, CMV is known to elicit Vδ1+ TCRγδ+ T cell-specific responses [17]. 
Additionally, we have recently demonstrated the effect of CMV on the TCRγδ+ T cell 
immune system, through increasing Vδ1+ TCRγδ+ T cells in elderly carrying CMV [48], 
and it has been shown that latent CMV carriage is related to the expansion of CMV spe- cific T cells [53]. By zooming in on the antigen-binding part, the CDR3 region, we could 
identify CMV specific CDR3 regions in a few donors, albeit without a significant effect 
of age. This could reflect high anti-CMV responses mounted by Vδ1+ TCRγδ+ T cells, 
although such responses were mainly observed in renal allograft recipients and not in healthy controls [17]. Given that CMV infects mainly fibroblasts and epithelial cells [54], 
and that the majority of Vδ1+ TCRγδ+ T cells reside in epithelial and mucosal tissues 
[55-57] these findings could indicate that healthy individuals have a local, rather than 
circulatory, protection by Vδ1+ TCRγδ+ T cells against CMV. 
Investigating the TRG / TRD repertoires of tissue-residing TCRγδ+ T cells is not only 
relevant for CMV-specific responses, but also for other local antigens contributing to 
the TCRγδ+ T cell repertoire. Although the ability of TCRγδ+ T cells moving in and out 
of tissues has not been proven yet, sequencing TCRγδ+ T cells from different tissues 
could provide insight in both residing, migrating and circulating properties, as well as in development of local immune repertoires and additional functions and specificities of 
TCRγδ+ T cells. 
We also examined other dominant TRG / TRD clonotypes, such as for M. tuberculo- sis, since TCRγδ+ T cells are known to elicit strong responses [16], but these were not 
identified. This could be related to the recruitment of our donors (mostly of Caucasian 
descent) via the national Dutch blood bank, and the fact that donors are tested prior to blood donation. Furthermore, open tuberculosis is not endemic in the Netherlands.
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N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
o f  a g e ,  b u t  h i g h  v o l u m e s  o f  b l o o d  a r e  n e e d e d  t o  o b t a i n  s u f f i c i e n t  n u m b e r s  o f  n a i v e  
T C R γ δ +  T  c e l l s  c o m p l i c a t e  s u c h  s t u d i e s .  F u r t h e r m o r e ,  l o w  c e l l  n u m b e r s  f o r m  l i m i t a t i o n s  
i n  s t u d y i n g  t h e  r e p e r t o i r e  d u e  t o  p o s s i b l y  l o w  l e v e l s  o f  i n p u t  D N A .  T o  o v e r c o m e  s u c h  
l i m i t a t i o n s  a n d  t o  d i r e c t l y  l i n k  o v e r a l l  r e c e p t o r  u s a g e  f o r  b o t h  T R G  a n d  T R D  l o c i  e . g .  
s i n g l e  m o l e c u l e - b a s e d  a s s a y s  c o u l d  b e  a p p l i e d .  H o w e v e r ,  t h e s e  a s s a y s  r e q u i r e  e x t e n s i v e  
o p t i m i z a t i o n  a n d  v a l i d a t i o n  e x p e r i m e n t s  a s  w e l l .  
A g e - r e l a t e d  d i f f e r e n c e s  w e r e  m o s t  e v i d e n t  i n  c e n t r a l  a n d  e f f e c t o r  m e m o r y  p o p u l a -
t i o n s :  V γ 9  u s a g e  w a s  h i g h l y  i m p o r t a n t  i n  y o u n g  i n d i v i d u a l s ,  w h i l e  a  s h i f t  t o w a r d s  V γ 2 ,  
b u t  a l s o  t o  o t h e r  V γ 1 - f a m i l y  g e n e s  w a s  o b s e r v e d  i n  e f f e c t o r  m e m o r y  T C R γ δ +  T  c e l l s  o f  
e l d e r l y .  T h e  s i g n i f i c a n t  i n c r e a s e  i n  V γ 2  u s a g e  i n  e l d e r l y  w a s  a c c o m p a n i e d  b y  a  s i g n i f i c a n t  
d e c r e a s e  i n  V δ 2  a n d  i n c r e a s e  i n  V δ 1  u s a g e ,  c o l l e c t i v e l y  i n d i c a t i n g  a  s h i f t  f r o m  V γ 9 / V δ 2  
s p e c i f i c i t y  i n  y o u n g  t o  V γ 2 / V δ 1  i n  e l d e r l y .  T h e s e  f i n d i n g s  m i g h t  s u g g e s t  d i f f e r e n c e s  i n  
a n t i g e n i c  s e l e c t i o n ,  o r  m i g h t  b e  d u e  t o  u n d e r l y i n g  c l o n a l  e x p a n s i o n  i n  t h e s e  p o p u l a t i o n s  
[ 5 2 ] .  F u r t h e r m o r e ,  C M V  i s  k n o w n  t o  e l i c i t  V δ 1 +  T C R γ δ +  T  c e l l - s p e c i f i c  r e s p o n s e s  [ 1 7 ] .  
A d d i t i o n a l l y ,  w e  h a v e  r e c e n t l y  d e m o n s t r a t e d  t h e  e f f e c t  o f  C M V  o n  t h e  T C R γ δ +  T  c e l l  
i m m u n e  s y s t e m ,  t h r o u g h  i n c r e a s i n g  V δ 1 +  T C R γ δ +  T  c e l l s  i n  e l d e r l y  c a r r y i n g  C M V  [ 4 8 ] ,  
a n d  i t  h a s  b e e n  s h o w n  t h a t  l a t e n t  C M V  c a r r i a g e  i s  r e l a t e d  t o  t h e  e x p a n s i o n  o f  C M V  s p e -
c i f i c  T  c e l l s  [ 5 3 ] .  B y  z o o m i n g  i n  o n  t h e  a n t i g e n - b i n d i n g  p a r t ,  t h e  C D R 3  r e g i o n ,  w e  c o u l d  
i d e n t i f y  C M V  s p e c i f i c  C D R 3  r e g i o n s  i n  a  f e w  d o n o r s ,  a l b e i t  w i t h o u t  a  s i g n i f i c a n t  e f f e c t  
o f  a g e .  T h i s  c o u l d  r e f l e c t  h i g h  a n t i - C M V  r e s p o n s e s  m o u n t e d  b y  V δ 1 +  T C R γ δ +  T  c e l l s ,  
a l t h o u g h  s u c h  r e s p o n s e s  w e r e  m a i n l y  o b s e r v e d  i n  r e n a l  a l l o g r a f t  r e c i p i e n t s  a n d  n o t  i n  
h e a l t h y  c o n t r o l s  [ 1 7 ] .  G i v e n  t h a t  C M V  i n f e c t s  m a i n l y  f i b r o b l a s t s  a n d  e p i t h e l i a l  c e l l s  [ 5 4 ] ,  
a n d  t h a t  t h e  m a j o r i t y  o f  V δ 1 +  T C R γ δ +  T  c e l l s  r e s i d e  i n  e p i t h e l i a l  a n d  m u c o s a l  t i s s u e s  
[ 5 5 - 5 7 ]  t h e s e  f i n d i n g s  c o u l d  i n d i c a t e  t h a t  h e a l t h y  i n d i v i d u a l s  h a v e  a  l o c a l ,  r a t h e r  t h a n  
c i r c u l a t o r y ,  p r o t e c t i o n  b y  V δ 1 +  T C R γ δ +  T  c e l l s  a g a i n s t  C M V .  
I n v e s t i g a t i n g  t h e  T R G  /  T R D  r e p e r t o i r e s  o f  t i s s u e - r e s i d i n g  T C R γ δ +  T  c e l l s  i s  n o t  o n l y  
r e l e v a n t  f o r  C M V - s p e c i f i c  r e s p o n s e s ,  b u t  a l s o  f o r  o t h e r  l o c a l  a n t i g e n s  c o n t r i b u t i n g  t o  
t h e  T C R γ δ +  T  c e l l  r e p e r t o i r e .  A l t h o u g h  t h e  a b i l i t y  o f  T C R γ δ +  T  c e l l s  m o v i n g  i n  a n d  o u t  
o f  t i s s u e s  h a s  n o t  b e e n  p r o v e n  y e t ,  s e q u e n c i n g  T C R γ δ +  T  c e l l s  f r o m  d i f f e r e n t  t i s s u e s  
c o u l d  p r o v i d e  i n s i g h t  i n  b o t h  r e s i d i n g ,  m i g r a t i n g  a n d  c i r c u l a t i n g  p r o p e r t i e s ,  a s  w e l l  a s  
i n  d e v e l o p m e n t  o f  l o c a l  i m m u n e  r e p e r t o i r e s  a n d  a d d i t i o n a l  f u n c t i o n s  a n d  s p e c i f i c i t i e s  o f  
T C R γ δ +  T  c e l l s .  
W e  a l s o  e x a m i n e d  o t h e r  d o m i n a n t  T R G  /  T R D  c l o n o t y p e s ,  s u c h  a s  f o r  M .  t u b e r c u l o -
s i s ,  s i n c e  T C R γ δ +  T  c e l l s  a r e  k n o w n  t o  e l i c i t  s t r o n g  r e s p o n s e s  [ 1 6 ] ,  b u t  t h e s e  w e r e  n o t  
i d e n t i f i e d .  T h i s  c o u l d  b e  r e l a t e d  t o  t h e  r e c r u i t m e n t  o f  o u r  d o n o r s  ( m o s t l y  o f  C a u c a s i a n  
d e s c e n t )  v i a  t h e  n a t i o n a l  D u t c h  b l o o d  b a n k ,  a n d  t h e  f a c t  t h a t  d o n o r s  a r e  t e s t e d  p r i o r  t o  
b l o o d  d o n a t i o n .  F u r t h e r m o r e ,  o p e n  t u b e r c u l o s i s  i s  n o t  e n d e m i c  i n  t h e  N e t h e r l a n d s .
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Curiously, TRG / TRD clonotypes derived from complete TCRγδ+ T-LGL leukemia 
receptors were identified in the healthy effector subset repertoire. These findings con-
firmed earlier correlations identified between TCRγδ+ T-LGL leukemia cells and healthy 
effector TCRγδ+ T cells [48] and highlight the fact that TCRγδ+ T-LGL is typically a disease that arises in effector cells of elderly. This also correlates with a recent study 
from Davey et al., in which they have shown that the Vδ1 population in CB is unfocused, while in adult PB clonal expansions could be found, which have direct differentiation from naive into effector phenotypes, together with the down-regulation of CD27. In con-
trast, Vδ2 cells maintained the invariant TCR expression observed from birth to adult-
hood. Linking these findings to our results, together with the effect of CMV upon ageing, 
could both give a suggestion for the increasing Vδ1 usage in elderly, possibly providing a source of clonopathies [58].The application of our optimized multiplex PCR assays for NGS analysis could also 
be applicable for other disease states, such as TCRγδ+ T cell lymphomas, or treatments, 
such as bone marrow transplantation (BMTx). TCRγδ+ T cells have been described to reconstitute in increased numbers after BMTx in acute leukemia patients [59]. It would be interesting to investigate to what extent the TRG / TRD repertoire has changed upon 
BMTx, and how the TCRγδ+ T cell compartment regenerates. Also, circulating TCRγδ+ T cells have been described in metastatic melanomas, in which it would be interesting 
to distinguish pro- and anti-tumor specific TCRγδ+ T cells [60], the latter particularly in view of anti-tumor effects [61,62]. 
In summary, using an optimized NGS assay we identified specific TRG / TRD reper-
toires during ontogeny and upon ageing. Despite strong individual-specific repertoire 
compositions, significant differences in Vγ and Vδ gene usage were identified upon 
ageing in specifically memory TCRγδ+ T cell subsets. These age-dependent effects caused 
shifts in Vγ9/Vδ2 in young, to Vγ2/Vδ1 dominance in elderly. Additionally, TRG / TRD 
clonotypes related to TCRγδ+ T-LGL leukemia were identified in normal effector TCRγδ+ 
T cells of especially elderly individuals, strongly suggesting that TCRγδ+ T-LGL leukemia 
originate from normal circulating, antigen-experienced effector TCRγδ+ T cells.
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Supplementary Figure 1. Gating strategies for sorting experiments of TCRγδ+ T cell subsets.General gating strategies for determining viable cells using FSC/SSC, single cells using FSC-H/FSC-A, leukocytes 
using CD45, T cells (CD3+/CD45+) and TCRγδ+ T cells (TCRγδ+TCRαβ-) (a). Further determination of CD45 
splice variants CD45RA vs. CD45RO to sort within CD45RA+CD45RO- for naive (CD27+CD197+) and effector 
(CD27-CD197-) TCRγδ+ T cells, and within CD45RA-CD45RO+ for central memory (CD27+CD197+) and 
effector memory (CD27-CD197-) TCRγδ+ T cells (b). Antibodies used for these experiments are summarized in Supplementary Table 1.
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Supplementary Figure 1. Gating strategies for sorting experiments of TCRγδ+ T cell subsets.
General gating strategies for determining viable cells using FSC/SSC, single cells using FSC-H/FSC-A, leukocytes 
using CD45, T cells (CD3+/CD45+) and TCRγδ+ T cells (TCRγδ+TCRαβ-) (a). Further determination of CD45 
splice variants CD45RA vs. CD45RO to sort within CD45RA+CD45RO- for naive (CD27+CD197+) and effector 
(CD27-CD197-) TCRγδ+ T cells, and within CD45RA-CD45RO+ for central memory (CD27+CD197+) and 
effector memory (CD27-CD197-) TCRγδ+ T cells (b). Antibodies used for these experiments are summarized 
in Supplementary Table 1.
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Supplementary Figure 2. Relative TCRγδ+ T cell subset distributions in young and elderly individuals.
Mean frequencies of naive (CD45RA+CD45RO-CD27+CD197+), central memory (CD45RA-
CD45RO+CD27+CD197+), effector memory (CD45RA-CD45RO+CD27-CD197-) and effector (CD45RA+CD45RO-
CD27-CD197-) TCRγδ+ T cells as analyzed during sorting experiments. Absolute cell numbers and frequencies 
are summarized per donor in Supplementary Table 6.
4
1 4 5
N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  
S u p p l e m e n t a r y  F i g u r e  2 .  R e l a t i v e  T C R γ δ +  T  c e l l  s u b s e t  d i s t r i b u t i o n s  i n  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s .
M e a n  f r e q u e n c i e s  o f  n a i v e  ( C D 4 5 R A + C D 4 5 R O - C D 2 7 + C D 1 9 7 + ) ,  c e n t r a l  m e m o r y  ( C D 4 5 R A -
C D 4 5 R O + C D 2 7 + C D 1 9 7 + ) ,  e f f e c t o r  m e m o r y  ( C D 4 5 R A - C D 4 5 R O + C D 2 7 - C D 1 9 7 - )  a n d  e f f e c t o r  ( C D 4 5 R A + C D 4 5 R O -
C D 2 7 - C D 1 9 7 - )  T C R γ δ +  T  c e l l s  a s  a n a l y z e d  d u r i n g  s o r t i n g  e x p e r i m e n t s .  A b s o l u t e  c e l l  n u m b e r s  a n d  f r e q u e n c i e s  
a r e  s u m m a r i z e d  p e r  d o n o r  i n  S u p p l e m e n t a r y  T a b l e  6 .
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Supplementary Figure 3 (see also the next three pages). Circoletto visualizations of naive, central 
memory, effector memory and effector subsets of young and elderly individuals.V-J distributions of TRG young (a), TRG elderly (b), and TRD young (c) and TRD elderly (d) rearrangements per donor and subset of young and elderly individuals. Figures were made using the Circoletto online software tool (www.circos.ca, [35]). Each band represents a V-J rearrangement, with different colors reflecting different V gene usage.
Chapter 4
146
Supplementary Figure 3 (see also the next three pages). Circoletto visualizations of naive, central 
memory, effector memory and effector subsets of young and elderly individuals.
V-J distributions of TRG young (a), TRG elderly (b), and TRD young (c) and TRD elderly (d) rearrangements 
per donor and subset of young and elderly individuals. Figures were made using the Circoletto online software 
tool (www.circos.ca, [35]). Each band represents a V-J rearrangement, with different colors reflecting different 
V gene usage.
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Supplementary Figure 4. Frequencies of coincidence sequences in 1, 2 or 3 PCR replicates per subset 
and age group.Box-whiskers plots (range 10-90%) depicting numbers of sequences present in either one (#1), two (#2) or three (#3) PCR replicates within all unique sequences based on V-J combination and CDR3 region on nucleotide level. Error bars indicate the SD.
Supplementary Figure 5. TRG and TRD CDR3-length distributions in thymus (Thy) and cord blood (CB) 
samples.Mean frequencies of four replicates per Thy and CB sample are depicted for TRG and TRD CDR3-regions (a). CB samples showed more prominent peaks in TRG CDR3-lengths, while TRD CDR3-regions showed relatively normal distributions (b). Number of replicates per sample, N=3/4.
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Supplementary Figure 4. Frequencies of coincidence sequences in 1, 2 or 3 PCR replicates per subset 
and age group.
Box-whiskers plots (range 10-90%) depicting numbers of sequences present in either one (#1), two (#2) 
or three (#3) PCR replicates within all unique sequences based on V-J combination and CDR3 region on 
nucleotide level. Error bars indicate the SD.
Supplementary Figure 5. TRG and TRD CDR3-length distributions in thymus (Thy) and cord blood (CB) 
samples.
Mean frequencies of four replicates per Thy and CB sample are depicted for TRG and TRD CDR3-regions (a). 
CB samples showed more prominent peaks in TRG CDR3-lengths, while TRD CDR3-regions showed relatively 
normal distributions (b). Number of replicates per sample, N=3/4.
4151
NGS analysis of the ageing human TCRγδ+ T cell repertoire 
4
1 5 1
N G S  a n a l y s i s  o f  t h e  a g e i n g  h u m a n  T C R γ δ +  T  c e l l  r e p e r t o i r e  

Part II Aberrant TCRγδ+ T cells
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A b e r r a n t  T C R γ δ +  T  c e l l s
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ABSTRACT
Clonal CD8+ T cell receptor (TCR)αβ+ T cell large granular lympho-cyte (T-LGL) proliferations constitute the most common subtype of T-LGL leukemia. Although the etiology of T-LGL leukemia is largely unknown, it has been hypothesized that chronic antigenic stimulation contributes to the pathogenesis of this disorder. In the present study, we explored 
the association between expanded TCR-Vβ and TCR-Vα clonotypes in a 
cohort of 26 CD8+TCRαβ+ T-LGL leukemia patients, in conjunction with 
the HLA-ABC genotype, to find indications for common antigenic stimuli. In addition, we applied purpose-built sophisticated computational tools 
for an in-depth evaluation of clustering of TCRβ (TCRB) complementarity determining region 3 (CDR3) amino-acid LGL clonotypes. We observed 
a lack of clear TCRA and TCRB CDR3 homology in CD8+TCRαβ+ T-LGL, with only low level similarity between small numbers of cases. This is 
in strong contrast to the homology that is seen in CD4+TCRαβ+ T-LGL 
and TCRγδ+ T-LGL and thus underlines the idea that the LGL types have 
different etiopathogenesis. The heterogeneity of clonal CD8+TCRαβ+ T-LGL proliferations might in fact suggest that multiple pathogens or autoantigens are involved.
Keyword(s): T-LGL, TCRB, TCRA, CDR3, HLA, antigenic stimulation.
ABSTRACT
Clonal CD8+ T cell receptor (TCR)αβ+ T cell large granular lympho-
cyte (T-LGL) proliferations constitute the most common subtype of T-LGL 
leukemia. Although the etiology of T-LGL leukemia is largely unknown, 
it has been hypothesized that chronic antigenic stimulation contributes 
to the pathogenesis of this disorder. In the present study, we explored 
the association between expanded TCR-Vβ and TCR-Vα clonotypes in a 
cohort of 26 CD8+TCRαβ+ T-LGL leukemia patients, in conjunction with 
the HLA-ABC genotype, to find indications for common antigenic stimuli. 
In addition, we applied purpose-built sophisticated computational tools 
for an in-depth evaluation of clustering of TCRβ (TCRB) complementarity 
determining region 3 (CDR3) amino-acid LGL clonotypes. We observed 
a lack of clear TCRA and TCRB CDR3 homology in CD8+TCRαβ+ T-LGL, 
with only low level similarity between small numbers of cases. This is 
in strong contrast to the homology that is seen in CD4+TCRαβ+ T-LGL 
and TCRγδ+ T-LGL and thus underlines the idea that the LGL types have 
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T-LGL proliferations might in fact suggest that multiple pathogens or 
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INTRODUCTION
Large granular lymphocyte (LGL) proliferations are derived from normal cytotoxic LGL cells, which comprise 10–15% of peripheral blood (PB) mononuclear cells (MNCs) 
[1–3]. The majority of the normal LGL cells (85%) are of NK cell origin, and a minority is 
derived from mature (post-thymic) T lymphocytes. Lymphoproliferations of LGLs range from activated polyclonal expansions to clinically overt leukemias. T cell LGL (T-LGL) 
leukemia is the most common subtype, representing ~85% of all LGL leukemia cases diagnosed in western countries. 
T-LGL leukemia is a rare and heterogeneous disorder and about one-third of patients is asymptomatic at diagnosis. The main clinical manifestations are related to chronic 
neutropenia and/or anemia [3–7]. There is a frequent association with a wide variety 
of autoimmune diseases (33%) and other malignancies (13%) [8]. Its diagnosis is based on a persistent (>6 months) morphologically and/or immunophenotypically increased 
clonal CD3+CD57+ LGL population in PB, usually >2 x 109/l, though a lower count (range 0.4–2 x 109/l) may also be compatible with a diagnosis of T-LGL leukemia [9,10]. 
T-LGL leukemias can be divided into three groups on the basis of their immunopheno- typical and molecular characteristics: CD8+, CD4+ and T cell receptor (TCR)γδ+ T-LGL. 
Monoclonal CD8+TCRαβ+ T-LGL leukemia forms the largest subgroup (80–90%) of 
monoclonal T-LGL lymphoproliferative disorders [11]. It presents in elderly individuals (mean age 60 years) and generally has an indolent clinical course [3,12]. However, cases 
with a more aggressive clinical course that are associated with a CD3+CD8+CD56+CD57- 
phenotype have been reported as well [13,14]. CD3+CD4+TCRαβ+ T-LGL leukemia and 
CD3+TCRγδ+ T-LGL leukemia are far less common (<5 and 5–10%, respectively), but a 
considerable number of cases from both disease entities have recently been described in detail [15,16]. 
Clonality assessment via PCR-based studies of TCR genes is essential to discriminate true T-LGL leukemia from other reactive proliferations. It should be stressed that the 
finding of clonality does not necessarily imply malignancy in this disease, since most 
cases are indolent and do not require therapy. Therefore, patients are often diagnosed as having T cell clonopathy of undetermined significance [1,4,17]. 
Although the etiology of T-LGL leukemia is still largely unknown, it has been hypothe- sized that chronic antigenic stimulation contributes to the pathogenesis of this disorder. 
This is in line with the activation-associated effector phenotype and the skewed TCR expression pattern found in T-LGL leukemia. An exaggerated response to immunodomi-
nant autoantigens or viral/bacterial antigens might be the initial step in the development of this disorder [18–21]. Recently, the T cell repertoire has been demonstrated to be 
dynamic in a large proportion (37%) of T-LGL leukemia patients, a phenomenon referred 
5
1 5 7
A n t i g e n i c  s e l e c t i o n  i n  T - L G L  l e u k e m i a  i m m u n o p a t h o g e n e s i s  
I N T R O D U C T I O N
L a r g e  g r a n u l a r  l y m p h o c y t e  ( L G L )  p r o l i f e r a t i o n s  a r e  d e r i v e d  f r o m  n o r m a l  c y t o t o x i c  
L G L  c e l l s ,  w h i c h  c o m p r i s e  1 0 – 1 5 %  o f  p e r i p h e r a l  b l o o d  ( P B )  m o n o n u c l e a r  c e l l s  ( M N C s )  
[ 1 – 3 ] .  T h e  m a j o r i t y  o f  t h e  n o r m a l  L G L  c e l l s  ( 8 5 % )  a r e  o f  N K  c e l l  o r i g i n ,  a n d  a  m i n o r i t y  i s  
d e r i v e d  f r o m  m a t u r e  ( p o s t - t h y m i c )  T  l y m p h o c y t e s .  L y m p h o p r o l i f e r a t i o n s  o f  L G L s  r a n g e  
f r o m  a c t i v a t e d  p o l y c l o n a l  e x p a n s i o n s  t o  c l i n i c a l l y  o v e r t  l e u k e m i a s .  T  c e l l  L G L  ( T - L G L )  
l e u k e m i a  i s  t h e  m o s t  c o m m o n  s u b t y p e ,  r e p r e s e n t i n g  ~ 8 5 %  o f  a l l  L G L  l e u k e m i a  c a s e s  
d i a g n o s e d  i n  w e s t e r n  c o u n t r i e s .  
T - L G L  l e u k e m i a  i s  a  r a r e  a n d  h e t e r o g e n e o u s  d i s o r d e r  a n d  a b o u t  o n e - t h i r d  o f  p a t i e n t s  
i s  a s y m p t o m a t i c  a t  d i a g n o s i s .  T h e  m a i n  c l i n i c a l  m a n i f e s t a t i o n s  a r e  r e l a t e d  t o  c h r o n i c  
n e u t r o p e n i a  a n d / o r  a n e m i a  [ 3 – 7 ] .  T h e r e  i s  a  f r e q u e n t  a s s o c i a t i o n  w i t h  a  w i d e  v a r i e t y  
o f  a u t o i m m u n e  d i s e a s e s  ( 3 3 % )  a n d  o t h e r  m a l i g n a n c i e s  ( 1 3 % )  [ 8 ] .  I t s  d i a g n o s i s  i s  b a s e d  
o n  a  p e r s i s t e n t  ( > 6  m o n t h s )  m o r p h o l o g i c a l l y  a n d / o r  i m m u n o p h e n o t y p i c a l l y  i n c r e a s e d  
c l o n a l  C D 3 + C D 5 7 +  L G L  p o p u l a t i o n  i n  P B ,  u s u a l l y  > 2  x  1 0
9
/ l ,  t h o u g h  a  l o w e r  c o u n t  
( r a n g e  0 . 4 – 2  x  1 0
9
/ l )  m a y  a l s o  b e  c o m p a t i b l e  w i t h  a  d i a g n o s i s  o f  T - L G L  l e u k e m i a  [ 9 , 1 0 ] .  
T - L G L  l e u k e m i a s  c a n  b e  d i v i d e d  i n t o  t h r e e  g r o u p s  o n  t h e  b a s i s  o f  t h e i r  i m m u n o p h e n o -
t y p i c a l  a n d  m o l e c u l a r  c h a r a c t e r i s t i c s :  C D 8 + ,  C D 4 +  a n d  T  c e l l  r e c e p t o r  ( T C R ) γ δ +  T - L G L .  
M o n o c l o n a l  C D 8 + T C R α β +  T - L G L  l e u k e m i a  f o r m s  t h e  l a r g e s t  s u b g r o u p  ( 8 0 – 9 0 % )  o f  
m o n o c l o n a l  T - L G L  l y m p h o p r o l i f e r a t i v e  d i s o r d e r s  [ 1 1 ] .  I t  p r e s e n t s  i n  e l d e r l y  i n d i v i d u a l s  
( m e a n  a g e  6 0  y e a r s )  a n d  g e n e r a l l y  h a s  a n  i n d o l e n t  c l i n i c a l  c o u r s e  [ 3 , 1 2 ] .  H o w e v e r ,  c a s e s  
w i t h  a  m o r e  a g g r e s s i v e  c l i n i c a l  c o u r s e  t h a t  a r e  a s s o c i a t e d  w i t h  a  C D 3 + C D 8 + C D 5 6 + C D 5 7 -  
p h e n o t y p e  h a v e  b e e n  r e p o r t e d  a s  w e l l  [ 1 3 , 1 4 ] .  C D 3 + C D 4 + T C R α β +  T - L G L  l e u k e m i a  a n d  
C D 3 + T C R γ δ +  T - L G L  l e u k e m i a  a r e  f a r  l e s s  c o m m o n  ( < 5  a n d  5 – 1 0 % ,  r e s p e c t i v e l y ) ,  b u t  a  
c o n s i d e r a b l e  n u m b e r  o f  c a s e s  f r o m  b o t h  d i s e a s e  e n t i t i e s  h a v e  r e c e n t l y  b e e n  d e s c r i b e d  
i n  d e t a i l  [ 1 5 , 1 6 ] .  
C l o n a l i t y  a s s e s s m e n t  v i a  P C R - b a s e d  s t u d i e s  o f  T C R  g e n e s  i s  e s s e n t i a l  t o  d i s c r i m i n a t e  
t r u e  T - L G L  l e u k e m i a  f r o m  o t h e r  r e a c t i v e  p r o l i f e r a t i o n s .  I t  s h o u l d  b e  s t r e s s e d  t h a t  t h e  
f i n d i n g  o f  c l o n a l i t y  d o e s  n o t  n e c e s s a r i l y  i m p l y  m a l i g n a n c y  i n  t h i s  d i s e a s e ,  s i n c e  m o s t  
c a s e s  a r e  i n d o l e n t  a n d  d o  n o t  r e q u i r e  t h e r a p y .  T h e r e f o r e ,  p a t i e n t s  a r e  o f t e n  d i a g n o s e d  
a s  h a v i n g  T  c e l l  c l o n o p a t h y  o f  u n d e t e r m i n e d  s i g n i f i c a n c e  [ 1 , 4 , 1 7 ] .  
A l t h o u g h  t h e  e t i o l o g y  o f  T - L G L  l e u k e m i a  i s  s t i l l  l a r g e l y  u n k n o w n ,  i t  h a s  b e e n  h y p o t h e -
s i z e d  t h a t  c h r o n i c  a n t i g e n i c  s t i m u l a t i o n  c o n t r i b u t e s  t o  t h e  p a t h o g e n e s i s  o f  t h i s  d i s o r d e r .  
T h i s  i s  i n  l i n e  w i t h  t h e  a c t i v a t i o n - a s s o c i a t e d  e f f e c t o r  p h e n o t y p e  a n d  t h e  s k e w e d  T C R  
e x p r e s s i o n  p a t t e r n  f o u n d  i n  T - L G L  l e u k e m i a .  A n  e x a g g e r a t e d  r e s p o n s e  t o  i m m u n o d o m i -
n a n t  a u t o a n t i g e n s  o r  v i r a l / b a c t e r i a l  a n t i g e n s  m i g h t  b e  t h e  i n i t i a l  s t e p  i n  t h e  d e v e l o p m e n t  
o f  t h i s  d i s o r d e r  [ 1 8 – 2 1 ] .  R e c e n t l y ,  t h e  T  c e l l  r e p e r t o i r e  h a s  b e e n  d e m o n s t r a t e d  t o  b e  
d y n a m i c  i n  a  l a r g e  p r o p o r t i o n  ( 3 7 % )  o f  T - L G L  l e u k e m i a  p a t i e n t s ,  a  p h e n o m e n o n  r e f e r r e d  
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to as “clonal drift” [22]. This supports the hypothesis that extreme clonal evolution is the result of a polarized reactive process. On top of that, secondary molecular events are assumed to be required to establish the full leukemic phenotype of the chronically anti-gen stimulated T-LGL population. Those events especially lead to dysregulated apoptosis 
and constitutively activation of multiple cell survival pathways [11,12,23–26]. To further substantiate the potential involvement of a common antigen in driving development of clonal T-LGL proliferations, the complementarity determining region 3 (CDR3) sequences of the rearranged TCR genes are being analyzed. The CDR3 region of 
the TCR molecule has the highest antigenic specificity and directly binds to the antigenic peptide presented in the context of HLA [27]. Garrido et al. [28] demonstrated strikingly 
similar motifs in CDR3 TCR-Vβ13 sequences in 42% of CD4+TCRαβ+ T-LGL leukemia 
cases and a clear association with the HLA-DR*0701 genotype. Interestingly, highly 
similar CDR3 sequences could also be detected in TCRγ (TCRG) and TCRδ (TCRD) genes 
in nearly half of patients diagnosed with TCRγδ+ T-LGL leukemia, supporting a common antigen-driven origin of this disorder [16]. 
In CD8+TCRαβ+ T-LGL leukemia non-random clonal selection has been suggested [18,29], even though no consistent single structural homologous motif could be detected 
in CDR3 sequences of TCRβ (TCRB) genes, The seeming lack of such identical TCR speci-
ficities could however also be explained by the diverse HLA background of these patients. 
Furthermore, the TCRα chain might have an important role next to the TCRβ chain, espe-
cially in the initial phase of high-affinity clonal TCR selection [30]. However, the CDR3 
regions of the TCRα (TCRA) genes have not been extensively studied in CD8+TCRαβ+ T-LGL leukemia. In the present study, we therefore explored the existence of a potential association between CDR3 sequences of both the TCRA and TCRB clonotypes in a cohort of 26 
patients diagnosed with CD8+TCRαβ+ T-LGL leukemia in conjunction with the HLA genotype. In addition, we applied purpose-built sophisticated computational tools, 
specifically developed for sequence pattern discovery in CDR3 amino-acid sequences to evaluate clustering of a large number of TCRB CDR3 amino-acid clonotypes of 
CD8+TCRαβ+ T-LGL leukemia patients. 
MATERIALS & METHODS
Patients and cell samples
PB and/or bone marrow (BM) samples from 26 patients with CD8+TCRαβ+ T-LGL leukemia were obtained. The diagnosis of T-LGL leukemia was established by clinical 
and laboratory parameters as defined previously [7,9,31]. Patients with a persistent (>6 
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to as “clonal drift” [22]. This supports the hypothesis that extreme clonal evolution is the 
result of a polarized reactive process. On top of that, secondary molecular events are 
assumed to be required to establish the full leukemic phenotype of the chronically anti-
gen stimulated T-LGL population. Those events especially lead to dysregulated apoptosis 
and constitutively activation of multiple cell survival pathways [11,12,23–26]. 
To further substantiate the potential involvement of a common antigen in driving 
development of clonal T-LGL proliferations, the complementarity determining region 3 
(CDR3) sequences of the rearranged TCR genes are being analyzed. The CDR3 region of 
the TCR molecule has the highest antigenic specificity and directly binds to the antigenic 
peptide presented in the context of HLA [27]. Garrido et al. [28] demonstrated strikingly 
similar motifs in CDR3 TCR-Vβ13 sequences in 42% of CD4+TCRαβ+ T-LGL leukemia 
cases and a clear association with the HLA-DR*0701 genotype. Interestingly, highly 
similar CDR3 sequences could also be detected in TCRγ (TCRG) and TCRδ (TCRD) genes 
in nearly half of patients diagnosed with TCRγδ+ T-LGL leukemia, supporting a common 
antigen-driven origin of this disorder [16]. 
In CD8+TCRαβ+ T-LGL leukemia non-random clonal selection has been suggested 
[18,29], even though no consistent single structural homologous motif could be detected 
in CDR3 sequences of TCRβ (TCRB) genes, The seeming lack of such identical TCR speci-
ficities could however also be explained by the diverse HLA background of these patients. 
Furthermore, the TCRα chain might have an important role next to the TCRβ chain, espe-
cially in the initial phase of high-affinity clonal TCR selection [30]. However, the CDR3 
regions of the TCRα (TCRA) genes have not been extensively studied in CD8+TCRαβ+ 
T-LGL leukemia. 
In the present study, we therefore explored the existence of a potential association 
between CDR3 sequences of both the TCRA and TCRB clonotypes in a cohort of 26 
patients diagnosed with CD8+TCRαβ+ T-LGL leukemia in conjunction with the HLA 
genotype. In addition, we applied purpose-built sophisticated computational tools, 
specifically developed for sequence pattern discovery in CDR3 amino-acid sequences 
to evaluate clustering of a large number of TCRB CDR3 amino-acid clonotypes of 
CD8+TCRαβ+ T-LGL leukemia patients. 
MATERIALS & METHODS
Patients and cell samples
PB and/or bone marrow (BM) samples from 26 patients with CD8+TCRαβ+ T-LGL 
leukemia were obtained. The diagnosis of T-LGL leukemia was established by clinical 
and laboratory parameters as defined previously [7,9,31]. Patients with a persistent (>6 
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months) and increased (>1 x 109/l) monoclonal CD3+CD8+TCRαβ+ T-LGL proliferation in PB were included. All patient samples were obtained according to the Helsinki decla-
ration following guidelines of the Medical Ethics Committee of Erasmus MC, University Medical Center (Rotterdam, The Netherlands). PB/BM MNCs were isolated by Ficoll-
Paque (density: 1.077 g/ml; Pharmacia, Uppsala, Sweden) centrifugation and were used for DNA isolation and RNA isolation. Immunophenotyping was performed on whole PB 
or BM samples and occasionally on MNC fractions. Cytomorphological May-Grünwald- Giemsa staining of PB smears was used for morphological evaluation of LGLs. HLA 
genotyping for HLA-ABC was performed by Luminex-based SSOP-PCR techniques (One Lambda Inc., Canoga Park, CA, USA). 
Immunophenotypical analysis 
Cells were analyzed for membrane expression using a routine panel of monoclonal antibodies, including CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, anti-TCRαβ 
(BMA031 and WT31), anti-TCRγδ (11F2) and anti- HLA-DR. Immunofluorescence stain- ings were performed as described [32] and evaluated on a FACSCalibur or FACSCanto II 
(BD Biosciences, San Jose, CA, USA) flow cytometer. Data analysis was performed using 
CellQuest and Paint-A-Gate Pro software (BD Biosciences). The PB and/or BM samples 
were studied in more detail for Vβ domain expression to quantify the contribution of 
each Vβ family to the CD8+ lymphocyte population. To this end, flow-cytometric anal- ysis was performed using the IO Test Beta Mark kit (Beckman Coulter, Brea, CA, USA) 
as described [32]. Samples in which the Vβ restriction of the expansion could not be 
identified by flow cytometry were analyzed by TCRB RT–PCR as described [33]. 
DNA and RNA isolation and cDNA synthesis 
High-molecular weight DNA from fresh or frozen PB MNCs was extracted using a phenol-chloroform extraction-based protocol, followed by ethanol precipitation and 
resolution in Tris-EDTA buffer [34]. In a subset of cases, DNA was isolated using the GenElute Mammalian Genomic DNA miniprep kit (Sigma-Aldrich, St Louis, MO, USA) 
according to the manufacturer’s protocol. Total RNA was extracted from fresh or frozen PB and/or BM MNCs from patients and reverse transcribed into cDNA as previously 
described [35]. cDNA quality was checked using ABL as a control gene. 
TCRA and TCRB gene rearrangement analysis 
For TCRA gene rearrangement analysis, cDNA was amplified using newly developed 
TCRA primers: one constant region reverse primer (Cα) and 54 different Vα fami- ly-specific forward primers distributed over 5 different multiplex tubes; each of these 
multiplex contained 10 (TCRA tube B) or 11 (TCRA tubes A, C, D and E) Vα primers 
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A n t i g e n i c  s e l e c t i o n  i n  T - L G L  l e u k e m i a  i m m u n o p a t h o g e n e s i s  
m o n t h s )  a n d  i n c r e a s e d  ( > 1  x  1 0
9
/ l )  m o n o c l o n a l  C D 3 + C D 8 + T C R α β +  T - L G L  p r o l i f e r a t i o n  
i n  P B  w e r e  i n c l u d e d .  A l l  p a t i e n t  s a m p l e s  w e r e  o b t a i n e d  a c c o r d i n g  t o  t h e  H e l s i n k i  d e c l a -
r a t i o n  f o l l o w i n g  g u i d e l i n e s  o f  t h e  M e d i c a l  E t h i c s  C o m m i t t e e  o f  E r a s m u s  M C ,  U n i v e r s i t y  
M e d i c a l  C e n t e r  ( R o t t e r d a m ,  T h e  N e t h e r l a n d s ) .  P B / B M  M N C s  w e r e  i s o l a t e d  b y  F i c o l l -
P a q u e  ( d e n s i t y :  1 . 0 7 7  g / m l ;  P h a r m a c i a ,  U p p s a l a ,  S w e d e n )  c e n t r i f u g a t i o n  a n d  w e r e  u s e d  
f o r  D N A  i s o l a t i o n  a n d  R N A  i s o l a t i o n .  I m m u n o p h e n o t y p i n g  w a s  p e r f o r m e d  o n  w h o l e  P B  
o r  B M  s a m p l e s  a n d  o c c a s i o n a l l y  o n  M N C  f r a c t i o n s .  C y t o m o r p h o l o g i c a l  M a y - G r ü n w a l d -  
G i e m s a  s t a i n i n g  o f  P B  s m e a r s  w a s  u s e d  f o r  m o r p h o l o g i c a l  e v a l u a t i o n  o f  L G L s .  H L A  
g e n o t y p i n g  f o r  H L A - A B C  w a s  p e r f o r m e d  b y  L u m i n e x - b a s e d  S S O P - P C R  t e c h n i q u e s  ( O n e  
L a m b d a  I n c . ,  C a n o g a  P a r k ,  C A ,  U S A ) .  
I m m u n o p h e n o t y p i c a l  a n a l y s i s  
C e l l s  w e r e  a n a l y z e d  f o r  m e m b r a n e  e x p r e s s i o n  u s i n g  a  r o u t i n e  p a n e l  o f  m o n o c l o n a l  
a n t i b o d i e s ,  i n c l u d i n g  C D 2 ,  C D 3 ,  C D 4 ,  C D 5 ,  C D 7 ,  C D 8 ,  C D 1 6 ,  C D 5 6 ,  C D 5 7 ,  a n t i - T C R α β  
( B M A 0 3 1  a n d  W T 3 1 ) ,  a n t i - T C R γ δ  ( 1 1 F 2 )  a n d  a n t i -  H L A - D R .  I m m u n o f l u o r e s c e n c e  s t a i n -
i n g s  w e r e  p e r f o r m e d  a s  d e s c r i b e d  [ 3 2 ]  a n d  e v a l u a t e d  o n  a  F A C S C a l i b u r  o r  F A C S C a n t o  I I  
( B D  B i o s c i e n c e s ,  S a n  J o s e ,  C A ,  U S A )  f l o w  c y t o m e t e r .  D a t a  a n a l y s i s  w a s  p e r f o r m e d  u s i n g  
C e l l Q u e s t  a n d  P a i n t - A - G a t e  P r o  s o f t w a r e  ( B D  B i o s c i e n c e s ) .  T h e  P B  a n d / o r  B M  s a m p l e s  
w e r e  s t u d i e d  i n  m o r e  d e t a i l  f o r  V β  d o m a i n  e x p r e s s i o n  t o  q u a n t i f y  t h e  c o n t r i b u t i o n  o f  
e a c h  V β  f a m i l y  t o  t h e  C D 8 +  l y m p h o c y t e  p o p u l a t i o n .  T o  t h i s  e n d ,  f l o w - c y t o m e t r i c  a n a l -
y s i s  w a s  p e r f o r m e d  u s i n g  t h e  I O  T e s t  B e t a  M a r k  k i t  ( B e c k m a n  C o u l t e r ,  B r e a ,  C A ,  U S A )  
a s  d e s c r i b e d  [ 3 2 ] .  S a m p l e s  i n  w h i c h  t h e  V β  r e s t r i c t i o n  o f  t h e  e x p a n s i o n  c o u l d  n o t  b e  
i d e n t i f i e d  b y  f l o w  c y t o m e t r y  w e r e  a n a l y z e d  b y  T C R B  R T – P C R  a s  d e s c r i b e d  [ 3 3 ] .  
D N A  a n d  R N A  i s o l a t i o n  a n d  c D N A  s y n t h e s i s  
H i g h - m o l e c u l a r  w e i g h t  D N A  f r o m  f r e s h  o r  f r o z e n  P B  M N C s  w a s  e x t r a c t e d  u s i n g  a  
p h e n o l - c h l o r o f o r m  e x t r a c t i o n - b a s e d  p r o t o c o l ,  f o l l o w e d  b y  e t h a n o l  p r e c i p i t a t i o n  a n d  
r e s o l u t i o n  i n  T r i s - E D T A  b u f f e r  [ 3 4 ] .  I n  a  s u b s e t  o f  c a s e s ,  D N A  w a s  i s o l a t e d  u s i n g  t h e  
G e n E l u t e  M a m m a l i a n  G e n o m i c  D N A  m i n i p r e p  k i t  ( S i g m a - A l d r i c h ,  S t  L o u i s ,  M O ,  U S A )  
a c c o r d i n g  t o  t h e  m a n u f a c t u r e r ’ s  p r o t o c o l .  T o t a l  R N A  w a s  e x t r a c t e d  f r o m  f r e s h  o r  f r o z e n  
P B  a n d / o r  B M  M N C s  f r o m  p a t i e n t s  a n d  r e v e r s e  t r a n s c r i b e d  i n t o  c D N A  a s  p r e v i o u s l y  
d e s c r i b e d  [ 3 5 ] .  c D N A  q u a l i t y  w a s  c h e c k e d  u s i n g  A B L  a s  a  c o n t r o l  g e n e .  
T C R A  a n d  T C R B  g e n e  r e a r r a n g e m e n t  a n a l y s i s  
F o r  T C R A  g e n e  r e a r r a n g e m e n t  a n a l y s i s ,  c D N A  w a s  a m p l i f i e d  u s i n g  n e w l y  d e v e l o p e d  
T C R A  p r i m e r s :  o n e  c o n s t a n t  r e g i o n  r e v e r s e  p r i m e r  ( C α )  a n d  5 4  d i f f e r e n t  V α  f a m i -
l y - s p e c i f i c  f o r w a r d  p r i m e r s  d i s t r i b u t e d  o v e r  5  d i f f e r e n t  m u l t i p l e x  t u b e s ;  e a c h  o f  t h e s e  
m u l t i p l e x  c o n t a i n e d  1 0  ( T C R A  t u b e  B )  o r  1 1  ( T C R A  t u b e s  A ,  C ,  D  a n d  E )  V α  p r i m e r s  
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in combination with the Cα primer (Supplementary Table 1). In each 50 ml PCR, 2 ml of cDNA, 10 pmol of 50 and 30 oligonucleotide primers, 3 mmol/l MgCl2, 0.2 mmol/l 
dNTP, 5 ml 10x buffer II, and 1–2 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA) were used. TCRB gene rearrangement analysis was performed according to the BIOMED-2 multiplex PCR protocol [36]. BIOMED-2 multiplex PCR kits were obtained from InVivoScribe Technologies (San Diego, CA, USA; www.invivoscribe.
com). Amplification reactions were performed in an automated thermocycler (model ABI 2700; Applied Biosystems).
Sequence analysis
After PCR amplification of TCRA and TCRB gene rearrangements, products were sub-jected to heteroduplex analysis [37]. Products found to be monoclonal in heteroduplex analysis were directly sequenced except for cases with more than one clonal product. In such cases, homoduplexes were excised from the polyacrylamide gel and DNA was eluted before sequencing. Sequencing was performed on the ABI 3100 or 3130xl Genetic Analyzers (Applied Biosystems), using the dye terminator cycle sequencing kit and 
AmpliTaqFS DNA polymerase (Applied Biosystems). Assignment of Vβ, Dβ, Jβ, Vα and 
Jα genes and reading frames of the involved TCRB and TCRA gene rearrangements was done using the IMGT database (www.imgt.org) [38].
In silico analysis and data visualizationV-J combinatorial diversity was visualized using Circoletto, an online visualization tool based on Circos (bat.ina.certh.gr/tools/circoletto/) [39]. The collected TCRB CDR3 amino-acid diversity was further analyzed using the TEIRESIAS algorithm, a compu-tational tool developed by the Bioinformatics and Pattern Discovery group at the IBM Computational Biology Center, as described previously [40]. This algorithm uses a motif-
based clustering approach with predefined thresholds for amino-acid identity and sim-ilarity, CDR3 length differences and offsets for sequence motifs within CDR3 sequences. TCRB CDR3 amino-acid patterns of different subsets were visualized using WebLogo (weblogo.berkeley.edu/). Each logo consists of multiple stacks of symbols, one stack for 
each position of the sequence. CDR3 is shown based on IMGT position definitions. 
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Antigenic selection in T-LGL leukemia immunopathogenesis 
RESULTS
Clinical and hematological features are heterogeneous in CD8+TCRαβ+ 
T-LGL leukemia
The most relevant clinical and hematological findings at diagnosis of the 26 
CD8+TCRαβ+ T-LGL leukemia patients enrolled in this study are summarized in Table 
1. The median age was 58 years (range 31–86 years) and there was no male or female 
predominance. Out of the 26 patients, 21 (81%) were symptomatic at presentation. Nine of the 26 patients (35%) had an episode of bacterial infection or B symptoms (fever, 
night sweats and weight loss). Most frequent presentations concerned neutropenia and/or anemia (62%), whereas some T-LGL leukemias presented with neutropenia plus 
thrombocytopenia (12%). Thrombocytopenia with coexistent anemia was found in just one case (4%), splenomegaly in two (8%) and lymphadenopathy also in only one (4%). 
Examination of PB smears showed an increased number of LGLs with abundant cyto- plasm containing azurophilic granules in virtually all analyzed cases. 
An associated disease was found in 11 cases (42%) (Table 1). In our cohort, 7 patients (27%) had a co-existent autoimmune disorder. The most common autoimmune manifes-
tation was rheumatoid arthritis, which was diagnosed in 3 patients (12%). Co-existence of a malignancy was found in five cases (18%), three of which showed a second hema-
tological malignancy (12%). To compare the relative frequencies of associated cytope- nias, autoimmune disorders and malignancies in all three types of T-LGL leukemia, we 
analyzed the clinical data of our CD8+ T-LGL cohort (N=26) and the data of 56 CD8+ 
T-LGL leukemia patients described by Wlodarski et al. [29] and compared those with the clinical features of 36 patients with CD4+ T-LGL leukemia [28] and our cohort of 44 
published [16] and 19 novel TCRγδ+ T-LGL leukemia patients. On average, similar clin- ical features were observed between CD8+TCRαβ+ T-LGL leukemia and TCRγδ+ T-LGL 
leukemia. Notably, the frequency of cytopenias and autoimmune disorders appeared to be much lower in CD4+TCRαβ+ T-LGL leukemia as compared with other types (Fig. 1). 
At closing of the study, the median follow-up of the patients was 34 months (range 6–122 months). Two-thirds of patients required therapy with one or more agents 
(Table 1). The therapeutic strategy was largely aimed at improving cytopenias and included erythrocyte transfusions and various immunosuppressive drugs. We observed 
one disease-related death in these 26 patients (case 86-041) which is in line with the generally indolent clinical course of this disease. 
Typical LGL immunophenotype is seen in all CD8+TCRαβ+ T-LGL
T-LGL cells of all 26 cases showed membrane co-expression of CD3, CD8 and TCRαβ 
molecules. The majority of leukemic LGLs expressed CD2 (100%), CD5 (77%) and CD7 
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1 6 1
A n t i g e n i c  s e l e c t i o n  i n  T - L G L  l e u k e m i a  i m m u n o p a t h o g e n e s i s  
R E S U LT S
C l i n i c a l  a n d  h e m a t o l o g i c a l  f e a t u r e s  a r e  h e t e r o g e n e o u s  i n  C D 8 + T C R α β +  
T - L G L  l e u k e m i a
T h e  m o s t  r e l e v a n t  c l i n i c a l  a n d  h e m a t o l o g i c a l  f i n d i n g s  a t  d i a g n o s i s  o f  t h e  2 6  
C D 8 + T C R α β +  T - L G L  l e u k e m i a  p a t i e n t s  e n r o l l e d  i n  t h i s  s t u d y  a r e  s u m m a r i z e d  i n  T a b l e  
1 .  T h e  m e d i a n  a g e  w a s  5 8  y e a r s  ( r a n g e  3 1 – 8 6  y e a r s )  a n d  t h e r e  w a s  n o  m a l e  o r  f e m a l e  
p r e d o m i n a n c e .  O u t  o f  t h e  2 6  p a t i e n t s ,  2 1  ( 8 1 % )  w e r e  s y m p t o m a t i c  a t  p r e s e n t a t i o n .  N i n e  
o f  t h e  2 6  p a t i e n t s  ( 3 5 % )  h a d  a n  e p i s o d e  o f  b a c t e r i a l  i n f e c t i o n  o r  B  s y m p t o m s  ( f e v e r ,  
n i g h t  s w e a t s  a n d  w e i g h t  l o s s ) .  M o s t  f r e q u e n t  p r e s e n t a t i o n s  c o n c e r n e d  n e u t r o p e n i a  
a n d / o r  a n e m i a  ( 6 2 % ) ,  w h e r e a s  s o m e  T - L G L  l e u k e m i a s  p r e s e n t e d  w i t h  n e u t r o p e n i a  p l u s  
t h r o m b o c y t o p e n i a  ( 1 2 % ) .  T h r o m b o c y t o p e n i a  w i t h  c o e x i s t e n t  a n e m i a  w a s  f o u n d  i n  j u s t  
o n e  c a s e  ( 4 % ) ,  s p l e n o m e g a l y  i n  t w o  ( 8 % )  a n d  l y m p h a d e n o p a t h y  a l s o  i n  o n l y  o n e  ( 4 % ) .  
E x a m i n a t i o n  o f  P B  s m e a r s  s h o w e d  a n  i n c r e a s e d  n u m b e r  o f  L G L s  w i t h  a b u n d a n t  c y t o -
p l a s m  c o n t a i n i n g  a z u r o p h i l i c  g r a n u l e s  i n  v i r t u a l l y  a l l  a n a l y z e d  c a s e s .  
A n  a s s o c i a t e d  d i s e a s e  w a s  f o u n d  i n  1 1  c a s e s  ( 4 2 % )  ( T a b l e  1 ) .  I n  o u r  c o h o r t ,  7  p a t i e n t s  
( 2 7 % )  h a d  a  c o - e x i s t e n t  a u t o i m m u n e  d i s o r d e r .  T h e  m o s t  c o m m o n  a u t o i m m u n e  m a n i f e s -
t a t i o n  w a s  r h e u m a t o i d  a r t h r i t i s ,  w h i c h  w a s  d i a g n o s e d  i n  3  p a t i e n t s  ( 1 2 % ) .  C o - e x i s t e n c e  
o f  a  m a l i g n a n c y  w a s  f o u n d  i n  f i v e  c a s e s  ( 1 8 % ) ,  t h r e e  o f  w h i c h  s h o w e d  a  s e c o n d  h e m a -
t o l o g i c a l  m a l i g n a n c y  ( 1 2 % ) .  T o  c o m p a r e  t h e  r e l a t i v e  f r e q u e n c i e s  o f  a s s o c i a t e d  c y t o p e -
n i a s ,  a u t o i m m u n e  d i s o r d e r s  a n d  m a l i g n a n c i e s  i n  a l l  t h r e e  t y p e s  o f  T - L G L  l e u k e m i a ,  w e  
a n a l y z e d  t h e  c l i n i c a l  d a t a  o f  o u r  C D 8 +  T - L G L  c o h o r t  ( N = 2 6 )  a n d  t h e  d a t a  o f  5 6  C D 8 +  
T - L G L  l e u k e m i a  p a t i e n t s  d e s c r i b e d  b y  W l o d a r s k i  e t  a l .  [ 2 9 ]  a n d  c o m p a r e d  t h o s e  w i t h  
t h e  c l i n i c a l  f e a t u r e s  o f  3 6  p a t i e n t s  w i t h  C D 4 +  T - L G L  l e u k e m i a  [ 2 8 ]  a n d  o u r  c o h o r t  o f  4 4  
p u b l i s h e d  [ 1 6 ]  a n d  1 9  n o v e l  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s .  O n  a v e r a g e ,  s i m i l a r  c l i n -
i c a l  f e a t u r e s  w e r e  o b s e r v e d  b e t w e e n  C D 8 + T C R α β +  T - L G L  l e u k e m i a  a n d  T C R γ δ +  T - L G L  
l e u k e m i a .  N o t a b l y ,  t h e  f r e q u e n c y  o f  c y t o p e n i a s  a n d  a u t o i m m u n e  d i s o r d e r s  a p p e a r e d  t o  
b e  m u c h  l o w e r  i n  C D 4 + T C R α β +  T - L G L  l e u k e m i a  a s  c o m p a r e d  w i t h  o t h e r  t y p e s  ( F i g .  1 ) .  
A t  c l o s i n g  o f  t h e  s t u d y ,  t h e  m e d i a n  f o l l o w - u p  o f  t h e  p a t i e n t s  w a s  3 4  m o n t h s  ( r a n g e  
6 – 1 2 2  m o n t h s ) .  T w o - t h i r d s  o f  p a t i e n t s  r e q u i r e d  t h e r a p y  w i t h  o n e  o r  m o r e  a g e n t s  
( T a b l e  1 ) .  T h e  t h e r a p e u t i c  s t r a t e g y  w a s  l a r g e l y  a i m e d  a t  i m p r o v i n g  c y t o p e n i a s  a n d  
i n c l u d e d  e r y t h r o c y t e  t r a n s f u s i o n s  a n d  v a r i o u s  i m m u n o s u p p r e s s i v e  d r u g s .  W e  o b s e r v e d  
o n e  d i s e a s e - r e l a t e d  d e a t h  i n  t h e s e  2 6  p a t i e n t s  ( c a s e  8 6 - 0 4 1 )  w h i c h  i s  i n  l i n e  w i t h  t h e  
g e n e r a l l y  i n d o l e n t  c l i n i c a l  c o u r s e  o f  t h i s  d i s e a s e .  
T y p i c a l  L G L  i m m u n o p h e n o t y p e  i s  s e e n  i n  a l l  C D 8 + T C R α β +  T - L G L
T - L G L  c e l l s  o f  a l l  2 6  c a s e s  s h o w e d  m e m b r a n e  c o - e x p r e s s i o n  o f  C D 3 ,  C D 8  a n d  T C R α β  
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(81%). Furthermore, the T-LGL cells of all cases showed expression of one or more markers like CD16, CD56 or CD57 that have typically been associated with LGL and 
that reflect the antigen-experienced nature of the cells (Table 1). Out of 22 cases 11 
were CD16 positive (50%), whereas CD56 expression was seen in 7 out of 20 cases ana- lyzed (35%). Heterogeneous expression of CD57 could be demonstrated in 23 out of 24 
evaluable cases (96%). Thus, these CD8+TCRαβ+ T-LGLs show the typical effector T cell 
phenotype.
TCRA and TCRB combinatorial diversity greatly differs between 
CD8+TCRαβ+ T-LGL and CD4+TCRαβ+ T-LGL 
To evaluate whether CD8+TCRαβ+ T-LGL shows signs of antigen stimulation in their 
antigen receptors, we aimed for a comprehensive analysis of both the TCRα and the 
TCRβ chain in parallel to the HLA genotype. 
First, we studied the clonotypic TCRB repertoire using specific anti-TCRVβ domain 
MoAbs. Dominant TCR-Vβ reactivity was observed in 22 out of 26 cases (Table 2). All 
Figure 1. Relative frequency (%) of associated cytopenias, auto-immune diseases and malignancies in 
CD8+TCRαβ+, CD4+TCRαβ+ and TCRγδ+ T-LGL leukemia.
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A n t i g e n i c  s e l e c t i o n  i n  T - L G L  l e u k e m i a  i m m u n o p a t h o g e n e s i s  
( 8 1 % ) .  F u r t h e r m o r e ,  t h e  T - L G L  c e l l s  o f  a l l  c a s e s  s h o w e d  e x p r e s s i o n  o f  o n e  o r  m o r e  
m a r k e r s  l i k e  C D 1 6 ,  C D 5 6  o r  C D 5 7  t h a t  h a v e  t y p i c a l l y  b e e n  a s s o c i a t e d  w i t h  L G L  a n d  
t h a t  r e f l e c t  t h e  a n t i g e n - e x p e r i e n c e d  n a t u r e  o f  t h e  c e l l s  ( T a b l e  1 ) .  O u t  o f  2 2  c a s e s  1 1  
w e r e  C D 1 6  p o s i t i v e  ( 5 0 % ) ,  w h e r e a s  C D 5 6  e x p r e s s i o n  w a s  s e e n  i n  7  o u t  o f  2 0  c a s e s  a n a -
l y z e d  ( 3 5 % ) .  H e t e r o g e n e o u s  e x p r e s s i o n  o f  C D 5 7  c o u l d  b e  d e m o n s t r a t e d  i n  2 3  o u t  o f  2 4  
e v a l u a b l e  c a s e s  ( 9 6 % ) .  T h u s ,  t h e s e  C D 8 + T C R α β +  T - L G L s  s h o w  t h e  t y p i c a l  e f f e c t o r  T  c e l l  
p h e n o t y p e .
T C R A  a n d  T C R B  c o m b i n a t o r i a l  d i v e r s i t y  g r e a t l y  d i f f e r s  b e t w e e n  
C D 8 + T C R α β +  T - L G L  a n d  C D 4 + T C R α β +  T - L G L  
T o  e v a l u a t e  w h e t h e r  C D 8 + T C R α β +  T - L G L  s h o w s  s i g n s  o f  a n t i g e n  s t i m u l a t i o n  i n  t h e i r  
a n t i g e n  r e c e p t o r s ,  w e  a i m e d  f o r  a  c o m p r e h e n s i v e  a n a l y s i s  o f  b o t h  t h e  T C R α  a n d  t h e  
T C R β  c h a i n  i n  p a r a l l e l  t o  t h e  H L A  g e n o t y p e .  
F i r s t ,  w e  s t u d i e d  t h e  c l o n o t y p i c  T C R B  r e p e r t o i r e  u s i n g  s p e c i f i c  a n t i - T C R V β  d o m a i n  
M o A b s .  D o m i n a n t  T C R - V β  r e a c t i v i t y  w a s  o b s e r v e d  i n  2 2  o u t  o f  2 6  c a s e s  ( T a b l e  2 ) .  A l l  
F i g u r e  1 .  R e l a t i v e  f r e q u e n c y  ( % )  o f  a s s o c i a t e d  c y t o p e n i a s ,  a u t o - i m m u n e  d i s e a s e s  a n d  m a l i g n a n c i e s  i n  
C D 8 + T C R α β + ,  C D 4 + T C R α β +  a n d  T C R γ δ +  T - L G L  l e u k e m i a .
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cases, including the four cases without detectable TCRVβ expression, demonstrated 
clonal in-frame TCRB gene rearrangements in multiplex PCR and/ or RT–PCR analysis 
(Table 3). Results of sequence analysis of Vβ-Jβ gene rearrangements and Vβ protein/mRNA expression were concordant in all cases. On the basis of these results, a slight 
predominance of Vβ2, Vβ5 and Vβ12 was noted. Jβ2 genes were used more frequently 
than Jβ1 genes (62 vs. 38%), with the Jβ2.1 proportion being highest (15%). This Jβ2 
predominance is in line with the non-random Jβ gene distribution as it is known from 
mature polyclonal PB TCRαβ+ T cells of healthy individuals [41]. To study the clonotypic TCRA repertoire, we developed a novel multiplex RT-PCR assay. Using this assay, clonal TCRA gene rearrangements could be demonstrated in all 22 cases that were analyzed (Table 2). In the remaining four cases no RNA could be 
isolated due to lack of material. Similar to Vβ usage, there was also no common Vα gene 
usage among the 22 patients studied. Genes from the Vα19, Vα8 and Vα12 families were 
used most frequently, being expressed in three cases each. Jα gene usage was also highly diverse (Table 4). When visualizing the TCRA and TCRB combinatorial diversity using the Circoletto 
tool, both the Vα-Jα and Vβ-Jβ diversities were indeed largely random in CD8+TCRαβ+ 
T-LGL (Fig. 2a, 2b). This is in strong contrast to the non-random distribution of Vβ-Jβ 
combinations as seen in monoclonal CD4+TCRαβ+ T-LGL lymphocytosis patients [28] 
(Fig. 2c); unfortunately, from these CD4+TCRαβ+ T-LGLs no Vα-Jα combinatorial data are available for a direct comparison of the TCRA combinatorial diversity. For a complete picture on the combinatorial diversity of all three T-LGL subtypes, we also analyzed the 
Vγ-Jγ and Vδ-Jδ combinations in our cohort of 63 TCRγδ+ LGL patients using Circoletto. 
Similar to the diversity in CD4+TCRαβ+ T-LGL, but unlike CD8+TCRαβ+ T-LGL, the com-binatorial diversity in TCRG and TCRD appeared to be non-random as well (Fig. 2d, 2e). It should be noted that the lower number of V genes might already impact on the more limited combinatorial diversity of these two loci. 
Finally, we evaluated the HLA-ABC genotype of the CD8+TCRαβ+ T-LGL patients. No clear predominance of HLA-A, -B or -C alleles or combinations thereof was observed 
(Table 2). When evaluating the expanded Vβ and Vα families in conjunction with the 
HLA-ABC alleles, also no clear association was observed between a particular TCR-Vα/
Vβ specificity and the involved HLA genotype. Collectively, these data show a clear heterogeneity in the combinatorial diversity of 
the TCR clonotypes in CD8+TCRαβ+ T-LGL, which does not seem to be directly linked to the HLA genotype. This heterogeneity clearly differs from the more homogeneous 
patterns seen in TCRγδ+ T-LGL and especially CD4+TCRαβ+ T-LGL. 
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Lack of common TCRA and TCRB CDR3 motifs in CD8+TCRαβ+T-LGLGiven the lack of skewing of TCRA and TCRB combinatorial diversity, we then 
explored the possibility of a more subtle TCR homology in CD8+TCRαβ+T-LGL leukemia patients. To this end, we analyzed TCRA and TCRB junctional diversity by studying CDR3 sequences in more detail. A total of 24 T-LGL TCRA CDR3 clonotypes from 22 patients and 27 T-LGL TCRB CDR3 clonotypes from 25 patients were evaluated, but the TCRA and TCRB CDR3 motifs of the immunodominant T cell clones did not show clearly identical sequences (Tables 3 and 4). To exclude the possibility that the number of evaluable TCRB CDR3 sequences was 
limiting the possibility to find clear similarities, additional CDR3 sequences that had been published in the literature were included for further analysis. In this way, 81 addi-
tional TCRB CDR3 motifs of a large series of 56 CD8+TCRαβ+ T-LGL leukemia patients [29] could be evaluated. Similar to our cohort, in a proportion of patients more than one immunodominant clone was found, suggesting that some T-LGL proliferations are 
Figure 2. Frequencies of V-J pairing in TCRαβ+ T-LGL and TCRγδ+ T-LGL leukemia.
Highly diverse Vα-Jα (a) and Vβ-Jβ (b) combinations are seen in our cohort of 26 patients with CD8+ T-LGL 
leukemia, while the Vβ-Jβ pairing is clearly non-random in monoclonal CD4+ T-LGL proliferations (c). Also in 
TCRγδ+ T-LGL leukemia limited combinatorial diversity of TCRG and TCR genes (d and e, respectively) is seen. (Blue to purple rectangular bands) J genes and (red to cyan rectangular bands) V genes. The width of the bands 
is proportional to the number of times the V and J genes are connected. This figure was generated using the Circos software package [47].
Chapter 5
168
Lack of common TCRA and TCRB CDR3 motifs in CD8+TCRαβ+T-LGL
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biclonal. In this extended data set, the Vβ-Jβ combinatorial diversity appeared to be 
equally heterogeneous (Supplementary Fig. 1) as in our own cohort. For a more comprehensive evaluation 
of CDR3 motifs, detailed in silico analy- sis was performed on the 108 combined 
TCRB CDR3 sequences in parallel to 14 TCRB CDR3 sequences of earlier described 
CD4+ T-LGL [28]. By applying a recently 
described sequence motif-based cluster- ing methodology [40] using thresholds of 
50% amino-acid identity and 70% similar- ity between any two CDR3 sequences, 13 
out of 14 CD4+ T-LGL displayed a highly 
homogeneous and similar TCR with clear similarities in length and amino-acid posi-
tions in the CDR3 sequence logo (Fig. 3a). The similarity of the CDR3 sequence logo 
was even more impressive when concen- trating on a higher level cluster of 11 CD4+ 
T-LGL cases that are all characterized by TCRVβ13.1-Jβ1.1 rearrangements (Fig. 
3b). This is in line with the proposed CMV antigen-driven selection in the pathogene-
sis of this type of T-LGL. Interestingly, the two CD4+ T-LGL that were slightly different 
from the other 11 CD4+ T-LGLs based on 
Jβ1.5 usage did show low level cluster- ing with two CD8+ T-LGLs, as evidenced 
from the common Jβ1.5 and Vβ8/Vβ13 
gene usage, and the CDR3 sequence logo (Fig. 3c). Finally, some clustering was seen 
between four other CD8+ T-LGL cases that 
Figure 3. Sequence logos of selected subsets in T-LGL leukemia.
(a) Subset 1 comprises 13 Vβ13.1-Jβ1.1/Jβ1.5 gene rearrangements in CD4+ T-LGL leukemia cases, characterized by pronounced overall similarity. (b) The largest high-level subset in the present study is present in subset 2, comprising clonally expanded CD4+ T-LGL showing Vβ13.1-Jβ1.1. (c) Low level clustering 
was seen in the Vβ8/Vβ13-Jβ1.5 gene rearrangements in two CD4+ LGL and two CD8+ LGL cases. (d) Some higher level clustering is present in Vβn.-Jβ2.3/2.7 gene rearrangements in four CD8+ T-LGL leukemia cases. The height of the symbols within the stack indicates the relative frequency of each amino acid at that position. 




A n t i g e n i c  s e l e c t i o n  i n  T - L G L  l e u k e m i a  i m m u n o p a t h o g e n e s i s  
b i c l o n a l .  I n  t h i s  e x t e n d e d  d a t a  s e t ,  t h e  V β - J β  c o m b i n a t o r i a l  d i v e r s i t y  a p p e a r e d  t o  b e  
e q u a l l y  h e t e r o g e n e o u s  ( S u p p l e m e n t a r y  F i g .  1 )  a s  i n  o u r  o w n  c o h o r t .  
F o r  a  m o r e  c o m p r e h e n s i v e  e v a l u a t i o n  
o f  C D R 3  m o t i f s ,  d e t a i l e d  i n  s i l i c o  a n a l y -
s i s  w a s  p e r f o r m e d  o n  t h e  1 0 8  c o m b i n e d  
T C R B  C D R 3  s e q u e n c e s  i n  p a r a l l e l  t o  1 4  
T C R B  C D R 3  s e q u e n c e s  o f  e a r l i e r  d e s c r i b e d  
C D 4 +  T - L G L  [ 2 8 ] .  B y  a p p l y i n g  a  r e c e n t l y  
d e s c r i b e d  s e q u e n c e  m o t i f - b a s e d  c l u s t e r -
i n g  m e t h o d o l o g y  [ 4 0 ]  u s i n g  t h r e s h o l d s  o f  
5 0 %  a m i n o - a c i d  i d e n t i t y  a n d  7 0 %  s i m i l a r -
i t y  b e t w e e n  a n y  t w o  C D R 3  s e q u e n c e s ,  1 3  
o u t  o f  1 4  C D 4 +  T - L G L  d i s p l a y e d  a  h i g h l y  
h o m o g e n e o u s  a n d  s i m i l a r  T C R  w i t h  c l e a r  
s i m i l a r i t i e s  i n  l e n g t h  a n d  a m i n o - a c i d  p o s i -
t i o n s  i n  t h e  C D R 3  s e q u e n c e  l o g o  ( F i g .  3 a ) .  
T h e  s i m i l a r i t y  o f  t h e  C D R 3  s e q u e n c e  l o g o  
w a s  e v e n  m o r e  i m p r e s s i v e  w h e n  c o n c e n -
t r a t i n g  o n  a  h i g h e r  l e v e l  c l u s t e r  o f  1 1  C D 4 +  
T - L G L  c a s e s  t h a t  a r e  a l l  c h a r a c t e r i z e d  b y  
T C R V β 1 3 . 1 - J β 1 . 1  r e a r r a n g e m e n t s  ( F i g .  
3 b ) .  T h i s  i s  i n  l i n e  w i t h  t h e  p r o p o s e d  C M V  
a n t i g e n - d r i v e n  s e l e c t i o n  i n  t h e  p a t h o g e n e -
s i s  o f  t h i s  t y p e  o f  T - L G L .  I n t e r e s t i n g l y ,  t h e  
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f r o m  t h e  o t h e r  1 1  C D 4 +  T - L G L s  b a s e d  o n  
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f r o m  t h e  c o m m o n  J β 1 . 5  a n d  V β 8 / V β 1 3  
g e n e  u s a g e ,  a n d  t h e  C D R 3  s e q u e n c e  l o g o  
( F i g .  3 c ) .  F i n a l l y ,  s o m e  c l u s t e r i n g  w a s  s e e n  
b e t w e e n  f o u r  o t h e r  C D 8 +  T - L G L  c a s e s  t h a t  
F i g u r e  3 .  S e q u e n c e  l o g o s  o f  s e l e c t e d  s u b s e t s  i n  T - L G L  l e u k e m i a .
( a )  S u b s e t  1  c o m p r i s e s  1 3  V β 1 3 . 1 - J β 1 . 1 / J β 1 . 5  g e n e  r e a r r a n g e m e n t s  i n  C D 4 +  T - L G L  l e u k e m i a  c a s e s ,  
c h a r a c t e r i z e d  b y  p r o n o u n c e d  o v e r a l l  s i m i l a r i t y .  ( b )  T h e  l a r g e s t  h i g h - l e v e l  s u b s e t  i n  t h e  p r e s e n t  s t u d y  i s  
p r e s e n t  i n  s u b s e t  2 ,  c o m p r i s i n g  c l o n a l l y  e x p a n d e d  C D 4 +  T - L G L  s h o w i n g  V β 1 3 . 1 - J β 1 . 1 .  ( c )  L o w  l e v e l  c l u s t e r i n g  
w a s  s e e n  i n  t h e  V β 8 / V β 1 3 - J β 1 . 5  g e n e  r e a r r a n g e m e n t s  i n  t w o  C D 4 +  L G L  a n d  t w o  C D 8 +  L G L  c a s e s .  ( d )  S o m e  
h i g h e r  l e v e l  c l u s t e r i n g  i s  p r e s e n t  i n  V β n . - J β 2 . 3 / 2 . 7  g e n e  r e a r r a n g e m e n t s  i n  f o u r  C D 8 +  T - L G L  l e u k e m i a  c a s e s .  
T h e  h e i g h t  o f  t h e  s y m b o l s  w i t h i n  t h e  s t a c k  i n d i c a t e s  t h e  r e l a t i v e  f r e q u e n c y  o f  e a c h  a m i n o  a c i d  a t  t h a t  p o s i t i o n .  
A m i n o - a c i d  p o s i t i o n  i s  a c c o r d i n g  t o  t h e  I M G T  n u m b e r i n g  f o r  t h e  V  d o m a i n .  T h i s  f i g u r e  w a s  g e n e r a t e d  u s i n g  
W e b L o g o  ( w e b l o g o . b e r k e l e y . e d u / ) .  
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were characterized by Jβ2.3/2.7 usage and a CDR3 length of 12 (Fig. 3d). Unfortunately not enough TCRA sequences were available for a meaningful in silico TCRA CDR3 analysis. Collectively the in silico analyses illustrate that, in strong contrast to CD4+ T-LGL, 
CD8+ T-LGL do not show clear and consistent signs of TCR homology that would reflect involvement of a common antigen. 
DISCUSSION AND CONCLUSION
Molecular analysis of the TCR repertoire can be a powerful tool in the study of T cell responses to pathogens and in autoimmune diseases. Thus, analysis of the TCR expression pattern in patients with T-LGL leukemia might provide insight into the pathogenesis of this disorder. Similar TCR clonotypes between T-LGL clones of different patients would in that respect be suggestive of a common antigenic stimulus underlying the pathogenesis of this disorder. Furthermore, it has been suggested that the cytope-
nias associated with T-LGL leukemia would be the result of highly specific recognition and killing of individual hematopoietic cell lineages by T-LGL clones.
In the present study, we identified and characterized TCR clonotypes in a group of 
CD8+TCRαβ+ T-LGL leukemia patients. We could not detect specific predominant Vβ 
family usage in our CD8+TCRαβ+ T-LGL cohort. Immunophenotypical analysis of TCR Vα 
expression has so far only been explored in a minority of TCRαβ+ T-LGL leukemia cases. Likewise, complete sequencing of TCRA gene rearrangements has only been performed 
in few (N=5) T-LGL leukemia patients, thus far not showing any signs of common Vα or 
Jα gene usage [42]. In our cohort of 22 patients, we could not detect preferential Vα or 
Jα gene usage; moreover, TCRA CDR3 sequence analysis did not show a common ami-no-acid motif between the various patients, which is thus in line with the TCRB results. 
In silico analysis using a recent purpose-built bioinformatics method did not identify 
common TCRB CDR3 amino-acid sequences in a large cohort of CD8+ T-LGL leukemia 
patients. This is in strong contrast to monoclonal CD4+Vβ13.1+ T-LGL proliferations, in which virtually all published TCRB CDR3 sequences can be assigned to one cluster with unique characteristics. Our current results therefore underline the distinct pathogenesis 
between the CD4+ and CD8+ T-LGL disease entities.
On the basis of our findings, we did not find straightforward evidence for common 
(super)antigen involvement in the pathogenesis of CD8+TCRαβ+ T-LGL leukemia, since no immunodominant clones with identical or highly similar TCRA and TCRB 
CDR3 amino-acid sequences could be identified in a majority of patients. In the study of Wlodarski et al. [29] identical expanded clonotypes were found in only 2 out of 56 
patients. However, clonotypes specific for malignant clones were not encountered to a 
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On the basis of our findings, we did not find straightforward evidence for common 
(super)antigen involvement in the pathogenesis of CD8+TCRαβ+ T-LGL leukemia, 
since no immunodominant clones with identical or highly similar TCRA and TCRB 
CDR3 amino-acid sequences could be identified in a majority of patients. In the study 
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patients. However, clonotypes specific for malignant clones were not encountered to a 
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great extent in 172 clones from healthy individuals. We did not encounter the 108 clo- notypes of the 82 evaluated leukemic LGL cases in CD8+ T cells of healthy individuals 
(data not shown), although high-throughput analysis of the TCRB repertoire of CD8+ 
T cells would be needed to draw firm conclusions. Recently, deep sequencing of the T 
cell repertoire in healthy controls and CD8+ T-LGL leukemia has been performed and 
confirms that T-LGL clonotypes are not present in the general public and are therefore 
private to the disease [43]. The heterogeneity of TCR clonotypes in clonal CD8+TCRαβ+ T-LGL proliferations is 
partially explained by the presence of biclonal LGL proliferations and clonal switching. Both have been described in T-LGL leukemia and are suggestive of pervasive antigenic 
drive [22]. In addition, Clemente et al. [43] recently demonstrated that individual T-LGL clones were present at basal levels in almost all other T-LGL leukemia cases. This sug-
gests the presence of an as yet undefined mechanism whereby certain clonotypes may 
predispose an individual toward the extreme monoclonal expansions commonly found in T-LGL leukemia [43]. Another explanation for the seemingly low level of similarity 
between the dominant clonotypes in our study might be the large variability in HLA genotype in our patient series. Peptide binding is affected through the physical amino 
acid properties and the tertiary CDR3 structure. Therefore, the linear amino acid homol- ogy comparisons might not be the most appropriate method to identify common motifs 
in TCR molecules. Altogether this may suggest that CD8+TCRαβ+ T-LGL clones could have evolved in 
a stepwise manner from an initial polyclonal/oligoclonal immune response directed against multiple (auto)antigenic targets. Following an exaggerated immune response, 
secondary molecular events would then lead to global deregulation of cell proliferation and survival of one or a few clonotypes. Among the survival signaling pathways, the 
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway has been associated with LGL transformation [26]. Most recently, the role of STAT family 
genes (STAT3 and STAT5b) in the pathogenesis of T-LGL leukemia has been emphasized [44]. Activating somatic mutations in STAT3 were found in up to 40% of T-LGL leukemia 
patients and it has been suggested that mutational analysis of STAT3 might distinguish true T-LGL leukemia cases from clonally skewed reactive processes [11,45,46]. 
In summary, no clear indications for common TCRA or TCRB CDR3 motifs were found in our CD8+TCRαβ+ T-LGL cohort. When clonotypes of our 26 patients were 
cross-referenced against the previously reported clonotypic database of 56 T-LGL leuke- mia patients, we could only identify homologous clonotypes between a limited number 
of patients. This is in contrast to the shared clonotypes as seen in CD4+TCRαβ+ and 
TCRγδ+ T-LGL leukemia and might point to a more random clonal selection in TCRαβ+ 
T-LGL leukemia. The heterogeneity of clonal CD8+TCRαβ+ T-LGL proliferations might 
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n o t y p e s  o f  t h e  8 2  e v a l u a t e d  l e u k e m i c  L G L  c a s e s  i n  C D 8 +  T  c e l l s  o f  h e a l t h y  i n d i v i d u a l s  
( d a t a  n o t  s h o w n ) ,  a l t h o u g h  h i g h - t h r o u g h p u t  a n a l y s i s  o f  t h e  T C R B  r e p e r t o i r e  o f  C D 8 +  
T  c e l l s  w o u l d  b e  n e e d e d  t o  d r a w  f i r m  c o n c l u s i o n s .  R e c e n t l y ,  d e e p  s e q u e n c i n g  o f  t h e  T  
c e l l  r e p e r t o i r e  i n  h e a l t h y  c o n t r o l s  a n d  C D 8 +  T - L G L  l e u k e m i a  h a s  b e e n  p e r f o r m e d  a n d  
c o n f i r m s  t h a t  T - L G L  c l o n o t y p e s  a r e  n o t  p r e s e n t  i n  t h e  g e n e r a l  p u b l i c  a n d  a r e  t h e r e f o r e  
p r i v a t e  t o  t h e  d i s e a s e  [ 4 3 ] .  
T h e  h e t e r o g e n e i t y  o f  T C R  c l o n o t y p e s  i n  c l o n a l  C D 8 + T C R α β +  T - L G L  p r o l i f e r a t i o n s  i s  
p a r t i a l l y  e x p l a i n e d  b y  t h e  p r e s e n c e  o f  b i c l o n a l  L G L  p r o l i f e r a t i o n s  a n d  c l o n a l  s w i t c h i n g .  
B o t h  h a v e  b e e n  d e s c r i b e d  i n  T - L G L  l e u k e m i a  a n d  a r e  s u g g e s t i v e  o f  p e r v a s i v e  a n t i g e n i c  
d r i v e  [ 2 2 ] .  I n  a d d i t i o n ,  C l e m e n t e  e t  a l .  [ 4 3 ]  r e c e n t l y  d e m o n s t r a t e d  t h a t  i n d i v i d u a l  T - L G L  
c l o n e s  w e r e  p r e s e n t  a t  b a s a l  l e v e l s  i n  a l m o s t  a l l  o t h e r  T - L G L  l e u k e m i a  c a s e s .  T h i s  s u g -
g e s t s  t h e  p r e s e n c e  o f  a n  a s  y e t  u n d e f i n e d  m e c h a n i s m  w h e r e b y  c e r t a i n  c l o n o t y p e s  m a y  
p r e d i s p o s e  a n  i n d i v i d u a l  t o w a r d  t h e  e x t r e m e  m o n o c l o n a l  e x p a n s i o n s  c o m m o n l y  f o u n d  
i n  T - L G L  l e u k e m i a  [ 4 3 ] .  A n o t h e r  e x p l a n a t i o n  f o r  t h e  s e e m i n g l y  l o w  l e v e l  o f  s i m i l a r i t y  
b e t w e e n  t h e  d o m i n a n t  c l o n o t y p e s  i n  o u r  s t u d y  m i g h t  b e  t h e  l a r g e  v a r i a b i l i t y  i n  H L A  
g e n o t y p e  i n  o u r  p a t i e n t  s e r i e s .  P e p t i d e  b i n d i n g  i s  a f f e c t e d  t h r o u g h  t h e  p h y s i c a l  a m i n o  
a c i d  p r o p e r t i e s  a n d  t h e  t e r t i a r y  C D R 3  s t r u c t u r e .  T h e r e f o r e ,  t h e  l i n e a r  a m i n o  a c i d  h o m o l -
o g y  c o m p a r i s o n s  m i g h t  n o t  b e  t h e  m o s t  a p p r o p r i a t e  m e t h o d  t o  i d e n t i f y  c o m m o n  m o t i f s  
i n  T C R  m o l e c u l e s .  
A l t o g e t h e r  t h i s  m a y  s u g g e s t  t h a t  C D 8 + T C R α β +  T - L G L  c l o n e s  c o u l d  h a v e  e v o l v e d  i n  
a  s t e p w i s e  m a n n e r  f r o m  a n  i n i t i a l  p o l y c l o n a l / o l i g o c l o n a l  i m m u n e  r e s p o n s e  d i r e c t e d  
a g a i n s t  m u l t i p l e  ( a u t o ) a n t i g e n i c  t a r g e t s .  F o l l o w i n g  a n  e x a g g e r a t e d  i m m u n e  r e s p o n s e ,  
s e c o n d a r y  m o l e c u l a r  e v e n t s  w o u l d  t h e n  l e a d  t o  g l o b a l  d e r e g u l a t i o n  o f  c e l l  p r o l i f e r a t i o n  
a n d  s u r v i v a l  o f  o n e  o r  a  f e w  c l o n o t y p e s .  A m o n g  t h e  s u r v i v a l  s i g n a l i n g  p a t h w a y s ,  t h e  
J a n u s  k i n a s e / s i g n a l  t r a n s d u c e r  a n d  a c t i v a t o r  o f  t r a n s c r i p t i o n  ( J A K / S T A T )  p a t h w a y  h a s  
b e e n  a s s o c i a t e d  w i t h  L G L  t r a n s f o r m a t i o n  [ 2 6 ] .  M o s t  r e c e n t l y ,  t h e  r o l e  o f  S T A T  f a m i l y  
g e n e s  ( S T A T 3  a n d  S T A T 5 b )  i n  t h e  p a t h o g e n e s i s  o f  T - L G L  l e u k e m i a  h a s  b e e n  e m p h a s i z e d  
[ 4 4 ] .  A c t i v a t i n g  s o m a t i c  m u t a t i o n s  i n  S T A T 3  w e r e  f o u n d  i n  u p  t o  4 0 %  o f  T - L G L  l e u k e m i a  
p a t i e n t s  a n d  i t  h a s  b e e n  s u g g e s t e d  t h a t  m u t a t i o n a l  a n a l y s i s  o f  S T A T 3  m i g h t  d i s t i n g u i s h  
t r u e  T - L G L  l e u k e m i a  c a s e s  f r o m  c l o n a l l y  s k e w e d  r e a c t i v e  p r o c e s s e s  [ 1 1 , 4 5 , 4 6 ] .  
I n  s u m m a r y ,  n o  c l e a r  i n d i c a t i o n s  f o r  c o m m o n  T C R A  o r  T C R B  C D R 3  m o t i f s  w e r e  
f o u n d  i n  o u r  C D 8 + T C R α β +  T - L G L  c o h o r t .  W h e n  c l o n o t y p e s  o f  o u r  2 6  p a t i e n t s  w e r e  
c r o s s - r e f e r e n c e d  a g a i n s t  t h e  p r e v i o u s l y  r e p o r t e d  c l o n o t y p i c  d a t a b a s e  o f  5 6  T - L G L  l e u k e -
m i a  p a t i e n t s ,  w e  c o u l d  o n l y  i d e n t i f y  h o m o l o g o u s  c l o n o t y p e s  b e t w e e n  a  l i m i t e d  n u m b e r  
o f  p a t i e n t s .  T h i s  i s  i n  c o n t r a s t  t o  t h e  s h a r e d  c l o n o t y p e s  a s  s e e n  i n  C D 4 + T C R α β +  a n d  
T C R γ δ +  T - L G L  l e u k e m i a  a n d  m i g h t  p o i n t  t o  a  m o r e  r a n d o m  c l o n a l  s e l e c t i o n  i n  T C R α β +  
T - L G L  l e u k e m i a .  T h e  h e t e r o g e n e i t y  o f  c l o n a l  C D 8 + T C R α β +  T - L G L  p r o l i f e r a t i o n s  m i g h t  
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in fact suggest that multiple pathogens or autoantigens are involved. Additional studies 
taking into account the triad of HLA genotype, peptide-groove binding and TCR specific-
ity are needed to precisely define the impact of (auto)-antigen stimulation in the patho-
genesis of CD8+TCRαβ+  T-LGL leukemia.
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Supplementary Figure 1. Frequencies of Vβ-Jβ pairing in TCRαβ+ T-LGL leukemia patients.
Highly diverse combinations are seen in a cohort of 82 patients with CD8
+
 T-LGL leukemia, representing 108 clonotypes.
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ABSTRACT
TCRγδ+ T-LGL leukemia is a rare form of chronic mature T cell dis-orders in elderly, which is generally characterized by a persistently 
enlarged CD3+CD57+TCRγδ+ large granular lymphocyte population in the peripheral blood with a monoclonal phenotype. Clinically, the disease is heterogeneous, most patients being largely asymptomatic, although neutropenia, fatigue and B symptoms and underlying diseases such as autoimmune diseases or malignancies are also often observed. 
The etiology of TCRγδ+ T-LGL proliferations is largely unknown. Here, we aimed to investigate underlying molecular mechanisms of these rare 
proliferations by performing gene expression profiling of TCRγδ+ T-LGL 
versus normal TCRγδ+ T cell subsets.
From our initial microarray dataset we observed that TCRγδ+ T-LGL leukemia forms a separate group when compared with different healthy 
control TCRγδ+ T cell subsets, correlating best with the healthy TemRA subset. The lowest correlation was seen with the naive subset. Based on 
specific comparison between healthy control cells and TCRγδ+ T-LGL leukemia cells we observed up-regulation of survival, proliferation and hematopoietic system related genes, with a remarkable down-regula-
tion of apoptotic pathway genes. RQ-PCR validation of important genes representative for the dataset, including apoptosis (XIAP, CASP1, BCLAF1 
and CFLAR), proliferation/development (ID3) and inflammation (CD28, 
CCR7, CX3CR1 and IFNG) processes largely confirmed the dysregulation in proliferation and apoptosis. 
Based on these expression data we conclude that TCRγδ+ T-LGL leu-kemia is likely the result of an underlying aberrant molecular mecha-nisms leading to increased proliferation and reduced apoptosis. 
Keyword(s): TCRγδ+ T cells, T-LGL, leukemia, gene expression profil-ing, apoptosis.
ABSTRACT
TCRγδ+ T-LGL leukemia is a rare form of chronic mature T cell dis-
orders in elderly, which is generally characterized by a persistently 
enlarged CD3+CD57+TCRγδ+ large granular lymphocyte population 
in the peripheral blood with a monoclonal phenotype. Clinically, the 
disease is heterogeneous, most patients being largely asymptomatic, 
although neutropenia, fatigue and B symptoms and underlying diseases 
such as autoimmune diseases or malignancies are also often observed. 
The etiology of TCRγδ+ T-LGL proliferations is largely unknown. Here, 
we aimed to investigate underlying molecular mechanisms of these rare 
proliferations by performing gene expression profiling of TCRγδ+ T-LGL 
versus normal TCRγδ+ T cell subsets.
From our initial microarray dataset we observed that TCRγδ+ T-LGL 
leukemia forms a separate group when compared with different healthy 
control TCRγδ+ T cell subsets, correlating best with the healthy TemRA 
subset. The lowest correlation was seen with the naive subset. Based on 
specific comparison between healthy control cells and TCRγδ+ T-LGL 
leukemia cells we observed up-regulation of survival, proliferation and 
hematopoietic system related genes, with a remarkable down-regula-
tion of apoptotic pathway genes. RQ-PCR validation of important genes 
representative for the dataset, including apoptosis (XIAP, CASP1, BCLAF1 
and CFLAR), proliferation/development (ID3) and inflammation (CD28, 
CCR7, CX3CR1 and IFNG) processes largely confirmed the dysregulation 
in proliferation and apoptosis. 
Based on these expression data we conclude that TCRγδ+ T-LGL leu-
kemia is likely the result of an underlying aberrant molecular mecha-
nisms leading to increased proliferation and reduced apoptosis. 
Keyword(s): TCRγδ+ T cells, T-LGL, leukemia, gene expression profil-
ing, apoptosis.
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INTRODUCTION
T cell large granular lymphocytic (T-LGL) leukemia is a heterogeneous chronic mature T cell neoplasia, which is recognized as a separate hematological disorder according 
to the World Health Organization (WHO) classification [1]. T-LGL leukemia originates 
from normal LGL cells which comprise 10-15% of peripheral blood mononuclear cells (PBMCs) [2] and can be subdivided into two major groups based on the type of T cell 
receptor (TCR): TCRαβ or TCRγδ. The majority of T-LGL leukemia involves the TCRαβ+ 
CD8+ variant (80-90%), while only a small part of the T-LGL leukemia has a TCRαβ+CD4+ 
(1-5%) or TCRγδ+ phenotype (5%) [3,4]. TCRγδ+ T-LGL leukemia is a chronic and het- erogeneous disorder, which in fact comprises a spectrum – from lymphoproliferative 
disease to leukemia – and generally shows an indolent disease course, affecting mostly 
elderly patients with an average age of 60 years [5-7]. Approximately one-third of the patients is asymptomatic at diagnosis [8,9]. Most clinical features concern neutropenia, 
recurrent bacterial infections and B symptoms that are associated with chronic leuke- mia. Typically, TCRγδ+ T-LGL leukemia is highly associated with cytopenia, autoimmune 
diseases such as rheumatoid arthritis, and malignancies varying from other hemato- logical cancers to solid tumors [4]. The diagnosis is based on a persistent (>6 months) 
monoclonal CD3+CD57+TCRγδ+ LGL population (>0.4 x 109/L) in the peripheral blood (PB) and/or bone marrow (BM), confirmed by flow cytometry or cell morphology [9]. 
Furthermore, TCRγδ+ T-LGL leukemia is mostly CD4-negative, partly CD8-positive, and 
approximately 50% show CD16 and CD56 expression [6]. Despite recent advances for T-LGL leukemia in general, the disease etiology of TCRγδ+ 
T-LGL leukemia remains largely unknown. It has been hypothesized that chronic (anti- genic) stimulation would play a major role in the development of the proliferation, as 
has actually been shown for the TCRαβ+CD4+ T-LGL leukemia type [10]. Also, in 2006 
Sandberg et al. identified the presence of the so-called invariant T selection determinant leading to a conserved amino acid at the relative second position of the CDR3 region in 
Vδ2 – Jδ1 rearrangements in a large subgroup of TCRγδ+ T-LGL proliferations, indicating 
that these cells are antigen-experienced. Furthermore, an activation-associated effector phenotype and a skewed and dynamic TCR repertoire – also referred to as clonal drift 
[11] – have been found in T-LGL proliferations, again suggestive of a role for antigens, 
but the exact antigen or the type of antigens have so far not been elucidated [3,12]. Even though the involved antigen(s) are unknown and might be variable, and the disease is 
clinically heterogeneous, we hypothesized that TCRγδ+ T-LGL leukemia patients have 
common underlying molecular defects that contribute to the leukemogenesis. In order to obtain more in-depth insights into the mechanisms driving these TCRγδ+ T-LGL 
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G e n e  e x p r e s s i o n  p r o f i l i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
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I N T R O D U C T I O N
T  c e l l  l a r g e  g r a n u l a r  l y m p h o c y t i c  ( T - L G L )  l e u k e m i a  i s  a  h e t e r o g e n e o u s  c h r o n i c  m a t u r e  
T  c e l l  n e o p l a s i a ,  w h i c h  i s  r e c o g n i z e d  a s  a  s e p a r a t e  h e m a t o l o g i c a l  d i s o r d e r  a c c o r d i n g  
t o  t h e  W o r l d  H e a l t h  O r g a n i z a t i o n  ( W H O )  c l a s s i f i c a t i o n  [ 1 ] .  T - L G L  l e u k e m i a  o r i g i n a t e s  
f r o m  n o r m a l  L G L  c e l l s  w h i c h  c o m p r i s e  1 0 - 1 5 %  o f  p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  
( P B M C s )  [ 2 ]  a n d  c a n  b e  s u b d i v i d e d  i n t o  t w o  m a j o r  g r o u p s  b a s e d  o n  t h e  t y p e  o f  T  c e l l  
r e c e p t o r  ( T C R ) :  T C R α β  o r  T C R γ δ .  T h e  m a j o r i t y  o f  T - L G L  l e u k e m i a  i n v o l v e s  t h e  T C R α β +  
C D 8 +  v a r i a n t  ( 8 0 - 9 0 % ) ,  w h i l e  o n l y  a  s m a l l  p a r t  o f  t h e  T - L G L  l e u k e m i a  h a s  a  T C R α β + C D 4 +  
( 1 - 5 % )  o r  T C R γ δ +  p h e n o t y p e  ( 5 % )  [ 3 , 4 ] .  T C R γ δ +  T - L G L  l e u k e m i a  i s  a  c h r o n i c  a n d  h e t -
e r o g e n e o u s  d i s o r d e r ,  w h i c h  i n  f a c t  c o m p r i s e s  a  s p e c t r u m  –  f r o m  l y m p h o p r o l i f e r a t i v e  
d i s e a s e  t o  l e u k e m i a  –  a n d  g e n e r a l l y  s h o w s  a n  i n d o l e n t  d i s e a s e  c o u r s e ,  a f f e c t i n g  m o s t l y  
e l d e r l y  p a t i e n t s  w i t h  a n  a v e r a g e  a g e  o f  6 0  y e a r s  [ 5 - 7 ] .  A p p r o x i m a t e l y  o n e - t h i r d  o f  t h e  
p a t i e n t s  i s  a s y m p t o m a t i c  a t  d i a g n o s i s  [ 8 , 9 ] .  M o s t  c l i n i c a l  f e a t u r e s  c o n c e r n  n e u t r o p e n i a ,  
r e c u r r e n t  b a c t e r i a l  i n f e c t i o n s  a n d  B  s y m p t o m s  t h a t  a r e  a s s o c i a t e d  w i t h  c h r o n i c  l e u k e -
m i a .  T y p i c a l l y ,  T C R γ δ +  T - L G L  l e u k e m i a  i s  h i g h l y  a s s o c i a t e d  w i t h  c y t o p e n i a ,  a u t o i m m u n e  
d i s e a s e s  s u c h  a s  r h e u m a t o i d  a r t h r i t i s ,  a n d  m a l i g n a n c i e s  v a r y i n g  f r o m  o t h e r  h e m a t o -
l o g i c a l  c a n c e r s  t o  s o l i d  t u m o r s  [ 4 ] .  T h e  d i a g n o s i s  i s  b a s e d  o n  a  p e r s i s t e n t  ( > 6  m o n t h s )  
m o n o c l o n a l  C D 3 + C D 5 7 + T C R γ δ +  L G L  p o p u l a t i o n  ( > 0 . 4  x  1 0
9
/ L )  i n  t h e  p e r i p h e r a l  b l o o d  
( P B )  a n d / o r  b o n e  m a r r o w  ( B M ) ,  c o n f i r m e d  b y  f l o w  c y t o m e t r y  o r  c e l l  m o r p h o l o g y  [ 9 ] .  
F u r t h e r m o r e ,  T C R γ δ +  T - L G L  l e u k e m i a  i s  m o s t l y  C D 4 - n e g a t i v e ,  p a r t l y  C D 8 - p o s i t i v e ,  a n d  
a p p r o x i m a t e l y  5 0 %  s h o w  C D 1 6  a n d  C D 5 6  e x p r e s s i o n  [ 6 ] .  
D e s p i t e  r e c e n t  a d v a n c e s  f o r  T - L G L  l e u k e m i a  i n  g e n e r a l ,  t h e  d i s e a s e  e t i o l o g y  o f  T C R γ δ +  
T - L G L  l e u k e m i a  r e m a i n s  l a r g e l y  u n k n o w n .  I t  h a s  b e e n  h y p o t h e s i z e d  t h a t  c h r o n i c  ( a n t i -
g e n i c )  s t i m u l a t i o n  w o u l d  p l a y  a  m a j o r  r o l e  i n  t h e  d e v e l o p m e n t  o f  t h e  p r o l i f e r a t i o n ,  a s  
h a s  a c t u a l l y  b e e n  s h o w n  f o r  t h e  T C R α β + C D 4 +  T - L G L  l e u k e m i a  t y p e  [ 1 0 ] .  A l s o ,  i n  2 0 0 6  
S a n d b e r g  e t  a l .  i d e n t i f i e d  t h e  p r e s e n c e  o f  t h e  s o - c a l l e d  i n v a r i a n t  T  s e l e c t i o n  d e t e r m i n a n t  
l e a d i n g  t o  a  c o n s e r v e d  a m i n o  a c i d  a t  t h e  r e l a t i v e  s e c o n d  p o s i t i o n  o f  t h e  C D R 3  r e g i o n  i n  
V δ 2  –  J δ 1  r e a r r a n g e m e n t s  i n  a  l a r g e  s u b g r o u p  o f  T C R γ δ +  T - L G L  p r o l i f e r a t i o n s ,  i n d i c a t i n g  
t h a t  t h e s e  c e l l s  a r e  a n t i g e n - e x p e r i e n c e d .  F u r t h e r m o r e ,  a n  a c t i v a t i o n - a s s o c i a t e d  e f f e c t o r  
p h e n o t y p e  a n d  a  s k e w e d  a n d  d y n a m i c  T C R  r e p e r t o i r e  –  a l s o  r e f e r r e d  t o  a s  c l o n a l  d r i f t  
[ 1 1 ]  –  h a v e  b e e n  f o u n d  i n  T - L G L  p r o l i f e r a t i o n s ,  a g a i n  s u g g e s t i v e  o f  a  r o l e  f o r  a n t i g e n s ,  
b u t  t h e  e x a c t  a n t i g e n  o r  t h e  t y p e  o f  a n t i g e n s  h a v e  s o  f a r  n o t  b e e n  e l u c i d a t e d  [ 3 , 1 2 ] .  E v e n  
t h o u g h  t h e  i n v o l v e d  a n t i g e n ( s )  a r e  u n k n o w n  a n d  m i g h t  b e  v a r i a b l e ,  a n d  t h e  d i s e a s e  i s  
c l i n i c a l l y  h e t e r o g e n e o u s ,  w e  h y p o t h e s i z e d  t h a t  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  h a v e  
c o m m o n  u n d e r l y i n g  m o l e c u l a r  d e f e c t s  t h a t  c o n t r i b u t e  t o  t h e  l e u k e m o g e n e s i s .  I n  o r d e r  
t o  o b t a i n  m o r e  i n - d e p t h  i n s i g h t s  i n t o  t h e  m e c h a n i s m s  d r i v i n g  t h e s e  T C R γ δ +  T - L G L  
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proliferations we therefore performed gene expression profiling analysis in purified 
TCRγδ+ T-LGL leukemia samples. 
Here we present data that TCRγδ+ T-LGL leukemia cells originate from the most 
common antigen-experienced TCRγδ+ T cell population in the adult peripheral blood, and that they have undergone a transformation leading to an imbalance in proliferation 
and apoptosis, eventually contributing to the TCRγδ+ T-LGL leukemia pathogenesis.
MATERIALS AND METHODS
Patients and healthy controls
The database files from the department of Immunology, Erasmus MC, University Medical Center (Rotterdam, The Netherlands) were retrospectively reviewed for cases 
with a proven mature persistent (>6 months) TCRγδ+ T cell proliferation in PB and/or BM based on a combination of clinical, histological (HE sections), cytomorphological (May-Grünwald-Giemsa staining), laboratory, immunophenotypical (including for the 
majority of cases most of the following markers: CD3, TCRγδ, CD4, CD8, CD16, CD56, CD57, CD45RA, CD45RO, CD27, CD197) and molecular data (monoclonal TRG and 
TRD gene rearrangements) [13,14]. Other TCRγδ+ T cell proliferation diseases such as hepatosplenic lymphomas were excluded based on clinical, cytomorphological and/or 
histopathological data. From 10 TCRγδ+ T-LGL leukemia cases frozen cell material was available for inclusion in the current study. The immunophenotypical and molecular analyses were performed on PB and/or BM samples which were erythrocyte-lysed using FACS lysing solution (BD Biosciences, San Jose, CA, USA). PB- or BMMC were isolated by means of Ficoll-Paque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden). As controls, healthy blood donors from Sanquin Blood Bank (Amsterdam, The Netherlands) were included upon informed consent, which were anonymized for further use. PBMCs were 
obtained with Ficoll density gradient separation and cryopreserved in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza, Basel, Switzerland) with dimethyl sulfoxide and stored in vials at -180 °C until further use. Use of all samples for the study was approved by the Erasmus MC Medical Ethics Committee (MEC-2015-617). Studies were conducted in accordance with the principles of the Declaration of Helsinki.
Immunophenotyping and cell sorting
Control PB samples were immunophenotyped to examine the composition of TCRγδ+ T cell subsets based on membrane marker expression, including CD3, CD4, CD8, CD19, 
CD27, CD45RA, CD45RO, CD27, CD197, TCRαβ, TCRVδ1 and TCRVδ2 (Supplementary 
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Table 1). Measurements were performed with a FACS Canto II or FACS LSR Fortessa flow cytometer (BD Biosciences). The immunophenotype of the LGL proliferations 
was already determined during diagnostic work-up, and was therefore available in the database.
For sorting experiments cryopreserved PB- and/or BMMCs were thawed and sorted. Sorting was performed specifically on the tumor cells from the patient samples, using 
CD3, CD45, TCRαβ, TCRγδ, TCRVδ1 and TCRVδ2 markers. 
Healthy control samples were sorted into five different CD3+TCRγδ+ T cell subsets 
based on gating strategies in Supplementary Fig. 1: total TCRVδ1, total TCRVδ2, effec- tor memory (=TemRO population, CD45RO+CD27-CD197-), effector (=TemRA popu-
lation, CD45RA+CD27-CD197-) subsets and a naive, non-antigen stimulated control 
(CD45RA+CD27+CD197+) subset. Sorting was performed with a FACS Aria I or III (BD 
Biosciences).
RNA isolation, cDNA synthesis
After sorting the cells were lysed and subjected to combined DNA/ RNA isolation with the QIAGEN DNA/RNA/miRNA AllPrepKit (QIAGEN, Hilden, Germany).  
For the gene expression profiling experiments RNA from the sorted healthy control 
TCRγδ+ T cell subsets was pooled in order to obtain higher amounts of RNA and to 
create pooled healthy control subset samples; N=3 for Vδ1 and Vδ2 subsets, N=8 for 
naive, TemRO and TemRA subsets due to lower sorting yields. For RQ-PCR tests cDNA was synthesized from isolated RNA as well as cryopreserved 
RNA with reverse transcriptase Superscript II (Invitrogen Life Technologies, Waltham, MA, USA), 10x CA buffer (0.2 M Tris pH 8.3, 0.5M KCl), dNTP (GE Healthcare, Cleveland, 
OH, USA), dithiotreitol (Invitrogen Life Technologies), MgCl2 (Applied Biosystems Life Technologies, Waltham, MA, USA), recombinant RNAsin (Promega, Fitchburg, WI, USA) 
and random primers (Invitrogen Life Technologies). 
Gene expression profiling
Isolated RNA from sorted patient tumor cells and the 5 control TCRγδ+ T cell sub- sets was further amplified, reverse transcribed into cDNA, purified, fragmented, bioti-
nylated and hybridized to Affymetrix HG-U133 Plus 2.0 GeneChip arrays (containing 54,675 probe sets) according to the Affymetrix GeneChip 3’ IVT Express Kit user manual 
(Affymetrix, Santa Clara, CA, USA), as described previously [15-17]. Robust multi-array average (RMA) background removal, compensation for systematic technical differences, 
quantile normalization and probe set summary were performed [18]. Unsupervised correlation and clustering plots were made based on selected probe sets that showed 
signal, i.e. for which the median absolute deviation (MAD) from the median exceeded a 
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G e n e  e x p r e s s i o n  p r o f i l i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
.
T a b l e  1 ) .  M e a s u r e m e n t s  w e r e  p e r f o r m e d  w i t h  a  F A C S  C a n t o  I I  o r  F A C S  L S R  F o r t e s s a  
f l o w  c y t o m e t e r  ( B D  B i o s c i e n c e s ) .  T h e  i m m u n o p h e n o t y p e  o f  t h e  L G L  p r o l i f e r a t i o n s  
w a s  a l r e a d y  d e t e r m i n e d  d u r i n g  d i a g n o s t i c  w o r k - u p ,  a n d  w a s  t h e r e f o r e  a v a i l a b l e  i n  t h e  
d a t a b a s e .
F o r  s o r t i n g  e x p e r i m e n t s  c r y o p r e s e r v e d  P B -  a n d / o r  B M M C s  w e r e  t h a w e d  a n d  s o r t e d .  
S o r t i n g  w a s  p e r f o r m e d  s p e c i f i c a l l y  o n  t h e  t u m o r  c e l l s  f r o m  t h e  p a t i e n t  s a m p l e s ,  u s i n g  
C D 3 ,  C D 4 5 ,  T C R α β ,  T C R γ δ ,  T C R V δ 1  a n d  T C R V δ 2  m a r k e r s .  
H e a l t h y  c o n t r o l  s a m p l e s  w e r e  s o r t e d  i n t o  f i v e  d i f f e r e n t  C D 3 + T C R γ δ +  T  c e l l  s u b s e t s  
b a s e d  o n  g a t i n g  s t r a t e g i e s  i n  S u p p l e m e n t a r y  F i g .  1 :  t o t a l  T C R V δ 1 ,  t o t a l  T C R V δ 2 ,  e f f e c -
t o r  m e m o r y  ( = T e m R O  p o p u l a t i o n ,  C D 4 5 R O + C D 2 7 - C D 1 9 7 - ) ,  e f f e c t o r  ( = T e m R A  p o p u -
l a t i o n ,  C D 4 5 R A + C D 2 7 - C D 1 9 7 - )  s u b s e t s  a n d  a  n a i v e ,  n o n - a n t i g e n  s t i m u l a t e d  c o n t r o l  
( C D 4 5 R A + C D 2 7 + C D 1 9 7 + )  s u b s e t .  S o r t i n g  w a s  p e r f o r m e d  w i t h  a  F A C S  A r i a  I  o r  I I I  ( B D  
B i o s c i e n c e s ) .
R N A  i s o l a t i o n ,  c D N A  s y n t h e s i s
A f t e r  s o r t i n g  t h e  c e l l s  w e r e  l y s e d  a n d  s u b j e c t e d  t o  c o m b i n e d  D N A /  R N A  i s o l a t i o n  
w i t h  t h e  Q I A G E N  D N A / R N A / m i R N A  A l l P r e p K i t  ( Q I A G E N ,  H i l d e n ,  G e r m a n y ) .   
F o r  t h e  g e n e  e x p r e s s i o n  p r o f i l i n g  e x p e r i m e n t s  R N A  f r o m  t h e  s o r t e d  h e a l t h y  c o n t r o l  
T C R γ δ +  T  c e l l  s u b s e t s  w a s  p o o l e d  i n  o r d e r  t o  o b t a i n  h i g h e r  a m o u n t s  o f  R N A  a n d  t o  
c r e a t e  p o o l e d  h e a l t h y  c o n t r o l  s u b s e t  s a m p l e s ;  N = 3  f o r  V δ 1  a n d  V δ 2  s u b s e t s ,  N = 8  f o r  
n a i v e ,  T e m R O  a n d  T e m R A  s u b s e t s  d u e  t o  l o w e r  s o r t i n g  y i e l d s .
F o r  R Q - P C R  t e s t s  c D N A  w a s  s y n t h e s i z e d  f r o m  i s o l a t e d  R N A  a s  w e l l  a s  c r y o p r e s e r v e d  
R N A  w i t h  r e v e r s e  t r a n s c r i p t a s e  S u p e r s c r i p t  I I  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s ,  W a l t h a m ,  
M A ,  U S A ) ,  1 0 x  C A  b u f f e r  ( 0 . 2  M  T r i s  p H  8 . 3 ,  0 . 5 M  K C l ) ,  d N T P  ( G E  H e a l t h c a r e ,  C l e v e l a n d ,  
O H ,  U S A ) ,  d i t h i o t r e i t o l  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s ) ,  M g C l
2
 ( A p p l i e d  B i o s y s t e m s  L i f e  
T e c h n o l o g i e s ,  W a l t h a m ,  M A ,  U S A ) ,  r e c o m b i n a n t  R N A s i n  ( P r o m e g a ,  F i t c h b u r g ,  W I ,  U S A )  
a n d  r a n d o m  p r i m e r s  ( I n v i t r o g e n  L i f e  T e c h n o l o g i e s ) .  
G e n e  e x p r e s s i o n  p r o f i l i n g
I s o l a t e d  R N A  f r o m  s o r t e d  p a t i e n t  t u m o r  c e l l s  a n d  t h e  5  c o n t r o l  T C R γ δ +  T  c e l l  s u b -
s e t s  w a s  f u r t h e r  a m p l i f i e d ,  r e v e r s e  t r a n s c r i b e d  i n t o  c D N A ,  p u r i f i e d ,  f r a g m e n t e d ,  b i o t i -
n y l a t e d  a n d  h y b r i d i z e d  t o  A f f y m e t r i x  H G - U 1 3 3  P l u s  2 . 0  G e n e C h i p  a r r a y s  ( c o n t a i n i n g  
5 4 , 6 7 5  p r o b e  s e t s )  a c c o r d i n g  t o  t h e  A f f y m e t r i x  G e n e C h i p  3 ’  I V T  E x p r e s s  K i t  u s e r  m a n u a l  
( A f f y m e t r i x ,  S a n t a  C l a r a ,  C A ,  U S A ) ,  a s  d e s c r i b e d  p r e v i o u s l y  [ 1 5 - 1 7 ] .  R o b u s t  m u l t i - a r r a y  
a v e r a g e  ( R M A )  b a c k g r o u n d  r e m o v a l ,  c o m p e n s a t i o n  f o r  s y s t e m a t i c  t e c h n i c a l  d i f f e r e n c e s ,  
q u a n t i l e  n o r m a l i z a t i o n  a n d  p r o b e  s e t  s u m m a r y  w e r e  p e r f o r m e d  [ 1 8 ] .  U n s u p e r v i s e d  
c o r r e l a t i o n  a n d  c l u s t e r i n g  p l o t s  w e r e  m a d e  b a s e d  o n  s e l e c t e d  p r o b e  s e t s  t h a t  s h o w e d  
s i g n a l ,  i . e .  f o r  w h i c h  t h e  m e d i a n  a b s o l u t e  d e v i a t i o n  ( M A D )  f r o m  t h e  m e d i a n  e x c e e d e d  a  
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certain threshold Thr on a log2 scale. To further assess differential expression, a number of supervised analyses were applied: fold change calculation (FC), analysis of variance 
(ANOVA) [19] and significance analysis of microarrays (SAM) were applied [20]. All comparisons concerned disease cases versus normal control cases. Data were analyzed through the use of the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID Database) [21,22], and QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood City, USA; www.qiagen.com/ingenuity).
Real-time quantitative PCR (RQ-PCR)Assays were designed with the Roche Universal Probe Library (Roche, Basel, 
Switzerland) (Supplementary Table 2). RQ-PCR experiments were performed with TaqMan Universal PCR master mix (2x) (Applied Biosystems) on the StepOnePlus instru-ment (Thermo Fisher, Waltham, MA, USA). Ct values of disease samples were normalized to the Ct value of the ABL housekeeping gene [23] and normalized Ct values of healthy 
control samples (ΔΔCt method).
Statistical analysis
Supervised statistical analyses for the gene expression profiling data were performed 
using analysis of variance (ANOVA), with significance cutoff at p<0.05 and as threshold 
of up- and/or down-regulation ≥2 fold change. Significance of microarray analysis (SAM) 
with significance cutoff <0.05 was included in the analysis as comparison. Bonferroni and Benjamini-Hochberg p-value adjustment were applied for multiple testing correc-tion and comparison of different statistical tests on the data set.
RESULTS 
Heterogeneity in clinical presentation, associated diseases and 
immunophenotype and –genotype among TCRγδ+ T-LGL leukemia 
patients
In all ten patients a proven TCRγδ+ T-LGL leukemia was identified, based on immuno-
phenotype, immunogenotype, high leukocyte count, and high percentage of TCRγδ+ 
T-LGL cells compared with reference values of PB TCRγδ+ T cells (<5% of all lymphocytes 
in general) [6]. All cases were diagnosed as TCRγδ+ T-LGL leukemia, while other causes 
of TCRγδ+ T cell proliferation, such as hepatosplenic lymphoma, were excluded. There was a slight male predominance among the patients (seven males, three females). Most patients showed chronic leukemia-associated symptoms, such as fever and cytopenia, and underlying (auto)immune diseases such as rheumatoid arthritis, Graves’ disease and 
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uveitis (Table 1).  In general, immunophenotyping showed CD3-positivity, CD4-negativity and in some cases CD8-positivity, together with variable expression of markers that have 
been associated with LGL cells such as CD16, CD56 and/or CD57, and frequent CD45RA positivity in combination with CD27 and/or CD197 negativity, pointing towards TemRA 
and TemRO phenotypes (Table 1). For some patients Vγ and Vδ-usage was determined 
with flow cytometry as well, which correlated with the immunogenotyping data (Table 
1). Among the patients half showed Vδ1 – Jδ1 rearrangements, whereas the other half 
showed Vδ2 – Jδ1 rearrangements. Most patients had a Vγ9 – Jγ1.1/2.1 or Jγ1.3/2.3 
rearrangement, leading to an overall receptor predominance of Vγ9/Vδ1 and Vγ9/Vδ2. 
Most patients showed a monoclonal TCRγδ+ T-LGL cell population at the receptor level, 
whereas two patients showed a somewhat oligoclonal profile albeit with a dominant 
clone, possibly indicating the presence of additional non-aberrant TCRγδ+ T cells or 
subclones (Table 1).
Unsupervised clustering of TCRγδ+ T-LGL leukemia cases shows 
highest resemblance to normal effector TCRγδ+ T cells
Despite some level of phenotypical heterogeneity between patients, we next evaluated the transcriptomes of 10 TCRγδ+ T-LGL leukemia patients versus 5 healthy 
control TCRγδ+ T cell subsets in order to obtain more insight into the immunobiology 
of the disease and to possibly identify common downstream pathogenic events in TCRγδ+ T-LGL leukemia. As from literature it is known that TCRγδ+ T-LGL leukemias 
are antigen-experienced [4,6], TemRO and TemRA TCRγδ+ subsets were used as healthy 
control counterparts for the TCRγδ+ T-LGL cells. As a non-antigen stimulated control 
the naive TCRγδ+ population was included. In order to get a general view from gene 
expression profiling, first a correlation analysis was performed based on selected probe 
sets that showed significant variation between all microarrays (with a median absolute 
deviation from the median (MAD) of at least Thr = 0.7). In the heatmap TCRγδ+ T-LGL leukemia cases and healthy control TCRγδ+ T cell subsets were on purpose represented 
separately, as they represent distinct groups. The heatmap showed a clear distinction between TCRγδ+ T-LGL leukemia cases and healthy control TCRγδ+ T cell subsets, 
suggesting that the TCRγδ+ T-LGL leukemia cases indeed form a separate group with 
a distinct transcriptome (Fig. 1a). The healthy control subset that correlated best with the TCRγδ+ T-LGL leukemia cases was the TemRA TCRγδ+ T cell subset, and to a lesser 
extent the TemRO subset, in line with our patient phenotype data (Table 1), whereas the naive TCRγδ+ T cell subsets showed the lowest correlation, as was expected (Fig. 1b). 
Hierarchical clustering confirmed that 8/10 TCRγδ+ T-LGL leukemia cases indeed 
formed a separate group from the healthy control subsets, whilst two cases, LGL087 and LGL113, grouped together with TemRA, TemRO and TCRVδ2 subsets (Fig. 1c). The same 
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u v e i t i s  ( T a b l e  1 ) .   I n  g e n e r a l ,  i m m u n o p h e n o t y p i n g  s h o w e d  C D 3 - p o s i t i v i t y ,  C D 4 - n e g a t i v i t y  
a n d  i n  s o m e  c a s e s  C D 8 - p o s i t i v i t y ,  t o g e t h e r  w i t h  v a r i a b l e  e x p r e s s i o n  o f  m a r k e r s  t h a t  h a v e  
b e e n  a s s o c i a t e d  w i t h  L G L  c e l l s  s u c h  a s  C D 1 6 ,  C D 5 6  a n d / o r  C D 5 7 ,  a n d  f r e q u e n t  C D 4 5 R A  
p o s i t i v i t y  i n  c o m b i n a t i o n  w i t h  C D 2 7  a n d / o r  C D 1 9 7  n e g a t i v i t y ,  p o i n t i n g  t o w a r d s  T e m R A  
a n d  T e m R O  p h e n o t y p e s  ( T a b l e  1 ) .  F o r  s o m e  p a t i e n t s  V γ  a n d  V δ - u s a g e  w a s  d e t e r m i n e d  
w i t h  f l o w  c y t o m e t r y  a s  w e l l ,  w h i c h  c o r r e l a t e d  w i t h  t h e  i m m u n o g e n o t y p i n g  d a t a  ( T a b l e  
1 ) .  A m o n g  t h e  p a t i e n t s  h a l f  s h o w e d  V δ 1  –  J δ 1  r e a r r a n g e m e n t s ,  w h e r e a s  t h e  o t h e r  h a l f  
s h o w e d  V δ 2  –  J δ 1  r e a r r a n g e m e n t s .  M o s t  p a t i e n t s  h a d  a  V γ 9  –  J γ 1 . 1 / 2 . 1  o r  J γ 1 . 3 / 2 . 3  
r e a r r a n g e m e n t ,  l e a d i n g  t o  a n  o v e r a l l  r e c e p t o r  p r e d o m i n a n c e  o f  V γ 9 / V δ 1  a n d  V γ 9 / V δ 2 .  
M o s t  p a t i e n t s  s h o w e d  a  m o n o c l o n a l  T C R γ δ +  T - L G L  c e l l  p o p u l a t i o n  a t  t h e  r e c e p t o r  l e v e l ,  
w h e r e a s  t w o  p a t i e n t s  s h o w e d  a  s o m e w h a t  o l i g o c l o n a l  p r o f i l e  a l b e i t  w i t h  a  d o m i n a n t  
c l o n e ,  p o s s i b l y  i n d i c a t i n g  t h e  p r e s e n c e  o f  a d d i t i o n a l  n o n - a b e r r a n t  T C R γ δ +  T  c e l l s  o r  
s u b c l o n e s  ( T a b l e  1 ) .
U n s u p e r v i s e d  c l u s t e r i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  s h o w s  
h i g h e s t  r e s e m b l a n c e  t o  n o r m a l  e f f e c t o r  T C R γ δ +  T  c e l l s
D e s p i t e  s o m e  l e v e l  o f  p h e n o t y p i c a l  h e t e r o g e n e i t y  b e t w e e n  p a t i e n t s ,  w e  n e x t  
e v a l u a t e d  t h e  t r a n s c r i p t o m e s  o f  1 0  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  v e r s u s  5  h e a l t h y  
c o n t r o l  T C R γ δ +  T  c e l l  s u b s e t s  i n  o r d e r  t o  o b t a i n  m o r e  i n s i g h t  i n t o  t h e  i m m u n o b i o l o g y  
o f  t h e  d i s e a s e  a n d  t o  p o s s i b l y  i d e n t i f y  c o m m o n  d o w n s t r e a m  p a t h o g e n i c  e v e n t s  i n  
T C R γ δ +  T - L G L  l e u k e m i a .  A s  f r o m  l i t e r a t u r e  i t  i s  k n o w n  t h a t  T C R γ δ +  T - L G L  l e u k e m i a s  
a r e  a n t i g e n - e x p e r i e n c e d  [ 4 , 6 ] ,  T e m R O  a n d  T e m R A  T C R γ δ +  s u b s e t s  w e r e  u s e d  a s  h e a l t h y  
c o n t r o l  c o u n t e r p a r t s  f o r  t h e  T C R γ δ +  T - L G L  c e l l s .  A s  a  n o n - a n t i g e n  s t i m u l a t e d  c o n t r o l  
t h e  n a i v e  T C R γ δ +  p o p u l a t i o n  w a s  i n c l u d e d .  I n  o r d e r  t o  g e t  a  g e n e r a l  v i e w  f r o m  g e n e  
e x p r e s s i o n  p r o f i l i n g ,  f i r s t  a  c o r r e l a t i o n  a n a l y s i s  w a s  p e r f o r m e d  b a s e d  o n  s e l e c t e d  p r o b e  
s e t s  t h a t  s h o w e d  s i g n i f i c a n t  v a r i a t i o n  b e t w e e n  a l l  m i c r o a r r a y s  ( w i t h  a  m e d i a n  a b s o l u t e  
d e v i a t i o n  f r o m  t h e  m e d i a n  ( M A D )  o f  a t  l e a s t  T h r  =  0 . 7 ) .  I n  t h e  h e a t m a p  T C R γ δ +  T - L G L  
l e u k e m i a  c a s e s  a n d  h e a l t h y  c o n t r o l  T C R γ δ +  T  c e l l  s u b s e t s  w e r e  o n  p u r p o s e  r e p r e s e n t e d  
s e p a r a t e l y ,  a s  t h e y  r e p r e s e n t  d i s t i n c t  g r o u p s .  T h e  h e a t m a p  s h o w e d  a  c l e a r  d i s t i n c t i o n  
b e t w e e n  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  a n d  h e a l t h y  c o n t r o l  T C R γ δ +  T  c e l l  s u b s e t s ,  
s u g g e s t i n g  t h a t  t h e  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  i n d e e d  f o r m  a  s e p a r a t e  g r o u p  w i t h  
a  d i s t i n c t  t r a n s c r i p t o m e  ( F i g .  1 a ) .  T h e  h e a l t h y  c o n t r o l  s u b s e t  t h a t  c o r r e l a t e d  b e s t  w i t h  
t h e  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  w a s  t h e  T e m R A  T C R γ δ +  T  c e l l  s u b s e t ,  a n d  t o  a  l e s s e r  
e x t e n t  t h e  T e m R O  s u b s e t ,  i n  l i n e  w i t h  o u r  p a t i e n t  p h e n o t y p e  d a t a  ( T a b l e  1 ) ,  w h e r e a s  t h e  
n a i v e  T C R γ δ +  T  c e l l  s u b s e t s  s h o w e d  t h e  l o w e s t  c o r r e l a t i o n ,  a s  w a s  e x p e c t e d  ( F i g .  1 b ) .  
H i e r a r c h i c a l  c l u s t e r i n g  c o n f i r m e d  t h a t  8 / 1 0  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  i n d e e d  
f o r m e d  a  s e p a r a t e  g r o u p  f r o m  t h e  h e a l t h y  c o n t r o l  s u b s e t s ,  w h i l s t  t w o  c a s e s ,  L G L 0 8 7  a n d  
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clustering was observed when a principal component analysis (PCA) was performed (Fig. 1d). One case was studied in duplo (LGL058, Fig. 1) to assess reproducibility of the 
arrays, which was indeed high. Overall the TCRγδ+ T-LGL leukemia cases thus mostly 
form a separate group based on their gene expression profile, showing closest correla- tion with the healthy normal TemRA TCRγδ+ T cell subset.
Figure 1. Unsupervised gene expression data analysis.
(a) Heatmap analysis shows clear correlations between TCRγδ+ T-LGL proliferation cases, and lower correlations to the healthy control TCRγδ+ T cell subsets, (b) the highest being to the TemRA TCRγδ+ T cell subset. (c) The clustergram shows that the TCRγδ+ T-LGL proliferation cases indeed form a distinct group, 
except for two cases which cluster closer to healthy control TemRA, TemRO and TCRVδ2 TCRγδ+ T cell subsets. 
(d) Principal component analysis (PCA) in three-dimensional (3D) graph shows similar clustering results. Thr=0.7; 1336 probe sets. Case LGL058 indicated in italics was studied in duplo to assess reproducibility of the assay.
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c l u s t e r i n g  w a s  o b s e r v e d  w h e n  a  p r i n c i p a l  c o m p o n e n t  a n a l y s i s  ( P C A )  w a s  p e r f o r m e d  
( F i g .  1 d ) .  O n e  c a s e  w a s  s t u d i e d  i n  d u p l o  ( L G L 0 5 8 ,  F i g .  1 )  t o  a s s e s s  r e p r o d u c i b i l i t y  o f  t h e  
a r r a y s ,  w h i c h  w a s  i n d e e d  h i g h .  O v e r a l l  t h e  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  t h u s  m o s t l y  
f o r m  a  s e p a r a t e  g r o u p  b a s e d  o n  t h e i r  g e n e  e x p r e s s i o n  p r o f i l e ,  s h o w i n g  c l o s e s t  c o r r e l a -
t i o n  w i t h  t h e  h e a l t h y  n o r m a l  T e m R A  T C R γ δ +  T  c e l l  s u b s e t .
F i g u r e  1 .  U n s u p e r v i s e d  g e n e  e x p r e s s i o n  d a t a  a n a l y s i s .
( a )  H e a t m a p  a n a l y s i s  s h o w s  c l e a r  c o r r e l a t i o n s  b e t w e e n  T C R γ δ +  T - L G L  p r o l i f e r a t i o n  c a s e s ,  a n d  l o w e r  
c o r r e l a t i o n s  t o  t h e  h e a l t h y  c o n t r o l  T C R γ δ +  T  c e l l  s u b s e t s ,  ( b )  t h e  h i g h e s t  b e i n g  t o  t h e  T e m R A  T C R γ δ +  T  c e l l  
s u b s e t .  ( c )  T h e  c l u s t e r g r a m  s h o w s  t h a t  t h e  T C R γ δ +  T - L G L  p r o l i f e r a t i o n  c a s e s  i n d e e d  f o r m  a  d i s t i n c t  g r o u p ,  
e x c e p t  f o r  t w o  c a s e s  w h i c h  c l u s t e r  c l o s e r  t o  h e a l t h y  c o n t r o l  T e m R A ,  T e m R O  a n d  T C R V δ 2  T C R γ δ +  T  c e l l  s u b s e t s .  
( d )  P r i n c i p a l  c o m p o n e n t  a n a l y s i s  ( P C A )  i n  t h r e e - d i m e n s i o n a l  ( 3 D )  g r a p h  s h o w s  s i m i l a r  c l u s t e r i n g  r e s u l t s .  
T h r = 0 . 7 ;  1 3 3 6  p r o b e  s e t s .  C a s e  L G L 0 5 8  i n d i c a t e d  i n  i t a l i c s  w a s  s t u d i e d  i n  d u p l o  t o  a s s e s s  r e p r o d u c i b i l i t y  o f  
t h e  a s s a y .
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Supervised analysis showed a dysregulated balance in proliferation 
and apoptosis
Following unsupervised clustering analysis, specific comparisons were performed 
between all TCRγδ+ T-LGL leukemia cases vs. naive, TemRO and TemRA healthy control 
TCRγδ+ T cell subsets. Two statistical comparisons, significance analysis of microarrays (SAM) and two-way analysis of variance (ANOVA) were applied that yielded varying numbers of differentially expressed probe sets (Supplementary Table 3). Stringent 
statistical filtering using SAM showed low numbers of mainly down-regulated genes in 
the comparison between TCRγδ+ T-LGL leukemia cases and TemRO and TemRA sub-sets. When the comparison was performed with the naive subset, the numbers of dif-ferentially expressed probe sets found by both statistical analysis methods were high. 
Both methods confirmed the relatively high similarity of TCRγδ+ T-LGL leukemia cases 
to the healthy TemRO and TemRA subsets, and the lower similarity to naive TCRγδ+ T cells as also observed in the unsupervised clustering. Since the SAM analysis showed low numbers of differentially expressed probe sets, and in order to reduce the risk of missing data, we therefore used the two-way ANOVA set for further supervised analysis. 
Top up- and down-regulated genes in TCRγδ+ T-LGL leukemia cells vs. the best correlat-
ing subset, the TemRA TCRγδ+ T cells, are depicted in Supplementary Table 4. Most 
up-regulated genes appeared to be involved in the inflammatory response and response to bacteria: LYZ, S100A8, S100A9, ALOX5 and LTB according to the DAVID database. The top down-regulated genes were mostly associated with the process of transcription; these genes included amongst others GTF2H3, CTBP2 and ZNF260. In order to identify genes associated with biologically more relevant pathways and 
processes, the probe sets that were significantly differentially expressed with a fold 
change of at least 2 (both up- and down-regulated) in TCRγδ+ T-LGL leukemia cells 
when compared to the healthy TemRA TCRγδ+ T cell subset were then further analyzed with the DAVID database [21,22]. Gene Ontology biological process analysis showed pro-cesses involved in the regulation of the immune system and response, T cell activation, and response to stress to be affected (Table 2). Enrichment analysis of KEGG pathways in DAVID showed that differentially expressed genes were largely involved in the hema-
topoietic cell lineage, osteoclast differentiation, rheumatoid arthritis disease and NFκB signaling, although after correction for multiple testing none of these were found to be 
significant. Nevertheless, similar processes, such as hematopoietic system and inflam-
mation, were identified (Table 3). Differentially expressed probe sets in the comparison 
between TCRγδ+ T-LGL leukemia cells vs. TemRO cells showed similar processes to be affected (Supplementary Table 5). Taken together, both annotation enrichment analyses 
(Gene Ontology, KEGG) indicated that proliferation, cell survival signaling and inflamma-tory processes were affected. 
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For further interpretation and visualization of differentially expressed genes, Ingenuity Pathway Analysis (IPA) was used. First, TCRγδ+ T-LGL leukemia cases were 
compared to healthy TemRA TCRγδ+ T cells, showing a number of processes which were 
up-regulated in the TCRγδ+ T-LGL leukemia cases, such as hematological development 
and function. However, cell death and survival processes appeared to be significantly 
down-regulated (Fig. 2a). Again, similar results were obtained after analyzing the 
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F o r  f u r t h e r  i n t e r p r e t a t i o n  a n d  v i s u a l i z a t i o n  o f  d i f f e r e n t i a l l y  e x p r e s s e d  g e n e s ,  
I n g e n u i t y  P a t h w a y  A n a l y s i s  ( I P A )  w a s  u s e d .  F i r s t ,  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  w e r e  
c o m p a r e d  t o  h e a l t h y  T e m R A  T C R γ δ +  T  c e l l s ,  s h o w i n g  a  n u m b e r  o f  p r o c e s s e s  w h i c h  w e r e  
u p - r e g u l a t e d  i n  t h e  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s ,  s u c h  a s  h e m a t o l o g i c a l  d e v e l o p m e n t  
a n d  f u n c t i o n .  H o w e v e r ,  c e l l  d e a t h  a n d  s u r v i v a l  p r o c e s s e s  a p p e a r e d  t o  b e  s i g n i f i c a n t l y  
d o w n - r e g u l a t e d  ( F i g .  2 a ) .  A g a i n ,  s i m i l a r  r e s u l t s  w e r e  o b t a i n e d  a f t e r  a n a l y z i n g  t h e  
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differentially expressed probe sets between TCRγδ+ T-LGL leukemia cases and the 
healthy TemRO subset (Fig. 2b), confirming comparable correlation of both subsets with 
the TCRγδ+ T-LGL leukemias as described from the unsupervised analysis (Fig. 1). 
After identifying affected processes we focused more in-depth on specific genes. Genes involved in apoptosis, such as BCLAF1, CASP1, XIAP and CFLAR, appeared to be the most relevant candidate genes. The apoptosis-inducing genes CASP1 and CFLAR were down-regulated, as well as the apoptosis inhibitor XIAP, while BCLAF1 was up-regulated. Furthermore, transcription factors such as ID3, KLF4, LEF1 and SOX4 in the up-regulated cell survival process were all found to be up-regulated. Finally, altered expressions of 
CD28, CCR7, CX3CR1, IFNG, LTB and PRF1 were all contributing to the inflammatory pro-
file of the TCRγδ+ T-LGL leukemias. Collectively, data from all analysis methods (DAVID Gene Ontology, DAVID KEGG, IPA) thus showed that proliferation and cell survival signaling were up-regulated, while 
apoptosis was down-regulated in TCRγδ+ T-LGL leukemia cells when compared to 
normal TCRγδ+ T cell subsets.
RQ-PCR validation indicates possible signature genes within a highly 
heterogeneous disease profileNext, representative candidate genes, which were found in the comparison between 
TCRγδ+ T-LGL leukemia cells and healthy TemRA and TemRO TCRγδ+ T cells in both IPA and DAVID analysis, and which appeared biologically relevant for the disease, were selected. These included genes involved in cell death and survival processes (BCLAF1, 
CFLAR, CASP1, and XIAP), genes associated with proliferation-driving transcription or 
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cancer (KLF4, LEF1, SOX4, ID3), and genes associated with inflammation (CD28, CCR7, CX3CR1 and IFNG). Differences in gene expression levels were analyzed by means of 
real-time quantitative (RQ)-PCR using Universal Probe Library reagents. Sorted healthy 
control TemRA TCRγδ+ T cells were compared with the sorted TCRγδ+ T-LGL leukemia 
cells from patients (both from patients included in the microarray analysis, and from new patients). In order to validate the fold changes obtained from microarray analy-
sis, expression ratios between patients and healthy controls were calculated from the RQ-PCR data. All selected apoptosis-related genes from our microarray analysis, were 
confirmed to be differentially expressed in TCRγδ+ T-LGL leukemia cases when compared 
to healthy controls; XIAP, CASP1, BCLAF1 were all validated to be over two-fold higher, and especially CFLAR to an even higher extent than observed in the microarrays (Fig. 3). 
Transcription factor ID3 could also be validated in RQ-PCR; the ratio between TCRγδ+ T-LGL leukemia patients and healthy controls was even higher than that observed in 
the microarrays. Other transcription factors identified from the microarray analysis 
(KLF4, LEF1 and SOX4) could not be confirmed by RQ-PCR validation (Supplementary 
Figure 2. Functional annotation of genes differentially expressed between TCRγδ+ T-LGL leukemia 
cases and healthy control TCRγδ+ T cell subsets.
(a) Comparison of TCRγδ+ T-LGL leukemia cases versus healthy control TemRA and (b) TemRO TCRγδ+ T cell subsets showing similar patterns with down-regulation of apoptosis and up-regulation of cancer-related processes. Sizing based on significance level (ANOVA), up- and down-regulation based on z-scoring. Plots were 
generated in QIAGEN’s Ingenuity Pathway Analysis. 
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c a n c e r  ( K L F 4 ,  L E F 1 ,  S O X 4 ,  I D 3 ) ,  a n d  g e n e s  a s s o c i a t e d  w i t h  i n f l a m m a t i o n  ( C D 2 8 ,  C C R 7 ,  
C X 3 C R 1  a n d  I F N G ) .  D i f f e r e n c e s  i n  g e n e  e x p r e s s i o n  l e v e l s  w e r e  a n a l y z e d  b y  m e a n s  o f  
r e a l - t i m e  q u a n t i t a t i v e  ( R Q ) - P C R  u s i n g  U n i v e r s a l  P r o b e  L i b r a r y  r e a g e n t s .  S o r t e d  h e a l t h y  
c o n t r o l  T e m R A  T C R γ δ +  T  c e l l s  w e r e  c o m p a r e d  w i t h  t h e  s o r t e d  T C R γ δ +  T - L G L  l e u k e m i a  
c e l l s  f r o m  p a t i e n t s  ( b o t h  f r o m  p a t i e n t s  i n c l u d e d  i n  t h e  m i c r o a r r a y  a n a l y s i s ,  a n d  f r o m  
n e w  p a t i e n t s ) .  I n  o r d e r  t o  v a l i d a t e  t h e  f o l d  c h a n g e s  o b t a i n e d  f r o m  m i c r o a r r a y  a n a l y -
s i s ,  e x p r e s s i o n  r a t i o s  b e t w e e n  p a t i e n t s  a n d  h e a l t h y  c o n t r o l s  w e r e  c a l c u l a t e d  f r o m  t h e  
R Q - P C R  d a t a .  A l l  s e l e c t e d  a p o p t o s i s - r e l a t e d  g e n e s  f r o m  o u r  m i c r o a r r a y  a n a l y s i s ,  w e r e  
c o n f i r m e d  t o  b e  d i f f e r e n t i a l l y  e x p r e s s e d  i n  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  w h e n  c o m p a r e d  
t o  h e a l t h y  c o n t r o l s ;  X I A P,  C A S P 1 ,  B C L A F 1  w e r e  a l l  v a l i d a t e d  t o  b e  o v e r  t w o - f o l d  h i g h e r ,  
a n d  e s p e c i a l l y  C F L A R  t o  a n  e v e n  h i g h e r  e x t e n t  t h a n  o b s e r v e d  i n  t h e  m i c r o a r r a y s  ( F i g .  3 ) .  
T r a n s c r i p t i o n  f a c t o r  I D 3  c o u l d  a l s o  b e  v a l i d a t e d  i n  R Q - P C R ;  t h e  r a t i o  b e t w e e n  T C R γ δ +  
T - L G L  l e u k e m i a  p a t i e n t s  a n d  h e a l t h y  c o n t r o l s  w a s  e v e n  h i g h e r  t h a n  t h a t  o b s e r v e d  i n  
t h e  m i c r o a r r a y s .  O t h e r  t r a n s c r i p t i o n  f a c t o r s  i d e n t i f i e d  f r o m  t h e  m i c r o a r r a y  a n a l y s i s  
( K L F 4 ,  L E F 1  a n d  S O X 4 )  c o u l d  n o t  b e  c o n f i r m e d  b y  R Q - P C R  v a l i d a t i o n  ( S u p p l e m e n t a r y  
F i g u r e  2 .  F u n c t i o n a l  a n n o t a t i o n  o f  g e n e s  d i f f e r e n t i a l l y  e x p r e s s e d  b e t w e e n  T C R γ δ +  T - L G L  l e u k e m i a  
c a s e s  a n d  h e a l t h y  c o n t r o l  T C R γ δ +  T  c e l l  s u b s e t s .
( a )  C o m p a r i s o n  o f  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  v e r s u s  h e a l t h y  c o n t r o l  T e m R A  a n d  ( b )  T e m R O  T C R γ δ +  T  
c e l l  s u b s e t s  s h o w i n g  s i m i l a r  p a t t e r n s  w i t h  d o w n - r e g u l a t i o n  o f  a p o p t o s i s  a n d  u p - r e g u l a t i o n  o f  c a n c e r - r e l a t e d  
p r o c e s s e s .  S i z i n g  b a s e d  o n  s i g n i f i c a n c e  l e v e l  ( A N O V A ) ,  u p -  a n d  d o w n - r e g u l a t i o n  b a s e d  o n  z - s c o r i n g .  P l o t s  w e r e  
g e n e r a t e d  i n  Q I A G E N ’ s  I n g e n u i t y  P a t h w a y  A n a l y s i s .  
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Table 6). CD28, CCR7 and CX3CR1 were validated as well, albeit with a lower fold change than in the microarrays. IFNG was validated with an approximately two-fold higher fold 
change in RQ-PCR than in the microarrays (Fig. 3). Of note, considerable heterogeneity 
in RQ-PCR levels was observed within the samples used for validation (Supplementary 
Table 6), thus reflecting the heterogeneity of the disease. Taken together, we were able to identify possible candidate genes to distinguish 
aberrant from normal TCRγδ+ T cells, although the known largely heterogeneous profile of the disease remains noticeable, which may partly mask differences between leukemic 
TCRγδ+ T-LGL cells and normal TCRγδ+ T cell subsets. 
DISCUSSION AND CONCLUSION
T cell large granular lymphocyte disorders form a large group of heterogeneous 
mature T cell neoplasms, of which the TCRγδ+ T cell variant is rare and most poorly 
understood. TCRγδ+ T-LGL leukemia is known to have a slowly progressive indolent 
Figure 3. RQ-PCR validation of most representative genes.
Fold changes of representative genes identified through gene expression profiling and by RQ-PCR. Relative 
expression of genes found differentially expressed using microarrays was first normalized to ABL housekeeping 
gene (ΔCt). Average ΔCt values from healthy controls (N=6) were used to calculate patient (N=10) to healthy 
control ratios per patient to obtain fold change values (ΔΔCt). White bars depict fold change values obtained 
from microarray data, grey bars depict average ΔΔCt values after RQ-PCR validation. For RQ-PCR validation 4 patients from the original microarray dataset were used and 6 novel patients. Mean expression fold change values are indicated with the standard deviation.
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disease course, mostly affecting elderly individuals, while showing similar (initial) clin- ical presentations such as neutropenia, anemia and pancytopenia [4,6,25]. Most of our 
patients displayed malignancy, autoimmunity or cytopenia as underlying or associated diseases, as described previously [26], but there was no consistent pattern. Furthermore, 
immunophenotypic features did not correlate with the symptomatic status or under- lying diseases. Underlying (chronic) diseases could play a role in the pathogenesis of 
TCRγδ+ T-LGL leukemia, possibly as a (chronic) stimulus that causes the TCRγδ+ T cells 
to expand, in line with the idea that TCRγδ+ T-LGL leukemia develops from dominant 
normal TCRγδ+ T cell populations in the adult peripheral blood. However, underlying 
molecular mechanisms in TCRγδ+ T-LGL leukemogenesis are largely unknown, and a 
common underlying molecular defect has not been described earlier. TCRγδ+ T-LGL leukemias are characterized by skewed receptor expression and an 
antigen stimulation-associated activation status, but are also considered to harbour particular changes in gene expression. In our current study we aimed to address this 
by means of gene expression profiling, which revealed that the TCRγδ+ T-LGL leukemia 
cells displayed different gene expression profiles when compared to healthy, polyclon- ally expanded TCRγδ+ T cells. Initial unsupervised clustering based on microarray data 
from aberrant TCRγδ+ T cells and different healthy TCRγδ+ T cell subsets, showed a 
clear distinction between the TCRγδ+ T-LGL leukemia and its healthy counterparts. Even 
though TCRγδ+ T-LGL leukemia forms a separate group, with the lowest correlation with 
the naive subset as expected, the correlation with the TemRA subset was quite high, sug- gesting that it is derived from the most predominant and antigen-experienced type of 
TCRγδ+ T cell populations in adult peripheral blood, in line with earlier published data 
[27]. When focusing more in-depth on differences in comparison with normal TemRA TCRγδ+ T cells it became clear that particular biological functions, processes and genes 
were affected. Most relevant genes involved processes such as proliferation, stimulation and apoptosis, with an increase in proliferation and cell survival, and a decrease in apop-
tosis. One clear example concerned transcription factor ID3, which is involved in prolif- eration and haematological development, a.o. by enhancing TCRγδ+ T cell development 
[28]. Up-regulation in TCRγδ+ T-LGL leukemia cases could be confirmed with RQ-PCR. 
As opposed to proliferation genes, some apoptosis-inducing genes such as CASP1 and CFLAR were down-regulated. Caspase-1 is an apoptosis-related cysteine peptidase, 
which is involved in inflammation and apoptosis by proteolysis of pro-inflammatory 
cytokines and activating other caspases and pro-apoptotic proteins [29,30]. CFLAR has been described in multiple studies as being important in the development of cancer, 
and is therefore also being described as a target for therapy (reviewed by Fulda in 2013 [31]); it induces apoptosis [32], but is also a key role player in autophagy and necro-
ptosis [33]. XIAP, which normally regulates and inhibits apoptosis [34] was also shown 
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G e n e  e x p r e s s i o n  p r o f i l i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
.
d i s e a s e  c o u r s e ,  m o s t l y  a f f e c t i n g  e l d e r l y  i n d i v i d u a l s ,  w h i l e  s h o w i n g  s i m i l a r  ( i n i t i a l )  c l i n -
i c a l  p r e s e n t a t i o n s  s u c h  a s  n e u t r o p e n i a ,  a n e m i a  a n d  p a n c y t o p e n i a  [ 4 , 6 , 2 5 ] .  M o s t  o f  o u r  
p a t i e n t s  d i s p l a y e d  m a l i g n a n c y ,  a u t o i m m u n i t y  o r  c y t o p e n i a  a s  u n d e r l y i n g  o r  a s s o c i a t e d  
d i s e a s e s ,  a s  d e s c r i b e d  p r e v i o u s l y  [ 2 6 ] ,  b u t  t h e r e  w a s  n o  c o n s i s t e n t  p a t t e r n .  F u r t h e r m o r e ,  
i m m u n o p h e n o t y p i c  f e a t u r e s  d i d  n o t  c o r r e l a t e  w i t h  t h e  s y m p t o m a t i c  s t a t u s  o r  u n d e r -
l y i n g  d i s e a s e s .  U n d e r l y i n g  ( c h r o n i c )  d i s e a s e s  c o u l d  p l a y  a  r o l e  i n  t h e  p a t h o g e n e s i s  o f  
T C R γ δ +  T - L G L  l e u k e m i a ,  p o s s i b l y  a s  a  ( c h r o n i c )  s t i m u l u s  t h a t  c a u s e s  t h e  T C R γ δ +  T  c e l l s  
t o  e x p a n d ,  i n  l i n e  w i t h  t h e  i d e a  t h a t  T C R γ δ +  T - L G L  l e u k e m i a  d e v e l o p s  f r o m  d o m i n a n t  
n o r m a l  T C R γ δ +  T  c e l l  p o p u l a t i o n s  i n  t h e  a d u l t  p e r i p h e r a l  b l o o d .  H o w e v e r ,  u n d e r l y i n g  
m o l e c u l a r  m e c h a n i s m s  i n  T C R γ δ +  T - L G L  l e u k e m o g e n e s i s  a r e  l a r g e l y  u n k n o w n ,  a n d  a  
c o m m o n  u n d e r l y i n g  m o l e c u l a r  d e f e c t  h a s  n o t  b e e n  d e s c r i b e d  e a r l i e r .
T C R γ δ +  T - L G L  l e u k e m i a s  a r e  c h a r a c t e r i z e d  b y  s k e w e d  r e c e p t o r  e x p r e s s i o n  a n d  a n  
a n t i g e n  s t i m u l a t i o n - a s s o c i a t e d  a c t i v a t i o n  s t a t u s ,  b u t  a r e  a l s o  c o n s i d e r e d  t o  h a r b o u r  
p a r t i c u l a r  c h a n g e s  i n  g e n e  e x p r e s s i o n .  I n  o u r  c u r r e n t  s t u d y  w e  a i m e d  t o  a d d r e s s  t h i s  
b y  m e a n s  o f  g e n e  e x p r e s s i o n  p r o f i l i n g ,  w h i c h  r e v e a l e d  t h a t  t h e  T C R γ δ +  T - L G L  l e u k e m i a  
c e l l s  d i s p l a y e d  d i f f e r e n t  g e n e  e x p r e s s i o n  p r o f i l e s  w h e n  c o m p a r e d  t o  h e a l t h y ,  p o l y c l o n -
a l l y  e x p a n d e d  T C R γ δ +  T  c e l l s .  I n i t i a l  u n s u p e r v i s e d  c l u s t e r i n g  b a s e d  o n  m i c r o a r r a y  d a t a  
f r o m  a b e r r a n t  T C R γ δ +  T  c e l l s  a n d  d i f f e r e n t  h e a l t h y  T C R γ δ +  T  c e l l  s u b s e t s ,  s h o w e d  a  
c l e a r  d i s t i n c t i o n  b e t w e e n  t h e  T C R γ δ +  T - L G L  l e u k e m i a  a n d  i t s  h e a l t h y  c o u n t e r p a r t s .  E v e n  
t h o u g h  T C R γ δ +  T - L G L  l e u k e m i a  f o r m s  a  s e p a r a t e  g r o u p ,  w i t h  t h e  l o w e s t  c o r r e l a t i o n  w i t h  
t h e  n a i v e  s u b s e t  a s  e x p e c t e d ,  t h e  c o r r e l a t i o n  w i t h  t h e  T e m R A  s u b s e t  w a s  q u i t e  h i g h ,  s u g -
g e s t i n g  t h a t  i t  i s  d e r i v e d  f r o m  t h e  m o s t  p r e d o m i n a n t  a n d  a n t i g e n - e x p e r i e n c e d  t y p e  o f  
T C R γ δ +  T  c e l l  p o p u l a t i o n s  i n  a d u l t  p e r i p h e r a l  b l o o d ,  i n  l i n e  w i t h  e a r l i e r  p u b l i s h e d  d a t a  
[ 2 7 ] .  W h e n  f o c u s i n g  m o r e  i n - d e p t h  o n  d i f f e r e n c e s  i n  c o m p a r i s o n  w i t h  n o r m a l  T e m R A  
T C R γ δ +  T  c e l l s  i t  b e c a m e  c l e a r  t h a t  p a r t i c u l a r  b i o l o g i c a l  f u n c t i o n s ,  p r o c e s s e s  a n d  g e n e s  
w e r e  a f f e c t e d .  M o s t  r e l e v a n t  g e n e s  i n v o l v e d  p r o c e s s e s  s u c h  a s  p r o l i f e r a t i o n ,  s t i m u l a t i o n  
a n d  a p o p t o s i s ,  w i t h  a n  i n c r e a s e  i n  p r o l i f e r a t i o n  a n d  c e l l  s u r v i v a l ,  a n d  a  d e c r e a s e  i n  a p o p -
t o s i s .  O n e  c l e a r  e x a m p l e  c o n c e r n e d  t r a n s c r i p t i o n  f a c t o r  I D 3 ,  w h i c h  i s  i n v o l v e d  i n  p r o l i f -
e r a t i o n  a n d  h a e m a t o l o g i c a l  d e v e l o p m e n t ,  a . o .  b y  e n h a n c i n g  T C R γ δ +  T  c e l l  d e v e l o p m e n t  
[ 2 8 ] .  U p - r e g u l a t i o n  i n  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  c o u l d  b e  c o n f i r m e d  w i t h  R Q - P C R .  
A s  o p p o s e d  t o  p r o l i f e r a t i o n  g e n e s ,  s o m e  a p o p t o s i s - i n d u c i n g  g e n e s  s u c h  a s  C A S P 1  a n d  
C F L A R  w e r e  d o w n - r e g u l a t e d .  C a s p a s e - 1  i s  a n  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t i d a s e ,  
w h i c h  i s  i n v o l v e d  i n  i n f l a m m a t i o n  a n d  a p o p t o s i s  b y  p r o t e o l y s i s  o f  p r o - i n f l a m m a t o r y  
c y t o k i n e s  a n d  a c t i v a t i n g  o t h e r  c a s p a s e s  a n d  p r o - a p o p t o t i c  p r o t e i n s  [ 2 9 , 3 0 ] .  C F L A R  h a s  
b e e n  d e s c r i b e d  i n  m u l t i p l e  s t u d i e s  a s  b e i n g  i m p o r t a n t  i n  t h e  d e v e l o p m e n t  o f  c a n c e r ,  
a n d  i s  t h e r e f o r e  a l s o  b e i n g  d e s c r i b e d  a s  a  t a r g e t  f o r  t h e r a p y  ( r e v i e w e d  b y  F u l d a  i n  2 0 1 3  
[ 3 1 ] ) ;  i t  i n d u c e s  a p o p t o s i s  [ 3 2 ] ,  b u t  i s  a l s o  a  k e y  r o l e  p l a y e r  i n  a u t o p h a g y  a n d  n e c r o -
p t o s i s  [ 3 3 ] .  X I A P,  w h i c h  n o r m a l l y  r e g u l a t e s  a n d  i n h i b i t s  a p o p t o s i s  [ 3 4 ]  w a s  a l s o  s h o w n  
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to be down-regulated, resulting in a net effect of inhibited apoptosis. The up-regulated apoptosis-related gene BCLAF1 induces apoptosis and represses transcription [35]. Our 
RQ-PCR validation data also showed up-regulation of BCLAF1, and down-regulation of 
CFLAR and CASP1. All apoptosis-related genes could be confirmed with RQ-PCR, thus 
showing consistency of these shared aberrancies in different TCRγδ+ T-LGL leukemia 
patients. Interestingly, our data on TCRγδ+ T-LGL leukemia are thus completely in line with  earlier studies, showing signaling  towards survival through positive regulation of T cell receptor signaling and an enhanced immune response, rather than towards induction of apoptosis [36,37]. Additionally, the supervised analysis yielded aberran-
cies in the normal functioning of the TCRγδ+ T-LGL lymphoproliferative cells, with more 
skewing towards activation and inflammation given the up-regulation of CD28 and CCR7. IFNG on the other hand was down-regulated, implying that normal functioning of 
TCRγδ+ T cells through IFN-γ production upon activation during infection [38], is lost. 
These expression levels were also confirmed on fold change level by means of RQ-PCR. 
Furthermore, communication of the TCRγδ+ T-LGL leukemia cells with other immune 
cells was affected as reflected by the down-regulation of chemokine CX3CR1. 
In CD8+ TCRαβ+ T-LGL leukemia altered signaling through STATs has been implicated in the leukemogenesis, based on the frequent occurrence in mutations in the STAT3 
and/or STAT5b genes [39,40]. In our cohort of 10 TCRγδ+ T-LGL leukemia cases ana-
lyzed with gene expression profiling we checked expression levels of STAT3 and STAT5b 
genes but did not find significant alterations as compared to healthy control TCRγδ+ T cell subsets. This might suggest that STAT3 and STAT5b are less clearly implicated in 
the pathogenesis of TCRγδ+ T-LGL leukemia than CD8+TCRαβ+ T-LGL and/or NK-LGL leukemia. Furthermore, it has been shown previously that the survival of leukemic T-LGL cells is rather through STAT3-independent signaling [36].
Notably, not all genes could be confirmed with the same fold change in microarrays 
and RQ-PCR. High heterogeneity in expression levels within both healthy controls and patients was observed. This could be due to general differences between individuals, 
displaying different gene expression profiles, ranging from ones with high proliferative 
activity of TemRA TCRγδ+ T cells, to ones with low activity. Therefore, a more extended 
investigation into the aberrant apoptotic profile of a higher number of TCRγδ+ T-LGL 
leukemia patients is warranted. Furthermore, stimulation of the TCRγδ+ T-LGL leukemia 
cells, or in vitro blocking of the apoptotic genes identified and validated in our study, 
should provide more insights in the activation profile or the activity against for instance other blood cells, which could potentially explain the accompanying cytopenia as seen in 
these patients. Also, this could shed light on the underlying stimulations of the TCRγδ+ T cells required for proliferation. Additionally, novel techniques such as RNA-sequencing 
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investigation into the aberrant apoptotic profile of a higher number of TCRγδ+ T-LGL 
leukemia patients is warranted. Furthermore, stimulation of the TCRγδ+ T-LGL leukemia 
cells, or in vitro blocking of the apoptotic genes identified and validated in our study, 
should provide more insights in the activation profile or the activity against for instance 
other blood cells, which could potentially explain the accompanying cytopenia as seen in 
these patients. Also, this could shed light on the underlying stimulations of the TCRγδ+ T 
cells required for proliferation. Additionally, novel techniques such as RNA-sequencing 
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might be helpful in creating a broader perspective on the disease, including more infor- mation about possible splice variants and single nucleotide variants. 
Overall, our current study provides more insight in the pathogenesis of TCRγδ+ 
T-LGL leukemia by showing a disturbed balance in proliferation and apoptosis, but also in immune and inflammatory responses and normal functioning of the TCRγδ+ T 
cells. TCRγδ+ T-LGL leukemia cells originate from antigen-experienced normal TemRA/
TemRO TCRγδ+ T cells in adult peripheral blood, but these TCRγδ+ T-LGL cells have 
undergone a shift in the proliferation-apoptosis balance, towards increased prolifera- tion and survival.
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G e n e  e x p r e s s i o n  p r o f i l i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
.
m i g h t  b e  h e l p f u l  i n  c r e a t i n g  a  b r o a d e r  p e r s p e c t i v e  o n  t h e  d i s e a s e ,  i n c l u d i n g  m o r e  i n f o r -
m a t i o n  a b o u t  p o s s i b l e  s p l i c e  v a r i a n t s  a n d  s i n g l e  n u c l e o t i d e  v a r i a n t s .  
O v e r a l l ,  o u r  c u r r e n t  s t u d y  p r o v i d e s  m o r e  i n s i g h t  i n  t h e  p a t h o g e n e s i s  o f  T C R γ δ +  
T - L G L  l e u k e m i a  b y  s h o w i n g  a  d i s t u r b e d  b a l a n c e  i n  p r o l i f e r a t i o n  a n d  a p o p t o s i s ,  b u t  
a l s o  i n  i m m u n e  a n d  i n f l a m m a t o r y  r e s p o n s e s  a n d  n o r m a l  f u n c t i o n i n g  o f  t h e  T C R γ δ +  T  
c e l l s .  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  o r i g i n a t e  f r o m  a n t i g e n - e x p e r i e n c e d  n o r m a l  T e m R A /
T e m R O  T C R γ δ +  T  c e l l s  i n  a d u l t  p e r i p h e r a l  b l o o d ,  b u t  t h e s e  T C R γ δ +  T - L G L  c e l l s  h a v e  
u n d e r g o n e  a  s h i f t  i n  t h e  p r o l i f e r a t i o n - a p o p t o s i s  b a l a n c e ,  t o w a r d s  i n c r e a s e d  p r o l i f e r a -
t i o n  a n d  s u r v i v a l .
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Supplementary Figure 1. Gating strategies for FACS-based sorting experiments for sorting patient and 
healthy control material.
(a) General gating strategy to exclude debris and doublets, and to define lymphocytes based on CD45. (b) Further gating strategy for sorting patient material and TCRVδ1 and TCRVδ2 healthy subsets, and (c) gating strategy for sorting maturation subsets naive (CD45RA+CD45RO-CD197+CD27+), central memory (CD45RA-
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h e a l t h y  c o n t r o l  m a t e r i a l .
( a )  G e n e r a l  g a t i n g  s t r a t e g y  t o  e x c l u d e  d e b r i s  a n d  d o u b l e t s ,  a n d  t o  d e f i n e  l y m p h o c y t e s  b a s e d  o n  C D 4 5 .  ( b )  
F u r t h e r  g a t i n g  s t r a t e g y  f o r  s o r t i n g  p a t i e n t  m a t e r i a l  a n d  T C R V δ 1  a n d  T C R V δ 2  h e a l t h y  s u b s e t s ,  a n d  ( c )  g a t i n g  
s t r a t e g y  f o r  s o r t i n g  m a t u r a t i o n  s u b s e t s  n a i v e  ( C D 4 5 R A + C D 4 5 R O - C D 1 9 7 + C D 2 7 + ) ,  c e n t r a l  m e m o r y  ( C D 4 5 R A -
C D 4 5 R O + C D 1 9 7 + C D 2 7 + ) ,  T e m R O  ( C D 4 5 R A - C D 4 5 R O + C D 1 9 7 - C D 2 7 - )  a n d  T e m R A  ( C D 4 5 R A + C D 4 5 R O - C D 1 9 7 -
C D 2 7 - ) .
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ABSTRACT
TCRγδ+ T-LGL leukemia is a rare type of mature chronic T cell lym-phocytic disorder in the peripheral blood. Previous studies have shown that these cells originate from antigen-experienced terminally differen-
tiated effector TCRγδ+ T cells with a disturbance in normal signaling, and most importantly a dysregulated balance between proliferation and apoptosis. As the clinical disease phenotype is rather heterogeneous, this raises questions about a possible common pathogenic mechanism 
in TCRγδ+ T-LGL leukemia. Recently, the presence of somatic STAT3 and 
STAT5B mutations in in has provided insights in the pathogenesis of both 
NK and CD8+TCRαβ+ T-LGL leukemia, but this has not been confirmed in 
TCRγδ+ T-LGL leukemia cells. Here, we applied whole exome sequencing 
on sorted tumor cell populations of patients with proven TCRγδ+ T-LGL leukemia, and in parallel we sorted healthy monocytes to be used as internal control to correct for germline associated variants. Our data 
showed a rather heterogeneous profile of possible pathogenic gene variants, with affected genes being involved in transcription, immune cell activation and lymphangiogenesis. Gene variants were validated via Sanger-based sequencing and were evaluated in the context of gene expression data. A selected gene set showed homozygous variants, that were present in all patient tumor cells, but absent in healthy monocytes, 
and which could act as common factor in the pathogenesis of TCRγδ+ T-LGL leukemia.
Keywords: TCRγδ+ T cells, T-LGL, leukemia, whole exome sequencing.
ABSTRACT
TCRγδ+ T-LGL leukemia is a rare type of mature chronic T cell lym-
phocytic disorder in the peripheral blood. Previous studies have shown 
that these cells originate from antigen-experienced terminally differen-
tiated effector TCRγδ+ T cells with a disturbance in normal signaling, 
and most importantly a dysregulated balance between proliferation and 
apoptosis. As the clinical disease phenotype is rather heterogeneous, 
this raises questions about a possible common pathogenic mechanism 
in TCRγδ+ T-LGL leukemia. Recently, the presence of somatic STAT3 and 
STAT5B mutations in in has provided insights in the pathogenesis of both 
NK and CD8+TCRαβ+ T-LGL leukemia, but this has not been confirmed in 
TCRγδ+ T-LGL leukemia cells. Here, we applied whole exome sequencing 
on sorted tumor cell populations of patients with proven TCRγδ+ T-LGL 
leukemia, and in parallel we sorted healthy monocytes to be used as 
internal control to correct for germline associated variants. Our data 
showed a rather heterogeneous profile of possible pathogenic gene 
variants, with affected genes being involved in transcription, immune 
cell activation and lymphangiogenesis. Gene variants were validated 
via Sanger-based sequencing and were evaluated in the context of gene 
expression data. A selected gene set showed homozygous variants, that 
were present in all patient tumor cells, but absent in healthy monocytes, 
and which could act as common factor in the pathogenesis of TCRγδ+ 
T-LGL leukemia.
Keywords: TCRγδ+ T cells, T-LGL, leukemia, whole exome sequencing.
7207
Whole exome sequencing of TCRγδ+ T-LGL leukemia 
INTRODUCTION
T cell large granular lymphocyte (T-LGL) leukemia is a heterogeneous chronic mature T cell neoplasia, which is recognized as a separate hematological disorder 
according to the World Health Organization (WHO) classification [1]. T-LGL leukemia 
originates from normal LGL cells which comprise 10-15% of peripheral blood mononu- clear cells (PBMNCs) [2] and can be subdivided into two major groups based on the type 
of T cell receptor (TCR): TCRαβ or TCRγδ. The majority of the T-LGL leukemias involve 
the CD8+TCRαβ+ variant (80-90%) [3], whereas only a small part has a CD4+TCRαβ+ 
(1-5%) or TCRγδ+ phenotype (5%) [4]. T-LGL leukemia is part of a spectrum, ranging 
from lymphoproliferation to leukemia [5-7]. T-LGL leukemia generally shows an indo- lent disease course, with approximately 33% of patients being asymptomatic at diag-
nosis [7,8], and affects mostly elderly patients with an average age of 60 years. Most prominent clinical features involve neutropenia, recurrent bacterial infections and typi-
cal B symptoms which are generally associated with chronic leukemia. Typically, TCRγδ+ T-LGL leukemia shows high association with cytopenia (thrombo-
cytopenia, neutropenia), autoimmune diseases such as rheumatoid arthritis, and malig- nancies varying from other hematological cancers to solid tumors [4]. Diagnosis is based 
on a persistent (>6 months) monoclonal CD3+CD57+TCRγδ+ LGL cell population (>0.4 x 
109/L), established by flow cytometry and/or cell morphology [9]. Furthermore variable expression of CD8, CD16 and CD56 is associated with TCRγδ+ T-LGL leukemia as well 
[6]. Monoclonality can also be assessed with PCR-based assays [10]. Despite recent advances the LGL disease etiology remains largely unknown. It 
has been hypothesized that chronic (antigenic) stimulation plays a major role in the development of the proliferation [6]. An activation-associated effector phenotype and a 
(time-dependent) skewed TCR expression pattern – also referred to as clonal drift [11] 
– has been observed in LGL, which could be driven by autoantigens or pathogens [3,12]. 
Both the clinical characteristics and the observed clonal drifts illustrate the high hetero- geneity of the disease. Furthermore, in our previous gene expression profiling study we 
observed that the TCRγδ+ T-LGL cells correlated best with antigen-experienced effector 
cells. Transcriptome data of the LGL cells disclosed an anti-apoptotic and pro-survival phenotype [13]. 
Some years ago CD8+TCRαβ+ T- and NK-LGL leukemias were analyzed by means of 
whole exome sequencing, revealing shared somatic mutations in the STAT3 and STAT5B genes [14,15]. Four somatic mutational hotspots were identified in the Src Homology 2 
(SH2) domain of STAT3 [14], and two in the STAT5B gene, also in the SH2 domain [15]. These mutations were shown to affect expression of downstream genes in the STAT3 and 
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I N T R O D U C T I O N
T  c e l l  l a r g e  g r a n u l a r  l y m p h o c y t e  ( T - L G L )  l e u k e m i a  i s  a  h e t e r o g e n e o u s  c h r o n i c  
m a t u r e  T  c e l l  n e o p l a s i a ,  w h i c h  i s  r e c o g n i z e d  a s  a  s e p a r a t e  h e m a t o l o g i c a l  d i s o r d e r  
a c c o r d i n g  t o  t h e  W o r l d  H e a l t h  O r g a n i z a t i o n  ( W H O )  c l a s s i f i c a t i o n  [ 1 ] .  T - L G L  l e u k e m i a  
o r i g i n a t e s  f r o m  n o r m a l  L G L  c e l l s  w h i c h  c o m p r i s e  1 0 - 1 5 %  o f  p e r i p h e r a l  b l o o d  m o n o n u -
c l e a r  c e l l s  ( P B M N C s )  [ 2 ]  a n d  c a n  b e  s u b d i v i d e d  i n t o  t w o  m a j o r  g r o u p s  b a s e d  o n  t h e  t y p e  
o f  T  c e l l  r e c e p t o r  ( T C R ) :  T C R α β  o r  T C R γ δ .  T h e  m a j o r i t y  o f  t h e  T - L G L  l e u k e m i a s  i n v o l v e  
t h e  C D 8 + T C R α β +  v a r i a n t  ( 8 0 - 9 0 % )  [ 3 ] ,  w h e r e a s  o n l y  a  s m a l l  p a r t  h a s  a  C D 4 + T C R α β +  
( 1 - 5 % )  o r  T C R γ δ +  p h e n o t y p e  ( 5 % )  [ 4 ] .  T - L G L  l e u k e m i a  i s  p a r t  o f  a  s p e c t r u m ,  r a n g i n g  
f r o m  l y m p h o p r o l i f e r a t i o n  t o  l e u k e m i a  [ 5 - 7 ] .  T - L G L  l e u k e m i a  g e n e r a l l y  s h o w s  a n  i n d o -
l e n t  d i s e a s e  c o u r s e ,  w i t h  a p p r o x i m a t e l y  3 3 %  o f  p a t i e n t s  b e i n g  a s y m p t o m a t i c  a t  d i a g -
n o s i s  [ 7 , 8 ] ,  a n d  a f f e c t s  m o s t l y  e l d e r l y  p a t i e n t s  w i t h  a n  a v e r a g e  a g e  o f  6 0  y e a r s .  M o s t  
p r o m i n e n t  c l i n i c a l  f e a t u r e s  i n v o l v e  n e u t r o p e n i a ,  r e c u r r e n t  b a c t e r i a l  i n f e c t i o n s  a n d  t y p i -
c a l  B  s y m p t o m s  w h i c h  a r e  g e n e r a l l y  a s s o c i a t e d  w i t h  c h r o n i c  l e u k e m i a .  
T y p i c a l l y ,  T C R γ δ +  T - L G L  l e u k e m i a  s h o w s  h i g h  a s s o c i a t i o n  w i t h  c y t o p e n i a  ( t h r o m b o -
c y t o p e n i a ,  n e u t r o p e n i a ) ,  a u t o i m m u n e  d i s e a s e s  s u c h  a s  r h e u m a t o i d  a r t h r i t i s ,  a n d  m a l i g -
n a n c i e s  v a r y i n g  f r o m  o t h e r  h e m a t o l o g i c a l  c a n c e r s  t o  s o l i d  t u m o r s  [ 4 ] .  D i a g n o s i s  i s  b a s e d  
o n  a  p e r s i s t e n t  ( > 6  m o n t h s )  m o n o c l o n a l  C D 3 + C D 5 7 + T C R γ δ +  L G L  c e l l  p o p u l a t i o n  ( > 0 . 4  x  
1 0
9
/ L ) ,  e s t a b l i s h e d  b y  f l o w  c y t o m e t r y  a n d / o r  c e l l  m o r p h o l o g y  [ 9 ] .  F u r t h e r m o r e  v a r i a b l e  
e x p r e s s i o n  o f  C D 8 ,  C D 1 6  a n d  C D 5 6  i s  a s s o c i a t e d  w i t h  T C R γ δ +  T - L G L  l e u k e m i a  a s  w e l l  
[ 6 ] .  M o n o c l o n a l i t y  c a n  a l s o  b e  a s s e s s e d  w i t h  P C R - b a s e d  a s s a y s  [ 1 0 ] .
D e s p i t e  r e c e n t  a d v a n c e s  t h e  L G L  d i s e a s e  e t i o l o g y  r e m a i n s  l a r g e l y  u n k n o w n .  I t  
h a s  b e e n  h y p o t h e s i z e d  t h a t  c h r o n i c  ( a n t i g e n i c )  s t i m u l a t i o n  p l a y s  a  m a j o r  r o l e  i n  t h e  
d e v e l o p m e n t  o f  t h e  p r o l i f e r a t i o n  [ 6 ] .  A n  a c t i v a t i o n - a s s o c i a t e d  e f f e c t o r  p h e n o t y p e  a n d  a  
( t i m e - d e p e n d e n t )  s k e w e d  T C R  e x p r e s s i o n  p a t t e r n  –  a l s o  r e f e r r e d  t o  a s  c l o n a l  d r i f t  [ 1 1 ]  
–  h a s  b e e n  o b s e r v e d  i n  L G L ,  w h i c h  c o u l d  b e  d r i v e n  b y  a u t o a n t i g e n s  o r  p a t h o g e n s  [ 3 , 1 2 ] .  
B o t h  t h e  c l i n i c a l  c h a r a c t e r i s t i c s  a n d  t h e  o b s e r v e d  c l o n a l  d r i f t s  i l l u s t r a t e  t h e  h i g h  h e t e r o -
g e n e i t y  o f  t h e  d i s e a s e .  F u r t h e r m o r e ,  i n  o u r  p r e v i o u s  g e n e  e x p r e s s i o n  p r o f i l i n g  s t u d y  w e  
o b s e r v e d  t h a t  t h e  T C R γ δ +  T - L G L  c e l l s  c o r r e l a t e d  b e s t  w i t h  a n t i g e n - e x p e r i e n c e d  e f f e c t o r  
c e l l s .  T r a n s c r i p t o m e  d a t a  o f  t h e  L G L  c e l l s  d i s c l o s e d  a n  a n t i - a p o p t o t i c  a n d  p r o - s u r v i v a l  
p h e n o t y p e  [ 1 3 ] .  
S o m e  y e a r s  a g o  C D 8 + T C R α β +  T -  a n d  N K - L G L  l e u k e m i a s  w e r e  a n a l y z e d  b y  m e a n s  o f  
w h o l e  e x o m e  s e q u e n c i n g ,  r e v e a l i n g  s h a r e d  s o m a t i c  m u t a t i o n s  i n  t h e  S T A T 3  a n d  S T A T 5 B  
g e n e s  [ 1 4 , 1 5 ] .  F o u r  s o m a t i c  m u t a t i o n a l  h o t s p o t s  w e r e  i d e n t i f i e d  i n  t h e  S r c  H o m o l o g y  2  
( S H 2 )  d o m a i n  o f  S T A T 3  [ 1 4 ] ,  a n d  t w o  i n  t h e  S T A T 5 B  g e n e ,  a l s o  i n  t h e  S H 2  d o m a i n  [ 1 5 ] .  
T h e s e  m u t a t i o n s  w e r e  s h o w n  t o  a f f e c t  e x p r e s s i o n  o f  d o w n s t r e a m  g e n e s  i n  t h e  S T A T 3  a n d  
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STAT5B pathways, including IFNGR2, BCL2L1 and JAK2. From these studies it became clear that the different mutations are associated with different clinical phenotypes and prognoses, thus partially explaining the heterogeneity of the disease, despite common 
morphological and cellular features. In TCRγδ+ T-LGL leukemia the presence of these 
STAT3 and STAT5B mutations has not been documented yet. Of note, approximately 33% 
of patients with TCRγδ+ T cell lymphoma has been associated with a STAT5B mutation [16]. Even though differences at the cytogenetic level have been associated with diag-
nosis and prognosis [17,18], other mutations associated with TCRγδ+ T-LGL leukemia have not yet been described. In the current study we aimed to perform whole exome 
sequencing analysis on tumor cells from ten patients with a proven TCRγδ+ T cell leu-
kemia. We also included monocyte DNA of these cases to filter out germline variants present in hematopoietic cells and to establish true tumor-associated variants and/or mutations. Here we report on mutations in genes involved in cell cycle progression and nuclear repression (NCOR2), cancer development (HAVCR1, CREB3L2), immune cell acti-vation (HAVCR1, KLRF1), metastasis (VEGFC) and small molecule synthesis (NUDT11), 
which were commonly associated with TCRγδ+ T-LGL leukemia with minor allele fre-quency MAF=1.000 within the dataset, and which could contribute to the pathogenesis. Additionally, through transcription factor target enrichment analysis we could identify 
transcription factors that could be driving factors in TCRγδ+ T-LGL leukemogenesis, based on the appearance of protein-altering variants in tumor cases only.
MATERIALS & METHODS
Patient samples
Patient database files from the department of Immunology, Erasmus MC (Rotterdam, The Netherlands) were reviewed retrospectively for selection of cases 
with a proven persistent (>6 months) mature TCRγδ+ T cell leukemia in peripheral blood (PB) and/or bone marrow (BM) based on combined clinical, histological (HE sections), cytomorphological (May-Grünwald-Giemsa staining), immunophenotypical 
(CD3+CD56+CD57+TCRγδ+TCRαβ-) and molecular data. Isolation of PB and / or BM mononuclear cells (MNCs) had been performed by means of Ficoll-Paque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden) density gradient separation and cells were stored 
in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza, Basel, Switzerland) containing 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Saint Louis, MI, USA) at -180 °C until 
further use. Our retrospective search resulted in 10 TCRγδ+ T-LGL leukemia patients of 
whom 6 patient samples had sufficient material to also include control monocyte pop-ulations for paired analysis (Supplementary Table 1). All samples had been obtained 
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upon informed consent and the study was approved by the Erasmus MC Medical Ethics Committee (MEC-2015-617). All studies were conducted in accordance with the princi-
ples of the Declaration of Helsinki. 
Cell sorting
For sorting experiments cryopreserved PB- or BM-MNCs were thawed. Based on the immunophenotype of the particular TCRγδ+ T-LGL leukemia as determined during 
diagnostic work-up, tumor cells were sorted using CD45, CD3, TCRαβ, TCRVδ1 and 
TCRVδ2 markers. In addition, from the same sample monocytes were sorted as control 
cell population, using CD45, CD3, CD19 and CD14 markers (Supplementary Table 2). Sorting experiments were performed on FACS Aria I and III sorting instruments (BD 
Biosciences). Employed gating strategies are depicted in Supplementary Fig. 1. 
DNA/RNA isolation
After sorting the cells were lysed and subjected to combined DNA / RNA isolation using the Qiagen DNA/RNA/miRNA AllPrepKit (Qiagen, Hilden, Germany). DNA concen-
tration was measured with the NanoDrop 1000 spectrophotometer (Thermo Fischer Scientific, Waltham, MA, USA), and the A260/A280 ratio was determined to check DNA 
quality for further whole exome sequencing.
Exome capture and sequencing
Isolated DNA (1 µg) from sorted patient tumor cells and monocytes was subjected to exome capture and library preparation with the NimbleGen SeqCap EZ v2 (Roche, Basel, 
Switzerland). Exome sequencing was performed with the Illumina TruSeq V3 2x100 PE sequencing protocol (Illumina, San Diego, CA, USA).
Mutation annotation and analysis pipeline
Paired-end reads were aligned to the hg19 (GRCh37) reference, built using the Burrows-Wheeler Aligner (BWA) [19]. The Genome Analysis Toolkit (GATK) version 3.4 
[20] was used to remove duplicates (Samtools), realign insertions and deletions (indels), recalibrate the base quality score and to remove duplicate reads. Furthermore, single 
nucleotide variants (SNVs) and indels were called via standard default parameters. The ANNOVAR tool [21] was used to annotate mutations based on RefSeq (Release 70). To 
analyze SNVs and indels present in tumor material only we excluded all variants found in monocyte control samples, using either pooled tumor samples vs. pooled monocyte 
samples or paired tumor and monocyte samples on a per patient basis. Genes with highest density scores based on the Rotterdam Study [22] were excluded. Severity scores 
of missense variants were calculated using the LJB prediction database, as incorporated 
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W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
u p o n  i n f o r m e d  c o n s e n t  a n d  t h e  s t u d y  w a s  a p p r o v e d  b y  t h e  E r a s m u s  M C  M e d i c a l  E t h i c s  
C o m m i t t e e  ( M E C - 2 0 1 5 - 6 1 7 ) .  A l l  s t u d i e s  w e r e  c o n d u c t e d  i n  a c c o r d a n c e  w i t h  t h e  p r i n c i -
p l e s  o f  t h e  D e c l a r a t i o n  o f  H e l s i n k i .  
C e l l  s o r t i n g
F o r  s o r t i n g  e x p e r i m e n t s  c r y o p r e s e r v e d  P B -  o r  B M - M N C s  w e r e  t h a w e d .  B a s e d  o n  
t h e  i m m u n o p h e n o t y p e  o f  t h e  p a r t i c u l a r  T C R γ δ +  T - L G L  l e u k e m i a  a s  d e t e r m i n e d  d u r i n g  
d i a g n o s t i c  w o r k - u p ,  t u m o r  c e l l s  w e r e  s o r t e d  u s i n g  C D 4 5 ,  C D 3 ,  T C R α β ,  T C R V δ 1  a n d  
T C R V δ 2  m a r k e r s .  I n  a d d i t i o n ,  f r o m  t h e  s a m e  s a m p l e  m o n o c y t e s  w e r e  s o r t e d  a s  c o n t r o l  
c e l l  p o p u l a t i o n ,  u s i n g  C D 4 5 ,  C D 3 ,  C D 1 9  a n d  C D 1 4  m a r k e r s  ( S u p p l e m e n t a r y  T a b l e  2 ) .  
S o r t i n g  e x p e r i m e n t s  w e r e  p e r f o r m e d  o n  F A C S  A r i a  I  a n d  I I I  s o r t i n g  i n s t r u m e n t s  ( B D  
B i o s c i e n c e s ) .  E m p l o y e d  g a t i n g  s t r a t e g i e s  a r e  d e p i c t e d  i n  S u p p l e m e n t a r y  F i g .  1 .  
D N A / R N A  i s o l a t i o n
A f t e r  s o r t i n g  t h e  c e l l s  w e r e  l y s e d  a n d  s u b j e c t e d  t o  c o m b i n e d  D N A  /  R N A  i s o l a t i o n  
u s i n g  t h e  Q i a g e n  D N A / R N A / m i R N A  A l l P r e p K i t  ( Q i a g e n ,  H i l d e n ,  G e r m a n y ) .  D N A  c o n c e n -
t r a t i o n  w a s  m e a s u r e d  w i t h  t h e  N a n o D r o p  1 0 0 0  s p e c t r o p h o t o m e t e r  ( T h e r m o  F i s c h e r  
S c i e n t i f i c ,  W a l t h a m ,  M A ,  U S A ) ,  a n d  t h e  A 2 6 0 / A 2 8 0  r a t i o  w a s  d e t e r m i n e d  t o  c h e c k  D N A  
q u a l i t y  f o r  f u r t h e r  w h o l e  e x o m e  s e q u e n c i n g .
E x o m e  c a p t u r e  a n d  s e q u e n c i n g
I s o l a t e d  D N A  ( 1  µ g )  f r o m  s o r t e d  p a t i e n t  t u m o r  c e l l s  a n d  m o n o c y t e s  w a s  s u b j e c t e d  t o  
e x o m e  c a p t u r e  a n d  l i b r a r y  p r e p a r a t i o n  w i t h  t h e  N i m b l e G e n  S e q C a p  E Z  v 2  ( R o c h e ,  B a s e l ,  
S w i t z e r l a n d ) .  E x o m e  s e q u e n c i n g  w a s  p e r f o r m e d  w i t h  t h e  I l l u m i n a  T r u S e q  V 3  2 x 1 0 0  P E  
s e q u e n c i n g  p r o t o c o l  ( I l l u m i n a ,  S a n  D i e g o ,  C A ,  U S A ) .
M u t a t i o n  a n n o t a t i o n  a n d  a n a l y s i s  p i p e l i n e
P a i r e d - e n d  r e a d s  w e r e  a l i g n e d  t o  t h e  h g 1 9  ( G R C h 3 7 )  r e f e r e n c e ,  b u i l t  u s i n g  t h e  
B u r r o w s - W h e e l e r  A l i g n e r  ( B W A )  [ 1 9 ] .  T h e  G e n o m e  A n a l y s i s  T o o l k i t  ( G A T K )  v e r s i o n  3 . 4  
[ 2 0 ]  w a s  u s e d  t o  r e m o v e  d u p l i c a t e s  ( S a m t o o l s ) ,  r e a l i g n  i n s e r t i o n s  a n d  d e l e t i o n s  ( i n d e l s ) ,  
r e c a l i b r a t e  t h e  b a s e  q u a l i t y  s c o r e  a n d  t o  r e m o v e  d u p l i c a t e  r e a d s .  F u r t h e r m o r e ,  s i n g l e  
n u c l e o t i d e  v a r i a n t s  ( S N V s )  a n d  i n d e l s  w e r e  c a l l e d  v i a  s t a n d a r d  d e f a u l t  p a r a m e t e r s .  T h e  
A N N O V A R  t o o l  [ 2 1 ]  w a s  u s e d  t o  a n n o t a t e  m u t a t i o n s  b a s e d  o n  R e f S e q  ( R e l e a s e  7 0 ) .  T o  
a n a l y z e  S N V s  a n d  i n d e l s  p r e s e n t  i n  t u m o r  m a t e r i a l  o n l y  w e  e x c l u d e d  a l l  v a r i a n t s  f o u n d  
i n  m o n o c y t e  c o n t r o l  s a m p l e s ,  u s i n g  e i t h e r  p o o l e d  t u m o r  s a m p l e s  v s .  p o o l e d  m o n o c y t e  
s a m p l e s  o r  p a i r e d  t u m o r  a n d  m o n o c y t e  s a m p l e s  o n  a  p e r  p a t i e n t  b a s i s .  G e n e s  w i t h  
h i g h e s t  d e n s i t y  s c o r e s  b a s e d  o n  t h e  R o t t e r d a m  S t u d y  [ 2 2 ]  w e r e  e x c l u d e d .  S e v e r i t y  s c o r e s  
o f  m i s s e n s e  v a r i a n t s  w e r e  c a l c u l a t e d  u s i n g  t h e  L J B  p r e d i c t i o n  d a t a b a s e ,  a s  i n c o r p o r a t e d  
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in the ANNOVAR analysis pipeline, and a database for nonsynonymous SNVs’ functional predictions (dbNSFP), version ljb2B [23], which included SIFT [24], PolyPhen2 [25], MutationTaster [26], MutationAssessor [27,28], likelihood ratio test (LRT), Functional Analysis through Hidden Markov Models (FATHMM) [29], and conservation prediction methods such as GERP [30] and PhyloP [31] tools. For other functional predictions asso-ciated with diseases and metabolism pathways the COSMIC database [32] and Reactome Knowledgebase [33,34] were applied. 
Functional dataset analyses
Further data filtering was performed with R Studio [35; www.rstudio.com] and 
TIBCO Spotfire (TIBCO Software Inc., Palo Alto, CA, USA). Data interpretation and analy-sis was performed with WebGestalt [36,37; bioinf.vanderbilt.edu/webgestalt], Database for Annotation, Visualization, and Integrated Discovery (DAVID Database) [38,39], and 
QIAGEN’s Ingenuity Pathway Analysis (IPA) [40; QIAGEN, Redwood City, USA; www.qiagen.com/ingenuity]. WebGestalt gene ID mapping was based on Entrez gene IDs [41]. SNP rs IDs were based on the NCBI dbSNP database [42].
Validation of mutations
Candidate variants were selected based on different filtering methods. DNA from samples included in the whole exome sequencing study cohort (N=11) as well as addi-
tional DNA samples from other TCRγδ+ (N=33, total TCRγδ+ T-LGL patient number 
N=44) and CD8+TCRαβ+ (N=19) T-LGL patients were used to validate the presence of the mutation or variant via Sanger sequencing using primers as listed in Supplementary Table 3. Primers were developed using Oligo 6.41 software (Molecular Biology Insights, 
Cascade, CO, USA), Primer Express 3.0 software (Thermo Fischer Scientific) and Primer3 software [43,44]. Sequencing was performed using the Big Dye Terminator (BDT) enzyme (Life Technologies, Carlsbad, CA, USA) and the ABI Prism 3130 sequencer (Applied Biosystems, Foster City, CA, USA). Potential effects of variants on gene expres-
sion were measured with real-time quantitative (RQ)-PCR. RQ-PCR assays containing primers and probes were designed using the Roche Universal Probe Library (Roche, 
Basel, Switzerland) (Supplementary Table 4). RQ-PCR experiments were performed with 2x TaqMan Universal Mastermix (Applied Biosystems) on the StepOnePlus instru-
ment (Thermo Fischer Scientific). Ct values of tumor samples were normalized to the Ct 
value of the ABL housekeeping gene (ΔCt) [45]. Fold changes were calculated based on 
the ΔCt values (2-ΔCt) and used for calculation of the LGL cells to control cells ratio (ΔΔCt).
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Whole exome sequencing of TCRγδ+ T-LGL leukemia 
Statistical analyses
WebGestalt GO and KEGG enrichment analyses were statistically analyzed with the hypergeometric method (default settings). Multiple test adjustments were based on 
the Benjamini-Hochberg correction. Level of significance was set at 0.05. The minimum 
number of genes for a category was set at 10 for the comparison of all tumor samples vs. all monocyte samples, and set at 2 for the paired-wise tumor vs. monocyte analysis on a 
per patient basis (default settings due to lower number of differential variants). DAVID database OMIM disease functional annotation related genes indicated with Cohen’s 
kappa score, were calculated by the percentage for chance of corrected observed agree- ment divided by the percentage for chance of corrected potential agreement to rate the 
inter-rater agreement for qualitative (categorical) subjects. The kappa score is indicated between 1 (highest, best agreement) and 0 (lowest, no agreement). IPA calculations for 
p-values interpreting functions, processes and pathways in IPA Knowledgebase, Global Functional Analysis (GFA) and Global Canonical Pathways (GCP) were performed with 
the right-tailed Fisher Exact Test. The p-value is therefore a measure of the likelihood that the association between the gene set and processes or canonical pathways is due to 
random chance. The smaller the p-value the less likely the association is considered to be random, and thus the more significant. 
RESULTS
Whole exome sequencing of TCRγδ+ T-LGL leukemia cells shows a high 
frequency of nonsynonymous missense variants
First, sequencing data were subjected to genome alignment, variant calling and quality control checks. As all patients were from Caucasian descent, the expected number 
of single nucleotide polymorphisms (SNPs) from the whole exome sequencing (WES) dataset would be approximately 30,000 per sample, and the expected number of indels 
around 3,000. Furthermore, coverage should reach >50X, contamination should be <5% (0.05) and transition/transversion (TiTv) ratio should reach around 2.0-2.1, all accord-
ing to recent 1000Genomes human whole genome sequencing studies [46]. All samples, except for the monocyte sample from patient LGL092 – which was therefore excluded 
from further analysis – fulfilled this initial quality control check (Supplementary Table 
5). Based on total comparison of all TCRγδ+ T-LGL leukemia samples versus all mono-
cyte control samples, to exclude germline hematopoietic variants, most variants were found in the intronic and exonic regions, although variants were also found in other 
regions, such as splicing, intergenic, 5-prime (5’) untranslated region (UTR), 3’-UTR and 
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S t a t i s t i c a l  a n a l y s e s
W e b G e s t a l t  G O  a n d  K E G G  e n r i c h m e n t  a n a l y s e s  w e r e  s t a t i s t i c a l l y  a n a l y z e d  w i t h  t h e  
h y p e r g e o m e t r i c  m e t h o d  ( d e f a u l t  s e t t i n g s ) .  M u l t i p l e  t e s t  a d j u s t m e n t s  w e r e  b a s e d  o n  
t h e  B e n j a m i n i - H o c h b e r g  c o r r e c t i o n .  L e v e l  o f  s i g n i f i c a n c e  w a s  s e t  a t  0 . 0 5 .  T h e  m i n i m u m  
n u m b e r  o f  g e n e s  f o r  a  c a t e g o r y  w a s  s e t  a t  1 0  f o r  t h e  c o m p a r i s o n  o f  a l l  t u m o r  s a m p l e s  v s .  
a l l  m o n o c y t e  s a m p l e s ,  a n d  s e t  a t  2  f o r  t h e  p a i r e d - w i s e  t u m o r  v s .  m o n o c y t e  a n a l y s i s  o n  a  
p e r  p a t i e n t  b a s i s  ( d e f a u l t  s e t t i n g s  d u e  t o  l o w e r  n u m b e r  o f  d i f f e r e n t i a l  v a r i a n t s ) .  D A V I D  
d a t a b a s e  O M I M  d i s e a s e  f u n c t i o n a l  a n n o t a t i o n  r e l a t e d  g e n e s  i n d i c a t e d  w i t h  C o h e n ’ s  
k a p p a  s c o r e ,  w e r e  c a l c u l a t e d  b y  t h e  p e r c e n t a g e  f o r  c h a n c e  o f  c o r r e c t e d  o b s e r v e d  a g r e e -
m e n t  d i v i d e d  b y  t h e  p e r c e n t a g e  f o r  c h a n c e  o f  c o r r e c t e d  p o t e n t i a l  a g r e e m e n t  t o  r a t e  t h e  
i n t e r - r a t e r  a g r e e m e n t  f o r  q u a l i t a t i v e  ( c a t e g o r i c a l )  s u b j e c t s .  T h e  k a p p a  s c o r e  i s  i n d i c a t e d  
b e t w e e n  1  ( h i g h e s t ,  b e s t  a g r e e m e n t )  a n d  0  ( l o w e s t ,  n o  a g r e e m e n t ) .  I P A  c a l c u l a t i o n s  f o r  
p - v a l u e s  i n t e r p r e t i n g  f u n c t i o n s ,  p r o c e s s e s  a n d  p a t h w a y s  i n  I P A  K n o w l e d g e b a s e ,  G l o b a l  
F u n c t i o n a l  A n a l y s i s  ( G F A )  a n d  G l o b a l  C a n o n i c a l  P a t h w a y s  ( G C P )  w e r e  p e r f o r m e d  w i t h  
t h e  r i g h t - t a i l e d  F i s h e r  E x a c t  T e s t .  T h e  p - v a l u e  i s  t h e r e f o r e  a  m e a s u r e  o f  t h e  l i k e l i h o o d  
t h a t  t h e  a s s o c i a t i o n  b e t w e e n  t h e  g e n e  s e t  a n d  p r o c e s s e s  o r  c a n o n i c a l  p a t h w a y s  i s  d u e  t o  
r a n d o m  c h a n c e .  T h e  s m a l l e r  t h e  p - v a l u e  t h e  l e s s  l i k e l y  t h e  a s s o c i a t i o n  i s  c o n s i d e r e d  t o  
b e  r a n d o m ,  a n d  t h u s  t h e  m o r e  s i g n i f i c a n t .  
R E S U LT S
W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  s h o w s  a  h i g h  
f r e q u e n c y  o f  n o n s y n o n y m o u s  m i s s e n s e  v a r i a n t s
F i r s t ,  s e q u e n c i n g  d a t a  w e r e  s u b j e c t e d  t o  g e n o m e  a l i g n m e n t ,  v a r i a n t  c a l l i n g  a n d  
q u a l i t y  c o n t r o l  c h e c k s .  A s  a l l  p a t i e n t s  w e r e  f r o m  C a u c a s i a n  d e s c e n t ,  t h e  e x p e c t e d  n u m b e r  
o f  s i n g l e  n u c l e o t i d e  p o l y m o r p h i s m s  ( S N P s )  f r o m  t h e  w h o l e  e x o m e  s e q u e n c i n g  ( W E S )  
d a t a s e t  w o u l d  b e  a p p r o x i m a t e l y  3 0 , 0 0 0  p e r  s a m p l e ,  a n d  t h e  e x p e c t e d  n u m b e r  o f  i n d e l s  
a r o u n d  3 , 0 0 0 .  F u r t h e r m o r e ,  c o v e r a g e  s h o u l d  r e a c h  > 5 0 X ,  c o n t a m i n a t i o n  s h o u l d  b e  < 5 %  
( 0 . 0 5 )  a n d  t r a n s i t i o n / t r a n s v e r s i o n  ( T i T v )  r a t i o  s h o u l d  r e a c h  a r o u n d  2 . 0 - 2 . 1 ,  a l l  a c c o r d -
i n g  t o  r e c e n t  1 0 0 0 G e n o m e s  h u m a n  w h o l e  g e n o m e  s e q u e n c i n g  s t u d i e s  [ 4 6 ] .  A l l  s a m p l e s ,  
e x c e p t  f o r  t h e  m o n o c y t e  s a m p l e  f r o m  p a t i e n t  L G L 0 9 2  –  w h i c h  w a s  t h e r e f o r e  e x c l u d e d  
f r o m  f u r t h e r  a n a l y s i s  –  f u l f i l l e d  t h i s  i n i t i a l  q u a l i t y  c o n t r o l  c h e c k  ( S u p p l e m e n t a r y  T a b l e  
5 ) .  
B a s e d  o n  t o t a l  c o m p a r i s o n  o f  a l l  T C R γ δ +  T - L G L  l e u k e m i a  s a m p l e s  v e r s u s  a l l  m o n o -
c y t e  c o n t r o l  s a m p l e s ,  t o  e x c l u d e  g e r m l i n e  h e m a t o p o i e t i c  v a r i a n t s ,  m o s t  v a r i a n t s  w e r e  
f o u n d  i n  t h e  i n t r o n i c  a n d  e x o n i c  r e g i o n s ,  a l t h o u g h  v a r i a n t s  w e r e  a l s o  f o u n d  i n  o t h e r  
r e g i o n s ,  s u c h  a s  s p l i c i n g ,  i n t e r g e n i c ,  5 - p r i m e  ( 5 ’ )  u n t r a n s l a t e d  r e g i o n  ( U T R ) ,  3 ’ - U T R  a n d  
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noncoding RNA (ncRNA) (Fig. 1). Only exonic variants could be annotated, of which most were nonsynonymous single nucleotide variants (SNVs), indicating protein alterations. Other SNVs included synonymous (nonsense) SNVs, SNVs causing stop codons (stop gain) and causing loss of stop codons (stop loss), or (non-)frameshift substitutions, and 
insertions or deletions (Fig. 1). These results indicate that TCRγδ+ T-LGL leukemia cells have a high frequency of missense mutations underlying their pathogenesis.
Protein-changing variants affect pathways in metabolism, signaling, 
proliferation and apoptosis based on oncogenic transcription factors 
targeting affected genesAfter selecting variants i) only present in tumor cells (N=18449), ii) being exonic (N=7663), iii) excluding synonymous and unknown variants (N=4662), iv) excluding genes with the highest SNP density in general (N=3882, based on results Rotterdam Study, [22]) and v) selecting variants of which all alleles were called in all samples, a total of 3645 variants in 2733 remaining genes were further analyzed in WebGestalt and 
DAVID databases. WebGestalt’s Gene Ontology (GO) slim classifications resulted in sum-maries of variants which affected genes associated with biological processes (Fig. 2a), molecular functions (Fig. 2b) and cellular components (Fig. 2c). Numbers of genes in each process, function or component are indicated above the bars in the graphs, with 
most affected genes being involved in “metabolism”, “signaling” and “nuclear activities”. 
Upon GO enrichment analysis biological processes involved in “cell adhesion”, molecular 
functions involved in “molecule binding”, “catalytic activity” and “receptor signaling”, 
and cellular components such as “plasma membrane”, “cell-cell junction” and “cyto-
skeleton were found to be significantly affected (Table 1, Supplementary Fig. 2). When focusing more in-depth by means of KEGG enrichment analyses, pathways involved in 
“metabolism”, “lysosome”, “signaling” (e.g. Calcium, cytokines, phosphatidylinositol, 
Notch), “cancer pathways” (cancer in general, prostate cancer, colorectal cancer) and 
“apoptosis” appeared significantly affected (Table 1). To investigate which transcription factors were driving the expression of these genes, transcription factor target (TFT) enrichment analysis was performed. The majority of the genes was regulated by typical T cell-, T cell signaling- and proliferation-related transcription factors such as E12, NFAT, PAX4 and STAT5B. Furthermore, many of the variant genes appeared to be regulated by (proto-)oncogenes involved in solid tumors and hematopoietic malignancies, including FOXO4, LEF1, SP1, HNF3, ETS2, MEIS1, MYC and AML1 (Table 1). From six patients we obtained both tumor DNA and control monocyte DNA on which WES could be performed (Supplementary Tables 1 and 5). After separate paired analyses of these samples (i.e. tumor versus monocyte WES data for each patient), the numbers of 
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noncoding RNA (ncRNA) (Fig. 1). Only exonic variants could be annotated, of which most 
were nonsynonymous single nucleotide variants (SNVs), indicating protein alterations. 
Other SNVs included synonymous (nonsense) SNVs, SNVs causing stop codons (stop 
gain) and causing loss of stop codons (stop loss), or (non-)frameshift substitutions, and 
insertions or deletions (Fig. 1). These results indicate that TCRγδ+ T-LGL leukemia cells 
have a high frequency of missense mutations underlying their pathogenesis.
Protein-changing variants affect pathways in metabolism, signaling, 
proliferation and apoptosis based on oncogenic transcription factors 
targeting affected genes
After selecting variants i) only present in tumor cells (N=18449), ii) being exonic 
(N=7663), iii) excluding synonymous and unknown variants (N=4662), iv) excluding 
genes with the highest SNP density in general (N=3882, based on results Rotterdam 
Study, [22]) and v) selecting variants of which all alleles were called in all samples, a 
total of 3645 variants in 2733 remaining genes were further analyzed in WebGestalt and 
DAVID databases. WebGestalt’s Gene Ontology (GO) slim classifications resulted in sum-
maries of variants which affected genes associated with biological processes (Fig. 2a), 
molecular functions (Fig. 2b) and cellular components (Fig. 2c). Numbers of genes in 
each process, function or component are indicated above the bars in the graphs, with 
most affected genes being involved in “metabolism”, “signaling” and “nuclear activities”. 
Upon GO enrichment analysis biological processes involved in “cell adhesion”, molecular 
functions involved in “molecule binding”, “catalytic activity” and “receptor signaling”, 
and cellular components such as “plasma membrane”, “cell-cell junction” and “cyto-
skeleton were found to be significantly affected (Table 1, Supplementary Fig. 2). When 
focusing more in-depth by means of KEGG enrichment analyses, pathways involved in 
“metabolism”, “lysosome”, “signaling” (e.g. Calcium, cytokines, phosphatidylinositol, 
Notch), “cancer pathways” (cancer in general, prostate cancer, colorectal cancer) and 
“apoptosis” appeared significantly affected (Table 1). 
To investigate which transcription factors were driving the expression of these genes, 
transcription factor target (TFT) enrichment analysis was performed. The majority of 
the genes was regulated by typical T cell-, T cell signaling- and proliferation-related 
transcription factors such as E12, NFAT, PAX4 and STAT5B. Furthermore, many of the 
variant genes appeared to be regulated by (proto-)oncogenes involved in solid tumors 
and hematopoietic malignancies, including FOXO4, LEF1, SP1, HNF3, ETS2, MEIS1, MYC 
and AML1 (Table 1). 
From six patients we obtained both tumor DNA and control monocyte DNA on which 
WES could be performed (Supplementary Tables 1 and 5). After separate paired analyses 
of these samples (i.e. tumor versus monocyte WES data for each patient), the numbers of 
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i a - o n l y  e x o n i c ,  p r o t e i n - a l t e r i n g  v a r i a n t s  ( e x c l u d i n g  s y n o n y m
o u s  o r  u n k n o w
n  v a r i a n t s  a n d  g e n e s  w
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P
 d e n s i t y  
s c o r e )  a r e  d e p i c t e d  i n  G
O
 s l i m
 c l a s s i f i c a t i o n  b a r  g r a p h s  a d a p t e d  f r o m
 W
e b G
e s t a l t ’ s  a n a l y s i s .  O
f  n o t e ,  m
a n y  g e n e s  c o n t a i n e d  m
u l t i p l e  v a r i a n t s ,  b u t  h e r e  o n l y  
g e n e s  a r e  s h o w n .  B a r  g r a p h s  d e p i c t  g e n e s  b e a r i n g  v a r i a n t s  a f f e c t i n g  b i o l o g i c a l  p r o c e s s e s  ( a ) ,  m o l e c u l a r  f u n c t i o n s  ( b )  a n d  c e l l u l a r  c o m p o n e n t s  ( c ) .  N u m b e r s  
o f  g e n e s  p e r  p r o c e s s ,  f u n c t i o n  o r  o r g a n e l l e  a r e  i n d i c a t e d  a b o v e  t h e  c o r r e s p o n d i n g  b a r s .  T o t a l  n u m b e r  o f  g e n e s  w a s  2 , 7 3 3 ,  o f  w h i c h  2 , 6 3 4  w e r e  u n a m b i g u o u s l y  
m a p p e d  t o  2 , 6 3 4  E n t r e z  g e n e  I D s .  T h e  r e m a i n i n g  9 9  g e n e s  w e r e  m a p p e d  t o  m u l t i p l e  I D s ,  o r  c o u l d  n o t  b e  m a p p e d  t o  a n y  E n t r e z  I D .  O f  n o t e ,  g e n e s  c a n  b e  
o v e r l a p p i n g  b e t w e e n  d i f f e r e n t  b i o l o g i c a l  p r o c e s s e s ,  m o l e c u l a r  f u n c t i o n s  a n d  c e l l u l a r  c o m p o n e n t s .
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genes bearing tumor-only, exonic, protein-changing variants were lower than in case of all variants of the pooled tumor and the pooled monocyte samples (Supplementary Table 
6). Yet, GO slim summarizing classifications showed similar bar graphs, with processes, 
functions and cellular components in similar orders and with similar gene numbers (Supplementary Fig. 3). In-depth GO, KEGG and TFT enrichment analysis showed the 
same processes, pathways and transcription factors as observed in the overall analysis (Supplementary Table 6). 
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g e n e s  b e a r i n g  t u m o r - o n l y ,  e x o n i c ,  p r o t e i n - c h a n g i n g  v a r i a n t s  w e r e  l o w e r  t h a n  i n  c a s e  o f  
a l l  v a r i a n t s  o f  t h e  p o o l e d  t u m o r  a n d  t h e  p o o l e d  m o n o c y t e  s a m p l e s  ( S u p p l e m e n t a r y  T a b l e  
6 ) .  Y e t ,  G O  s l i m  s u m m a r i z i n g  c l a s s i f i c a t i o n s  s h o w e d  s i m i l a r  b a r  g r a p h s ,  w i t h  p r o c e s s e s ,  
f u n c t i o n s  a n d  c e l l u l a r  c o m p o n e n t s  i n  s i m i l a r  o r d e r s  a n d  w i t h  s i m i l a r  g e n e  n u m b e r s  
( S u p p l e m e n t a r y  F i g .  3 ) .  I n - d e p t h  G O ,  K E G G  a n d  T F T  e n r i c h m e n t  a n a l y s i s  s h o w e d  t h e  
s a m e  p r o c e s s e s ,  p a t h w a y s  a n d  t r a n s c r i p t i o n  f a c t o r s  a s  o b s e r v e d  i n  t h e  o v e r a l l  a n a l y s i s  
( S u p p l e m e n t a r y  T a b l e  6 ) .  
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Collectively, these results show that TCRγδ+ T-LGL leukemia cells contained variants affecting metabolism, signaling pathways, proliferation and apoptosis, with well-known oncogenic transcription factors as potential main drivers.
DAVID database and Ingenuity Pathway Analysis confirm affected 
pathways in DNA replication, damage response, and normal signalingSince the paired analyses of the patients’ tumor vs. monocyte samples resulted in 
low numbers of genes with tumor-specific exonic, protein-altering variants, we then further used the overall dataset in which all tumor samples were compared with mono-cyte control samples. For further insights in possible affected pathways we validated 
the WebGestalt results with DAVID database [38,39] and Qiagen’s Ingenuity Pathway Analysis (IPA) [40]. Using DAVID database GO analysis the biological processes, molec-
ular functions and cellular components that were identified were similar to what was observed in WebGestalt analysis (Table 2). However, KEGG analyses showed fewer asso-
ciated pathways, and most were not significant anymore after multiple testing adjust-ments. Clusters of orthologous group analysis (COG) of ontology mainly showed involve-
ment of the “cytoskeleton” as well as “DNA replication”, “recombination” and “repair”, as also predicted by WebGestalt analysis (Table 2). In order to obtain more visual insights in affected pathways, additional IPA analysis 
was then applied. From all genes bearing tumor-specific exonic, protein-altering vari-ants (n=2733) a total of 2706 genes were mapped and ready for analysis in IPA, which 
revealed as top disease and biological function “cancer”, varying from solid tumors to hematologic malignancies (Fig. 3a). Additional canonical pathway analysis revealed that affected genes were involved in DNA double-strand break repair by homologous recom-
bination and base-excision repair (BER) pathways, but also “bupropion degradation” 
and “granzyme B signaling” were found to be affected (Fig. 3b). Together these analyses imply that variants causing defects in DNA damage repair 
pathways might play an important role in TCRγδ+ T-LGL leukemogenesis, whereas altered or defective granzyme B signaling would also be associated with dysregulated 
functioning of TCRγδ+ T-LGL leukemia cells. 
Stringent selection with MAF <= 0.500 revealed candidate genes 
involved in DNA replication, transcription, DNA damage repair and 
immune signaling pathways
Following extensive filtering based on tumor-specific, exonic variants, as described above, we aimed to further reduce the total list of 3645 remaining variants in 2733 genes to a smaller number of the most relevant genes and variants potentially involved 
in the pathogenesis of TCRγδ+ T-LGL leukemia. We therefore looked into the minor allele 
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Collectively, these results show that TCRγδ+ T-LGL leukemia cells contained variants 
affecting metabolism, signaling pathways, proliferation and apoptosis, with well-known 
oncogenic transcription factors as potential main drivers.
DAVID database and Ingenuity Pathway Analysis confirm affected 
pathways in DNA replication, damage response, and normal signaling
Since the paired analyses of the patients’ tumor vs. monocyte samples resulted in 
low numbers of genes with tumor-specific exonic, protein-altering variants, we then 
further used the overall dataset in which all tumor samples were compared with mono-
cyte control samples. For further insights in possible affected pathways we validated 
the WebGestalt results with DAVID database [38,39] and Qiagen’s Ingenuity Pathway 
Analysis (IPA) [40]. Using DAVID database GO analysis the biological processes, molec-
ular functions and cellular components that were identified were similar to what was 
observed in WebGestalt analysis (Table 2). However, KEGG analyses showed fewer asso-
ciated pathways, and most were not significant anymore after multiple testing adjust-
ments. Clusters of orthologous group analysis (COG) of ontology mainly showed involve-
ment of the “cytoskeleton” as well as “DNA replication”, “recombination” and “repair”, as 
also predicted by WebGestalt analysis (Table 2). 
In order to obtain more visual insights in affected pathways, additional IPA analysis 
was then applied. From all genes bearing tumor-specific exonic, protein-altering vari-
ants (n=2733) a total of 2706 genes were mapped and ready for analysis in IPA, which 
revealed as top disease and biological function “cancer”, varying from solid tumors to 
hematologic malignancies (Fig. 3a). Additional canonical pathway analysis revealed that 
affected genes were involved in DNA double-strand break repair by homologous recom-
bination and base-excision repair (BER) pathways, but also “bupropion degradation” 
and “granzyme B signaling” were found to be affected (Fig. 3b). 
Together these analyses imply that variants causing defects in DNA damage repair 
pathways might play an important role in TCRγδ+ T-LGL leukemogenesis, whereas 
altered or defective granzyme B signaling would also be associated with dysregulated 
functioning of TCRγδ+ T-LGL leukemia cells. 
Stringent selection with MAF <= 0.500 revealed candidate genes 
involved in DNA replication, transcription, DNA damage repair and 
immune signaling pathways
Following extensive filtering based on tumor-specific, exonic variants, as described 
above, we aimed to further reduce the total list of 3645 remaining variants in 2733 
genes to a smaller number of the most relevant genes and variants potentially involved 
in the pathogenesis of TCRγδ+ T-LGL leukemia. We therefore looked into the minor allele 
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frequency (MAF) of the alternative alleles (variants), as observed in our tumor data- set. We set our MAF cut-off at >=0.500, meaning that the protein-altering variant was 
present in at least half of all called alleles (i.e. at least heterozygous in all cases and/or homozygous in part of the cases), which resulted in 121 variants in 99 genes. Further 
analysis of this remaining gene list in IPA again showed “cancer” (86/99 genes associ- ated) as the highest and most significant hit (Table 3). Involved cancers ranged from 
hematological malignancies to solid tumors, of mainly the thyroid gland, brain and gut, but also involved skin cancers such as melanoma. Most genes were associated with these 
diseases (>50/99 genes associated), and defects in the CREB3L2, HAVCR1, NCOR2, and VEGFC genes were commonly shared between the different types of cancer. We further 
investigated these genes and discovered that all of our patients were homozygous for 
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W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
f r e q u e n c y  ( M A F )  o f  t h e  a l t e r n a t i v e  a l l e l e s  ( v a r i a n t s ) ,  a s  o b s e r v e d  i n  o u r  t u m o r  d a t a -
s e t .  W e  s e t  o u r  M A F  c u t - o f f  a t  > = 0 . 5 0 0 ,  m e a n i n g  t h a t  t h e  p r o t e i n - a l t e r i n g  v a r i a n t  w a s  
p r e s e n t  i n  a t  l e a s t  h a l f  o f  a l l  c a l l e d  a l l e l e s  ( i . e .  a t  l e a s t  h e t e r o z y g o u s  i n  a l l  c a s e s  a n d / o r  
h o m o z y g o u s  i n  p a r t  o f  t h e  c a s e s ) ,  w h i c h  r e s u l t e d  i n  1 2 1  v a r i a n t s  i n  9 9  g e n e s .  F u r t h e r  
a n a l y s i s  o f  t h i s  r e m a i n i n g  g e n e  l i s t  i n  I P A  a g a i n  s h o w e d  “ c a n c e r ”  ( 8 6 / 9 9  g e n e s  a s s o c i -
a t e d )  a s  t h e  h i g h e s t  a n d  m o s t  s i g n i f i c a n t  h i t  ( T a b l e  3 ) .  I n v o l v e d  c a n c e r s  r a n g e d  f r o m  
h e m a t o l o g i c a l  m a l i g n a n c i e s  t o  s o l i d  t u m o r s ,  o f  m a i n l y  t h e  t h y r o i d  g l a n d ,  b r a i n  a n d  g u t ,  
b u t  a l s o  i n v o l v e d  s k i n  c a n c e r s  s u c h  a s  m e l a n o m a .  M o s t  g e n e s  w e r e  a s s o c i a t e d  w i t h  t h e s e  
d i s e a s e s  ( > 5 0 / 9 9  g e n e s  a s s o c i a t e d ) ,  a n d  d e f e c t s  i n  t h e  C R E B 3 L 2 ,  H A V C R 1 ,  N C O R 2 ,  a n d  
V E G F C  g e n e s  w e r e  c o m m o n l y  s h a r e d  b e t w e e n  t h e  d i f f e r e n t  t y p e s  o f  c a n c e r .  W e  f u r t h e r  








































































































































































































































































F i g u
r e  3
.  F u
n
c t i o n
a l  c l a s s i f i c a t i o n
 o f  a f f e c t e d
 p
r o c e s s e s  a n
d
 c a n
o n
i c a l  p
a t h w
a y s  i n
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A
l l  T
C R
γ δ +  T - L G
L  l e u k e m
i a - o n l y  e x o n i c ,  p r o t e i n - a l t e r i n g  v a r i a n t s  ( e x c l u d i n g  s y n o n y m
o u s  o r  n o n s e n s e  v a r i a n t s  a n d  g e n e s  w
i t h  a  g e n e r a l l y  h i g h  S N
P
 d e n s i t y  
s c o r e )  a r e  s h o w n  b a s e d  o n  I n g e n u i t y  P a t h w a y  A n a l y s i s  ( I P A )  ( a ) .  C o l o r  c o d i n g  i s  b a s e d  o n  p - v a l u e s ,  w h i c h  i n  I P A  a r e  c a l c u l a t e d  u s i n g  t h e  r i g h t - t a i l e d  F i s h e r  
e x a c t  t e s t ,  b a s e d  o n  t h e  a s s o c i a t i o n  w i t h  a  f u n c t i o n  o r  p a t h w a y  i n  t h e  I P A  K n o w l e d g e b a s e .  T h i s  m e a s u r e s  t h e  l i k e l i h o o d  t h a t  t h e  a s s o c i a t i o n  b e t w e e n  a  g e n e  s e t  
a n d  a  g i v e n  p r o c e s s  o r  ( c a n o n i c a l )  p a t h w a y  i s  d u e  t o  r a n d o m  c h a n c e  ( i . e .  t h e  s m a l l e r  t h e  p - v a l u e ,  t h e  l e s s  l i k e l y  t h a t  t h e  o b s e r v e d  a s s o c i a t i o n  i s  r a n d o m ,  a n d  
t h e  m
o r e  s i g n i f i c a n t  t h e  a s s o c i a t i o n  i s ) .  M
o s t  i m
p o r t a n t  g e n e s  d e s c r i b e d  i n  t h e  a f f e c t e d  p a t h w
a y s  ( b ) .  T h e  p - v a l u e s  i n d i c a t e  t h e  r e l a t i o n  b e t w e e n  t h e  a f f e c t e d  
g e n e  a n d  p a t h w a y  b a s e d  o n  t h e  F i s c h e r  e x a c t  t e s t  c a l c u l a t e d  b y  I P A .
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the alternative allele of NCOR2 and VEGFC (MAF=1.000), meaning that all tumor cells from our leukemic patients shared this nonsynonymous variant, which was not present 
in their monocyte control sample. We then checked the original gene list whether there were more variants with MAF=1.000, which showed 18 other homozygous gene variants 
in only the leukemic tumor cells in all patients (Supplementary Table 7). Among these genes were the genes as identified from IPA (Table 4), but also some other candidate 
genes of potential interest. One of these concerned the KLRF1 gene, encoding an NK cell-related receptor that is expressed on TCRγδ+ T cells [47]. Also striking was the 
complete deletion of the whole NUDT11 gene on the X-chromosome (Supplementary Table 7), which is an important phosphohydrolase involved in the inositol phosphate 
metabolism pathway [33,34,48]. 
Gene expression analysis of candidate variant genes identified in 
TCRγδ+ T-LGL leukemia
Since we, previously performed gene expression profiling of TCRγδ+ T-LGL leuke- mia cells versus normal TCRγδ+ T cell effector and effector memory cells [13], we then 
checked the expression levels of the above described genes (Table 4). Even though not all genes could be traced within the gene expression profiling data set, occasionally 
other gene family members or closely related genes did show altered expression levels compared to healthy cells. The NCOR, HAVCR2, KLRF1, NUDT6, NUDT9, and CREB-related 
genes were all found to be down-regulated (Table 4). Additionally, since we repeatedly observed the same transcription factors being associated with the gene set upon tran-
scription factor target enrichment analysis, we also looked into expression levels of the E12, LEF1, P53, TCF1, STAT3 and STAT5B transcription factors (Supplementary Table 6, 
highlighted transcription factors). Altogether, these results suggest that defects in DNA replication and transcription 
(NCOR2, CREB3L2, TCF3, TCF7, LEF1), DNA damage repair (TP53) and normal signaling 
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t h e  a l t e r n a t i v e  a l l e l e  o f  N C O R 2  a n d  V E G F C  ( M A F = 1 . 0 0 0 ) ,  m e a n i n g  t h a t  a l l  t u m o r  c e l l s  
f r o m  o u r  l e u k e m i c  p a t i e n t s  s h a r e d  t h i s  n o n s y n o n y m o u s  v a r i a n t ,  w h i c h  w a s  n o t  p r e s e n t  
i n  t h e i r  m o n o c y t e  c o n t r o l  s a m p l e .  W e  t h e n  c h e c k e d  t h e  o r i g i n a l  g e n e  l i s t  w h e t h e r  t h e r e  
w e r e  m o r e  v a r i a n t s  w i t h  M A F = 1 . 0 0 0 ,  w h i c h  s h o w e d  1 8  o t h e r  h o m o z y g o u s  g e n e  v a r i a n t s  
i n  o n l y  t h e  l e u k e m i c  t u m o r  c e l l s  i n  a l l  p a t i e n t s  ( S u p p l e m e n t a r y  T a b l e  7 ) .  A m o n g  t h e s e  
g e n e s  w e r e  t h e  g e n e s  a s  i d e n t i f i e d  f r o m  I P A  ( T a b l e  4 ) ,  b u t  a l s o  s o m e  o t h e r  c a n d i d a t e  
g e n e s  o f  p o t e n t i a l  i n t e r e s t .  O n e  o f  t h e s e  c o n c e r n e d  t h e  K L R F 1  g e n e ,  e n c o d i n g  a n  N K  
c e l l - r e l a t e d  r e c e p t o r  t h a t  i s  e x p r e s s e d  o n  T C R γ δ +  T  c e l l s  [ 4 7 ] .  A l s o  s t r i k i n g  w a s  t h e  
c o m p l e t e  d e l e t i o n  o f  t h e  w h o l e  N U D T 1 1  g e n e  o n  t h e  X - c h r o m o s o m e  ( S u p p l e m e n t a r y  
T a b l e  7 ) ,  w h i c h  i s  a n  i m p o r t a n t  p h o s p h o h y d r o l a s e  i n v o l v e d  i n  t h e  i n o s i t o l  p h o s p h a t e  
m e t a b o l i s m  p a t h w a y  [ 3 3 , 3 4 , 4 8 ] .  
G e n e  e x p r e s s i o n  a n a l y s i s  o f  c a n d i d a t e  v a r i a n t  g e n e s  i d e n t i f i e d  i n  
T C R γ δ +  T - L G L  l e u k e m i a
S i n c e  w e ,  p r e v i o u s l y  p e r f o r m e d  g e n e  e x p r e s s i o n  p r o f i l i n g  o f  T C R γ δ +  T - L G L  l e u k e -
m i a  c e l l s  v e r s u s  n o r m a l  T C R γ δ +  T  c e l l  e f f e c t o r  a n d  e f f e c t o r  m e m o r y  c e l l s  [ 1 3 ] ,  w e  t h e n  
c h e c k e d  t h e  e x p r e s s i o n  l e v e l s  o f  t h e  a b o v e  d e s c r i b e d  g e n e s  ( T a b l e  4 ) .  E v e n  t h o u g h  n o t  
a l l  g e n e s  c o u l d  b e  t r a c e d  w i t h i n  t h e  g e n e  e x p r e s s i o n  p r o f i l i n g  d a t a  s e t ,  o c c a s i o n a l l y  
o t h e r  g e n e  f a m i l y  m e m b e r s  o r  c l o s e l y  r e l a t e d  g e n e s  d i d  s h o w  a l t e r e d  e x p r e s s i o n  l e v e l s  
c o m p a r e d  t o  h e a l t h y  c e l l s .  T h e  N C O R ,  H A V C R 2 ,  K L R F 1 ,  N U D T 6 ,  N U D T 9 ,  a n d  C R E B - r e l a t e d  
g e n e s  w e r e  a l l  f o u n d  t o  b e  d o w n - r e g u l a t e d  ( T a b l e  4 ) .  A d d i t i o n a l l y ,  s i n c e  w e  r e p e a t e d l y  
o b s e r v e d  t h e  s a m e  t r a n s c r i p t i o n  f a c t o r s  b e i n g  a s s o c i a t e d  w i t h  t h e  g e n e  s e t  u p o n  t r a n -
s c r i p t i o n  f a c t o r  t a r g e t  e n r i c h m e n t  a n a l y s i s ,  w e  a l s o  l o o k e d  i n t o  e x p r e s s i o n  l e v e l s  o f  t h e  
E 1 2 ,  L E F 1 ,  P 5 3 ,  T C F 1 ,  S T A T 3  a n d  S T A T 5 B  t r a n s c r i p t i o n  f a c t o r s  ( S u p p l e m e n t a r y  T a b l e  6 ,  
h i g h l i g h t e d  t r a n s c r i p t i o n  f a c t o r s ) .  
A l t o g e t h e r ,  t h e s e  r e s u l t s  s u g g e s t  t h a t  d e f e c t s  i n  D N A  r e p l i c a t i o n  a n d  t r a n s c r i p t i o n  
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pathways (KLRF1, VEGFC, HAVCR1, NUDT11, STAT3, STAT5B) both at the genetic and mRNA expression level could be involved in TCRγδ+ T-LGL leukemogenesis.
Evaluation of transcript levels of candidate variant genes in TCRαβ+ 
T-LGL leukemia type samples
As our previous gene expression profiling data from TCRγδ+ T-LGL leukemia patients 
provided a validation dataset for the identified candidate variants, cDNA RQ-PCR 
analysis of clinically and phenotypically similar CD8+TCRαβ+ T-LGL leukemia patient 
cells could provide further insight into the role of these candidate genes in this disease type. In the RQ-PCR analysis we also included the factors as identified from transcription 
factor enrichment analysis (Supplementary Table 6), using a total of 9 healthy controls and 36 CD8+TCRαβ+ T-LGL leukemia samples. Gene expression was adjusted using the 
ABL housekeeping gene (ΔCt), and calculated as fold change (FC). Relative mRNA expres- sion in patients was corrected with the FC of the corresponding genes as identified from 
healthy control cells (ΔΔCt). KLRF1 (>30-fold), and VEGFC (>10-fold) were found to be up-regulated in LGL patients when compared to the healthy control T cells (Fig. 4). 
Furthermore, even though STAT3 and STAT5B did not contain protein-altering variants, their expression profiles did seem to be altered, possibly driving other oncogenic genes 
and processes as well, as identified before [14,15]. HAVCR1, LEF1 and TP53 were all up-regulated, albeit to a lesser extent. Expression levels of NCOR2, CREB3L2, NUDT11 
and TCF7 did not clearly differ compared with healthy control T cells (Fig. 4).
Sanger sequencing confirms VEGFC and HAVCR1 gene variants in both 
TCRγδ+ and CD8+TCRαβ+ T-LGL leukemia, whereas NUDT11 deletion 
is only seen in TCRγδ+ T-LGL leukemia
Based on the above analyses in different databases, we selected the most important candidate genes that were present in almost all leukemia patient sam-
ples, but not in the control monocyte samples (Table 4), including genes encoding transcription factors that could act as main driving factors for the mutation-bearing 
genes. In order to validate the presence of these variants we developed primers for Sanger sequencing (Supplementary Table 3). Sanger sequencing-based validation 
also included CD4+TCRαβ+, CD8+TCRαβ+ and TCRγδ+ T cell DNA from sorted cells 
of five healthy donors. Furthermore, we also checked the presence of these vari- ants in CD8+TCRαβ+ T-LGL leukemia, in view of the clear clinical overlap between 
these diseases and the intrinsic functional similarities of their cell types of origin. The VEGFC variant was found in 100% of the CD8+TCRαβ+ T-LGL leukemia patients, and 
in 75% of our TCRγδ+ T-LGL leukemia cohort. Also the HAVCR1 variant was found in high percentages of both CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia cases (Fig. 5). However, 
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W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
p a t h w a y s  ( K L R F 1 ,  V E G F C ,  H A V C R 1 ,  N U D T 1 1 ,  S T A T 3 ,  S T A T 5 B )  b o t h  a t  t h e  g e n e t i c  a n d  
m R N A  e x p r e s s i o n  l e v e l  c o u l d  b e  i n v o l v e d  i n  T C R γ δ +  T - L G L  l e u k e m o g e n e s i s .
E v a l u a t i o n  o f  t r a n s c r i p t  l e v e l s  o f  c a n d i d a t e  v a r i a n t  g e n e s  i n  T C R α β +  
T - L G L  l e u k e m i a  t y p e  s a m p l e s
A s  o u r  p r e v i o u s  g e n e  e x p r e s s i o n  p r o f i l i n g  d a t a  f r o m  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  
p r o v i d e d  a  v a l i d a t i o n  d a t a s e t  f o r  t h e  i d e n t i f i e d  c a n d i d a t e  v a r i a n t s ,  c D N A  R Q - P C R  
a n a l y s i s  o f  c l i n i c a l l y  a n d  p h e n o t y p i c a l l y  s i m i l a r  C D 8 + T C R α β +  T - L G L  l e u k e m i a  p a t i e n t  
c e l l s  c o u l d  p r o v i d e  f u r t h e r  i n s i g h t  i n t o  t h e  r o l e  o f  t h e s e  c a n d i d a t e  g e n e s  i n  t h i s  d i s e a s e  
t y p e .  I n  t h e  R Q - P C R  a n a l y s i s  w e  a l s o  i n c l u d e d  t h e  f a c t o r s  a s  i d e n t i f i e d  f r o m  t r a n s c r i p t i o n  
f a c t o r  e n r i c h m e n t  a n a l y s i s  ( S u p p l e m e n t a r y  T a b l e  6 ) ,  u s i n g  a  t o t a l  o f  9  h e a l t h y  c o n t r o l s  
a n d  3 6  C D 8 + T C R α β +  T - L G L  l e u k e m i a  s a m p l e s .  G e n e  e x p r e s s i o n  w a s  a d j u s t e d  u s i n g  t h e  
A B L  h o u s e k e e p i n g  g e n e  ( Δ C t ) ,  a n d  c a l c u l a t e d  a s  f o l d  c h a n g e  ( F C ) .  R e l a t i v e  m R N A  e x p r e s -
s i o n  i n  p a t i e n t s  w a s  c o r r e c t e d  w i t h  t h e  F C  o f  t h e  c o r r e s p o n d i n g  g e n e s  a s  i d e n t i f i e d  f r o m  
h e a l t h y  c o n t r o l  c e l l s  ( Δ Δ C t ) .  K L R F 1  ( > 3 0 - f o l d ) ,  a n d  V E G F C  ( > 1 0 - f o l d )  w e r e  f o u n d  t o  
b e  u p - r e g u l a t e d  i n  L G L  p a t i e n t s  w h e n  c o m p a r e d  t o  t h e  h e a l t h y  c o n t r o l  T  c e l l s  ( F i g .  4 ) .  
F u r t h e r m o r e ,  e v e n  t h o u g h  S T A T 3  a n d  S T A T 5 B  d i d  n o t  c o n t a i n  p r o t e i n - a l t e r i n g  v a r i a n t s ,  
t h e i r  e x p r e s s i o n  p r o f i l e s  d i d  s e e m  t o  b e  a l t e r e d ,  p o s s i b l y  d r i v i n g  o t h e r  o n c o g e n i c  g e n e s  
a n d  p r o c e s s e s  a s  w e l l ,  a s  i d e n t i f i e d  b e f o r e  [ 1 4 , 1 5 ] .  H A V C R 1 ,  L E F 1  a n d  T P 5 3  w e r e  a l l  
u p - r e g u l a t e d ,  a l b e i t  t o  a  l e s s e r  e x t e n t .  E x p r e s s i o n  l e v e l s  o f  N C O R 2 ,  C R E B 3 L 2 ,  N U D T 1 1  
a n d  T C F 7  d i d  n o t  c l e a r l y  d i f f e r  c o m p a r e d  w i t h  h e a l t h y  c o n t r o l  T  c e l l s  ( F i g .  4 ) .
S a n g e r  s e q u e n c i n g  c o n f i r m s  V E G F C  a n d  H A V C R 1  g e n e  v a r i a n t s  i n  b o t h  
T C R γ δ +  a n d  C D 8 + T C R α β +  T - L G L  l e u k e m i a ,  w h e r e a s  N U D T 1 1  d e l e t i o n  
i s  o n l y  s e e n  i n  T C R γ δ +  T - L G L  l e u k e m i a
B a s e d  o n  t h e  a b o v e  a n a l y s e s  i n  d i f f e r e n t  d a t a b a s e s ,  w e  s e l e c t e d  t h e  m o s t  
i m p o r t a n t  c a n d i d a t e  g e n e s  t h a t  w e r e  p r e s e n t  i n  a l m o s t  a l l  l e u k e m i a  p a t i e n t  s a m -
p l e s ,  b u t  n o t  i n  t h e  c o n t r o l  m o n o c y t e  s a m p l e s  ( T a b l e  4 ) ,  i n c l u d i n g  g e n e s  e n c o d i n g  
t r a n s c r i p t i o n  f a c t o r s  t h a t  c o u l d  a c t  a s  m a i n  d r i v i n g  f a c t o r s  f o r  t h e  m u t a t i o n - b e a r i n g  
g e n e s .  I n  o r d e r  t o  v a l i d a t e  t h e  p r e s e n c e  o f  t h e s e  v a r i a n t s  w e  d e v e l o p e d  p r i m e r s  f o r  
S a n g e r  s e q u e n c i n g  ( S u p p l e m e n t a r y  T a b l e  3 ) .  S a n g e r  s e q u e n c i n g - b a s e d  v a l i d a t i o n  
a l s o  i n c l u d e d  C D 4 + T C R α β + ,  C D 8 + T C R α β +  a n d  T C R γ δ +  T  c e l l  D N A  f r o m  s o r t e d  c e l l s  
o f  f i v e  h e a l t h y  d o n o r s .  F u r t h e r m o r e ,  w e  a l s o  c h e c k e d  t h e  p r e s e n c e  o f  t h e s e  v a r i -
a n t s  i n  C D 8 + T C R α β +  T - L G L  l e u k e m i a ,  i n  v i e w  o f  t h e  c l e a r  c l i n i c a l  o v e r l a p  b e t w e e n  
t h e s e  d i s e a s e s  a n d  t h e  i n t r i n s i c  f u n c t i o n a l  s i m i l a r i t i e s  o f  t h e i r  c e l l  t y p e s  o f  o r i g i n .  
T h e  V E G F C  v a r i a n t  w a s  f o u n d  i n  1 0 0 %  o f  t h e  C D 8 + T C R α β +  T - L G L  l e u k e m i a  p a t i e n t s ,  a n d  
i n  7 5 %  o f  o u r  T C R γ δ +  T - L G L  l e u k e m i a  c o h o r t .  A l s o  t h e  H A V C R 1  v a r i a n t  w a s  f o u n d  i n  h i g h  
p e r c e n t a g e s  o f  b o t h  C D 8 + T C R α β +  a n d  T C R γ δ +  T - L G L  l e u k e m i a  c a s e s  ( F i g .  5 ) .  H o w e v e r ,  
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Figure 4. RQ-PCR validation of the effect of the identified variants in candidate genes.
Relative mRNA expression of genes containing protein-altering variants and transcription factors as identified through transcription factor target enrichment analysis, following normalization to the ABL housekeeping 
gene (=ΔCt). ΔCt values were calculated into fold change values. Average fold changes from healthy controls (N=9) were used to calculate patient (N=36) to healthy control ratios translating into fold change values 
(=ΔΔCt) (a). Bar graphs are indicated with mean and SD (b). Mean absolute values of the fold change gene expression for genes shown in (a). Abbreviations used: FC, fold change; HC, healthy control; PT, patient.
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Figure 4. RQ-PCR validation of the effect of the identified variants in candidate genes.
Relative mRNA expression of genes containing protein-altering variants and transcription factors as identified 
through transcription factor target enrichment analysis, following normalization to the ABL housekeeping 
gene (=ΔCt). ΔCt values were calculated into fold change values. Average fold changes from healthy controls 
(N=9) were used to calculate patient (N=36) to healthy control ratios translating into fold change values 
(=ΔΔCt) (a). Bar graphs are indicated with mean and SD (b). Mean absolute values of the fold change gene 
expression for genes shown in (a). Abbreviations used: FC, fold change; HC, healthy control; PT, patient.
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both variants were also identified in healthy control CD8+TCRαβ+ and TCRγδ+ T cells 
(Fig. 5). The variants identified in the KLRF1, NCOR2 and CREB3L2 genes could not be 
confirmed via Sanger sequencing (Fig. 5). The NUDT11 sequence could not be identified 
in 24 out of 44 TCRγδ+ T-LGL leukemia samples, but the NUDT11 gene was normally 
present in all healthy controls and CD8+TCRαβ+ T-LGL leukemia cells (Fig. 5). 
DISCUSSION
Recently, Lamy et al. reviewed the LGL leukemia pathogenesis and treatment developments [49], highlighting the contribution of STAT gain-of-function mutations, 
which were first described in 2012-2013 [14,15] and which are currently included in 
the latest WHO classification of chronic leukemias [1]. Another possible mechanism involved in the pathogenesis of LGL leukemia could be Fas/FasL apoptosis resistance [50,51], related to up-regulated Ras activity and thus down-regulated Fas-mediated 
apoptosis [52]. Furthermore, dysregulation in the PI3K/Akt and NFκB pathways has also been described and reviewed by Lamy et al., which was mostly associated with altered gene and protein expression levels. Despite all these recent advances, pathogenic mech-
anisms have only been described for the CD4+TCRαβ+, CD8+TCRαβ+ T-LGL and NK-LGL 
leukemia types, whereas the TCRγδ+ variant and its possible genetic aberrancies were 
largely neglected. Despite overlapping clinical presentations with CD8+TCRαβ+ T-LGL 
leukemia, the pathogenesis of TCRγδ+ T-LGL leukemia therefor remains largely elusive, 
making the TCRγδ+ T cell variant of chronic T-LGL leukemia the most poorly understood form of this disease.
In our previous study we identified differential gene expression profiles between 
normal TCRγδ+ T cells and aberrant TCRγδ+ T-LGL leukemia cells at the level of dysregulated signaling, disturbed proliferation and apoptosis, and increased survival [13,53]. Here we attempted to investigate the underlying genetic aberrancies contribut-
ing to TCRγδ+ T-LGL leukemia by means of whole exome sequencing technology. In order 
to increase the relevance of our findings for leukemia cells, we included healthy mono-cyte cell populations from our patients as normal hematopoietic control cells, to exclude 
possible germline or individual-specific polymorphic variants. With this approach we were able to identify homozygous variants that are present in all leukemia samples, but not in control monocyte cell populations. Using an in-depth analysis including several 
distinct databases, we initially identified 99 candidate genes, which could be narrowed 
down to six major candidate genes that are affected in a statistically significant way. 
In our top list of candidate genes involved in TCRγδ+ T-LGL leukemogenesis, the gene encoding the CREB3L2 transcription factor was found to contain a homozygous 
Chapter 7
224
both variants were also identified in healthy control CD8+TCRαβ+ and TCRγδ+ T cells 
(Fig. 5). The variants identified in the KLRF1, NCOR2 and CREB3L2 genes could not be 
confirmed via Sanger sequencing (Fig. 5). The NUDT11 sequence could not be identified 
in 24 out of 44 TCRγδ+ T-LGL leukemia samples, but the NUDT11 gene was normally 
present in all healthy controls and CD8+TCRαβ+ T-LGL leukemia cells (Fig. 5). 
DISCUSSION
Recently, Lamy et al. reviewed the LGL leukemia pathogenesis and treatment 
developments [49], highlighting the contribution of STAT gain-of-function mutations, 
which were first described in 2012-2013 [14,15] and which are currently included in 
the latest WHO classification of chronic leukemias [1]. Another possible mechanism 
involved in the pathogenesis of LGL leukemia could be Fas/FasL apoptosis resistance 
[50,51], related to up-regulated Ras activity and thus down-regulated Fas-mediated 
apoptosis [52]. Furthermore, dysregulation in the PI3K/Akt and NFκB pathways has also 
been described and reviewed by Lamy et al., which was mostly associated with altered 
gene and protein expression levels. Despite all these recent advances, pathogenic mech-
anisms have only been described for the CD4+TCRαβ+, CD8+TCRαβ+ T-LGL and NK-LGL 
leukemia types, whereas the TCRγδ+ variant and its possible genetic aberrancies were 
largely neglected. Despite overlapping clinical presentations with CD8+TCRαβ+ T-LGL 
leukemia, the pathogenesis of TCRγδ+ T-LGL leukemia therefor remains largely elusive, 
making the TCRγδ+ T cell variant of chronic T-LGL leukemia the most poorly understood 
form of this disease.
In our previous study we identified differential gene expression profiles between 
normal TCRγδ+ T cells and aberrant TCRγδ+ T-LGL leukemia cells at the level of 
dysregulated signaling, disturbed proliferation and apoptosis, and increased survival 
[13,53]. Here we attempted to investigate the underlying genetic aberrancies contribut-
ing to TCRγδ+ T-LGL leukemia by means of whole exome sequencing technology. In order 
to increase the relevance of our findings for leukemia cells, we included healthy mono-
cyte cell populations from our patients as normal hematopoietic control cells, to exclude 
possible germline or individual-specific polymorphic variants. With this approach we 
were able to identify homozygous variants that are present in all leukemia samples, but 
not in control monocyte cell populations. Using an in-depth analysis including several 
distinct databases, we initially identified 99 candidate genes, which could be narrowed 
down to six major candidate genes that are affected in a statistically significant way. 
In our top list of candidate genes involved in TCRγδ+ T-LGL leukemogenesis, the 
gene encoding the CREB3L2 transcription factor was found to contain a homozygous 
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Whole exome sequencing of TCRγδ+ T-LGL leukemia 
non-frameshift deletion. CREB3L2 targets (proto-) oncogenes such as cFOS, but also neuropeptides, and is known to be associated with various types of cancer according 
to the COSMIC database [cancer.sanger.ac.uk, 32]. Gene expression profiling data only 
provided information on other CREB isoforms, but using RQ-PCR we could show a slight up-regulation of this gene. This could indicate a slight enhancement in driving (proto-) 
oncogene activation, thus contributing to the leukemogenesis. On the other hand, the NCOR2 repressive transcriptional regulator for e.g. cFOS, but also other oncogenes 
[54,55], contained a non-frameshift insertion leading to similar expression levels as observed in healthy controls. This nuclear corepressor is involved in transcriptional 
co-regulation through recruitment of histone deacetylases, and therefore in down-regu- lation of gene expression. The NCOR2 gene has been described earlier to be involved in 
human colon and rectal carcinomas [56]. Although, direct (functional) associations have not been described, a slight up-regulation of CREB3L2 transcription together with a rela-
tively normal NCOR2 expression level of could contribute to enhanced (proto-) oncogene activation and thus to the proliferative capacity of leukemic cells. In spite of the NCOR2 
and CREB3L2 variants being identified by WES, they could not be validated by means of Sanger sequencing in CD8+TCRαβ+ or TCRγδ+ T-LGL leukemia samples. This could be 
explained by admixture of normal cells in the leukemia cell population, since there is no specific T-LGL leukemia marker that allows sorting the leukemia cells to purity. Besides, 
WES technology provides a higher resolution than Sanger sequencing. Other candidate genes from our top list of gene variants are involved in immune 
cell activation and cytotoxicity and cytokine production. The HAVCR1 gene, also known as TIM-1 or KIM-1, is involved in kidney injury and plays a critical role in the regula-
tion of immune cell activation in response to virus infections [57]. Furthermore, IPA analysis showed associations of this gene with the development of melanoma and 
skin cancer, indicating an important role of its gene product in skin physiology. This indicates the cells are activated and ready to respond to antigens or other stimuli. 
Activated TCRγδ+ T cells are also known to express NK cell like receptors [58], espe- cially in the context of tumor immunity [59] and virus infections such as EBV [60]. The 
HAVCR1 variant was validated to be present in T-LGL leukemia patients, although it was also seen in healthy CD8+TCRαβ+ and TCRγδ+ T cells, but not in CD4+TCRαβ+ T 
cells. CD4+TCRαβ+ T cells might follow a different activation to T-LGL leukemogenesis 
[61]. KLRF1 is also an NK cell marker, and in particular an inhibitory molecule involved in NK cell and monocyte activation, but also in other lymphocyte subsets [62]. KLRF1 
has also been found to be associated with melanoma cell proliferation [63]. The KLRF1 gene displayed a dramatic difference in gene expression between healthy control and 
LGL leukemia cells, indicating that up-regulation of an inhibitory molecule might lead to dysregulated normal functioning and regulation of the immune response, which 
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W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
n o n - f r a m e s h i f t  d e l e t i o n .  C R E B 3 L 2  t a r g e t s  ( p r o t o - )  o n c o g e n e s  s u c h  a s  c F O S ,  b u t  a l s o  
n e u r o p e p t i d e s ,  a n d  i s  k n o w n  t o  b e  a s s o c i a t e d  w i t h  v a r i o u s  t y p e s  o f  c a n c e r  a c c o r d i n g  
t o  t h e  C O S M I C  d a t a b a s e  [ c a n c e r . s a n g e r . a c . u k ,  3 2 ] .  G e n e  e x p r e s s i o n  p r o f i l i n g  d a t a  o n l y  
p r o v i d e d  i n f o r m a t i o n  o n  o t h e r  C R E B  i s o f o r m s ,  b u t  u s i n g  R Q - P C R  w e  c o u l d  s h o w  a  s l i g h t  
u p - r e g u l a t i o n  o f  t h i s  g e n e .  T h i s  c o u l d  i n d i c a t e  a  s l i g h t  e n h a n c e m e n t  i n  d r i v i n g  ( p r o t o - )  
o n c o g e n e  a c t i v a t i o n ,  t h u s  c o n t r i b u t i n g  t o  t h e  l e u k e m o g e n e s i s .  O n  t h e  o t h e r  h a n d ,  t h e  
N C O R 2  r e p r e s s i v e  t r a n s c r i p t i o n a l  r e g u l a t o r  f o r  e . g .  c F O S ,  b u t  a l s o  o t h e r  o n c o g e n e s  
[ 5 4 , 5 5 ] ,  c o n t a i n e d  a  n o n - f r a m e s h i f t  i n s e r t i o n  l e a d i n g  t o  s i m i l a r  e x p r e s s i o n  l e v e l s  a s  
o b s e r v e d  i n  h e a l t h y  c o n t r o l s .  T h i s  n u c l e a r  c o r e p r e s s o r  i s  i n v o l v e d  i n  t r a n s c r i p t i o n a l  
c o - r e g u l a t i o n  t h r o u g h  r e c r u i t m e n t  o f  h i s t o n e  d e a c e t y l a s e s ,  a n d  t h e r e f o r e  i n  d o w n - r e g u -
l a t i o n  o f  g e n e  e x p r e s s i o n .  T h e  N C O R 2  g e n e  h a s  b e e n  d e s c r i b e d  e a r l i e r  t o  b e  i n v o l v e d  i n  
h u m a n  c o l o n  a n d  r e c t a l  c a r c i n o m a s  [ 5 6 ] .  A l t h o u g h ,  d i r e c t  ( f u n c t i o n a l )  a s s o c i a t i o n s  h a v e  
n o t  b e e n  d e s c r i b e d ,  a  s l i g h t  u p - r e g u l a t i o n  o f  C R E B 3 L 2  t r a n s c r i p t i o n  t o g e t h e r  w i t h  a  r e l a -
t i v e l y  n o r m a l  N C O R 2  e x p r e s s i o n  l e v e l  o f  c o u l d  c o n t r i b u t e  t o  e n h a n c e d  ( p r o t o - )  o n c o g e n e  
a c t i v a t i o n  a n d  t h u s  t o  t h e  p r o l i f e r a t i v e  c a p a c i t y  o f  l e u k e m i c  c e l l s .  I n  s p i t e  o f  t h e  N C O R 2  
a n d  C R E B 3 L 2  v a r i a n t s  b e i n g  i d e n t i f i e d  b y  W E S ,  t h e y  c o u l d  n o t  b e  v a l i d a t e d  b y  m e a n s  o f  
S a n g e r  s e q u e n c i n g  i n  C D 8 + T C R α β +  o r  T C R γ δ +  T - L G L  l e u k e m i a  s a m p l e s .  T h i s  c o u l d  b e  
e x p l a i n e d  b y  a d m i x t u r e  o f  n o r m a l  c e l l s  i n  t h e  l e u k e m i a  c e l l  p o p u l a t i o n ,  s i n c e  t h e r e  i s  n o  
s p e c i f i c  T - L G L  l e u k e m i a  m a r k e r  t h a t  a l l o w s  s o r t i n g  t h e  l e u k e m i a  c e l l s  t o  p u r i t y .  B e s i d e s ,  
W E S  t e c h n o l o g y  p r o v i d e s  a  h i g h e r  r e s o l u t i o n  t h a n  S a n g e r  s e q u e n c i n g .
O t h e r  c a n d i d a t e  g e n e s  f r o m  o u r  t o p  l i s t  o f  g e n e  v a r i a n t s  a r e  i n v o l v e d  i n  i m m u n e  
c e l l  a c t i v a t i o n  a n d  c y t o t o x i c i t y  a n d  c y t o k i n e  p r o d u c t i o n .  T h e  H A V C R 1  g e n e ,  a l s o  k n o w n  
a s  T I M - 1  o r  K I M - 1 ,  i s  i n v o l v e d  i n  k i d n e y  i n j u r y  a n d  p l a y s  a  c r i t i c a l  r o l e  i n  t h e  r e g u l a -
t i o n  o f  i m m u n e  c e l l  a c t i v a t i o n  i n  r e s p o n s e  t o  v i r u s  i n f e c t i o n s  [ 5 7 ] .  F u r t h e r m o r e ,  I P A  
a n a l y s i s  s h o w e d  a s s o c i a t i o n s  o f  t h i s  g e n e  w i t h  t h e  d e v e l o p m e n t  o f  m e l a n o m a  a n d  
s k i n  c a n c e r ,  i n d i c a t i n g  a n  i m p o r t a n t  r o l e  o f  i t s  g e n e  p r o d u c t  i n  s k i n  p h y s i o l o g y .  T h i s  
i n d i c a t e s  t h e  c e l l s  a r e  a c t i v a t e d  a n d  r e a d y  t o  r e s p o n d  t o  a n t i g e n s  o r  o t h e r  s t i m u l i .  
A c t i v a t e d  T C R γ δ +  T  c e l l s  a r e  a l s o  k n o w n  t o  e x p r e s s  N K  c e l l  l i k e  r e c e p t o r s  [ 5 8 ] ,  e s p e -
c i a l l y  i n  t h e  c o n t e x t  o f  t u m o r  i m m u n i t y  [ 5 9 ]  a n d  v i r u s  i n f e c t i o n s  s u c h  a s  E B V  [ 6 0 ] .  T h e  
H A V C R 1  v a r i a n t  w a s  v a l i d a t e d  t o  b e  p r e s e n t  i n  T - L G L  l e u k e m i a  p a t i e n t s ,  a l t h o u g h  i t  
w a s  a l s o  s e e n  i n  h e a l t h y  C D 8 + T C R α β +  a n d  T C R γ δ +  T  c e l l s ,  b u t  n o t  i n  C D 4 + T C R α β +  T  
c e l l s .  C D 4 + T C R α β +  T  c e l l s  m i g h t  f o l l o w  a  d i f f e r e n t  a c t i v a t i o n  t o  T - L G L  l e u k e m o g e n e s i s  
[ 6 1 ] .  K L R F 1  i s  a l s o  a n  N K  c e l l  m a r k e r ,  a n d  i n  p a r t i c u l a r  a n  i n h i b i t o r y  m o l e c u l e  i n v o l v e d  
i n  N K  c e l l  a n d  m o n o c y t e  a c t i v a t i o n ,  b u t  a l s o  i n  o t h e r  l y m p h o c y t e  s u b s e t s  [ 6 2 ] .  K L R F 1  
h a s  a l s o  b e e n  f o u n d  t o  b e  a s s o c i a t e d  w i t h  m e l a n o m a  c e l l  p r o l i f e r a t i o n  [ 6 3 ] .  T h e  K L R F 1  
g e n e  d i s p l a y e d  a  d r a m a t i c  d i f f e r e n c e  i n  g e n e  e x p r e s s i o n  b e t w e e n  h e a l t h y  c o n t r o l  a n d  
L G L  l e u k e m i a  c e l l s ,  i n d i c a t i n g  t h a t  u p - r e g u l a t i o n  o f  a n  i n h i b i t o r y  m o l e c u l e  m i g h t  l e a d  
t o  d y s r e g u l a t e d  n o r m a l  f u n c t i o n i n g  a n d  r e g u l a t i o n  o f  t h e  i m m u n e  r e s p o n s e ,  w h i c h  
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could be driving the cytopenias that are clinically associated with T-LGL leukemia [4,6]. However, also the KLRF1 variant could not be validated with Sanger sequencing, again possibly due to admixture of non-leukemic cells and the sequencing depth. Furthermore, from our analyses we also observed frameshift deletions in VEGFC and 
NUDT11 genes. These variants potentially cause more downstream problems due to the complete change in protein through these frameshift deletions. VEGFC is known to be important in lymphangiogenesis [64] and plays major roles in this process in gastric cancer [65] and metastatic breast cancer [66]. Our study showed an increase in the 
VEGFC gene expression level in LGL leukemia samples when compared to healthy con-trol cells, suggestive of altered lymphangiogenic and metastatic effects. The frameshift deletion was also validated with Sanger sequencing in both leukemic and healthy con-
trol CD8+TCRαβ+ and TCRγδ+ T cells, but not in healthy control CD4+TCRαβ+ T cells, thus induced high increases in VEGFC gene expression, contributing to the leukemic character. Finally, also the NUDT11 gene contained a frameshift deletion; which in fact was a deletion of the entire gene. We also observed relatively similar gene expression as observed from healthy controls and patients. Normally, the NUDT11 gene is associ-ated with phosphohydrolase activity, playing a role in signal transduction according 
to GeneCards database [67]. Particularly in TCRγδ+ T-LGL leukemia patients this gene 
was absent, indicating that it might underlie processes specifically for TCRγδ+ T-LGL leukemia cells. However, further evaluation of the exact role of this gene requires more functional studies in which the gene is for example silenced by means CRISPR-Cas9 technology.Besides genes containing protein-altering variants, further enrichment analysis 
using WebGestalt also identified specific transcription factors that could act upstream of affected genes. These included the transcription factors TCF7, LEF1, TP53, and the well-known STAT3 and STAT5B factors. TCF7 and LEF1 are the main downstream signal transduction molecules in the Wnt signaling pathway, up-regulation of which is associ-ated with colon carcinoma [68]. TP53 is a well-known important transcription factor 
involved in tumor suppression mechanisms [69]. Finally, the “central hub” in LGL pro-
liferations STAT3 was also identified as main driving transcription factor of our gene list [49]. However, we did not observe the described mutations in STAT3 and STAT5B 
genes as identified before in CD8+TCRαβ+ T-LGL leukemia [14,15], indicating that these 
mutations are probably not as common in TCRγδ+ T-LGL leukemia, as they are in the 
CD8+TCRαβ+ variant. However, since we were limited in the number of samples available for our current WES analysis, we cannot fully exclude the possibility that STAT mutations 
are present in TCRγδ+ T-LGL leukemia variants, but only at a low frequency. In order to 
prove this, a larger cohort of patients is needed, and preferably the specific leukemia cell populations need to be sorted to purity to rule out any other role of remaining normal 
Chapter 7
226
could be driving the cytopenias that are clinically associated with T-LGL leukemia 
[4,6]. However, also the KLRF1 variant could not be validated with Sanger sequencing, 
again possibly due to admixture of non-leukemic cells and the sequencing depth. 
Furthermore, from our analyses we also observed frameshift deletions in VEGFC and 
NUDT11 genes. These variants potentially cause more downstream problems due to the 
complete change in protein through these frameshift deletions. VEGFC is known to be 
important in lymphangiogenesis [64] and plays major roles in this process in gastric 
cancer [65] and metastatic breast cancer [66]. Our study showed an increase in the 
VEGFC gene expression level in LGL leukemia samples when compared to healthy con-
trol cells, suggestive of altered lymphangiogenic and metastatic effects. The frameshift 
deletion was also validated with Sanger sequencing in both leukemic and healthy con-
trol CD8+TCRαβ+ and TCRγδ+ T cells, but not in healthy control CD4+TCRαβ+ T cells, 
thus induced high increases in VEGFC gene expression, contributing to the leukemic 
character. Finally, also the NUDT11 gene contained a frameshift deletion; which in fact 
was a deletion of the entire gene. We also observed relatively similar gene expression 
as observed from healthy controls and patients. Normally, the NUDT11 gene is associ-
ated with phosphohydrolase activity, playing a role in signal transduction according 
to GeneCards database [67]. Particularly in TCRγδ+ T-LGL leukemia patients this gene 
was absent, indicating that it might underlie processes specifically for TCRγδ+ T-LGL 
leukemia cells. However, further evaluation of the exact role of this gene requires more 
functional studies in which the gene is for example silenced by means CRISPR-Cas9 
technology.
Besides genes containing protein-altering variants, further enrichment analysis 
using WebGestalt also identified specific transcription factors that could act upstream 
of affected genes. These included the transcription factors TCF7, LEF1, TP53, and the 
well-known STAT3 and STAT5B factors. TCF7 and LEF1 are the main downstream signal 
transduction molecules in the Wnt signaling pathway, up-regulation of which is associ-
ated with colon carcinoma [68]. TP53 is a well-known important transcription factor 
involved in tumor suppression mechanisms [69]. Finally, the “central hub” in LGL pro-
liferations STAT3 was also identified as main driving transcription factor of our gene 
list [49]. However, we did not observe the described mutations in STAT3 and STAT5B 
genes as identified before in CD8+TCRαβ+ T-LGL leukemia [14,15], indicating that these 
mutations are probably not as common in TCRγδ+ T-LGL leukemia, as they are in the 
CD8+TCRαβ+ variant. However, since we were limited in the number of samples available 
for our current WES analysis, we cannot fully exclude the possibility that STAT mutations 
are present in TCRγδ+ T-LGL leukemia variants, but only at a low frequency. In order to 
prove this, a larger cohort of patients is needed, and preferably the specific leukemia cell 
populations need to be sorted to purity to rule out any other role of remaining normal 
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TCRγδ+ T cells in the sample. Since there is no clear LGL leukemia-related marker [4], 
it remains difficult to distinguish the remaining normal TCRγδ+ T cells from aberrant 
leukemic cells. Future experiments should include more LGL leukemia patients from which the leukemia cells need to be sorted based on a combination of markers also 
including a.o. CD56 and CD57, in order to perform WES, Sanger sequencing and RQ-PCR 
validations. Furthermore, extra cells should be preserved for functional assays, to fully understand the potential of the variants identified. 
In summary, so far our data show leukemia-specific homozygous (non-)frameshift 
insertions and deletions in six genes involved in transcription, immune cell activation and metastasis. These genes mainly exhibited increased gene expression levels when 
compared to healthy controls without having the gene variants. These variants could point to underlying molecular and/or genetic defects in the development of TCRγδ+ 
T-LGL leukemia specifically, but perhaps also CD8+TCRαβ+ T-LGL leukemia. However, 
further (functional) studies are required to disclose the impact of these gene defects on T-LGL leukemogenesis.
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W h o l e  e x o m e  s e q u e n c i n g  o f  T C R γ δ +  T - L G L  l e u k e m i a  
T C R γ δ +  T  c e l l s  i n  t h e  s a m p l e .  S i n c e  t h e r e  i s  n o  c l e a r  L G L  l e u k e m i a - r e l a t e d  m a r k e r  [ 4 ] ,  
i t  r e m a i n s  d i f f i c u l t  t o  d i s t i n g u i s h  t h e  r e m a i n i n g  n o r m a l  T C R γ δ +  T  c e l l s  f r o m  a b e r r a n t  
l e u k e m i c  c e l l s .  F u t u r e  e x p e r i m e n t s  s h o u l d  i n c l u d e  m o r e  L G L  l e u k e m i a  p a t i e n t s  f r o m  
w h i c h  t h e  l e u k e m i a  c e l l s  n e e d  t o  b e  s o r t e d  b a s e d  o n  a  c o m b i n a t i o n  o f  m a r k e r s  a l s o  
i n c l u d i n g  a . o .  C D 5 6  a n d  C D 5 7 ,  i n  o r d e r  t o  p e r f o r m  W E S ,  S a n g e r  s e q u e n c i n g  a n d  R Q - P C R  
v a l i d a t i o n s .  F u r t h e r m o r e ,  e x t r a  c e l l s  s h o u l d  b e  p r e s e r v e d  f o r  f u n c t i o n a l  a s s a y s ,  t o  f u l l y  
u n d e r s t a n d  t h e  p o t e n t i a l  o f  t h e  v a r i a n t s  i d e n t i f i e d .  
I n  s u m m a r y ,  s o  f a r  o u r  d a t a  s h o w  l e u k e m i a - s p e c i f i c  h o m o z y g o u s  ( n o n - ) f r a m e s h i f t  
i n s e r t i o n s  a n d  d e l e t i o n s  i n  s i x  g e n e s  i n v o l v e d  i n  t r a n s c r i p t i o n ,  i m m u n e  c e l l  a c t i v a t i o n  
a n d  m e t a s t a s i s .  T h e s e  g e n e s  m a i n l y  e x h i b i t e d  i n c r e a s e d  g e n e  e x p r e s s i o n  l e v e l s  w h e n  
c o m p a r e d  t o  h e a l t h y  c o n t r o l s  w i t h o u t  h a v i n g  t h e  g e n e  v a r i a n t s .  T h e s e  v a r i a n t s  c o u l d  
p o i n t  t o  u n d e r l y i n g  m o l e c u l a r  a n d / o r  g e n e t i c  d e f e c t s  i n  t h e  d e v e l o p m e n t  o f  T C R γ δ +  
T - L G L  l e u k e m i a  s p e c i f i c a l l y ,  b u t  p e r h a p s  a l s o  C D 8 + T C R α β +  T - L G L  l e u k e m i a .  H o w e v e r ,  
f u r t h e r  ( f u n c t i o n a l )  s t u d i e s  a r e  r e q u i r e d  t o  d i s c l o s e  t h e  i m p a c t  o f  t h e s e  g e n e  d e f e c t s  o n  
T - L G L  l e u k e m o g e n e s i s .
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Supplementary Figure 1. Gating strategies to obtain TCRγδ+ T-LGL leukemia and monocyte cell 
populations.
General gating strategy to define viable cells, single cells and lymphocytes (a). Gating strategy for sorting 
leukemic tumor cells, further defined by Vδ-usage (b). Gating strategy for sorting control monocytes within the same sample (c). 
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Supplementary Figure 2. GO enrichment graph.
GO enrichment analysis results depicted in tree graph (adapted from WebGestalt). Biological processes, molecular functions and cellular components affected by the genes bearing variants are indicated in red. Number of genes and statistical significance indicated below the named process, function or component. 
Adjusted P-value is based on Benjamini-Hochberg adjustment for multiple testing correction.
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S u p p l e m e n t a r y  F i g u r e  2 .  G O  e n r i c h m e n t  g r a p h .
G O  e n r i c h m e n t  a n a l y s i s  r e s u l t s  d e p i c t e d  i n  t r e e  g r a p h  ( a d a p t e d  f r o m  W e b G e s t a l t ) .  B i o l o g i c a l  p r o c e s s e s ,  
m o l e c u l a r  f u n c t i o n s  a n d  c e l l u l a r  c o m p o n e n t s  a f f e c t e d  b y  t h e  g e n e s  b e a r i n g  v a r i a n t s  a r e  i n d i c a t e d  i n  r e d .  
N u m b e r  o f  g e n e s  a n d  s t a t i s t i c a l  s i g n i f i c a n c e  i n d i c a t e d  b e l o w  t h e  n a m e d  p r o c e s s ,  f u n c t i o n  o r  c o m p o n e n t .  
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TCRγδ+ T-LGL leukemia is a chronic, rare and heterogeneous disorder, affecting 
mostly elderly individuals of average age above 60 [1,2, Chapter 1 this thesis]. The etiology of the disease still remains largely elusive, due to the low incidence of the 
disease, the frequent lack  of symptoms and a highly heterogeneous disease spectrum [1,3, Chapter 5 this thesis]. In this thesis we aimed to identify underlying (molecular) 
pathways and mechanisms that might contribute to the pathogenesis of this disease. Currently it has been hypothesized that chronic and/or continuous stimulation, due to 
signals from the (micro-)environment of TCRγδ+ T cells, underlies proliferation, which 
ultimately results in a monoclonal population [4]. Since it is a chronic disease affecting mostly elderly individuals above age 60, continuous stimulation has often been linked to 
ageing processes [5,6]. On the other hand, cell-intrinsic mechanisms could contribute to the aberrant profile of TCRγδ+ T cells, as cancers are known to result from underlying 
genetic aberrancies both on DNA and RNA level. In this thesis we aimed to investigate the underlying pathology of TCRγδ+ T-LGL leukemia by focusing on both cell-intrinsic 
and external mechanisms, using multiple approaches.
CELL-INTRINSIC MECHANISMS
Genetic aberrancies as the foundation of leukemia
Cancer results from genetic aberrancies that have occurred in healthy cells, even- tually leading to uncontrolled proliferation [7]. Most cancers develop by acquisition 
of multiple mutations over time [8], while 5-10% of all cancers have a predisposition in the germline sequence [9], as originally described in 1971 by Alfred Knudson in his 
“two-hit” hypothesis [10,11]. In this model hereditary cancer syndromes, e.g. childhood 
cancers (0-19 years of age), would already have their onset or first hit in the germline, 
[12], which includes amongst others mutations in DNA repair genes [13], or specific 
BRCA mutations in ovarian and breast cancer [14,15]. In these hereditary cases at least one additional mutation can cause neoplastic development, whereas sporadic cancers 
and more chronic type of cancers develop spontaneously or with ageing after acquiring two (or more) somatic mutations (Fig. 1). 
In the hematopoietic system several forms of chronic cancer exist, which involve different (immune) cell types: chronic myeloid leukemia (CML; myeloid cells), chronic 
lymphocytic leukemia (CLL; B cells) [16], and also the less common large granular lym- phocyte leukemia (LGL; T and NK cells) [17]. As underlying pathogenic mechanisms 
also somatic mutations have been described, such as mutations in the TP53, ATM, EGR2, 
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T C R γ δ +  T - L G L  l e u k e m i a  i s  a  c h r o n i c ,  r a r e  a n d  h e t e r o g e n e o u s  d i s o r d e r ,  a f f e c t i n g  
m o s t l y  e l d e r l y  i n d i v i d u a l s  o f  a v e r a g e  a g e  a b o v e  6 0  [ 1 , 2 ,  C h a p t e r  1  t h i s  t h e s i s ] .  T h e  
e t i o l o g y  o f  t h e  d i s e a s e  s t i l l  r e m a i n s  l a r g e l y  e l u s i v e ,  d u e  t o  t h e  l o w  i n c i d e n c e  o f  t h e  
d i s e a s e ,  t h e  f r e q u e n t  l a c k   o f  s y m p t o m s  a n d  a  h i g h l y  h e t e r o g e n e o u s  d i s e a s e  s p e c t r u m  
[ 1 , 3 ,  C h a p t e r  5  t h i s  t h e s i s ] .  I n  t h i s  t h e s i s  w e  a i m e d  t o  i d e n t i f y  u n d e r l y i n g  ( m o l e c u l a r )  
p a t h w a y s  a n d  m e c h a n i s m s  t h a t  m i g h t  c o n t r i b u t e  t o  t h e  p a t h o g e n e s i s  o f  t h i s  d i s e a s e .  
C u r r e n t l y  i t  h a s  b e e n  h y p o t h e s i z e d  t h a t  c h r o n i c  a n d / o r  c o n t i n u o u s  s t i m u l a t i o n ,  d u e  t o  
s i g n a l s  f r o m  t h e  ( m i c r o - ) e n v i r o n m e n t  o f  T C R γ δ +  T  c e l l s ,  u n d e r l i e s  p r o l i f e r a t i o n ,  w h i c h  
u l t i m a t e l y  r e s u l t s  i n  a  m o n o c l o n a l  p o p u l a t i o n  [ 4 ] .  S i n c e  i t  i s  a  c h r o n i c  d i s e a s e  a f f e c t i n g  
m o s t l y  e l d e r l y  i n d i v i d u a l s  a b o v e  a g e  6 0 ,  c o n t i n u o u s  s t i m u l a t i o n  h a s  o f t e n  b e e n  l i n k e d  t o  
a g e i n g  p r o c e s s e s  [ 5 , 6 ] .  O n  t h e  o t h e r  h a n d ,  c e l l - i n t r i n s i c  m e c h a n i s m s  c o u l d  c o n t r i b u t e  t o  
t h e  a b e r r a n t  p r o f i l e  o f  T C R γ δ +  T  c e l l s ,  a s  c a n c e r s  a r e  k n o w n  t o  r e s u l t  f r o m  u n d e r l y i n g  
g e n e t i c  a b e r r a n c i e s  b o t h  o n  D N A  a n d  R N A  l e v e l .  I n  t h i s  t h e s i s  w e  a i m e d  t o  i n v e s t i g a t e  
t h e  u n d e r l y i n g  p a t h o l o g y  o f  T C R γ δ +  T - L G L  l e u k e m i a  b y  f o c u s i n g  o n  b o t h  c e l l - i n t r i n s i c  
a n d  e x t e r n a l  m e c h a n i s m s ,  u s i n g  m u l t i p l e  a p p r o a c h e s .
C E L L - I N T R I N S I C  M E C H A N I S M S
G e n e t i c  a b e r r a n c i e s  a s  t h e  f o u n d a t i o n  o f  l e u k e m i a
C a n c e r  r e s u l t s  f r o m  g e n e t i c  a b e r r a n c i e s  t h a t  h a v e  o c c u r r e d  i n  h e a l t h y  c e l l s ,  e v e n -
t u a l l y  l e a d i n g  t o  u n c o n t r o l l e d  p r o l i f e r a t i o n  [ 7 ] .  M o s t  c a n c e r s  d e v e l o p  b y  a c q u i s i t i o n  
o f  m u l t i p l e  m u t a t i o n s  o v e r  t i m e  [ 8 ] ,  w h i l e  5 - 1 0 %  o f  a l l  c a n c e r s  h a v e  a  p r e d i s p o s i t i o n  
i n  t h e  g e r m l i n e  s e q u e n c e  [ 9 ] ,  a s  o r i g i n a l l y  d e s c r i b e d  i n  1 9 7 1  b y  A l f r e d  K n u d s o n  i n  h i s  
“ t w o - h i t ”  h y p o t h e s i s  [ 1 0 , 1 1 ] .  I n  t h i s  m o d e l  h e r e d i t a r y  c a n c e r  s y n d r o m e s ,  e . g .  c h i l d h o o d  
c a n c e r s  ( 0 - 1 9  y e a r s  o f  a g e ) ,  w o u l d  a l r e a d y  h a v e  t h e i r  o n s e t  o r  f i r s t  h i t  i n  t h e  g e r m l i n e ,  
[ 1 2 ] ,  w h i c h  i n c l u d e s  a m o n g s t  o t h e r s  m u t a t i o n s  i n  D N A  r e p a i r  g e n e s  [ 1 3 ] ,  o r  s p e c i f i c  
B R C A  m u t a t i o n s  i n  o v a r i a n  a n d  b r e a s t  c a n c e r  [ 1 4 , 1 5 ] .  I n  t h e s e  h e r e d i t a r y  c a s e s  a t  l e a s t  
o n e  a d d i t i o n a l  m u t a t i o n  c a n  c a u s e  n e o p l a s t i c  d e v e l o p m e n t ,  w h e r e a s  s p o r a d i c  c a n c e r s  
a n d  m o r e  c h r o n i c  t y p e  o f  c a n c e r s  d e v e l o p  s p o n t a n e o u s l y  o r  w i t h  a g e i n g  a f t e r  a c q u i r i n g  
t w o  ( o r  m o r e )  s o m a t i c  m u t a t i o n s  ( F i g .  1 ) .  
I n  t h e  h e m a t o p o i e t i c  s y s t e m  s e v e r a l  f o r m s  o f  c h r o n i c  c a n c e r  e x i s t ,  w h i c h  i n v o l v e  
d i f f e r e n t  ( i m m u n e )  c e l l  t y p e s :  c h r o n i c  m y e l o i d  l e u k e m i a  ( C M L ;  m y e l o i d  c e l l s ) ,  c h r o n i c  
l y m p h o c y t i c  l e u k e m i a  ( C L L ;  B  c e l l s )  [ 1 6 ] ,  a n d  a l s o  t h e  l e s s  c o m m o n  l a r g e  g r a n u l a r  l y m -
p h o c y t e  l e u k e m i a  ( L G L ;  T  a n d  N K  c e l l s )  [ 1 7 ] .  A s  u n d e r l y i n g  p a t h o g e n i c  m e c h a n i s m s  
a l s o  s o m a t i c  m u t a t i o n s  h a v e  b e e n  d e s c r i b e d ,  s u c h  a s  m u t a t i o n s  i n  t h e  T P 5 3 ,  A T M ,  E G R 2 ,  
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BRAF, RPS15, IKZF3 genes in CLL [18,19] (reviewed by [20]), or the BCR-ABL1 trans-location in CML [21]. T-LGL leukemia however has only recently been associated with somatic STAT3 and STAT5b mutations [22,23], thereby unifying this chronic leukemia with NK-LGL in which such mutations have also been described [24]. Of these, the STAT3 
mutations were identified most frequently in LGL leukemia patients (11-70%). Initially, the somatic STAT3 mutations were mainly located in the SH2 domain, but more recently also gain-of-function mutations outside this domain were observed [25]. STAT muta-
tions are currently highlighted in the latest World Health Organization classification of LGL leukemias [3,26] as diagnostic and therapeutic targets [27]. Of note, STAT mutations 
have only been described for CD8+TCRαβ+ T-LGL leukemia. An association of TCRγδ+ T-LGL leukemia and STAT3 and/or STAT5b mutations has not been reported yet, although 
activating mutations have been found in lymphomas of the TCRγδ+ T cell type [28]. Due 
Figure 1. Two-hit hypothesis in carcinogenesis.Alfred Knudson proposed his two-hit model of oncogenesis [10] based on acquisition of two genetic aberrancies that are required to initiate neoplastic development. In hereditary cancers a germline mutation is already present (a), which requires one additional somatic mutation, while spontaneous cancers (b) require two (or more) genetic events prior to neoplastic transformation.  Figure adapted from Jozwiak et al. 2008 [11].
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BRAF, RPS15, IKZF3 genes in CLL [18,19] (reviewed by [20]), or the BCR-ABL1 trans-
location in CML [21]. T-LGL leukemia however has only recently been associated with 
somatic STAT3 and STAT5b mutations [22,23], thereby unifying this chronic leukemia 
with NK-LGL in which such mutations have also been described [24]. Of these, the STAT3 
mutations were identified most frequently in LGL leukemia patients (11-70%). Initially, 
the somatic STAT3 mutations were mainly located in the SH2 domain, but more recently 
also gain-of-function mutations outside this domain were observed [25]. STAT muta-
tions are currently highlighted in the latest World Health Organization classification of 
LGL leukemias [3,26] as diagnostic and therapeutic targets [27]. Of note, STAT mutations 
have only been described for CD8+TCRαβ+ T-LGL leukemia. An association of TCRγδ+ 
T-LGL leukemia and STAT3 and/or STAT5b mutations has not been reported yet, although 
activating mutations have been found in lymphomas of the TCRγδ+ T cell type [28]. Due 
Figure 1. Two-hit hypothesis in carcinogenesis.
Alfred Knudson proposed his two-hit model of oncogenesis [10] based on acquisition of two genetic 
aberrancies that are required to initiate neoplastic development. In hereditary cancers a germline mutation is 
already present (a), which requires one additional somatic mutation, while spontaneous cancers (b) require 




to recent (technical) advances in sequencing methodologies more and more mutations are disclosed that underlie these chronic leukemias, and possibly explain their patho-
genesis and/or etiology.
Novel genetic aberrancies potentially associated with TCRγδ+ T-LGL 
leukemia development
TCRγδ+ T-LGL leukemia is associated with clonal drifts and shifts, leading to 
differences in dominant clones over time [29]. A clear common underlying mechanism has not been described yet. Based on earlier whole exome sequencing (WES) studies, as 
performed in NK- and CD8+TCRαβ+ T-LGL leukemias and which mainly revealed STAT3 gain-of-function mutations, we aimed for WES analysis using TCRγδ+ T-LGL leukemic 
cells sorted from patients, in parallel with sorted monocytes as internal control to dis- tinguish tumor-specific mutations from individual-specific single nucleotide variants 
(SNV) [Chapter 7, this thesis]. Based on our WES data, we could define and validate six 
candidate genes containing homozygous variants that were present in patient leukemic cells, but absent in healthy monocyte cells (Table 1; Fig. 2). 
Firstly, we observed an insert in the gene encoding the CREB3L2 transcription factor, which is involved in the regulation of transcription of (proto-) oncogenes such as c-Fos 
and c-Jun that are part of the AP-1 early response transcription factors [30] and that targets a.o. c-Fos for auto-regulation [31] (Fig. 2). Another target of CREB3L2 is E2F, 
which is driving expression of genes in tissue regeneration, proliferation [32], cancer cell growth and tumor invasiveness [33].
Transcriptional regulator NCOR2 also contained a homozygous insertion. This gene is associated with histone deacetylase recruitment and thus with down-regulation of 
gene expression [34]. A different variant in the NCOR2 gene has been associated with Tamoxifen resistance in breast cancer [35] and early tumor recurrence [36]. At the 
protein level NCOR2 can show aberrant cytoplasmic occurrence; nuclear exclusion of NCOR2 been associated with colorectal cancers, thus supporting the role for NCOR2 in 
tumorigenesis [37]. This could lead to blocked repression of target genes such as E2F, Fos and also CREBBP [38] (Fig. 2). Other associations have been described with mela-
noma [39] and leukemogenesis in general [40]. As TCRγδ+ T cells are known to reside 
in epithelial tissues of the gut and skin, genes related to colorectal and skin cancer could also impact on the function and anatomical position of TCRγδ+ T cells [41]. The alter-
ation of both CREB3L2 and NCOR2 thus could have detrimental downstream effects on the development of clones in mainly TCRγδ+ T-LGL leukemia, but it should be noted that 
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t o  r e c e n t  ( t e c h n i c a l )  a d v a n c e s  i n  s e q u e n c i n g  m e t h o d o l o g i e s  m o r e  a n d  m o r e  m u t a t i o n s  
a r e  d i s c l o s e d  t h a t  u n d e r l i e  t h e s e  c h r o n i c  l e u k e m i a s ,  a n d  p o s s i b l y  e x p l a i n  t h e i r  p a t h o -
g e n e s i s  a n d / o r  e t i o l o g y .
N o v e l  g e n e t i c  a b e r r a n c i e s  p o t e n t i a l l y  a s s o c i a t e d  w i t h  T C R γ δ +  T - L G L  
l e u k e m i a  d e v e l o p m e n t
T C R γ δ +  T - L G L  l e u k e m i a  i s  a s s o c i a t e d  w i t h  c l o n a l  d r i f t s  a n d  s h i f t s ,  l e a d i n g  t o  
d i f f e r e n c e s  i n  d o m i n a n t  c l o n e s  o v e r  t i m e  [ 2 9 ] .  A  c l e a r  c o m m o n  u n d e r l y i n g  m e c h a n i s m  
h a s  n o t  b e e n  d e s c r i b e d  y e t .  B a s e d  o n  e a r l i e r  w h o l e  e x o m e  s e q u e n c i n g  ( W E S )  s t u d i e s ,  a s  
p e r f o r m e d  i n  N K -  a n d  C D 8 + T C R α β +  T - L G L  l e u k e m i a s  a n d  w h i c h  m a i n l y  r e v e a l e d  S T A T 3  
g a i n - o f - f u n c t i o n  m u t a t i o n s ,  w e  a i m e d  f o r  W E S  a n a l y s i s  u s i n g  T C R γ δ +  T - L G L  l e u k e m i c  
c e l l s  s o r t e d  f r o m  p a t i e n t s ,  i n  p a r a l l e l  w i t h  s o r t e d  m o n o c y t e s  a s  i n t e r n a l  c o n t r o l  t o  d i s -
t i n g u i s h  t u m o r - s p e c i f i c  m u t a t i o n s  f r o m  i n d i v i d u a l - s p e c i f i c  s i n g l e  n u c l e o t i d e  v a r i a n t s  
( S N V )  [ C h a p t e r  7 ,  t h i s  t h e s i s ] .  B a s e d  o n  o u r  W E S  d a t a ,  w e  c o u l d  d e f i n e  a n d  v a l i d a t e  s i x  
c a n d i d a t e  g e n e s  c o n t a i n i n g  h o m o z y g o u s  v a r i a n t s  t h a t  w e r e  p r e s e n t  i n  p a t i e n t  l e u k e m i c  
c e l l s ,  b u t  a b s e n t  i n  h e a l t h y  m o n o c y t e  c e l l s  ( T a b l e  1 ;  F i g .  2 ) .  
F i r s t l y ,  w e  o b s e r v e d  a n  i n s e r t  i n  t h e  g e n e  e n c o d i n g  t h e  C R E B 3 L 2  t r a n s c r i p t i o n  f a c t o r ,  
w h i c h  i s  i n v o l v e d  i n  t h e  r e g u l a t i o n  o f  t r a n s c r i p t i o n  o f  ( p r o t o - )  o n c o g e n e s  s u c h  a s  c - F o s  
a n d  c - J u n  t h a t  a r e  p a r t  o f  t h e  A P - 1  e a r l y  r e s p o n s e  t r a n s c r i p t i o n  f a c t o r s  [ 3 0 ]  a n d  t h a t  
t a r g e t s  a . o .  c - F o s  f o r  a u t o - r e g u l a t i o n  [ 3 1 ]  ( F i g .  2 ) .  A n o t h e r  t a r g e t  o f  C R E B 3 L 2  i s  E 2 F ,  
w h i c h  i s  d r i v i n g  e x p r e s s i o n  o f  g e n e s  i n  t i s s u e  r e g e n e r a t i o n ,  p r o l i f e r a t i o n  [ 3 2 ] ,  c a n c e r  
c e l l  g r o w t h  a n d  t u m o r  i n v a s i v e n e s s  [ 3 3 ] .
T r a n s c r i p t i o n a l  r e g u l a t o r  N C O R 2  a l s o  c o n t a i n e d  a  h o m o z y g o u s  i n s e r t i o n .  T h i s  g e n e  
i s  a s s o c i a t e d  w i t h  h i s t o n e  d e a c e t y l a s e  r e c r u i t m e n t  a n d  t h u s  w i t h  d o w n - r e g u l a t i o n  o f  
g e n e  e x p r e s s i o n  [ 3 4 ] .  A  d i f f e r e n t  v a r i a n t  i n  t h e  N C O R 2  g e n e  h a s  b e e n  a s s o c i a t e d  w i t h  
T a m o x i f e n  r e s i s t a n c e  i n  b r e a s t  c a n c e r  [ 3 5 ]  a n d  e a r l y  t u m o r  r e c u r r e n c e  [ 3 6 ] .  A t  t h e  
p r o t e i n  l e v e l  N C O R 2  c a n  s h o w  a b e r r a n t  c y t o p l a s m i c  o c c u r r e n c e ;  n u c l e a r  e x c l u s i o n  o f  
N C O R 2  b e e n  a s s o c i a t e d  w i t h  c o l o r e c t a l  c a n c e r s ,  t h u s  s u p p o r t i n g  t h e  r o l e  f o r  N C O R 2  i n  
t u m o r i g e n e s i s  [ 3 7 ] .  T h i s  c o u l d  l e a d  t o  b l o c k e d  r e p r e s s i o n  o f  t a r g e t  g e n e s  s u c h  a s  E 2 F ,  
F o s  a n d  a l s o  C R E B B P  [ 3 8 ]  ( F i g .  2 ) .  O t h e r  a s s o c i a t i o n s  h a v e  b e e n  d e s c r i b e d  w i t h  m e l a -
n o m a  [ 3 9 ]  a n d  l e u k e m o g e n e s i s  i n  g e n e r a l  [ 4 0 ] .  A s  T C R γ δ +  T  c e l l s  a r e  k n o w n  t o  r e s i d e  
i n  e p i t h e l i a l  t i s s u e s  o f  t h e  g u t  a n d  s k i n ,  g e n e s  r e l a t e d  t o  c o l o r e c t a l  a n d  s k i n  c a n c e r  c o u l d  
a l s o  i m p a c t  o n  t h e  f u n c t i o n  a n d  a n a t o m i c a l  p o s i t i o n  o f  T C R γ δ +  T  c e l l s  [ 4 1 ] .  T h e  a l t e r -
a t i o n  o f  b o t h  C R E B 3 L 2  a n d  N C O R 2  t h u s  c o u l d  h a v e  d e t r i m e n t a l  d o w n s t r e a m  e f f e c t s  o n  
t h e  d e v e l o p m e n t  o f  c l o n e s  i n  m a i n l y  T C R γ δ +  T - L G L  l e u k e m i a ,  b u t  i t  s h o u l d  b e  n o t e d  t h a t  
a l t e r e d  e x p r e s s i o n  l e v e l s  w e r e  o b s e r v e d  i n  C D 8 + T C R α β +  T - L G L  l e u k e m i a  [ C h a p t e r  7 ,  
t h i s  t h e s i s ] .  
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Since CREB3L2 contained a gain-of-function variant, this would lead to increased expression of proto-oncogenes c-Fos and c-Jun, which have also been implicated in invasive tumor growth [33]. Interestingly, our WES study showed a more direct relation to invasive tumor growth with a frameshift deletion in the VEGFC gene. VEGFC is an important factor in lymphangiogenesis due to its native expression in epithelial cells [42], and has been described to be associated with metastatic gastric [43] and breast cancer [44]. The frameshift deletion that we found in our study ws associated with 
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Candidate genes from both datasets are indicated in bold, associated molecules and genes in regular font type. Oncogenes and other genes playing major roles 
in cancer development are indicated in red font. Up- and down-regulation are indicated with red and blue color intensities respectively indicated in gradient 
bar in figure: up-regulated genes are colored red gradients based on their level of up-regulation; dark red strong, lighter red/orange less strong or w
eakly up-
regulated. Down-regulated genes are colored in a similar gradient in blue: dark blue strong, light blue weak down-regulation. Green lines between molecules 
indicate a positive regulation, while blue lines show negative regulations and black lines show movements. Solid lines represent direct interactions, dotted 
lines indicate indirect interactions between molecules and/or genes. Apoptosis-related genes are clustered together as a complex. Figure is created using My 
Pathw
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enhanced gene expression in patients (Fig. 2). Given the fact that TCRγδ+ T cells can reside as intra-epithelial lymphocytes (IEL) in mucosal and epithelial tissues, the ele-vated expression of VEGFC in especially leukemic cells [Chapter 7 this thesis] and the association with epithelial esophageal squamous cell carcinoma [45] and melanoma [46] are intriguing. However, to further gain insights in the origin of the leukemic cells 
in TCRγδ+ T-LGL leukemia, more extensive validation studies on these gene aberrancies would be required, including functional assays to determine the effect of the variants on transformation and neoplastic development. Genes related to immune cell activation, cytotoxicity and cytokine production such as 
HAVCR1 and KLRF1 also contained damaging variants. HAVCR1 is known to be important in the regulation of immune cell activation in virus infection [47] (Fig. 2). Additionally, 
the role of HAVCR1 in cancer progression was recently defined through elevated IL-6 
production, which in turn activated the STAT3 pathway and increased HIF-1α produc-tion in various tumors, and thus increased angiogenesis and cancer metastasis [48,49]. Notably, T-LGL leukemia clones have also been found to highly express the HAVCR1 gene [50]. Together with the variant in the KLRF1 gene and the increased expression of this gene that is known to encode an inhibitory NK cell like receptor involved in tumor immu-
nity [51,52], this could be associated with dysregulated functioning of TCRγδ+ T cells in 
TCRγδ+ T-LGL leukemia, resulting in increased cytotoxicity towards other blood cells and causing cytopenias [1]. Such dysregulated immune responses might also explain the 
association between TCRγδ+ T-LGL leukemia and underlying autoimmune diseases and other (hematological) malignancies [1; Chapter 5, this thesis].
Altered gene expression profiles associated with TCRγδ+ T cell 
leukemia developmentUpon extended WES transcription factor target (TFT) enrichment analysis major transcription factors in hematopoietic development, proliferation, survival and immune cell activity/signaling (TCF7, LEF1, TP53, STAT3 and STAT5b) were found to be the main drivers of genes containing genetic variants [Chapter 7, this thesis] (Fig. 2). Expression 
levels of these transcription factors were found to be up-regulated in TCRγδ+ and 
CD8+TCRαβ+ T-LGL leukemia cells, thereby indicating a possible role in driving T-LGL leukemia pathogenesis. Notably, even though the STAT3 and STAT5b genes did not bear 
exonic mutations in our TCRγδ+ T-LGL leukemia WES dataset, they did appear as main driving factors in aberrant transcription of target genes. Moreover, gene expression 
analysis of both STAT3 and STAT5b showed clear increases in TCRγδ+ T-LGL leukemia 
cells, thus further supporting a role for STAT factors in TCRγδ+ T-LGL leukemia as well [Chapter 7, this thesis].
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In the broader gene expression profiling (GEP) data set the ID3 transcription factor gene was found to be highly up-regulated in TCRγδ+ T-LGL leukemia cells. ID3 has been 
described to be clearly up-regulated and associated with high resistance to spontaneous apoptosis and chemotherapy in B cell CLL [53-55] and has been associated with cell cycle 
progression, differentiation and tumor invasiveness [56]. Furthermore, ID3 is important in cell survival, as evidenced from Ingenuity Pathway Analysis (IPA) [57] (Fig. 2). The 
role of ID3 in TCRγδ+ T cells has been addressed in transgenic mouse models showing 
a disruption in TCRαβ+ but not in TCRγδ+ T cell development [58], while in absence 
of ID3 T cell precursors failed to adopt the TCRγδ fate [59], suggesting TCRγδ+ T cell 
dependency on ID3 expression [60]. Given that mouse and human TCRγδ+ T cells are 
structurally and functionally different [61,62] it is difficult to compare both systems in 
order to understand TCRγδ+ T cell biology and aberrant GEP in human diseases such as 
TCRγδ+ T-LGL leukemia. Nevertheless, these findings would underline the importance 
of ID3 in survival, which could explain the major up-regulation of this gene. Our GEP analysis further revealed significantly altered expression of genes involved 
in proliferation, apoptosis and normal immune cell activation [Chapter 6, this thesis]. Due to the chronic disease character and the underlying autoimmune diseases in T-LGL 
leukemia patients, it was hypothesized that T-LGL leukemia cells might be resistant to FAS-mediated apoptosis [63]. Normal LGL cells are programmed to undergo apoptosis 
after fulfilling effector functions (known as activation induced cell death, AICD) [64], a 
feature that appears to be lost in LGL leukemia [65]. Furthermore, the CD95/CD95 ligand apoptosis resistance was found to be related to aggressive disease showing resistance to 
chemotherapy. However, GEP of TCRγδ+ T-LGL leukemia cells did not show significantly 
altered genes in the CD95/CD95 ligand pathway, but other genes involved in apopto- sis induction were actually down-regulated [Chapter 6, this thesis] (Fig. 2). Clinically, 
TCRγδ+ T-LGL leukemia is not an aggressive disease [1], which might explain why aber- rancies in the CD95/CD95 ligand-apoptotic pathway are less likely to play a major role 
in its pathogenesis. In TCRγδ+ T-LGL leukemia down-regulation of the Caspase-8 and 
FADD like apoptosis regulator (CFLAR) gene was observed. To date, only one variant in the enhancer region of CFLAR was found to be linked with the development of breast 
cancer, but without direct functional association [66]. Even though this genetic variant unfortunately could not be evaluated in our WES study due to its location outside the 
exome, CFLAR might be an interesting candidate for further functional studies, espe- cially since it has been found to be associated with breast cancer and altered expression 
levels in TCRγδ+ T-LGL leukemia. 
Another increasingly important gene in the cancer field is the Bcl-2-associated tran- scription factor-1 (BCLAF1) gene. It has been identified as tumor suppressor gene in 
leukemias and lymphomas in particular, acting through promotion of TP53 activation 
8
2 5 1
G e n e r a l  D i s c u s s i o n
I n  t h e  b r o a d e r  g e n e  e x p r e s s i o n  p r o f i l i n g  ( G E P )  d a t a  s e t  t h e  I D 3  t r a n s c r i p t i o n  f a c t o r  
g e n e  w a s  f o u n d  t o  b e  h i g h l y  u p - r e g u l a t e d  i n  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s .  I D 3  h a s  b e e n  
d e s c r i b e d  t o  b e  c l e a r l y  u p - r e g u l a t e d  a n d  a s s o c i a t e d  w i t h  h i g h  r e s i s t a n c e  t o  s p o n t a n e o u s  
a p o p t o s i s  a n d  c h e m o t h e r a p y  i n  B  c e l l  C L L  [ 5 3 - 5 5 ]  a n d  h a s  b e e n  a s s o c i a t e d  w i t h  c e l l  c y c l e  
p r o g r e s s i o n ,  d i f f e r e n t i a t i o n  a n d  t u m o r  i n v a s i v e n e s s  [ 5 6 ] .  F u r t h e r m o r e ,  I D 3  i s  i m p o r t a n t  
i n  c e l l  s u r v i v a l ,  a s  e v i d e n c e d  f r o m  I n g e n u i t y  P a t h w a y  A n a l y s i s  ( I P A )  [ 5 7 ]  ( F i g .  2 ) .  T h e  
r o l e  o f  I D 3  i n  T C R γ δ +  T  c e l l s  h a s  b e e n  a d d r e s s e d  i n  t r a n s g e n i c  m o u s e  m o d e l s  s h o w i n g  
a  d i s r u p t i o n  i n  T C R α β +  b u t  n o t  i n  T C R γ δ +  T  c e l l  d e v e l o p m e n t  [ 5 8 ] ,  w h i l e  i n  a b s e n c e  
o f  I D 3  T  c e l l  p r e c u r s o r s  f a i l e d  t o  a d o p t  t h e  T C R γ δ  f a t e  [ 5 9 ] ,  s u g g e s t i n g  T C R γ δ +  T  c e l l  
d e p e n d e n c y  o n  I D 3  e x p r e s s i o n  [ 6 0 ] .  G i v e n  t h a t  m o u s e  a n d  h u m a n  T C R γ δ +  T  c e l l s  a r e  
s t r u c t u r a l l y  a n d  f u n c t i o n a l l y  d i f f e r e n t  [ 6 1 , 6 2 ]  i t  i s  d i f f i c u l t  t o  c o m p a r e  b o t h  s y s t e m s  i n  
o r d e r  t o  u n d e r s t a n d  T C R γ δ +  T  c e l l  b i o l o g y  a n d  a b e r r a n t  G E P  i n  h u m a n  d i s e a s e s  s u c h  a s  
T C R γ δ +  T - L G L  l e u k e m i a .  N e v e r t h e l e s s ,  t h e s e  f i n d i n g s  w o u l d  u n d e r l i n e  t h e  i m p o r t a n c e  
o f  I D 3  i n  s u r v i v a l ,  w h i c h  c o u l d  e x p l a i n  t h e  m a j o r  u p - r e g u l a t i o n  o f  t h i s  g e n e .  
O u r  G E P  a n a l y s i s  f u r t h e r  r e v e a l e d  s i g n i f i c a n t l y  a l t e r e d  e x p r e s s i o n  o f  g e n e s  i n v o l v e d  
i n  p r o l i f e r a t i o n ,  a p o p t o s i s  a n d  n o r m a l  i m m u n e  c e l l  a c t i v a t i o n  [ C h a p t e r  6 ,  t h i s  t h e s i s ] .  
D u e  t o  t h e  c h r o n i c  d i s e a s e  c h a r a c t e r  a n d  t h e  u n d e r l y i n g  a u t o i m m u n e  d i s e a s e s  i n  T - L G L  
l e u k e m i a  p a t i e n t s ,  i t  w a s  h y p o t h e s i z e d  t h a t  T - L G L  l e u k e m i a  c e l l s  m i g h t  b e  r e s i s t a n t  t o  
F A S - m e d i a t e d  a p o p t o s i s  [ 6 3 ] .  N o r m a l  L G L  c e l l s  a r e  p r o g r a m m e d  t o  u n d e r g o  a p o p t o s i s  
a f t e r  f u l f i l l i n g  e f f e c t o r  f u n c t i o n s  ( k n o w n  a s  a c t i v a t i o n  i n d u c e d  c e l l  d e a t h ,  A I C D )  [ 6 4 ] ,  a  
f e a t u r e  t h a t  a p p e a r s  t o  b e  l o s t  i n  L G L  l e u k e m i a  [ 6 5 ] .  F u r t h e r m o r e ,  t h e  C D 9 5 / C D 9 5  l i g a n d  
a p o p t o s i s  r e s i s t a n c e  w a s  f o u n d  t o  b e  r e l a t e d  t o  a g g r e s s i v e  d i s e a s e  s h o w i n g  r e s i s t a n c e  t o  
c h e m o t h e r a p y .  H o w e v e r ,  G E P  o f  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  d i d  n o t  s h o w  s i g n i f i c a n t l y  
a l t e r e d  g e n e s  i n  t h e  C D 9 5 / C D 9 5  l i g a n d  p a t h w a y ,  b u t  o t h e r  g e n e s  i n v o l v e d  i n  a p o p t o -
s i s  i n d u c t i o n  w e r e  a c t u a l l y  d o w n - r e g u l a t e d  [ C h a p t e r  6 ,  t h i s  t h e s i s ]  ( F i g .  2 ) .  C l i n i c a l l y ,  
T C R γ δ +  T - L G L  l e u k e m i a  i s  n o t  a n  a g g r e s s i v e  d i s e a s e  [ 1 ] ,  w h i c h  m i g h t  e x p l a i n  w h y  a b e r -
r a n c i e s  i n  t h e  C D 9 5 / C D 9 5  l i g a n d - a p o p t o t i c  p a t h w a y  a r e  l e s s  l i k e l y  t o  p l a y  a  m a j o r  r o l e  
i n  i t s  p a t h o g e n e s i s .  I n  T C R γ δ +  T - L G L  l e u k e m i a  d o w n - r e g u l a t i o n  o f  t h e  C a s p a s e - 8  a n d  
F A D D  l i k e  a p o p t o s i s  r e g u l a t o r  ( C F L A R )  g e n e  w a s  o b s e r v e d .  T o  d a t e ,  o n l y  o n e  v a r i a n t  i n  
t h e  e n h a n c e r  r e g i o n  o f  C F L A R  w a s  f o u n d  t o  b e  l i n k e d  w i t h  t h e  d e v e l o p m e n t  o f  b r e a s t  
c a n c e r ,  b u t  w i t h o u t  d i r e c t  f u n c t i o n a l  a s s o c i a t i o n  [ 6 6 ] .  E v e n  t h o u g h  t h i s  g e n e t i c  v a r i a n t  
u n f o r t u n a t e l y  c o u l d  n o t  b e  e v a l u a t e d  i n  o u r  W E S  s t u d y  d u e  t o  i t s  l o c a t i o n  o u t s i d e  t h e  
e x o m e ,  C F L A R  m i g h t  b e  a n  i n t e r e s t i n g  c a n d i d a t e  f o r  f u r t h e r  f u n c t i o n a l  s t u d i e s ,  e s p e -
c i a l l y  s i n c e  i t  h a s  b e e n  f o u n d  t o  b e  a s s o c i a t e d  w i t h  b r e a s t  c a n c e r  a n d  a l t e r e d  e x p r e s s i o n  
l e v e l s  i n  T C R γ δ +  T - L G L  l e u k e m i a .  
A n o t h e r  i n c r e a s i n g l y  i m p o r t a n t  g e n e  i n  t h e  c a n c e r  f i e l d  i s  t h e  B c l - 2 - a s s o c i a t e d  t r a n -
s c r i p t i o n  f a c t o r - 1  ( B C L A F 1 )  g e n e .  I t  h a s  b e e n  i d e n t i f i e d  a s  t u m o r  s u p p r e s s o r  g e n e  i n  
l e u k e m i a s  a n d  l y m p h o m a s  i n  p a r t i c u l a r ,  a c t i n g  t h r o u g h  p r o m o t i o n  o f  T P 5 3  a c t i v a t i o n  
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in DNA damage repair (DDR) [67,68], but also as oncogene in colorectal cancer [69]. This controversial role of BCLAF1 in different cancers strongly underlines the neces-sity to further investigate functional consequences, but a complicating factor is that complete BCLAF1 knock-outs are lethal [70]. In TCRγδ+ T-LGL leukemia BCLAF1 gene expression levels were up-regulated, possibly suggesting an apoptosis-inhibitory role, 
based on apoptosis-resistance findings associated with T-LGL leukemia pathogenesis 
[63]. Together with the observed Caspase-1 down-regulation in TCRγδ+ T-LGL cells, this 
would strongly suggest that further apoptosis profiling of these leukemic cells might 
provide essential insights on the full apoptosis profile (Fig. 2). Application of a multiplex 
ligation-dependent amplification (MLPA) procedure using specific inflammation and apoptosis probe sets [71,72] should help to establish a more comprehensive expression 
profile of apoptosis- and inflammation-related genes. Finally, clinical symptoms such as cytopenias point to altered immune functioning 
and autoimmune characteristics in TCRγδ+ T-LGL leukemia. This idea is supported by the WES and GEP datasets, which both showed altered expression of genes associated 
with enhanced immune responses, i.e. increased inflammation through up-regulation of 
CD28 and CCR7, while infection-specific interferon (IFN)-γ production was down-regu-lated (Fig. 2). The ability to communicate with other cells could be lost through CX3CR1 chemokine receptor down-regulation (Fig. 2). This fractalkine receptor is associated with adhesion and migration of cells that are armed with perforin and granzyme B to act in a cytotoxic response at the site of infection [73,74]. Furthermore, when cells lack CX3CR1, their migration into tissues would be reduced, which could be linked to the 
increased numbers of circulating leukemic TCRγδ+ T cells seen in these patients.  
Whole exome sequencing and gene expression profiling cross-
validation of aberrations in TCRγδ+ T-LGL leukemia As discussed above, the WES and GEP methods both revealed candidate genes that 
are affected (i.e. altered and/or differentially expressed) in TCRγδ+ T cell leukemia cells. Notably, each of these datasets can serve for validation purposes for the other dataset. WES data can provide clues for differential gene expression of especially downstream target genes, while GEP data can illustrate the effect of genetic variants on expression of a particular gene. In fact, WES and GEP datasets can be analyzed in parallel using IPA Comparison Analysis, which integrates both datasets, thus providing gene interconnec-
tions with variants identified from WES, and significantly differentially expressed genes from GEP [57]. When we performed this direct IPA comparison analysis we observed sig-
nificant alterations in “T and B cell signaling in rheumatoid arthritis (RA)”, “nitric oxide 
(NO)” and “reactive oxygen species (ROS) production” pathways in the GEP dataset only, 
whereas the canonical pathways “xenobiotic metabolism signaling”, “triggering receptor 
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expressed on myeloid cells 1 (TREM1) signaling”, “B cell activating factor signaling” 
and “liver X receptor/retinoid X receptor (LXR/RXR) activation” were all significantly 
affected according to both datasets using the Fisher Exact test (Fig. 3a, indicated in red). Each of the significantly affected canonical pathways showed affected genes in both 
WES and GEP datasets upon Ingenuity Target Explorer analysis [75]. These pathways and their specific genes have been described to play roles in pathogenic events, par-
ticularly in immunopathogenesis and carcinogenesis (Fig. 3b). An important pathway in the development and propagation of cancer is to gain resistance to therapy through 
e.g. altered xenobiotic metabolism. Of note, not only genes involved in actual metabo- lism, but also genes involved in active removal of chemotherapeutic agents were found 
(ABC receptors). This could suggest that TCRγδ+ T-LGL leukemia cells have undergone 
additional transformation in the recognition and metabolism of foreign molecules [41]. Some patients received treatment, either for an underlying autoimmune disease or 
malignancy (Table 2). Next to these overlapping genes and affected canonical pathways, both datasets 
showed distinct sets of affected genes which could be explained by the difference between DNA (WES) and RNA (GEP) levels and methods of investigation (Table 1, Fig. 3). 
The up-regulation of the xenobiotic metabolism pathway could actually be the result of such treatment. Altered metabolic signaling was also observed in the LXR/RXR meta-
bolic signaling pathway. This pathway has been shown to contain SERPINA1, a possi- ble biomarker in e.g. thyroid and cutaneous squamous cell carcinoma [76]. LXR/RXR 
signaling is also involved in immune regulation with antimicrobial effects. The TREM1 signaling pathway is involved in the regulation of inflammation, but rather at the level of 
cell-cell and cell-extracellular matrix interactions. Aberrant TREM1 signaling has been shown to be associated with immune-suppression and thus with tumor-favorable envi-
ronments, an effect that could also be achieved through altered B cell signaling. TCRγδ+ 
T cells could be connected with such immune regulation pathways based on their ability to recognize a wide variety of antigens including microbes, due to their anatomical posi-
tions, and their ability to communicate with a large number of cell and tissue types [41]. Strikingly, all pathways showed overlapping genes, including NFKB1 and 2, which form a 
central hub in immune regulation [77]. Furthermore, the combined WES / GEP analysis also confirmed that STAT3 forms a central feature in LGL pathogenesis. This also holds 
true for PIK3CA; even though no directly damaging mutations were observed in these genes, there seemed to be an altered expression, possibly due to other upstream genes 
(Fig. 3b). Datasets showed distinct sets of affected genes, which could be explained by the difference between DNA (WES) and RNA (GEP) levels and methods of investigation. 
Linking genetic aberrancies with variable gene expression through expression quanti- tative trait loci (eQTL) analysis allows to identify underlying biological mechanisms of 
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e x p r e s s e d  o n  m y e l o i d  c e l l s  1  ( T R E M 1 )  s i g n a l i n g ” ,  “ B  c e l l  a c t i v a t i n g  f a c t o r  s i g n a l i n g ”  
a n d  “ l i v e r  X  r e c e p t o r / r e t i n o i d  X  r e c e p t o r  ( L X R / R X R )  a c t i v a t i o n ”  w e r e  a l l  s i g n i f i c a n t l y  
a f f e c t e d  a c c o r d i n g  t o  b o t h  d a t a s e t s  u s i n g  t h e  F i s h e r  E x a c t  t e s t  ( F i g .  3 a ,  i n d i c a t e d  i n  r e d ) .
E a c h  o f  t h e  s i g n i f i c a n t l y  a f f e c t e d  c a n o n i c a l  p a t h w a y s  s h o w e d  a f f e c t e d  g e n e s  i n  b o t h  
W E S  a n d  G E P  d a t a s e t s  u p o n  I n g e n u i t y  T a r g e t  E x p l o r e r  a n a l y s i s  [ 7 5 ] .  T h e s e  p a t h w a y s  
a n d  t h e i r  s p e c i f i c  g e n e s  h a v e  b e e n  d e s c r i b e d  t o  p l a y  r o l e s  i n  p a t h o g e n i c  e v e n t s ,  p a r -
t i c u l a r l y  i n  i m m u n o p a t h o g e n e s i s  a n d  c a r c i n o g e n e s i s  ( F i g .  3 b ) .  A n  i m p o r t a n t  p a t h w a y  
i n  t h e  d e v e l o p m e n t  a n d  p r o p a g a t i o n  o f  c a n c e r  i s  t o  g a i n  r e s i s t a n c e  t o  t h e r a p y  t h r o u g h  
e . g .  a l t e r e d  x e n o b i o t i c  m e t a b o l i s m .  O f  n o t e ,  n o t  o n l y  g e n e s  i n v o l v e d  i n  a c t u a l  m e t a b o -
l i s m ,  b u t  a l s o  g e n e s  i n v o l v e d  i n  a c t i v e  r e m o v a l  o f  c h e m o t h e r a p e u t i c  a g e n t s  w e r e  f o u n d  
( A B C  r e c e p t o r s ) .  T h i s  c o u l d  s u g g e s t  t h a t  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  h a v e  u n d e r g o n e  
a d d i t i o n a l  t r a n s f o r m a t i o n  i n  t h e  r e c o g n i t i o n  a n d  m e t a b o l i s m  o f  f o r e i g n  m o l e c u l e s  [ 4 1 ] .  
S o m e  p a t i e n t s  r e c e i v e d  t r e a t m e n t ,  e i t h e r  f o r  a n  u n d e r l y i n g  a u t o i m m u n e  d i s e a s e  o r  
m a l i g n a n c y  ( T a b l e  2 ) .
N e x t  t o  t h e s e  o v e r l a p p i n g  g e n e s  a n d  a f f e c t e d  c a n o n i c a l  p a t h w a y s ,  b o t h  d a t a s e t s  
s h o w e d  d i s t i n c t  s e t s  o f  a f f e c t e d  g e n e s  w h i c h  c o u l d  b e  e x p l a i n e d  b y  t h e  d i f f e r e n c e  
b e t w e e n  D N A  ( W E S )  a n d  R N A  ( G E P )  l e v e l s  a n d  m e t h o d s  o f  i n v e s t i g a t i o n  ( T a b l e  1 ,  F i g .  3 ) .  
T h e  u p - r e g u l a t i o n  o f  t h e  x e n o b i o t i c  m e t a b o l i s m  p a t h w a y  c o u l d  a c t u a l l y  b e  t h e  r e s u l t  o f  
s u c h  t r e a t m e n t .  A l t e r e d  m e t a b o l i c  s i g n a l i n g  w a s  a l s o  o b s e r v e d  i n  t h e  L X R / R X R  m e t a -
b o l i c  s i g n a l i n g  p a t h w a y .  T h i s  p a t h w a y  h a s  b e e n  s h o w n  t o  c o n t a i n  S E R P I N A 1 ,  a  p o s s i -
b l e  b i o m a r k e r  i n  e . g .  t h y r o i d  a n d  c u t a n e o u s  s q u a m o u s  c e l l  c a r c i n o m a  [ 7 6 ] .  L X R / R X R  
s i g n a l i n g  i s  a l s o  i n v o l v e d  i n  i m m u n e  r e g u l a t i o n  w i t h  a n t i m i c r o b i a l  e f f e c t s .  T h e  T R E M 1  
s i g n a l i n g  p a t h w a y  i s  i n v o l v e d  i n  t h e  r e g u l a t i o n  o f  i n f l a m m a t i o n ,  b u t  r a t h e r  a t  t h e  l e v e l  o f  
c e l l - c e l l  a n d  c e l l - e x t r a c e l l u l a r  m a t r i x  i n t e r a c t i o n s .  A b e r r a n t  T R E M 1  s i g n a l i n g  h a s  b e e n  
s h o w n  t o  b e  a s s o c i a t e d  w i t h  i m m u n e - s u p p r e s s i o n  a n d  t h u s  w i t h  t u m o r - f a v o r a b l e  e n v i -
r o n m e n t s ,  a n  e f f e c t  t h a t  c o u l d  a l s o  b e  a c h i e v e d  t h r o u g h  a l t e r e d  B  c e l l  s i g n a l i n g .  T C R γ δ +  
T  c e l l s  c o u l d  b e  c o n n e c t e d  w i t h  s u c h  i m m u n e  r e g u l a t i o n  p a t h w a y s  b a s e d  o n  t h e i r  a b i l i t y  
t o  r e c o g n i z e  a  w i d e  v a r i e t y  o f  a n t i g e n s  i n c l u d i n g  m i c r o b e s ,  d u e  t o  t h e i r  a n a t o m i c a l  p o s i -
t i o n s ,  a n d  t h e i r  a b i l i t y  t o  c o m m u n i c a t e  w i t h  a  l a r g e  n u m b e r  o f  c e l l  a n d  t i s s u e  t y p e s  [ 4 1 ] .  
S t r i k i n g l y ,  a l l  p a t h w a y s  s h o w e d  o v e r l a p p i n g  g e n e s ,  i n c l u d i n g  N F K B 1  a n d  2 ,  w h i c h  f o r m  a  
c e n t r a l  h u b  i n  i m m u n e  r e g u l a t i o n  [ 7 7 ] .  F u r t h e r m o r e ,  t h e  c o m b i n e d  W E S  /  G E P  a n a l y s i s  
a l s o  c o n f i r m e d  t h a t  S T A T 3  f o r m s  a  c e n t r a l  f e a t u r e  i n  L G L  p a t h o g e n e s i s .  T h i s  a l s o  h o l d s  
t r u e  f o r  P I K 3 C A ;  e v e n  t h o u g h  n o  d i r e c t l y  d a m a g i n g  m u t a t i o n s  w e r e  o b s e r v e d  i n  t h e s e  
g e n e s ,  t h e r e  s e e m e d  t o  b e  a n  a l t e r e d  e x p r e s s i o n ,  p o s s i b l y  d u e  t o  o t h e r  u p s t r e a m  g e n e s  
( F i g .  3 b ) .  D a t a s e t s  s h o w e d  d i s t i n c t  s e t s  o f  a f f e c t e d  g e n e s ,  w h i c h  c o u l d  b e  e x p l a i n e d  b y  
t h e  d i f f e r e n c e  b e t w e e n  D N A  ( W E S )  a n d  R N A  ( G E P )  l e v e l s  a n d  m e t h o d s  o f  i n v e s t i g a t i o n .  
L i n k i n g  g e n e t i c  a b e r r a n c i e s  w i t h  v a r i a b l e  g e n e  e x p r e s s i o n  t h r o u g h  e x p r e s s i o n  q u a n t i -
t a t i v e  t r a i t  l o c i  ( e Q T L )  a n a l y s i s  a l l o w s  t o  i d e n t i f y  u n d e r l y i n g  b i o l o g i c a l  m e c h a n i s m s  o f  
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Figure 3. IPA comparison analysis of GEP and WES datasets.
Shown are –log(p-value) scores of canonical pathways affected according to both datasets. Pathways of interest that are affected equally according to both datasets are highlighted in red (a). Input datasets concern 
the supervised GEP analyses of T-LGL leukemia cells vs. effector TCRγδ+ T cells [Chapter 6 this thesis] and 
the WES dataset of N=2733 affected genes after filtering and exclusion of high density genes [Chapter 7 this thesis]. The Table summarizes genes that were affected according to both GEP and WES analysis in IPA using 
Fischer Exact test [57] and Ingenuity Target Explorer [Ingenuity Target Explorer, QIAGEN, Inc., targetexplorer.ingenuity.com, 75]. Genes overlapping between pathways are indicated in bold (b). p-values are calculated 
with IPA [57, QIAGEN, Inc.] with the Fisher Exact test. Grey boxes indicate lowest p-value (0.05). White boxes 
indicate that the gene was not found to be significantly affected in the corresponding dataset. 
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the gene variant and expression level association [78]. By using RNA-sequencing direct associations can be made, since paired-end RNA-sequencing data is able to provide insights in both the genetic variants (qualitative) and the level of expression (quanti-tative genetic information). Due to disease heterogeneity in T-LGL leukemia patients in 
general, both cis- and trans-eQTL information can provide in-depth information on the 
mechanisms driving this heterogeneity. Cis-eQTLs are located on the same chromosome 
as the variant gene, regulating the transcription of the target gene, giving allele-specific 
expression and patient-specific and T-LGL leukemia specific patterns, whereas trans-
eQTLs are located anywhere in the genome, regulating target gene transcription through 
modification of the activity and abundance of other proteins or enzymes regulating the target gene, which does not discriminate between alleles of which the data is useful for identifying common underlying biological mechanisms [79]. Whole genome sequencing 
(WGS) can also provide cis- and trans-eQTL information, but since information on gene 
Figure 4. Schematic overview of different NGS methods (WGS vs. WES vs. RNA-seq) for mutation 
detection.Overview of NGS techniques targeting mutations located in exons and intergenic regions. The number of short-read alignments marked in grey represents the sequencing depth of the techniques. WGS covers all areas of the genome, whereas WES mainly covers the coding regions (exons), and RNA-seq also provides expression-
related data. Dotted lines between RNA-sequencing reads represent the “align-then-assemble” methods of 
RNA-sequencing data alignment: first short RNA-sequencing reads are aligned to the reference genome, taking splicing events into account, then transcripts are reconstructed from spliced alignments [82]. Gene X 
exemplifies an expressed gene, and gene Y a non-expressed gene. Figure adapted from Schneeberger, 2014 [81].
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expression levels is lacking [80-82], other approaches such as RNA-sequencing should follow the WGS analysis (Fig. 4). 
These techniques are highly useful for addressing research questions, together with functional assays based on CRISPR (clustered regularly interspaced palindromic repeat)-
Cas9 technology [83] to further investigate down-stream functional and mechanistic effects involving these pathways on T-LGL leukemia development. Besides, owing to 
recent major advances, such NGS techniques also show high potential in diagnostic and prognostic settings in clinical care. NGS techniques provide high quality, fast and robust 
data, upon which data analysis algorithms tackle the limitations of the complex features of the sequencing results [84]. Using only small amounts of materials, standardized NGS 
protocols in multicenter settings contribute to easy and quick diagnosis and prognosis, thereby increasing feasibility and reducing invasive investigations in patients [85].
Future research should be focused on functionally validating the WES and GEP candi- date genes to define their role in cell-intrinsic molecular mechanisms that contribute to 
LGL leukemogenesis. In this context, not only genetic aberrations should be considered, but also epigenetic changes (e.g. non-coding RNAs, methylation profiles etc.) will have 
to be included.  
EXTERNAL STIMULATION AND ACTIVATION PROCESSES
Besides the presence of variants (WES) and altered expression levels (GEP) in genes involved in proliferation, apoptosis, survival and immune cell functioning, GEP also 
shows a high transcriptome similarity between TCRγδ+ T-LGL leukemia cells with (ter- minally differentiated) effector TCRγδ+ T cells was observed. As TCRγδ+ T-LGL leukemia 
typically presents in elderly individuals, additional processes such as immunological ageing, continuous stimulation, exhaustion and senescence (all possibly related to per-
sistence of CMV or other pathogens), which are acting on normal TCRγδ+ T cells could 
contribute to the TCRγδ+ T-LGL leukemia pathogenesis.
Stimulation of normal TCRγδ+ T cells and their involvement in tumor 
immunity
TCRγδ+ T cells are well-known in establishing anti-tumor responses, and are pro- posed as immunotherapy through the direct killing of tumor cells [86].  Vδ1+ cells 
generally recognize hematological malignancies [87], whereas the more common cir- culating Vγ9+/Vδ2+ cells recognize and kill diverse solid tumors [88]. Already in 1990 
human TCRγδ+ T cells were found to recognize and lyse Daudi (Burkitt lymphoma) cells 
[89]. In 1995 it was found that TCRγδ+ T cells respond to microbial products, such as 
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e x p r e s s i o n  l e v e l s  i s  l a c k i n g  [ 8 0 - 8 2 ] ,  o t h e r  a p p r o a c h e s  s u c h  a s  R N A - s e q u e n c i n g  s h o u l d  
f o l l o w  t h e  W G S  a n a l y s i s  ( F i g .  4 ) .  
T h e s e  t e c h n i q u e s  a r e  h i g h l y  u s e f u l  f o r  a d d r e s s i n g  r e s e a r c h  q u e s t i o n s ,  t o g e t h e r  w i t h  
f u n c t i o n a l  a s s a y s  b a s e d  o n  C R I S P R  ( c l u s t e r e d  r e g u l a r l y  i n t e r s p a c e d  p a l i n d r o m i c  r e p e a t ) -
C a s 9  t e c h n o l o g y  [ 8 3 ]  t o  f u r t h e r  i n v e s t i g a t e  d o w n - s t r e a m  f u n c t i o n a l  a n d  m e c h a n i s t i c  
e f f e c t s  i n v o l v i n g  t h e s e  p a t h w a y s  o n  T - L G L  l e u k e m i a  d e v e l o p m e n t .  B e s i d e s ,  o w i n g  t o  
r e c e n t  m a j o r  a d v a n c e s ,  s u c h  N G S  t e c h n i q u e s  a l s o  s h o w  h i g h  p o t e n t i a l  i n  d i a g n o s t i c  a n d  
p r o g n o s t i c  s e t t i n g s  i n  c l i n i c a l  c a r e .  N G S  t e c h n i q u e s  p r o v i d e  h i g h  q u a l i t y ,  f a s t  a n d  r o b u s t  
d a t a ,  u p o n  w h i c h  d a t a  a n a l y s i s  a l g o r i t h m s  t a c k l e  t h e  l i m i t a t i o n s  o f  t h e  c o m p l e x  f e a t u r e s  
o f  t h e  s e q u e n c i n g  r e s u l t s  [ 8 4 ] .  U s i n g  o n l y  s m a l l  a m o u n t s  o f  m a t e r i a l s ,  s t a n d a r d i z e d  N G S  
p r o t o c o l s  i n  m u l t i c e n t e r  s e t t i n g s  c o n t r i b u t e  t o  e a s y  a n d  q u i c k  d i a g n o s i s  a n d  p r o g n o s i s ,  
t h e r e b y  i n c r e a s i n g  f e a s i b i l i t y  a n d  r e d u c i n g  i n v a s i v e  i n v e s t i g a t i o n s  i n  p a t i e n t s  [ 8 5 ] .
F u t u r e  r e s e a r c h  s h o u l d  b e  f o c u s e d  o n  f u n c t i o n a l l y  v a l i d a t i n g  t h e  W E S  a n d  G E P  c a n d i -
d a t e  g e n e s  t o  d e f i n e  t h e i r  r o l e  i n  c e l l - i n t r i n s i c  m o l e c u l a r  m e c h a n i s m s  t h a t  c o n t r i b u t e  t o  
L G L  l e u k e m o g e n e s i s .  I n  t h i s  c o n t e x t ,  n o t  o n l y  g e n e t i c  a b e r r a t i o n s  s h o u l d  b e  c o n s i d e r e d ,  
b u t  a l s o  e p i g e n e t i c  c h a n g e s  ( e . g .  n o n - c o d i n g  R N A s ,  m e t h y l a t i o n  p r o f i l e s  e t c . )  w i l l  h a v e  
t o  b e  i n c l u d e d .   
E X T E R N A L  S T I M U L A T I O N  A N D  A C T I V A T I O N  P R O C E S S E S
B e s i d e s  t h e  p r e s e n c e  o f  v a r i a n t s  ( W E S )  a n d  a l t e r e d  e x p r e s s i o n  l e v e l s  ( G E P )  i n  g e n e s  
i n v o l v e d  i n  p r o l i f e r a t i o n ,  a p o p t o s i s ,  s u r v i v a l  a n d  i m m u n e  c e l l  f u n c t i o n i n g ,  G E P  a l s o  
s h o w s  a  h i g h  t r a n s c r i p t o m e  s i m i l a r i t y  b e t w e e n  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  w i t h  ( t e r -
m i n a l l y  d i f f e r e n t i a t e d )  e f f e c t o r  T C R γ δ +  T  c e l l s  w a s  o b s e r v e d .  A s  T C R γ δ +  T - L G L  l e u k e m i a  
t y p i c a l l y  p r e s e n t s  i n  e l d e r l y  i n d i v i d u a l s ,  a d d i t i o n a l  p r o c e s s e s  s u c h  a s  i m m u n o l o g i c a l  
a g e i n g ,  c o n t i n u o u s  s t i m u l a t i o n ,  e x h a u s t i o n  a n d  s e n e s c e n c e  ( a l l  p o s s i b l y  r e l a t e d  t o  p e r -
s i s t e n c e  o f  C M V  o r  o t h e r  p a t h o g e n s ) ,  w h i c h  a r e  a c t i n g  o n  n o r m a l  T C R γ δ +  T  c e l l s  c o u l d  
c o n t r i b u t e  t o  t h e  T C R γ δ +  T - L G L  l e u k e m i a  p a t h o g e n e s i s .
S t i m u l a t i o n  o f  n o r m a l  T C R γ δ +  T  c e l l s  a n d  t h e i r  i n v o l v e m e n t  i n  t u m o r  
i m m u n i t y
T C R γ δ +  T  c e l l s  a r e  w e l l - k n o w n  i n  e s t a b l i s h i n g  a n t i - t u m o r  r e s p o n s e s ,  a n d  a r e  p r o -
p o s e d  a s  i m m u n o t h e r a p y  t h r o u g h  t h e  d i r e c t  k i l l i n g  o f  t u m o r  c e l l s  [ 8 6 ] .   V δ 1 +  c e l l s  
g e n e r a l l y  r e c o g n i z e  h e m a t o l o g i c a l  m a l i g n a n c i e s  [ 8 7 ] ,  w h e r e a s  t h e  m o r e  c o m m o n  c i r -
c u l a t i n g  V γ 9 + / V δ 2 +  c e l l s  r e c o g n i z e  a n d  k i l l  d i v e r s e  s o l i d  t u m o r s  [ 8 8 ] .  A l r e a d y  i n  1 9 9 0  
h u m a n  T C R γ δ +  T  c e l l s  w e r e  f o u n d  t o  r e c o g n i z e  a n d  l y s e  D a u d i  ( B u r k i t t  l y m p h o m a )  c e l l s  
[ 8 9 ] .  I n  1 9 9 5  i t  w a s  f o u n d  t h a t  T C R γ δ +  T  c e l l s  r e s p o n d  t o  m i c r o b i a l  p r o d u c t s ,  s u c h  a s  
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phosphates. Metabolites produced by e.g. mycobacteria and tumor cells include isopen-tenyl and prenyl pyrophosphates, both derivatives of poly-isoprenoid synthesis [90], or intermediates of the mevalonate synthesis pathway, a pathway that is elevated in tumor cells due to high cell turnover [91]. Also, patients with bone resorption receiving pamid-
ronate displayed a significant increase in CD3+TCRγδ+ T cells in the PB, suggesting that this aminobisphosphonate could be a stimulating agent as well. Furthermore, all patients experienced an acute-phase reaction upon administration of pamidronate, which led to 
fever and a flu-like response, indicative of high IFN-γ release [92]. Further evaluation of 
this side-effect showed that TCRγδ+ T cells elicited anti-plasma cell activities in multiple myeloma after stimulation with e.g. pamidronate [93,94]. Watanabe et al. demonstrated that the TCRγδ+ T cell expansion and cytotoxic response against leukemia cells, from both cell lines and fresh material, through ami-nobisphosphonate treatment was indeed mediated by type-I IFN responses [95] (Fig. 5a). In 2008 these authors presented data from a clinical trial, using in vitro generated 
tumor-specific patient-derived zoledronate-activated TCRγδ+ T cells. Despite some vari-
ation in expansion and response of these TCRγδ+ T cells, cytotoxicity against patient 
myeloma and lymphoma cells could be measured [96]. Currently, TCRγδ+ T cells are being tested in the clinic, but this type of immunotherapy still requires improvements, as 
TCRγδ+ T cells can easily undergo apoptosis upon continuous stimulation. Furthermore, 
many patients developed side effects, as activated TCRγδ+ T cells are known to be highly 
pro-inflammatory. While favorable for killing the tumor cells, this pro-inflammatory effect is at the same time unfavorable for the patients themselves [97]. Also, different patients responded differently, indicating that other mechanisms in tumor immunity 
could play a role in skewing TCRγδ+ T cell responses, such as differences in the involved 
TCRγδ+ T cell subsets. 
Importantly, an ambiguous role of TCRγδ+ T cells in tumor immunity has been recog-
nized, as TCRγδ+ T cells recognize and respond to tumor cells, but have also been asso-
ciated with tumorigenesis. The latter occurs through TGF-β production, which inhibits CTLs, and through IL-17 production, which leads to neutrophil-related inhibition of CTLs and thus to promotion of tumorigenesis and metastasis [98] (Fig. 5b). 
Although an increased proportion of Vγ9/Vδ2 cells, acting as tumor-infiltrating lym-phocytes (TILs), has generally been associated with good prognoses [99], tumor-pro-
moting Vδ1+ cells were also found. These have been associated with poor prognoses in breast and colon cancer, since they suppress the immune response by negatively 
regulating dendritic cells. Pro-tumor activities of Vδ1+ T cells were often found to be 
correlated with IL-17 [100], rather than IFN-γ production [101] (Fig. 5). 
TCRγδ+ T cells are not only able to exert anti- and pro-tumor activities, in rare cases 
they can also transform into cancer cells themselves, e.g. into TCRγδ+ T-LGL leukemia 
Chapter 8
258
phosphates. Metabolites produced by e.g. mycobacteria and tumor cells include isopen-
tenyl and prenyl pyrophosphates, both derivatives of poly-isoprenoid synthesis [90], or 
intermediates of the mevalonate synthesis pathway, a pathway that is elevated in tumor 
cells due to high cell turnover [91]. Also, patients with bone resorption receiving pamid-
ronate displayed a significant increase in CD3+TCRγδ+ T cells in the PB, suggesting that 
this aminobisphosphonate could be a stimulating agent as well. Furthermore, all patients 
experienced an acute-phase reaction upon administration of pamidronate, which led to 
fever and a flu-like response, indicative of high IFN-γ release [92]. Further evaluation of 
this side-effect showed that TCRγδ+ T cells elicited anti-plasma cell activities in multiple 
myeloma after stimulation with e.g. pamidronate [93,94]. 
Watanabe et al. demonstrated that the TCRγδ+ T cell expansion and cytotoxic 
response against leukemia cells, from both cell lines and fresh material, through ami-
nobisphosphonate treatment was indeed mediated by type-I IFN responses [95] (Fig. 
5a). In 2008 these authors presented data from a clinical trial, using in vitro generated 
tumor-specific patient-derived zoledronate-activated TCRγδ+ T cells. Despite some vari-
ation in expansion and response of these TCRγδ+ T cells, cytotoxicity against patient 
myeloma and lymphoma cells could be measured [96]. Currently, TCRγδ+ T cells are 
being tested in the clinic, but this type of immunotherapy still requires improvements, as 
TCRγδ+ T cells can easily undergo apoptosis upon continuous stimulation. Furthermore, 
many patients developed side effects, as activated TCRγδ+ T cells are known to be highly 
pro-inflammatory. While favorable for killing the tumor cells, this pro-inflammatory 
effect is at the same time unfavorable for the patients themselves [97]. Also, different 
patients responded differently, indicating that other mechanisms in tumor immunity 
could play a role in skewing TCRγδ+ T cell responses, such as differences in the involved 
TCRγδ+ T cell subsets. 
Importantly, an ambiguous role of TCRγδ+ T cells in tumor immunity has been recog-
nized, as TCRγδ+ T cells recognize and respond to tumor cells, but have also been asso-
ciated with tumorigenesis. The latter occurs through TGF-β production, which inhibits 
CTLs, and through IL-17 production, which leads to neutrophil-related inhibition of 
CTLs and thus to promotion of tumorigenesis and metastasis [98] (Fig. 5b). 
Although an increased proportion of Vγ9/Vδ2 cells, acting as tumor-infiltrating lym-
phocytes (TILs), has generally been associated with good prognoses [99], tumor-pro-
moting Vδ1+ cells were also found. These have been associated with poor prognoses 
in breast and colon cancer, since they suppress the immune response by negatively 
regulating dendritic cells. Pro-tumor activities of Vδ1+ T cells were often found to be 
correlated with IL-17 [100], rather than IFN-γ production [101] (Fig. 5). 
TCRγδ+ T cells are not only able to exert anti- and pro-tumor activities, in rare cases 




[1, Chapter 5, this thesis] (Fig. 5c). T-LGL leukemia patients frequently display underly- ing autoimmune diseases or malignancies which are hypothesized to be a driving factor 
for leukemia development. In contrast to CD4+TCRαβ+ T-LGL leukemia where the dis- ease etiology is strongly linked to CMV infection [102], in TCRγδ+ and CD8+TCRαβ+ 
T-LGL leukemia specific antigens, epitopes or stimuli are virtually unknown. 
Figure 5. Multiple roles of TCRγδ+ T cells in tumor immunity and cancer development.
Schematic overview of the ambiguous roles of TCRγδ+ T cells in tumor immunity and cancer development. 
TCRγδ+ T cells can express inhibitory molecules and death receptors directed to tumor cells, which together 
with IFN-γ, perforins and granzymes trigger tumor cells to undergo apoptosis (a). TCRγδ+ T cells are able to 
express inhibitory molecules for CTLs, thereby blocking induction of tumor cell death; TCRγδ+ T cells also 
produce IL-17 that activates neutrophils and myeloid derived suppressor cells (MDSC), which in turn also inhibit CTLs (b). This contributes to pro-tumor environment and leads subsequently to metastasis. In case of chronic or continuous (antigenic) stimulation TCRγδ+ T cells can accumulate and develop into cancer cells 
themselves, as is the case in TCRγδ+ T-LGL leukemia (c). Figure adapted from Chitadze et al. 2017 [98].
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[ 1 ,  C h a p t e r  5 ,  t h i s  t h e s i s ]  ( F i g .  5 c ) .  T - L G L  l e u k e m i a  p a t i e n t s  f r e q u e n t l y  d i s p l a y  u n d e r l y -
i n g  a u t o i m m u n e  d i s e a s e s  o r  m a l i g n a n c i e s  w h i c h  a r e  h y p o t h e s i z e d  t o  b e  a  d r i v i n g  f a c t o r  
f o r  l e u k e m i a  d e v e l o p m e n t .  I n  c o n t r a s t  t o  C D 4 + T C R α β +  T - L G L  l e u k e m i a  w h e r e  t h e  d i s -
e a s e  e t i o l o g y  i s  s t r o n g l y  l i n k e d  t o  C M V  i n f e c t i o n  [ 1 0 2 ] ,  i n  T C R γ δ +  a n d  C D 8 + T C R α β +  
T - L G L  l e u k e m i a  s p e c i f i c  a n t i g e n s ,  e p i t o p e s  o r  s t i m u l i  a r e  v i r t u a l l y  u n k n o w n .  
F i g u r e  5 .  M u l t i p l e  r o l e s  o f  T C R γ δ +  T  c e l l s  i n  t u m o r  i m m u n i t y  a n d  c a n c e r  d e v e l o p m e n t .
S c h e m a t i c  o v e r v i e w  o f  t h e  a m b i g u o u s  r o l e s  o f  T C R γ δ +  T  c e l l s  i n  t u m o r  i m m u n i t y  a n d  c a n c e r  d e v e l o p m e n t .  
T C R γ δ +  T  c e l l s  c a n  e x p r e s s  i n h i b i t o r y  m o l e c u l e s  a n d  d e a t h  r e c e p t o r s  d i r e c t e d  t o  t u m o r  c e l l s ,  w h i c h  t o g e t h e r  
w i t h  I F N - γ ,  p e r f o r i n s  a n d  g r a n z y m e s  t r i g g e r  t u m o r  c e l l s  t o  u n d e r g o  a p o p t o s i s  ( a ) .  T C R γ δ +  T  c e l l s  a r e  a b l e  t o  
e x p r e s s  i n h i b i t o r y  m o l e c u l e s  f o r  C T L s ,  t h e r e b y  b l o c k i n g  i n d u c t i o n  o f  t u m o r  c e l l  d e a t h ;  T C R γ δ +  T  c e l l s  a l s o  
p r o d u c e  I L - 1 7  t h a t  a c t i v a t e s  n e u t r o p h i l s  a n d  m y e l o i d  d e r i v e d  s u p p r e s s o r  c e l l s  ( M D S C ) ,  w h i c h  i n  t u r n  a l s o  
i n h i b i t  C T L s  ( b ) .  T h i s  c o n t r i b u t e s  t o  p r o - t u m o r  e n v i r o n m e n t  a n d  l e a d s  s u b s e q u e n t l y  t o  m e t a s t a s i s .  I n  c a s e  o f  
c h r o n i c  o r  c o n t i n u o u s  ( a n t i g e n i c )  s t i m u l a t i o n  T C R γ δ +  T  c e l l s  c a n  a c c u m u l a t e  a n d  d e v e l o p  i n t o  c a n c e r  c e l l s  
t h e m s e l v e s ,  a s  i s  t h e  c a s e  i n  T C R γ δ +  T - L G L  l e u k e m i a  ( c ) .  F i g u r e  a d a p t e d  f r o m  C h i t a d z e  e t  a l .  2 0 1 7  [ 9 8 ] .
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Effect of ageing on (terminally differentiated effector) TCRγδ+ T cells 
As TCRγδ+ T-LGL leukemia cells show characteristics of antigen-experienced cells [1], it can be hypothesized that the LGL leukemic cells have an effector cell origin [Chapters 4 and 5, this thesis]. Indeed, our unsupervised GEP data showed a high correlation 
between TCRγδ+ T-LGL leukemia cells and healthy TCRγδ+ effector T cells [Chapter 6, this thesis]. During ageing, a phenomenon of accumulating terminally differentiated effector cells has been described [103, Chapter 2, this thesis], and an increase in both 
late-stage effector TCRγδ+ T cells, senescent and exhausted cells was observed in 
healthy elderly. Flow cytometric analysis of PB from healthy individuals aged 20 – 95 
years showed a progressive decrease in TCRγδ+ T cell absolute numbers, including a 
relative shift in Vδ-usage; upon ageing Vδ1+ cells increased, whereas the most common 
Vγ9/Vδ2 cell type in PB decreased. Furthermore, we found that ageing (along with CMV infection; see later) affected the relative distributions of naive, central memory, effector memory and effector subsets towards late-stage effector phenotypes, with a profound increase in the expression of senescence markers [Chapter 2, this thesis]. These shifts 
in elderly towards effector and CD57+KLRG1+ subsets were especially observed in the presence of CMV [Chapter 2, this thesis]. Although exhausted T cells are generally observed during chronic viral infections, 
exhausted cells could also be identified in healthy individuals [Chapter 2, this thesis]. During chronic viral infections T cells are heavily subjected to continuous antigenic stimulation, upon which the cells become anergic. This results in T cell exhaustion, and eventually apoptosis. The exhaustion process can be reversed by means of PD-L1 blockade, as was shown for HIV-infections [104]. As there is no functional proof that T cells become exhausted in the context of the beta-herpesvirus CMV (reviewed by [105]), CMV infection and persistence is associated more with immunosenescence than exhaus-tion [106].
Effect of CMV infection on development and responsiveness of normal 
TCRγδ+ T cellsCMV is known to have major effects on the T cell population, especially with come of age [107]. CMV latency is established in hematopoietic stem cells, monocytes, mac-
rophages, dendritic cells, and epithelial cells [108]. Despite CD8+ CTL responses upon acute infection, viral shedding continues, thus preventing the contraction phase of the 
CMV-specific CD8+ CTLs and resulting in “memory inflation” [109]. Furthermore, CMV is able to elicit immune evasion by modulating antigen presentation and producing miRNAs to up-regulate inhibitory molecules in the host cell in order to survive the host’s immune response [110,111]. Several factors have been investigated for their contribu-
tion to CMV-induced immunosenescence; these include the initial inoculum upon first 
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infection, the inflation of CMV-specific T cell responses, and the balance in functional 
effector T cells [112]. More recently, it has also been shown that CMV can evade the immune system by interfering with antigen loading onto MHC-I [113-115] and MHC-II 
[116] molecules. The CMV immune evasion tactics as described above mostly apply to TCRαβ+ T cells 
and their corresponding antigen-presenting cells (APCs). TCRγδ+ T cells on the other 
hand, do not necessarily need MHC-molecules presented by APCs to recognize antigens. In fact, TCRγδ+ T cells are able to recognize also freely floating non-peptide antigens 
[117-119]. They can readily recognize a wide variety of antigens via their TCRs, upon which they can also directly respond in a CTL and NK-cell like manner, eliciting quick 
immune responses and thus forming a bridge between innate and adaptive immunity [41]. Also MHC-molecules themselves, especially the non-classical T22 MHC molecule 
[120,121] (reviewed by [119]), form antigens for TCRγδ+ T cells [122,123], linking them 
to NK cells and to roles in autoimmunity and viral recognition (Fig. 3 of the Prologue, page number 16). 
Responsiveness of TCRγδ+ T cells to CMV has first been identified in 1999 in kidney 
allograft recipients, who displayed major expansions of TCRγδ+ T cells upon CMV reac- tivation and/or infection [124]. These expansions were thought to be a consequence 
rather than a cause of the CMV infection due to immunosuppressive therapy [125]. This was concluded from experiments showing that TCRγδ+ T cells could recognize and 
respond to viral epitopes in vitro [126]. Déchanet et al. were able to directly correlate the less common Vδ1+ and Vδ3+ T cells in PB to CMV responses and observed an increased 
long-lasting TCRγδ+ T cell expansion in the PB of kidney allograft recipients [127]. 
These cells expressed activation markers, specific TCRγ and δ chains with restricted 
junctional diversity, thus responding to CMV epitopes in vitro [127]. This increase in particularly Vδ1+ cells was also observed in healthy CMV-positive elderly [Chapter 2, 
this thesis], again implying that CMV-specific cells at least partly reside in the Vδ1+ 
cell population. Other studies have shown an association between Vδ1+ cells and CMV 
infection as well, but additionally showed that CMV also affects the total TCRγδ+ T cell 
compartment [128-130; Chapter 2, this thesis]. In vitro studies revealed that circulating CMV-specific Vδ2-negative – and thus Vδ1+ or Vδ3+ cells – produced large amounts of 
TNF-α and IFN-γ upon co-culture with CMV-infected cells or IgG-opsonized CMV. Next to 
that, TCRγδ+ T cells were also cytotoxic against CMV-infected cells through production 
of perforin and granzyme B (reviewed by [131]). CMV recognition by TCRγδ+ T cells can occur at different levels, since CMV is able 
to inhibit immune cells through NKG2D-ligand expression on infected cells [132], and through altering the MHC-I and MHC-II trafficking as described above. Since TCRγδ+ 
T cells do not necessarily need MHC-molecules to recognize freely floating antigens, 
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G e n e r a l  D i s c u s s i o n
i n f e c t i o n ,  t h e  i n f l a t i o n  o f  C M V - s p e c i f i c  T  c e l l  r e s p o n s e s ,  a n d  t h e  b a l a n c e  i n  f u n c t i o n a l  
e f f e c t o r  T  c e l l s  [ 1 1 2 ] .  M o r e  r e c e n t l y ,  i t  h a s  a l s o  b e e n  s h o w n  t h a t  C M V  c a n  e v a d e  t h e  
i m m u n e  s y s t e m  b y  i n t e r f e r i n g  w i t h  a n t i g e n  l o a d i n g  o n t o  M H C - I  [ 1 1 3 - 1 1 5 ]  a n d  M H C - I I  
[ 1 1 6 ]  m o l e c u l e s .
T h e  C M V  i m m u n e  e v a s i o n  t a c t i c s  a s  d e s c r i b e d  a b o v e  m o s t l y  a p p l y  t o  T C R α β +  T  c e l l s  
a n d  t h e i r  c o r r e s p o n d i n g  a n t i g e n - p r e s e n t i n g  c e l l s  ( A P C s ) .  T C R γ δ +  T  c e l l s  o n  t h e  o t h e r  
h a n d ,  d o  n o t  n e c e s s a r i l y  n e e d  M H C - m o l e c u l e s  p r e s e n t e d  b y  A P C s  t o  r e c o g n i z e  a n t i g e n s .  
I n  f a c t ,  T C R γ δ +  T  c e l l s  a r e  a b l e  t o  r e c o g n i z e  a l s o  f r e e l y  f l o a t i n g  n o n - p e p t i d e  a n t i g e n s  
[ 1 1 7 - 1 1 9 ] .  T h e y  c a n  r e a d i l y  r e c o g n i z e  a  w i d e  v a r i e t y  o f  a n t i g e n s  v i a  t h e i r  T C R s ,  u p o n  
w h i c h  t h e y  c a n  a l s o  d i r e c t l y  r e s p o n d  i n  a  C T L  a n d  N K - c e l l  l i k e  m a n n e r ,  e l i c i t i n g  q u i c k  
i m m u n e  r e s p o n s e s  a n d  t h u s  f o r m i n g  a  b r i d g e  b e t w e e n  i n n a t e  a n d  a d a p t i v e  i m m u n i t y  
[ 4 1 ] .  A l s o  M H C - m o l e c u l e s  t h e m s e l v e s ,  e s p e c i a l l y  t h e  n o n - c l a s s i c a l  T 2 2  M H C  m o l e c u l e  
[ 1 2 0 , 1 2 1 ]  ( r e v i e w e d  b y  [ 1 1 9 ] ) ,  f o r m  a n t i g e n s  f o r  T C R γ δ +  T  c e l l s  [ 1 2 2 , 1 2 3 ] ,  l i n k i n g  t h e m  
t o  N K  c e l l s  a n d  t o  r o l e s  i n  a u t o i m m u n i t y  a n d  v i r a l  r e c o g n i t i o n  ( F i g .  3  o f  t h e  P r o l o g u e ,  
p a g e  n u m b e r  1 6 ) .  
R e s p o n s i v e n e s s  o f  T C R γ δ +  T  c e l l s  t o  C M V  h a s  f i r s t  b e e n  i d e n t i f i e d  i n  1 9 9 9  i n  k i d n e y  
a l l o g r a f t  r e c i p i e n t s ,  w h o  d i s p l a y e d  m a j o r  e x p a n s i o n s  o f  T C R γ δ +  T  c e l l s  u p o n  C M V  r e a c -
t i v a t i o n  a n d / o r  i n f e c t i o n  [ 1 2 4 ] .  T h e s e  e x p a n s i o n s  w e r e  t h o u g h t  t o  b e  a  c o n s e q u e n c e  
r a t h e r  t h a n  a  c a u s e  o f  t h e  C M V  i n f e c t i o n  d u e  t o  i m m u n o s u p p r e s s i v e  t h e r a p y  [ 1 2 5 ] .  T h i s  
w a s  c o n c l u d e d  f r o m  e x p e r i m e n t s  s h o w i n g  t h a t  T C R γ δ +  T  c e l l s  c o u l d  r e c o g n i z e  a n d  
r e s p o n d  t o  v i r a l  e p i t o p e s  i n  v i t r o  [ 1 2 6 ] .  D é c h a n e t  e t  a l .  w e r e  a b l e  t o  d i r e c t l y  c o r r e l a t e  t h e  
l e s s  c o m m o n  V δ 1 +  a n d  V δ 3 +  T  c e l l s  i n  P B  t o  C M V  r e s p o n s e s  a n d  o b s e r v e d  a n  i n c r e a s e d  
l o n g - l a s t i n g  T C R γ δ +  T  c e l l  e x p a n s i o n  i n  t h e  P B  o f  k i d n e y  a l l o g r a f t  r e c i p i e n t s  [ 1 2 7 ] .  
T h e s e  c e l l s  e x p r e s s e d  a c t i v a t i o n  m a r k e r s ,  s p e c i f i c  T C R γ  a n d  δ  c h a i n s  w i t h  r e s t r i c t e d  
j u n c t i o n a l  d i v e r s i t y ,  t h u s  r e s p o n d i n g  t o  C M V  e p i t o p e s  i n  v i t r o  [ 1 2 7 ] .  T h i s  i n c r e a s e  i n  
p a r t i c u l a r l y  V δ 1 +  c e l l s  w a s  a l s o  o b s e r v e d  i n  h e a l t h y  C M V - p o s i t i v e  e l d e r l y  [ C h a p t e r  2 ,  
t h i s  t h e s i s ] ,  a g a i n  i m p l y i n g  t h a t  C M V - s p e c i f i c  c e l l s  a t  l e a s t  p a r t l y  r e s i d e  i n  t h e  V δ 1 +  
c e l l  p o p u l a t i o n .  O t h e r  s t u d i e s  h a v e  s h o w n  a n  a s s o c i a t i o n  b e t w e e n  V δ 1 +  c e l l s  a n d  C M V  
i n f e c t i o n  a s  w e l l ,  b u t  a d d i t i o n a l l y  s h o w e d  t h a t  C M V  a l s o  a f f e c t s  t h e  t o t a l  T C R γ δ +  T  c e l l  
c o m p a r t m e n t  [ 1 2 8 - 1 3 0 ;  C h a p t e r  2 ,  t h i s  t h e s i s ] .  I n  v i t r o  s t u d i e s  r e v e a l e d  t h a t  c i r c u l a t i n g  
C M V - s p e c i f i c  V δ 2 - n e g a t i v e  –  a n d  t h u s  V δ 1 +  o r  V δ 3 +  c e l l s  –  p r o d u c e d  l a r g e  a m o u n t s  o f  
T N F - α  a n d  I F N - γ  u p o n  c o - c u l t u r e  w i t h  C M V - i n f e c t e d  c e l l s  o r  I g G - o p s o n i z e d  C M V .  N e x t  t o  
t h a t ,  T C R γ δ +  T  c e l l s  w e r e  a l s o  c y t o t o x i c  a g a i n s t  C M V - i n f e c t e d  c e l l s  t h r o u g h  p r o d u c t i o n  
o f  p e r f o r i n  a n d  g r a n z y m e  B  ( r e v i e w e d  b y  [ 1 3 1 ] ) .  
C M V  r e c o g n i t i o n  b y  T C R γ δ +  T  c e l l s  c a n  o c c u r  a t  d i f f e r e n t  l e v e l s ,  s i n c e  C M V  i s  a b l e  
t o  i n h i b i t  i m m u n e  c e l l s  t h r o u g h  N K G 2 D - l i g a n d  e x p r e s s i o n  o n  i n f e c t e d  c e l l s  [ 1 3 2 ] ,  a n d  
t h r o u g h  a l t e r i n g  t h e  M H C - I  a n d  M H C - I I  t r a f f i c k i n g  a s  d e s c r i b e d  a b o v e .  S i n c e  T C R γ δ +  
T  c e l l s  d o  n o t  n e c e s s a r i l y  n e e d  M H C - m o l e c u l e s  t o  r e c o g n i z e  f r e e l y  f l o a t i n g  a n t i g e n s ,  
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CMV epitopes can still be recognized via the TCRγδ-receptor. Specific CDR3 clonotypes 
[133] in Vγ8/Vδ1 cells have been found to be associated with the recognition of CMV by 
TCRγδ+ T cells [134]. Following repetitive technical optimization experiments to reduce potential PCR-biases [Chapter 3, this thesis], we observed during ageing in healthy 
individuals, dominance towards Vγ2 or Vγ8 plus Vδ1 usage memory cells, which was 
in strong contrast to the Vγ9/Vδ2 dominance in young individuals. However, only in a 
few individuals the presence of both CMV-specific TRG and TRD clonotypes could be 
shown [Chapter 4, this thesis]. These findings could indicate that active, circulating CMV-
specific TCRγδ+ T cells are only present in individuals with active CMV-infection, e.g. in patients undergoing immunosuppressive therapy during transplantation [127,131,135]. Alternatively, this occurs only locally, since CMV infects mainly lymphocytes and epithe-
lial cells, a location where TCRγδ+ T cells are also present [41,88]. Given that TCRγδ+ T 
cells can respond to a wide variety of antigens, it is very likely that TCRγδ+ T cells also recognize CMV at different levels, as described above. More insights in the recognition of 
CMV by TCRγδ+ T cells could also provide valuable knowledge when applying TCRγδ+ T cells for immunotherapy in other viral infections such as other herpes viruses (HSV, 
EBV), hepatitis viruses (HBV, HCV), or even HIV. However, when using TCRγδ+ T cells in immunotherapy (either for cancer, or for (chronic/latent) viral infections) senescence and exhaustion phenomena should  be considered, in view of chronic stimulation.
Immunosenescence impacts on TCRγδ+ T cell function and repertoireTo date, no functional signs of immune exhaustion have been associated with per-sistent CMV infections. Since CMV is a latent virus, it is highly important for the virus that the host cell survives. As the ultimate outcome of exhaustion is apoptosis [136], this would be unfavorable for viruses. Hence, the effect of CMV on the immune system is more apparent in the context of immune suppression, e.g. following organ transplantation or upon immunosuppressive therapy. CMV has also been associated with lymphoprolifera-
tive diseases since it is known to elicit “memory inflation”, and thus causing a dramatic increase in effector memory cells without these cells undergoing the contraction phase 
[109]. Furthermore, CD4+TCRαβ+ T-LGL leukemia pathogenesis has been linked to CMV infection [102], underlining the role of CMV as a continuous antigen in the develop-ment of this rare type of LGL leukemia. Immunosenescence per se is associated with co-morbidity and mortality at different levels of the human immune system. Age-related 
changes in immunity do not only concern reduced antigen-specific responses and vaccine responses, but also involve an imbalance in effector and regulatory T cells, possibly con-tributing to autoimmune diseases, varying from diabetes mellitus to psoriasis, and even 
neurodegenerative diseases [137]. This increased level of inflammation has been asso-
ciated with the secretion-associated senescence profile or “inflammageing” [104,138]. 
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that the host cell survives. As the ultimate outcome of exhaustion is apoptosis [136], this 
would be unfavorable for viruses. Hence, the effect of CMV on the immune system is more 
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tive diseases since it is known to elicit “memory inflation”, and thus causing a dramatic 
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[109]. Furthermore, CD4+TCRαβ+ T-LGL leukemia pathogenesis has been linked to CMV 
infection [102], underlining the role of CMV as a continuous antigen in the develop-
ment of this rare type of LGL leukemia. Immunosenescence per se is associated with 
co-morbidity and mortality at different levels of the human immune system. Age-related 
changes in immunity do not only concern reduced antigen-specific responses and vaccine 
responses, but also involve an imbalance in effector and regulatory T cells, possibly con-
tributing to autoimmune diseases, varying from diabetes mellitus to psoriasis, and even 
neurodegenerative diseases [137]. This increased level of inflammation has been asso-




Inflammageing is a phenomenon characterized by chronically activated immune cells, 
initially only macrophages (“macrophageing”). Interestingly, also in inflammageing a 
two-hit hypothesis has been proposed, i.e. involving genetic and environmental factors. The first hit is provided by the genetic background, which determines susceptibility to 
age-related disease development, whereas the second – environmental – hit is necessary 
to develop overt age-related disease, morbidity and mortality [138,139]. Immune ageing and inflammageing could be at the basis of CD8+TCRαβ+ and 
TCRγδ+ T-LGL leukemia as these cells display high correlation with terminally differ- entiated effector cells, a subset which is also increasingly present in individuals upon 
ageing. Moreover, these leukemia cells display mixed exhaustion and senescence pheno- types in terms of surface markers, cytotoxicity and AICD resistance features (see below). 
Notably, CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia patients often display underlying 
autoimmune diseases and cytopenias, which are both also more frequent upon ageing. As discussed above, immune ageing plays a major role in shaping the immune system 
[5], which thus logically also impacts on the immune repertoire. (Long-term) exposure to particular antigens could provide selective pressure for immune cells bearing spe-
cific antigen-specific receptors (immune repertoire). Humans become exposed to many 
different environmental factors throughout their life, but these exposures might differ between individuals and at different ages. Immune repertoire shaping already starts at a 
very early life stage, namely in the womb and during early T cell development, which is evident from consequences of serious Rubella [140] and HIV [141] infections that occur 
during pregnancy. Therefore it has been hypothesized that both T cell development and antigenic exposure play a major role in shaping the TCRγδ immune repertoire [1]. This 
is indeed apparent from both phenotypic and genotypic characteristics [Chapters 2 and 4, this thesis]. The phenotype of thymic and cord blood TCRγδ+ T cells has been inves-
tigated by Sandberg et al. in 2006, showing dominance of Vδ1 expression in thymic and cord blood material, with a shift towards Vγ9/Vδ2 expression after birth and during 
adulthood. In Chapter 2 we observed progressive decreases of absolute and relative numbers of total TCRγδ+ T cells, which mainly affected the most common TCRγδ+ T cell 
population in adult peripheral blood, i.e. Vγ9/Vδ2+ cells. Strikingly, upon ageing Vδ1 
cells were relatively more frequent, especially in CMV-seropositive elderly individuals, suggesting a role for CMV in shaping the TCRγδ+ T cell immune system towards Vδ1-
expressing cells [124,127]. Additionally, NGS-based TCR gamma (TRG) / TCR delta (TRD) repertoire anal-
ysis was performed in TCRγδ+ T cells from thymus, cord blood, young adult PB, and 
elderly PB samples [Chapter 4, this thesis]. One of the main findings was that we 
generally observed maintenance of the naive diversity during ageing. In contrast to the lack of changes in the naive repertoire in both young and elderly, major shifts in 
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G e n e r a l  D i s c u s s i o n
I n f l a m m a g e i n g  i s  a  p h e n o m e n o n  c h a r a c t e r i z e d  b y  c h r o n i c a l l y  a c t i v a t e d  i m m u n e  c e l l s ,  
i n i t i a l l y  o n l y  m a c r o p h a g e s  ( “ m a c r o p h a g e i n g ” ) .  I n t e r e s t i n g l y ,  a l s o  i n  i n f l a m m a g e i n g  a  
t w o - h i t  h y p o t h e s i s  h a s  b e e n  p r o p o s e d ,  i . e .  i n v o l v i n g  g e n e t i c  a n d  e n v i r o n m e n t a l  f a c t o r s .  
T h e  f i r s t  h i t  i s  p r o v i d e d  b y  t h e  g e n e t i c  b a c k g r o u n d ,  w h i c h  d e t e r m i n e s  s u s c e p t i b i l i t y  t o  
a g e - r e l a t e d  d i s e a s e  d e v e l o p m e n t ,  w h e r e a s  t h e  s e c o n d  –  e n v i r o n m e n t a l  –  h i t  i s  n e c e s s a r y  
t o  d e v e l o p  o v e r t  a g e - r e l a t e d  d i s e a s e ,  m o r b i d i t y  a n d  m o r t a l i t y  [ 1 3 8 , 1 3 9 ] .  
I m m u n e  a g e i n g  a n d  i n f l a m m a g e i n g  c o u l d  b e  a t  t h e  b a s i s  o f  C D 8 + T C R α β +  a n d  
T C R γ δ +  T - L G L  l e u k e m i a  a s  t h e s e  c e l l s  d i s p l a y  h i g h  c o r r e l a t i o n  w i t h  t e r m i n a l l y  d i f f e r -
e n t i a t e d  e f f e c t o r  c e l l s ,  a  s u b s e t  w h i c h  i s  a l s o  i n c r e a s i n g l y  p r e s e n t  i n  i n d i v i d u a l s  u p o n  
a g e i n g .  M o r e o v e r ,  t h e s e  l e u k e m i a  c e l l s  d i s p l a y  m i x e d  e x h a u s t i o n  a n d  s e n e s c e n c e  p h e n o -
t y p e s  i n  t e r m s  o f  s u r f a c e  m a r k e r s ,  c y t o t o x i c i t y  a n d  A I C D  r e s i s t a n c e  f e a t u r e s  ( s e e  b e l o w ) .  
N o t a b l y ,  C D 8 + T C R α β +  a n d  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  o f t e n  d i s p l a y  u n d e r l y i n g  
a u t o i m m u n e  d i s e a s e s  a n d  c y t o p e n i a s ,  w h i c h  a r e  b o t h  a l s o  m o r e  f r e q u e n t  u p o n  a g e i n g .  
A s  d i s c u s s e d  a b o v e ,  i m m u n e  a g e i n g  p l a y s  a  m a j o r  r o l e  i n  s h a p i n g  t h e  i m m u n e  s y s t e m  
[ 5 ] ,  w h i c h  t h u s  l o g i c a l l y  a l s o  i m p a c t s  o n  t h e  i m m u n e  r e p e r t o i r e .  ( L o n g - t e r m )  e x p o s u r e  
t o  p a r t i c u l a r  a n t i g e n s  c o u l d  p r o v i d e  s e l e c t i v e  p r e s s u r e  f o r  i m m u n e  c e l l s  b e a r i n g  s p e -
c i f i c  a n t i g e n - s p e c i f i c  r e c e p t o r s  ( i m m u n e  r e p e r t o i r e ) .  H u m a n s  b e c o m e  e x p o s e d  t o  m a n y  
d i f f e r e n t  e n v i r o n m e n t a l  f a c t o r s  t h r o u g h o u t  t h e i r  l i f e ,  b u t  t h e s e  e x p o s u r e s  m i g h t  d i f f e r  
b e t w e e n  i n d i v i d u a l s  a n d  a t  d i f f e r e n t  a g e s .  I m m u n e  r e p e r t o i r e  s h a p i n g  a l r e a d y  s t a r t s  a t  a  
v e r y  e a r l y  l i f e  s t a g e ,  n a m e l y  i n  t h e  w o m b  a n d  d u r i n g  e a r l y  T  c e l l  d e v e l o p m e n t ,  w h i c h  i s  
e v i d e n t  f r o m  c o n s e q u e n c e s  o f  s e r i o u s  R u b e l l a  [ 1 4 0 ]  a n d  H I V  [ 1 4 1 ]  i n f e c t i o n s  t h a t  o c c u r  
d u r i n g  p r e g n a n c y .  T h e r e f o r e  i t  h a s  b e e n  h y p o t h e s i z e d  t h a t  b o t h  T  c e l l  d e v e l o p m e n t  a n d  
a n t i g e n i c  e x p o s u r e  p l a y  a  m a j o r  r o l e  i n  s h a p i n g  t h e  T C R γ δ  i m m u n e  r e p e r t o i r e  [ 1 ] .  T h i s  
i s  i n d e e d  a p p a r e n t  f r o m  b o t h  p h e n o t y p i c  a n d  g e n o t y p i c  c h a r a c t e r i s t i c s  [ C h a p t e r s  2  a n d  
4 ,  t h i s  t h e s i s ] .  T h e  p h e n o t y p e  o f  t h y m i c  a n d  c o r d  b l o o d  T C R γ δ +  T  c e l l s  h a s  b e e n  i n v e s -
t i g a t e d  b y  S a n d b e r g  e t  a l .  i n  2 0 0 6 ,  s h o w i n g  d o m i n a n c e  o f  V δ 1  e x p r e s s i o n  i n  t h y m i c  a n d  
c o r d  b l o o d  m a t e r i a l ,  w i t h  a  s h i f t  t o w a r d s  V γ 9 / V δ 2  e x p r e s s i o n  a f t e r  b i r t h  a n d  d u r i n g  
a d u l t h o o d .  I n  C h a p t e r  2  w e  o b s e r v e d  p r o g r e s s i v e  d e c r e a s e s  o f  a b s o l u t e  a n d  r e l a t i v e  
n u m b e r s  o f  t o t a l  T C R γ δ +  T  c e l l s ,  w h i c h  m a i n l y  a f f e c t e d  t h e  m o s t  c o m m o n  T C R γ δ +  T  c e l l  
p o p u l a t i o n  i n  a d u l t  p e r i p h e r a l  b l o o d ,  i . e .  V γ 9 / V δ 2 +  c e l l s .  S t r i k i n g l y ,  u p o n  a g e i n g  V δ 1  
c e l l s  w e r e  r e l a t i v e l y  m o r e  f r e q u e n t ,  e s p e c i a l l y  i n  C M V - s e r o p o s i t i v e  e l d e r l y  i n d i v i d u a l s ,  
s u g g e s t i n g  a  r o l e  f o r  C M V  i n  s h a p i n g  t h e  T C R γ δ +  T  c e l l  i m m u n e  s y s t e m  t o w a r d s  V δ 1 -
e x p r e s s i n g  c e l l s  [ 1 2 4 , 1 2 7 ] .  
A d d i t i o n a l l y ,  N G S - b a s e d  T C R  g a m m a  ( T R G )  /  T C R  d e l t a  ( T R D )  r e p e r t o i r e  a n a l -
y s i s  w a s  p e r f o r m e d  i n  T C R γ δ +  T  c e l l s  f r o m  t h y m u s ,  c o r d  b l o o d ,  y o u n g  a d u l t  P B ,  a n d  
e l d e r l y  P B  s a m p l e s  [ C h a p t e r  4 ,  t h i s  t h e s i s ] .  O n e  o f  t h e  m a i n  f i n d i n g s  w a s  t h a t  w e  
g e n e r a l l y  o b s e r v e d  m a i n t e n a n c e  o f  t h e  n a i v e  d i v e r s i t y  d u r i n g  a g e i n g .  I n  c o n t r a s t  t o  
t h e  l a c k  o f  c h a n g e s  i n  t h e  n a i v e  r e p e r t o i r e  i n  b o t h  y o u n g  a n d  e l d e r l y ,  m a j o r  s h i f t s  i n  
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memory population compositions were observed, with a clear Vγ9/Vδ2 dominance in 
young individuals (aged 20-34) to a Vγ2/Vδ1 dominance in elderly (aged 56-70). This 
increasing Vδ1 dominance in elderly could -at least partly- be due to CMV persistence, 
although no clear TRG / TRD clonotype co-existence was identified with proven CMV 
specificity. Nevertheless, it would be interesting to further investigate the major epi-topes recognized by these different memory populations, as this could provide insights in what could possibly drive the further shaping of the TRG / TRD repertoire, and could 
give suggestions on potential antigens driving LGL pathogenesis. In order to confirm the 
origin of aberrant TCRγδ+ T cells in T-LGL leukemia, TCRγδ+ T-LGL-related clonotypes 
as identified from the dominant LGL clones in patients were traced back in the reper-
toire of healthy young and elderly individuals. Strikingly, some TCRγδ+ T-LGL-related clonotypes were indeed found in the healthy repertoire, especially in the effector sub-sets of healthy elderly [Chapter 4, this thesis]. Though preliminary and restricted, this 
would indeed fit the hypothesis that TCRγδ+ T-LGL leukemia cells do originate from the 
normal, antigen-experienced, circulating effector TCRγδ+ T cells that have ultimately undergone transformation towards more survival and proliferation, rather than apopto-
sis, and towards an inflammatory state. To further investigate this, single cell sequenc-ing could be applied, to truly identify the complete TRG/TRD receptor combination in a 
single cell. This would however require single-cell sorting of large numbers of TCRγδ+ T cells (and thus large volumes of blood) to generate a representative picture of the TRG / TRD repertoire. Nevertheless, further studying the TRG / TRD immune reper-toire remains highly interesting, as there are many relevant aspects to study with an increasing availability of high-throughput techniques. As the starting material could pose serious limitations and challenges to address the relevant questions, the material to be investigated and the way of investigation should be carefully considered.
Functional alterations in TCRγδ+ and TCRαβ+ T-LGL leukemia cells 
seem to be very similarImmunological ageing in an important biological phenomenon characterized by two major processes: senescence and exhaustion. Senescence affects the immune system 
at different levels, varying from reduced antigen-specific responses [5] to thymic invo-lution and subsequently reduced naive T cell outputs [5,6,142], whereas exhaustion 
reflects a diminished immune response due to chronic (antigenic) T cell stimulation 
[136]. Both processes are characterized by specific surface membrane markers, cyto-
kine profiles and changes in proliferative capacity, as summarized in Figure 6 in the General Introduction of this thesis, page number 33. In short, senescent cells are charac-terized by a high level of DNA damage due to aged DDR mechanisms and increased ROS activity, decreased telomere length, decreased proliferation, but polyfunctional cytokine 
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General Introduction of this thesis, page number 33. In short, senescent cells are charac-
terized by a high level of DNA damage due to aged DDR mechanisms and increased ROS 




production and cytotoxicity. Strikingly, senescent cells have the ability to “multitask” 
in the sense that they produce TNF-α and IFN-γ as well as granzyme B. Furthermore, 
senescent cells are less likely to undergo apoptosis and thus seem to have gained apop- tosis resistance. On the other hand, exhausted cells also obtain DNA damage by similar 
mechanisms as senescent cells, but exhausted cells do not proliferate, do not renew telomeres, and do not produce (any) cytokines. In fact, these cells are highly sensitive 
to apoptosis (reviewed by [143]). Major differences between senescent and exhausted cells lie in (antigenic) stimulation: senescent cells are still able to respond to antigens 
and/or stimuli, while exhausted cells are saturated and irresponsive. T-LGL leukemic cells display variable senescence-related markers, but it is unclear 
why they do not undergo apoptosis, assuming that they are possibly subjected to chronic (antigenic) selection [1, Chapters 5 and 6, this thesis]. This raises the question to what 
extent T-LGL leukemic cells are senescent or even exhausted. To address this, we first 
optimized stimulation, proliferation and apoptosis assays for T-LGL leukemic cells. Based on TCR-mediated stimulation using αCD3/αCD28 stimuli, in the presence and/or 
absence of IL-2, IL-15 and zoledronic acid (the latter being a phospho-antigen stimulus for TCRγδ+ T cells), the level of senescence and exhaustion with respect to cell surface 
and intracellular marker expression, cytokine production, survival and transcription factor expression was investigated in a small series of T-LGL leukemia samples. 
When healthy and tumor T cells from patients were screened for senescence and/or exhaustion marker expression, both CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia patients 
showed increased percentages of CD244+CD57+ cells (Fig. 6a). Apart from being an NK 
cell marker, CD57 is also a marker for T cell replicative senescence and LGL leukemia [1,144], and therefore expected to be highly expressed in LGL patients but less so in 
healthy subsets. CD244 (2B4) is also an NK cell marker, which is more associated with exhaustion, especially in combination with CD57 and PD-1 expression in triple positive 
cells [136]. Even though CD244+CD57+ cells were increased in both T-LGL leukemia 
types, only in CD8+TCRαβ+ T-LGL leukemia a significant increase in the triple positive 
cells was found (Fig. 6a), suggesting that CD8+TCRαβ+ leukemic T cells are slightly more 
affected by exhaustion and senescence than TCRγδ+ leukemic T cells, which is in line 
with our earlier data [Chapter 2, this thesis]. Next, we determined the proliferative capacities of T-LGL cells. Even though LGL cells 
are expressing CD57, and thus are showing signs of replicative senescence, it was obvious that these cells could still proliferate to some extent upon TCR-dependent stimulation 
(Fig. 6b, upper panels). From direct comparison with healthy cells it was clear that espe- cially the CD8+TCRαβ+ T-LGL leukemia cells lost their replicative capacity after two gen-
erations, whereas TCRγδ+ leukemic T cells were capable of undergoing more divisions 
than CD8+TCRαβ+ leukemic T cells (Fig. 6b, lower panels). Since especially TCRγδ+ T 
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p r o d u c t i o n  a n d  c y t o t o x i c i t y .  S t r i k i n g l y ,  s e n e s c e n t  c e l l s  h a v e  t h e  a b i l i t y  t o  “ m u l t i t a s k ”  
i n  t h e  s e n s e  t h a t  t h e y  p r o d u c e  T N F - α  a n d  I F N - γ  a s  w e l l  a s  g r a n z y m e  B .  F u r t h e r m o r e ,  
s e n e s c e n t  c e l l s  a r e  l e s s  l i k e l y  t o  u n d e r g o  a p o p t o s i s  a n d  t h u s  s e e m  t o  h a v e  g a i n e d  a p o p -
t o s i s  r e s i s t a n c e .  O n  t h e  o t h e r  h a n d ,  e x h a u s t e d  c e l l s  a l s o  o b t a i n  D N A  d a m a g e  b y  s i m i l a r  
m e c h a n i s m s  a s  s e n e s c e n t  c e l l s ,  b u t  e x h a u s t e d  c e l l s  d o  n o t  p r o l i f e r a t e ,  d o  n o t  r e n e w  
t e l o m e r e s ,  a n d  d o  n o t  p r o d u c e  ( a n y )  c y t o k i n e s .  I n  f a c t ,  t h e s e  c e l l s  a r e  h i g h l y  s e n s i t i v e  
t o  a p o p t o s i s  ( r e v i e w e d  b y  [ 1 4 3 ] ) .  M a j o r  d i f f e r e n c e s  b e t w e e n  s e n e s c e n t  a n d  e x h a u s t e d  
c e l l s  l i e  i n  ( a n t i g e n i c )  s t i m u l a t i o n :  s e n e s c e n t  c e l l s  a r e  s t i l l  a b l e  t o  r e s p o n d  t o  a n t i g e n s  
a n d / o r  s t i m u l i ,  w h i l e  e x h a u s t e d  c e l l s  a r e  s a t u r a t e d  a n d  i r r e s p o n s i v e .  
T - L G L  l e u k e m i c  c e l l s  d i s p l a y  v a r i a b l e  s e n e s c e n c e - r e l a t e d  m a r k e r s ,  b u t  i t  i s  u n c l e a r  
w h y  t h e y  d o  n o t  u n d e r g o  a p o p t o s i s ,  a s s u m i n g  t h a t  t h e y  a r e  p o s s i b l y  s u b j e c t e d  t o  c h r o n i c  
( a n t i g e n i c )  s e l e c t i o n  [ 1 ,  C h a p t e r s  5  a n d  6 ,  t h i s  t h e s i s ] .  T h i s  r a i s e s  t h e  q u e s t i o n  t o  w h a t  
e x t e n t  T - L G L  l e u k e m i c  c e l l s  a r e  s e n e s c e n t  o r  e v e n  e x h a u s t e d .  T o  a d d r e s s  t h i s ,  w e  f i r s t  
o p t i m i z e d  s t i m u l a t i o n ,  p r o l i f e r a t i o n  a n d  a p o p t o s i s  a s s a y s  f o r  T - L G L  l e u k e m i c  c e l l s .  
B a s e d  o n  T C R - m e d i a t e d  s t i m u l a t i o n  u s i n g  α C D 3 / α C D 2 8  s t i m u l i ,  i n  t h e  p r e s e n c e  a n d / o r  
a b s e n c e  o f  I L - 2 ,  I L - 1 5  a n d  z o l e d r o n i c  a c i d  ( t h e  l a t t e r  b e i n g  a  p h o s p h o - a n t i g e n  s t i m u l u s  
f o r  T C R γ δ +  T  c e l l s ) ,  t h e  l e v e l  o f  s e n e s c e n c e  a n d  e x h a u s t i o n  w i t h  r e s p e c t  t o  c e l l  s u r f a c e  
a n d  i n t r a c e l l u l a r  m a r k e r  e x p r e s s i o n ,  c y t o k i n e  p r o d u c t i o n ,  s u r v i v a l  a n d  t r a n s c r i p t i o n  
f a c t o r  e x p r e s s i o n  w a s  i n v e s t i g a t e d  i n  a  s m a l l  s e r i e s  o f  T - L G L  l e u k e m i a  s a m p l e s .  
W h e n  h e a l t h y  a n d  t u m o r  T  c e l l s  f r o m  p a t i e n t s  w e r e  s c r e e n e d  f o r  s e n e s c e n c e  a n d / o r  
e x h a u s t i o n  m a r k e r  e x p r e s s i o n ,  b o t h  C D 8 + T C R α β +  a n d  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  
s h o w e d  i n c r e a s e d  p e r c e n t a g e s  o f  C D 2 4 4 + C D 5 7 +  c e l l s  ( F i g .  6 a ) .  A p a r t  f r o m  b e i n g  a n  N K  
c e l l  m a r k e r ,  C D 5 7  i s  a l s o  a  m a r k e r  f o r  T  c e l l  r e p l i c a t i v e  s e n e s c e n c e  a n d  L G L  l e u k e m i a  
[ 1 , 1 4 4 ] ,  a n d  t h e r e f o r e  e x p e c t e d  t o  b e  h i g h l y  e x p r e s s e d  i n  L G L  p a t i e n t s  b u t  l e s s  s o  i n  
h e a l t h y  s u b s e t s .  C D 2 4 4  ( 2 B 4 )  i s  a l s o  a n  N K  c e l l  m a r k e r ,  w h i c h  i s  m o r e  a s s o c i a t e d  w i t h  
e x h a u s t i o n ,  e s p e c i a l l y  i n  c o m b i n a t i o n  w i t h  C D 5 7  a n d  P D - 1  e x p r e s s i o n  i n  t r i p l e  p o s i t i v e  
c e l l s  [ 1 3 6 ] .  E v e n  t h o u g h  C D 2 4 4 + C D 5 7 +  c e l l s  w e r e  i n c r e a s e d  i n  b o t h  T - L G L  l e u k e m i a  
t y p e s ,  o n l y  i n  C D 8 + T C R α β +  T - L G L  l e u k e m i a  a  s i g n i f i c a n t  i n c r e a s e  i n  t h e  t r i p l e  p o s i t i v e  
c e l l s  w a s  f o u n d  ( F i g .  6 a ) ,  s u g g e s t i n g  t h a t  C D 8 + T C R α β +  l e u k e m i c  T  c e l l s  a r e  s l i g h t l y  m o r e  
a f f e c t e d  b y  e x h a u s t i o n  a n d  s e n e s c e n c e  t h a n  T C R γ δ +  l e u k e m i c  T  c e l l s ,  w h i c h  i s  i n  l i n e  
w i t h  o u r  e a r l i e r  d a t a  [ C h a p t e r  2 ,  t h i s  t h e s i s ] .  
N e x t ,  w e  d e t e r m i n e d  t h e  p r o l i f e r a t i v e  c a p a c i t i e s  o f  T - L G L  c e l l s .  E v e n  t h o u g h  L G L  c e l l s  
a r e  e x p r e s s i n g  C D 5 7 ,  a n d  t h u s  a r e  s h o w i n g  s i g n s  o f  r e p l i c a t i v e  s e n e s c e n c e ,  i t  w a s  o b v i o u s  
t h a t  t h e s e  c e l l s  c o u l d  s t i l l  p r o l i f e r a t e  t o  s o m e  e x t e n t  u p o n  T C R - d e p e n d e n t  s t i m u l a t i o n  
( F i g .  6 b ,  u p p e r  p a n e l s ) .  F r o m  d i r e c t  c o m p a r i s o n  w i t h  h e a l t h y  c e l l s  i t  w a s  c l e a r  t h a t  e s p e -
c i a l l y  t h e  C D 8 + T C R α β +  T - L G L  l e u k e m i a  c e l l s  l o s t  t h e i r  r e p l i c a t i v e  c a p a c i t y  a f t e r  t w o  g e n -
e r a t i o n s ,  w h e r e a s  T C R γ δ +  l e u k e m i c  T  c e l l s  w e r e  c a p a b l e  o f  u n d e r g o i n g  m o r e  d i v i s i o n s  







cells still showed proliferative capacity, this could reflect a level of exhaustion that can be 
saved upon proper stimuli (136). However, the fact that both TCRγδ+ and CD8+TCRαβ+ 
T-LGL leukemic cells did not replicate as good as healthy cells, also correlates with the chronic disease phenotype, which is less associated with highly proliferating cells than 
for example acute leukemia [Chapter 5, this thesis]. Next, we evaluated cytokine and cytotoxicity profiles in the context of exhaustion and 
senescence. Senescent cells are known to be polyfunctional, which implies the produc- tion of multiple cytokines [145], while exhausted cells lose this feature during the first 
steps of exhaustion (reviewed in [136]). CD8+TCRαβ+ T-LGL leukemia cells generally 
showed normal levels of cytokines when compared to healthy CD8+TCRαβ+ T cells; in 
fact, granzyme B production was even significantly increased (Fig. 6c). However, TCRγδ+ 
T-LGL leukemia cells did show significant decreases of all cytokines and the degranula- tion marker CD107a, whereas granzyme B was also significantly increased in TCRγδ+ 
T-LGL leukemia cells (Fig. 6c). The increased granzyme B levels may explain the cytope- nia symptoms that T-LGL patients frequently present with [Chapter 5, this thesis]. High 
cytokine levels and also high levels of cytotoxicity might result in autoimmunity against other blood cells, and thus in cytopenias. Approximately 20% of the T-LGL leukemia 
patients indeed have underlying or associated autoimmune diseases, which could result from the high cytotoxic state (Fig. 6c) [Chapter 5, this thesis]. 
Activated CTLs undergo activation induced cell death (AICD) [146]. When the level of apoptotic cells upon TCR stimulation (18 hours) was assessed in T-LGL leukemia patient 
samples, in the CD8+TCRαβ+ T-LGL leukemia samples a significant difference was 
observed between leukemic CD8+TCRαβ+ and normal TCRγδ+ T cells. While the fraction 
of apoptotic CD8+TCRαβ+ leukemic T cells was as low as for normal CD4+TCRαβ+ T cells, 
TCRγδ+ T cells in CD8+TCRαβ+ T-LGL leukemia patients did undergo apoptosis (Fig. 6d). 
In TCRγδ+ T-LGL leukemia patients no significant differences were observed, although 
a decreasing, but non-significant, effect was seen with respect to the percentages of 
Figure 6 (see left page). Evaluation of senescence and/or exhaustion features in CD8+TCRαβ+ and 
TCRγδ+ T-LGL leukemia cells upon stimulation, proliferation and apoptosis.
Data from functional assays represent CD8+TCRαβ+ T-LGL leukemia cells (left column) and TCRγδ+ T-LGL leukemia cells (right column). Relative numbers of T-LGL leukemia cells expressing surface exhaustion/ senescence markers (a). Proliferation levels as determined based on histogram plots and dilution of 
proliferation dye and as quantified data (bar graphs). The number of divisions is indicated as P0-P4 (b). Cytokine production and degranulation marker measurement CD107a (level of cytotoxicity) based on intracellular cytokine staining (c). Levels of apoptosis induction in CD4+TCRαβ+, CD8+TCRαβ+ and TCRγδ+ T 
cell populations in the two patient groups upon AICD following TCR-mediated stimulation (d). Relative mRNA transcription factor expression indicated as fold change upon normalization to ABL housekeeping gene (ΔCt) in healthy control versus patient samples (e). All data visualized with bar graphs and SD error bars indicate 
median values, whereas histogram plots (b) indicate representative experiments. Statistical significance of the apoptosis assay was tested using the Kruskal Wallis test followed by a post-Dunn’s test. Other statistical significances were tested using the Mann Whitney U test. Level of significance indicated in the plots: *, p<0.05; 
**, p<0.01; ***, p<0.001.
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c e l l s  s t i l l  s h o w e d  p r o l i f e r a t i v e  c a p a c i t y ,  t h i s  c o u l d  r e f l e c t  a  l e v e l  o f  e x h a u s t i o n  t h a t  c a n  b e  
s a v e d  u p o n  p r o p e r  s t i m u l i  ( 1 3 6 ) .  H o w e v e r ,  t h e  f a c t  t h a t  b o t h  T C R γ δ +  a n d  C D 8 + T C R α β +  
T - L G L  l e u k e m i c  c e l l s  d i d  n o t  r e p l i c a t e  a s  g o o d  a s  h e a l t h y  c e l l s ,  a l s o  c o r r e l a t e s  w i t h  t h e  
c h r o n i c  d i s e a s e  p h e n o t y p e ,  w h i c h  i s  l e s s  a s s o c i a t e d  w i t h  h i g h l y  p r o l i f e r a t i n g  c e l l s  t h a n  
f o r  e x a m p l e  a c u t e  l e u k e m i a  [ C h a p t e r  5 ,  t h i s  t h e s i s ] .  
N e x t ,  w e  e v a l u a t e d  c y t o k i n e  a n d  c y t o t o x i c i t y  p r o f i l e s  i n  t h e  c o n t e x t  o f  e x h a u s t i o n  a n d  
s e n e s c e n c e .  S e n e s c e n t  c e l l s  a r e  k n o w n  t o  b e  p o l y f u n c t i o n a l ,  w h i c h  i m p l i e s  t h e  p r o d u c -
t i o n  o f  m u l t i p l e  c y t o k i n e s  [ 1 4 5 ] ,  w h i l e  e x h a u s t e d  c e l l s  l o s e  t h i s  f e a t u r e  d u r i n g  t h e  f i r s t  
s t e p s  o f  e x h a u s t i o n  ( r e v i e w e d  i n  [ 1 3 6 ] ) .  C D 8 + T C R α β +  T - L G L  l e u k e m i a  c e l l s  g e n e r a l l y  
s h o w e d  n o r m a l  l e v e l s  o f  c y t o k i n e s  w h e n  c o m p a r e d  t o  h e a l t h y  C D 8 + T C R α β +  T  c e l l s ;  i n  
f a c t ,  g r a n z y m e  B  p r o d u c t i o n  w a s  e v e n  s i g n i f i c a n t l y  i n c r e a s e d  ( F i g .  6 c ) .  H o w e v e r ,  T C R γ δ +  
T - L G L  l e u k e m i a  c e l l s  d i d  s h o w  s i g n i f i c a n t  d e c r e a s e s  o f  a l l  c y t o k i n e s  a n d  t h e  d e g r a n u l a -
t i o n  m a r k e r  C D 1 0 7 a ,  w h e r e a s  g r a n z y m e  B  w a s  a l s o  s i g n i f i c a n t l y  i n c r e a s e d  i n  T C R γ δ +  
T - L G L  l e u k e m i a  c e l l s  ( F i g .  6 c ) .  T h e  i n c r e a s e d  g r a n z y m e  B  l e v e l s  m a y  e x p l a i n  t h e  c y t o p e -
n i a  s y m p t o m s  t h a t  T - L G L  p a t i e n t s  f r e q u e n t l y  p r e s e n t  w i t h  [ C h a p t e r  5 ,  t h i s  t h e s i s ] .  H i g h  
c y t o k i n e  l e v e l s  a n d  a l s o  h i g h  l e v e l s  o f  c y t o t o x i c i t y  m i g h t  r e s u l t  i n  a u t o i m m u n i t y  a g a i n s t  
o t h e r  b l o o d  c e l l s ,  a n d  t h u s  i n  c y t o p e n i a s .  A p p r o x i m a t e l y  2 0 %  o f  t h e  T - L G L  l e u k e m i a  
p a t i e n t s  i n d e e d  h a v e  u n d e r l y i n g  o r  a s s o c i a t e d  a u t o i m m u n e  d i s e a s e s ,  w h i c h  c o u l d  r e s u l t  
f r o m  t h e  h i g h  c y t o t o x i c  s t a t e  ( F i g .  6 c )  [ C h a p t e r  5 ,  t h i s  t h e s i s ] .  
A c t i v a t e d  C T L s  u n d e r g o  a c t i v a t i o n  i n d u c e d  c e l l  d e a t h  ( A I C D )  [ 1 4 6 ] .  W h e n  t h e  l e v e l  o f  
a p o p t o t i c  c e l l s  u p o n  T C R  s t i m u l a t i o n  ( 1 8  h o u r s )  w a s  a s s e s s e d  i n  T - L G L  l e u k e m i a  p a t i e n t  
s a m p l e s ,  i n  t h e  C D 8 + T C R α β +  T - L G L  l e u k e m i a  s a m p l e s  a  s i g n i f i c a n t  d i f f e r e n c e  w a s  
o b s e r v e d  b e t w e e n  l e u k e m i c  C D 8 + T C R α β +  a n d  n o r m a l  T C R γ δ +  T  c e l l s .  W h i l e  t h e  f r a c t i o n  
o f  a p o p t o t i c  C D 8 + T C R α β +  l e u k e m i c  T  c e l l s  w a s  a s  l o w  a s  f o r  n o r m a l  C D 4 + T C R α β +  T  c e l l s ,  
T C R γ δ +  T  c e l l s  i n  C D 8 + T C R α β +  T - L G L  l e u k e m i a  p a t i e n t s  d i d  u n d e r g o  a p o p t o s i s  ( F i g .  6 d ) .  
I n  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t s  n o  s i g n i f i c a n t  d i f f e r e n c e s  w e r e  o b s e r v e d ,  a l t h o u g h  
a  d e c r e a s i n g ,  b u t  n o n - s i g n i f i c a n t ,  e f f e c t  w a s  s e e n  w i t h  r e s p e c t  t o  t h e  p e r c e n t a g e s  o f  
F i g u r e  6  ( s e e  l e f t  p a g e ) .  E v a l u a t i o n  o f  s e n e s c e n c e  a n d / o r  e x h a u s t i o n  f e a t u r e s  i n  C D 8 + T C R α β +  a n d  
T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  u p o n  s t i m u l a t i o n ,  p r o l i f e r a t i o n  a n d  a p o p t o s i s .
D a t a  f r o m  f u n c t i o n a l  a s s a y s  r e p r e s e n t  C D 8 + T C R α β +  T - L G L  l e u k e m i a  c e l l s  ( l e f t  c o l u m n )  a n d  T C R γ δ +  T - L G L  
l e u k e m i a  c e l l s  ( r i g h t  c o l u m n ) .  R e l a t i v e  n u m b e r s  o f  T - L G L  l e u k e m i a  c e l l s  e x p r e s s i n g  s u r f a c e  e x h a u s t i o n /
s e n e s c e n c e  m a r k e r s  ( a ) .  P r o l i f e r a t i o n  l e v e l s  a s  d e t e r m i n e d  b a s e d  o n  h i s t o g r a m  p l o t s  a n d  d i l u t i o n  o f  
p r o l i f e r a t i o n  d y e  a n d  a s  q u a n t i f i e d  d a t a  ( b a r  g r a p h s ) .  T h e  n u m b e r  o f  d i v i s i o n s  i s  i n d i c a t e d  a s  P 0 - P 4  ( b ) .  
C y t o k i n e  p r o d u c t i o n  a n d  d e g r a n u l a t i o n  m a r k e r  m e a s u r e m e n t  C D 1 0 7 a  ( l e v e l  o f  c y t o t o x i c i t y )  b a s e d  o n  
i n t r a c e l l u l a r  c y t o k i n e  s t a i n i n g  ( c ) .  L e v e l s  o f  a p o p t o s i s  i n d u c t i o n  i n  C D 4 + T C R α β + ,  C D 8 + T C R α β +  a n d  T C R γ δ +  T  
c e l l  p o p u l a t i o n s  i n  t h e  t w o  p a t i e n t  g r o u p s  u p o n  A I C D  f o l l o w i n g  T C R - m e d i a t e d  s t i m u l a t i o n  ( d ) .  R e l a t i v e  m R N A  
t r a n s c r i p t i o n  f a c t o r  e x p r e s s i o n  i n d i c a t e d  a s  f o l d  c h a n g e  u p o n  n o r m a l i z a t i o n  t o  A B L  h o u s e k e e p i n g  g e n e  ( Δ C t )  
i n  h e a l t h y  c o n t r o l  v e r s u s  p a t i e n t  s a m p l e s  ( e ) .  A l l  d a t a  v i s u a l i z e d  w i t h  b a r  g r a p h s  a n d  S D  e r r o r  b a r s  i n d i c a t e  
m e d i a n  v a l u e s ,  w h e r e a s  h i s t o g r a m  p l o t s  ( b )  i n d i c a t e  r e p r e s e n t a t i v e  e x p e r i m e n t s .  S t a t i s t i c a l  s i g n i f i c a n c e  o f  
t h e  a p o p t o s i s  a s s a y  w a s  t e s t e d  u s i n g  t h e  K r u s k a l  W a l l i s  t e s t  f o l l o w e d  b y  a  p o s t - D u n n ’ s  t e s t .  O t h e r  s t a t i s t i c a l  
s i g n i f i c a n c e s  w e r e  t e s t e d  u s i n g  t h e  M a n n  W h i t n e y  U  t e s t .  L e v e l  o f  s i g n i f i c a n c e  i n d i c a t e d  i n  t h e  p l o t s :  * ,  p < 0 . 0 5 ;  
* * ,  p < 0 . 0 1 ;  * * * ,  p < 0 . 0 0 1 .
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apoptotic normal CD4+TCRαβ+ and CD8+TCRαβ+ cells, and aberrant TCRγδ+ T-LGL 
leukemia cells (Fig. 6d). These preliminary data would imply that both the CD8+TCRαβ+ 
leukemia T cells and the TCRγδ+ leukemia T cells are less prone to undergo AICD, which is in line with the disease phenotype. However, as only a limited number of patient sam-ples was available for these experiments, the AICD assays should be repeated with a 
sufficient sample size, in order to confirm our preliminary findings.
Finally, specific transcription factors have been associated with exhaustion and sur-vival processes. In fact, high levels of Eomesodermin (Eomes) are known to be associated with more exhausted cells (with cytotoxic activity) [147], while cells with high T-bet expression are less exhausted and also less cytotoxic [148]. As high T-bet expression is also associated with repression of PD-1, exhausted cells logically show high Eomes levels and low T-bet levels [149]. Exhaustion is not only controlled by transcription factors Eomes and T-bet, but also by Blimp1 (PRDM1) and Bcl-6 (reviewed by [150]). Up-regulation of transcription repressor Blimp1 [151], and down-regulation of survival-related tran-scription factor Bcl-6 are both linked with exhaustion, due to the resulting loss of sur-
vival [148]. Our preliminary RQ-PCR analysis of TCRγδ+ T-LGL leukemia cells showed 
differences in transcription factor expression when compared with healthy TCRγδ+ T cells under similar stimulatory conditions. T-bet expression was down-regulated in patients, while Eomes expression remained unchanged. Blimp1 expression was slightly 
up-regulated, though not significant, and Bcl-6 was highly down-regulated, reflecting drastic alterations in gene expression (Fig. 6e). Altogether, the transcription factor 
expression levels in the leukemic TCRγδ+ T cells correlated most with exhaustion, due to the down-regulation of both T-bet and Bcl-6, and the slight up-regulation of Blimp1. So 
far we have not produced RQ-PCR data for CD8+TCRαβ+ T-LGL leukemia cells. In conclusion, based on the preliminary data from our functional analyses in T-LGL 
leukemia cells we identified increased exhaustion and senescence surface marker expres-sion, especially of CD57 and CD244, in combination with PD1, which would correlate with an exhaustion state. Despite the high CD57 expression, which is also associated with replicative senescence, T-LGL leukemia cells were able to proliferate. This seems contradictory, but it should be stressed that a state of exhaustion can be rescued upon proper stimulation. Furthermore, T-LGL leukemia cells showed an ability to produce high levels of granzyme B, which might correlate with cytopenias that are associated with LGL leukemia disease. Granzyme B production could be involved in autoimmunity 
against other blood cells, possibly underlying the autoinflammatory or autoimmune 
diseases and flu-like symptoms seen in those patients [1, Chapter 5, this thesis]. This 
cytotoxicity profile might also reflect a state of low level inflammation, termed inflam-
mageing [143], which is considered a hallmark of senescence and which fits the clinical presentation of most LGL leukemias at older age [1, Chapter 5, this thesis]. Finally, T-LGL 
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leukemia cells were less prone to AICD, although the altered transcription factor pro- files still partially associated with exhaustion. It should be stressed that these data are 
preliminary and given the heterogeneity between different T-LGL leukemia patients, a larger series of both CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia patient samples should 
provide more insights on the functional properties of T-LGL leukemia cells in general. In this context it should also be noted that a better definition and sorting of the leukemic 
population based on unique markers, would be instrumental to fully disclose the func- tional properties of these leukemic LGL cells.
T-LGL leukemia cells and immune dysregulation
As noted above, T-LGL leukemia shows typical clinical characteristics beyond leukemia, which include autoimmune and other immune dysregulation features that 
are overlapping with other diseases. For example, in Felty syndrome (FS) patients the associated RA, neutropenia and (hepato)splenomegaly [152], together with the 
presence of oligo-/monoclonal LGL cells, and the recently reported high frequency of somatic STAT3 and STAT5b mutations [153], all indicate an overlap between clonal 
T-LGL leukemic proliferations and FS. Not only in case of FS, but also in other (auto) immune dysregulation diseases LGL clones were identified, thus reflecting a common 
(auto)immune pathogenesis in which STAT3 mutations could be relevant. This raises the question whether T-LGL leukemia is a consequence of autoimmune diseases due 
to continuous stimulation by (auto)antigens, or whether the STAT3 mutated T-LGL leukemia cells might actually cause dysregulation of the immune system, leading to e.g. 
autoimmune disease [154]. In this respect it is relevant to remark that T-LGL leukemia mostly develops in elderly individuals, while autoimmune diseases sometimes have an 
early age onset, even though most appear later in life (from age 20-40 onwards or even >80) [155,156]. Based on this, it would be tempting to conclude that T-LGL leukemias 
would therefore be a consequence of the continuous exposure to autoantigens and subsequent damage-associated epitopes. However, this could work both ways, i.e. upon 
autoimmune disease development autoantigens could trigger immune cells including LGL cells, whereas proliferating LGL cells that develop into clones could also mediate 
(auto)immune dysregulation and cytopenias [1, Chapter 5 this thesis]. To further address “the chicken or the egg” question, patients diagnosed at a young age with for example 
RA would have to be followed over time to monitor the LGL cell numbers, clonality, and responsiveness. 
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G e n e r a l  D i s c u s s i o n
l e u k e m i a  c e l l s  w e r e  l e s s  p r o n e  t o  A I C D ,  a l t h o u g h  t h e  a l t e r e d  t r a n s c r i p t i o n  f a c t o r  p r o -
f i l e s  s t i l l  p a r t i a l l y  a s s o c i a t e d  w i t h  e x h a u s t i o n .  I t  s h o u l d  b e  s t r e s s e d  t h a t  t h e s e  d a t a  a r e  
p r e l i m i n a r y  a n d  g i v e n  t h e  h e t e r o g e n e i t y  b e t w e e n  d i f f e r e n t  T - L G L  l e u k e m i a  p a t i e n t s ,  a  
l a r g e r  s e r i e s  o f  b o t h  C D 8 + T C R α β +  a n d  T C R γ δ +  T - L G L  l e u k e m i a  p a t i e n t  s a m p l e s  s h o u l d  
p r o v i d e  m o r e  i n s i g h t s  o n  t h e  f u n c t i o n a l  p r o p e r t i e s  o f  T - L G L  l e u k e m i a  c e l l s  i n  g e n e r a l .  I n  
t h i s  c o n t e x t  i t  s h o u l d  a l s o  b e  n o t e d  t h a t  a  b e t t e r  d e f i n i t i o n  a n d  s o r t i n g  o f  t h e  l e u k e m i c  
p o p u l a t i o n  b a s e d  o n  u n i q u e  m a r k e r s ,  w o u l d  b e  i n s t r u m e n t a l  t o  f u l l y  d i s c l o s e  t h e  f u n c -
t i o n a l  p r o p e r t i e s  o f  t h e s e  l e u k e m i c  L G L  c e l l s .
T - L G L  l e u k e m i a  c e l l s  a n d  i m m u n e  d y s r e g u l a t i o n
A s  n o t e d  a b o v e ,  T - L G L  l e u k e m i a  s h o w s  t y p i c a l  c l i n i c a l  c h a r a c t e r i s t i c s  b e y o n d  
l e u k e m i a ,  w h i c h  i n c l u d e  a u t o i m m u n e  a n d  o t h e r  i m m u n e  d y s r e g u l a t i o n  f e a t u r e s  t h a t  
a r e  o v e r l a p p i n g  w i t h  o t h e r  d i s e a s e s .  F o r  e x a m p l e ,  i n  F e l t y  s y n d r o m e  ( F S )  p a t i e n t s  
t h e  a s s o c i a t e d  R A ,  n e u t r o p e n i a  a n d  ( h e p a t o ) s p l e n o m e g a l y  [ 1 5 2 ] ,  t o g e t h e r  w i t h  t h e  
p r e s e n c e  o f  o l i g o - / m o n o c l o n a l  L G L  c e l l s ,  a n d  t h e  r e c e n t l y  r e p o r t e d  h i g h  f r e q u e n c y  
o f  s o m a t i c  S T A T 3  a n d  S T A T 5 b  m u t a t i o n s  [ 1 5 3 ] ,  a l l  i n d i c a t e  a n  o v e r l a p  b e t w e e n  c l o n a l  
T - L G L  l e u k e m i c  p r o l i f e r a t i o n s  a n d  F S .  N o t  o n l y  i n  c a s e  o f  F S ,  b u t  a l s o  i n  o t h e r  ( a u t o )
i m m u n e  d y s r e g u l a t i o n  d i s e a s e s  L G L  c l o n e s  w e r e  i d e n t i f i e d ,  t h u s  r e f l e c t i n g  a  c o m m o n  
( a u t o ) i m m u n e  p a t h o g e n e s i s  i n  w h i c h  S T A T 3  m u t a t i o n s  c o u l d  b e  r e l e v a n t .  T h i s  r a i s e s  
t h e  q u e s t i o n  w h e t h e r  T - L G L  l e u k e m i a  i s  a  c o n s e q u e n c e  o f  a u t o i m m u n e  d i s e a s e s  d u e  
t o  c o n t i n u o u s  s t i m u l a t i o n  b y  ( a u t o ) a n t i g e n s ,  o r  w h e t h e r  t h e  S T A T 3  m u t a t e d  T - L G L  
l e u k e m i a  c e l l s  m i g h t  a c t u a l l y  c a u s e  d y s r e g u l a t i o n  o f  t h e  i m m u n e  s y s t e m ,  l e a d i n g  t o  e . g .  
a u t o i m m u n e  d i s e a s e  [ 1 5 4 ] .  I n  t h i s  r e s p e c t  i t  i s  r e l e v a n t  t o  r e m a r k  t h a t  T - L G L  l e u k e m i a  
m o s t l y  d e v e l o p s  i n  e l d e r l y  i n d i v i d u a l s ,  w h i l e  a u t o i m m u n e  d i s e a s e s  s o m e t i m e s  h a v e  a n  
e a r l y  a g e  o n s e t ,  e v e n  t h o u g h  m o s t  a p p e a r  l a t e r  i n  l i f e  ( f r o m  a g e  2 0 - 4 0  o n w a r d s  o r  e v e n  
> 8 0 )  [ 1 5 5 , 1 5 6 ] .  B a s e d  o n  t h i s ,  i t  w o u l d  b e  t e m p t i n g  t o  c o n c l u d e  t h a t  T - L G L  l e u k e m i a s  
w o u l d  t h e r e f o r e  b e  a  c o n s e q u e n c e  o f  t h e  c o n t i n u o u s  e x p o s u r e  t o  a u t o a n t i g e n s  a n d  
s u b s e q u e n t  d a m a g e - a s s o c i a t e d  e p i t o p e s .  H o w e v e r ,  t h i s  c o u l d  w o r k  b o t h  w a y s ,  i . e .  u p o n  
a u t o i m m u n e  d i s e a s e  d e v e l o p m e n t  a u t o a n t i g e n s  c o u l d  t r i g g e r  i m m u n e  c e l l s  i n c l u d i n g  
L G L  c e l l s ,  w h e r e a s  p r o l i f e r a t i n g  L G L  c e l l s  t h a t  d e v e l o p  i n t o  c l o n e s  c o u l d  a l s o  m e d i a t e  
( a u t o ) i m m u n e  d y s r e g u l a t i o n  a n d  c y t o p e n i a s  [ 1 ,  C h a p t e r  5  t h i s  t h e s i s ] .  T o  f u r t h e r  a d d r e s s  
“ t h e  c h i c k e n  o r  t h e  e g g ”  q u e s t i o n ,  p a t i e n t s  d i a g n o s e d  a t  a  y o u n g  a g e  w i t h  f o r  e x a m p l e  
R A  w o u l d  h a v e  t o  b e  f o l l o w e d  o v e r  t i m e  t o  m o n i t o r  t h e  L G L  c e l l  n u m b e r s ,  c l o n a l i t y ,  a n d  




Based on results presented in this thesis, it has become clear that TCRγδ+ T cells are 
subjected to ageing, immuneageing and inflammageing processes, in a way similar to other T cell types. As a consequence, differences in subset composition and distribution were apparent upon ageing with reduced naive and central memory cells, and increased 
effector memory, effector and senescent CD57+KLRG1+ cells. In these subset compo-
sition alterations CMV also appeared to play a major role. Differences in TCRγδ+ T cell compositions have also been observed in our molecular studies, as performed on naive, 
central memory, effector memory and effector TCRγδ+ T cell subsets. The dominance 
of Vγ9/Vδ2 memory cells at younger age shifted to Vγ2/Vδ1 and Vγ8/Vδ1 memory cell dominance in elderly individuals, most probably illustrating the impact of peripheral antigenic selection throughout life. In this process, also a role for CMV could be envi-
sioned. Notably, normal elderly effector TCRγδ+ T cells showed TCRγδ+ T-LGL leuke-
mia-related clonotypes as part of their TRG/TRD repertoire. Even though the TCRγδ+ T cells bearing these LGL receptors are not necessarily malignantly transformed from the beginning, they might have undergone changes upon ageing leading to an excessive 
imbalance towards proliferation, survival and inflammation. These underlying changes 
might result from the process of “inflammageing”, one individual being more susceptible than the other. However, underlying mutations could also contribute to these transfor-mations. All these aberrations contribute to immune dysregulation, with the produc-tion of cytokines, perforins and granzymes, eventually also resulting in an uncontrolled immune responses to self, thus explaining the underlying autoimmune diseases and cytopenias as observed in T-LGL leukemia patients. Conversely, the underlying autoim-mune diseases and malignancies could also provide stimuli for the T-LGL leukemia cells 
in general, and perhaps especially for TCRγδ+ T cells, since they are able to recognize a wide variety of antigens, with or without MHC-molecules, peptides and non-peptides, 
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were apparent upon ageing with reduced naive and central memory cells, and increased 
effector memory, effector and senescent CD57+KLRG1+ cells. In these subset compo-
sition alterations CMV also appeared to play a major role. Differences in TCRγδ+ T cell 
compositions have also been observed in our molecular studies, as performed on naive, 
central memory, effector memory and effector TCRγδ+ T cell subsets. The dominance 
of Vγ9/Vδ2 memory cells at younger age shifted to Vγ2/Vδ1 and Vγ8/Vδ1 memory cell 
dominance in elderly individuals, most probably illustrating the impact of peripheral 
antigenic selection throughout life. In this process, also a role for CMV could be envi-
sioned. Notably, normal elderly effector TCRγδ+ T cells showed TCRγδ+ T-LGL leuke-
mia-related clonotypes as part of their TRG/TRD repertoire. Even though the TCRγδ+ 
T cells bearing these LGL receptors are not necessarily malignantly transformed from 
the beginning, they might have undergone changes upon ageing leading to an excessive 
imbalance towards proliferation, survival and inflammation. These underlying changes 
might result from the process of “inflammageing”, one individual being more susceptible 
than the other. However, underlying mutations could also contribute to these transfor-
mations. All these aberrations contribute to immune dysregulation, with the produc-
tion of cytokines, perforins and granzymes, eventually also resulting in an uncontrolled 
immune responses to self, thus explaining the underlying autoimmune diseases and 
cytopenias as observed in T-LGL leukemia patients. Conversely, the underlying autoim-
mune diseases and malignancies could also provide stimuli for the T-LGL leukemia cells 
in general, and perhaps especially for TCRγδ+ T cells, since they are able to recognize a 
wide variety of antigens, with or without MHC-molecules, peptides and non-peptides, 
self and non-self. Despite this senescent profile of T-LGL leukemia cells, they did not lose 
their replicative potential and thus will continue to proliferate, thereby contributing to 




Figure 7. Summary of this thesis.
Upon stimulation from an unknown source TCRγδ+ T cells become activated, possibly involving up-regulated 
STAT3 signaling. Through persistent activation genetic aberrancies can occur, resulting in transcription of genes involved in survival and inflammation, anti-apoptosis genes and oncogenes. This results in elevated STAT3 expression, granzyme B production and decreased apoptosis with subsequent increased survival. The 
high inflammatory state of the T-LGL leukemia cells with elevated granzyme B possibly results in an immune 
response, also against other blood cells, leading to cytopenias. Epitopes and self-antigens can subsequently act as stimuli for TCRγδ+ T cells, potentially resulting in amplification of the process through a positive feedback loop.
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F i g u r e  7 .  S u m m a r y  o f  t h i s  t h e s i s .
U p o n  s t i m u l a t i o n  f r o m  a n  u n k n o w n  s o u r c e  T C R γ δ +  T  c e l l s  b e c o m e  a c t i v a t e d ,  p o s s i b l y  i n v o l v i n g  u p - r e g u l a t e d  
S T A T 3  s i g n a l i n g .  T h r o u g h  p e r s i s t e n t  a c t i v a t i o n  g e n e t i c  a b e r r a n c i e s  c a n  o c c u r ,  r e s u l t i n g  i n  t r a n s c r i p t i o n  o f  
g e n e s  i n v o l v e d  i n  s u r v i v a l  a n d  i n f l a m m a t i o n ,  a n t i - a p o p t o s i s  g e n e s  a n d  o n c o g e n e s .  T h i s  r e s u l t s  i n  e l e v a t e d  
S T A T 3  e x p r e s s i o n ,  g r a n z y m e  B  p r o d u c t i o n  a n d  d e c r e a s e d  a p o p t o s i s  w i t h  s u b s e q u e n t  i n c r e a s e d  s u r v i v a l .  T h e  
h i g h  i n f l a m m a t o r y  s t a t e  o f  t h e  T - L G L  l e u k e m i a  c e l l s  w i t h  e l e v a t e d  g r a n z y m e  B  p o s s i b l y  r e s u l t s  i n  a n  i m m u n e  
r e s p o n s e ,  a l s o  a g a i n s t  o t h e r  b l o o d  c e l l s ,  l e a d i n g  t o  c y t o p e n i a s .  E p i t o p e s  a n d  s e l f - a n t i g e n s  c a n  s u b s e q u e n t l y  a c t  
a s  s t i m u l i  f o r  T C R γ δ +  T  c e l l s ,  p o t e n t i a l l y  r e s u l t i n g  i n  a m p l i f i c a t i o n  o f  t h e  p r o c e s s  t h r o u g h  a  p o s i t i v e  f e e d b a c k  
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T cell receptor (TCR) γδ+ T cells form a distinct T cell type, which follows a different 
path of development and exerts different types of immune responses to a wide variety of peptide and non-peptide antigens. Just like any other immune cell, TCRγδ+ T cells 
are highly likely to be subjected to the effect of ageing. Ageing has been considered to be increasingly important, regarding the higher life expectancy in the Western World. 
For many immune cell types it has been well described how ageing affects composition, functionality and the possible gain of aberrancies of immune cells. Remarkably, it is still 
largely unknown how ageing impacts on TCRγδ+ T cells. As TCRγδ+ T cells show a high 
level of similarity to CD8+TCRαβ+ cytotoxic T lymphocytes, regarding their responses, 
we hypothesized that TCRγδ+ T cells show a similar impact of ageing as CD8+TCRαβ+ 
T cells, characterized by reduced responses, decreased (absolute) numbers and altered subset compositions. 
In our immunophenotyping study in Chapter 2 we observed that upon ageing the absolute numbers of total TCRγδ+ T cells decreased drastically, especially the most 
common population in the peripheral blood: Vγ9/Vδ2 cells. Furthermore, subset dis- tributions shifted towards effector memory and effector cells, while the fractions of 
especially naive and central memory cell populations decreased. These effects were enhanced upon persistence of CMV, a virus which is known for its effects on the T cell 
compartment. An additional CMV effect was observed, leading to a reduction of Vγ9/Vδ2 
cells, and therefore a relative increase of Vδ1+, mostly late-stage effector cells. 
In order to further investigate the effect of ageing and the change in TCRγδ usage we 
applied next generation sequencing to study the repertoire of TCRγδ+ T cells from dif- ferent ages (starting from developmental stages in thymus and cord blood to circulating 
cells in young and elderly individuals) and from different subsets (including immature, naive mature, central and effector memory, and effector cells). Prior to these investi-
gations we first optimized TCR gamma (TRG) and delta (TRD) NGS assays in Chapter 
3 to reduce the effect of technical biases. Following titration of primer concentrations, establishing the most optimal annealing temperatures to reduce primer competition, 
and reduction of cycle numbers to prevent plateau effects in the PCR reaction, we were able to generate results that are representative for the actual repertoire composition. 
Following this optimization, we could conclude from our biological study, as presented in Chapter 4, that naive TCRγδ+ T cells maintain a highly diverse repertoire during 
development and ageing, as seen from thymus and cord blood TCRγδ+ T cells and circu- lating TCRγδ+ T cells from young and elderly individuals. The most clear changes upon 
ageing were observed in memory cell populations: young individuals showed a Vγ9/
Vδ2 dominance in circulating TCRγδ+ T cells, while elderly individuals showed more a 
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T  c e l l  r e c e p t o r  ( T C R )  γ δ +  T  c e l l s  f o r m  a  d i s t i n c t  T  c e l l  t y p e ,  w h i c h  f o l l o w s  a  d i f f e r e n t  
p a t h  o f  d e v e l o p m e n t  a n d  e x e r t s  d i f f e r e n t  t y p e s  o f  i m m u n e  r e s p o n s e s  t o  a  w i d e  v a r i e t y  
o f  p e p t i d e  a n d  n o n - p e p t i d e  a n t i g e n s .  J u s t  l i k e  a n y  o t h e r  i m m u n e  c e l l ,  T C R γ δ +  T  c e l l s  
a r e  h i g h l y  l i k e l y  t o  b e  s u b j e c t e d  t o  t h e  e f f e c t  o f  a g e i n g .  A g e i n g  h a s  b e e n  c o n s i d e r e d  t o  
b e  i n c r e a s i n g l y  i m p o r t a n t ,  r e g a r d i n g  t h e  h i g h e r  l i f e  e x p e c t a n c y  i n  t h e  W e s t e r n  W o r l d .  
F o r  m a n y  i m m u n e  c e l l  t y p e s  i t  h a s  b e e n  w e l l  d e s c r i b e d  h o w  a g e i n g  a f f e c t s  c o m p o s i t i o n ,  
f u n c t i o n a l i t y  a n d  t h e  p o s s i b l e  g a i n  o f  a b e r r a n c i e s  o f  i m m u n e  c e l l s .  R e m a r k a b l y ,  i t  i s  s t i l l  
l a r g e l y  u n k n o w n  h o w  a g e i n g  i m p a c t s  o n  T C R γ δ +  T  c e l l s .  A s  T C R γ δ +  T  c e l l s  s h o w  a  h i g h  
l e v e l  o f  s i m i l a r i t y  t o  C D 8 + T C R α β +  c y t o t o x i c  T  l y m p h o c y t e s ,  r e g a r d i n g  t h e i r  r e s p o n s e s ,  
w e  h y p o t h e s i z e d  t h a t  T C R γ δ +  T  c e l l s  s h o w  a  s i m i l a r  i m p a c t  o f  a g e i n g  a s  C D 8 + T C R α β +  
T  c e l l s ,  c h a r a c t e r i z e d  b y  r e d u c e d  r e s p o n s e s ,  d e c r e a s e d  ( a b s o l u t e )  n u m b e r s  a n d  a l t e r e d  
s u b s e t  c o m p o s i t i o n s .  
I n  o u r  i m m u n o p h e n o t y p i n g  s t u d y  i n  C h a p t e r  2  w e  o b s e r v e d  t h a t  u p o n  a g e i n g  t h e  
a b s o l u t e  n u m b e r s  o f  t o t a l  T C R γ δ +  T  c e l l s  d e c r e a s e d  d r a s t i c a l l y ,  e s p e c i a l l y  t h e  m o s t  
c o m m o n  p o p u l a t i o n  i n  t h e  p e r i p h e r a l  b l o o d :  V γ 9 / V δ 2  c e l l s .  F u r t h e r m o r e ,  s u b s e t  d i s -
t r i b u t i o n s  s h i f t e d  t o w a r d s  e f f e c t o r  m e m o r y  a n d  e f f e c t o r  c e l l s ,  w h i l e  t h e  f r a c t i o n s  o f  
e s p e c i a l l y  n a i v e  a n d  c e n t r a l  m e m o r y  c e l l  p o p u l a t i o n s  d e c r e a s e d .  T h e s e  e f f e c t s  w e r e  
e n h a n c e d  u p o n  p e r s i s t e n c e  o f  C M V ,  a  v i r u s  w h i c h  i s  k n o w n  f o r  i t s  e f f e c t s  o n  t h e  T  c e l l  
c o m p a r t m e n t .  A n  a d d i t i o n a l  C M V  e f f e c t  w a s  o b s e r v e d ,  l e a d i n g  t o  a  r e d u c t i o n  o f  V γ 9 / V δ 2  
c e l l s ,  a n d  t h e r e f o r e  a  r e l a t i v e  i n c r e a s e  o f  V δ 1 + ,  m o s t l y  l a t e - s t a g e  e f f e c t o r  c e l l s .  
I n  o r d e r  t o  f u r t h e r  i n v e s t i g a t e  t h e  e f f e c t  o f  a g e i n g  a n d  t h e  c h a n g e  i n  T C R γ δ  u s a g e  w e  
a p p l i e d  n e x t  g e n e r a t i o n  s e q u e n c i n g  t o  s t u d y  t h e  r e p e r t o i r e  o f  T C R γ δ +  T  c e l l s  f r o m  d i f -
f e r e n t  a g e s  ( s t a r t i n g  f r o m  d e v e l o p m e n t a l  s t a g e s  i n  t h y m u s  a n d  c o r d  b l o o d  t o  c i r c u l a t i n g  
c e l l s  i n  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s )  a n d  f r o m  d i f f e r e n t  s u b s e t s  ( i n c l u d i n g  i m m a t u r e ,  
n a i v e  m a t u r e ,  c e n t r a l  a n d  e f f e c t o r  m e m o r y ,  a n d  e f f e c t o r  c e l l s ) .  P r i o r  t o  t h e s e  i n v e s t i -
g a t i o n s  w e  f i r s t  o p t i m i z e d  T C R  g a m m a  ( T R G )  a n d  d e l t a  ( T R D )  N G S  a s s a y s  i n  C h a p t e r  
3  t o  r e d u c e  t h e  e f f e c t  o f  t e c h n i c a l  b i a s e s .  F o l l o w i n g  t i t r a t i o n  o f  p r i m e r  c o n c e n t r a t i o n s ,  
e s t a b l i s h i n g  t h e  m o s t  o p t i m a l  a n n e a l i n g  t e m p e r a t u r e s  t o  r e d u c e  p r i m e r  c o m p e t i t i o n ,  
a n d  r e d u c t i o n  o f  c y c l e  n u m b e r s  t o  p r e v e n t  p l a t e a u  e f f e c t s  i n  t h e  P C R  r e a c t i o n ,  w e  w e r e  
a b l e  t o  g e n e r a t e  r e s u l t s  t h a t  a r e  r e p r e s e n t a t i v e  f o r  t h e  a c t u a l  r e p e r t o i r e  c o m p o s i t i o n .  
F o l l o w i n g  t h i s  o p t i m i z a t i o n ,  w e  c o u l d  c o n c l u d e  f r o m  o u r  b i o l o g i c a l  s t u d y ,  a s  p r e s e n t e d  
i n  C h a p t e r  4 ,  t h a t  n a i v e  T C R γ δ +  T  c e l l s  m a i n t a i n  a  h i g h l y  d i v e r s e  r e p e r t o i r e  d u r i n g  
d e v e l o p m e n t  a n d  a g e i n g ,  a s  s e e n  f r o m  t h y m u s  a n d  c o r d  b l o o d  T C R γ δ +  T  c e l l s  a n d  c i r c u -
l a t i n g  T C R γ δ +  T  c e l l s  f r o m  y o u n g  a n d  e l d e r l y  i n d i v i d u a l s .  T h e  m o s t  c l e a r  c h a n g e s  u p o n  
a g e i n g  w e r e  o b s e r v e d  i n  m e m o r y  c e l l  p o p u l a t i o n s :  y o u n g  i n d i v i d u a l s  s h o w e d  a  V γ 9 /
V δ 2  d o m i n a n c e  i n  c i r c u l a t i n g  T C R γ δ +  T  c e l l s ,  w h i l e  e l d e r l y  i n d i v i d u a l s  s h o w e d  m o r e  a  
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Vγ2/Vδ1 dominance. These immunogenotyping data thus confirmed our immunophe-notyping data, especially with regards to the effect of both ageing and CMV persistence. 
Based on both the immunophenotyping and –genotyping datasets, we thus could show 
that TCRγδ+ T cells are subjected to ageing in a way that is very similar to CD8+TCRαβ+ T cells. In elderly individuals chronic leukemias and lymphomas may develop, potentially as a consequence of ageing processes. These chronic lymphoid malignancies mainly involve B cells, but T cells can also transform into chronic leukemias and/or lymphomas. One of these is the T cell large granular lymphocyte (T-LGL) leukemia, which is a relatively rare and heterogeneous disorder consisting of three variants based on the T cell type that is 
involved in the disease, i.e. CD4+TCRαβ+, CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia. As 
the etiology for CD4+TCRαβ+ T-LGL leukemia has been extensively described before, we 
reviewed existing knowledge on the TCRγδ+ and CD8+TCRαβ+ T-LGL leukemia variants in Chapter 5. Both T-LGL leukemias mostly involve elderly individuals (above age 60), and have a rather indolent disease course, but a direct cause of both types of leukemia 
has not yet been identified. Most patients display associated cytopenias, autoimmune diseases and other malignancies, which could be considered as cause or consequence of the disease. Based on the obvious lack of identity or even homology in TCR usage between patients, involvement of a common (auto)antigen in T-LGL leukemia seems less likely.
Based on the fact that TCRγδ+ T-LGL leukemia is a chronic disorder affecting mostly elderly individuals, we hypothesized that the initial cause might lie in a continuous stimulation of these cells, which would then have to be followed by genetic aberrations. In Chapter 6 we therefore investigated, whether underlying molecular mechanisms such as signaling pathways, could be aberrant and thus contributing to leukemia devel-
opment. To this end, we performed gene expression profiling studies and observed a 
high correlation between the TCRγδ+ T-LGL leukemia transcriptome and that of healthy 
effector and effector memory TCRγδ+ T cells, but not of other healthy TCRγδ+ T cell 
subsets. More in-depth comparison between effector TCRγδ+ T cells and TCRγδ+ T-LGL leukemia cells revealed an altered expression of genes involved in increased prolifera-tion, reduced apoptosis and aberrant immune cell responses in the latter. This could not only explain the enhanced proliferative capacity and additional apoptosis resistance of these leukemic cells, but also enhanced immune responses that can possibly linked to the autoimmune diseases and cytopenias that are seen in these patients. 
Altered gene expression profiles might result from external factors, causing overstimulation of cells, thus resulting in stress and altered gene transcription, but might also be caused by intrinsic events involving genetic aberrancies and the loss or gain of function of genes. Nowadays, advances in sequencing technologies allow determining 
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Vγ2/Vδ1 dominance. These immunogenotyping data thus confirmed our immunophe-
notyping data, especially with regards to the effect of both ageing and CMV persistence. 
Based on both the immunophenotyping and –genotyping datasets, we thus could show 
that TCRγδ+ T cells are subjected to ageing in a way that is very similar to CD8+TCRαβ+ 
T cells. 
In elderly individuals chronic leukemias and lymphomas may develop, potentially as 
a consequence of ageing processes. These chronic lymphoid malignancies mainly involve 
B cells, but T cells can also transform into chronic leukemias and/or lymphomas. One of 
these is the T cell large granular lymphocyte (T-LGL) leukemia, which is a relatively rare 
and heterogeneous disorder consisting of three variants based on the T cell type that is 
involved in the disease, i.e. CD4+TCRαβ+, CD8+TCRαβ+ and TCRγδ+ T-LGL leukemia. As 
the etiology for CD4+TCRαβ+ T-LGL leukemia has been extensively described before, we 
reviewed existing knowledge on the TCRγδ+ and CD8+TCRαβ+ T-LGL leukemia variants 
in Chapter 5. Both T-LGL leukemias mostly involve elderly individuals (above age 60), 
and have a rather indolent disease course, but a direct cause of both types of leukemia 
has not yet been identified. Most patients display associated cytopenias, autoimmune 
diseases and other malignancies, which could be considered as cause or consequence 
of the disease. Based on the obvious lack of identity or even homology in TCR usage 
between patients, involvement of a common (auto)antigen in T-LGL leukemia seems less 
likely.
Based on the fact that TCRγδ+ T-LGL leukemia is a chronic disorder affecting mostly 
elderly individuals, we hypothesized that the initial cause might lie in a continuous 
stimulation of these cells, which would then have to be followed by genetic aberrations. 
In Chapter 6 we therefore investigated, whether underlying molecular mechanisms 
such as signaling pathways, could be aberrant and thus contributing to leukemia devel-
opment. To this end, we performed gene expression profiling studies and observed a 
high correlation between the TCRγδ+ T-LGL leukemia transcriptome and that of healthy 
effector and effector memory TCRγδ+ T cells, but not of other healthy TCRγδ+ T cell 
subsets. More in-depth comparison between effector TCRγδ+ T cells and TCRγδ+ T-LGL 
leukemia cells revealed an altered expression of genes involved in increased prolifera-
tion, reduced apoptosis and aberrant immune cell responses in the latter. This could not 
only explain the enhanced proliferative capacity and additional apoptosis resistance of 
these leukemic cells, but also enhanced immune responses that can possibly linked to 
the autoimmune diseases and cytopenias that are seen in these patients. 
Altered gene expression profiles might result from external factors, causing 
overstimulation of cells, thus resulting in stress and altered gene transcription, but might 
also be caused by intrinsic events involving genetic aberrancies and the loss or gain of 
function of genes. Nowadays, advances in sequencing technologies allow determining 
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Summary 
the full genome of cancer cells, thus providing tools to identify all possible underlying genetic variants. By applying one of these novel technologies, whole exome sequencing 
(WES), on both healthy control cells and TCRγδ+ T-LGL leukemia cells from the same 
patients, we were able to determine leukemia-specific gene variants as described 
in Chapter 7. After extensive filtering, we identified six candidate genes which could contribute to the aberrant character of TCRγδ+ T-LGL leukemia cells. Gene variants 
concerned (non-)frameshift insertions and deletions, which could contribute to altered transcription, immune activation and responses, and metastasis. In validation experi-
ments we then identified some of the variants to be present in CD8+TCRαβ+ T-LGL leu- kemia cells as well, thereby further linking the two T-LGL leukemia types. Future studies 
should be directed at functionally validating these gene variants to fully link the genetic aberrancies with altered gene transcription and protein levels, and altered function with 
respect to proliferation, apoptosis resistance, and/or cytotoxicity against other (blood) cells. 
In the General Discussion extrinsic factors and cell-intrinsic aspects of TCRγδ+ T-LGL leukemia cells are integrated and critically discussed. Additionally, preliminary 
data on senescence and exhaustion profiles of T-LGL leukemia cells are presented, which 
may also be relevant for LGL leukemia disease pathology. Finally, the link between LGL leukemia cells and immune dysregulations such as autoimmune diseases is discussed in 
view of “the chicken or the egg” question. 
In summary, the studies described in this thesis illustrate the complex interactions of genetic aberrations, altered gene expression levels, functional properties, receptor 
and surface marker expression during TCRγδ+ T cell ontogeny, peripheral (antigenic) 
selection, ageing and leukemogenesis. The research performed within the framework of this thesis does not only form a basis for better understanding of both normal and 
aberrant TCRγδ+ T cell development, but might eventually also impact on better diagno- sis, prognosis, treatment and prevention possibilities. Finally, this thesis underlines the 
important role of TCRγδ+ T cells in normal physiology, but also highlights their potential 
to transform into leukemia; TCRγδ+ T cells should not be ignored or underestimated.
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S u m m a r y  
t h e  f u l l  g e n o m e  o f  c a n c e r  c e l l s ,  t h u s  p r o v i d i n g  t o o l s  t o  i d e n t i f y  a l l  p o s s i b l e  u n d e r l y i n g  
g e n e t i c  v a r i a n t s .  B y  a p p l y i n g  o n e  o f  t h e s e  n o v e l  t e c h n o l o g i e s ,  w h o l e  e x o m e  s e q u e n c i n g  
( W E S ) ,  o n  b o t h  h e a l t h y  c o n t r o l  c e l l s  a n d  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s  f r o m  t h e  s a m e  
p a t i e n t s ,  w e  w e r e  a b l e  t o  d e t e r m i n e  l e u k e m i a - s p e c i f i c  g e n e  v a r i a n t s  a s  d e s c r i b e d  
i n  C h a p t e r  7 .  A f t e r  e x t e n s i v e  f i l t e r i n g ,  w e  i d e n t i f i e d  s i x  c a n d i d a t e  g e n e s  w h i c h  c o u l d  
c o n t r i b u t e  t o  t h e  a b e r r a n t  c h a r a c t e r  o f  T C R γ δ +  T - L G L  l e u k e m i a  c e l l s .  G e n e  v a r i a n t s  
c o n c e r n e d  ( n o n - ) f r a m e s h i f t  i n s e r t i o n s  a n d  d e l e t i o n s ,  w h i c h  c o u l d  c o n t r i b u t e  t o  a l t e r e d  
t r a n s c r i p t i o n ,  i m m u n e  a c t i v a t i o n  a n d  r e s p o n s e s ,  a n d  m e t a s t a s i s .  I n  v a l i d a t i o n  e x p e r i -
m e n t s  w e  t h e n  i d e n t i f i e d  s o m e  o f  t h e  v a r i a n t s  t o  b e  p r e s e n t  i n  C D 8 + T C R α β +  T - L G L  l e u -
k e m i a  c e l l s  a s  w e l l ,  t h e r e b y  f u r t h e r  l i n k i n g  t h e  t w o  T - L G L  l e u k e m i a  t y p e s .  F u t u r e  s t u d i e s  
s h o u l d  b e  d i r e c t e d  a t  f u n c t i o n a l l y  v a l i d a t i n g  t h e s e  g e n e  v a r i a n t s  t o  f u l l y  l i n k  t h e  g e n e t i c  
a b e r r a n c i e s  w i t h  a l t e r e d  g e n e  t r a n s c r i p t i o n  a n d  p r o t e i n  l e v e l s ,  a n d  a l t e r e d  f u n c t i o n  w i t h  
r e s p e c t  t o  p r o l i f e r a t i o n ,  a p o p t o s i s  r e s i s t a n c e ,  a n d / o r  c y t o t o x i c i t y  a g a i n s t  o t h e r  ( b l o o d )  
c e l l s .  
I n  t h e  G e n e r a l  D i s c u s s i o n  e x t r i n s i c  f a c t o r s  a n d  c e l l - i n t r i n s i c  a s p e c t s  o f  T C R γ δ +  
T - L G L  l e u k e m i a  c e l l s  a r e  i n t e g r a t e d  a n d  c r i t i c a l l y  d i s c u s s e d .  A d d i t i o n a l l y ,  p r e l i m i n a r y  
d a t a  o n  s e n e s c e n c e  a n d  e x h a u s t i o n  p r o f i l e s  o f  T - L G L  l e u k e m i a  c e l l s  a r e  p r e s e n t e d ,  w h i c h  
m a y  a l s o  b e  r e l e v a n t  f o r  L G L  l e u k e m i a  d i s e a s e  p a t h o l o g y .  F i n a l l y ,  t h e  l i n k  b e t w e e n  L G L  
l e u k e m i a  c e l l s  a n d  i m m u n e  d y s r e g u l a t i o n s  s u c h  a s  a u t o i m m u n e  d i s e a s e s  i s  d i s c u s s e d  i n  
v i e w  o f  “ t h e  c h i c k e n  o r  t h e  e g g ”  q u e s t i o n .  
I n  s u m m a r y ,  t h e  s t u d i e s  d e s c r i b e d  i n  t h i s  t h e s i s  i l l u s t r a t e  t h e  c o m p l e x  i n t e r a c t i o n s  
o f  g e n e t i c  a b e r r a t i o n s ,  a l t e r e d  g e n e  e x p r e s s i o n  l e v e l s ,  f u n c t i o n a l  p r o p e r t i e s ,  r e c e p t o r  
a n d  s u r f a c e  m a r k e r  e x p r e s s i o n  d u r i n g  T C R γ δ +  T  c e l l  o n t o g e n y ,  p e r i p h e r a l  ( a n t i g e n i c )  
s e l e c t i o n ,  a g e i n g  a n d  l e u k e m o g e n e s i s .  T h e  r e s e a r c h  p e r f o r m e d  w i t h i n  t h e  f r a m e w o r k  
o f  t h i s  t h e s i s  d o e s  n o t  o n l y  f o r m  a  b a s i s  f o r  b e t t e r  u n d e r s t a n d i n g  o f  b o t h  n o r m a l  a n d  
a b e r r a n t  T C R γ δ +  T  c e l l  d e v e l o p m e n t ,  b u t  m i g h t  e v e n t u a l l y  a l s o  i m p a c t  o n  b e t t e r  d i a g n o -
s i s ,  p r o g n o s i s ,  t r e a t m e n t  a n d  p r e v e n t i o n  p o s s i b i l i t i e s .  F i n a l l y ,  t h i s  t h e s i s  u n d e r l i n e s  t h e  
i m p o r t a n t  r o l e  o f  T C R γ δ +  T  c e l l s  i n  n o r m a l  p h y s i o l o g y ,  b u t  a l s o  h i g h l i g h t s  t h e i r  p o t e n t i a l  




T cellen, een belangrijk type afweercellen, kunnen worden onderverdeeld in 
twee groepen op basis van hun T cel receptor (TCR), nl. TCR alfa beta (TCRαβ) en 
TCR gamma delta (TCRγδ) positieve T cellen. Deze twee typen T cellen volgen eigen ontwikkelingspaden en zorgen voor verschillende afweerreacties tegen verschillende 
soorten (eiwit)moleculen, ook wel antigenen genoemd. TCRαβ+ T cellen – de meest 
voorkomende T cellen in het bloed – herkennen peptide antigenen gepresenteerd in de context van zogenaamde major histocompatibility complex (MHC) moleculen op 
het oppervlak van cellen. TCRγδ+ T cellen daarentegen hebben deze beperking niet en kunnen ook andersoortige cel-gebonden of zelfs vrije antigenen herkennen. Net als 
alle andere cellen zijn ook TCRγδ+ T cellen onderhevig aan het verouderingsproces. Veroudering wordt in toenemende mate een belangrijk onderwerp in de wetenschap, mede dankzij de toegenomen levensverwachting in de Westerse wereld. Voor veel afweercellen is het effect van veroudering duidelijk beschreven; veroudering zorgt voor een veranderde samenstelling van de afweercellen, de cellen hebben een veranderde functionaliteit en activiteit, en ze kunnen genetische afwijkingen verkrijgen. Het is echter 
nog vrij onduidelijk wat er met TCRγδ+ T cellen gebeurt tijdens veroudering. Hoewel er 
duidelijke verschillen zijn tussen TCRαβ+ en TCRγδ+ T cellen, worden ook diverse over-
eenkomsten gezien tussen CD8+TCRαβ+ cytotoxische T cellen en TCRγδ+ T cellen, m.n. 
in hun reactie tegen antigeen. Op basis hiervan veronderstelden wij dat TCRγδ+ T cellen 
eenzelfde manier van veroudering ondergaan als CD8+TCRαβ+ cytotoxische T cellen, nl. afwijkende afweerreacties, verlaagde aantallen en veranderde subset samenstellingen.In onze immunofenotyperingsstudies in Hoofdstuk 2, waarin wij op basis van oppervlaktemoleculen cellen in zogenaamde populaties en subsets indelen, zien wij 
dat tijdens veroudering het absolute aantal TCRγδ+ T cellen in het bloed drastisch daalt 
en dat dit met name effect heeft op de meest voorkomende TCRγδ+ T cel populatie in 
het bloed, de Vγ9/Vδ2 cellen. Verder verandert de verdeling in subsets richting effector geheugen en effector cellen, terwijl de fracties van naieve en centraal geheugen cellen afnemen. Deze effecten worden versterkt in ouderen wanneer er sprake is van blijvende aanwezigheid van CMV, een virus dat bekend staat om zijn indrukwekkende effecten op het T cel compartiment van het afweersysteem. In geval van CMV positiviteit wordt een 
drastische daling van Vγ9/Vδ2 cellen gezien, en daarbij een relatieve stijging van Vδ1+ cellen, die bovendien vrijwel allemaal terminale effector cellen betreffen.




T cellen, een belangrijk type afweercellen, kunnen worden onderverdeeld in 
twee groepen op basis van hun T cel receptor (TCR), nl. TCR alfa beta (TCRαβ) en 
TCR gamma delta (TCRγδ) positieve T cellen. Deze twee typen T cellen volgen eigen 
ontwikkelingspaden en zorgen voor verschillende afweerreacties tegen verschillende 
soorten (eiwit)moleculen, ook wel antigenen genoemd. TCRαβ+ T cellen – de meest 
voorkomende T cellen in het bloed – herkennen peptide antigenen gepresenteerd in 
de context van zogenaamde major histocompatibility complex (MHC) moleculen op 
het oppervlak van cellen. TCRγδ+ T cellen daarentegen hebben deze beperking niet 
en kunnen ook andersoortige cel-gebonden of zelfs vrije antigenen herkennen. Net als 
alle andere cellen zijn ook TCRγδ+ T cellen onderhevig aan het verouderingsproces. 
Veroudering wordt in toenemende mate een belangrijk onderwerp in de wetenschap, 
mede dankzij de toegenomen levensverwachting in de Westerse wereld. Voor veel 
afweercellen is het effect van veroudering duidelijk beschreven; veroudering zorgt voor 
een veranderde samenstelling van de afweercellen, de cellen hebben een veranderde 
functionaliteit en activiteit, en ze kunnen genetische afwijkingen verkrijgen. Het is echter 
nog vrij onduidelijk wat er met TCRγδ+ T cellen gebeurt tijdens veroudering. Hoewel er 
duidelijke verschillen zijn tussen TCRαβ+ en TCRγδ+ T cellen, worden ook diverse over-
eenkomsten gezien tussen CD8+TCRαβ+ cytotoxische T cellen en TCRγδ+ T cellen, m.n. 
in hun reactie tegen antigeen. Op basis hiervan veronderstelden wij dat TCRγδ+ T cellen 
eenzelfde manier van veroudering ondergaan als CD8+TCRαβ+ cytotoxische T cellen, nl. 
afwijkende afweerreacties, verlaagde aantallen en veranderde subset samenstellingen.
In onze immunofenotyperingsstudies in Hoofdstuk 2, waarin wij op basis van 
oppervlaktemoleculen cellen in zogenaamde populaties en subsets indelen, zien wij 
dat tijdens veroudering het absolute aantal TCRγδ+ T cellen in het bloed drastisch daalt 
en dat dit met name effect heeft op de meest voorkomende TCRγδ+ T cel populatie in 
het bloed, de Vγ9/Vδ2 cellen. Verder verandert de verdeling in subsets richting effector 
geheugen en effector cellen, terwijl de fracties van naieve en centraal geheugen cellen 
afnemen. Deze effecten worden versterkt in ouderen wanneer er sprake is van blijvende 
aanwezigheid van CMV, een virus dat bekend staat om zijn indrukwekkende effecten op 
het T cel compartiment van het afweersysteem. In geval van CMV positiviteit wordt een 
drastische daling van Vγ9/Vδ2 cellen gezien, en daarbij een relatieve stijging van Vδ1+ 
cellen, die bovendien vrijwel allemaal terminale effector cellen betreffen.
Om de verouderingseffecten op TCRγδ+ T cellen verder te onderzoeken hebben 
wij daarnaast gebruik gemaakt van next generation sequencing (NGS) technologie. Met 
deze techniek is het mogelijk een bepaald stuk van het genoom van heel veel cellen 
tegelijkertijd in kaart te brengen. Wij hebben deze NGS technologie toegepast om het T 
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cel receptor repertoire, ofwel de samenstelling van T cel receptoren, van TCRγδ+ T cellen 
in verschillende subsets te onderzoeken. Hierbij kijken wij vanaf de ontwikkeling in de thymus en navelstrengbloed, tot circulerende cellen in jong volwassenen en ouderen, en 
maken onderscheid tussen onrijp/rijp, naief, centraal en effector geheugen, en effector cellen. Om een zo duidelijk en nauwkeurig mogelijk beeld te krijgen van de samenstelling 
van het repertoire hebben wij eerst de TCR gamma (TRG) en TCR delta (TRD) testen geoptimaliseerd (Hoofdstuk 3), om daarmee het effect van technische afwijkingen 
in de procedure zoveel mogelijk te beperken. Na deze optimalisatie experimenten hebben wij gezien dat naieve TCRγδ+ T cellen hun brede diversiteit behouden, zowel 
tijdens ontwikkeling in de thymus en navelstrengbloed, als in jong volwassenen en tijdens veroudering (Hoofdstuk 4). De meest duidelijke ouderdom-gerelateerde 
veranderingen worden dan ook gezien in de geheugencellen. Geheugencellen in jonge individuen laten voornamelijk Vγ9/Vδ2 dominantie zien, terwijl deze in ouderen juist 
meer een Vγ2/Vδ1 dominantie vertonen (Hoofdstuk 4). Deze data bevestigen tevens het beeld dat we hadden gekregen vanuit de immunofenotyperingsstudies m.b.t. de 
effecten van zowel veroudering als CMV positiviteit (Hoofdstuk 2). Op basis van de immunofenotyperingsstudies en TCR repertoire data concluderen wij dat TCRγδ+ T 
cellen op een vergelijkbare manier onderworpen worden aan een verouderingsproces als CD8+TCRαβ+ T cellen. 
Tijdens veroudering kunnen tumoren ontstaan, waaronder ook chronische leuke- mieën (vorm van bloedkanker) en lymfomen (lymfeklierkanker). Deze tumoren van het 
afweersysteem ontstaan vaak vanuit zogenaamde B cellen, maar ook T cellen kunnen transformeren tot leukemie of lymfoom. Één daarvan is de T cel large granular lymphoyte 
(T-LGL) leukemie, welke een relatief zeldzame ziekte is en bestaat uit drie varianten op basis van het T cel type, nl. CD4+TCRαβ+, CD8+TCRαβ+ en TCRγδ+ T-LGL leukemie. 
Wij hebben ons voornamelijk gericht op de TCRγδ+ en CD8+TCRαβ+ varianten van de 
ziekte, welke veel overeenkomsten vertonen (Hoofdstuk 5). Beide typen worden met name gezien in oudere individuen (leeftijd vanaf 60 jaar) en kennen een vrij rustig ziek-
tebeloop. De meeste T-LGL leukemiepatiënten laten een tekort aan bepaalde bloedcellen zien (zogenaamde cytopenieën), wat tot bloedarmoede, verlaagde afweer en bloeduit-
stortingen kan leiden. Verder hebben deze patiënten vaak al bestaande onderliggende (afweer)ziekten in de vorm van autoimmuunziekten of andere tumoren. In tegenstelling 
tot de CD4+TCRαβ+ variant waarin in verschillende patiënten vaak een zelfde TCR op 
het oppervlakte wordt gezien en waarin CMV als aanjager is beschreven, worden geen overeenkomsten gevonden tussen de TCR moleculen bij de andere twee T-LGL leukemie 
varianten (Hoofdstuk 5). Dit betekent dat in de TCRγδ+ en CD8+TCRαβ+ T-LGL tumoren, de ongecontroleerde celdeling waarschijnlijk niet door één gemeenschappelijk (auto-)
antigeen wordt veroorzaakt, maar dat meerdere antigenen betrokken kunnen zijn. 
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c e l  r e c e p t o r  r e p e r t o i r e ,  o f w e l  d e  s a m e n s t e l l i n g  v a n  T  c e l  r e c e p t o r e n ,  v a n  T C R γ δ +  T  c e l l e n  
i n  v e r s c h i l l e n d e  s u b s e t s  t e  o n d e r z o e k e n .  H i e r b i j  k i j k e n  w i j  v a n a f  d e  o n t w i k k e l i n g  i n  d e  
t h y m u s  e n  n a v e l s t r e n g b l o e d ,  t o t  c i r c u l e r e n d e  c e l l e n  i n  j o n g  v o l w a s s e n e n  e n  o u d e r e n ,  e n  
m a k e n  o n d e r s c h e i d  t u s s e n  o n r i j p / r i j p ,  n a i e f ,  c e n t r a a l  e n  e f f e c t o r  g e h e u g e n ,  e n  e f f e c t o r  
c e l l e n .  O m  e e n  z o  d u i d e l i j k  e n  n a u w k e u r i g  m o g e l i j k  b e e l d  t e  k r i j g e n  v a n  d e  s a m e n s t e l l i n g  
v a n  h e t  r e p e r t o i r e  h e b b e n  w i j  e e r s t  d e  T C R  g a m m a  ( T R G )  e n  T C R  d e l t a  ( T R D )  t e s t e n  
g e o p t i m a l i s e e r d  ( H o o f d s t u k  3 ) ,  o m  d a a r m e e  h e t  e f f e c t  v a n  t e c h n i s c h e  a f w i j k i n g e n  
i n  d e  p r o c e d u r e  z o v e e l  m o g e l i j k  t e  b e p e r k e n .  N a  d e z e  o p t i m a l i s a t i e  e x p e r i m e n t e n  
h e b b e n  w i j  g e z i e n  d a t  n a i e v e  T C R γ δ +  T  c e l l e n  h u n  b r e d e  d i v e r s i t e i t  b e h o u d e n ,  z o w e l  
t i j d e n s  o n t w i k k e l i n g  i n  d e  t h y m u s  e n  n a v e l s t r e n g b l o e d ,  a l s  i n  j o n g  v o l w a s s e n e n  e n  
t i j d e n s  v e r o u d e r i n g  ( H o o f d s t u k  4 ) .  D e  m e e s t  d u i d e l i j k e  o u d e r d o m - g e r e l a t e e r d e  
v e r a n d e r i n g e n  w o r d e n  d a n  o o k  g e z i e n  i n  d e  g e h e u g e n c e l l e n .  G e h e u g e n c e l l e n  i n  j o n g e  
i n d i v i d u e n  l a t e n  v o o r n a m e l i j k  V γ 9 / V δ 2  d o m i n a n t i e  z i e n ,  t e r w i j l  d e z e  i n  o u d e r e n  j u i s t  
m e e r  e e n  V γ 2 / V δ 1  d o m i n a n t i e  v e r t o n e n  ( H o o f d s t u k  4 ) .  D e z e  d a t a  b e v e s t i g e n  t e v e n s  
h e t  b e e l d  d a t  w e  h a d d e n  g e k r e g e n  v a n u i t  d e  i m m u n o f e n o t y p e r i n g s s t u d i e s  m . b . t .  d e  
e f f e c t e n  v a n  z o w e l  v e r o u d e r i n g  a l s  C M V  p o s i t i v i t e i t  ( H o o f d s t u k  2 ) .  O p  b a s i s  v a n  d e  
i m m u n o f e n o t y p e r i n g s s t u d i e s  e n  T C R  r e p e r t o i r e  d a t a  c o n c l u d e r e n  w i j  d a t  T C R γ δ +  T  
c e l l e n  o p  e e n  v e r g e l i j k b a r e  m a n i e r  o n d e r w o r p e n  w o r d e n  a a n  e e n  v e r o u d e r i n g s p r o c e s  
a l s  C D 8 + T C R α β +  T  c e l l e n .  
T i j d e n s  v e r o u d e r i n g  k u n n e n  t u m o r e n  o n t s t a a n ,  w a a r o n d e r  o o k  c h r o n i s c h e  l e u k e -
m i e ë n  ( v o r m  v a n  b l o e d k a n k e r )  e n  l y m f o m e n  ( l y m f e k l i e r k a n k e r ) .  D e z e  t u m o r e n  v a n  h e t  
a f w e e r s y s t e e m  o n t s t a a n  v a a k  v a n u i t  z o g e n a a m d e  B  c e l l e n ,  m a a r  o o k  T  c e l l e n  k u n n e n  
t r a n s f o r m e r e n  t o t  l e u k e m i e  o f  l y m f o o m .  É é n  d a a r v a n  i s  d e  T  c e l  l a r g e  g r a n u l a r  l y m p h o y t e  
( T - L G L )  l e u k e m i e ,  w e l k e  e e n  r e l a t i e f  z e l d z a m e  z i e k t e  i s  e n  b e s t a a t  u i t  d r i e  v a r i a n t e n  
o p  b a s i s  v a n  h e t  T  c e l  t y p e ,  n l .  C D 4 + T C R α β + ,  C D 8 + T C R α β +  e n  T C R γ δ +  T - L G L  l e u k e m i e .  
W i j  h e b b e n  o n s  v o o r n a m e l i j k  g e r i c h t  o p  d e  T C R γ δ +  e n  C D 8 + T C R α β +  v a r i a n t e n  v a n  d e  
z i e k t e ,  w e l k e  v e e l  o v e r e e n k o m s t e n  v e r t o n e n  ( H o o f d s t u k  5 ) .  B e i d e  t y p e n  w o r d e n  m e t  
n a m e  g e z i e n  i n  o u d e r e  i n d i v i d u e n  ( l e e f t i j d  v a n a f  6 0  j a a r )  e n  k e n n e n  e e n  v r i j  r u s t i g  z i e k -
t e b e l o o p .  D e  m e e s t e  T - L G L  l e u k e m i e p a t i ë n t e n  l a t e n  e e n  t e k o r t  a a n  b e p a a l d e  b l o e d c e l l e n  
z i e n  ( z o g e n a a m d e  c y t o p e n i e ë n ) ,  w a t  t o t  b l o e d a r m o e d e ,  v e r l a a g d e  a f w e e r  e n  b l o e d u i t -
s t o r t i n g e n  k a n  l e i d e n .  V e r d e r  h e b b e n  d e z e  p a t i ë n t e n  v a a k  a l  b e s t a a n d e  o n d e r l i g g e n d e  
( a f w e e r ) z i e k t e n  i n  d e  v o r m  v a n  a u t o i m m u u n z i e k t e n  o f  a n d e r e  t u m o r e n .  I n  t e g e n s t e l l i n g  
t o t  d e  C D 4 + T C R α β +  v a r i a n t  w a a r i n  i n  v e r s c h i l l e n d e  p a t i ë n t e n  v a a k  e e n  z e l f d e  T C R  o p  
h e t  o p p e r v l a k t e  w o r d t  g e z i e n  e n  w a a r i n  C M V  a l s  a a n j a g e r  i s  b e s c h r e v e n ,  w o r d e n  g e e n  
o v e r e e n k o m s t e n  g e v o n d e n  t u s s e n  d e  T C R  m o l e c u l e n  b i j  d e  a n d e r e  t w e e  T - L G L  l e u k e m i e  
v a r i a n t e n  ( H o o f d s t u k  5 ) .  D i t  b e t e k e n t  d a t  i n  d e  T C R γ δ +  e n  C D 8 + T C R α β +  T - L G L  t u m o r e n ,  
d e  o n g e c o n t r o l e e r d e  c e l d e l i n g  w a a r s c h i j n l i j k  n i e t  d o o r  é é n  g e m e e n s c h a p p e l i j k  ( a u t o - )
a n t i g e e n  w o r d t  v e r o o r z a a k t ,  m a a r  d a t  m e e r d e r e  a n t i g e n e n  b e t r o k k e n  k u n n e n  z i j n .  
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Omdat TCRγδ+ T-LGL leukemie een chronische ziekte is, die voornamelijk wordt gediagnosticeerd bij ouderen, veronderstelden wij dat continue en langdurige stimulatie van de T cellen een rol speelt in het ontstaan van de leukemie via het ontwikkelen van genetische afwijkingen en een verhoogde celdeling. In Hoofdstuk 6 hebben wij onder-zocht of er welke afwijkende, onderliggende moleculaire mechanismen mogelijk ten 
grondslag liggen aan de ontwikkeling van TCRγδ+ T-LGL leukemie. Hiertoe hebben wij zogenaamde genexpressie studies uitgevoerd, waarbij wij een zeer duidelijke overeen-
komst tussen de TCRγδ+ T-LGL leukemiecellen en gezonde TCRγδ+ effector en effector geheugencellen zagen. Bij diepgaander onderzoek naar de verschillen tussen de gezonde en leukemiecellen blijken bepaalde genen een afwijkende expressie te vertonen, wat zorgt voor toegenomen celdeling, verminderde celdood en afwijkende afweerreacties. Dit afwijkende patroon van expressie lijkt niet alleen te duiden op mechanismen die bij de ontwikkeling van de leukemie zijn betrokken, maar kan mogelijk ook de relatie met de autoimmuunziekten en cytopenieën in patiënten verklaren.De veranderde genexpressiepatronen, zoals we die hebben gezien in Hoofdstuk 6, kunnen worden veroorzaakt door externe factoren, zoals overmatige prikkeling van cellen en stress. Maar intrinsieke veranderingen in de cellen, zoals genetische afwijkin-gen, kunnen er ook toe leiden dat genen meer of minder actief kunnen worden. Dankzij recente ontwikkelingen in de sequencing technologie zijn wij in staat het complete genoom van kankercellen in kaart te brengen. Door één van deze nieuwe technologieën, 
whole exome sequencing (WES), toe te passen, hebben wij T-LGL leukemie-specifieke 
genetische varianten kunnen identificeren (Hoofdstuk 7). Na uitgebreide analysestap-pen hebben wij nu een lijst van zes kandidaatgenen, die een directe correlatie lijken 
te vertonen met TCRγδ+ T-LGL leukemie. In deze genen zijn kleine toegevoegde of verwijderde stukken DNA te zien, wat leidt tot  verschuivingen in de genetische code. Uiteindelijk kunnen de verschuivingen in de kandidaatgenen leiden tot veranderde genexpressie, en daarmee bijdragen aan activatie van afweerreacties en uitzaaiingen. In toekomstige experimenten zal de directe relatie tussen deze genetische afwijkingen en de daadwerkelijke veranderingen in celdeling, resistentie tegen celdood en de toxiciteit tegen andere (bloed)cellen verder vastgesteld moeten worden.In de Algemene Discussie worden alle mogelijke externe en cel-intrinsieke 
aspecten van TCRγδ+ T-LGL leukemie samengevat en kritisch besproken. Daarnaast presenteren wij nieuwe data over aspecten van veroudering en uitputting van T-LGL leukemiecellen, waar eveneens sleutels kunnen liggen om LGL leukemievorming beter te gaan begrijpen. Ook proberen wij een verbinding te maken tussen LGL leukemie en 
immuundysregulaties in de vorm van autoimmuunziekten, waarbij ook de vraag van “de kip en het ei” ter sprake komt.
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Samenvatting
Samenvattend, de studies zoals gepresenteerd in dit proefschrift beschrijven de complexe interacties van genetische afwijkingen, veranderde genexpressieniveaus, 
functionele eigenschappen, expressie van TCR en andere oppervlaktemoleculen tijdens TCRγδ+ T celontogenie, perifere (antigene) selectie, veroudering en leukemogenese. 
Het onderzoek in deze thesis vormt niet alleen een basis voor het beter begrijpen van zowel normale als afwijkende TCRγδ+ T cellen, maar draagt mogelijk ook bij aan 
nieuwe inzichten die uiteindelijk moeten leiden tot betere diagnosestelling, prognose, behandeling en/of preventie. Ten slotte benadrukt dit proefschrift het belang van 
TCRγδ+ T cellen in de normale fysiologie, maar tevens hun potentie om een leukemie te 
vormen: “negeer ze niet, want ze kunnen bijten”.
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S a m e n v a t t i n g
S a m e n v a t t e n d ,  d e  s t u d i e s  z o a l s  g e p r e s e n t e e r d  i n  d i t  p r o e f s c h r i f t  b e s c h r i j v e n  d e  
c o m p l e x e  i n t e r a c t i e s  v a n  g e n e t i s c h e  a f w i j k i n g e n ,  v e r a n d e r d e  g e n e x p r e s s i e n i v e a u s ,  
f u n c t i o n e l e  e i g e n s c h a p p e n ,  e x p r e s s i e  v a n  T C R  e n  a n d e r e  o p p e r v l a k t e m o l e c u l e n  t i j d e n s  
T C R γ δ +  T  c e l o n t o g e n i e ,  p e r i f e r e  ( a n t i g e n e )  s e l e c t i e ,  v e r o u d e r i n g  e n  l e u k e m o g e n e s e .  
H e t  o n d e r z o e k  i n  d e z e  t h e s i s  v o r m t  n i e t  a l l e e n  e e n  b a s i s  v o o r  h e t  b e t e r  b e g r i j p e n  
v a n  z o w e l  n o r m a l e  a l s  a f w i j k e n d e  T C R γ δ +  T  c e l l e n ,  m a a r  d r a a g t  m o g e l i j k  o o k  b i j  a a n  
n i e u w e  i n z i c h t e n  d i e  u i t e i n d e l i j k  m o e t e n  l e i d e n  t o t  b e t e r e  d i a g n o s e s t e l l i n g ,  p r o g n o s e ,  
b e h a n d e l i n g  e n / o f  p r e v e n t i e .  T e n  s l o t t e  b e n a d r u k t  d i t  p r o e f s c h r i f t  h e t  b e l a n g  v a n  
T C R γ δ +  T  c e l l e n  i n  d e  n o r m a l e  f y s i o l o g i e ,  m a a r  t e v e n s  h u n  p o t e n t i e  o m  e e n  l e u k e m i e  t e  




Dr. A.W. Langerak, beste Ton, al sinds het begin van de Master in 2011 hadden we een connectie: CLL. Maar jij had wat anders voor mij in gedachten, wat later ook veel leuker bleek te zijn dan CLL: gammadelta T cellen. Tijdens mijn stage, maar ook tijdens de PhD, heb je mij heel veel vrijheid gegeven. Dit was soms moeilijk, maar uiteindelijk is dit alleen maar goed geweest. Je geduld, adviezen, begeleiding, maar vooral je grote benaderbaarheid heb ik zeer gewaardeerd. Bedankt hiervoor, maar ook voor dat je altijd in mij hebt geloofd en deze kans hebt gegeven.Prof.dr. J.J.M. van Dongen, beste Jacques, bedankt dat ik destijds mocht beginnen als masterstudent en uiteindelijk het onderzoek zelfs mocht voortzetten als PhD student. Deze afgelopen tijd heb ik als heel prettig ervaren, omdat ik werd vrijgelaten in de ontwikkeling tot onderzoeker. Ik ben dankbaar dat ik deze kans heb gekregen en dat ik 
een mooi proefschrift heb mogen en kunnen afleveren.Kleine commissieleden prof.dr. A.M.H. Boots, prof.dr. E.F. Eldering, dr. J.N. Samsom: hartelijk dank voor jullie waardevolle beoordeling. Dankzij jullie is het een compleet boekje. In het bijzonder wil ik Mieke bedanken voor de mooie samenwerkingen. Grote commissieleden, bedankt dat jullie als opponenten wilden deelnemen aan mijn verdediging: het is mij een eer.Lieve MIDjes, al sinds mijn Master-labrotatie november 2011 kwam ik in een warm nest terecht. Bedankt hiervoor, en voor al het lief en leed wat wij met elkaar hebben gedeeld. Joyce, bedankt voor je master-stage-begeleiding, gezelligheid en steun; door jouw gepush ben ik mooi PhD student bij de MIDjes geworden. Kim (Kimmie), bedankt 
voor de gezellige uurtjes, zowel op het lab, als in een sushitent of op de fiets. Ik heb enorme bewondering voor je sterkte en doorzettingsvermogen. Alice, bedankt voor je 
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een connectie: CLL. Maar jij had wat anders voor mij in gedachten, wat later ook veel 
leuker bleek te zijn dan CLL: gammadelta T cellen. Tijdens mijn stage, maar ook tijdens 
de PhD, heb je mij heel veel vrijheid gegeven. Dit was soms moeilijk, maar uiteindelijk 
is dit alleen maar goed geweest. Je geduld, adviezen, begeleiding, maar vooral je grote 
benaderbaarheid heb ik zeer gewaardeerd. Bedankt hiervoor, maar ook voor dat je altijd 
in mij hebt geloofd en deze kans hebt gegeven.
Prof.dr. J.J.M. van Dongen, beste Jacques, bedankt dat ik destijds mocht beginnen als 
masterstudent en uiteindelijk het onderzoek zelfs mocht voortzetten als PhD student. 
Deze afgelopen tijd heb ik als heel prettig ervaren, omdat ik werd vrijgelaten in de 
ontwikkeling tot onderzoeker. Ik ben dankbaar dat ik deze kans heb gekregen en dat ik 
een mooi proefschrift heb mogen en kunnen afleveren.
Kleine commissieleden prof.dr. A.M.H. Boots, prof.dr. E.F. Eldering, dr. J.N. Samsom: 
hartelijk dank voor jullie waardevolle beoordeling. Dankzij jullie is het een compleet 
boekje. In het bijzonder wil ik Mieke bedanken voor de mooie samenwerkingen. 
Grote commissieleden, bedankt dat jullie als opponenten wilden deelnemen aan mijn 
verdediging: het is mij een eer.
Lieve MIDjes, al sinds mijn Master-labrotatie november 2011 kwam ik in een warm 
nest terecht. Bedankt hiervoor, en voor al het lief en leed wat wij met elkaar hebben 
gedeeld. Joyce, bedankt voor je master-stage-begeleiding, gezelligheid en steun; door 
jouw gepush ben ik mooi PhD student bij de MIDjes geworden. Kim (Kimmie), bedankt 
voor de gezellige uurtjes, zowel op het lab, als in een sushitent of op de fiets. Ik heb 
enorme bewondering voor je sterkte en doorzettingsvermogen. Alice, bedankt voor je 
“senior” steun tijdens mijn PhD project. Ook al zijn we weg, het contact blijft hetzelfde. 
Ellen, bedankt voor je nuchterheid en onbezorgdheid. Tamara (de Zeeuwsche taele is 
’t mooist van oallemaele), Irene, Brigitte, Fatemeh, bedankt voor de dikke pret in onze 
groep. Ruud, je paste precies in de MID-groep. Bedankt voor je zwarte humor en gezel-
ligheid zo vroeg in de ochtend. Michèle, Jorn, mijn (oud-)studenten: wat heb ik het met 
jullie getroffen. Ik ben trots op jullie. Michèle, toen je je afstudeerpresentatie had gedaan, 
slaakten we beiden een zucht van opluchting: nu kunnen we samen gaan shoppen. Menig 
etentje en stedentripje is voorbij gekomen. Bedankt voor alles èn dat je mijn paranimf 
wilde zijn! Jorn, februari 2017 begon ik de druk van de PhD en de afronding te voelen. 
Na overleg met Ton, die toevallig een sollicitatie van een student uit Wageningen had 
gekregen, lieten we je last-minute langskomen. We besloten een gok op je te wagen, en 
zodra in de eerste paar weken bleek dat je goed was, smeedden we een plannetje om je 
te houden. Uiteindelijk is dit een hele goede gok geweest, en ga je verder als PhD student. 
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Dankwoord
Bedankt voor je inzet, motivatie, en je vreselijke humor. Ingrid, lieve Ing, wat een vechter ben jij geweest. Bedankt voor je hulp en wijsheid. Ik mis je.
Lieve Kamergenootjes: Diana, Diaantje: jij was er altijd voor mij als beginnende PhD’er. Je had genoeg voor je kiezen gekregen, maar daar kwam je sterker dan voorheen 
uit. Ik ben blij dat je nu je plekje hebt gevonden. Marjolein, ik zag jou vaker dan wie dan ook, omdat we namelijk ook vaak een (hotel)kamer deelden op congressen. Het was 
altijd een dolle boel met theetjes, “SB”, etc. Heel veel succes met alles! Anne, ik heb nog 
nooit iemand ontmoet die zowel computer-, programmeer-, statistiek-gek, als humoris- tisch is. Je bent al een heel eind op weg. Heel veel succes met alles, en blijf lekker wie je 
bent. Grote dank aan alle mede-PhD’ers en postdocs, voor de geweldige etentjes en 
retreats: Jamie, Liza, Fabian (mein verrückter deutscher Freund), Jorn, Britt, Christina, Chris, Jenna, Hanna, Pauline, Malou, Willem Jan, Wouter, Iris, Dew, Prayer, Marieke, 
Prisca, Wendy, Wida, Marlieke, and all the others that I forgot to mention: thanks! Tijdens een PhD-project komt steun van allerlei kanten. Daarom wil ik graag de LLD 
analisten, Mirjam & PID, en alle andere analisten bedanken: voor reagentia, technieken of data kon ik altijd bij jullie terecht. Monique, eventjes lekker bij jou kletsen was zo’n 
heerlijke afleiding en oppepper, bedankt! François van de Hematologie, bedankt voor je 
enorme inzet en het meedenken over ons project/experimenten, paper, etc. Ik vond het een fijne en vruchtbare samenwerking! Lieve Gellof, Marie Joan, Sascha, Bibi, Erna en 
Daniëlle, bedankt voor jullie hulp en gezelligheid. Daniëlle, bedankt voor het ineenzetten van het boekje. Je dacht aan zoveel dingen, waaraan ik nooit had gedacht. Bedankt voor 
de fijne praatjes, welke ook serieus konden zijn.
Lieve Denise, al sinds 2008 zijn wij vriendinnen. Alles is met jou bespreek- baar, en ik kan altijd bij je terecht: dát is echte vriendschap. Het is fijn 
om te weten dat je altijd voor mij klaarstaat (en ik uiteraard voor jou!). Ashley, samen met de MIDjes waren we een hecht groepje, ook toen je 
een Master en PhD ging doen. Bedankt voor de gezellige uurtjes en goede gesprekken, en veel geluk met alles. Ik ben blij dat ik jou heb leren kennen! 
Astari, Tari, I remember the exact day we’ve met during the Master (Wed. August 17th, 2011). From that day on we were friends. It’s amazing to have so many things in common 
with a person from a totally different continent, culture and religion. I am happy this never changed. Many thanks for your friendship. Bianca, As, ik had nooit gedacht dat ik 
zulke vriendinnen zou overhouden aan een bijbaan tijdens mijn opleidingen. Die peri- ode bij jullie op het secretariaat is zeer sterk bij mij blijven hangen. Bedankt voor alle 
lunchloopjes en ontspanningen, gekkigheid, Rotterdamse uitspraken en levenslessen! Lieve Wouter, mijn grote broer, voorbeeld en paranimf: op 8 april 2014 mocht ik jouw 
paranimf zijn bij jouw verdediging “Activity-based probes for retaining β-glucosidases: 
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D a n k w o o r d
B e d a n k t  v o o r  j e  i n z e t ,  m o t i v a t i e ,  e n  j e  v r e s e l i j k e  h u m o r .  I n g r i d ,  l i e v e  I n g ,  w a t  e e n  v e c h t e r  
b e n  j i j  g e w e e s t .  B e d a n k t  v o o r  j e  h u l p  e n  w i j s h e i d .  I k  m i s  j e .
L i e v e  K a m e r g e n o o t j e s :  D i a n a ,  D i a a n t j e :  j i j  w a s  e r  a l t i j d  v o o r  m i j  a l s  b e g i n n e n d e  
P h D ’ e r .  J e  h a d  g e n o e g  v o o r  j e  k i e z e n  g e k r e g e n ,  m a a r  d a a r  k w a m  j e  s t e r k e r  d a n  v o o r h e e n  
u i t .  I k  b e n  b l i j  d a t  j e  n u  j e  p l e k j e  h e b t  g e v o n d e n .  M a r j o l e i n ,  i k  z a g  j o u  v a k e r  d a n  w i e  d a n  
o o k ,  o m d a t  w e  n a m e l i j k  o o k  v a a k  e e n  ( h o t e l ) k a m e r  d e e l d e n  o p  c o n g r e s s e n .  H e t  w a s  
a l t i j d  e e n  d o l l e  b o e l  m e t  t h e e t j e s ,  “ S B ” ,  e t c .  H e e l  v e e l  s u c c e s  m e t  a l l e s !  A n n e ,  i k  h e b  n o g  
n o o i t  i e m a n d  o n t m o e t  d i e  z o w e l  c o m p u t e r - ,  p r o g r a m m e e r - ,  s t a t i s t i e k - g e k ,  a l s  h u m o r i s -
t i s c h  i s .  J e  b e n t  a l  e e n  h e e l  e i n d  o p  w e g .  H e e l  v e e l  s u c c e s  m e t  a l l e s ,  e n  b l i j f  l e k k e r  w i e  j e  
b e n t .  
G r o t e  d a n k  a a n  a l l e  m e d e - P h D ’ e r s  e n  p o s t d o c s ,  v o o r  d e  g e w e l d i g e  e t e n t j e s  e n  
r e t r e a t s :  J a m i e ,  L i z a ,  F a b i a n  ( m e i n  v e r r ü c k t e r  d e u t s c h e r  F r e u n d ) ,  J o r n ,  B r i t t ,  C h r i s t i n a ,  
C h r i s ,  J e n n a ,  H a n n a ,  P a u l i n e ,  M a l o u ,  W i l l e m  J a n ,  W o u t e r ,  I r i s ,  D e w ,  P r a y e r ,  M a r i e k e ,  
P r i s c a ,  W e n d y ,  W i d a ,  M a r l i e k e ,  a n d  a l l  t h e  o t h e r s  t h a t  I  f o r g o t  t o  m e n t i o n :  t h a n k s !
T i j d e n s  e e n  P h D - p r o j e c t  k o m t  s t e u n  v a n  a l l e r l e i  k a n t e n .  D a a r o m  w i l  i k  g r a a g  d e  L L D  
a n a l i s t e n ,  M i r j a m  &  P I D ,  e n  a l l e  a n d e r e  a n a l i s t e n  b e d a n k e n :  v o o r  r e a g e n t i a ,  t e c h n i e k e n  
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e n o r m e  i n z e t  e n  h e t  m e e d e n k e n  o v e r  o n s  p r o j e c t / e x p e r i m e n t e n ,  p a p e r ,  e t c .  I k  v o n d  h e t  
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D a n i ë l l e ,  b e d a n k t  v o o r  j u l l i e  h u l p  e n  g e z e l l i g h e i d .  D a n i ë l l e ,  b e d a n k t  v o o r  h e t  i n e e n z e t t e n  
v a n  h e t  b o e k j e .  J e  d a c h t  a a n  z o v e e l  d i n g e n ,  w a a r a a n  i k  n o o i t  h a d  g e d a c h t .  B e d a n k t  v o o r  
d e  f i j n e  p r a a t j e s ,  w e l k e  o o k  s e r i e u s  k o n d e n  z i j n .
L i e v e  D e n i s e ,  a l  s i n d s  2 0 0 8  z i j n  w i j  v r i e n d i n n e n .  A l l e s  i s  m e t  j o u  b e s p r e e k -
b a a r ,  e n  i k  k a n  a l t i j d  b i j  j e  t e r e c h t :  d á t  i s  e c h t e  v r i e n d s c h a p .  H e t  i s  f i j n  
o m  t e  w e t e n  d a t  j e  a l t i j d  v o o r  m i j  k l a a r s t a a t  ( e n  i k  u i t e r a a r d  v o o r  j o u ! ) .  
A s h l e y ,  s a m e n  m e t  d e  M I D j e s  w a r e n  w e  e e n  h e c h t  g r o e p j e ,  o o k  t o e n  j e  
e e n  M a s t e r  e n  P h D  g i n g  d o e n .  B e d a n k t  v o o r  d e  g e z e l l i g e  u u r t j e s  e n  g o e d e  
g e s p r e k k e n ,  e n  v e e l  g e l u k  m e t  a l l e s .  I k  b e n  b l i j  d a t  i k  j o u  h e b  l e r e n  k e n n e n !  
A s t a r i ,  T a r i ,  I  r e m e m b e r  t h e  e x a c t  d a y  w e ’ v e  m e t  d u r i n g  t h e  M a s t e r  ( W e d .  A u g u s t  1 7 t h ,  
2 0 1 1 ) .  F r o m  t h a t  d a y  o n  w e  w e r e  f r i e n d s .  I t ’ s  a m a z i n g  t o  h a v e  s o  m a n y  t h i n g s  i n  c o m m o n  
w i t h  a  p e r s o n  f r o m  a  t o t a l l y  d i f f e r e n t  c o n t i n e n t ,  c u l t u r e  a n d  r e l i g i o n .  I  a m  h a p p y  t h i s  
n e v e r  c h a n g e d .  M a n y  t h a n k s  f o r  y o u r  f r i e n d s h i p .  B i a n c a ,  A s ,  i k  h a d  n o o i t  g e d a c h t  d a t  i k  
z u l k e  v r i e n d i n n e n  z o u  o v e r h o u d e n  a a n  e e n  b i j b a a n  t i j d e n s  m i j n  o p l e i d i n g e n .  D i e  p e r i -
o d e  b i j  j u l l i e  o p  h e t  s e c r e t a r i a a t  i s  z e e r  s t e r k  b i j  m i j  b l i j v e n  h a n g e n .  B e d a n k t  v o o r  a l l e  
l u n c h l o o p j e s  e n  o n t s p a n n i n g e n ,  g e k k i g h e i d ,  R o t t e r d a m s e  u i t s p r a k e n  e n  l e v e n s l e s s e n !
L i e v e  W o u t e r ,  m i j n  g r o t e  b r o e r ,  v o o r b e e l d  e n  p a r a n i m f :  o p  8  a p r i l  2 0 1 4  m o c h t  i k  j o u w  
p a r a n i m f  z i j n  b i j  j o u w  v e r d e d i g i n g  “A c t i v i t y - b a s e d  p r o b e s  f o r  r e t a i n i n g  β - g l u c o s i d a s e s :  
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novel tools for research and diagnostics”. Jij bent mij altijd voor geweest, dus kon ik heel veel van je leren. Wout, fantastisch dat je grant na grant binnensleept en een eigen lab hebt aan Imperial College London. Echt een broer waar ik trots op mag zijn! Marusela, my dear sister-in-law. I really enjoyed your company, our lunch dates when you worked at Erasmus, your support in my career development. Many thanks. 
Lieve omie, het is altijd fijn eventjes met je te bellen; een goed moment om te worden herinnerd dat er ook andere dingen belangrijk zijn. Bedankt voor je steun, liefs, en het branden van kaarsen. Lieve opie, opeens was je er niet meer, en ik zie je nog steeds midden in de Schepenenlaan ons uitzwaaien. Je fameuze uitspraken klinken vaak in mijn hoofd. Lieve opie, Wouter en ik hebben altijd zoveel aan je gehad. Bedankt voor alles!Lieve Regeertjes en Köhlertjes, jullie hebben mij vanaf het eerste moment opge-nomen in de familie. Niets is te gek, en het is altijd gezellig bij jullie. Alle weekendjes bij jullie of in Limburg of Nijmegen waren erg welkome ontspanningen. Jullie hebben ons altijd gesteund, bedankt.
Lief, wat rest mij nog te zeggen? Als er iemand was die mij begreep, of mij nog meer begreep dan ikzelf, dan was jij het wel. We hoeven geen gesprek meer te voeren, want óf 
één blik volstaat, óf we kunnen elkaars antwoorden invullen – inclusief gezichtsuitdruk-kingen en reacties. Jouw steun heeft mij tot dingen gebracht, die ik soms in de eerste instantie niet zou durven. We hebben veel lief en leed gedeeld, en er gaat vast nog een hele hoop komen. Maar één ding is zeker: jij zal er zijn.Lieve pep en mama. Bedankt voor het engelengeduld en de betrokkenheid. Mama, bedankt voor de heerlijke daagjes winkelen, kletsen, lachen, handwerkjes: gewoon even 
“niks moet”. Pep, bedankt voor de HD toertjes, hoofd leegmaken, nieuwe energie opdoen. Jullie eeuwig durende motivatie, medeleven, steun en liefde valt niet onder woorden te brengen: geen enkele uitdrukking volstaat mijn dankbaarheid. Jullie zijn de beste.
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